Rank,NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL
2,NCT02638103,Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine,HALO,Completed,Has Results,Migraine,Drug: Fremanezumab|Drug: Placebo,Number of Participants With Adverse Events (AEs)|Number of Participants With Potentially Clinically Significant Abnormal Serum Chemistry Results|Number of Participants With Potentially Clinically Significant Abnormal Hematology Results|Number of Participants With Potentially Clinically Significant Abnormal Urinalysis Laboratory Tests Results|Number of Participants With Potentially Clinically Significant Abnormal Vital Signs Values|Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters|Number of Participants With Shift From Baseline to Endpoint in Coagulation Laboratory Test Results|Number of Participants With Injection Site Reactions|Number of Participants With Suicidal Ideation and Suicidal Behavior as Assessed by the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS),"Teva Branded Pharmaceutical Products R&D, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,1890,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TV48125-CNS-30051|2015-004550-18,"February 26, 2016","June 6, 2018","December 8, 2018","December 22, 2015","August 28, 2019","November 9, 2021","Teva Investigational Site 13628, Birmingham, Alabama, United States|Teva Investigational Site 13577, Birmingham, Alabama, United States|Teva Investigational Site 13606, Phoenix, Arizona, United States|Teva Investigational Site 13579, Phoenix, Arizona, United States|Teva Investigational Site 13602, Little Rock, Arkansas, United States|Teva Investigational Site 13568, Encino, California, United States|Teva Investigational Site 13546, Fullerton, California, United States|Teva Investigational Site 13540, Long Beach, California, United States|Teva Investigational Site 13632, Redlands, California, United States|Teva Investigational Site 13571, Redondo Beach, California, United States|Teva Investigational Site 13573, San Diego, California, United States|Teva Investigational Site 13538, Santa Monica, California, United States|Teva Investigational Site 13594, Santa Rosa, California, United States|Teva Investigational Site 13595, Walnut Creek, California, United States|Teva Investigational Site 13629, Aurora, Colorado, United States|Teva Investigational Site 13557, Boulder, Colorado, United States|Teva Investigational Site 13593, Colorado Springs, Colorado, United States|Teva Investigational Site 13633, Denver, Colorado, United States|Teva Investigational Site 13612, Denver, Colorado, United States|Teva Investigational Site 13631, Englewood, Colorado, United States|Teva Investigational Site 13563, East Hartford, Connecticut, United States|Teva Investigational Site 13550, Stamford, Connecticut, United States|Teva Investigational Site 13635, Bradenton, Florida, United States|Teva Investigational Site 13597, Gainesville, Florida, United States|Teva Investigational Site 13607, Hialeah, Florida, United States|Teva Investigational Site 13559, Jacksonville, Florida, United States|Teva Investigational Site 13584, Ocala, Florida, United States|Teva Investigational Site 13587, Orlando, Florida, United States|Teva Investigational Site 13567, Palm Beach Gardens, Florida, United States|Teva Investigational Site 13553, Pembroke Pines, Florida, United States|Teva Investigational Site 13616, Pinellas Park, Florida, United States|Teva Investigational Site 13620, Atlanta, Georgia, United States|Teva Investigational Site 13537, Atlanta, Georgia, United States|Teva Investigational Site 13604, Boise, Idaho, United States|Teva Investigational Site 13585, Chicago, Illinois, United States|Teva Investigational Site 13621, Chicago, Illinois, United States|Teva Investigational Site 13627, Evanston, Illinois, United States|Teva Investigational Site 13596, Indianapolis, Indiana, United States|Teva Investigational Site 13617, Wichita, Kansas, United States|Teva Investigational Site 13598, Wichita, Kansas, United States|Teva Investigational Site 13566, Louisville, Kentucky, United States|Teva Investigational Site 13603, Metairie, Louisiana, United States|Teva Investigational Site 13582, Pikesville, Maryland, United States|Teva Investigational Site 13590, Boston, Massachusetts, United States|Teva Investigational Site 13589, New Bedford, Massachusetts, United States|Teva Investigational Site 13543, Watertown, Massachusetts, United States|Teva Investigational Site 13539, Ann Arbor, Michigan, United States|Teva Investigational Site 13542, Golden Valley, Minnesota, United States|Teva Investigational Site 13534, Kansas City, Missouri, United States|Teva Investigational Site 13619, Saint Louis, Missouri, United States|Teva Investigational Site 13536, Springfield, Missouri, United States|Teva Investigational Site 13618, Fremont, Nebraska, United States|Teva Investigational Site 13605, Las Vegas, Nevada, United States|Teva Investigational Site 13578, Lebanon, New Hampshire, United States|Teva Investigational Site 13575, Martinsville, New Jersey, United States|Teva Investigational Site 13622, Princeton, New Jersey, United States|Teva Investigational Site 13588, Albuquerque, New Mexico, United States|Teva Investigational Site 13576, Amherst, New York, United States|Teva Investigational Site 13565, Plainview, New York, United States|Teva Investigational Site 13544, Greensboro, North Carolina, United States|Teva Investigational Site 13574, Greensboro, North Carolina, United States|Teva Investigational Site 13545, Raleigh, North Carolina, United States|Teva Investigational Site 13609, Akron, Ohio, United States|Teva Investigational Site 13625, Akron, Ohio, United States|Teva Investigational Site 13634, Akron, Ohio, United States|Teva Investigational Site 13533, Cincinnati, Ohio, United States|Teva Investigational Site 13624, Cincinnati, Ohio, United States|Teva Investigational Site 13569, Cleveland, Ohio, United States|Teva Investigational Site 13626, Columbus, Ohio, United States|Teva Investigational Site 13561, Oklahoma City, Oklahoma, United States|Teva Investigational Site 13601, Eugene, Oregon, United States|Teva Investigational Site 13591, Jenkintown, Pennsylvania, United States|Teva Investigational Site 13554, Philadelphia, Pennsylvania, United States|Teva Investigational Site 13608, Uniontown, Pennsylvania, United States|Teva Investigational Site 13615, Greer, South Carolina, United States|Teva Investigational Site 13556, Mount Pleasant, South Carolina, United States|Teva Investigational Site 13560, Bristol, Tennessee, United States|Teva Investigational Site 13551, Memphis, Tennessee, United States|Teva Investigational Site 13532, Nashville, Tennessee, United States|Teva Investigational Site 13552, Nashville, Tennessee, United States|Teva Investigational Site 13541, Austin, Texas, United States|Teva Investigational Site 13623, Dallas, Texas, United States|Teva Investigational Site 13611, Plano, Texas, United States|Teva Investigational Site 13572, San Antonio, Texas, United States|Teva Investigational Site 13614, Murray, Utah, United States|Teva Investigational Site 13581, West Jordan, Utah, United States|Teva Investigational Site 13630, Virginia Beach, Virginia, United States|Teva Investigational Site 13564, Seattle, Washington, United States|Teva Investigational Site 13586, Seattle, Washington, United States|Teva Investigational Site 13600, Morgantown, West Virginia, United States|Teva Investigational Site 11124, Hamilton, Ontario, Canada|Teva Investigational Site 11122, Newmarket, Ontario, Canada|Teva Investigational Site 11120, Calgary, Canada|Teva Investigational Site 11121, Montreal, Canada|Teva Investigational Site 11123, Sarnia, Canada|Teva Investigational Site 54144, Brno, Czechia|Teva Investigational Site 54141, Kunratice, Czechia|Teva Investigational Site 54145, Pardubice, Czechia|Teva Investigational Site 54142, Prague 4, Czechia|Teva Investigational Site 54146, Praha 3, Czechia|Teva Investigational Site 54143, Praha, Czechia|Teva Investigational Site 40018, Helsinki, Finland|Teva Investigational Site 40017, Helsinki, Finland|Teva Investigational Site 40016, Turku, Finland|Teva Investigational Site 80096, Holon, Israel|Teva Investigational Site 80099, Jerusalem, Israel|Teva Investigational Site 80098, Nahariya, Israel|Teva Investigational Site 80097, Netanya, Israel|Teva Investigational Site 80100, Ramat Gan, Israel|Teva Investigational Site 80095, Tel Aviv, Israel|Teva Investigational Site 84072, Chofu-shi, Japan|Teva Investigational Site 84066, Kagoshima-shi, Japan|Teva Investigational Site 84069, Kai, Japan|Teva Investigational Site 84073, Kawasaki, Japan|Teva Investigational Site 84067, Kyoto, Japan|Teva Investigational Site 84062, Osaka-shi, Japan|Teva Investigational Site 84070, Saitama, Japan|Teva Investigational Site 84061, Sendai-shi, Japan|Teva Investigational Site 84063, Shinjuku-ku, Japan|Teva Investigational Site 84068, Shizuoka, Japan|Teva Investigational Site 84065, Tochigi, Japan|Teva Investigational Site 84064, Tokyo, Japan|Teva Investigational Site 84071, Toyonaka, Japan|Teva Investigational Site 53364, Krakow, Poland|Teva Investigational Site 53363, Krakow, Poland|Teva Investigational Site 53366, Lublin, Poland|Teva Investigational Site 53365, Poznan, Poland|Teva Investigational Site 53367, Warsaw, Poland|Teva Investigational Site 50399, Kazan, Russian Federation|Teva Investigational Site 50395, Kazan, Russian Federation|Teva Investigational Site 50394, Moscow, Russian Federation|Teva Investigational Site 50400, Moscow, Russian Federation|Teva Investigational Site 50398, Nizhniy Novgorod, Russian Federation|Teva Investigational Site 50396, Nizhniy Novgorod, Russian Federation|Teva Investigational Site 50397, Ufa, Russian Federation|Teva Investigational Site 31207, Madrid, Spain|Teva Investigational Site 31208, Pamplona, Spain|Teva Investigational Site 31205, Valladolid, Spain|Teva Investigational Site 31206, Zaragoza, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02638103/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02638103/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02638103
3,NCT02956486,A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease,MissionAD1,Terminated,Has Results,Alzheimer's Disease,Drug: Elenbecestat|Drug: Placebo,Core Phase: Change From Baseline up to Month 24 in the Clinical Dementia Rating-sum of Boxes (CDR-SB) Score|Extension Phase: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)|Core Phase: Change From Baseline up to Month 24 in Alzheimer's Disease Composite Score (ADCOMS)|Core Phase: Change From Baseline up to Month 24 in Amyloid Positron Emission Tomography (PET) Standardized Uptake Value Ratio (SUVR)|Core Phase: Change From Baseline up to Month 24 in the CDR-SB Score for Participants Enriched by Baseline Amyloid PET SUVR Between 1.2 and 1.6|Core Phase: Change From Baseline up to Month 24 in the ADCOMS for Participants Enriched by Baseline Amyloid PET SUVR Between 1.2 and 1.6|Core Phase: Change Per Year (Mean Slope) in CDR-SB Score up to Month 24|Core Phase: Time to Worsening of CDR Score up to Month 24|Core Phase: Time to Conversion to Dementia for Participants Who Were Not Clinically Staged as Having Dementia at the Core Phase Baseline up to Month 24|Core Phase: Change From Baseline up to Month 24 in the Alzheimer's Disease Assessment Scale-cognition14 (ADAS-Cog14) Score|Core Phase: Change From Baseline up to Month 24 in the MMSE Score|Core Phase: Change From Baseline up to Month 24 in the Functional Assessment Questionnaire (FAQ) Score|Core Phase: Change From Baseline up to Month 24 in the ADAS-cog14 Word List (Immediate Recall and Delayed Recall) Score|Core Phase: Change From Baseline up to Month 24 in the Alzheimer's Disease Assessment Scale-cognition11 (ADAS-Cog11) Score|Core Phase: Change From Last Dose in the CDR-SB Score|Core Phase: Change From Last Dose in the ADCOMS|Core Phase: Change From Last Dose in the ADAS-cog11 Score|Core Phase: Change From Last Dose in the ADAS-cog14 Score|Core Phase: Change From Last Dose in the MMSE Score|Core Phase: Change From Last Dose in the ADAS-cog14 Word List (Immediate Recall and Delayed Recall) Score|Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in CDR-SB Score|Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in ADCOMS|Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in MMSE Score|Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in FAQ Score|Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in ADAS-cog14 Score|Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in ADAS-cog14 Word List (Immediate Recall and Delayed Recall) Score|Extension Phase: Time to Conversion to Dementia for Participants Who Were Not Clinically Staged as Having Dementia at the Core Phase Baseline up to Month 12 of the Extension Phase,"Eisai Co., Ltd.|Biogen|Eisai Inc.",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,2212,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",E2609-G000-301|2016-003928-23|2016-004128-42,"October 20, 2016","January 15, 2020","January 15, 2020","November 6, 2016","February 3, 2021","February 3, 2021","Facility #1, Chandler, Arizona, United States|Facility #1, Colton, California, United States|Facility #1, Costa Mesa, California, United States|Facility #1, Fullerton, California, United States|Facility #1, Imperial, California, United States|Facility #1, Irvine, California, United States|Facility #1, Lemon Grove, California, United States|Facility #1, Oceanside, California, United States|Facility #2, Oceanside, California, United States|Facility #1, Oxnard, California, United States|Facility #1, Panorama City, California, United States|Facility #1, San Diego, California, United States|Facility #1, Denver, Colorado, United States|Facility #1, Atlantis, Florida, United States|Facility #1, Aventura, Florida, United States|Facility #2, Aventura, Florida, United States|Facility #1, Boynton Beach, Florida, United States|Facility #1, Coral Gables, Florida, United States|Facility #2, Coral Gables, Florida, United States|Facility #1, Delray Beach, Florida, United States|Facility #1, Doral, Florida, United States|Facility #1, Hialeah, Florida, United States|Facility #2, Miami, Florida, United States|Facility #11, Miami, Florida, United States|Facility #9, Miami, Florida, United States|Facility #10, Miami, Florida, United States|Facility #4, Miami, Florida, United States|Facility #1, Miami, Florida, United States|Facility #6, Miami, Florida, United States|Facility #3, Miami, Florida, United States|Facility #7, Miami, Florida, United States|Facility #8, Miami, Florida, United States|Facility #2, Orlando, Florida, United States|Facility #1, Orlando, Florida, United States|Facility #3, Orlando, Florida, United States|Facility #1, Palm Beach Gardens, Florida, United States|Facility #1, Pompano Beach, Florida, United States|Facility #1, Port Charlotte, Florida, United States|Facility #1, Port Orange, Florida, United States|Facility #1, Spring Hill, Florida, United States|Facility #1, Tampa, Florida, United States|Facility #2, Tampa, Florida, United States|Facility #1, The Villages, Florida, United States|Facility #1, Atlanta, Georgia, United States|Facility #1, Columbus, Georgia, United States|Facility #1, Decatur, Georgia, United States|Facility #1, Suwanee, Georgia, United States|Facility #1, Meridian, Idaho, United States|Facility #1, Northbrook, Illinois, United States|Facility #2, Wichita, Kansas, United States|Facility #1, Boston, Massachusetts, United States|Facility #1, Farmington Hills, Michigan, United States|Facility #1, Chesterfield, Missouri, United States|Facility #1, O'Fallon, Missouri, United States|Facility #2, Saint Louis, Missouri, United States|Facility #1, Saint Peters, Missouri, United States|Facility #1, Mount Arlington, New Jersey, United States|Facility #2, Springfield, New Jersey, United States|Facility #1, West Long Branch, New Jersey, United States|Facility #1, Amherst, New York, United States|Facility #1, Brooklyn, New York, United States|Facility #1, New York, New York, United States|Facility #1, Canton, Ohio, United States|Facility #1, Centerville, Ohio, United States|Facility #1, Cleveland, Ohio, United States|Facility #1, Dayton, Ohio, United States|Facility #1, Lakewood, Ohio, United States|Facility #1, Westerville, Ohio, United States|Facility #1, Oklahoma City, Oklahoma, United States|Facility #1, Portland, Oregon, United States|Facility #1, Jenkintown, Pennsylvania, United States|Facility #1, Media, Pennsylvania, United States|Facility #1, Philadelphia, Pennsylvania, United States|Facility #1, East Providence, Rhode Island, United States|Facility #1, Providence, Rhode Island, United States|Facility #1, Port Royal, South Carolina, United States|Facility #1, Cordova, Tennessee, United States|Facility #2, Nashville, Tennessee, United States|Facility #1, Nashville, Tennessee, United States|Facility #1, Austin, Texas, United States|Facility #1, Dallas, Texas, United States|Facility #1, Houston, Texas, United States|Facility #1, San Antonio, Texas, United States|Facility #3, San Antonio, Texas, United States|Facility #1, Salt Lake City, Utah, United States|Facility #1, Bennington, Vermont, United States|Facility #1, Hampton, Virginia, United States|Facility #1, Madison, Wisconsin, United States|Facility #2, Caba, Buenos Aires, Argentina|Facility #1, Caba, Buenos Aires, Argentina|Facility #4, Caba, Buenos Aires, Argentina|Facility #3, Caba, Buenos Aires, Argentina|Facility #1, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Facility #3, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Facility #2, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Facility #1, Cordoba, Capital, Argentina|Facility #1, Rosario, Santa Fe, Argentina|Facility #4, Buenos Aires, Argentina|Facility #5, Caba, Argentina|Facility #2, Cordoba, Argentina|Facility #3, Cordoba, Argentina|Facility #1, Santa Fe, Argentina|Facility #1, Darlinghurst, New South Wales, Australia|Facility #1, Macquarie Park, New South Wales, Australia|Facility #1, Tumbi Umbi, New South Wales, Australia|Facility #1, Brisbane, Queensland, Australia|Facility #1, Caulfield, Victoria, Australia|Facility #1, Geelong, Victoria, Australia|Facility #1, Heidelberg, Victoria, Australia|Facility #1, Malvern, Victoria, Australia|Facility #2, Melbourne, Victoria, Australia|Facility #1, Parkville, Victoria, Australia|Facility #1, Nedlands, Western Australia, Australia|Facility #3, Melbourne, Australia|Facility #1, Vienna, Austria|Facility #1, Pleven, Bulgaria|Facility #1, Plovdiv, Bulgaria|Facility #1, Ruse, Bulgaria|Facility #4, Sofia, Bulgaria|Facility #3, Sofia, Bulgaria|Facility #1, Sofia, Bulgaria|Facility #2, Sofia, Bulgaria|Facility #1, Kamloops, British Columbia, Canada|Facility #1, Kelowna, British Columbia, Canada|Facility #1, West Vancouver, British Columbia, Canada|Facility #1, Halifax, Nova Scotia, Canada|Facility #1, Kentville, Nova Scotia, Canada|Facility #1, Ottawa, Ontario, Canada|Facility #1, Peterborough, Ontario, Canada|Facility #1, Montreal, Quebec, Canada|Facility #1, Sherbrooke, Quebec, Canada|Facility #1, Hradec Kralove, Czechia|Facility #1, Kladno, Czechia|Facility #1, Olomouc, Czechia|Facility #1, Praha 10, Czechia|Facility #1, Montpellier, Herault, France|Facility #1, Bordeaux, France|Facility #1, Bron Cedex, France|Facility #1, Marseille Cedex 05, France|Facility #1, Nantes, France|Facility #1, Paris, France|Facility #1, Rouen, France|Facility #1, Toulouse, France|Facility #1, Neuburg, Bayern, Germany|Facility #1, Hoppegarten, Brandenburg, Germany|Facility #1, Oranienburg, Brandenburg, Germany|Facility #1, Frankfurt, Hessen, Germany|Facility #1, Leipzig, Saxony, Germany|Facility #1, Berlin, Germany|Facility #2, Berlin, Germany|Facility #1, Gera, Germany|Facility #1, Homburg/Saar, Germany|Facility #1, Schwerin, Germany|Facility #5, Athens, Greece|Facility #4, Athens, Greece|Eisai Trial Site 1, Anjo-shi, Aichi, Japan|Eisai Trial Site 1, Nagoya-shi, Aichi, Japan|Eisai Trial Site 1, Obu-shi, Aichi, Japan|Eisai Trial Site 1, Yoshida-gun, Fukui, Japan|Eisai Trail Site 1, Kitakyushu-shi, Fukuoka, Japan|Eisai Trial Site 1, Omuta-shi, Fukuoka, Japan|Eisai Trial Site 1, Fujioka-shi, Gunma, Japan|Eisai Trial Site 1, Otake-shi, Hiroshima, Japan|Eisai Trial Site 2, Himeji-shi, Hyogo, Japan|Eisai Trial Site 1, Himeji, Hyogo, Japan|Eisai Trial Site 1, Kobe, Hyogo, Japan|Facility #1, Miki, Kagawa, Japan|Eisai Trial Site 3, Takamatsu City, Kagawa, Japan|Eisai Trial Site 1, Fujisawa-shi, Kanagawa, Japan|Eisai Trial Site 4, Kyoto City, Kyoto, Japan|Eisai Trial Site 1, Kyoto-shi, Kyoto, Japan|Eisai Trial Site 2, Kyoto-shi, Kyoto, Japan|Eisai Trial site 5, Kyoto-shi, Kyoto, Japan|Eisai Trial Site 1, Shimogyo-ku, Kyoto, Japan|Eisai Trial Site 1, Higashimorokatagun, Miyazaki, Japan|Eisai Trial Site 2, Okayama-shi, Okayama-ken, Japan|Eisai Trial Site 1, Kurashiki-shi, Okayama, Japan|Eisai Trial Site 2, Kurashiki-shi, Okayama, Japan|Eisai Trial Site 1, Okayama-shi, Okayama, Japan|Eisai Trial Site 1, Hirakata, Osaka, Japan|Eisai Trial Site 1, Naniwa-Ku, Osaka, Japan|Eisai Trial Site 1, Osaka-shi, Osaka, Japan|Eisai Trial Site 3, Osaka-shi, Osaka, Japan|Eisai Trial Site 2, Osaka-shi, Osaka, Japan|Eisai Trial site 2, Sakai-shi, Osaka, Japan|Eisai Trial Site 1, Suita-shi, Osaka, Japan|Eisai Trial Site 2, Suita-shi, Osaka, Japan|Eisai Trial Site 1, Suminoe-ku, Osaka, Japan|Eisai Trial Site 1, Kanzaki-gun, Saga, Japan|Eisai Trial Site 1, Otsu-shi, Shiga, Japan|Eisai Trial Site 2, Otsu, Shiga, Japan|Eisai Trial Site 1, Tokushima-shi, Tokushima, Japan|Eisai Trial Site 1, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site 2, Bunkyo-ku, Tokyo, Japan|Eisai Trial Site 1, Kodaira-shi, Tokyo, Japan|Eisai Trial Site 1, Minato-ku, Tokyo, Japan|Eisai Trial Site 1, Setagaya-ku, Tokyo, Japan|Eisai Trial Site 1, Shinjuku-ku, Tokyo, Japan|Eisai Trial Site 1, Sumida-ku, Tokyo, Japan|Eisai Trial Site 1, Hofu-shi, Yamaguchi, Japan|Eisai Trial Site 1, Kumamoto, Japan|Eisai Trial Site 3, Kyoto, Japan|Eisai Trial Site 1, Osaka, Japan|Facility #1, Bucheon-si, Gyeonggi-do, Korea, Republic of|Facility #1, Seongnam, Gyeonggi, Korea, Republic of|Facility #1, Busan, Korea, Republic of|Facility #1, Incheon, Korea, Republic of|Facility #5, Seoul, Korea, Republic of|Facility #3, Seoul, Korea, Republic of|Facility #1, Seoul, Korea, Republic of|Facility #4, Seoul, Korea, Republic of|Facility #6, Seoul, Korea, Republic of|Facility #2, Seoul, Korea, Republic of|Facility #1, Katowice, Poland|Facility #1, Kielce, Poland|Facility #1, Krakow, Poland|Facility #1, Poznari, Poland|Facility #1, Poznań, Poland|Facility #1, Siemianowice Śląskie, Poland|Facility #1, Warszawa, Poland|Facility #1, Guimarães, Portugal|Facility #1, Moscow, Russian Federation|Facility #1, Bratislava, Slovakia|Facility #1, Elche, Alicante, Spain|Facility #1, Sant Cugat Del Valles, Barcelona, Spain|Facility #1, Getxo, Bizkaia, Spain|Facility #1, Donostia/San Sebastian, Gipuzkoa, Spain|Facility #1, Palma de Mallorca, Illes Balears, Spain|Facility #1, El Palmar, Murcia, Spain|Facility #1, Barcelona, Spain|Facility #2, Madrid, Spain|Facility #1, Madrid, Spain|Facility #1, Valencia, Spain|Facility #2, Valencia, Spain|Facility #1, Cambridge, Cambridgeshire, United Kingdom|Facility #1, Chester, Cheshire, United Kingdom|Facility #1, Winwick, Warrington, Cheshire, United Kingdom|Facility #1, Plymouth, Devon, United Kingdom|Facility #1, Bournemouth, Dorset, United Kingdom|Facility #1, Crowborough, East Sussex, United Kingdom|Facility #1, Manchester, Greater Manchester, United Kingdom|Facility #1, Southampton, Hampshire, United Kingdom|Facility #1, Glasgow, Lanarkshire, United Kingdom|Facility #1, Blackpool, Lancashire, United Kingdom|Facility #1, Preston, Lancashire, United Kingdom|Facility #2, London, Middlesex, United Kingdom|Facility #1, Bath, North East Somerset, United Kingdom|Facility #1, Oxford, Oxfordshire, United Kingdom|Facility #1, Aberdeen, Scotland, United Kingdom|Facility #1, Sheffield, South Yorkshire, United Kingdom|Facility #1, Leatherhead, Surrey, United Kingdom|Facility #1, Birmingham, West Midlands, United Kingdom|Facility #1, Swindon, Wilts, United Kingdom|Facility #2, Glasgow, United Kingdom|Facility #1, Guildford, United Kingdom|Facility #1, London, United Kingdom|Facility #4, London, United Kingdom|Facility #3, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02956486/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02956486/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02956486
4,NCT00762411,"Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo",IDENTITY-2,Completed,Has Results,Alzheimer's Disease,Drug: LY450139|Drug: Placebo,Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks|Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 16 Weeks After Cessation of Study Drug|Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) at 76 Weeks|Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) at 16 Weeks After Cessation of Study Drug|Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) at 76 Weeks|Change From Baseline in Neuropsychiatric Inventory (NPI) at 76 Weeks|Change From Baseline in the Resource Utilization in Dementia-Lite (RUD-Lite) up to 76 Weeks|Change From Baseline in the EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) at 76 Weeks|Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) at 76 Weeks|Change From Baseline in Mini Mental State Examination (MMSE) at 76 Weeks|Percent Change From Baseline in Amyloid Beta (Aβ) 1-42 Plasma Concentration at 52 Weeks|Change From Baseline in Positron Emission Tomography (PET) Using Fluorine-18 Fluorodeoxyglucose (18F-FDG) at 76 Weeks|Change From Baseline in Hippocampal Volume Using Volumetric Magnetic Resonance Imaging (vMRI) up to 76 Weeks|Change From Baseline in Amyloid Imaging Positron Emission Tomography (AV-45 PET) up to 76 Weeks|Change From Baseline in Tau Concentration in Spinal Fluid up to 76 Weeks|LY450139 Population Pharmacokinetics: Clearance of LY450139|LY450139 Population Pharmacokinetics: Volume of Distribution of LY450139|Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) at 4 Weeks After Cessation of Study Drug|Change From Baseline in Neuropsychiatric Inventory (NPI) at 4 Weeks After Cessation of Study Drug|Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) at 4 Weeks After Cessation of Study Drug|Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) at 4 Weeks After Cessation of Study Drug|Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) at 4 Weeks After Cessation of Study Drug|Change From Baseline in Mini Mental State Examination (MMSE) 4 Weeks After Cessation of Study Drug|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) at 76 Weeks|Change From Baseline in Alzheimer's Disease Assessment Scale (ADAS-Cog14) at 76 Weeks|Change From Baseline in Phosphorylated-Tau (P-tau) Concentration in Spinal Fluid up to 76 Weeks|Change From Baseline in Amyloid Beta (Aβ) 1-42 Concentration in Spinal Fluid up to 76 Weeks|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) at 16 Weeks After Cessation of Study Drug|Change From Baseline in Alzheimer's Disease Assessment Scale (ADAS-Cog14) at 16 Weeks After Cessation of Study Drug,Eli Lilly and Company,All,"55 Years and older   (Adult, Older Adult)",Phase 3,1111,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11271|H6L-MC-LFBC,September 2008,April 2011,April 2011,"September 30, 2008","September 25, 2014","February 16, 2015","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Costa Mesa, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Jolla, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Laguna Hills, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oxnard, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Francisco, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boca Raton, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hallandale Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Orleans, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shreveport, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hattiesburg, Mississippi, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albany, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manhasset, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio De Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salvador, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sofia, Bulgaria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winnipeg, Manitoba, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint John, New Brunswick, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ottawa, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Peterborough, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenfield Park, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Verdun, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Xi'An, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poitiers, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Esztergom, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boggiovara, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cassino, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Akita, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ibaraki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iwate, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kumamoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagasaki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saitama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suwon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aguascalientes, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saltillo, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Timisoara, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ekaterinburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kazan, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saratov, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belgrade, Serbia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kragujevac, Serbia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changhua, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eskisehir, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Istanbul, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Samsun, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dnipropetrovsk, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Donetsk, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kherson, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyiv, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Odesa, Ukraine",NA,https://ClinicalTrials.gov/show/NCT00762411
5,NCT00594568,Effect of LY450139 on the Long Term Progression of Alzheimer's Disease,NA,Completed,Has Results,Alzheimer's Disease,Drug: LY450139|Drug: Placebo,Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 16 Weeks After Cessation of Study Drug|Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score at 76 Weeks|Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score at 16 Weeks After Cessation of Study Drug|Percent Change From Baseline in Amyloid Beta (Aβ) 1-42 Plasma Concentration at 52 Weeks|Change From Baseline in Positron Emission Tomography (PET) Using Fluorine-18 Fluorodeoxyglucose (18F-FDG) at 76 Weeks|Change From Baseline in Hippocampal Volume Using Volumetric Magnetic Resonance Imaging (vMRI) up to 76 Weeks|Change From Baseline in Amyloid Imaging Positron Emission Tomography (AV-45 PET) up to 76 Weeks|Change From Baseline in Tau Concentration in Spinal Fluid up to 76 Weeks|LY450139 Population Pharmacokinetics: Clearance of LY450139|LY450139 Population Pharmacokinetics: Volume of Distribution of LY450139|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) Score at 76 Weeks|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score at 76 Weeks|Change From Baseline in Mini Mental State Examination (MMSE) Score at 76 Weeks|Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at 76 Weeks|Change From Baseline in Neuropsychiatric Inventory (NPI) Score at 76 Weeks|Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) Score at 76 Weeks|Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) Score (Number of Hospitalizations) up to 76 Weeks|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) Score at 16 Weeks After Cessation of Study Drug|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score at 16 Weeks After Cessation of Study Drug|Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at 4 Weeks After Cessation of Study Drug|Change From Baseline in Neuropsychiatric Inventory (NPI) Score at 4 Weeks After Cessation of Study Drug|Change From Baseline in Mini Mental State Examination (MMSE) Score at 4 Weeks After Cessation of Study Drug|Change From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) Score at 4 Weeks After Cessation of Study Drug|Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) Score (Number of Hospitalizations) at 4 Weeks After Cessation of Study Drug|Change From Baseline in Amyloid Beta (Aβ) 1-42 Concentration in Spinal Fluid up to 76 Weeks|Change From Baseline in Phosphorylated-Tau (P-Tau) Concentration in Spinal Fluid,Eli Lilly and Company,All,"55 Years and older   (Adult, Older Adult)",Phase 3,1537,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",7666|H6L-MC-LFAN|CTRI/2009/091/000090,March 2008,May 2011,May 2011,"January 15, 2008","September 25, 2014","March 17, 2015","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sun City, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fresno, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lomita, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orange, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sacramento, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Monica, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamden, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Washington, District of Columbia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brooksville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Lauderdale, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pompano Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Petersburg, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sunrise, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa Bay, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shreveport, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Burlington, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Yarmouth, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kansas City, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albany, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winston-Salem, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbus, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toledo, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eugene, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jenkintown, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pittsburgh, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., East Providence, Rhode Island, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., North Charleston, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bennington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cordoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Fe, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hornsby, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kogarah, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Randwick, Sydney, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Adelaide, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Geelong, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg West, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kew, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nedlands, Western Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aalst, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Antwerp, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brugge, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kelowna, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Penticton, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherbrooke, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Antofagasta, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Concepcion, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santiago De Chile, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santiago, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valdivia, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vina Del Mar, Chile|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kobenhavn, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roskilde, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Svendborg, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kuopio, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mikkeli, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oulu, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nice, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rouen, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tours, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goettingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Muenchen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Regensburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Siegen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chennai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyderabaad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kolkatta, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mangalore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thiruvananthapuram, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tirupati, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Varanasi, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ashkelon, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beer Sheva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jerusalem, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Petah Tikva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Aviv, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukui, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kochi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokushima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bialystok, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdynia, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lodz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellair, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellville, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cape Town, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., George, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Johannesburg, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosebank, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Somerset West, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Umhlanga, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albacete, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barakaldo, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plasencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmo, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Molndal, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Norrköping, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockholm, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uddevalla, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bath, Banes, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Southampton, Hants, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liverpool, Merseyside, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glasgow, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Swindon, Wilts, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belfast, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newcastle, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stoke-On-Trent, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT00594568
6,NCT04163185,Initiating Early Control of Migraine Pain and Associated Symptoms,INTERCEPT,Completed,No Results Available,Migraine,Drug: AXS-07 (MoSEIC meloxicam and rizatriptan)|Drug: Placebo,Percentage of subjects reporting headache pain freedom|Percentage of subjects with absence of Most Bothersome Symptom,"Axsome Therapeutics, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,302,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AXS-07-303,"October 8, 2019","March 23, 2020","March 23, 2020","November 14, 2019",NA,"April 30, 2021","Clinical Research Site, Birmingham, Alabama, United States|Clinical Research Site, Birmingham, Alabama, United States|Clinical Research Site, Mobile, Alabama, United States|Clinical Research Site, Colton, California, United States|Clinical Research Site, Encino, California, United States|Clinical Research Site, Los Alamitos, California, United States|Clinical Research Site, Los Angeles, California, United States|Clinical Research Site, Redlands, California, United States|Clinical Research Site, Santa Monica, California, United States|Clinical Research Site, Spring Valley, California, United States|Clinical Research Site, Walnut Creek, California, United States|Clinical Research Site, Hallandale Beach, Florida, United States|Clinical Research Site, Jacksonville, Florida, United States|Clinical Research Site, Lake City, Florida, United States|Clinical Research Site, Lake Worth, Florida, United States|Clinical Research Site, Ocoee, Florida, United States|Clinical Research Site, Orlando, Florida, United States|Clinical Research Site, Ormond Beach, Florida, United States|Clinical Research Site, South Miami, Florida, United States|Clinical Research Site, Sunrise, Florida, United States|Clinical Research Site, Tampa, Florida, United States|Clinical Research Site, Stockbridge, Georgia, United States|Clinical Research Site, Evanston, Illinois, United States|Clinical Research Site, Louisville, Kentucky, United States|Clinical Research Site, Boston, Massachusetts, United States|Clinical Research Site, Waltham, Massachusetts, United States|Clinical Research Site, Ann Arbor, Michigan, United States|Clinical Research Site, Springfield, Missouri, United States|Clinical Research Site, Albuquerque, New Mexico, United States|Clinical Research Site, Manlius, New York, United States|Clinical Research Site, Williamsville, New York, United States|Clinical Research Site, High Point, North Carolina, United States|Clinical Research Site, Oklahoma City, Oklahoma, United States|Clinical Research Site, Philadelphia, Pennsylvania, United States|Clinical Research Site, Charleston, South Carolina, United States|Clinical Research Site, Mount Pleasant, South Carolina, United States|Clinical Research Site, Memphis, Tennessee, United States|Clinical Research Site, Nashville, Tennessee, United States|Clinical Research Site, Austin, Texas, United States|Clinical Research Site, Salt Lake City, Utah, United States|Clinical Research Site, Charlottesville, Virginia, United States",NA,https://ClinicalTrials.gov/show/NCT04163185
7,NCT03896009,Maximizing Outcomes in Treating Acute Migraine,MOMENTUM,Completed,No Results Available,Migraine,Drug: AXS-07 (MoSEIC meloxicam and rizatriptan)|Drug: Meloxicam|Drug: Rizatriptan|Drug: Placebo,Percentage of subjects reporting headache pain freedom|Percentage of subjects with absence of Most Bothersome Symptom|Percentage of subjects reporting sustained headache pain freedom|Percentage of subjects reporting headache pain relief,"Axsome Therapeutics, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,1594,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AXS-07-301,"March 4, 2019","December 10, 2019","December 10, 2019","March 29, 2019",NA,"April 26, 2021","Clinical Research Site, Birmingham, Alabama, United States|Clinical Research Site, Birmingham, Alabama, United States|Clinical Research Site, Mobile, Alabama, United States|Clinical Research Site, Phoenix, Arizona, United States|Clinical Research Site, Tempe, Arizona, United States|Clinical Research Site, Little Rock, Arkansas, United States|Clinical Research Site, Canoga Park, California, United States|Clinical Research Site, Colton, California, United States|Clinical Research Site, Culver City, California, United States|Clinical Research Site, Encino, California, United States|Clinical Research Site, Los Alamitos, California, United States|Clinical Research Site, Los Angeles, California, United States|Clinical Research Site, Oceanside, California, United States|Clinical Research Site, Pomona, California, United States|Clinical Research Site, Redlands, California, United States|Clinical Research Site, Riverside, California, United States|Clinical Research Site, San Diego, California, United States|Clinical Research Site, Santa Monica, California, United States|Clinical Research Site, Spring Valley, California, United States|Clinical Research Site, Walnut Creek, California, United States|Clinical Research Site, Waterbury, Connecticut, United States|Clinical Research Site, Clermont, Florida, United States|Clinical Research Site, DeLand, Florida, United States|Clinical Research Site, Fernandina Beach, Florida, United States|Clinical Research Site, Hallandale Beach, Florida, United States|Clinical Research Site, Hialeah, Florida, United States|Clinical Research Site, Hollywood, Florida, United States|Clinical Research Site, Jacksonville, Florida, United States|Clinical Research Site, Lake City, Florida, United States|Clinical Research Site, Lake Worth, Florida, United States|Clinical Research Site, Miami, Florida, United States|Clinical Research Site, Ocoee, Florida, United States|Clinical Research Site, Orange City, Florida, United States|Clinical Research Site, Orlando, Florida, United States|Clinical Research Site, Ormond Beach, Florida, United States|Clinical Research Site, South Miami, Florida, United States|Clinical Research Site, Sunrise, Florida, United States|Clinical Research Site, Tampa, Florida, United States|Clinical Research Site, Atlanta, Georgia, United States|Clinical Research Site, Atlanta, Georgia, United States|Clinical Research Site, Stockbridge, Georgia, United States|Clinical Research Site, Meridian, Idaho, United States|Clinical Research Site, Evanston, Illinois, United States|Clinical Research Site, Lenexa, Kansas, United States|Clinical Research Site, Lexington, Kentucky, United States|Clinical Research Site, Louisville, Kentucky, United States|Clinical Research Site, New Orleans, Louisiana, United States|Clinical Research Site, Boston, Massachusetts, United States|Clinical Research Site, North Dartmouth, Massachusetts, United States|Clinical Research Site, Watertown, Massachusetts, United States|Clinical Research Site, Ann Arbor, Michigan, United States|Clinical Research Site, Minneapolis, Minnesota, United States|Clinical Research Site, Kansas City, Missouri, United States|Clinical Research Site, Springfield, Missouri, United States|Clinical Research Site, Las Vegas, Nevada, United States|Clinical Research Site, Berlin, New Jersey, United States|Clinical Research Site, Toms River, New Jersey, United States|Clinical Research Site, Albuquerque, New Mexico, United States|Clinical Research Site, Bronx, New York, United States|Clinical Research Site, Endwell, New York, United States|Clinical Research Site, Manlius, New York, United States|Clinical Research Site, New York, New York, United States|Clinical Research Site, Rochester, New York, United States|Clinical Research Site, Williamsville, New York, United States|Clinical Research Site, High Point, North Carolina, United States|Clinical Research Site, Wilmington, North Carolina, United States|Clinical Research Site, Cincinnati, Ohio, United States|Clinical Research Site, Cleveland, Ohio, United States|Clinical Research Site, Dublin, Ohio, United States|Clinical Research Site, Oklahoma City, Oklahoma, United States|Clinical Research Site, Portland, Oregon, United States|Clinical Research Site, Salem, Oregon, United States|Clinical Research Site, Philadelphia, Pennsylvania, United States|Clinical Research Site, Charleston, South Carolina, United States|Clinical Research Site, Mount Pleasant, South Carolina, United States|Clinical Research Site, Knoxville, Tennessee, United States|Clinical Research Site, Memphis, Tennessee, United States|Clinical Research Site, Nashville, Tennessee, United States|Clinical Research Site, Austin, Texas, United States|Clinical Research Site, San Antonio, Texas, United States|Clinical Research Site, Salt Lake City, Utah, United States|Clinical Research Site, Charlottesville, Virginia, United States|Clinical Research Site, Norfolk, Virginia, United States|Clinical Research Site, Bellevue, Washington, United States|Clinical Research Site, Seattle, Washington, United States",NA,https://ClinicalTrials.gov/show/NCT03896009
8,NCT03872453,Acute Treatment Trial in Adult Subjects With Migraines,NA,Completed,Has Results,Migraine,Drug: Zavegepant|Drug: Zavegepant matching placebo|Device: Intranasal Aptar Pharma Unit Dose System,Percentage of Participants With Freedom From Pain at 2 Hours Post-dose|Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose|Percentage of Participants With Pain Relief at 2 Hours Post-dose|Percentage of Participants Who Were Able to Function Normally at 2 Hours Post-dose|Percentage of Participants With Rescue Medication Use Within 24 Hours Post-dose|Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose|Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose|Percentage of Participants With Pain Relief at 60 Minutes Post-dose|Percentage of Participants Who Were Able to Function Normally at 60 Minutes Post-dose|Percentage of Participants With Pain Relief at 30 Minutes Post-dose|Percentage of Participants Who Were Able to Function Normally at 30 Minutes Post-dose|Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose|Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose|Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose|Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose|Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose|Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose,"Biohaven Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,2154,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",BHV3500-201,"March 25, 2019","October 31, 2019","November 11, 2019","March 13, 2019","October 13, 2022","December 20, 2022","Coastal Clinical Research, Inc., Mobile, Alabama, United States|Elite Clinical Studies, Phoenix, Arizona, United States|Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States|Pharmacology Research Institute, Encino, California, United States|eStudySite, La Mesa, California, United States|Synergy San Diego, Lemon Grove, California, United States|Collaborative Neuroscience Network, LLC, Long Beach, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|National Research Institute, Panorama City, California, United States|Optimus Medical Group, San Francisco, California, United States|Neurological Research Institute, Santa Monica, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Denver Neurological Research, LLC, Denver, Colorado, United States|CT Clinical Research, Cromwell, Connecticut, United States|Ki Health Partners, LLC, dba New England Institute for Clinical Research, Stamford, Connecticut, United States|MD Clinical, Hallandale Beach, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Multi-Specialty Research Associates, Inc., Lake City, Florida, United States|AGA Clinical Trials, Miami, Florida, United States|Qps Mra, Llc, Miami, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Ormond Medical Arts Pharmaceutical Research Center, Ormond Beach, Florida, United States|Meridien Research, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Meridian Clinical Research, Savannah, Georgia, United States|Family Medicine Specialists/CIS, Wauconda, Illinois, United States|Phoenix Medical Research, Prairie Village, Kansas, United States|Crescent City Headache and Neurology Center, LLC, Chalmette, Louisiana, United States|New Orleans Center for Clinical Research, New Orleans, Louisiana, United States|DelRicht Research, New Orleans, Louisiana, United States|Boston Clinical Trials, Boston, Massachusetts, United States|Community Clinical Research Network, Marlborough, Massachusetts, United States|Regeneris Medical, North Attleboro, Massachusetts, United States|MedVadis Research Corporation, Watertown, Massachusetts, United States|Michigan Head Pain & Neurological Institute, Ann Arbor, Michigan, United States|Clinical Research Institute, Inc., Minneapolis, Minnesota, United States|Clinical Research Institute, Inc., Plymouth, Minnesota, United States|MedPharmics, LLC, Biloxi, Mississippi, United States|Center for Pharmaceutical Research, LLC, Kansas City, Missouri, United States|Meritas Health Neurology, North Kansas City, Missouri, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|StudyMetrix Research, Saint Peters, Missouri, United States|QPS Bio-Kinetic Clinical Applications, LLC, Springfield, Missouri, United States|Clinvest Research LLC, Springfield, Missouri, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|Albuquerque Clinical Trials, Inc., Albuquerque, New Mexico, United States|Dent Neurosciences Research Center, Amherst, New York, United States|Montefiore Medical Center: Headache Center, Bronx, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|Upstate Clinical Research Associates, LLC, Williamsville, New York, United States|PMG Research of Charlotte, LLC, Charlotte, North Carolina, United States|Headache Wellness Center, Greensboro, North Carolina, United States|PharmQuest, Greensboro, North Carolina, United States|PMG Research of Raleigh, LLC, Raleigh, North Carolina, United States|Wilmington Health, PLLC, Wilmington, North Carolina, United States|Hometown Urgent Care and Research, Cincinnati, Ohio, United States|Hometown Urgent Care and Research, Columbus, Ohio, United States|Hometown Urgent Care and Research, Dayton, Ohio, United States|Hightower Clinical, Oklahoma City, Oklahoma, United States|Summit Research Network (Oregon) Inc., Portland, Oregon, United States|Oregon Center for Clinical Investigations, Inc. (OCCI, Inc.), Salem, Oregon, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Meridian Clinical Research, Dakota Dunes, South Dakota, United States|Alliance for Multispecialty Research/New Orleans Center for Clinical Research/Volunteer Research, Knoxville, Tennessee, United States|Clinical Neuroscience Solutions DBA CNS Healthcare, Memphis, Tennessee, United States|Clinical Research Associates, Inc., Nashville, Tennessee, United States|FutureSearch Trials of Neurology, Austin, Texas, United States|FutureSearch Trials of Dallas, Dallas, Texas, United States|Ventavia Research Group, Fort Worth, Texas, United States|Texas Center for Drug Development, Inc., Houston, Texas, United States|Red Star Research, LLC, Lake Jackson, Texas, United States|Advanced Pharmaceutical Development Clinical Research, Magnolia, Texas, United States|Victorium Clinical Research, San Antonio, Texas, United States|Dynamed Clinical Research, Tomball, Texas, United States|Wasatch Clinical Research, LLC, Salt Lake City, Utah, United States|Charlottesville Medical Research Center, LLC, Charlottesville, Virginia, United States|Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States|Northwest Clinical Research, Bellevue, Washington, United States|Clinical Investigation Specialists, Inc., Kenosha, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT03872453/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT03872453/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03872453
9,NCT03739840,A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy,DUET,Terminated,Has Results,Drug-Resistant Epilepsy|Focal-Onset Seizures,Drug: Padsevonil|Drug: Placebo,Change in Log-transformed Observable Focal-onset Seizure Frequency From Baseline Over the 12-week Maintenance Period|Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)|Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Study Withdrawal|Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)|75% Responder Rate From Baseline Over the 12-week Maintenance Period|50% Responder Rate From Baseline Over the 12-week Maintenance Period|Percent Change in Observable Focal-onset Seizure Frequency From Baseline Over the 12-week Maintenance Period,UCB Biopharma SRL|UCB Pharma,All,"18 Years and older   (Adult, Older Adult)",Phase 3,232,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EP0092|2018-002303-33,"March 6, 2019","September 28, 2020","September 28, 2020","November 14, 2018","October 25, 2021","December 21, 2022","Ep0092 839, Chandler, Arizona, United States|Ep0092 881, Tucson, Arizona, United States|Ep0092 633, Carlsbad, California, United States|Ep0092 629, Orange, California, United States|Ep0092 845, Washington, District of Columbia, United States|Ep0092 892, Bradenton, Florida, United States|Ep0092 640, Hialeah, Florida, United States|Ep0092 641, Jacksonville, Florida, United States|Ep0092 823, Orlando, Florida, United States|Ep0092 803, Honolulu, Hawaii, United States|Ep0092 637, Urbana, Illinois, United States|Ep0092 880, Anderson, Indiana, United States|Ep0092 638, Fort Wayne, Indiana, United States|Ep0092 630, Ames, Iowa, United States|Ep0092 707, Lexington, Kentucky, United States|Ep0092 822, Baltimore, Maryland, United States|Ep0092 818, Bethesda, Maryland, United States|Ep0092 889, Boston, Massachusetts, United States|Ep0092 645, Golden Valley, Minnesota, United States|Ep0092 644, Minneapolis, Minnesota, United States|Ep0092 895, Bronx, New York, United States|Ep0092 878, Brooklyn, New York, United States|Ep0092 876, New York, New York, United States|Ep0092 893, Syracuse, New York, United States|Ep0092 890, Chapel Hill, North Carolina, United States|Ep0092 884, Charlotte, North Carolina, United States|Ep0092 642, Columbus, Ohio, United States|Ep0092 647, Oklahoma City, Oklahoma, United States|Ep0092 882, Portland, Oregon, United States|Ep0092 802, Philadelphia, Pennsylvania, United States|Ep0092 829, Charlottesville, Virginia, United States|Ep0092 639, Renton, Washington, United States|Ep0092 855, Box Hill, Australia|Ep0092 861, Camperdown, Australia|Ep0092 850, Fitzroy, Australia|Ep0092 853, Heidelberg, Australia|Ep0092 852, Melbourne, Australia|Ep0092 109, Brussels, Belgium|Ep0092 107, Ottignies, Belgium|Ep0092 080, Bihać, Bosnia and Herzegovina|Ep0092 077, Mostar, Bosnia and Herzegovina|Ep0092 075, Sarajevo, Bosnia and Herzegovina|Ep0092 082, Tuzla, Bosnia and Herzegovina|Ep0092 150, Blagoevgrad, Bulgaria|Ep0092 151, Pleven, Bulgaria|Ep0092 156, Pleven, Bulgaria|Ep0092 154, Sofia, Bulgaria|Ep0092 125, Zagreb, Croatia|Ep0092 126, Zagreb, Croatia|Ep0092 127, Zagreb, Croatia|Ep0092 128, Zagreb, Croatia|Ep0092 254, Brno, Czechia|Ep0092 258, Ostrava, Czechia|Ep0092 250, Praha 5, Czechia|Ep0092 251, Praha 6, Czechia|Ep0092 016, Aarhus, Denmark|Ep0092 015, Odense, Denmark|Ep0092 276, Tallinn, Estonia|Ep0092 277, Tallinn, Estonia|Ep0092 275, Tartu, Estonia|Ep0092 027, Tampere, Finland|Ep0092 312, Lyon, France|Ep0092 310, Paris, France|Ep0092 301, Strasbourg, France|Ep0092 365, Berlin, Germany|Ep0092 362, Bernau, Germany|Ep0092 363, Bielefeld, Germany|Ep0092 350, Frankfurt, Germany|Ep0092 368, Jena, Germany|Ep0092 357, Leipzig, Germany|Ep0092 376, Regensburg, Germany|Ep0092 425, Ioánnina, Greece|Ep0092 426, Thessaloníki, Greece|Ep0092 427, Thessaloníki, Greece|Ep0092 428, Thessaloníki, Greece|Ep0092 403, Budapest, Hungary|Ep0092 405, Debrecen, Hungary|Ep0092 404, Pécs, Hungary|Ep0092 035, Cork, Ireland|Ep0092 036, Dublin, Ireland|Ep0092 452, Milano, Italy|Ep0092 526, Asahikawa, Japan|Ep0092 501, Asaka, Japan|Ep0092 521, Bunkyō-Ku, Japan|Ep0092 525, Bunkyō-Ku, Japan|Ep0092 504, Hamamatsu, Japan|Ep0092 505, Hiroshima, Japan|Ep0092 513, Hōfu, Japan|Ep0092 507, Itami, Japan|Ep0092 531, Izumi, Japan|Ep0092 539, Kumamoto, Japan|Ep0092 533, Kure, Japan|Ep0092 514, Kyoto, Japan|Ep0092 512, Nagakute, Japan|Ep0092 515, Saitama, Japan|Ep0092 508, Sapporo, Japan|Ep0092 527, Shinagawa-Ku, Japan|Ep0092 509, Shizuoka, Japan|Ep0092 529, Yonago, Japan|Ep0092 522, Ōmura, Japan|Ep0092 530, Ōsaka-sayama, Japan|Ep0092 775, Sandvika, Norway|Ep0092 605, Katowice, Poland|Ep0092 616, Katowice, Poland|Ep0092 603, Kraków, Poland|Ep0092 614, Kraków, Poland|Ep0092 610, Lublin, Poland|Ep0092 620, Lublin, Poland|Ep0092 606, Nowa Sól, Poland|Ep0092 611, Warszawa, Poland|Ep0092 615, Wrocław, Poland|Ep0092 619, Zamość, Poland|Ep0092 618, Zgierz, Poland|Ep0092 612, Łódź, Poland|Ep0092 952, Aveiro, Portugal|Ep0092 950, Matosinhos, Portugal|Ep0092 925, Bucuresti, Romania|Ep0092 926, Bucuresti, Romania|Ep0092 927, Târgu-Mureş, Romania|Ep0092 327, Belgrade, Serbia|Ep0092 325, Novi Sad, Serbia|Ep0092 004, Bardejov, Slovakia|Ep0092 662, Alicante, Spain|Ep0092 651, Barcelona, Spain|Ep0092 652, Barcelona, Spain|Ep0092 658, Barcelona, Spain|Ep0092 674, Madrid, Spain|Ep0092 657, Valencia, Spain|Ep0092 676, Zaragoza, Spain|Ep0092 576, Göteborg, Sweden|Ep0092 575, Linköping, Sweden|Ep0092 053, Zürich, Switzerland|Ep0092 913, Ankara, Turkey|Ep0092 915, Antalya, Turkey|Ep0092 900, Istanbul, Turkey|Ep0092 906, Istanbul, Turkey|Ep0092 909, Istanbul, Turkey|Ep0092 908, Trabzon, Turkey|Ep0092 766, Brighton, United Kingdom|Ep0092 750, Manchester, United Kingdom|Ep0092 764, Swansea, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03739840/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03739840/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03739840
10,NCT03541668,Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST),NA,Completed,No Results Available,Acute Ischaemic Stroke,Drug: Recombinant human urokinase|Drug: Alteplase,Functional handicap|Proportion of Neurological Improvement|Scores of Neurological Improvement|Long-term Change from Baseline|Proportion of Long-term Improvement|Systemic hemorrhage|Symptomatic intracerebral hemorrhage|Death|Recurrence|Liver function|Renal function,"Tasly Biopharmaceuticals Co., Ltd.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,674,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TASLY-B1440-CTP-Ⅲa,"May 18, 2018","April 14, 2020","May 24, 2020","May 30, 2018",NA,"June 22, 2020","Beijing Luhe Hospital,Capital Medical University, Beijing, Beijing, China|XuanWu Hospital, Capital Medical University, Beijing, Beijing, China|Liuzhou Worker's Hospital, Liuzhou, Guangxi, China|Cangzhou Central Hospital, Cangzhou, Hebei, China|The First Hospital of Handan, Handan, Hebei, China|Harrison International Peace Hospital, Hengshui, Hebei, China|The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Tangshan Gongren Hospital, Tangshan, Hebei, China|Daqing Oilfield General Hospital, Daqing, Heilongjiang, China|The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|The First Hospital of Changsha, Changsha, Hunan, China|First Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia, China|Baotou Central Hospital, Baotou, Inner Mongolia, China|Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China|Inner Mongolia People's Hospital, Hohhot, Inner Mongolia, China|Huai'an First People's Hospital, Huai'an, Jiangsu, China|The Second People'Hospital of Huai'an, Huai'an, Jiangsu, China|Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China|The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China|Xuzhou Central Hospital, Xuzhou, Jiangsu, China|Jiangxi Pingxiang People's Hospital, Pingxiang, Jiangxi, China|First Hospital of Jilin University, Changchun, Jilin, China|The Neuropsychiatric Hospital of Jilin Province, Siping, Jilin, China|Dalian Municipal Central Hospital, Dalian, Liaoning, China|Shenyang Military Region General Hospital, Shenyang, Liaoning, China|The 163th Hospital of the Chinese People's Liberation Army, Shenyang, Liaoning, China|Liaocheng People's Hospital, Liaocheng, Shandong, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China|The People's Hospital of Sichuan Province, Chengdu, Sichuan, China|Deyang people's hospital, Deyang, Sichuan, China|Tianjin Huanhu Hospital, Tianjin, Tianjin, China|Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, China|Luoyang Central Hospital, Luoyang, Zhengzhou, China",NA,https://ClinicalTrials.gov/show/NCT03541668
11,NCT03505021,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,REFALS,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Levosimendan|Drug: Placebo for levosimendan,Supine Slow Vital Capacity (SVC)|Combined Assessment of Function and Survival Through 48 Weeks|Time to Respiratory Event Through 48 Weeks|Change From the Baseline in Clinical Global Impression CGI at 48 Weeks|Change From Baseline in Respiratory Function of ALSFRS-R at 48 Weeks|Supine Borg Category Ratio 10 Scale at 12 Weeks,"Orion Corporation, Orion Pharma",All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 3,496,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3119002,"June 21, 2018","July 23, 2020","July 23, 2020","April 20, 2018","August 31, 2021","May 11, 2022","Phoenix Neurological Associates, Phoenix, Arizona, United States|Neuromuscular Research Center and Neuromuscular Clinic of Arizona, Phoenix, Arizona, United States|University of California San Diego, La Jolla, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California Irvine, Orange, California, United States|California Pacific Medical Center, San Francisco, California, United States|Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States|Hospital for Special Care, New Britain, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|The George Washington Medical Faculty Associates - Foggy Bottom North Pavilion, Washington, District of Columbia, United States|Providence Holy Cross Medical Center, Fort Lauderdale, Florida, United States|University of Florida, Gainesville, Florida, United States|University of Florida Health - Jacksonville, Jacksonville, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|University of South Florida, Tampa, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States|Kentucky Neuroscience Research, Louisville, Kentucky, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|HealthPartners Specialty Center, Saint Paul, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Neurology Associates, Lincoln, Nebraska, United States|Mount Sinai Beth Israel, New York, New York, United States|Hospital for Special Surgery, New York, New York, United States|Columbia Presbyterian Hospital, New York, New York, United States|Neurosciences Institute - Neurology Charlotte, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Providence Brain and Spine Institute, Portland, Oregon, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Texas Neurology, Dallas, Texas, United States|Nerve and Muscle Center of Texas, Houston, Texas, United States|University of Utah - Imaging & Neurosciences Center, Salt Lake City, Utah, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Froedtert Hospital, Milwaukee, Wisconsin, United States|Brain and Mind Centre, Camperdown, New South Wales, Australia|Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Calvary Health Care Bethlehem, Caulfield South, Victoria, Australia|Perron Institute for Neurological and Translational Science, Murdoch, Western Australia, Australia|Universität Innsbruck, Innsbruck, Tyrol, Austria|Salzkammergut-Klinikum Vöcklabruck, Vöcklabruck, Upper Austria, Austria|Medizinische Universität Wien, Wien, Austria|Universitaire Ziekenhuis Leuven, Leuven, Flemish Brabant, Belgium|Centre Hospitalier Régional de la Citadelle, Liège, Liege, Belgium|Algemeen Ziekenhuis St. Lucas Gent, Gent, Oost-Vlaanderen, Belgium|Alberta Health Services - Neuromuscular Clinic, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada|Moncton Hospital, Southeast Regional Health Authority, Moncton, New Brunswick, Canada|McMaster University Medical Centre, Hamilton, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Centre De Recherche Du Centre Hospitalier de l'Universite de Montreal - Hopital Notre-Dame, Montréal, Quebec, Canada|Montreal Neurological Institute and Hospital, Montréal, Quebec, Canada|Centre Hospitalier Affilie Universitaire de Quebec, Québec, Quebec, Canada|Neurologian Poliklinikka - Meilahden Tornisairaala 3, Helsinki, Finland|Etelä-Karjalan keskussairaala, Lappeenranta, Finland|Turku University Hospital, Turku, Finland|Centre Hospitalier Universitaire de Limoges, Limoges, France|Hôpital Gui de Chauliac, Montpellier, France|Hôpital Pasteur, Nice, France|Centre Hospitalier Régional et Universitaire de Tours Hôpital Bretonneau, Tours, France|Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany|Deutsche Klinik für Diagnostik, Wiesbaden, Hessen, Germany|Universitätsmedizin Rostock, Rostock, Mecklenburg-western-pommerania, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Alfried Krupp Krankenhaus Rüttenscheid, Essen, Nordrhein-westfalen, Germany|Universitätsklinikum Münster, Münster, Nordrhein-Westfalen, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Sachsen, Germany|Universitätsklinikum Jena, Jena, Thuringen, Germany|Charité Universitätsmedizin Berlin - Campus Virchow-Klinikum, Berlin, Germany|Beaumont Hospital - Ireland, Dublin, Ireland|Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Azienda Ospedaliera Universitaria-Maggiore della Carità di Novara, Novara, Italy|ICS Maugeri Spa SB, Pavia, Italy|Azienda Ospedaliero-Universitaria Pisana Ospedale Santa Chiara, Pisa, Italy|Policlinico Umberto I di Roma, Roma, Italy|Azienda Ospedaliera - Universitaria Città della Salute e della Scienza di Torino, Torino, Italy|Academisch Medisch Centrum, Amsterdam, Noord-Holland, Netherlands|Universitair Medisch Centrum Utrecht - Rudolf Magnus Instituut voor Neurowetenschappen, Utrecht, Netherlands|Hospital de Basurto, Bilbao, Vizcaya, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Hospital San Rafael - Madrid, Madrid, Spain|Hospital Universitario y Politécnico de La Fe, Valencia, Spain|Norrlands Universitetssjukhus, Umeå, Vasterbotten, Sweden|Centralsjukhuset Karlstad, Karlstad, Sweden|Karolinska Universitetssjukhuset, Stockholm, Sweden|Barts Health NHS Trust, London, England, United Kingdom|King's College Hospital NHS Foundation Trust, London, England, United Kingdom|The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03505021/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03505021/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03505021
12,NCT03461757,Trial in Adult Subjects With Acute Migraines,NA,Completed,Has Results,"Migraine, With or Without Aura",Drug: Rimegepant|Drug: Placebo,Percentage of Participants With Freedom From Pain at 2 Hours Post-dose|Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose|Percentage of Participants With Pain Relief at 2 Hours Post-dose|Percentage of Participants With Freedom From Functional Disability at 2 Hours Post-dose|Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose|Percentage of Participants With Sustained Freedom From Most Bothersome Symptom (MBS) From 2 to 24 Hours Post-dose|Percentage of Participants With Rescue Medication Use Within 24 Hours Post-dose|Percentage of Participants With Sustained Freedom From Functional Disability From 2 to 24 Hours Post-dose|Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose|Percentage of Participants With Sustained Freedom From Most Bothersome Symptom (MBS) From 2 to 48 Hours Post-dose|Percentage of Participants With Sustained Freedom From Functional Disability From 2 to 48 Hours Post-dose|Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose|Percentage of Participants With Freedom From Functional Disability at 90 Minutes Post-dose|Percentage of Participants With Pain Relief at 90 Minutes Post-dose|Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose|Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 90 Minutes Post-dose|Percentage of Participants With Freedom From Pain at 90 Minutes Post-dose|Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose|Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose|Percentage of Participants With Pain Relief at 60 Minutes Post-dose|Percentage of Participants With Freedom From Functional Disability at 60 Minutes Post-dose|Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose|Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose,Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1811,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",BHV3000-303,"February 27, 2018","October 8, 2018","October 15, 2018","March 12, 2018","March 27, 2020","February 16, 2023","Coastal Clinical Research, LLC, Mobile, Alabama, United States|Clinical Research Consortium, An AMR Company, Tempe, Arizona, United States|Radiant Research, Inc., Tucson, Arizona, United States|Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States|Woodland International Research Group, LLC, Little Rock, Arkansas, United States|Pharmacology Research Institute, Encino, California, United States|eStudySite, La Mesa, California, United States|Collaborative Neuroscience Network, LLC, Long Beach, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Synergy San Diego, National City, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Optimus Medical Group, San Francisco, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Yale University, New Haven, Connecticut, United States|Ki Health Partners LLC DBA New England Institute for Clinical Research, Stamford, Connecticut, United States|MD Clinical, Hallandale Beach, Florida, United States|AGA Clinical Trials, Hialeah, Florida, United States|Multi-Specialty Research Associates, Inc., Lake City, Florida, United States|Qps Mra, Llc, Miami, Florida, United States|Clinical Neuroscience Solutions, Inc, Orlando, Florida, United States|Ormond Medical Arts Pharmaceutical Research, Ormond Beach, Florida, United States|Synexus, Atlanta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Meridian Clinical Research, LLC, Savannah, Georgia, United States|Heartland Research Associates LLC, Augusta, Kansas, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Cresent City Headache and Neurology Center LLC, Chalmette, Louisiana, United States|New Orleans Center for Clinical Research, New Orleans, Louisiana, United States|DelRicht Research, New Orleans, Louisiana, United States|Boston Clinical Trials, Boston, Massachusetts, United States|NECCR Primacare Research, LLC, Fall River, Massachusetts, United States|Community Clinical Research Network/Milford Emergency Associates, Inc, Marlborough, Massachusetts, United States|Clinical Research Institute, Inc., Minneapolis, Minnesota, United States|Clinical Research Institute, Inc., Plymouth, Minnesota, United States|Center for Pharmaceutical Research, Kansas City, Missouri, United States|Sundance Clinical Research, Saint Louis, Missouri, United States|StudyMetrix Research, LLC, Saint Peters, Missouri, United States|Meridian Clinical Research, LLC, Norfolk, Nebraska, United States|Hassman Research Institute, Berlin, New Jersey, United States|Albuquerque Clinical Trials, Inc., Albuquerque, New Mexico, United States|SPRI Clinical Trials, LLC, Brooklyn, New York, United States|CNS Research Science, Inc., Jamaica, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|PharmQuest, LLC, Greensboro, North Carolina, United States|PMG Research of Raleigh, Raleigh, North Carolina, United States|Wilmington Health, PLLC, Wilmington, North Carolina, United States|Radiant Research, Inc., Columbus, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Hometown Urgent Care and Research, Dayton, Ohio, United States|Neurology Diagnostics, Inc., Dayton, Ohio, United States|Aventiv Research Inc, Dublin, Ohio, United States|Summit Research Network (Oregon) Inc., Portland, Oregon, United States|Clinical Research of Philadelphia, LLC, Philadelphia, Pennsylvania, United States|Coastal Carolina Research, Mount Pleasant, South Carolina, United States|Meridian Clinical Research, Dakota Dunes, South Dakota, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Clinical Research Institute, Inc., Nashville, Tennessee, United States|Nashville Neuroscience Group, Nashville, Tennessee, United States|Tekton Research, Inc, Austin, Texas, United States|FutureSearch Trials of Dallas, LP, Dallas, Texas, United States|Ventavia Research Group, LLC, Fort Worth, Texas, United States|Texas Center for Drug Development, Inc., Houston, Texas, United States|Red Star Research, Lake Jackson, Texas, United States|DM Clinical Research, Tomball, Texas, United States|Charlottesville Medical Research, Charlottesville, Virginia, United States|Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Seattle Women's: Health, Research, Gynecology, Seattle, Washington, United States|Clinical Investigation Specialists, Inc., Kenosha, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT03461757/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT03461757/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03461757
13,NCT03280056,Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients,NA,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Biological: NurOwn® (MSC-NTF cells)|Other: Placebo|Other: Bone Marrow aspiration,To evaluate the efficacy and safety of NurOwn® (autologous MSC-NTF cells) as compared to placebo as measured by the amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)|Biomarkers,Brainstorm-Cell Therapeutics|California Institute for Regenerative Medicine (CIRM),All,18 Years to 60 Years   (Adult),Phase 3,263,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BCT-002-US,"August 28, 2017","October 30, 2020","October 30, 2020","September 12, 2017",NA,"October 6, 2021","University of California Irvine Alpha Stem Cell Clinic, Irvine, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States",NA,https://ClinicalTrials.gov/show/NCT03280056
14,NCT03277261,Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ),ULTIMATE 1,Completed,Has Results,Relapsing Multiple Sclerosis (RMS),Biological: Ublituximab|Drug: Teriflunomide|Drug: Oral Placebo|Drug: IV Placebo,Annualized Relapse Rate (ARR)|Total Number of Gadolinium (Gd)-Enhancing T1-Lesions Per Magnetic Resonance Imaging (MRI) Scan Per Participant|Total Number of New and Enlarging T2 Hyperintense Lesions (NELs) Per MRI Scan Per Participant|Time to Confirmed Disability Progression (CDP) for at Least 12 Weeks|Percentage of Participants With No Evidence of Disease Activity (NEDA)|Percentage of Participants With Impaired Symbol Digit Modalities Test (SDMT)|Percent Change From Baseline in Brain Volume|Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs),"TG Therapeutics, Inc.",All,18 Years to 55 Years   (Adult),Phase 3,549,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TG1101-RMS301|2017-000638-75,"September 19, 2017","July 23, 2020","November 6, 2020","September 11, 2017","December 6, 2021","December 6, 2021","TG Therapeutics RMS Investigational Trial Site, Carlsbad, California, United States|TG Therapeutics RMS Investigational Trial Site, Long Beach, California, United States|TG Therapeutics RMS Investigational Trial Site, Pasadena, California, United States|TG Therapeutics RMS Investigational Trial Site, Stanford, California, United States|TG Therapeutics RMS Investigational Trial Site, Miami, Florida, United States|TG Therapeutics RMS Investigational Trial Site, Northbrook, Illinois, United States|TG Therapeutics RMS Investigational Trial Site, Kansas City, Kansas, United States|TG Therapeutics RMS Investigational Trial Site, Detroit, Michigan, United States|TG Therapeutics RMS Investigational Trial Site, Amherst, New York, United States|TG Therapeutics RMS Investigational Trial Site, Westerville, Ohio, United States|TG Therapeutics RMS Investigational Trial Site, Franklin, Tennessee, United States|TG Therapeutics RMS Investigational Trial Site, Knoxville, Tennessee, United States|TG Therapeutics RMS Investigational Trial Site, Dallas, Texas, United States|TG Therapeutics RMS Investigational Site, Round Rock, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT03277261/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT03277261/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03277261
15,NCT03277248,Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS),ULTIMATE II,Completed,Has Results,Relapsing Multiple Sclerosis (RMS),Biological: Ublituximab|Drug: Teriflunomide|Drug: Oral Placebo|Drug: IV Placebo,Annualized Relapse Rate (ARR)|Total Number of Gadolinium (Gd)-Enhancing T1-Lesions Per Magnetic Resonance Imaging (MRI) Scan Per Participant|Total Number of New and Enlarging T2 Hyperintense Lesions (NELs) Per MRI Scan Per Participant|Time to Confirmed Disability Progression (CDP) for at Least 12 Weeks|Percentage of Participants With No Evidence of Disease Activity (NEDA)|Percentage of Participants With Impaired Symbol Digit Modalities Test (SDMT)|Percent Change From Baseline in Brain Volume|Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs),"TG Therapeutics, Inc.",All,18 Years to 55 Years   (Adult),Phase 3,545,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TG1101-RMS302|2017-000639-15,"August 25, 2017","August 4, 2020","November 12, 2020","September 11, 2017","December 6, 2021","December 6, 2021","TG Therapeutics RMS Investigational Trial site, Phoenix, Arizona, United States|TG Therapeutics RMS Investigational Trial Site, Aurora, Colorado, United States|TG Therapeutics RMS Investigational Trial Site, Tampa, Florida, United States|TG Therapeutics RMS Investigational Trial Site, Lexington, Kentucky, United States|TG Therapeutics RMS Investigational Trial Site, Chesterfield, Missouri, United States|TG Therapeutics RMS Investigational Trial Site, Las Vegas, Nevada, United States|TG Therapeutics RMS Investigational Trial Site, Teaneck, New Jersey, United States|TG Therapeutics RMS Investigational Trial Site, Albuquerque, New Mexico, United States|TG Therapeutics RMS Investigational Trial Site, Patchogue, New York, United States|TG Therapeutics RMS Investigational Trial site, Columbus, Ohio, United States|TG Therapeutics RMS Investigational Trial Site, Pittsburgh, Pennsylvania, United States|TG Therapeutics RMS Investigational Trial site, San Antonio, Texas, United States|TG Therapeutics RMS Investigational Trial site, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03277248/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT03277248/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03277248
16,NCT03237845,Safety and Efficacy in Adult Subjects With Acute Migraines,NA,Completed,Has Results,"Migraine, With or Without Aura",Drug: Rimegepant|Drug: Placebo,Percentage of Participants With Freedom From Pain at 2 Hours Post-dose|Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose|Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose|Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose|Percentage of Participants With Pain Relief at 2 Hours Post-dose|Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose|Percentage of Participants With Rescue Medication Use Within 24 Hours Post-dose|Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose|Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose|Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose|Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose|Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose|Percentage of Participants With Freedom From Functional Disability at 2 Hours Post-dose,Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1499,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",BHV3000-302,"July 27, 2017","January 25, 2018","January 31, 2018","August 3, 2017","December 23, 2020","February 16, 2023","Coastal Clinical Research, Mobile, Alabama, United States|Thunderbird Internal Medicine / Radiant Research, Inc., Glendale, Arizona, United States|Woodland Research Northwest, LLC, Rogers, Arkansas, United States|eStudySite, La Mesa, California, United States|Collaborative Neuroscience Network, LLC, Long Beach, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Pacific Research Partners LLC, Oakland, California, United States|National Research Institute, Panorama City, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Clinical Trials of the Rockies, Denver, Colorado, United States|AGA Clinical Trials, Hialeah, Florida, United States|Clinical Neuroscience Solutions, Jacksonville, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Meridien Research, Tampa, Florida, United States|Radiant Research, Inc., Atlanta, Georgia, United States|Savannah Neurology Specialists, Savannah, Georgia, United States|Christie Clinic, LLC, Champaign, Illinois, United States|PMG Research of McFrland Clinic, Ames, Iowa, United States|Heartland Research Associates, LLC, Augusta, Kansas, United States|Heartland Research Associates, LLC, Newton, Kansas, United States|Heartland Research Associates, LLC, Park City, Kansas, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|MedPharmics, LLC, Metairie, Louisiana, United States|NECCR Primacare Research, LLC, Fall River, Massachusetts, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Radiant Research, Inc., Jamaica, New York, United States|PMG Research of Raleigh, Inc., Raleigh, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Radiant Research, Inc., Cincinnati, Ohio, United States|Radiant Research, Inc., Columbus, Ohio, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Neurology Diagnostics, Inc., Dayton, Ohio, United States|Aventiv Research, Inc., Dublin, Ohio, United States|Summit Research Network (Oregon), Inc., Portland, Oregon, United States|Oregon Center for Clinical Investigations, Inc, Salem, Oregon, United States|Fieve Clinical Research, Inc., Scranton, Pennsylvania, United States|Radiant Research, Inc., Anderson, South Carolina, United States|Clinical Research Associates, Inc., Nashville, Tennessee, United States|Tekton Research, Austin, Texas, United States|Ventavia Research Group, Fort Worth, Texas, United States|Red Star Research, Lake Jackson, Texas, United States|FMC Science, Lampasas, Texas, United States|PCP for Life, Magnolia, Texas, United States|Research Across America, Mesquite, Texas, United States|Doctors of Internal Medicine, LTD / Radiant Research, Inc., Plano, Texas, United States|DM Clinical Research, Tomball, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03237845/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03237845/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03237845
17,NCT03235479,Safety and Efficacy Study in Adult Subjects With Acute Migraines,NA,Completed,Has Results,"Migraine, With or Without Aura",Drug: Rimegepant|Drug: Placebo,Percentage of Participants With Freedom From Pain at 2 Hours Post-dose|Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose|Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose|Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose|Percentage of Participants With Pain Relief at 2 Hours Post-dose|Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose|Percentage of Participants With Rescue Medication Use Within 24 Hours Post-dose|Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose|Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose|Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose|Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose|Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose|Percentage of Participants With Freedom From Functional Disability at 2 Hours Post-dose,Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1485,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",BHV-3000-301,"July 18, 2017","January 21, 2018","January 26, 2018","August 1, 2017","December 23, 2020","February 16, 2023","Central Research Associates, Inc, Birmingham, Alabama, United States|Neurological Physicians of Arizona/Radiant Research Inc, Gilbert, Arizona, United States|Clinical Research Consortium Arizona, Tempe, Arizona, United States|Radiant Research, Inc., Tucson, Arizona, United States|Woodland International Research Group, LLC, Little Rock, Arkansas, United States|Pharmacology Research Institute, Encino, California, United States|Optimus Medical Group, San Francisco, California, United States|California Medical Clinic for Headache, Santa Monica, California, United States|Diablo Clinical Research, Inc, Walnut Creek, California, United States|Qps Mra, Llc, Hollywood, Florida, United States|Multi-Specialty Research Associates, Inc, Lake City, Florida, United States|Qps Mra, Llc, Miami, Florida, United States|Advanced Pharma CR, LLC, Miami, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Ormond Medical Arts Pharmaceutical Research, Ormond Beach, Florida, United States|Meridian Clinical Research, Savannah, Georgia, United States|New Orleans Center for Clinical Research, New Orleans, Louisiana, United States|Boston Clinical Trials, Inc, Boston, Massachusetts, United States|Milford Emergency Associates, Inc., Marlborough, Massachusetts, United States|Michigan Head Pain & Neurological Institute, Ann Arbor, Michigan, United States|Clinical Research Institute, Inc, Minneapolis, Minnesota, United States|Clinical Research Institute, Minneapolis, Minnesota, United States|The Center for Pharmaceutical Research, Kansas City, Missouri, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|Meridian Clinical Research -Norfolk, Norfolk, Nebraska, United States|Meridian Clinical Research, LLC, Omaha, Nebraska, United States|Clinical Research Consortium- Las Vegas, Las Vegas, Nevada, United States|Hassman Research Institute, LLC, Berlin, New Jersey, United States|SPRI Clinical Trials, LLC, Brooklyn, New York, United States|Regional Clinical Research, Inc., Endwell, New York, United States|Central New York Clinical Research, Manlius, New York, United States|Fieve Clinical Research, New York, New York, United States|Rochester Clinical Research, Inc, Rochester, New York, United States|PharmQuest, LLC, Greensboro, North Carolina, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|Oregon Center for Clinical Investigations, Inc, Portland, Oregon, United States|Clinical Research of Philadelphia, LLC, Philadelphia, Pennsylvania, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Omega Medical Research, Warwick, Rhode Island, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Meridian Clinical Research, Dakota Dunes, South Dakota, United States|FutureSearch Trials of Neurology, LP, Austin, Texas, United States|FutureSearch Trials of Neurology, LP, Dallas, Texas, United States|Texas Center for Drug Development, Houston, Texas, United States|J.Lewis Research Inc / Foothill Family Clinic South, Salt Lake City, Utah, United States|J.Lewis Research Inc. / Jordan River Family Med, South Jordan, Utah, United States|Clinical Research Associates of Tidewater, Inc., Norfolk, Virginia, United States|Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Seattle Women's:Health, Research & Gynecology, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03235479/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03235479/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03235479
18,NCT03197740,"A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease",NA,Completed,No Results Available,Alzheimer Disease,Drug: Donepezil patch|Drug: aricept Tab,ADAS-cog|CIBIC-plus,Icure Pharmaceutical Inc.,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,399,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",IPI-003,"October 12, 2017","July 3, 2020","July 20, 2020","June 23, 2017",NA,"February 11, 2021","46 Sites including Konkuk University Medical Center, Seoul, Korea, Republic of",NA,https://ClinicalTrials.gov/show/NCT03197740
19,NCT03185143,Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea,NA,Completed,No Results Available,Migraine With and Without Aura,Drug: Naltrexone and Acetaminophen Combination|Drug: Sumatriptan 100 mg|Drug: Placebo,"The proportion of patients having no headache pain at 2 hours.|The proportion of patients having the absence of the most bothersome migraine-associated symptom at 2 hours.|The proportion of patients having the absence of nausea, photophobia, phonophobia, and neck/shoulder pain at 2 hours.|The proportion of patients who used rescue medications within 24 hours.|The proportion of patients who are ""sustained pain-free"" at 24-hours and 48-hours.|The proportion of patients who had headache pain relapse within 48 hours|The proportion of patients who experienced adverse events","Allodynic Therapeutics, LLC",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,36,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ANODYNE-2,"June 27, 2017","May 7, 2018","May 7, 2018","June 14, 2017",NA,"April 14, 2021","Annette C. Toledano, M.D., North Miami, Florida, United States",NA,https://ClinicalTrials.gov/show/NCT03185143
20,NCT03143751,Continuous Hyperosomolar Therapy for Traumatic Brain-injured Patients,COBI,Completed,No Results Available,Moderate to Severe Traumatic Brain Injury,Drug: NaCl20% (Continuous hyperosmolar therapy),Score on the Extended Glasgow Outcome Scale (GOS-E) at 6 months|Mortality rate in ICU|GOS-E|functional independence measure : ADL (Activities of Daily Living) of Katz|Short Form 36|Rate of patients with anterograde amnesia|Intracranial pressure control|Blood level of sodium|blood osmolality|Rate of thrombo-embolic events|Rate of acute kidney injury|Rate of centropontine myelinolysis|Blood level of chlore|Blood level of potassium|Blood level of pH (Hydrogen Potention)|brain oxygenation (PtiO2)|blood level of creatinine|Diuresis|weight|Ancillary study: questionnaire HADS (Hospital Anxiety and Depression Scale) in patient's relative,Nantes University Hospital,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,370,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,RC16_0474,"October 31, 2017","March 5, 2020","March 5, 2020","May 8, 2017",NA,"December 8, 2020","CHU Angers, Angers, France|CHU Brest Hopital La Cavale Blanche, Brest, France|AP-HP Beaujon, Clichy, France|CHU Montpellier, Montpellier, France|CHU de Nantes, Nantes, France|Centre Hospitalier Sainte-Anne, Paris, France|CHU Poitiers, Poitiers, France|CHU Rennes-Hopital Pontchaillou, Rennes, France|CHU Toulouse Hôpital Pierre-Paul Riquet, Toulouse, France|CHU Tours, Tours, France",NA,https://ClinicalTrials.gov/show/NCT03143751
21,NCT03068754,Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),NA,Terminated,Has Results,Amyotrophic Lateral Sclerosis,Drug: Acthar|Drug: Placebo,Treatment Period: Scores on a Scale for Telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)|Number of Participants Experiencing an Adverse Event During the Treatment Period|Number of Participants Experiencing an Adverse Event by the End of the Trial in the OLE Period|Treatment Period: Spirometry (%)|Treatment Period: Scores on a Scale for Investigator-administered ALSFRS-R|Extension Period: Scores on a Scale for Investigator-administered ALSFRS-R,Mallinckrodt,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,143,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MNK14042068,"June 22, 2017","November 25, 2019","November 25, 2019","March 3, 2017","September 3, 2020","October 14, 2020","Neuromuscular Research Center, Phoenix, Arizona, United States|Mayo Clinic - Arizona, Scottsdale, Arizona, United States|University of California San Diego, La Jolla, California, United States|Loma Linda University Health System, Department of Neurology, Loma Linda, California, United States|Keck School of Medicine, University of Southern California, Los Angeles, California, United States|University of California Los Angeles, Los Angeles, California, United States|University of California Irvine Medical Center, Orange, California, United States|California Pacific Medical Center, San Francisco, California, United States|University of California San Francisco, San Francisco, California, United States|Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States|Georgetown University, Washington, District of Columbia, United States|George Washington University, Washington, District of Columbia, United States|University of Florida - McKnight Brain Institute, Gainesville, Florida, United States|University of South Florida, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Indiana University-Neuroscience Center of Excellence/Goodman Hall, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States|John Hopkins Outpatient Center, Baltimore, Maryland, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Mercy Health- Saint Mary's, Grand Rapids, Michigan, United States|Neurology Associates, Lincoln, Nebraska, United States|University of Nebraska Medical Center - Physicians Clinical Neurosciences Center, Omaha, Nebraska, United States|Las Vegas Clinic, Las Vegas, Nevada, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Columbia Presbyterian Hospital, New York, New York, United States|Providence ALS Center, Portland, Oregon, United States|Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Wesley Neurology Clinic, Cordova, Tennessee, United States|Austin Neuromuscular Center, Austin, Texas, United States|Texas Neurology, P.A., Dallas, Texas, United States|The Methodist Hospital, Houston, Texas, United States|University of Vermont Medical Center, Colchester, Vermont, United States|VCU Medical Center, Richmond, Virginia, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin, United States|IADIN, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|STAT Research, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|DIABAID, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|INEBA, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Hospital Español, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Hospital Británico de Buenos Aires, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|ILAIM, Ciudad de Córdoba, Córdoba, Argentina|Fundación Scherbovsky, Ciudad de Mendoza, Mendoza, Argentina|Instituto de Neurología y Neurorrehabilitación del Litoral (INNeL ), Ciudad De Santa Fe, Santa Fe, Argentina|Edmonton Kaye Clinic, Edmonton, Alberta, Canada|Recherche Sepmus inc, Greenfield Park, Quebec, Canada|Centre de recherché du Centre Hospitalier de l'Universite de Montreal (CRCHUM), Montréal, Quebec, Canada|Montreal Neurological Institute & Hospital, Montréal, Quebec, Canada|Centro de Trastornos del Movimiento (CETRAM), Santiago, Región Metropolitana, Chile|Clinica Dávila, Santiago, Región Metropolitana, Chile|Biomedica Research Group AV Salvador 149, oficina 1101, Santiago, Chile|Centro de Investigaciones Clínicas SAS, Cali, Colombia|Clinical Research Institute Saltillo S.A. de C.V., Saltillo, Coahuila, Mexico|Hospital Universitario ""Dr. José Eleuterio González"", Monterrey, Nuevo Leon, Mexico|SMIQ BRCR Global México, Querétaro City, Querétaro, Mexico|Clinical Research Institute S.C., San Lucas Tepetlacalco, Tlalnepantla De Baz, Mexico|Centro Especializado en Investigación Clínica S.C., Boca Del Río, Veracruz, Mexico|Phylasis Clinicas Research, Mexico City, Mexico|FAICIC Clinical Researc, Veracruz, Mexico|Hospital Nivel IV Carlos Alberto Seguin Escobedo, Arequipa, Peru|Hospital Nacional IV Alberto Sabogal Sologuren, Callao, Peru|Hospital Almenara, Lima, Peru|Instituto Neuro Cardiovascular de las Américas, Lima, Peru|Hospital Nacional Cayetano Heredia, Lima, Peru","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03068754/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03068754
22,NCT03031184,Study of Mirtazapine for Agitation in Dementia,SYMBAD,Completed,No Results Available,Dementia,Drug: Mirtazapine|Other: Placebo,"Cohen Mansfield Agitation Inventory (CMAI) score (Long Form, 29 questions)","University of Sussex|Norwich Clinical Trials Unit|University of East Anglia|University of Cambridge|University College, London|London School of Economics and Political Science|University of Manchester|University of Newcastle Upon-Tyne|Birmingham and Solihull Mental Health NHS Foundation Trust|Alzheimer's Society|The Centre for Dementia Studies, Brighton and Sussex Medical School and SPFT",All,"18 Years and older   (Adult, Older Adult)",Phase 3,207,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",15/SC/0606,January 2017,June 2020,March 2021,"January 25, 2017",NA,"April 19, 2021","Sube Banerjee, Brighton, Sussex, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT03031184
23,NCT03009019,"Efficacy, Tolerability, and Safety of DFN-15",NA,Completed,Has Results,Migraine Headache,Drug: DFN-15 Active|Other: DFN-15 Placebo,"Percentage of Subjects Who Are Pain-free at 2 Hours Postdose (First Treated Double-blind Treatment Period)|Percentage of Subjects Who Are Free From Their MBS at 2 Hours Postdose|The Number of Subjects With TEAEs After Study Drug Compared Between DFN-15 and Placebo|Freedom From Nausea, Photophobia, and Phonophobia Postdose (DB1 and DB2)|Time to Headache Pain Relief Postdose (DB1 and DB2)|Time to Headache Pain Freedom Postdose (DB1 and DB2)|Headache Pain Relief Postdose (DB1 and DB2)|Headache Pain Freedom Postdose (DB1 and DB2)|Absence of Screening MBS at Time Points Postdose (DB1 and DB2)|Change in Functional Disability Score Postdose (DB1 and DB2)|Headache Pain Freedom Among Subjects With Cutaneous Allodynia (DB1 and DB2)|Headache Pain Freedom Among BMI Category (DB1 and DB2)|Headache Pain Recurrence Postdose (DB1 and DB2)|Sustained Headache Pain Relief Postdose (DB1 and DB2)|Sustained Headache Pain Freedom Postdose (DB1 and DB2)|Use of Rescue Medication Postdose (DB1 and DB2)|Subject-Rated Treatment Satisfaction Postdose (DB1 and DB2)|Subject-Rated Treatment Satisfaction at 24 Hours Postdose - PPMQ-R (DB1 and DB2)",BioDelivery Sciences International|Dr. Reddy's Laboratories Limited,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,631,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DFN-15-CD-006,December 2016,November 2017,May 2019,"January 4, 2017","January 10, 2023","January 10, 2023","Site 609, Birmingham, Alabama, United States|Site 640, Mobile, Alabama, United States|Site 622, Tucson, Arizona, United States|Site 616, Hot Springs, Arkansas, United States|Site 637, Huntington Beach, California, United States|Site 615, Oakland, California, United States|Site 646, San Diego, California, United States|Site 619, San Francisco, California, United States|Site 624, San Marcos, California, United States|Site 631, Littleton, Colorado, United States|Site 603, Miami, Florida, United States|Site 641, Orange City, Florida, United States|Site 629, Orlando, Florida, United States|Site 601, West Palm Beach, Florida, United States|Site 625, Decatur, Georgia, United States|Site 630, Sandy Springs, Georgia, United States|Site 642, Meridian, Idaho, United States|Site 604, Blue Island, Illinois, United States|Site 602, Louisville, Kentucky, United States|Site 644, New Orleans, Louisiana, United States|Site 610, New Orleans, Louisiana, United States|Site 634, Ann Arbor, Michigan, United States|Site 623, Edina, Minnesota, United States|Site 638, Saint Peters, Missouri, United States|Site 606, Missoula, Montana, United States|Site 613, Omaha, Nebraska, United States|Site 647, Lebanon, New Hampshire, United States|Site 618, Nashua, New Hampshire, United States|Site 636, Albuquerque, New Mexico, United States|Site 645, Brooklyn, New York, United States|Site 608, Rochester, New York, United States|Site 620, High Point, North Carolina, United States|Site 643, Mooresville, North Carolina, United States|Site 626, Fargo, North Dakota, United States|Site 628, Cleveland, Ohio, United States|Site 614, Warwick, Rhode Island, United States|Site 639, Mount Pleasant, South Carolina, United States|Site 612, Dakota Dunes, South Dakota, United States|Site 627, Austin, Texas, United States|Site 611, Dallas, Texas, United States|Site 632, San Antonio, Texas, United States|Site 621, Taylorsville, Utah, United States|Site 635, Richmond, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03009019/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03009019/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03009019
24,NCT03006276,"Efficacy, Tolerability, and Safety Study of DFN-15",NA,Completed,Has Results,Migraine Headache,Drug: DFN-15 Active|Other: DFN-15 Placebo,"Percentage of Subjects Who Are Pain-free at 2 Hours Postdose (DB1)|Percentage of Subjects Who Are Free From Their MBS at 2 Hours Postdose (DB1)|Freedom From Nausea, Photophobia, and Phonophobia Postdose (DB1 and DB2)|Time to Headache Pain Relief Postdose (DB1 and DB2)|Time to Headache Pain Freedom Postdose (DB1 and DB2)|Headache Pain Relief Postdose (DB1 and DB2)|Headache Pain Freedom Postdose (DB1 and DB2)|Absence of Screening MBS at Time Points Postdose (DB1 and DB2)|Change in Functional Disability Score Postdose (DB1 and DB2)|Headache Pain Freedom Among Subjects With Cutaneous Allodynia (DB1 and DB2)|Headache Pain Freedom Among BMI Category (DB1 and DB2)|Headache Pain Recurrence Postdose (DB1 and DB2)|Sustained Headache Pain Relief Postdose (DB1 and DB2)|Sustained Headache Pain Freedom Postdose (DB1 and DB2)|Use of Rescue Medication Postdose (DB1 and DB2)|Subject-Rated Treatment Satisfaction Postdose (DB1 and DB2)|Subject-Rated Treatment Satisfaction at 24 Hours Postdose - PPMQ-R (DB1 and DB2)",BioDelivery Sciences International,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,622,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DFN-15-CD-007,December 2016,November 2017,May 2019,"December 30, 2016","January 10, 2023","January 10, 2023","Site 744, Birmingham, Alabama, United States|Site 727, Phoenix, Arizona, United States|Site 723, Little Rock, Arkansas, United States|Site 718, Rogers, Arkansas, United States|Site 709, Los Angeles, California, United States|Site 708, Orange, California, United States|Site 729, San Diego, California, United States|Site 725, Santa Monica, California, United States|Site 738, Simi Valley, California, United States|Site 733, Upland, California, United States|Site 726, Colorado Springs, Colorado, United States|Site 735, DeLand, Florida, United States|Site 711, Hialeah, Florida, United States|Site 721, Jacksonville, Florida, United States|Site 740, Blue Ridge, Georgia, United States|Site 720, Decatur, Georgia, United States|Site 734, West Des Moines, Iowa, United States|Site 739, Prairie Village, Kansas, United States|Site 713, Wichita, Kansas, United States|Site 706, Shreveport, Louisiana, United States|Site 712, Baltimore, Maryland, United States|Site 703, Boston, Massachusetts, United States|Site 730, New Bedford, Massachusetts, United States|Site 704, Minneapolis, Minnesota, United States|Site 736, Hazelwood, Missouri, United States|Site 737, Springfield, Missouri, United States|Site 745, Las Vegas, Nevada, United States|Site 716, Berlin, New Jersey, United States|Site 746, Amherst, New York, United States|Site 705, Manhattan, New York, United States|Site 743, Williamsville, New York, United States|Site 715, Raleigh, North Carolina, United States|Site 728, Cincinnati, Ohio, United States|Site 707, Dayton, Ohio, United States|Site 701, Oklahoma City, Oklahoma, United States|Site 741, Salem, Oregon, United States|Site 717, Media, Pennsylvania, United States|Site 731, Philadelphia, Pennsylvania, United States|Site 742, Lincoln, Rhode Island, United States|Site 710, Anderson, South Carolina, United States|Site 724, Chattanooga, Tennessee, United States|Site 719, Austin, Texas, United States|Site 702, Plano, Texas, United States|Site 714, Virginia Beach, Virginia, United States|Site 722, Bellevue, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT03006276/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT03006276/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03006276
25,NCT02964338,A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH),NA,Terminated,Has Results,Chronic Cluster Headache,Drug: Fremanezumab|Drug: Placebo,"Mean Change From Baseline in the Overall Monthly Average Number of CH Attacks Up to Week 12|Percentage of Participants With a ≥50% Reduction From Baseline in the Monthly Average Number of CH Attacks Up to Week 12|Mean Change From Baseline in the Monthly Average Number of CH Attacks at Week 4 and Week 12|Mean Change From Baseline in the Overall Weekly Average Number of Days With Use of Cluster-Specific Acute Headache Medications (Triptans and Ergot Compounds) Up to Week 12|Mean Change From Baseline in the Weekly Average Number of Days Oxygen Was Used to Treat CCH Up to Week 12|Number of Participants Who Perceived Improvement of CH-Associated Pain From Baseline as Measured by the Patient-Perceived Satisfactory Improvement (PPSI) Scale at Weeks 1, 4, 8, and 12|Number of Participants With Adverse Events (AEs)|Number of Participants With Potentially Clinically Significant Laboratory (Serum Chemistry, Hematology, and Urinalysis) Abnormal Results|Number of Participants With Shift From Baseline to Endpoint in Coagulation Laboratory Test Results|Number of Participants With Potentially Clinically Significant Abnormal Vital Signs Values|Number of Participants With Shift From Baseline to Endpoint (Last Assessment) in Electrocardiogram (ECG) Parameters|Number of Participants With Injection Site Reactions|Number of Participants With Suicidal Ideation and Suicidal Behavior as Assessed by the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)","Teva Branded Pharmaceutical Products R&D, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,259,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TV48125-CNS-30057|2016-003171-21,"January 17, 2017","July 18, 2018","July 18, 2018","November 16, 2016","September 18, 2019","November 9, 2021","Teva Investigational Site 13834, Phoenix, Arizona, United States|Teva Investigational Site 13819, Canoga Park, California, United States|Teva Investigational Site 13811, Santa Monica, California, United States|Teva Investigational Site 13823, Stanford, California, United States|Teva Investigational Site 13837, Aurora, Colorado, United States|Teva Investigational Site 13814, Colorado Springs, Colorado, United States|Teva Investigational Site 13836, Denver, Colorado, United States|Teva Investigational Site 13813, Englewood, Colorado, United States|Teva Investigational Site 13821, New Haven, Connecticut, United States|Teva Investigational Site 13812, Stamford, Connecticut, United States|Teva Investigational Site 13810, Gainesville, Florida, United States|Teva Investigational Site 13815, Orlando, Florida, United States|Teva Investigational Site 13829, Ormond Beach, Florida, United States|Teva Investigational Site 13830, Saint Petersburg, Florida, United States|Teva Investigational Site 13840, Tampa, Florida, United States|Teva Investigational Site 34222, Augusta, Georgia, United States|Teva Investigational Site 13833, Columbus, Georgia, United States|Teva Investigational Site 13826, Chicago, Illinois, United States|Teva Investigational Site 13818, Ann Arbor, Michigan, United States|Teva Investigational Site 13835, Las Vegas, Nevada, United States|Teva Investigational Site 13832, Las Vegas, Nevada, United States|Teva Investigational Site 13831, Lebanon, New Hampshire, United States|Teva Investigational Site 13820, Princeton, New Jersey, United States|Teva Investigational Site 13827, Albuquerque, New Mexico, United States|Teva Investigational Site 13816, Amherst, New York, United States|Teva Investigational Site 13817, New York, New York, United States|Teva Investigational Site 13809, Raleigh, North Carolina, United States|Teva Investigational Site 13839, Salisbury, North Carolina, United States|Teva Investigational Site 13825, Cleveland, Ohio, United States|Teva Investigational Site 13824, Philadelphia, Pennsylvania, United States|Teva Investigational Site 13841, Richmond, Texas, United States|Teva Investigational Site 13822, Virginia Beach, Virginia, United States|Teva Investigational Site 78120, Auchenflower, Australia|Teva Investigational Site 78118, Clayton, Australia|Teva Investigational Site 78123, Melbourne, Australia|Teva Investigational Site 78122, Parkville, Australia|Teva Investigational Site 78121, Randwick, Australia|Teva Investigational Site 11132, Newmarket, Ontario, Canada|Teva Investigational Site 11130, Calgary, Canada|Teva Investigational Site 11131, Toronto, Canada|Teva Investigational Site 40030, Helsinki, Finland|Teva Investigational Site 40031, Oulu, Finland|Teva Investigational Site 40029, Turku, Finland|Teva Investigational Site 32666, Berlin, Germany|Teva Investigational Site 32667, Bochum, Germany|Teva Investigational Site 32660, Essen, Germany|Teva Investigational Site 32665, Hamburg, Germany|Teva Investigational Site 32662, Kiel, Germany|Teva Investigational Site 32661, Konigstein im Taunus, Germany|Teva Investigational Site 32663, Rostock, Germany|Teva Investigational Site 80124, Ashkelon, Israel|Teva Investigational Site 80122, Hadera, Israel|Teva Investigational Site 80125, Holon, Israel|Teva Investigational Site 80121, Jerusalem, Israel|Teva Investigational Site 80123, Netanya, Israel|Teva Investigational Site 80120, Ramat Gan, Israel|Teva Investigational Site 80127, Tel Aviv, Israel|Teva Investigational Site 80126, Tel-Aviv, Israel|Teva Investigational Site 30190, Milan, Italy|Teva Investigational Site 30192, Modena, Italy|Teva Investigational Site 30194, Napoli, Italy|Teva Investigational Site 30193, Pavia, Italy|Teva Investigational Site 30191, Rome, Italy|Teva Investigational Site 30189, Rome, Italy|Teva Investigational Site 38118, Leiden, Netherlands|Teva Investigational Site 38119, Nijmegen, Netherlands|Teva Investigational Site 38117, Zwolle, Netherlands|Teva Investigational Site 53380, Bialystok, Poland|Teva Investigational Site 53383, Krakow, Poland|Teva Investigational Site 53379, Krakow, Poland|Teva Investigational Site 53382, Lodz, Poland|Teva Investigational Site 53381, Szczecin, Poland|Teva Investigational Site 31211, Galdakao., Spain|Teva Investigational Site 31214, Madrid, Spain|Teva Investigational Site 31213, Sevilla, Spain|Teva Investigational Site 31212, Valladolid, Spain|Teva Investigational Site 31215, Zaragoza, Spain|Teva Investigational Site 42047, Huddinge, Sweden|Teva Investigational Site 42045, Vallingby, Sweden|Teva Investigational Site 34224, Glasgow, United Kingdom|Teva Investigational Site 34220, London, United Kingdom|Teva Investigational Site 34223, London, United Kingdom|Teva Investigational Site 34221, Oxford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02964338/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02964338/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02964338
26,NCT02945046,A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH),NA,Terminated,Has Results,Episodic Cluster Headache,Drug: Fremanezumab|Drug: Placebo,"Mean Change From Baseline in the Weekly Average Number of Cluster Headache (CH) Attacks During the 4-Week Period After Administration of the First Dose of the IMP|Percentage of Participants With a ≥50% Reduction From Baseline in the Weekly Average Number of CH Attacks During the 4-Week Period After the First Dose of the IMP|Mean Change From Baseline in Weekly Average Number of CH Attacks During the 12-Week Period After Administration of the First Dose of the IMP|Mean Change From Baseline in Weekly Average Number of CH Attacks During the 4-Week Period After Administration of the Third Dose of the IMP|Mean Change From Baseline in the Weekly Average Number of Days With Use of Cluster-Specific Acute Headache Medications (Triptans and Ergot Compounds) During the 12-Week Period After the First Dose of the IMP|Mean Change From Baseline in the Weekly Average Number of Days Oxygen Was Used to Treat Episodic Cluster Headache (ECH) During the 12-Week Period After the First Dose of the IMP|Number of Participants Who Perceived Improvement of CH-Associated Pain From Baseline as Measured by the Patient-Perceived Satisfactory Improvement (PPSI) Scale at Weeks 1, 4, 8, and 12|Number of Participants With Adverse Events (AEs)|Number of Participants With Potentially Clinically Significant Laboratory (Serum Chemistry, Hematology, and Urinalysis) Abnormal Results|Number of Participants With Shift From Baseline to Endpoint in Coagulation Laboratory Test Results|Number of Participants With Potentially Clinically Significant Abnormal Vital Signs Values|Number of Participants With Shift From Baseline to Endpoint (Last Assessment) in Electrocardiogram (ECG) Parameters|Number of Participants Who Received Concomitant Medications|Number of Participants With Injection Site Reactions|Number of Participants With Hypersensitivity/Anaphylaxis Reactions|Number of Participants With Suicidal Ideation and Suicidal Behavior as Assessed by the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)","Teva Branded Pharmaceutical Products R&D, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,169,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TV48125-CNS-30056|2016-003278-42,"January 19, 2017","May 13, 2019","May 13, 2019","October 26, 2016","April 13, 2020","November 9, 2021","Teva Investigational Site 13834, Phoenix, Arizona, United States|Teva Investigational Site 13819, Canoga Park, California, United States|Teva Investigational Site 13811, Santa Monica, California, United States|Teva Investigational Site 13823, Stanford, California, United States|Teva Investigational Site 13837, Aurora, Colorado, United States|Teva Investigational Site 13814, Colorado Springs, Colorado, United States|Teva Investigational Site 13836, Denver, Colorado, United States|Teva Investigational Site 13813, Englewood, Colorado, United States|Teva Investigational Site 13821, New Haven, Connecticut, United States|Teva Investigational Site 13812, Stamford, Connecticut, United States|Teva Investigational Site 13810, Gainesville, Florida, United States|Teva Investigational Site 13815, Orlando, Florida, United States|Teva Investigational Site 13829, Ormond Beach, Florida, United States|Teva Investigational Site 13830, Saint Petersburg, Florida, United States|Teva Investigational Site 13840, Tampa, Florida, United States|Teva Investigational Site 13833, Columbus, Georgia, United States|Teva Investigational Site 13826, Chicago, Illinois, United States|Teva Investigational Site 13818, Ann Arbor, Michigan, United States|Teva Investigational Site 13835, Las Vegas, Nevada, United States|Teva Investigational Site 13832, Las Vegas, Nevada, United States|Teva Investigational Site 13831, Lebanon, New Hampshire, United States|Teva Investigational Site 13820, Princeton, New Jersey, United States|Teva Investigational Site 13827, Albuquerque, New Mexico, United States|Teva Investigational Site 13816, Amherst, New York, United States|Teva Investigational Site 13817, New York, New York, United States|Teva Investigational Site 13809, Raleigh, North Carolina, United States|Teva Investigational Site 13839, Salisbury, North Carolina, United States|Teva Investigational Site 13825, Cleveland, Ohio, United States|Teva Investigational Site 13824, Philadelphia, Pennsylvania, United States|Teva Investigational Site 13841, Richmond, Texas, United States|Teva Investigational Site 13822, Virginia Beach, Virginia, United States|Teva Investigational Site 78120, Auchenflower, Australia|Teva Investigational Site 78118, Clayton, Australia|Teva Investigational Site 78123, Melbourne, Australia|Teva Investigational Site 78122, Parkville, Australia|Teva Investigational Site 78121, Randwick, Australia|Teva Investigational Site 11130, Calgary, Canada|Teva Investigational Site 11131, Toronto, Canada|Teva Investigational Site 40030, Helsinki, Finland|Teva Investigational Site 40031, Oulu, Finland|Teva Investigational Site 40029, Turku, Finland|Teva Investigational Site 32666, Berlin, Germany|Teva Investigational Site 32667, Bochum, Germany|Teva Investigational Site 32660, Essen, Germany|Teva Investigational Site 32665, Hamburg, Germany|Teva Investigational Site 32662, Kiel, Germany|Teva Investigational Site 32661, Konigstein im Taunus, Germany|Teva Investigational Site 32663, Rostock, Germany|Teva Investigational Site 80124, Ashkelon, Israel|Teva Investigational Site 80122, Hadera, Israel|Teva Investigational Site 80125, Holon, Israel|Teva Investigational Site 80121, Jerusalem, Israel|Teva Investigational Site 80123, Netanya, Israel|Teva Investigational Site 80120, Ramat Gan, Israel|Teva Investigational Site 80127, Tel Aviv, Israel|Teva Investigational Site 80126, Tel-Aviv, Israel|Teva Investigational Site 30190, Milan, Italy|Teva Investigational Site 30192, Modena, Italy|Teva Investigational Site 30194, Napoli, Italy|Teva Investigational Site 30193, Pavia, Italy|Teva Investigational Site 30191, Rome, Italy|Teva Investigational Site 30189, Rome, Italy|Teva Investigational Site 38118, Leiden, Netherlands|Teva Investigational Site 38119, Nijmegen, Netherlands|Teva Investigational Site 38117, Zwolle, Netherlands|Teva Investigational Site 53380, Bialystok, Poland|Teva Investigational Site 53383, Krakow, Poland|Teva Investigational Site 53379, Krakow, Poland|Teva Investigational Site 53382, Lodz, Poland|Teva Investigational Site 53381, Szczecin, Poland|Teva Investigational Site 31211, Galdakao., Spain|Teva Investigational Site 31214, Madrid, Spain|Teva Investigational Site 31213, Sevilla, Spain|Teva Investigational Site 31212, Valladolid, Spain|Teva Investigational Site 31215, Zaragoza, Spain|Teva Investigational Site 42047, Huddinge, Sweden|Teva Investigational Site 42045, Vallingby, Sweden|Teva Investigational Site 34224, Glasgow, United Kingdom|Teva Investigational Site 34222, Liverpool, United Kingdom|Teva Investigational Site 34223, London, United Kingdom|Teva Investigational Site 34220, London, United Kingdom|Teva Investigational Site 34221, Oxford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02945046/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02945046/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02945046
27,NCT02930018,Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke,ESCAPE-NA1,Completed,Has Results,"Stroke, Acute","Drug: Nerinetide (NA-1), 2.6 mg/kg|Drug: Placebo",Number of Subjects With mRS Score of 0 to 2|Number of Subjects With NIHSS Score of 0 to 2|Mortality Rate,NoNO Inc.|University of Calgary,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1105,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NA-1-007","March 1, 2017","November 20, 2019","November 20, 2019","October 11, 2016","December 14, 2020","October 10, 2022","Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|California Pacific Medical Center - Davies Campus, San Francisco, California, United States|Providence Little Company of Mary Medical Center Torrance, Torrance, California, United States|Swedish Medical Center, Englewood, Colorado, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Baptist Health Medical Center, Jacksonville, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|WellStar Health Systems, Marietta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|NYU Lutheran Medical Center, Brooklyn, New York, United States|Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, United States|Riverside Radiology, Columbus, Ohio, United States|Abington Memorial Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Chattanooga Center for Neurologic Research, Chattanooga, Tennessee, United States|Valley Baptist Medical Center, Harlingen, Texas, United States|Swedish Medical Center- Cherry Hill Campus, Seattle, Washington, United States|Royal Adelaide Hospital, Adelaide, Australia|Royal Melbourne Hospital, Parkville, Australia|University of Calgary - Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Vancouver Stroke Program Research Office/ Vancouver General Hosptial, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Science Centre, Halifax, Nova Scotia, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|London Health Sciences Centre- University Hospital, London, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Sunnybrook Health Centre, Toronto, Ontario, Canada|St Michael's Hospital, Toronto, Ontario, Canada|University Health Network - Toronto Western Hospital, Toronto, Ontario, Canada|CHUM Hopital Notre-Dame, Montréal, Quebec, Canada|Montreal Neurological Institute and Hospital, Montréal, Quebec, Canada|CHU de Quebec- Universite Laval- Hopital de l'Enfant-Jesus, Quebec City, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada|Universitätsklinikum Carl Gustav Carus Dresdner Neurovaskulares Centrum, Dresden, Germany|Klinik für Radiologie und Neuroradiologie, Essen, Germany|University Medical Center Goettingen, Göttingen, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Neurologische Klinik, Universität Heidelberg, Heidelberg, Germany|Beaumont Hospital, Dublin, Ireland|Mater Hospital, Dublin, Ireland|Dongsan Medical Centre, Daegu, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Yonsei Univ, Severence, Seoul, Korea, Republic of|Skåne University Hospital, Lund, Sweden|Karolinksa Institutet, Stockholm, Sweden|Royal Victoria Hospital, Belfast, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02930018/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02930018/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02930018
28,NCT02926898,"A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome",NA,Completed,Has Results,Dravet Syndrome,Drug: ZX008 (Fenfluramine Hydrochloride)|Drug: Matching Placebo,Change in Convulsive Seizure Frequency (CSF) From the Baseline Period (Baseline) to the Combined Titration + Maintenance (T+M) Period|Percentage of Participants Who Achieved ≥ a 50% Reduction in Convulsive Seizure Frequency From Baseline to the Combined Titration + Maintenance Period|Longest Convulsive Seizure-Free Interval (Days),"Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.|UCB Pharma",All,"2 Years to 18 Years   (Child, Adult)",Phase 3,87,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ZX008-1504,"January 27, 2017","June 5, 2018","June 5, 2018","October 6, 2016","October 19, 2022","November 2, 2022","University of California San Francisco, San Francisco, California, United States|Children'S Hospital Colorado, Aurora, Colorado, United States|Ann & Robert H. Lurie Children'S Hospital of Chicago, Chicago, Illinois, United States|Children'S Hospital of Michigan, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Bc Children'S Hospital Division of Neurology, Vancouver, British Columbia, Canada|Chu Sainte-Justine Hospital Neurology Clinic, Montréal, Quebec, Canada|Chu Amiens Picardie Service de Neurologie Pédiatrique, Amiens, France|Chu de Bordeaux Hôpital Des Enfants, Bordeaux, France|HÔPITAL FEMME-MÈRE-ENFANT Hôpital Service de Neurologie Pédiatrique, Bron, France|Chru de Lille Hôpital Roger Salengro, Lille, France|Hôpital de La Timone, Service de Neuro-Métabolisme Pédiatrique, Marseille, France|Hôpital Necker-Enfants Malades, Paris, France|Hôpital Robert-Debré, Paris, France|Chu de Toulouse - Hôpital Des Enfants, Toulouse, France|Hôpital D'Enfants Chur de Nancy, Vandœuvre-lès-Nancy, France|Krankenhaus Mara, Epilepsie-Zentrum Bethel, Bielefeld, Germany|Universitätsklinikum Schleswig-Holstein, Klinik Für Neuropädiatrie, Kiel, Germany|Kleinwachau Sächsisches Epilepsiezentrum Radeberg, Radeberg, Germany|Epilepsiecentrum Kempenhaeghe, Heeze, Netherlands|Stichting Epilepsie Instellingen Nederland, Zwolle, Netherlands|Hospital Sant Joan de Déu Barcelona, Barcelona, Spain|Hospital Ruber Internacional-Servicio de Neurología, Madrid, Spain|Cliníca Universidad de Navarra Nidad de Neuropediatría, Pamplona, Spain|Royal Hospital For Children, Queen Elizabeth University, Institute of Neurosciences Hospital, Glasgow, Scotland, United Kingdom|Alder Hey Children'S Nhs Foundation Trust, Littlewood'S Neurosciences Unit, Liverpool, United Kingdom|Evelina London Children'S Hospital, Paediatric Neurosciences, London, United Kingdom|Great Ormond Street Hospital For Children Nhs Foundation Trust, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02926898/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02926898/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02926898
29,NCT02907177,Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®),POINT,Terminated,Has Results,Multiple Sclerosis,Drug: Ponesimod|Other: Placebo,Annualized Confirmed Relapse Rate (ARR)|Percentage of Participants With 12-Week Confirmed Disability Accumulation (CDA) as Assessed by Kaplan Meier Estimate at Week 96|Percentage of Participants Experiencing a Confirmed Relapse as Assessed by Kaplan Meier Estimate at Week 96|Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability,Actelion,All,18 Years to 55 Years   (Adult),Phase 3,136,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AC-058B302,"March 30, 2017","March 26, 2020","March 26, 2020","September 20, 2016","May 18, 2021","May 18, 2021","UAB Dpt of Neurology, Birmingham, Alabama, United States|Neuro-Pain Medical Center, Fresno, California, United States|SC3 Research - Pasadena, Pasadena, California, United States|Care Access Research - Santa Clarita, Santa Clarita, California, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Mountain View Clinical Research, Inc, Denver, Colorado, United States|Associated Neurologists, Danbury, Connecticut, United States|Bradenton Research Center, Bradenton, Florida, United States|Neurology Associates - MS Center of Greater Orlando, Maitland, Florida, United States|Neurology Assoc of Ormond Beach - CNS Trials, Ormond Beach, Florida, United States|Suncoast Neuroscience Associates, Inc, Saint Petersburg, Florida, United States|The MS Center of Vero Beach, Vero Beach, Florida, United States|Fort Wayne Neurological Center - North Office, Fort Wayne, Indiana, United States|University of Kansas Med Center, Kansas City, Kansas, United States|MidAmerica Neuroscience Research Foundation/Rowe Neurology, Lenexa, Kansas, United States|Henry Ford Health System - Neurology, Detroit, Michigan, United States|Univ of New Mexico - Health Sciences Center, Albuquerque, New Mexico, United States|NYU Langone Medical Center - MS Comprehensive Care Center, New York, New York, United States|Riverhills Healthcare, Inc., Cincinnati, Ohio, United States|OhioHealth Research Institute, Columbus, Ohio, United States|Neurology and Neuromuscular Center, Oklahoma City, Oklahoma, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital - Dpt Neurology MS Center, Philadelphia, Pennsylvania, United States|Advanced Neuroscience Institute, Franklin, Tennessee, United States|Neurology Center of San Antonio, San Antonio, Texas, United States|Austin Health - Neuro-Immunology Clinical Research, Education and Support Service, Heidelberg, Victoria, Australia|MS Ambulanz Maida, Wien, Austria|Medizinische Universität Wien, Universitätsklinik für Neurologie, Wien, Austria|Hospital universitair Brussels_neurology department, Brussels, Belgium|Hospital - Universitair Gent __Neurology Department, Gent, Belgium|Hospital - Revalidatie & MS Centrum Overpelt_Neurology Department, Overpelt, Belgium|""Multiprofile Hospital for Active Treatment of Neurology and Psychiatry - Sveti Naum"" EAD - Neurology Clinic for Movement Disorders, Sofia, Bulgaria|""University Multiprofile Hospital for Active Treatment - Alexandrovska"" EAD, Neurology Clinic, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sv. Ivan Rilski"" EAD, Neurology Clinic, Sofia, Bulgaria|University of Alberta, Edmonton, Canada|Fakultní nemocnice u sv. Anny Brno, RS Centrum, Brno, Czechia|Fakultní nemocnice Hradec Králové, Neurologická klinika, Hradec Králové, Czechia|Nemocnice Jihlava, Neurologické oddělení, Jihlava, Czechia|Pardubicka krajska nemocnice, MS Centrum, Pardubice, Czechia|Krajská zdravotní a.s. - Nemonice Teplice o.z., RS Centrum, Teplice, Czechia|Aalborg Universitetshospital, Skleroseklinikken Neurologisk afdelning, Aalborg, Denmark|Glostrup Hospital, Neurologisk afdelning, Glostrup, Denmark|Hôpital Avicenne, Service de Neurologie, Bobigny, France|Hosp Gabriel Montpied, Dept Neurology, Clermont Ferrand, France|Centre Hospitalier Sud Francilien - Service de Neurologie, Corbeil-Essonnes, France|CHU de Dijon - Hôpital François Miterrand, Service de Neurologie, Dijon, France|CHRU de Lille - Hôpital Roger Salengro, Service de Neurologie, Lille, France|Hopital Gui de Chauliac - CHU Montpellier, Montpellier, France|Hôpital Central - CHU Nancy, Département Neurologie, Nancy, France|Hôpital Universitaire Carémeau, Service de Neurologie, Nimes, France|CHI POISSY-Saint Germay en Laye_Service de Neurologie et Réeducation, Poissy, France|Hosp Pontchaillou, Dept Cardiology, Rennes, France|Hosp Charles Nicolle Dept Neurology, Rouen, France|Zentrum für klinische Forschung Dr. med. Irma Schöll, Bad Homburg, Germany|Neurologische Klinik und Poliklinik - Universitätsklinikum Carl Gustav Carus, Zentrum für klinische Neurowissenschaften, Dresden, Germany|Helios Klinikum Erfurt, Erfurt, Germany|Universitätsklinikum Giessen Klinik und Poliklinik für Neurologie, Giessen, Germany|Universitätsmedizin Greifswald - Körperschaft des öffentlichen Rechts - Klinik und Poliklinik für Neurologie, Greifswald, Germany|Medizinische Hochschule Hannover, Neurologie, Hannover, Germany|AFL Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Universitätsklinikum Münster, Klinik für Allgemeine Neurologie, Münster, Germany|Medizinzentrum Siegerland Weidenau, Siegen, Germany|NeuroPoint GmbH, Gesellschaft für vorbeugende Gesundheitspflege, Ulm, Germany|Gemeinschaftspraxis Dr. med. Joachim Springub / Wolfgang Schwarz, Studienzentrum Nord-West (Study Center), Westerstede, Germany|Naval Hospital of Athens - Neurology Dpt, Athens, Greece|401 Military Hospital of Athens - Neurology Dept, Athens, Greece|Aeginition Hospital - Neurology Department, Athens, Greece|Medical Center of Athens - Neurology Dpt, Marousi, Greece|General Hospital of Thessaloniki, Thessaloniki, Greece|Uzsoki utcai Kórház, Neurológiai Osztály, Budapest, Hungary|Valeomed EGÉSZSÉGÜGYI KÖZPONT, Esztergom, Hungary|Pest Megyei Flór Ferenc Kórház, Neurológia és Stroke ambulancia, Kistarcsa, Hungary|Fondazione Istituto San Raffaele , Unità Operativa di Neurologia, Cefalù, Italy|Università degli Studi di Firenze - Azienda Ospedaliero Universitaria Careggi - CTO - SOD Neurologia 2, Firenze, Italy|AOU San Martino di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DINOGMI), Genova, Italy|Istituto Neurologico Carlo Besta, UOC Neurologia 4, Neuroimmunologia e Malattie Neuromuscolari, Centro Sclerosi Multipla, Milano, Italy|Azienda Ospedaliera Universitaria (AOU) ""Federico II"" - Centro Regionale Per la Sclerosi Multipla c/o Clinica Neurologica II - Dipartimento di Scienze, Napoli, Italy|AOU Università degli Studi della Campania L. Vanvitelli - I° Policlinico - DAI di Medicina Interna e Specialistica CS, Centro Sclerosi Multipla, Napoli, Italy|Azienda Ospedaliero Universitaria San Luigi Gonzaga - Centro Sclerosi Multipla CRESM, Orbassano, Italy|IRCCS NEUROMED - Istituto Neurologico Mediterraneo - Unità Operativa di Neurologia I, Pozzilli, Italy|Azienda Ospedaliera S. Andrea di Roma - Unità Operativa Complessa di Neurologia, Roma, Italy|Azienda Ospedaliera Universitaria Senese - Dipartimento di Scienze Neurologiche e neurosensoriali - UOSA Neurologia Sperimentale, Siena, Italy|Unidad de Investigacion en Salud de Chihuahua SC, Médica Sur, Unidad de Neurociencias, Tlalpan, DF, Mexico|Desarrollo Ético en Investigación Clínica S.C ., Guadalajara, Jalisco, Mexico|Axis Heilsa S. de R.L. de C.V. (Althian), Nuevo Leon, Monterrey, Mexico|Unidad de Investigación de Salud en Chihuahua, Chihuahua, Mexico|Uniwersytecki Szpital Kliniczny w Bialymstoku, Klinika Neurologii i Oddziat Udarowy, Bialystok, Poland|B&B Robert Bonek, Pawel Bochniak S.C, Bydgoszcz, Poland|COPERNICUS - Podmiot Leczniczy Sp. z o.o., Gdansk, Poland|Centrum Terapii SM, Katowice, Poland|Neuro-Medic Janusz Zbrojkiewicz Poradnia Weilospecjalistyczna, Katowice, Poland|Centrum Kompleksowej Rehabilitacji, Konstancin-Jeziorna, Poland|Centrum Opieki Zdrowotnej Orkan - Med., Ksawerów, Poland|Instytut Psychiatrii i Neurologii, II Klinika Neurologiczna, Warszawa, Poland|WroMedica, J. Bielicka A. Strzałkowska SC, Wroclaw, Poland|Centro Hospitalar de Lisboa Central, Lisboa, Portugal|Hospital de Santa Maria - Neurology Department, Lisboa, Portugal|Centro Hospitalar de São João, E.P.E. - Hospital de São João - Neurology Department, Porto, Portugal|State Budgetary Healthcare Institution Regional Clinical Hospital No 3, Chelyabinsk, Russian Federation|Center of Professional Therapy, LLC, Krasnodar, Russian Federation|Moscow State Budgetary Healthcare Institution Filatov City Clinical Hospital No.15 of Moscow Health Department, Moscow, Russian Federation|Neuro-Clinic, LLC, Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution Pirogov City Clinical Hospital No. 1 of Moscow Health Department, Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution City Clinical Hospital No. 24 of Moscow Health Department, Moscow, Russian Federation|Hospital Santa Creu I Sant Pau - Neurology Dpt, Barcelona, Spain|Hosp Virgen de la Arrixaca, Neurology, El Palmar, Spain|Hosp Gregorio Marañón, Neurology, Madrid, Spain|Hospital Clinico San Carlos, Neurology, Madrid, Spain|Hospital Santa Caterina - Neurology Department, Salt, Spain|Complejo Hospitalario Universitario de Santiago de Compostela (CHUS) - Neurology Department 2, Santiago de Compostela, Spain|Hospital Universitario Virgen Macarena - Neurofisiology Department, Sevilla, Spain|Centro de Neurologia Avanzada, Neurology, Sevilla, Spain|Univeritätsspital Basel Neurologie, Neurologische Klinik und Poliklinik, Basel, Switzerland|Ospedale Regionale di Lugano - Civico e Italiano, Neurologia, Lugano, Lugano, Switzerland|Queen Square MS Centre / NMR research Unit UCL Institute of Neurology, London, United Kingdom|Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom|University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02907177/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02907177/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02907177
30,NCT02867709,"Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine",ACHIEVE II,Completed,Has Results,"Migraine, With or Without Aura",Drug: Ubrogepant|Drug: Placebo-matching Ubrogepant,Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose|Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose|Percentage of Participants With Pain Relief at 2 Hours After the Initial Dose|Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours After Initial Dose|Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose|Percentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose|Percentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose|Percentage of Participants With Absence of Nausea at 2 Hours After the Initial Dose,Allergan,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,1686,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",UBR-MD-02,"August 26, 2016","January 25, 2018","February 26, 2018","August 16, 2016","January 29, 2019","March 19, 2019","Clinical Research Advantage, Inc./Simon Williamson Clinic, Birmingham, Alabama, United States|Clinical Research Advantage, Inc./East Valley Family Physicians, PLC, Chandler, Arizona, United States|St. Joseph's Hospital & Medical Center - Barrow Neurologic Institute (BNI), Phoenix, Arizona, United States|Clinical Research Advantage, Inc./Central Phoenix Medical Clinic, LLC, Phoenix, Arizona, United States|Mayo Clinic Arizona, May Clinic Scottsdale, Scottsdale, Arizona, United States|Radiant Research Inc., Tucson, Arizona, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|Axiom Research, LLC, Apple Valley, California, United States|Hope Clinical Research, Canoga Park, California, United States|Axiom Research, LLC, Colton, California, United States|Pharmacology Research Institute, Encino, California, United States|Neuro-Pain Medical Center, Fresno, California, United States|California Headache and Balance Center, Fresno, California, United States|Sun Valley Research Center, Imperial, California, United States|Grossmont Center For Clinical Research, La Mesa, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|California Advanced Neurotherapeutic, Inc., Los Angeles, California, United States|Cedars Sinai Pain Center, Los Angeles, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Rancho Cucamonga Clinical Research, Rancho Cucamonga, California, United States|Desert Valley Research, Rancho Mirage, California, United States|George J Rederich MD, Inc, Redondo Beach, California, United States|Artemis Institute For Clinical Research, San Diego, California, United States|Clinical Research Advantage, Inc./Cassidy Medical Group-Vista, Vista, California, United States|Clinicos, LLC, Colorado Springs, Colorado, United States|Colorado Neurological Institute, Englewood, Colorado, United States|Advanced Neurosciences Research, LLC, Fort Collins, Colorado, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Radiant Clinical Research, Washington, District of Columbia, United States|Aventura Neurological Associates, Aventura, Florida, United States|Clinical Research South Florida, Coral Gables, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Broward Research Group, Hollywood, Florida, United States|Health Awareness, Inc., Jupiter, Florida, United States|Neurology Associates, P.A., Maitland, Florida, United States|Panax Clinical Research, Miami Lakes, Florida, United States|LCC Medical Research Institute, LLC, Miami, Florida, United States|Well Pharma Medical Research, Corp., Miami, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Sensible Healthcare, LLC, Ocoee, Florida, United States|QPS MRA, LLC (Miami Research Associates), South Miami, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|The Kaufmann Clinic, Inc., Atlanta, Georgia, United States|NeuroTrials Research, Inc., Atlanta, Georgia, United States|Advanced Clinical Research, Meridian, Idaho, United States|Clinical Research Advantage, Inc./Michigan Avenue Internists, Chicago, Illinois, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|Robbins Headache Clinic, Riverwoods, Illinois, United States|Josephson Wallack Munshower Neurology P.C., Indianapolis, Indiana, United States|Norton Neurology Services MS Services, Louisville, Kentucky, United States|L-MARC Research Center, Louisville, Kentucky, United States|Seton Medical Group, Baltimore, Maryland, United States|Overlea Personal Physicians, Baltimore, Maryland, United States|BTC of New Bedford, New Bedford, Massachusetts, United States|Beacon Clinical Research, LLC, Quincy, Massachusetts, United States|New England Regional Headache Center, Inc., Worcester, Massachusetts, United States|Quest Research Institute, Farmington Hills, Michigan, United States|Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States|The Headache Center, Ridgeland, Mississippi, United States|Clinical Research Advantage, Inc./Prairie Fields Family Medicine, PC, Fremont, Nebraska, United States|Clinical Research Advantage, Inc, Omaha, Nebraska, United States|Meridian Clinical Research, LLC, Omaha, Nebraska, United States|Hope Research Institute, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Princeton Center for Clinical Research, Skillman, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|DENT Neurosciences Research Center, Amherst, New York, United States|Cushing Neuroscience Institute North Shore-LIJ Medical Group, Great Neck, New York, United States|ProHealth Care Associates, LLP, Plainview, New York, United States|Upstate Clinical Research Associates, LLC, Williamsville, New York, United States|Westchester Neuro. Const, Yonkers, New York, United States|Carolina Headache Institute, Durham, North Carolina, United States|Headache Wellness Center, PC, Greensboro, North Carolina, United States|Lake Shore Clinical Research, LLC, Mooresville, North Carolina, United States|Raleigh Neurology Associates, PA, Raleigh, North Carolina, United States|Plains Clinical Research Center, LLC, Fargo, North Dakota, United States|Radiant Research, Inc., Akron, Ohio, United States|Sentral Clinical Research Services, Cincinnati, Ohio, United States|Patient Priority Clinical Sites, LLC, Cincinnati, Ohio, United States|University of Cincinnati Dept of Psychiatry & Behavioral Neuroscience, Cincinnati, Ohio, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Sooner Clinical Research, Oklahoma City, Oklahoma, United States|Preferred Primary Care Physicians, Inc., Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Abington Neurological Associates, Ltd., Willow Grove, Pennsylvania, United States|Radiant Research, Inc., Anderson, South Carolina, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|Vista Clinical Research, Columbia, South Carolina, United States|Hillcrest Clinical Research, LLC, Simpsonville, South Carolina, United States|Middle Tennessee Clinical Research, Fayetteville, Tennessee, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Baptist Memorial Medical Group (Neurology Specialist - Headache Clinic), Memphis, Tennessee, United States|Texas Neurology, P.A., Dallas, Texas, United States|Radiant Research, Inc, Dallas, Texas, United States|Research Trials Worldwide, LLC, Humble, Texas, United States|Advanced Research Institute, Ogden, Utah, United States|Charlottesville Medical Research Center, LLC, Charlottesville, Virginia, United States|iNeuro Headache Specialist, McLean, Virginia, United States|Clinical Research Associates of Tidewater, Norfolk, Virginia, United States|Blue Ridge Research Center, LLC, Roanoke, Virginia, United States|Sentara Neurology Specialists, Virginia Beach, Virginia, United States|Summit Research Network Seattle, LLC, Seattle, Washington, United States|South Puget Sound Neurology, Tacoma, Washington, United States|West Virginia University, Department of Neurology, Morgantown, West Virginia, United States|Medical College of Wisconsin, Department of Neurology, Milwaukee, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02867709/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02867709/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02867709
31,NCT02848326,"Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention",NA,Completed,Has Results,"Migraine, With or Without Aura",Drug: Atogepant|Drug: Placebo-matching Atogepant,Change From Baseline in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period|Change From Baseline in Mean Monthly Headache Days Across the 12-Week Treatment Period|Percentage of Participants With at Least a 50% Reduction in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period|Change From Baseline in Mean Monthly Acute Medication Use Days Across the 12-Week Treatment Period,Allergan,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,834,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",CGP-MD-01,"September 6, 2016","April 2, 2018","April 23, 2018","July 28, 2016","December 6, 2018","December 6, 2018","Achieve Clinical Research, Birmingham, Alabama, United States|Radiant Research, Inc., Chandler, Arizona, United States|The Research Center of Southern California, LLC, Carlsbad, California, United States|Neuro-Pain Medical Center, Inc, Fresno, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|Downtown LA Research Center, Inc., Los Angeles, California, United States|Excell Research, Oceanside, California, United States|Artemis Institute for Clinical Research, San Marcos, California, United States|Diablo Clinical Research Inc, Walnut Creek, California, United States|Advanced Neurosciences Research, Fort Collins, Colorado, United States|Hartford Headache Center, East Hartford, Connecticut, United States|Associated Neurologists of Southern Connecticut, P. C., Fairfield, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|The George Washington University, Washington, District of Columbia, United States|Clinical Research South Florida, Coral Gables, Florida, United States|Infinity Clinical Research, Hollywood, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Clinical Neuroscience Solutions Inc, Jacksonville, Florida, United States|Meridien Research, Maitland, Florida, United States|Suncoast Research, Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Clinical Neuroscience Solutions, Orlando, Florida, United States|Palm Beach Neurological Center / Advanced Research Consultants, Inc., Palm Beach Gardens, Florida, United States|Suncoast Neuroscience Associates, Inc., Saint Petersburg, Florida, United States|Infinity Clinical Research LLC, Sunrise, Florida, United States|Meridien Research, Tampa, Florida, United States|Neurology Research Institute Palm Beach, West Palm Beach, Florida, United States|Institute for Advanced Medical Research, Alpharetta, Georgia, United States|Radiant Research, Atlanta, Georgia, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|Pediatric and Adolescent NeuroDevelopmental Associates (PANDA) Neurology, Sandy Springs, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Northwest Clinical Trials, Inc., Boise, Idaho, United States|Healthcare Research Network II, LLC, Blue Island, Illinois, United States|Rowe Neurology Institute, Lenexa, Kansas, United States|Boston Clinical Trials Inc, Boston, Massachusetts, United States|Northeast Medical Research Associates, Inc., North Dartmouth, Massachusetts, United States|Medvadis Research Corporation, Watertown, Massachusetts, United States|New England Regional Headache Center, Worcester, Massachusetts, United States|Michigan Head Pain and Neurological Institute, Ann Arbor, Michigan, United States|Clinical Research Institute, Inc., Minneapolis, Minnesota, United States|Mercy Research, Springfield, Missouri, United States|Clinvest, Springfield, Missouri, United States|Quality Clinical Research, Inc, Omaha, Nebraska, United States|Altea Research Institute, Las Vegas, Nevada, United States|Renown Institute for Neuroscience, Reno, Nevada, United States|Hassman Research Institute - NJ, Berlin, New Jersey, United States|Amici Clinical Research, Warren, New Jersey, United States|DENT Neurosciences Research Center, Amherst, New York, United States|Radiant Research, Inc., Jamaica, New York, United States|Carolina Headache Institute, Durham, North Carolina, United States|Wake Research Associates LLC, Raleigh, North Carolina, United States|Ohio Clinical Research, LLC, Willoughby Hills, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Oregon Center for Clinical Investigations, Inc., Salem, Oregon, United States|Lehigh Center For Clinical Research, Allentown, Pennsylvania, United States|Suburban Research Associates, Media, Pennsylvania, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Cns Healthcare, Memphis, Tennessee, United States|Nashville Neuroscience Group, Nashville, Tennessee, United States|Tekton Research, Austin, Texas, United States|DermResearch Inc, Austin, Texas, United States|DiscoveResearch, Inc., Bryan, Texas, United States|Synexus US, L.P. Formally known as Texas Pharmaceutical Research, LP, DBA Research Across America, Dallas, Texas, United States|Central Texas Neurology Consultant, Round Rock, Texas, United States|Radiant Research, San Antonio Center for Clinical Research, San Antonio, Texas, United States|Road Runner Research LTD, San Antonio, Texas, United States|ClinPoint Trials, LLC, Waxahachie, Texas, United States|Advanced Clinical Research, West Jordan, Utah, United States|Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Women's Clinical Research Center, Seattle, Washington, United States|Kingfisher Cooperative, LLC, Spokane, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02848326/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02848326/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02848326
32,NCT02828020,"Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine",ACHIEVE I,Completed,Has Results,"Migraine, With or Without Aura",Drug: Ubrogepant|Drug: Placebo-matching Ubrogepant,Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose|Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose|Percentage of Participants With Pain Relief at 2 Hours After the Initial Dose|Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours After Initial Dose|Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose|Percentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose|Percentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose|Percentage of Participants With Absence of Nausea at 2 Hours After the Initial Dose,Allergan,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,1672,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",UBR-MD-01,"July 22, 2016","December 13, 2017","December 14, 2017","July 11, 2016","January 3, 2019","January 3, 2019","Clinical Research Advantage, Inc./Desert Clinical Research, LLC., Mesa, Arizona, United States|Xenoscience, Inc., Phoenix, Arizona, United States|Clinical Research Advantage, Inc./Orange Grove Family Practice, Tucson, Arizona, United States|Principals Research Group, Inc., Hot Springs, Arkansas, United States|KLR Business Group, Inc. dba Arkansas Clinical Research, Little Rock, Arkansas, United States|The Research Center of Southern California, LLC, Carlsbad, California, United States|Med Center, Carmichael, California, United States|T. Joseph Raoof MD, Inc./Encino Research Center, Encino, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Prime Care Clinical Research, Laguna Hills, California, United States|Collaborative Neuroscience Network, LLC., Long Beach, California, United States|Synergy San Diego, National City, California, United States|Newport Beach Clinical Research Associates, Inc., Newport Beach, California, United States|North County Clinical Research, Oceanside, California, United States|Medical Center for Clinical Research, San Diego, California, United States|CA Medical Clinic for Headache, Santa Monica, California, United States|Southern California Research LLC, Simi Valley, California, United States|Encompass Clinical Research, Spring Valley, California, United States|Alpine Clinical Research Center, Inc., Boulder, Colorado, United States|Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States|Delta Waves, Inc, Colorado Springs, Colorado, United States|Denver Neurological Research, Denver, Colorado, United States|Associated Neurologists, P.C., Danbury, Connecticut, United States|Associated Neurolgists of Southern Connecticut, PC, Fairfield, Connecticut, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|CPI MD Clinical, Hallandale Beach, Florida, United States|Infinity Clinical Research, LLC, Hollywood, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Palm Beach Neurological Center/Advanced Research Consultants, Inc., Palm Beach Gardens, Florida, United States|Meridien Research, Spring Hill, Florida, United States|University of South Florida, Tampa, Florida, United States|Meridien Research, Tampa, Florida, United States|Neurology Research Institute, West Palm Beach, Florida, United States|Midtown Neurology, Atlanta, Georgia, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Deaconess Clinic, Medical Office Building 1 Research Institute, Newburgh, Indiana, United States|Rowe Neurology Institute, Lenexa, Kansas, United States|Kansas Institute of Research, Overland Park, Kansas, United States|College Park Family Care Center Physicians Group - Neurology Research Department, Overland Park, Kansas, United States|Kentucky Pediatric/Adult Research, Bardstown, Kentucky, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|Boston Clinical Trials, Boston, Massachusetts, United States|Northeast Medical Research Associates, Inc, South Dartmouth, Massachusetts, United States|MedVadis Research Corporation, Watertown, Massachusetts, United States|Michigan Head-Pain & Neurological Institute, Ann Arbor, Michigan, United States|Beyer Research, Kalamazoo, Michigan, United States|Clinical Research Institute, Inc., Minneapolis, Minnesota, United States|Olive Branch Family Medical Center, Olive Branch, Mississippi, United States|Clinvest Research, LLC, Springfield, Missouri, United States|Quality Clinical Research, Inc., Omaha, Nebraska, United States|Clinical Research Advantage, Inc./Diagnostic Center of Medicine - Durango, Las Vegas, Nevada, United States|Albuquerque Clinical Trials, Inc., Albuquerque, New Mexico, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Regional Clinical Research, Inc., Endwell, New York, United States|Central New York Clinical Research, Manlius, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|Neurology Associates, P.A., Hickory, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|PMG Research of Winston-Salem, LLC., Winston-Salem, North Carolina, United States|Neuro-Behavioral Clinical Research, Inc., Canton, Ohio, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|Aventiv Research, Inc, Columbus, Ohio, United States|Ohio Clinical Research, LLC, Lyndhurst, Ohio, United States|MPH IPS Research Company, Oklahoma City, Oklahoma, United States|NPC Research, Oklahoma City, Oklahoma, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Summit Research Network, Portland, Oregon, United States|Oregon Center For Clinical Investigations Inc. (OCCI, Inc.), Portland, Oregon, United States|Clinical Research of Philadelphia, LLC, Philadelphia, Pennsylvania, United States|BTC of Lincoln, Lincoln, Rhode Island, United States|WR-ClinSearch, LLC, Chattanooga, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|FutureSearch Trials of Neurology, Austin, Texas, United States|Tekton Research, Inc., Austin, Texas, United States|FutureSearch Trials of Dallas, LP, Dallas, Texas, United States|Red Star Research, LLC, Lake Jackson, Texas, United States|Clinical Trials Texas, Inc, San Antonio, Texas, United States|Road Runner Research, Ltd., San Antonio, Texas, United States|J. Lewis Research, Inc. / Foothill Family Clinic Draper, Draper, Utah, United States|Granger Medical Clinic-Riverton, Riverton, Utah, United States|Optimum Clinical Research, Inc., Salt Lake City, Utah, United States|Highland Clinical Research, Salt Lake City, Utah, United States|Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|The Polyclinic Madison Center, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02828020/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02828020/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02828020
33,NCT02794168,Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury,NOSTRA-III,Completed,No Results Available,Traumatic Brain Injury,Drug: VAS203|Drug: Saline,extended Glasgow Outcome Scale|Quality of life after brain injury (QOLIBRI)|QOLIBRI overall scale|Therapy Intensity Level|Number of decompressive craniectomies,Vasopharm GmbH|ICON plc,All,18 Years to 60 Years   (Adult),Phase 3,224,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",VAS203/III/1/04,June 2016,"June 30, 2020","June 30, 2020","June 8, 2016",NA,"October 11, 2021","Universitätsklinik für Neurochirurgie, Graz, Austria|Neurologie und Neurochirurgie Medizinische Universität Innsbruck, Innsbruck, Austria|Klinik für Allgemeine Anästhesie und Intensivmedizin AKH Wien, Wien, Austria|Hôpital Pellegrin Service de réanimation traumatologique et chirurgicale, Bordeaux, France|Hopital Gabriel Montpied, Clermont-Ferrand, France|Pôle Anesthésie Réanimation Douleur Urgence, Nimes, France|HIA Sainte-Anne Boulevard Sainte-Anne, Toulon, France|Charite Virchow-Klinikum, Berlin, Germany|Berufsgenossenschaftliche Kliniken Bergmannsheil Klinik für Neurochirurgie, Bochum, Germany|Allgemeines Krankenhaus Celle Neurotraumatologie, Celle, Germany|Universitätsklinikum Düsseldorf Neurochirurgische Klinik, Düsseldorf, Germany|Klinik für Neurochirurgie Universität Frankfurt, Frankfurt, Germany|Universitätsklinikum Göttingen Klinik für Neurochirurgie, Göttingen, Germany|Berufsgenossenschaftliche Kliniken Bergmannstrost Halle Klinik für Neurochirurgie, Halle, Germany|Universitätsklinikum Hamburg-Eppendorf Klinik und Poliklinik für Neurochirurgie, Hamburg, Germany|Medizinische Hochschule Hannover Klinik für Neurochirurgie, Hannover, Germany|Neurochirurgische Universitätsklinik Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlands, Homburg, Germany|Universitätsklinikum Jena Klinik und Poliklinik für Neurochirurgie, Jena, Germany|Universitätsklinikum Schleswig-Holstein Klinik für Neurochirurgie, Kiel, Germany|Universitätsklinikum Leipzig Klinik und Poliklinik für Neurochirurgie, Leipzig, Germany|Vall d'Hebron University Hospital Department of Neurosurgery, Barcelona, Spain|Hospital General Universitario, Elche, Spain|Hospital 12 de Octubre, Madrid, Spain|Son Espases University Hospital, Palma, Spain|Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom|NHS Lothian University of Edinburgh, Edinburgh, United Kingdom|Kings College Hospital London, London, United Kingdom|Southampton University Hospital Division of Clinical Neurosciences, Southampton, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT02794168
34,NCT02793687,Study of Efficacy and Safety of MEXIDOL®,NA,Completed,No Results Available,Ischemic Stroke,Drug: MEXIDOL® (ethylmethylhydroxypyridine succinate)|Other: Placebo,modified Rankin Scale|The National Institutes of Health Stroke Scale|Barthel Index|Beck Depression Inventory|EuroQoL Quality of Life Scale,Pharmasoft,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 3,150,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2013-08-11,October 2014,May 2016,NA,"June 8, 2016",NA,"June 8, 2016",NA,NA,https://ClinicalTrials.gov/show/NCT02793687
35,NCT02792231,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.,ASCLEPIOS II,Completed,Has Results,Relapsing Multiple Scelrosis,Drug: Ofatumumab subcutaneous injection|Drug: Teriflunomide-matching placebo capsules|Drug: Teriflunomide capsule|Drug: Matching placebo of ofatumumab subcutaneous injections,Annualized Relapse Rate (ARR)|3-month Confirmed Disability Worsening (3mCDW) Based on EDSS - Pooled Data|3-month Confirmed Disability Worsening (3mCDW) Based on EDSS - Study COMB157G2302|6-month Confirmed Disability Worsening (6mCDW) Based on EDSS - Pooled Data|6-month Confirmed Disability Worsening (6mCDW) Based on EDSS - Study COMB157G2302|6-month Confirmed Disability Improvement (6mCDI ) Based on EDSS - Pooled Data|6-month Confirmed Disability Improvement (6mCDI ) Based on EDSS - Study COMB157G2302|Number of Gadolinium-enhancing T1 Lesions Per MRI Scan|Number of New or Enlarging T2 Lesions on MRI Per Year (Annualized Lesion Rate)|Neurofilament Light Chain (NfL) Concentration in Serum|Annualized Rate of Brain Volume Loss Based on Assessments of Percent Brain Volume Change From Baseline|Participants With Confirmed Relapse|Annualized Relapse Rate (ARR) >8 Weeks After Onset of Treatment|3-month Confirmed Disability Worsening (3mCDW) Based on EDSS > 8 Weeks After Onset of Treatment - Pooled Data|6-month Confirmed Disability Worsening (6mCDW) Based on EDSS > 8 Weeks After Onset of Treatment - Pooled Data|6-month Confirmed Cognitive Decline on Symbol Digit Modalities Test (SDMT) - Pooled Data|6-month Confirmed Disability Worsening (6mCDW) or 6-month Confirmed Cognitive Decline (6mCCD) - Pooled Data|Change in Cognitive Performance Measured by the Symbol Digit Modalities Test (SDMT) - Pooled Data|6-month Confirmed Worsening of at Least 20% in the Timed 25-Foot Walk (T25FW) - Pooled Data|6-month Confirmed Worsening of at Least 20% in the 9-Hole Peg Test (9HPT) - Pooled Data|6-month Confirmed Disability Improvement (6mCDI) Sustained Until End of Study (EOS) as Measured by EDSS - Pooled Data|Number of New or Enlarging T2 Lesions on MRI Per Year From Month 12 Until End of Study (EOS)|Percent Change in T2 Lesion Volume Relative to Baseline|No Evidence of Disease Activity (NEDA-4)|Multiple Sclerosis Impact Scale (MSIS-29) Physical Impact Score Change From Baseline|Multiple Sclerosis Impact Scale (MSIS-29) Psychological Impact Score Change From Baseline|Annualized Relapse Rates (ARR) by NfL High-low Subgroups - Pooled Data|Number of New or Enlarging T2 Lesions Per Year by NfL High-low Subgroups - Pooled Data|Brain Volume Loss by NfL High-low Subgroups - Pooled Data|Pharmacokinetic (PK) Concentrations of Ofatumumab,Novartis Pharmaceuticals|Novartis,All,18 Years to 55 Years   (Adult),Phase 3,955,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",COMB157G2302|2015-005419-33,"August 26, 2016","July 10, 2019","October 22, 2020","June 7, 2016","October 19, 2020","November 22, 2021","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Cullman, Alabama, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Basalt, Colorado, United States|Novartis Investigative Site, Boulder, Colorado, United States|Novartis Investigative Site, Centennial, Colorado, United States|Novartis Investigative Site, Colorado Springs, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Fort Collins, Colorado, United States|Novartis Investigative Site, Fort Collins, Colorado, United States|Novartis Investigative Site, Fairfield, Connecticut, United States|Novartis Investigative Site, Newark, Delaware, United States|Novartis Investigative Site, Bradenton, Florida, United States|Novartis Investigative Site, Gainesville, Florida, United States|Novartis Investigative Site, Maitland, Florida, United States|Novartis Investigative Site, Ocala, Florida, United States|Novartis Investigative Site, Oldsmar, Florida, United States|Novartis Investigative Site, Ormond Beach, Florida, United States|Novartis Investigative Site, Palm Coast, Florida, United States|Novartis Investigative Site, Saint Petersburg, Florida, United States|Novartis Investigative Site, Sarasota, Florida, United States|Novartis Investigative Site, Tallahassee, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Suwanee, Georgia, United States|Novartis Investigative Site, Anderson, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Wellesley, Massachusetts, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Golden Valley, Minnesota, United States|Novartis Investigative Site, Billings, Montana, United States|Novartis Investigative Site, Great Falls, Montana, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Asheville, North Carolina, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Greensboro, North Carolina, United States|Novartis Investigative Site, Akron, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Westerville, Ohio, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Willow Grove, Pennsylvania, United States|Novartis Investigative Site, Greer, South Carolina, United States|Novartis Investigative Site, Cordova, Tennessee, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Greenville, Texas, United States|Novartis Investigative Site, Lubbock, Texas, United States|Novartis Investigative Site, Sherman, Texas, United States|Novartis Investigative Site, Orem, Utah, United States|Novartis Investigative Site, Salt Lake City, Utah, United States|Novartis Investigative Site, Salt Lake City, Utah, United States|Novartis Investigative Site, Kirkland, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Waukesha, Wisconsin, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Tucuman, Argentina|Novartis Investigative Site, Liverpool, New South Wales, Australia|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Aalst, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Osijek, Croatia|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Brno, Czech Republic, Czechia|Novartis Investigative Site, Havirov, Czech Republic, Czechia|Novartis Investigative Site, Teplice, Czech Republic, Czechia|Novartis Investigative Site, Ostrava-Poruba, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Tampere, Finland|Novartis Investigative Site, Turku, Finland|Novartis Investigative Site, Nice, Cedex1, France|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Clermont-Ferrand, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Paris Cedex 13, France|Novartis Investigative Site, Rennes Cedex, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Homburg, Germany|Novartis Investigative Site, Koln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Minden, Germany|Novartis Investigative Site, Siegen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Unterhaching, Germany|Novartis Investigative Site, Budapest, HUN, Hungary|Novartis Investigative Site, Esztergom, HUN, Hungary|Novartis Investigative Site, Hyderabad, Andhra Pradesh, India|Novartis Investigative Site, New Delhi, Delhi, India|Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Ludhiana, Punjab, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Genova, Italy|Novartis Investigative Site, Milano, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Rome, Italy|Novartis Investigative Site, Riga, LV, Latvia|Novartis Investigative Site, Riga, Latvia|Novartis Investigative Site, Riga, Latvia|Novartis Investigative Site, Kaunas, LTU, Lithuania|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Chihuahua, Mexico|Novartis Investigative Site, Drammen, Norway|Novartis Investigative Site, Cercado De Lima, Lima, Peru|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Glogow, Poland|Novartis Investigative Site, Rzeszow, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Zabrze, Poland|Novartis Investigative Site, Matosinhos, Porto, Portugal|Novartis Investigative Site, Amadora, Portugal|Novartis Investigative Site, Braga, Portugal|Novartis Investigative Site, Coimbra, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Loures, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Santa Maria da Feira, Portugal|Novartis Investigative Site, Ekaterinburg, Russian Federation|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Krasnoyarsk, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Nizhny Novgorod, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Martin, Slovakia|Novartis Investigative Site, Ruzomberok, Slovakia|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Rosebank, South Africa|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Pozuelo de Alarcon, Madrid, Spain|Novartis Investigative Site, Baracaldo, Vizcaya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, San Sebastian, Spain|Novartis Investigative Site, Lugano, Switzerland|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Haseki / Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Mersin, Turkey|Novartis Investigative Site, Trabzon, Turkey|Novartis Investigative Site, Luton, Beds, United Kingdom|Novartis Investigative Site, Sheffield, South Yorkshire, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02792231/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02792231/SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02792231
36,NCT02792218,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,ASCLEPIOS I,Completed,Has Results,Relapsing Multiple Sclerosis,Drug: Ofatumumab subcutaneous injection|Drug: Teriflunomide-matching placebo capsules|Drug: Teriflunomide capsule|Drug: Matching placebo of ofatumumab subcutaneous injections,Annualized Relapse Rate (ARR)|3-month Confirmed Disability Worsening (3mCDW) Based on EDSS - Pooled Data|3-month Confirmed Disability Worsening (3mCDW) Based on EDSS - Study COMB157G2301|6-month Confirmed Disability Worsening (6mCDW) Based on EDSS - Pooled Data|6-month Confirmed Disability Worsening (6mCDW) Based on EDSS - Study COMB157G2301|6-month Confirmed Disability Improvement (6mCDI ) Based on EDSS - Pooled Data|6-month Confirmed Disability Improvement (6mCDI ) Based on EDSS - Study COMB157G2301|Number of Gd-enhancing T1 Lesions Per MRI Scan|Number of New or Enlarging T2 Lesions on MRI Per Year (Annualized Lesion Rate)|Neurofilament Light Chain (NfL) Concentration in Serum|Annualized Rate of Brain Volume Loss Based on Assessments of Percent Brain Volume Change From Baseline|Percentage of Participants With Confirmed Relapse|Annualized Relapse Rate (ARR) >8 Weeks After Onset of Treatment|3-month Confirmed Disability Worsening (3mCDW) Based on EDSS > 8 Weeks After Onset of Treatment - Pooled Data|6-month Confirmed Disability Worsening (6mCDW) Based on EDSS > 8 Weeks After Onset of Treatment - Pooled Data|6-month Confirmed Cognitive Decline on Symbol Digit Modalities Test (SDMT) - Pooled Data|6-month Confirmed Disability Worsening (6mCDW) or 6-month Confirmed Cognitive Decline (6mCCD) - Pooled Data|Change in Cognitive Performance Measured by the Symbol Digit Modalities Test (SDMT) - Pooled Data|6-month Confirmed Worsening of at Least 20% in the Timed 25-Foot Walk (T25FW) - Pooled Data|6-month Confirmed Worsening of at Least 20% in the 9-Hole Peg Test (9HPT) - Pooled Data|6-month Confirmed Disability Improvement (6mCDI) Sustained Until End of Study (EOS) as Measured by EDSS - Pooled Data|Number of New or Enlarging T2 Lesions on MRI Per Year From Month 12 Until End of Study (EOS)|Percent Change in T2 Lesion Volume Relative to Baseline|No Evidence of Disease Activity (NEDA-4)|Multiple Sclerosis Impact Scale (MSIS-29) Physical Impact Score Change From Baseline|Multiple Sclerosis Impact Scale (MSIS-29) Psychological Impact Score Change From Baseline|Annualized Relapse Rates (ARR) by NfL High-low Subgroups - Pooled Data|Number of New or Enlarging T2 Lesions Per Year by NfL High-low Subgroups - Pooled Data|Annual Rate of Percent Change in Brain Volume Loss by NfL High-low Subgroups - Pooled Data|Pharmacokinetic (PK) Concentrations of Ofatumumab,Novartis Pharmaceuticals|Novartis,All,18 Years to 55 Years   (Adult),Phase 3,930,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",COMB157G2301|2015-005418-31,"September 20, 2016","July 5, 2019","July 20, 2020","June 7, 2016","October 19, 2020","October 1, 2021","Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Berkeley, California, United States|Novartis Investigative Site, Fullerton, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Atlantis, Florida, United States|Novartis Investigative Site, Delray Beach, Florida, United States|Novartis Investigative Site, Hollywood, Florida, United States|Novartis Investigative Site, Loxahatchee Groves, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Naples, Florida, United States|Novartis Investigative Site, North Palm Beach, Florida, United States|Novartis Investigative Site, Pensacola, Florida, United States|Novartis Investigative Site, Port Charlotte, Florida, United States|Novartis Investigative Site, Sunrise, Florida, United States|Novartis Investigative Site, Vero Beach, Florida, United States|Novartis Investigative Site, West Palm Beach, Florida, United States|Novartis Investigative Site, Savannah, Georgia, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Northbrook, Illinois, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Kansas City, Kansas, United States|Novartis Investigative Site, Overland Park, Kansas, United States|Novartis Investigative Site, Alexandria, Louisiana, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Clinton Township, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Golden Valley, Minnesota, United States|Novartis Investigative Site, Chesterfield, Missouri, United States|Novartis Investigative Site, Ozark, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Latham, New York, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Raleigh, North Carolina, United States|Novartis Investigative Site, Winston-Salem, North Carolina, United States|Novartis Investigative Site, Winston-Salem, North Carolina, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Spartanburg, South Carolina, United States|Novartis Investigative Site, Johnson City, Tennessee, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, El Paso, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Round Rock, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Virginia Beach, Virginia, United States|Novartis Investigative Site, Green Bay, Wisconsin, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Neenah, Wisconsin, United States|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, New Lambton Heights, New South Wales, Australia|Novartis Investigative Site, St Leonards, New South Wales, Australia|Novartis Investigative Site, Brasschaat, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Pelt, Belgium|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Gatineau, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Rijeka, HRV, Croatia|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Praha 4 Krc, Czech Republic, Czechia|Novartis Investigative Site, Hradec Kralove, CZE, Czechia|Novartis Investigative Site, Olomouc, CZE, Czechia|Novartis Investigative Site, JIhlava, Czechia|Novartis Investigative Site, Pardubice, Czechia|Novartis Investigative Site, Praha 5, Czechia|Novartis Investigative Site, Aarhus, Denmark|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tartu, Estonia|Novartis Investigative Site, Nancy, Cedex, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Nantes Cedex 1, France|Novartis Investigative Site, Nimes Cedex, France|Novartis Investigative Site, Barsinghausen, Germany|Novartis Investigative Site, Bayreuth, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Neuburg an der Donau, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wiesbaden, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Budapest, HUN, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Kistarcsa, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, New Delhi, Delhi, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Kochi, Kerala, India|Novartis Investigative Site, Chandigarh, Punjab, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Mangalore, India|Novartis Investigative Site, Ashkelon, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Sefad, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Gallarate, VA, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Sittard-Geleen, BG, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Bydgoszcz, Poland|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Katowice, Poland|Novartis Investigative Site, Kielce, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Guaynabo, Puerto Rico|Novartis Investigative Site, Kemerovo, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Nizhny Novgorod, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saransk, Russian Federation|Novartis Investigative Site, Sestroretsk, Russian Federation|Novartis Investigative Site, Tyumen, Russian Federation|Novartis Investigative Site, Banska Bystrica, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Nitra, Slovakia|Novartis Investigative Site, Trnava, Slovakia|Novartis Investigative Site, Cadiz, Andalucia, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, L Hospitalet De Llobregat, Catalunya, Spain|Novartis Investigative Site, Salt, Cataluña, Spain|Novartis Investigative Site, El Palmar, Murcia, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Goeteborg, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Khon Kaen, THA, Thailand|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kocaeli, Turkey|Novartis Investigative Site, Samsun, Turkey|Novartis Investigative Site, Headington, Oxfordshire, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02792218/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02792218/SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02792218
37,NCT02779959,"Buccal Prochlorperazine Versus Intravenous Prochlorperazine for Migraine Headaches, a RCT",NA,Unknown status,No Results Available,Migraine Disorders,Drug: Prochlorperazine,Change in median pian VAS score|Change in median sedation VAS scores|Change in median nausea VAS scores|Rescue Medication|Follow-up for persistence or recurrence of headache,Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,80,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",30590-01,April 2016,October 2017,April 2018,"May 23, 2016",NA,"January 5, 2018","Harbor-UCLA Medical Center, Torrance, California, United States",NA,https://ClinicalTrials.gov/show/NCT02779959
38,NCT02750306,Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061),NA,Completed,Has Results,Sleep Initiation and Maintenance Disorders|Alzheimer Disease,Drug: Suvorexant|Drug: Placebo,Change From Baseline in Polysomnography-derived Total Sleep Time (TST) at Week 4|Percentage of Participants Who Experienced One or More Adverse Events|Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event|Change From Baseline in Polysomnography-derived Wakefulness After Persistent Sleep Onset (WASO) at Week 4,Merck Sharp & Dohme LLC,All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,285,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",4305-061|2015-003154-40|MK-4305-061,"May 23, 2016","September 30, 2018","September 30, 2018","April 25, 2016","October 16, 2019","October 16, 2019",NA,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02750306/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02750306
39,NCT02745392,Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine,Zotrip,Completed,Has Results,Acute Migraine,Drug: ZP-Zolmitriptan|Drug: Placebo,"Proportion of Subjects With Pain Freedom|Proportion of Subjects With Freedom From Most Bothersome Pre-specified Other Symptom (Nausea, Photophobia, or Phonophobia Pre-specified by Subject)",Zosano Pharma Corporation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,365,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CP-2016-001,June 2016,January 2017,January 2017,"April 20, 2016","February 14, 2018","March 13, 2018","Clinical Research Advantage, Inc./Thunderbird Internal Medicine, Glendale, Arizona, United States|The Research Center of Southern California, Carlsbad, California, United States|Allergy and Asthma Specialists Medical Group and Research Center, Huntington Beach, California, United States|Downtown LA Research Center, Los Angeles, California, United States|Allergy & Asthma Associates of Southern California, Mission Viejo, California, United States|Allergy and Asthma Associates of Santa Clara Valley Research Center, San Jose, California, United States|California Medical Clinic for Headache, Santa Monica, California, United States|Empire Clinical Research, Upland, California, United States|Colorado Allergy & AsthmaCenters, PC, Denver, Colorado, United States|Ki Health Partners, Stamford, Connecticut, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Meridien Research, Tampa, Florida, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Boston Clinical Trials, Boston, Massachusetts, United States|Novex Medical Research, New Bedford, Massachusetts, United States|Northeast Medical Research Associates, Inc., North Dartmouth, Massachusetts, United States|MedVadis Research Corporation, Watertown, Massachusetts, United States|Michigan Head Pain &Neurological Institute, Ann Arbor, Michigan, United States|Westside Family Medical Center, P.C, Kalamazoo, Michigan, United States|Clinical Research Institute, Inc., Minneapolis, Minnesota, United States|The Clinical Research Center, LLC, Saint Louis, Missouri, United States|Clinvest/A Division of Banyan Group Inc., Springfield, Missouri, United States|Nebraska Medical Research Institute, Bellevue, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Princeton Center for Clinical Research, Skillman, New Jersey, United States|Headache Wellness Center, PC, Greensboro, North Carolina, United States|Peters Medical Research LLC, High Point, North Carolina, United States|North Carolina Clinical Research, Raleigh, North Carolina, United States|PMG Research of Raleigh, Raleigh, North Carolina, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Nashville Neurosciences Group, Nashville, Tennessee, United States|Central Texas Health Research, New Braunfels, Texas, United States|Sylvana Research Associates, San Antonio, Texas, United States|Charlottesville Medical Research Center LLC, Charlottesville, Virginia, United States",NA,https://ClinicalTrials.gov/show/NCT02745392
40,NCT02683213,Efficacy of Fluoxetine - a Trial in Stroke,EFFECTS,Completed,No Results Available,Stroke,Drug: Fluoxetine|Drug: Placebo,"Functional status, measured with the modified Rankin scale.|Survival|Health status measured with the Stroke Impact Scale|Arm, hand, leg and foot strength assessed with the Stroke Impact Scale|Hand function assessed with the Stroke Impact Scale|Mobility assessed with the Stroke Impact Scale|Communication and understanding assessed with the Stroke Impact Scale|Memory and thinking assessed with the Stroke Impact Scale|Mood and emotions assessed with the Stroke Impact Scale|Daily activities assessed with the Stroke Impact Scale|Participation in work, leisure and social activities assessed with the Stroke Impact Scale|Overall rating of recovery assessed with the Stroke Impact Scale|Adverse events/outcomes|Depression using the Montgomery-Åsberg Depression Rating Scale (MADRS)|Number of participants with a recurrent stroke including ischaemic and hemorrhagic strokes|Number of participants with an acute coronary syndromes|Number of participants with an Epileptic seizures|Number of participants with an episodes of Hyponatraemia|Number of participants with an upper gastrointestinal bleeding|Number of participants with other major bleeds|Number of participants with poorly controlled diabetes|Number of participants with falls resulting in injury|Number of participants with new fractures|Fatigue measured with the vitality subscale of the Health Questionnaire|Cognition assessed with the Stroke Impact Scale|Health-related quality of life measured with the five-level Euroqol 5D (EQ5D-5 L)|Cost-effectiveness and cost-utility assessed by measuring costs, survival and health related quality of life (EQ5D)|Physical activity",Karolinska Institutet|The Swedish Research Council|Swedish Heart Lung Foundation|Stroke-Riksförbundet|Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse|Hjärnfonden (The Swedish Brain foundation)|The Swedish Medical Association,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1500,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFFECTS2012|2011-006130-16,"October 20, 2014",June 2020,June 2020,"February 17, 2016",NA,"September 2, 2020","Karolinska Institutet, Stockholm, Sweden",NA,https://ClinicalTrials.gov/show/NCT02683213
41,NCT02670083,A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).,CREAD,Terminated,Has Results,Alzheimer's Disease,Drug: Crenezumab|Drug: Placebo,"Change From Baseline to Week 105 in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score|Change From Baseline to Week 105 on Cognition, as Assessed by Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog) (Subscale) 13 (ADAS-Cog-13)|Change From Baseline to Week 105 on Cognition, as Assessed by Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog) (Subscale) 11 (ADAS-Cog-11)|Change From Baseline to Week 105 on Severity of Dementia, Assessed Using the CDR-Global Score (CDR-GS)|Change From Baseline to Week 105 on Severity of Dementia, Assessed Using the Mini Mental State Evaluation (MMSE)|Change From Baseline to Week 105 on Function as Assessed by the ADCS-ADL Total Score|Change From Baseline to Week 105 on Function as Assessed by the ADCS-instrumental (ADCS-iADL) Subscore|Change From Baseline to Week 105 on a Measure of Dependence Derived From the ADCS-ADL Score|Change From Baseline to Week 105 Assessed Using the Neuropsychiatric Inventory Questionnaire (NPI-Q)|Quality of Life-Alzheimer's Disease (QoL-AD) Scale Score|Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD) Scale Score|EQ-5D Questionnaire Domain Score for Participants|EQ-5D Questionnaire Domain Score for Caregivers|Percentage of Participants With Adverse Event (AEs) and Serious Adverse Event (SAEs)|Percentage of Participants With Anti-Crenezumab Antibodies|Serum Concentration of Crenezumab|Plasma Amyloid Beta (Abeta) 40 Concentrations|Plasma Amyloid Beta (Abeta) 42 Concentrations|Percentage Change From Baseline to Week 105 in Whole Brain Volume as Determined by Magnetic Resonance Imaging (MRI)|Percentage Change From Baseline to Week 105 in Ventricle Volume as Determined by Magnetic Resonance Imaging (MRI)|Percentage Change From Baseline to Week 105 in Hippocampal Volume as Determined by Magnetic Resonance Imaging (MRI)",Hoffmann-La Roche,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,813,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BN29552|2015-003034-27,"March 22, 2016","May 31, 2019","May 31, 2019","February 1, 2016","July 16, 2020","July 16, 2020","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Pharmacology Research Inst, Encino, California, United States|Collaborative Neuroscience Network Inc., Long Beach, California, United States|Alliance for Wellness, dba Alliance for Research, Long Beach, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|USC Keck School Of Medicine, Los Angeles, California, United States|UCLA Medical Center, Department of Neurology, Los Angeles, California, United States|Pharmacology Research Inst, Newport Beach, California, United States|Shankle Clinic, Newport Beach, California, United States|Stanford Univ Medical Center, Palo Alto, California, United States|Anderson Clinical Research, Inc., Redlands, California, United States|University of California, Davis; Alzheimers Disease Center, Department of Neurology, Sacramento, California, United States|UCSF - Memory and Aging Center, San Francisco, California, United States|Neurological Research Inst, Santa Monica, California, United States|North Bay Neuro Science Institute, Sebastopol, California, United States|Associated Neurologists PC - Danbury, Danbury, Connecticut, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|Bradenton Research Center, Bradenton, Florida, United States|Quantum Laboratories, Deerfield Beach, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Galiz Research, LLC, Hialeah, Florida, United States|Jacksonville Center For Clinical Research, Jacksonville, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Merritt - Island Medical Research, Merritt Island, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Johnnie B. Byrd Sr. Alzheimer's Center & Research Institute, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Compass Research, The Villages, Florida, United States|Emory University, Atlanta, Georgia, United States|NeuroStudies.net, LLC, Decatur, Georgia, United States|Alexian Brothers Neurosci Inst, Elk Grove Village, Illinois, United States|Southern Illinois University, School of Medicine, Springfield, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|MidAmerica Neuroscience Institute, Prairie Village, Kansas, United States|Maine Research Associates, Auburn, Maine, United States|MMP Neurology, Scarborough, Maine, United States|Springfield Neurology Associates, Springfield, Massachusetts, United States|Precise Research Centers, Flowood, Mississippi, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, United States|Advanced Memory Research Institute of NJ, Toms River, New Jersey, United States|Albany Medical Faculty Physicians COmmunity Division. The Neurology Group, Albany, New York, United States|Neurological Associates of Albany, PC, Albany, New York, United States|Dent Neurological Institute, Amherst, New York, United States|Columbia University Medical Center, New York, New York, United States|South Shore Neurologic Associates P.C., Patchogue, New York, United States|Behavioral Health Research, Charlotte, North Carolina, United States|Guilford Neurologic Associates, Greensboro, North Carolina, United States|Valley Medical Primary Care, Centerville, Ohio, United States|Insight Clinical Trials LLC, Shaker Heights, Ohio, United States|Oklahoma Clinical Research, Oklahoma City, Oklahoma, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Central States Research, Tulsa, Oklahoma, United States|Summit Research Network Inc., Portland, Oregon, United States|Drexel Univ College of Med; Clinical Research Group, Philadelphia, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Senior Adults Specialty Research, Austin, Texas, United States|Kerwin Research Center, LLC, Dallas, Texas, United States|University of North Texas Health Science Center; Fort Worth Patient Care Center, Fort Worth, Texas, United States|Sentara Medical Group, Norfolk, Virginia, United States|National Clinical Research Inc.-Richmond, Richmond, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|The Queen Elizabeth Hospital; Neurology, Woodville, South Australia, Australia|Caulfield Hospital; Aged Psychiatry Research Unit, Caulfield, Victoria, Australia|Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre, Heidelberg West, Victoria, Australia|Neurodegenerative Disorders Research; Neurology, West Perth, Western Australia, Australia|Konventhospital Barmherzige Brüder; Neurologie I, Linz, Austria|UZ Gent, Gent, Belgium|ACIBADEM CITY CLINIC TOKUDA HOSPITAL EAD; Clinic of Neurology and Sleep Medicine, Sofia, Bulgaria|Alexandrovska hospital; Neurology Department, Sofia, Bulgaria|Vancouver Hospital - UBC Hospital Site, Vancouver, British Columbia, Canada|Vancouver Island Health Authority, Victoria, British Columbia, Canada|Parkwood Hospital; Geriatric Medicine, London, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Kawartha Centre - Redefining Healthy Aging, Peterborough, Ontario, Canada|The Centre for Memory and Aging, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Devonshire Clinical Research Inc., Woodstock, Ontario, Canada|CHA Hopital de I enfant-Jesus, Quebec City, Quebec, Canada|ICIMED Instituto de Investigación en Ciencias Médicas, San Jose, Costa Rica|Hospital Clínica Biblica, San José, Costa Rica|Clinical Hospital Centre Zagreb;Clinic for Neurology, Zagreb, Croatia|Charles University, Medical faculty, Hradec Kralove ;Department of Neurology, Hradec Králové, Czechia|General Teaching Hospital, Departmetn of Neurology, Praha, Czechia|Aarhus Universitetshospital, Neurologisk Afdeling F, Demensklinikken, Aarhus N, Denmark|Rigshospitalet, Hukommelsesklinikken, København Ø, Denmark|Terveystalo Tampere, Tampere, Finland|CRST Oy, Turku, Finland|Hopital Avicenne; Neurologie, Bobigny, France|Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie, Bron, France|Hopital Gui de Chauliac; Neurologie, Montpellier, France|Hopital Lariboisiere, Paris, France|CHU Poitiers - Hopital La Miletrie, Poitiers, France|Hopital Hautepierre; Centre dInvestigation Clinique, Strasbourg, France|CHU Toulouse - La Grave, Toulouse, France|Neurologische Praxis Dr. Andrej Pauls, München, Germany|Klinikum rechts der Isar der TU München; Klinik für Psychiatrie und Psychotherapie, München, Germany|Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie, Münster, Germany|Steinwachs Klaus; Arztpraxis fur Neurologie u. Psychiatrie, Nürnberg, Germany|Universitätsklinikum Rostock Zentrum für Nervenheilkunde, Rostock, Germany|Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, Germany|Studienzentrum Nordwest, Dr. med. Joachim Springub / Herr Wolfgang Schwarz, Westerstede, Germany|Forschungszentrum Ruhr, Witten, Germany|Prince of Wales Hospital; Dept. of Medicine & Therapeutics, Hong Kong, Hong Kong|Queen Mary Hospital, Division of Geriatric Medicine, Hong Kong, Hong Kong|Semmelweis University; Department of Neurology, Budapest, Hungary|Szabolcs-Szatmár-Bereg Megyei Kórházak - Jósa András Oktatókórház; Pszichiátria, Nyíregyháza, Hungary|University of Szeged; Department of Psychiatry, Szeged, Hungary|Szent Borbala Korhaz; Neurologiai es Stroke Osztaly, Tatabánya, Hungary|Jávorszky Ödön Kórház, Neurológia és stroke osztály, VAC, Hungary|Fondazione Santa Lucia IRCCS; Neurologia e Riabilitazione Neurologica, Roma, Lazio, Italy|Ospedale San Giovanni Calibita Fatebenefratell;Neurologia, Roma, Lazio, Italy|Ente Ospedaliero Ospedali Galliera; Ambulatorio di Neurologia, Genova, Liguria, Italy|Casa di Cura Policlinico; Dipartimento di Scienze Neuroriabilitative, Milano, Lombardia, Italy|Ospedale S. Maria Nascente; Fondazione Don Gnocchi; Dip. Neurologia Riabilitativa, Milano, Lombardia, Italy|Ospedale Casati Passirana di Rho; Centro Regionale Alzheimer, Passirana, Lombardia, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; S.C. Geriatria, Perugia, Umbria, Italy|Miyoshi Clinic of Neurology, Hananosato, Hiroshima, Japan|National Hospital Organization Hiroshima-Nishi Medical Center, Hiroshima, Japan|Rakuwakai Otowarehabilitation Hospital, Kyoto, Japan|Mie University Hospital, Mie, Japan|National Hospital Organization Matsumoto Medical Center, Nagano, Japan|Saigata Medical Center, Niigata, Japan|Katayama Medical Clinic, Okayama, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan|National Center of Neurology and Psychiatry, Tokyo, Japan|Chonnam National University Hospital, Gwangju, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|KyungHee Medical Center, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital; Dept of Neurology, Seoul, Korea, Republic of|Vilnius University Hospital Santariskiu Clinic, Vilnius, Lithuania|Hospital Angeles de Culiacán, Neurociencias Estudios Clínicos SC, Culiacan, Mexico|Hospital Uni; Dr. Jose E. Gonzalez, Monterrey, Mexico|AVIX Investigación Clínica S.C, Monterrey, Mexico|Hospital Universitario de Saltillo, Saltillo, Mexico|Podlaskie Centrum Psychogeriatrii, Białystok, Poland|NZOZ NEURO-KARD Ilkowski i Partnerzy Sp. Partn. Lek, Poznań, Poland|NEURO-CARE Sp. z o.o. Sp. Komandytowa, Siemianowice Śląskie, Poland|Przychodnia Specjalistyczna PROSEN, Warszawa, Poland|Centrum Medyczne NeuroProtect, Warszawa, Poland|Optimum, Warszawa, Poland|Hospital Prof. Dr. Fernando Fonseca; Servico de Neurologia, Amadora, Portugal|Hospital Beatriz Angelo; Servico de Neurologia, Loures, Portugal|State Autonomous Healthcare Institution ""Republican Clinical Neurological Center, Kazan, Russian Federation|State autonomous institution of healthcare Inter-regional clinical and diagnostic center, Kazan, Russian Federation|Institution of RAMS (Mental Health Research Center of RAMS), Moscow, Russian Federation|SBEI of HPI The 1st Moscow State Medical University n.a. I.M. Sechenov of MOH of RF, Moscow, Russian Federation|City Clinical Hospital # 2 n.a. V.I. Razumovsky, Saratov, Russian Federation|SHI City Psychoneurological Dispensary #7, St Petersburg, Russian Federation|Russian Medical Military Academy n.a. S.M.Kirov; Neurology Department, St. Petersburg, Russian Federation|University Medical Centre Maribor, Maribor, Slovenia|Fundació ACE, BArcelon, Barcelona, Spain|Hospital Universitari de Bellvitge; Servicio de Neurologia, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Sant Joan de Deu; Servicio de Neurología, Manresa, Barcelona, Spain|Hospital General De Catalunya; Servicio de Neurologia, Sant Cugat del Valles, Barcelona, Spain|Hospital Mutua De Terrasa; Servicio de Neurologia, Terrassa, Barcelona, Spain|Hospital Virgen del Puerto. Servicio de Neurología, Plasencia, Caceres, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Neurología, Santander, Cantabria, Spain|Clinica Universitaria de Navarra; Servicio de Neurología, Pamplona, Navarra, Spain|Complejo Asistencial Universitario de Salamanca; Servicio de Psiquiatría, Salamaca, Salamanca, Spain|Hospital General Universitario de Albacete; Servicio de Neurología, Albacete, Spain|Hospital Vall d'Hebron; Servicio de Neurología, Barcelona, Spain|Hospital Universitario de Burgos. Servicio de Neurología, Burgos, Spain|Clinica Ruber, 4 planta; Servicio de Neurologia, Madrid, Spain|Universitario de La Princesa; Servicio de Neurología, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Neurologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Neurologia, Malaga, Spain|Hospital Universitario Virgen de Arrixaca; Servicio de Neurología, Murcia, Spain|Hospital Universitario la Fe; Servicio de Neurologia, Valencia, Spain|Servicio de Neurología Hospital Viamed Montecanal., Zaragoza, Spain|Skånes Universitetssjukhus Malmö, Minneskliniken, Malmö, Sweden|Sahlgrenska Academy University,Neuroscience and Physiology;Departmt of Psychiatry and Neurochemistry, Mölndal, Sweden|Karolinska Uni Hospital, Huddinge; Dept. of Geriatric Med, Stockholm, Sweden|Universitäres Zentrum für Altersmedizin und Rehabilitation, Basel, Switzerland|Hacettepe University School of Medicine; Neurology, Ankara, Turkey|Osmangazi University School of Medicine,Neurology Department, Eskişehir, Turkey|Istanbul University Istanbul School of Medicine; Neurology, Istanbul, Turkey|Ondokuz Mayis University School of Medicine; Neurology, Samsun, Turkey|Regional mental hospital; Department of psychiatry, psychology and sexology, Lviv, KIEV Governorate, Ukraine|National Medical Academy of Postgraduate Education named after P.L.Shupik; Neurology Department #1, Kiev, Ukraine|D.F.Chebotarev Institute of Gerontology NAMS;Depart of Age Physiology&Pathology of Nervous System, Kiev, Ukraine|Royal Preston Hospital, Blackburn, United Kingdom|Surrey and Borders NHS Foundation Trust; Brain Science Research Unit, Chertsey, United Kingdom|Coventry and Warwickshire Partnership NHS Trust, Coventry, United Kingdom|St George's Hospital, London, United Kingdom|Charing Cross Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Campus for Ageing and Vitality, Newcastle Upon Tyne, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02670083/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02670083
42,NCT02642393,"Study of Urate Elevation in Parkinson's Disease, Phase 3",SURE-PD3,Completed,Has Results,Parkinson's Disease,Drug: Inosine|Drug: Placebo,Rate of Clinical Decline|Rate of Developing Adverse Effects|Percentage Developing Adverse Effects|Percentage of Subjects Tolerant of the Treatment|Percentage of Participants Developing Disability Warranting Dopaminergic Therapy Over Time|Clinical Efficacy: Rate of Change in Parkinson's Disease Questionnaire - 39 Item Version (PDQ-39) Scale|Clinical Efficacy: Rate of Change in Quality of Life in Neurological Disorders (Neuro-QOL)|Clinical Efficacy: Rate of Change in Quality of Life in Neurological Disorders (Neuro-QOL) Depression Module|Clinical Efficacy: Rate of Change in Schwab and England Scale|Clinical Efficacy: Rate of Change in Montreal Cognitive Assessment (MoCA)|Symptomatic Effects,Michael Alan Schwarzschild|The Parkinson Study Group|Michael J. Fox Foundation for Parkinson's Research|University of Rochester|National Institute of Neurological Disorders and Stroke (NINDS)|Massachusetts General Hospital,All,"30 Years and older   (Adult, Older Adult)",Phase 3,298,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",INO-PD-P3-2014|1U01NS090259-01A1,June 2016,June 2019,June 2019,"December 30, 2015","July 28, 2020","July 28, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California San Diego, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of California Davis, Sacramento, California, United States|University of California San Francisco, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Rocky Mountain Movement Disorder Center, Englewood, Colorado, United States|Hartford HealthCare Movement Disorders Center, Vernon, Connecticut, United States|University of South Florida, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Neurosciences Institute at Central DuPage Hospital, Winfield, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Oschner Clinic Foundation, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Henry Ford Health System, West Bloomfield, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Overlook Medical Center, Atlantic Neuroscience Institute, Summit, New Jersey, United States|Albany Medical College, Albany, New York, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Weill Cornell Medical Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Duke University, Durham, North Carolina, United States|University of Cincinnati/Cincinnati Children's Hospital, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health & Sciences University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Wesley Neurology Clinic, PC, Cordova, Tennessee, United States|University of Tennessee Health Science Center, Memphis, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas Houston Medical School, Houston, Texas, United States|Baylor Scott & White Health, Temple, Texas, United States|The University of Vermont, Burlington, Vermont, United States|University of Virginia, Charlottesville, Virginia, United States|VCU Parkinson's & Movement Disorder Center (McGuire Veterans Hospital), Richmond, Virginia, United States|Sentara Neurology Specialists, Virginia Beach, Virginia, United States|Inland Northwest Research, Spokane, Washington, United States|Northwest Neurological PLLC, Spokane, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|University of Puerto Rico, San Juan, Puerto Rico","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02642393/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02642393/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02642393
43,NCT02629861,Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine,NA,Completed,Has Results,Migraine,Drug: Fremanezumab|Drug: Placebo,"Change From Baseline in the Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Study Drug|Participants With Adverse Events|Percentage of Participants With At Least 50% Reduction In Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Study Drug|Change From Baseline in the Monthly Average Number of Days of Use of Any Acute Headache Medicine During the 12 Week Period After the First Dose of Study Drug|Change From Baseline in the Number of Migraine Days During the 4 Week Period After the First Dose of Study Drug|Change From Baseline in the Monthly Average Number of Migraine Days During the 12 Week Period After the First Dose of Study Medication in Patients Not Receiving Concomitant Preventive Migraine Medications|Change From Baseline in Migraine-Related Disability Score (MIDAS), As Measured by the Migraine Disability Assessment At 4 Weeks After the Last (3rd) Dose of Study Drug|Electrocardiogram Finding Shifts From Baseline to Overall|Participants With Vital Signs Potentially Clinically Significant Abnormal Values|Participants With Serum Chemistry and Hematology Potentially Clinically Significant Abnormal Results|Participants With Urinalysis Laboratory Tests Potentially Clinically Significant Abnormal Results|Prothrombin Time Shifts From Baseline to Endpoint|Injection Site Reaction Adverse Events|Participants With Positive Electronic Columbia Suicide Severity Rating Scale Results After the First Dose of Study Drug","Teva Branded Pharmaceutical Products R&D, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,875,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TV48125-CNS-30050|2015-004598-34,"March 23, 2016","April 10, 2017","April 10, 2017","December 14, 2015","November 8, 2018","November 9, 2021","Teva Investigational Site 13628, Birmingham, Alabama, United States|Teva Investigational Site 13577, Birmingham, Alabama, United States|Teva Investigational Site 13577, Birmingham, Alabama, United States|Teva Investigational Site 13628, Birmingham, Alabama, United States|Teva Investigational Site 13606, Phoenix, Arizona, United States|Teva Investigational Site 13579, Phoenix, Arizona, United States|Teva Investigational Site 13579, Phoenix, Arizona, United States|Teva Investigational Site 13606, Phoenix, Arizona, United States|Teva Investigational Site 13602, Little Rock, Arkansas, United States|Teva Investigational Site 13602, Little Rock, Arkansas, United States|Teva Investigational Site 13568, Encino, California, United States|Teva Investigational Site 13568, Encino, California, United States|Teva Investigational Site 13546, Fullerton, California, United States|Teva Investigational Site 13546, Fullerton, California, United States|Teva Investigational Site 13540, Long Beach, California, United States|Teva Investigational Site 13540, Long Beach, California, United States|Teva Investigational Site 13632, Redlands, California, United States|Teva Investigational Site 13632, Redlands, California, United States|Teva Investigational Site 13571, Redondo Beach, California, United States|Teva Investigational Site 13571, Redondo Beach, California, United States|Teva Investigational Site 13573, San Diego, California, United States|Teva Investigational Site 13573, San Diego, California, United States|Teva Investigational Site 13538, Santa Monica, California, United States|Teva Investigational Site 13538, Santa Monica, California, United States|Teva Investigational Site 13594, Santa Rosa, California, United States|Teva Investigational Site 13594, Santa Rosa, California, United States|Teva Investigational Site 13595, Walnut Creek, California, United States|Teva Investigational Site 13595, Walnut Creek, California, United States|Teva Investigational Site 13629, Aurora, Colorado, United States|Teva Investigational Site 13629, Aurora, Colorado, United States|Teva Investigational Site 13557, Boulder, Colorado, United States|Teva Investigational Site 13557, Boulder, Colorado, United States|Teva Investigational Site 13593, Colorado Springs, Colorado, United States|Teva Investigational Site 13593, Colorado Springs, Colorado, United States|Teva Investigational Site 13633, Denver, Colorado, United States|Teva Investigational Site 13612, Denver, Colorado, United States|Teva Investigational Site 13612, Denver, Colorado, United States|Teva Investigational Site 13633, Denver, Colorado, United States|Teva Investigational Site 13631, Englewood, Colorado, United States|Teva Investigational Site 13631, Englewood, Colorado, United States|Teva Investigational Site 13563, East Hartford, Connecticut, United States|Teva Investigational Site 13563, East Hartford, Connecticut, United States|Teva Investigational Site 13550, Stamford, Connecticut, United States|Teva Investigational Site 13550, Stamford, Connecticut, United States|Teva Investigational Site 13635, Bradenton, Florida, United States|Teva Investigational Site 13635, Bradenton, Florida, United States|Teva Investigational Site 13597, Gainesville, Florida, United States|Teva Investigational Site 13597, Gainesville, Florida, United States|Teva Investigational Site 13607, Hialeah, Florida, United States|Teva Investigational Site 13607, Hialeah, Florida, United States|Teva Investigational Site 13559, Jacksonville, Florida, United States|Teva Investigational Site 13559, Jacksonville, Florida, United States|Teva Investigational Site 13584, Ocala, Florida, United States|Teva Investigational Site 13584, Ocala, Florida, United States|Teva Investigational Site 13587, Orlando, Florida, United States|Teva Investigational Site 13551, Orlando, Florida, United States|Teva Investigational Site 13555, Orlando, Florida, United States|Teva Investigational Site 13587, Orlando, Florida, United States|Teva Investigational Site 13599, Orlando, Florida, United States|Teva Investigational Site 13553, Pembroke Pines, Florida, United States|Teva Investigational Site 13553, Pembroke Pines, Florida, United States|Teva Investigational Site 13616, Pinellas Park, Florida, United States|Teva Investigational Site 13616, Pinellas Park, Florida, United States|Teva Investigational Site 13567, West Palm Beach, Florida, United States|Teva Investigational Site 13567, West Palm Beach, Florida, United States|Teva Investigational Site 13620, Atlanta, Georgia, United States|Teva Investigational Site 13537, Atlanta, Georgia, United States|Teva Investigational Site 13537, Atlanta, Georgia, United States|Teva Investigational Site 13620, Atlanta, Georgia, United States|Teva Investigational Site 13604, Boise, Idaho, United States|Teva Investigational Site 13604, Meridian, Idaho, United States|Teva Investigational Site 13585, Chicago, Illinois, United States|Teva Investigational Site 13621, Chicago, Illinois, United States|Teva Investigational Site 13585, Chicago, Illinois, United States|Teva Investigational Site 13621, Chicago, Illinois, United States|Teva Investigational Site 13627, Evanston, Illinois, United States|Teva Investigational Site 13627, Evanston, Illinois, United States|Teva Investigational Site 13596, Indianapolis, Indiana, United States|Teva Investigational Site 13596, Indianapolis, Indiana, United States|Teva Investigational Site 13617, Wichita, Kansas, United States|Teva Investigational Site 13598, Wichita, Kansas, United States|Teva Investigational Site 13598, Wichita, Kansas, United States|Teva Investigational Site 13617, Wichita, Kansas, United States|Teva Investigational Site 13566, Louisville, Kentucky, United States|Teva Investigational Site 13566, Louisville, Kentucky, United States|Teva Investigational Site 13603, Metairie, Louisiana, United States|Teva Investigational Site 13603, Metairie, Louisiana, United States|Teva Investigational Site 13582, Baltimore, Maryland, United States|Teva Investigational Site 13582, Pikesville, Maryland, United States|Teva Investigational Site 13590, Boston, Massachusetts, United States|Teva Investigational Site 13590, Boston, Massachusetts, United States|Teva Investigational Site 13589, New Bedford, Massachusetts, United States|Teva Investigational Site 13589, New Bedford, Massachusetts, United States|Teva Investigational Site 13543, Wellesley Hills, Massachusetts, United States|Teva Investigational Site 13543, Wellesley Hills, Massachusetts, United States|Teva Investigational Site 13539, Ann Arbor, Michigan, United States|Teva Investigational Site 13539, Ann Arbor, Michigan, United States|Teva Investigational Site 13542, Golden Valley, Minnesota, United States|Teva Investigational Site 13542, Golden Valley, Minnesota, United States|Teva Investigational Site 13534, Kansas City, Missouri, United States|Teva Investigational Site 13534, Kansas City, Missouri, United States|Teva Investigational Site 13619, Saint Louis, Missouri, United States|Teva Investigational Site 13619, Saint Louis, Missouri, United States|Teva Investigational Site 13536, Springfield, Missouri, United States|Teva Investigational Site 13618, Fremont, Nebraska, United States|Teva Investigational Site 13618, Fremont, Nebraska, United States|Teva Investigational Site 13605, Las Vegas, Nevada, United States|Teva Investigational Site 13605, Las Vegas, Nevada, United States|Teva Investigational Site 13578, Lebanon, New Hampshire, United States|Teva Investigational Site 13578, Lebanon, New Hampshire, United States|Teva Investigational Site 13575, Martinsville, New Jersey, United States|Teva Investigational Site 13575, Raritan, New Jersey, United States|Teva Investigational Site 13588, Albuquerque, New Mexico, United States|Teva Investigational Site 13588, Albuquerque, New Mexico, United States|Teva Investigational Site 13576, Amherst, New York, United States|Teva Investigational Site 13576, Amherst, New York, United States|Teva Investigational Site 13565, Plainview, New York, United States|Teva Investigational Site 13565, Plainview, New York, United States|Teva Investigational Site 13544, Greensboro, North Carolina, United States|Teva Investigational Site 13574, Greensboro, North Carolina, United States|Teva Investigational Site 13544, Greensboro, North Carolina, United States|Teva Investigational Site 13574, Greensboro, North Carolina, United States|Teva Investigational Site 13545, Raleigh, North Carolina, United States|Teva Investigational Site 13545, Raleigh, North Carolina, United States|Teva Investigational Site 13609, Akron, Ohio, United States|Teva Investigational Site 13634, Akron, Ohio, United States|Teva Investigational Site 13609, Akron, Ohio, United States|Teva Investigational Site 13634, Akron, Ohio, United States|Teva Investigational Site 13533, Cincinnati, Ohio, United States|Teva Investigational Site 13624, Cincinnati, Ohio, United States|Teva Investigational Site 13533, Cincinnati, Ohio, United States|Teva Investigational Site 13624, Cincinnati, Ohio, United States|Teva Investigational Site 13569, Cleveland, Ohio, United States|Teva Investigational Site 13569, Cleveland, Ohio, United States|Teva Investigational Site 13626, Columbus, Ohio, United States|Teva Investigational Site 13626, Columbus, Ohio, United States|Teva Investigational Site 13625, Mogadore, Ohio, United States|Teva Investigational Site 13625, Mogadore, Ohio, United States|Teva Investigational Site 13561, Oklahoma City, Oklahoma, United States|Teva Investigational Site 13561, Oklahoma City, Oklahoma, United States|Teva Investigational Site 13601, Eugene, Oregon, United States|Teva Investigational Site 13601, Eugene, Oregon, United States|Teva Investigational Site 13591, Jenkintown, Pennsylvania, United States|Teva Investigational Site 13591, Jenkintown, Pennsylvania, United States|Teva Investigational Site 13554, Philadelphia, Pennsylvania, United States|Teva Investigational Site 13554, Philadelphia, Pennsylvania, United States|Teva Investigational Site 13608, Uniontown, Pennsylvania, United States|Teva Investigational Site 13608, Uniontown, Pennsylvania, United States|Teva Investigational Site 13615, Greer, South Carolina, United States|Teva Investigational Site 13615, Greer, South Carolina, United States|Teva Investigational Site 13556, Mount Pleasant, South Carolina, United States|Teva Investigational Site 13556, Mount Pleasant, South Carolina, United States|Teva Investigational Site 13560, Bristol, Tennessee, United States|Teva Investigational Site 13560, Bristol, Tennessee, United States|Teva Investigational Site 13532, Nashville, Tennessee, United States|Teva Investigational Site 13552, Nashville, Tennessee, United States|Teva Investigational Site 13532, Nashville, Tennessee, United States|Teva Investigational Site 13552, Nashville, Tennessee, United States|Teva Investigational Site 13541, Austin, Texas, United States|Teva Investigational Site 13541, Austin, Texas, United States|Teva Investigational Site 13623, Dallas, Texas, United States|Teva Investigational Site 13623, Dallas, Texas, United States|Teva Investigational Site 13611, Plano, Texas, United States|Teva Investigational Site 13611, Plano, Texas, United States|Teva Investigational Site 13572, San Antonio, Texas, United States|Teva Investigational Site 13572, San Antonio, Texas, United States|Teva Investigational Site 13614, Murray, Utah, United States|Teva Investigational Site 13614, Murray, Utah, United States|Teva Investigational Site 13581, West Jordan, Utah, United States|Teva Investigational Site 13581, West Jordan, Utah, United States|Teva Investigational Site 13630, Virginia Beach, Virginia, United States|Teva Investigational Site 13630, Virginia Beach, Virginia, United States|Teva Investigational Site 13564, Seattle, Washington, United States|Teva Investigational Site 13586, Seattle, Washington, United States|Teva Investigational Site 13564, Seattle, Washington, United States|Teva Investigational Site 13586, Seattle, Washington, United States|Teva Investigational Site 13600, Morgantown, West Virginia, United States|Teva Investigational Site 13600, Morgantown, West Virginia, United States|Teva Investigational Site 11124, Hamilton, Ontario, Canada|Teva Investigational Site 11124, Hamilton, Ontario, Canada|Teva Investigational Site 11120, Calgary, Canada|Teva Investigational Site 11120, Calgary, Canada|Teva Investigational Site 11121, Montreal, Canada|Teva Investigational Site 11121, Montreal, Canada|Teva Investigational Site 11122, Newmarket, Canada|Teva Investigational Site 11122, Newmarket, Canada|Teva Investigational Site 11123, Sarnia, Canada|Teva Investigational Site 11123, Sarnia, Canada|Teva Investigational Site 54144, Brno, Czechia|Teva Investigational Site 54144, Brno, Czechia|Teva Investigational Site 54141, Kunratice, Czechia|Teva Investigational Site 54141, Kunratice, Czechia|Teva Investigational Site 54145, Pardubice, Czechia|Teva Investigational Site 54145, Pardubice, Czechia|Teva Investigational Site 54142, Prague 4, Czechia|Teva Investigational Site 54142, Prague-4-Krc, Czechia|Teva Investigational Site 54146, Praha 3, Czechia|Teva Investigational Site 54146, Praha 3, Czechia|Teva Investigational Site 54143, Praha, Czechia|Teva Investigational Site 54143, Praha, Czechia|Teva Investigational Site 40018, Helsinki, Finland|Teva Investigational Site 40017, Helsinki, Finland|Teva Investigational Site 40017, Helsinki, Finland|Teva Investigational Site 40018, Helsinki, Finland|Teva Investigational Site 40016, Turku, Finland|Teva Investigational Site 40016, Turku, Finland|Teva Investigational Site 80096, Holon, Israel|Teva Investigational Site 80096, Holon, Israel|Teva Investigational Site 80099, Jerusalem, Israel|Teva Investigational Site 80099, Jerusalem, Israel|Teva Investigational Site 80098, Nahariya, Israel|Teva Investigational Site 80098, Nahariya, Israel|Teva Investigational Site 80097, Netanya, Israel|Teva Investigational Site 80097, Netanya, Israel|Teva Investigational Site 80100, Ramat Gan, Israel|Teva Investigational Site 80100, Ramat Gan, Israel|Teva Investigational Site 80095, Tel Aviv, Israel|Teva Investigational Site 80095, Tel Aviv, Israel|Teva Investigational Site 84072, Chofu-shi, Japan|Teva Investigational Site 84064, Chofu-shi, Japan|Teva Investigational Site 84072, Chofu-shi, Japan|Teva Investigational Site 84066, Kagoshima-shi, Japan|Teva Investigational Site 84066, Kagoshima, Japan|Teva Investigational Site 84069, Kai-shi, Japan|Teva Investigational Site 84069, Kai, Japan|Teva Investigational Site 84073, Kawasaki-shi, Japan|Teva Investigational Site 84073, Kawasaki, Japan|Teva Investigational Site 84067, Kyoto, Japan|Teva Investigational Site 84067, Kyoto, Japan|Teva Investigational Site 84062, Osaka-shi, Japan|Teva Investigational Site 84062, Osaka-shi, Japan|Teva Investigational Site 84070, Saitama-shi, Japan|Teva Investigational Site 84070, Saitama, Japan|Teva Investigational Site 84061, Sendai-shi, Japan|Teva Investigational Site 84061, Sendai-shi, Japan|Teva Investigational Site 84065, Shimotsuma, Japan|Teva Investigational Site 84063, Shinjuku-ku, Japan|Teva Investigational Site 84068, Shizuoka-shi, Japan|Teva Investigational Site 84068, Shizuoka, Japan|Teva Investigational Site 84065, Tochigi, Japan|Teva Investigational Site 84064, Tokyo, Japan|Teva Investigational Site 84071, Toyonaka-shi, Japan|Teva Investigational Site 84071, Toyonaka, Japan|Teva Investigational Site 53364, Krakow, Poland|Teva Investigational Site 53363, Krakow, Poland|Teva Investigational Site 53363, Krakow, Poland|Teva Investigational Site 53364, Krakow, Poland|Teva Investigational Site 53366, Lublin, Poland|Teva Investigational Site 53366, Lublin, Poland|Teva Investigational Site 53365, Poznan, Poland|Teva Investigational Site 53365, Poznan, Poland|Teva Investigational Site 53367, Warsaw, Poland|Teva Investigational Site 53367, Warsaw, Poland|Teva Investigational Site 50399, Kazan, Russian Federation|Teva Investigational Site 50395, Kazan, Russian Federation|Teva Investigational Site 50395, Kazan, Russian Federation|Teva Investigational Site 50399, Kazan, Russian Federation|Teva Investigational Site 50394, Moscow, Russian Federation|Teva Investigational Site 50400, Moscow, Russian Federation|Teva Investigational Site 50394, Moscow, Russian Federation|Teva Investigational Site 50400, Moscow, Russian Federation|Teva Investigational Site 50398, Nizhniy Novgorod, Russian Federation|Teva Investigational Site 50396, Nizhniy Novgorod, Russian Federation|Teva Investigational Site 50396, Nizhniy Novgorod, Russian Federation|Teva Investigational Site 50398, Nizhniy Novgorod, Russian Federation|Teva Investigational Site 50397, Ufa, Russian Federation|Teva Investigational Site 50397, Ufa, Russian Federation|Teva Investigational Site 31207, Madrid, Spain|Teva Investigational Site 31207, Madrid, Spain|Teva Investigational Site 31208, Pamplona, Spain|Teva Investigational Site 31208, Pamplona, Spain|Teva Investigational Site 31205, Valladolid, Spain|Teva Investigational Site 31205, Valladolid, Spain|Teva Investigational Site 31206, Zaragoza, Spain|Teva Investigational Site 31206, Zaragoza, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02629861/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02629861/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02629861
44,NCT02621931,Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine,NA,Completed,Has Results,Migraine,Drug: Fremanezumab|Drug: Placebo,"Change From Baseline in the Monthly Average Number of Headache Days of At Least Moderate Severity During the 12-Week Period After the First Dose of Study Drug|Participants With Treatment-Emergent Adverse Events (TEAEs)|Change From Baseline in the Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Study Drug|Percentage of Participants With At Least 50% Reduction In Monthly Average Number of Headache Days of At Least Moderate Severity|Change From Baseline in the Monthly Average Number of Days of Use of Any Acute Headache Medicine During the 12 Week Period After the First Dose of Study Drug|Change From Baseline in the Number of Headache Days of At Least Moderate Severity During the 4 Week Period After the First Dose of Study Drug|Change From Baseline in the Monthly Average Number of Headache Days of At Least Moderate Severity During the 12 Week Period After the First Dose of Study Medication in Patients Not Receiving Concomitant Preventive Migraine Medications|Change From Baseline in Migraine-Related Disability Score, As Measured by the 6-Item Headache Impact Test (HIT) At Week 12|Electrocardiogram (ECG) Findings Shifts From Baseline to Overall|Participants With Vital Signs Potentially Clinically Significant Abnormal Values|Participants With Serum Chemistry and Hematology Potentially Clinically Significant Abnormal Results|Participants With Urinalysis Laboratory Tests Potentially Clinically Significant Abnormal Results|Prothrombin Time Shifts From Baseline to Endpoint|Injection Site Reaction Adverse Events|Participants With Positive Electronic Columbia Suicide Severity Rating Scale (eC-SSRS) Results After the First Dose of Study Drug","Teva Branded Pharmaceutical Products R&D, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,1130,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TV48125-CNS-30049|2015-004549-23,"March 22, 2016","April 11, 2017","April 11, 2017","December 4, 2015","December 6, 2018","November 9, 2021","Teva Investigational Site 13628, Birmingham, Alabama, United States|Teva Investigational Site 13577, Birmingham, Alabama, United States|Teva Investigational Site 13577, Birmingham, Alabama, United States|Teva Investigational Site 13628, Birmingham, Alabama, United States|Teva Investigational Site 13606, Phoenix, Arizona, United States|Teva Investigational Site 13579, Phoenix, Arizona, United States|Teva Investigational Site 13579, Phoenix, Arizona, United States|Teva Investigational Site 13606, Phoenix, Arizona, United States|Teva Investigational Site 13602, Little Rock, Arkansas, United States|Teva Investigational Site 13602, Little Rock, Arkansas, United States|Teva Investigational Site 13568, Encino, California, United States|Teva Investigational Site 13568, Encino, California, United States|Teva Investigational Site 13546, Fullerton, California, United States|Teva Investigational Site 13546, Fullerton, California, United States|Teva Investigational Site 13540, Long Beach, California, United States|Teva Investigational Site 13540, Long Beach, California, United States|Teva Investigational Site 13632, Redlands, California, United States|Teva Investigational Site 13632, Redlands, California, United States|Teva Investigational Site 13571, Redondo Beach, California, United States|Teva Investigational Site 13571, Redondo Beach, California, United States|Teva Investigational Site 13573, San Diego, California, United States|Teva Investigational Site 13573, San Diego, California, United States|Teva Investigational Site 13538, Santa Monica, California, United States|Teva Investigational Site 13538, Santa Monica, California, United States|Teva Investigational Site 13594, Santa Rosa, California, United States|Teva Investigational Site 13594, Santa Rosa, California, United States|Teva Investigational Site 13595, Walnut Creek, California, United States|Teva Investigational Site 13595, Walnut Creek, California, United States|Teva Investigational Site 13629, Aurora, Colorado, United States|Teva Investigational Site 13629, Aurora, Colorado, United States|Teva Investigational Site 13557, Boulder, Colorado, United States|Teva Investigational Site 13557, Boulder, Colorado, United States|Teva Investigational Site 13593, Colorado Springs, Colorado, United States|Teva Investigational Site 13593, Colorado Springs, Colorado, United States|Teva Investigational Site 13633, Denver, Colorado, United States|Teva Investigational Site 13612, Denver, Colorado, United States|Teva Investigational Site 13612, Denver, Colorado, United States|Teva Investigational Site 13633, Denver, Colorado, United States|Teva Investigational Site 13631, Englewood, Colorado, United States|Teva Investigational Site 13631, Englewood, Colorado, United States|Teva Investigational Site 13563, East Hartford, Connecticut, United States|Teva Investigational Site 13563, East Hartford, Connecticut, United States|Teva Investigational Site 13550, Stamford, Connecticut, United States|Teva Investigational Site 13550, Stamford, Connecticut, United States|Teva Investigational Site 13635, Bradenton, Florida, United States|Teva Investigational Site 13635, Bradenton, Florida, United States|Teva Investigational Site 13597, Gainesville, Florida, United States|Teva Investigational Site 13597, Gainesville, Florida, United States|Teva Investigational Site 13607, Hialeah, Florida, United States|Teva Investigational Site 13607, Hialeah, Florida, United States|Teva Investigational Site 13559, Jacksonville, Florida, United States|Teva Investigational Site 13559, Jacksonville, Florida, United States|Teva Investigational Site 13584, Ocala, Florida, United States|Teva Investigational Site 13584, Ocala, Florida, United States|Teva Investigational Site 13587, Orlando, Florida, United States|Teva Investigational Site 13599, Orlando, Florida, United States|Teva Investigational Site 13551, Orlando, Florida, United States|Teva Investigational Site 13555, Orlando, Florida, United States|Teva Investigational Site 13587, Orlando, Florida, United States|Teva Investigational Site 13599, Orlando, Florida, United States|Teva Investigational Site 13567, Palm Beach Gardens, Florida, United States|Teva Investigational Site 13567, Palm Beach Gardens, Florida, United States|Teva Investigational Site 13553, Pembroke Pines, Florida, United States|Teva Investigational Site 13553, Pembroke Pines, Florida, United States|Teva Investigational Site 13616, Pinellas Park, Florida, United States|Teva Investigational Site 13616, Pinellas Park, Florida, United States|Teva Investigational Site 13620, Atlanta, Georgia, United States|Teva Investigational Site 13537, Atlanta, Georgia, United States|Teva Investigational Site 13537, Atlanta, Georgia, United States|Teva Investigational Site 13620, Atlanta, Georgia, United States|Teva Investigational Site 13604, Boise, Idaho, United States|Teva Investigational Site 13604, Meridian, Idaho, United States|Teva Investigational Site 13585, Chicago, Illinois, United States|Teva Investigational Site 13621, Chicago, Illinois, United States|Teva Investigational Site 13585, Chicago, Illinois, United States|Teva Investigational Site 13621, Chicago, Illinois, United States|Teva Investigational Site 13627, Evanston, Illinois, United States|Teva Investigational Site 13627, Evanston, Illinois, United States|Teva Investigational Site 13596, Indianapolis, Indiana, United States|Teva Investigational Site 13596, Indianapolis, Indiana, United States|Teva Investigational Site 13617, Wichita, Kansas, United States|Teva Investigational Site 13598, Wichita, Kansas, United States|Teva Investigational Site 13598, Wichita, Kansas, United States|Teva Investigational Site 13617, Wichita, Kansas, United States|Teva Investigational Site 13566, Louisville, Kentucky, United States|Teva Investigational Site 13566, Louisville, Kentucky, United States|Teva Investigational Site 13603, Metairie, Louisiana, United States|Teva Investigational Site 13603, Metairie, Louisiana, United States|Teva Investigational Site 13582, Baltimore, Maryland, United States|Teva Investigational Site 13582, Pikesville, Maryland, United States|Teva Investigational Site 13590, Boston, Massachusetts, United States|Teva Investigational Site 13590, Boston, Massachusetts, United States|Teva Investigational Site 13589, New Bedford, Massachusetts, United States|Teva Investigational Site 13589, New Bedford, Massachusetts, United States|Teva Investigational Site 13543, Watertown, Massachusetts, United States|Teva Investigational Site 13543, Watertown, Massachusetts, United States|Teva Investigational Site 13539, Ann Arbor, Michigan, United States|Teva Investigational Site 13539, Ann Arbor, Michigan, United States|Teva Investigational Site 13542, Golden Valley, Minnesota, United States|Teva Investigational Site 13542, Golden Valley, Minnesota, United States|Teva Investigational Site 13534, Kansas City, Missouri, United States|Teva Investigational Site 13534, Kansas City, Missouri, United States|Teva Investigational Site 13619, Saint Louis, Missouri, United States|Teva Investigational Site 13619, Saint Louis, Missouri, United States|Teva Investigational Site 13536, Springfield, Missouri, United States|Teva Investigational Site 13618, Fremont, Nebraska, United States|Teva Investigational Site 13618, Fremont, Nebraska, United States|Teva Investigational Site 13605, Las Vegas, Nevada, United States|Teva Investigational Site 13605, Las Vegas, Nevada, United States|Teva Investigational Site 13578, Lebanon, New Hampshire, United States|Teva Investigational Site 13578, Lebanon, New Hampshire, United States|Teva Investigational Site 13575, Martinsville, New Jersey, United States|Teva Investigational Site 13575, Raritan, New Jersey, United States|Teva Investigational Site 13588, Albuquerque, New Mexico, United States|Teva Investigational Site 13588, Albuquerque, New Mexico, United States|Teva Investigational Site 13576, Amherst, New York, United States|Teva Investigational Site 13576, Amherst, New York, United States|Teva Investigational Site 13565, Plainview, New York, United States|Teva Investigational Site 13565, Plainview, New York, United States|Teva Investigational Site 13544, Greensboro, North Carolina, United States|Teva Investigational Site 13574, Greensboro, North Carolina, United States|Teva Investigational Site 13544, Greensboro, North Carolina, United States|Teva Investigational Site 13574, Greensboro, North Carolina, United States|Teva Investigational Site 13545, Raleigh, North Carolina, United States|Teva Investigational Site 13545, Raleigh, North Carolina, United States|Teva Investigational Site 13609, Akron, Ohio, United States|Teva Investigational Site 13634, Akron, Ohio, United States|Teva Investigational Site 13609, Akron, Ohio, United States|Teva Investigational Site 13634, Akron, Ohio, United States|Teva Investigational Site 13533, Cincinnati, Ohio, United States|Teva Investigational Site 13624, Cincinnati, Ohio, United States|Teva Investigational Site 13533, Cincinnati, Ohio, United States|Teva Investigational Site 13624, Cincinnati, Ohio, United States|Teva Investigational Site 13569, Cleveland, Ohio, United States|Teva Investigational Site 13569, Cleveland, Ohio, United States|Teva Investigational Site 13626, Columbus, Ohio, United States|Teva Investigational Site 13626, Columbus, Ohio, United States|Teva Investigational Site 13625, Mogadore, Ohio, United States|Teva Investigational Site 13625, Mogadore, Ohio, United States|Teva Investigational Site 13561, Oklahoma City, Oklahoma, United States|Teva Investigational Site 13561, Oklahoma City, Oklahoma, United States|Teva Investigational Site 13601, Eugene, Oregon, United States|Teva Investigational Site 13601, Eugene, Oregon, United States|Teva Investigational Site 13591, Jenkintown, Pennsylvania, United States|Teva Investigational Site 13591, Jenkintown, Pennsylvania, United States|Teva Investigational Site 13554, Philadelphia, Pennsylvania, United States|Teva Investigational Site 13554, Philadelphia, Pennsylvania, United States|Teva Investigational Site 13608, Uniontown, Pennsylvania, United States|Teva Investigational Site 13608, Uniontown, Pennsylvania, United States|Teva Investigational Site 13615, Greer, South Carolina, United States|Teva Investigational Site 13615, Greer, South Carolina, United States|Teva Investigational Site 13556, Mount Pleasant, South Carolina, United States|Teva Investigational Site 13556, Mount Pleasant, South Carolina, United States|Teva Investigational Site 13560, Bristol, Tennessee, United States|Teva Investigational Site 13560, Bristol, Tennessee, United States|Teva Investigational Site 13532, Nashville, Tennessee, United States|Teva Investigational Site 13552, Nashville, Tennessee, United States|Teva Investigational Site 13532, Nashville, Tennessee, United States|Teva Investigational Site 13552, Nashville, Tennessee, United States|Teva Investigational Site 13541, Austin, Texas, United States|Teva Investigational Site 13541, Austin, Texas, United States|Teva Investigational Site 13623, Dallas, Texas, United States|Teva Investigational Site 13623, Dallas, Texas, United States|Teva Investigational Site 13611, Plano, Texas, United States|Teva Investigational Site 13611, Plano, Texas, United States|Teva Investigational Site 13572, San Antonio, Texas, United States|Teva Investigational Site 13572, San Antonio, Texas, United States|Teva Investigational Site 13614, Murray, Utah, United States|Teva Investigational Site 13614, Murray, Utah, United States|Teva Investigational Site 13581, West Jordan, Utah, United States|Teva Investigational Site 13581, West Jordan, Utah, United States|Teva Investigational Site 13630, Virginia Beach, Virginia, United States|Teva Investigational Site 13630, Virginia Beach, Virginia, United States|Teva Investigational Site 13564, Seattle, Washington, United States|Teva Investigational Site 13586, Seattle, Washington, United States|Teva Investigational Site 13564, Seattle, Washington, United States|Teva Investigational Site 13586, Seattle, Washington, United States|Teva Investigational Site 13600, Morgantown, West Virginia, United States|Teva Investigational Site 13600, Morgantown, West Virginia, United States|Teva Investigational Site 11124, Hamilton, Ontario, Canada|Teva Investigational Site 11124, Hamilton, Ontario, Canada|Teva Investigational Site 11120, Calgary, Canada|Teva Investigational Site 11120, Calgary, Canada|Teva Investigational Site 11121, Montreal, Canada|Teva Investigational Site 11121, Montreal, Canada|Teva Investigational Site 11122, Newmarket, Canada|Teva Investigational Site 11122, Newmarket, Canada|Teva Investigational Site 11123, Sarnia, Canada|Teva Investigational Site 11123, Sarnia, Canada|Teva Investigational Site 54144, Brno, Czechia|Teva Investigational Site 54144, Brno, Czechia|Teva Investigational Site 54141, Kunratice, Czechia|Teva Investigational Site 54141, Kunratice, Czechia|Teva Investigational Site 54145, Pardubice, Czechia|Teva Investigational Site 54145, Pardubice, Czechia|Teva Investigational Site 54142, Prague 4, Czechia|Teva Investigational Site 54142, Prague 4, Czechia|Teva Investigational Site 54146, Praha 3, Czechia|Teva Investigational Site 54146, Praha 3, Czechia|Teva Investigational Site 54143, Praha, Czechia|Teva Investigational Site 54143, Praha, Czechia|Teva Investigational Site 40018, Helsinki, Finland|Teva Investigational Site 40017, Helsinki, Finland|Teva Investigational Site 40017, Helsinki, Finland|Teva Investigational Site 40018, Helsinki, Finland|Teva Investigational Site 40016, Turku, Finland|Teva Investigational Site 40016, Turku, Finland|Teva Investigational Site 80096, Holon, Israel|Teva Investigational Site 80096, Holon, Israel|Teva Investigational Site 80099, Jerusalem, Israel|Teva Investigational Site 80099, Jerusalem, Israel|Teva Investigational Site 80098, Nahariya, Israel|Teva Investigational Site 80097, Netanya, Israel|Teva Investigational Site 80097, Netanya, Israel|Teva Investigational Site 80100, Ramat Gan, Israel|Teva Investigational Site 80100, Ramat Gan, Israel|Teva Investigational Site 80095, Tel Aviv, Israel|Teva Investigational Site 84072, Chofu-shi, Japan|Teva Investigational Site 84064, Chofu-shi, Japan|Teva Investigational Site 84072, Chofu-shi, Japan|Teva Investigational Site 84066, Kagoshima-shi, Japan|Teva Investigational Site 84066, Kagoshima, Japan|Teva Investigational Site 84069, Kai-shi, Japan|Teva Investigational Site 84069, Kai, Japan|Teva Investigational Site 84073, Kawasaki-shi, Japan|Teva Investigational Site 84073, Kawasaki, Japan|Teva Investigational Site 84067, Kyoto, Japan|Teva Investigational Site 84067, Kyoto, Japan|Teva Investigational Site 84062, Osaka-shi, Japan|Teva Investigational Site 84062, Osaka-shi, Japan|Teva Investigational Site 84070, Saitama-shi, Japan|Teva Investigational Site 84070, Saitama, Japan|Teva Investigational Site 84061, Sendai-shi, Japan|Teva Investigational Site 84061, Sendai-shi, Japan|Teva Investigational Site 84065, Shimotsuma, Japan|Teva Investigational Site 84068, Shizuoka-shi, Japan|Teva Investigational Site 84068, Shizuoka, Japan|Teva Investigational Site 84065, Tochigi, Japan|Teva Investigational Site 84064, Tokyo, Japan|Teva Investigational Site 84071, Toyonaka-shi, Japan|Teva Investigational Site 84071, Toyonaka, Japan|Teva Investigational Site 53364, Krakow, Poland|Teva Investigational Site 53363, Krakow, Poland|Teva Investigational Site 53363, Krakow, Poland|Teva Investigational Site 53364, Krakow, Poland|Teva Investigational Site 53366, Lublin, Poland|Teva Investigational Site 53366, Lublin, Poland|Teva Investigational Site 53365, Poznan, Poland|Teva Investigational Site 53365, Poznan, Poland|Teva Investigational Site 53367, Warsaw, Poland|Teva Investigational Site 53367, Warsaw, Poland|Teva Investigational Site 50399, Kazan, Russian Federation|Teva Investigational Site 50395, Kazan, Russian Federation|Teva Investigational Site 50395, Kazan, Russian Federation|Teva Investigational Site 50399, Kazan, Russian Federation|Teva Investigational Site 50394, Moscow, Russian Federation|Teva Investigational Site 50400, Moscow, Russian Federation|Teva Investigational Site 50394, Moscow, Russian Federation|Teva Investigational Site 50400, Moscow, Russian Federation|Teva Investigational Site 50398, Nizhniy Novgorod, Russian Federation|Teva Investigational Site 50396, Nizhniy Novgorod, Russian Federation|Teva Investigational Site 50396, Nizhniy Novgorod, Russian Federation|Teva Investigational Site 50398, Nizhniy Novgorod, Russian Federation|Teva Investigational Site 50397, Ufa, Russian Federation|Teva Investigational Site 50397, Ufa, Russian Federation|Teva Investigational Site 31207, Madrid, Spain|Teva Investigational Site 31207, Madrid, Spain|Teva Investigational Site 31208, Pamplona, Spain|Teva Investigational Site 31208, Pamplona, Spain|Teva Investigational Site 31205, Valladolid, Spain|Teva Investigational Site 31205, Valladolid, Spain|Teva Investigational Site 31206, Zaragoza, Spain|Teva Investigational Site 31206, Zaragoza, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02621931/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02621931/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02621931
45,NCT02614261,Evaluation of Galcanezumab in the Prevention of Chronic Migraine,REGAIN,Completed,Has Results,Chronic Migraine,Drug: Galcanezumab|Drug: Placebo,"Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHD)|Number of Participants With Reduction From Baseline ≥50%, ≥75% and 100% in Monthly Migraine Headache Days|Mean Change From Baseline in the Migraine-Specific Quality of Life Questionnaire (MSQ) Role-function Restrictive Domain|Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days Requiring Medication for the Acute Treatment of Migraine or Headache|Mean Change From Baseline in the Patient Global Impression of Severity (PGI-S) Score|Overall Mean Change From Baseline in Headache Hours|Mean Change From Baseline on the Migraine Disability Assessment Test (MIDAS) Total Score|Percentage of Participants Developing Treatment Emergent Anti-drug Antibodies (ADA) to Galcanezumab|Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Galcanezumab|Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)|Serum Concentrations of Galcanezumab",Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,1117,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",15769|I5Q-MC-CGAI|2015-001883-21,"November 30, 2015","March 16, 2017","July 14, 2021","November 25, 2015","January 7, 2019","May 18, 2022","21st Century Neurology, Phoenix, Arizona, United States|Arizona Research Center, Phoenix, Arizona, United States|Pharmacology Research Institute, Encino, Encino, California, United States|Fullerton Neurology and Headache Center, Fullerton, California, United States|Pharmacology Research Institute, Los Alamitos, Los Alamitos, California, United States|Pharmacology Research Institute, Newport Beach, Newport Beach, California, United States|Desert Valley Research, Rancho Mirage, California, United States|Anderson Clinical Research, Redlands, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Medical Center for Clinical Research, San Diego, California, United States|Optimus Medical Group, San Francisco, California, United States|Colorado Neurological Institute, Englewood, Colorado, United States|Advanced Neurosciences Research, LLC, Fort Collins, Colorado, United States|Associated Neurologists of Southern Connecticut, Fairfield, Connecticut, United States|Avail Clinical Research LLC, DeLand, Florida, United States|Clinical Neuroscience Solutions Inc, Jacksonville, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Psychiatric Inst of Florida-Clinical Neuroscience Solutions, Orlando, Florida, United States|Compass Research, Oviedo, Florida, United States|Premiere Research Institute at Palm Beach Neurology, West Palm Beach, Florida, United States|Northwest Clinical Trials, Boise, Idaho, United States|Christie Clinic, LLC, Champaign, Illinois, United States|Robbins Headache Clinic, Riverwoods, Illinois, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Phoenix Medical Research, Inc, Prairie Village, Kansas, United States|Heartland Research Associates, Wichita, Kansas, United States|PharmaSite Research Inc, Baltimore, Maryland, United States|Boston Clinical Trials Inc, Boston, Massachusetts, United States|Michigan Head, Pain and Neurological Institute, Ann Arbor, Michigan, United States|Clinical Research Institute, Minneapolis, Minnesota, United States|Healthcare Research Network - Hazelwood, Hazelwood, Missouri, United States|ClinVest, Springfield, Missouri, United States|Albuquerque Clinical Trials, Albuquerque, New Mexico, United States|Dent Neurological Institute, Amherst, New York, United States|Island Neuro Associates,PC, Plainview, New York, United States|Univ of Cincinnati College of Medicine, Cincinnati, Ohio, United States|Healthcare Research Consultant, Tulsa, Oklahoma, United States|Preferred Primary Care Physicians, Pleasant Hills, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|University of South Carolina, Columbia, South Carolina, United States|Coastal Carolina Research Center, Inc., Mount Pleasant, South Carolina, United States|BG Neurology, Spartanburg, South Carolina, United States|ClinSearch, Chattanooga, Tennessee, United States|FutureSearch Trials of Neurology and Sleep Lab, Austin, Texas, United States|Headache Medicine Specialist of North Texas, Dallas, Texas, United States|Foothill Family Clinic, Salt Lake City, Utah, United States|Health Research of Hampton Roads Inc, Newport News, Virginia, United States|Sentara Neurology Specialists, Virginia Beach, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Premier Clinical Research, Spokane, Washington, United States|Dean Foundation for Health Research and Education, Middleton, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Autonoma de Buenos Aire, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Autonoma de Buenos Aire, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Autonoma de Buenos Aire, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Autonoma de Buenos Aire, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Autonoma de Buenos Aire, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Autonoma de Buenos Aire, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Autonoma de Buenos Aire, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cordoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cordoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Brampton, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Kelowna, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Montreal, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ottawa, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brno, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kladno, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 10, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 2, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 6, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 8, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bielefeld, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bochum, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Essen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kassel, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Königstein, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prien, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tübingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hadera, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kfar Saba, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ramat Gan, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Aviv, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bologna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Firenze, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Modena, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pavia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aguascalientes, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Culiacan, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., México City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leiden, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nijmegen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zwolle, Netherlands|Office of Dr. Ruddy Guerra, Manati, Puerto Rico|GCM Medical Group PSC, San Juan, Puerto Rico|Instituto de Neurologia Dra. Ivonne Fraga, San Juan, Puerto Rico|Neuro GI Wellness Center, San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pamplona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santander, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valladolid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glasgow, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hull, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stoke-on-Trent, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02614261/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02614261/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02614261
46,NCT02614196,Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study,EVOLVE-2,Completed,Has Results,Migraine,Drug: Galcanezumab|Drug: Placebo,"Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days|Mean Percentage of Participants With Reduction From Baseline ≥50%, ≥75%, and 100% in Monthly Migraine Headache Days|Mean Change From Baseline in the Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1 Role Function Restrictive Domain|Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days Requiring Medication for the Acute Treatment of Migraine or Headache|Mean Change From Baseline in Patient Global Impression of Severity (PGI-S) Rating|Overall Mean Change From Baseline in Headache Hours|Mean Change From Baseline in the Migraine Disability Assessment Test (MIDAS) Total Score|Percentage of Participants Developing Anti-drug Antibodies (ADA) to Galcanezumab|Pharmacokinetics (PK): Serum Concentrations of Galcanezumab|Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)",Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,986,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",15768|I5Q-MC-CGAH|2015-001882-17,"December 4, 2015","March 29, 2017","October 5, 2018","November 25, 2015","January 7, 2019","June 17, 2020","21st Century Neurology, Phoenix, Arizona, United States|Arizona Research Center, Phoenix, Arizona, United States|Axiom Research, Apple Valley, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Pacific Research Partners, LLC, Oakland, California, United States|Medical Center for Clinical Research, San Diego, California, United States|Optimus Medical Group, San Francisco, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|IMMUNOe International Research Centers, Centennial, Colorado, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Sunrise Clinical Research, Hollywood, Florida, United States|Westside Center for Clinical Research, Jacksonville, Florida, United States|Clinical Neuroscience Solutions Inc, Jacksonville, Florida, United States|Sensible Healthcare, Ocoee, Florida, United States|Meridien Research, Tampa, Florida, United States|Atlanta Center of Medical Research, Atlanta, Georgia, United States|Christie Clinic, LLC, Champaign, Illinois, United States|Diamond Headache Clinic, Chicago, Illinois, United States|Josephson Wallack Munshower Neurology, Indianapolis, Indiana, United States|Heartland Research Associates, Wichita, Kansas, United States|Novex Clinical Research, New Bedford, Massachusetts, United States|QUEST Research Institute, Farmington Hills, Michigan, United States|Healthcare Research Network - Hazelwood, Hazelwood, Missouri, United States|Nevada Headache Institute, Las Vegas, Nevada, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albuquerque Clinical Trials, Albuquerque, New Mexico, United States|Regional Clinical Research, Binghamton, New York, United States|SPRI Clinical Trials, LLC., Brooklyn, New York, United States|High Point Clinical Trials Center, High Point, North Carolina, United States|Neurology & Neuroscience Associates, Inc., Akron, Ohio, United States|Univ of Cincinnati College of Medicine, Cincinnati, Ohio, United States|Urgent Care Specialists, LLC, Columbus, Ohio, United States|Urgent Care Specialists, LLC, Dayton, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Oregon Neurology Associates, Springfield, Oregon, United States|Clinical Research of Philadelphia, Philadelphia, Pennsylvania, United States|Mountain View Clinical Research, Inc, Greer, South Carolina, United States|Coastal Carolina Research Center, Inc., Mount Pleasant, South Carolina, United States|FutureSearch Trials, Dallas, Texas, United States|Clinical Trial Network, Houston, Texas, United States|Clinpoint Trial, LLC, Waxahachie, Texas, United States|Foothill Family Clinic, Salt Lake City, Utah, United States|Jordan River Family Medicine, South Jordan, Utah, United States|Health Research of Hampton Roads Inc, Newport News, Virginia, United States|Sentara Neurology Specialists, Virginia Beach, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Polyclinic, Seattle, Washington, United States|Dean Foundation for Health Research and Education, Middleton, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Autonoma de Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Autonoma de Buenos Aire, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Autonoma de Buenos Aire, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Autonoma de Buenos Aire, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brno, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kladno, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 10, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 2, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 6, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 8, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bielefeld, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bochum, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bochum, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Essen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Halle, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jena, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kassel, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Königstein, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prien, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tübingen, Germany|Hillel Yaffe, Hadera, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kfar Saba, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ramat Gan, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hwaseong-si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aguascalientes, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Culiacan, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Merida, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., México City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Geleen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leiden, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nijmegen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tilburg, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zwolle, Netherlands|Cortex, PSC, Las Piedras, Puerto Rico|SomniCare Sleep Institute, San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Elda, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santander, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valladolid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glasgow, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hull, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liverpool, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stoke-on-Trent, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02614196/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02614196/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02614196
47,NCT02614183,Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study,EVOLVE-1,Completed,Has Results,Migraine,Drug: Galcanezumab|Drug: Placebo,"Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days|Mean Percentage of Participants With Reduction From Baseline ≥50%, ≥75% and 100% in Monthly Migraine Headache Days|Mean Change From Baseline in the Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1 (v2.1) Role Function Restrictive Domain|Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days Requiring Medication for the Acute Treatment of Migraine or Headache|Mean Change From Baseline in the Patient Global Impression of Severity (PGI-S) Rating|Overall Mean Change From Baseline in Headache Hours|Mean Change From Baseline on the Migraine Disability Assessment Test (MIDAS) Total Score|Percentage of Participants Developing Anti-drug Antibodies (ADA) to Galcanezumab|Pharmacokinetics (PK): Serum Concentrations of Galcanezumab|Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)",Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,862,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",15767|I5Q-MC-CGAG,"November 30, 2015","March 22, 2017","August 9, 2018","November 25, 2015","November 29, 2018","June 17, 2020","Territory Neurology & Research Institute, Tucson, Arizona, United States|Orange Grove Family Practice, Tucson, Arizona, United States|Arkansas Clinical Research, Little Rock, Arkansas, United States|Advanced Clinical Research, Carmichael, California, United States|Pharmacology Research Institute, Newport Beach, Encino, California, United States|Tooraj Joseph Raoof M.D., Inc., Encino, California, United States|Fullerton Neurology and Headache Center, Fullerton, California, United States|Sun Valley Research Center, Imperial, California, United States|Irvine Clinical Research Center, Irvine, California, United States|Pharmacology Research Institute, Newport Beach, Los Alamitos, California, United States|Pharmacology Research Institute, Newport Beach, Newport Beach, California, United States|Desert Valley Research, Rancho Mirage, California, United States|Anderson Clinical Research, Redlands, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Medical Center for Clinical Research, San Diego, California, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|MCB Clinical Research Centers, Colorado Springs, Colorado, United States|Mile High Research Center, Denver, Colorado, United States|Colorado Neurological Institute, Englewood, Colorado, United States|Advanced Neurosciences Research, LLC, Fort Collins, Colorado, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Meridien Research, Bradenton, Florida, United States|Sarkis Clinical Trials, Gainesville, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Sensible Healthcare, Ocoee, Florida, United States|Psychiatric Inst of Florida-Clinical Neuroscience Solutions, Orlando, Florida, United States|Compass Research, Oviedo, Florida, United States|Accord Clinical Research, LLC, Port Orange, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Infinity Clinical Reserach . LLC, Sunrise, Florida, United States|Premiere Research Institute at Palm Beach Neurology, West Palm Beach, Florida, United States|Advanced Clinical Research LLC, Meridian, Idaho, United States|Healthcare Research Network - Blue Island, Blue Island, Illinois, United States|Community Clinical Research Center, Anderson, Indiana, United States|Investigative Clinical Research of Indiana, LLC, Elwood, Indiana, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Deaconess Clinic Inc, Newburgh, Indiana, United States|Integrated Clinical Trial Services, Inc., West Des Moines, Iowa, United States|Phoenix Medical Research, Inc, Prairie Village, Kansas, United States|Otri-Med Corporation, Edgewood, Kentucky, United States|L-Marc Research Center, Louisville, Kentucky, United States|PharmaSite Research Inc, Baltimore, Maryland, United States|Boston Clinical Trials Inc, Boston, Massachusetts, United States|Michigan Head, Pain and Neurological Institute, Ann Arbor, Michigan, United States|Clinical Research Institute, Minneapolis, Minnesota, United States|ClinVest, Springfield, Missouri, United States|Healthy Perspectives Innovative Mental Health Services, PL, Nashua, New Hampshire, United States|Albuquerque Clinical Trials, Albuquerque, New Mexico, United States|Dent Neurological Institute, Amherst, New York, United States|Central New York Clinical Research, Manlius, New York, United States|NYU Langone, New York, New York, United States|Fieve Clincial Services, New York, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|Metrolina Neurological Associates, PA, Charlotte, North Carolina, United States|Headache Wellness Center, Greensboro, North Carolina, United States|Rapid Medical Research Inc, Cleveland, Ohio, United States|Medical College of Ohio at Toledo, Toledo, Ohio, United States|Healthcare Research Consultant, Tulsa, Oklahoma, United States|Summit Research Network Inc, Portland, Oregon, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Omega Medical Research, Warwick, Rhode Island, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|8 Medical Park, Columbia, South Carolina, United States|ClinSearch, Chattanooga, Tennessee, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Clinical Research Associates, Nashville, Tennessee, United States|FutureSearch Trials, Austin, Texas, United States|Protenium Clinical Research, Hurst, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Radiant Research - San Antonio, San Antonio, Texas, United States|Advanced Clinical Research, West Jordan, Utah, United States|Charlottesville Medical Research, Charlottesville, Virginia, United States|Clinical Research Associates of Tidewater, Norfolk, Virginia, United States|National Clinical Research - Richmond, Richmond, Virginia, United States|Premier Clinical Research, Spokane, Washington, United States|Vancouver Clinic, Vancouver, Washington, United States|Clinical Investigation Specialists Inc, Kenosha, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Brampton, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Kelowna, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Mississauga, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Montreal, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ottawa, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Sherbrooke, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Vancouver, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Waterloo, Canada|Office of Dr. Ruddy Guerra, Manati, Puerto Rico|NuFrontiers Clinical Research LLC, Rio Piedras, Puerto Rico|Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico|GCM Medical Group PSC, San Juan, Puerto Rico|Instituto de Neurologia Dra. Ivonne Fraga, San Juan, Puerto Rico|Neuro GI Wellness Center, San Juan, Puerto Rico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02614183/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02614183/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02614183
48,NCT02605434,A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients,Accordance,Unknown status,No Results Available,Parkinson's Disease,Drug: Accordion Pill™ Carbidopa/Levodopa|Drug: Sinemet®|Drug: Placebo -AP-CD/LD|Drug: Placebo- Sinemet,"Change from Baseline through study completion, an average of 27 weeks, in the percentage of daily ""Off time"" during waking hours|Change from Baseline through study completion, an average of 27 weeks, in ""On time"" without troublesome dyskinesia during waking hours|Change in the number of total daily LD doses from Baseline through study completion, an average of 27 weeks (hours)|CGI-I through study completion, an average of 27 weeks, as recorded by physician & patient|Change from Baseline through study completion, an average of 27 weeks, in total UPDRS Score (Sum of Parts I-III)",Intec Pharma Ltd.,All,"30 Years and older   (Adult, Older Adult)",Phase 3,420,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IN 11 004,March 2016,July 2019,December 2019,"November 16, 2015",NA,"August 8, 2019","University Alabama Hospital Neurology, Birmingham, Alabama, United States|Saint Joseph's Hospital and Medical Center Muhammad Ali Parkinson Research Center, Phoenix, Arizona, United States|Parkinson's Disease & Movement Disorders Center, Dept of Neu, Fountain Valley, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|University of Southern California, Los Angeles, California, United States|SC3 Research, Pasadena, California, United States|SC3 Research, Reseda, California, United States|UC Davis Medical Center, Sacramento, California, United States|University of Colorado Dept. of Neurology, Aurora, Colorado, United States|Hartford HealthCare, Vernon, Connecticut, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|Collier Neurologic Specialists, LLC, Naples, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Parkinson's Disease and Movement Disorders Center, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|The University of Kansas Hospital, Kansas City, Kansas, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Michigan State University, East Lansing, Michigan, United States|Quest Research Institute, Farmington Hills, Michigan, United States|Henry Ford Hospital, West Bloomfield, Michigan, United States|Dartmouth Hitchcock Neurology, Lebanon, New Hampshire, United States|Atlantic Health System Hospital Corp.-Overlook Hospital, Summit, New Jersey, United States|David L. Kreitzman, MD., PC, Commack, New York, United States|Fresco Institute for Parkinson's and Movement Disorders, New York, New York, United States|Weill Cornell Medical College of Cornell University, New York, New York, United States|Asheville Neurology Specialists, Asheville, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|University of Toledo, Toledo, Ohio, United States|The Movement Disorder Clinic of Oklahoma, Tulsa, Oklahoma, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center Vanderbilt Clinical Neurosciences, Nashville, Tennessee, United States|North Texas Movement Disorders Institute, Bedford, Texas, United States|Baylor College of Medicine Department of Neurology, Houston, Texas, United States|Charlottesville Medical Research, Charlottesville, Virginia, United States|Booth Garner Parkinson's Care Center, Kirkland, Washington, United States|MHAT 'Sv.Pantaleymon - Pleven' OOD, Pleven, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sveti Georgi"" EAD, Plovdiv, Bulgaria|Clinic for Neurology and Sleep Medicine, Sofia, Bulgaria|Clinic of Neurological Diseases, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment ""Sveta Marina'' EAD, Varna, Bulgaria|Neuroakademie Alzenau GbR, Aschaffenburg, Germany|Praxis für Neurologie und Psychiatrie, Berlin, Germany|Uniklinikum Carl-Gustav Carus an der TU Dresden, Dresden, Germany|Technischen Universitaet Muenchen (TUM) - Klinikum Rechts der Isar, Munchen, Germany|Praxis für Neurologie und Psychiatrie, Westerstede, Germany|Rambam Medical Center, Haifa, Israel|Rabin Medical Center, Petah Tiqva, Israel|Chaim Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Ospedale Generale Regionale Francesco Miulli, Acquaviva delle Fonti, Italy|Ospedali Riuniti di Ancona, Ancona, Italy|Spedali Civili Di Brescia Azienda Ospedaliera, Brescia, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Italy|IRCCS Neurologico Fondazione ""C. Mondino"", Pavia, Italy|Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy|IRCCS San Raffaele Pisana, Roma, Italy|Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy|Azienda Ospedaliera Universitaria San Giovanni di Dio Ruggi d'Aragona, Salerno, Italy|Ospedale di Circolo e Fondazione Macchi, Varese, Italy|Azienda Unitá Locale Socio Sanitaria 12 Veneziana - Ospedale dell'Angelo, Venezia, Italy|Casa di Cura Villa Margherita, Vicenza, Italy|Centrum Medyczne Damiana Holding, Warszawa, Mazowieckie, Poland|VITAMED Galaj i Cichomski spólka jawna, Bydgoszcz, Poland|Anna Kapustecka Prywatna Przychodnia Specjalistyczna STOMED, Czestochowa, Poland|NEURO-CARE Site Management Organization Gabriela Klodowska-Duda, Katowice, Poland|Centrum Medyczne Pratia Katowice I, Katowice, Poland|Krakowska Akademia Neurologii Sp. z o. o., Krakow, Poland|Gabinet Lekarski Prof. Andrzej Bogucki, Lodz, Poland|Centrum Medyczne Pratia Warszawa, Warszawa, Poland|Neurologicka ambulancia, Euro-Neuro s.r.o., Bratislava, Slovakia|KONZÍLIUM s.r.o., Považská Bystrica, Slovakia|NEURON - D.T. s.r.o., Zilina, Slovakia|HM Puerta del Sur, Mostoles, Madrid, Spain|Hospital Universitari Quirón Dexeus, Barcelona, Spain|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Ruber Internacional, Madrid, Spain|Hospital Puerta de Hierro Majadahonda, Majadahonda, Spain|Hospital Infanta Sofía, San Sebastian de los Reyes, Spain|Hospital General de Cataluña, Sant Cugat del Valles, Spain|Ukrainian State Scientific Research Institution of Medical and Social Problems of Disability, Cherkasy, Ukraine|Dnipropetrovsk medical academy MOH of Ukraine, Dnipropetrovs'k, Ukraine|Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine, Kharkiv, Ukraine|State Institution ""Institute of Gerontology of the AMS of Ukraine"", Kyiv, Ukraine|Lviv City Clinical Hospital, L'viv, Ukraine|Regional Clinical Hospital n.a. N.V. Sklifosovskyi, Poltava, Ukraine|Municipal Institution ""Zaporizhzhya City Clinical Multidisciplinary Hospital #9"", Zaporizhzhya, Ukraine|Municipal Institution 6¿ City Clinical Hospital, Zaporizhzhya, Ukraine|Clinical Hospital #2, Zaporozh'ye, Ukraine|Municipal Institution Zaporizhzhia Regional Clinical Hospital of Zaporizhzhia Regional Council, Zaporozh'ye, Ukraine|Fairfield General Hospital, Bury, United Kingdom|Newcastle University Clinical Ageing Research, Newcastle upon Tyne, United Kingdom|Queens Medical Centre Nottingham, University Hospital, Nottingham, United Kingdom|University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT02605434
49,NCT02593097,Metformin for the Prevention of Episodic Migraine (MPEM),MPEM,Completed,Has Results,Migraine,Drug: Metformin|Drug: Matching Placebo,Headache Days|Greater Than >50% Reduction in Migraine Days on Metformin|Adverse Events,Mayo Clinic,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,34,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",15-000422,February 2016,June 2019,June 2019,"October 30, 2015","July 1, 2020","July 1, 2020","Mayo Clinic in Arizona, Scottsdale, Arizona, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT02593097/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02593097
50,NCT02588677,Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS),NA,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Drug: Masitinib (4.5)|Drug: Riluzole|Drug: Placebo|Drug: Masitinib (3.0),Change in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-Revised|Change of Forced Vital Capacity (FVC)|Progression Free Survival|Overall Survival,AB Science,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,394,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",AB10015,April 2013,"December 5, 2016",March 2018,"October 28, 2015",NA,"December 17, 2018","Hospital Carlos III, Madrid, Spain",NA,https://ClinicalTrials.gov/show/NCT02588677
51,NCT02585934,Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study,NA,Completed,Has Results,Alzheimer's Disease,Drug: RVT-101|Drug: Placebo,Alzheimer's Disease Assessment Scale - Cognitive Subscale 11 Items (ADAS-Cog-11) Score Change From Baseline to Week 24|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Score Change From Baseline to Week 24|Clinical Global Impression of Change - Plus Caregiver Interview (CIBIC+) Score at Week 24|The Dependence Scale (DS) Score Change From Baseline to Week 24|Neuropsychiatric Inventory (NPI) Score Change From Baseline to Week 24|ADAS-Cog-13 Score Change From Baseline to Week 24|Measurement of Concentrations of RVT-101 (Intepirdine) in Plasma,Axovant Sciences Ltd.|Sio Gene Therapies,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,1315,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RVT-101-3001,October 2015,September 2017,September 2017,"October 26, 2015","December 5, 2018","December 5, 2018","US112, Phoenix, Arizona, United States|US220, Tucson, Arizona, United States|US168, Encino, California, United States|US117, Fullerton, California, United States|US214, Los Angeles, California, United States|US189, Pasadena, California, United States|US096, Rancho Mirage, California, United States|US0195, Santa Ana, California, United States|US016, Simi Valley, California, United States|US106, Temecula, California, United States|US179, Hamden, Connecticut, United States|US171, Norwich, Connecticut, United States|US088, Atlantis, Florida, United States|US007, Brooksville, Florida, United States|US002, Hallandale Beach, Florida, United States|US140, Hialeah, Florida, United States|US216, Miami, Florida, United States|US110, Miami, Florida, United States|US172, North Palm Beach, Florida, United States|US003, Orlando, Florida, United States|US256, Pensacola, Florida, United States|US037, Tampa, Florida, United States|US042, Tampa, Florida, United States|US004, The Villages, Florida, United States|US048, Atlanta, Georgia, United States|US046, Atlanta, Georgia, United States|US217, Columbus, Georgia, United States|US111, Baton Rouge, Louisiana, United States|US095, Shreveport, Louisiana, United States|US116, Newton, Massachusetts, United States|US174, Quincy, Massachusetts, United States|US144, Hattiesburg, Mississippi, United States|US094, Las Vegas, Nevada, United States|US135, Berlin, New Jersey, United States|US197, Lawrenceville, New Jersey, United States|US057, Manchester, New Jersey, United States|US215, Mount Arlington, New Jersey, United States|US209, Toms River, New Jersey, United States|US036, West Long Branch, New Jersey, United States|US001, Albany, New York, United States|US049, Brooklyn, New York, United States|US097, New Hyde Park, New York, United States|US177, New Windsor, New York, United States|US142, New York, New York, United States|US044, New York, New York, United States|US150, Chapel Hill, North Carolina, United States|US185, Charlotte, North Carolina, United States|US113, Beachwood, Ohio, United States|US136, Cincinnati, Ohio, United States|US008, Cincinnati, Ohio, United States|US119, Shaker Heights, Ohio, United States|US134, Portland, Oregon, United States|US169, Media, Pennsylvania, United States|US187, Philadelphia, Pennsylvania, United States|US162, Plains, Pennsylvania, United States|US148, Willow Grove, Pennsylvania, United States|US115, Houston, Texas, United States|US043, San Antonio, Texas, United States|US143, Orem, Utah, United States|US149, Charlottesville, Virginia, United States|US170, Spokane, Washington, United States|AR130, La Plata, Buenos Aires, Argentina|AR041, La Plata, Buenos Aires, Argentina|AR101, Buenos Aires, Argentina|AR060, Buenos Aires, Argentina|AR084, Ciudad Autónoma de Buenos Aire, Argentina|AR027, Ciudad Autónoma de Buenos Aire, Argentina|AR012, Ciudad Autónoma de Buenos Aire, Argentina|AR160, Ciudad Autónoma de Buenos Aire, Argentina|AR040, Ciudad Autónoma de Buenos Aire, Argentina|AR028, Ciudad Autónoma de Buenos Aire, Argentina|AR081, Ciudad Autónoma de Buenos Aire, Argentina|AR035, Ciudad Autónoma de Buenos Aire, Argentina|AR051, Cordoba, Argentina|AR137, Cordoba, Argentina|AR210, Mendoza, Argentina|AR219, Mendoza, Argentina|AR059, Santiago del Estero, Argentina|AU227, Caulfield, Australia|AU079, Chermside, Australia|AU032, Heidelberg West, Australia|AU062, Herston, Australia|AU011, Hornsby, Australia|AU138, West Perth, Australia|BU125, Ruse, Bulgaria|BU131, Sofia, Bulgaria|BU198, Sofia, Bulgaria|BU073, Varna, Bulgaria|CA151, Medicine Hat, Alberta, Canada|CA120, Kamloops, British Columbia, Canada|CA054, Kelowna, British Columbia, Canada|CA188, Kelowna, British Columbia, Canada|CA186, Penticton, British Columbia, Canada|CA141, West Vancouver, British Columbia, Canada|CA147, Newmarket, Ontario, Canada|CA196, North York, Ontario, Canada|CA237, Toronto, Ontario, Canada|CA236, Gatineau, Quebec, Canada|CH212, Antofagasta, II Región, Chile|CH076, Santiago, Region Metropolitana, Chile|CH061, Santiago, Región Metropolitana, Chile|CH075, Santiago, Región Metropolitana, Chile|CR069, Zagreb, Croatia|CR122, Zagreb, Croatia|CR068, Zagreb, Croatia|CR070, Zagreb, Croatia|CR083, Zagreb, Croatia|CZ128, Praha 10, Czechia|CZ207, Praha 10, Czechia|CZ132, Praha 2, Czechia|CZ129, Praha 6, Czechia|CZ161, Rychnov nad Kneznou, Czechia|FR231, Lille Cedex, France|FR182, Marseille Cedex 5, France|FR221, Paris Cedex, France|FR202, Villeurbanne, France|GE206, Bad Homburg, Germany|GE091, Berlin, Germany|GE071, Berlin, Germany|GE139, Berlin, Germany|GE230, Cologne, Germany|GE252, Ellwangen, Germany|GE180, Leipzig, Germany|GE228, Mannheim, Germany|GE017, Munchen, Germany|GE157, Nürnberg, Germany|GE098, Ulm, Germany|GE251, Westerstede, Germany|IT053, Brescia, Italy|IT124, Cefalù, Italy|IT030, Pavia, Italy|IT103, Perugia, Italy|IT072, Roma, Italy|IT183, Roma, Italy|IT029, Roma, Italy|IT175, Rome, Italy|IT085, Torino, Italy|SK066, Busan, Korea, Republic of|SK067, Seoul, Korea, Republic of|SK190, Seoul, Korea, Republic of|PO013, Bialystok, Poland|PO024, Bydgoszcz, Poland|PO010, Bydgoszcz, Poland|PO107, Katowice, Poland|PO092, Katowice, Poland|PO023, Krakow, Poland|PO025, Krakow, Poland|PO009, Poznan, Poland|PO014, Szczecin, Poland|PO074, Warszawa, Poland|SE164, Belgrade, Serbia|SE090, Belgrade, Serbia|SE166, Belgrade, Serbia|SE193, Belgrade, Serbia|SE155, Kragujevac, Serbia|SE031, Novi Knezevac, Serbia|SE165, Vrsac, Serbia|SI052, Singapore, Singapore|SI026, Singapore, Singapore|SL056, Banska Bystrica, Slovakia|SL192, Bratislava, Slovakia|SL200, Dubnica nad Váhom, Slovakia|SL191, Kosice, Slovakia|SL078, Krompachy, Slovakia|SL077, Svidnik, Slovakia|SP249, Alicante, Spain|SP176, Barcelona, Spain|SP022, Barcelona, Spain|SP021, Barcelona, Spain|SP250, Barcelona, Spain|SP019, Ceuta, Spain|SP194, Donostia, Spain|SP222, Getxo, Spain|SP018, Madrid, Spain|SP093, Madrid, Spain|SP184, Sant Cugat del Vallès, Spain|SP020, Terrassa, Spain|TA065, Kaohsiung, Taiwan|TA086, Taipei, Taiwan|TA121, Taoyuan, Taiwan|UK063, Bath, United Kingdom|UK038, Blackpool, United Kingdom|UK233, Cambridge, United Kingdom|UK033, Cannock, United Kingdom|UK211, Epping, United Kingdom|UK234, Guildford, United Kingdom|UK055, Leeds, United Kingdom|UK039, London, United Kingdom|UK034, Manchester, United Kingdom|UK229, Norwich, United Kingdom|UK087, Oxford, United Kingdom|UK235, Plymouth, United Kingdom|UK100, Sheffield, United Kingdom|UK064, Southampton, United Kingdom|UK152, Southampton, United Kingdom|UK153, Swindon, United Kingdom|UK154, Warrington, United Kingdom","""Study Protocol: Protocol"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02585934/Prot_000.pdf|""Statistical Analysis Plan: Statistical Analysis Plan Document"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02585934/SAP_001.pdf|""Statistical Analysis Plan: Statistical Analysis Plan Addendum Document"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02585934/SAP_002.pdf",https://ClinicalTrials.gov/show/NCT02585934
52,NCT02569853,DFN-11 Injection in Episodic Migraine With or Without Aura,RESTOR,Completed,Has Results,Episodic Migraine,Drug: DFN-11|Other: Placebo,The Percentage of Subjects in the Double-blind Period Who Are Pain Free at 2 Hours After Dosing as Reported by the Subject in the eDiary|The Percentage of Subjects in the Double-blind Period Who Are Pain Free at 1 Hour After Dosing as Reported by the Subject in the eDiary,Dr. Reddy's Laboratories Limited,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,268,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DFN-11-CD-004,"September 21, 2015","May 30, 2017","February 26, 2018","October 7, 2015","July 26, 2018","July 26, 2018","Dr. Reddy's Investigational Site #18, Santa Monica, California, United States|Dr. Reddy's Investigational Site #24, Jacksonville, Florida, United States|Dr. Reddy's Investigational Site #23, Maitland, Florida, United States|Dr. Reddy's Investigational Site #27, Boise, Idaho, United States|Dr. Reddy's Investigational Site #20, Watertown, Massachusetts, United States|Dr. Reddy's Investigational Site #19, Ann Arbor, Michigan, United States|Dr. Reddy's Investigational Site #13, Springfield, Missouri, United States|Dr. Reddy's Investigational Site #12, Albuquerque, New Mexico, United States|Dr. Reddy's Investigational Site #10, Williamsville, New York, United States|Dr. Reddy's Investigational Site #26, Greensboro, North Carolina, United States|Dr. Reddy's Investigational Site #15, Cleveland, Ohio, United States|Dr. Reddy's Investigational Site #21, Mount Pleasant, South Carolina, United States|Dr. Reddy's Investigational Site #25, Memphis, Tennessee, United States|Dr. Reddy's Investigational Site #14, Dallas, Texas, United States|Dr. Reddy's Investigational Site #16, Hurst, Texas, United States|Dr. Reddy's Investigational Site #17, West Jordan, Utah, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT02569853/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02569853
53,NCT02559895,A Multicenter Assessment of ALD403 in Frequent Episodic Migraine,PROMISE 1,Completed,Has Results,Migraine Disorders,Drug: ALD403|Drug: Placebo,"Change From Baseline in Monthly Migraine Days (Weeks 1-12)|75% Migraine Responder Rate|50% Migraine Responder Rate|Percentage of Participants With a Migraine on the Day After Dosing|75% Headache Responder Rate|50% Headache Responder Rate|100% Migraine Responder Rate|100% Headache Responder Rate|Change From Baseline in Acute Migraine Medication Days (Weeks 1-12)|Change From Baseline in Average Daily Migraine Prevalence to Week 4|Change From Baseline to Week 12 in Percentage of Migraines With Use of Acute Medication|Change From Baseline to Week 12 in Percentage of Headaches With Use of Acute Medication|Change From Baseline in Monthly Headache Days (Weeks 1-12)|Percent of Headaches With Severe Intensity|Percent of Migraines With Severe Intensity|Change From Baseline in Monthly Migraine Hours (Weeks 1-12)|Change From Baseline in Monthly Headache Hours, Weeks 1-12|Change From Baseline of Short Form Health Survey (SF-36 v 2.0) Scale Scores|Health Related Quality of Life (EQ-5D-5L) at Week 12|Change in Baseline of Allodynia Symptom Checklist-12 (ASC-12) Total Score","Alder Biopharmaceuticals, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,898,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",ALD403-CLIN-006,September 2015,February 2017,December 2017,"September 25, 2015","May 14, 2020","May 14, 2020","Research Site, Birmingham, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Fresno, California, United States|Research Site, Fullerton, California, United States|Research Site, Long Beach, California, United States|Research Site, Montclair, California, United States|Research Site, Oceanside, California, United States|Research Site, Redlands, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Monica, California, United States|Research Site, Sherman Oaks, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Fort Collins, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Bradenton, Florida, United States|Research Site, DeLand, Florida, United States|Research site, Fort Myers, Florida, United States|Research Site, Hallandale Beach, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Maitland, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Sunrise, Florida, United States|Research Site, Winter Haven, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Stockbridge, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Lisle, Illinois, United States|Research Site, Prairie Village, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Owensboro, Kentucky, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, North Attleboro, Massachusetts, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Watertown, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Jackson, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Flowood, Mississippi, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Springfield, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Reno, Nevada, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Brooklyn, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Hartsdale, New York, United States|Research Site, Rochester, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Dayton, Ohio, United States|Research Site, Edmond, Oklahoma, United States|Research Site, Norman, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Smithfield, Pennsylvania, United States|Research Site, Anderson, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Kingsport, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Virginia Beach, Virginia, United States|Research Site, Bellevue, Washington, United States|Research Site, Tbilisi, Georgia|Research Site, Tbilisi, Georgia|Research Site, Tbilisi, Georgia|Research Site, Tbilisi, Georgia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT02559895/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT02559895/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02559895
54,NCT02547818,Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease,COGNITE,Completed,No Results Available,Alzheimer's Disease,Drug: ALZT-OP1a|Drug: ALZT-OP1b|Other: Placebo ALZT-OP1a|Other: Placebo ALZT-OP1b,Clinical Dementia Rating-Sum of Boxes (CDR-SB)|Number of Treatment Emergent Adverse Events (TEAE),"AZTherapies, Inc.|PharmaConsulting Group|KCAS Bio|APCER Life Sciences",All,"55 Years to 79 Years   (Adult, Older Adult)",Phase 3,620,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AZT-001,"September 15, 2015","November 13, 2020","November 18, 2020","September 11, 2015",NA,"November 10, 2021","Cognitive Clinical Trials, Gilbert, Arizona, United States|Xenoscience, Phoenix, Arizona, United States|Cognitive Clinical Trials, Scottsdale, Arizona, United States|Territory Neurology & Research Institute, Tucson, Arizona, United States|Alliance Research Center, Laguna Hills, California, United States|Renew Behavioral Health, Long Beach, California, United States|Excell Research, Inc., Oceanside, California, United States|University of California Irvine School of Medicine, Orange, California, United States|Asclepes Research Center, Panorama City, California, United States|Artemis Clinical Research, Riverside, California, United States|CITrials, Riverside, California, United States|Northern California Research, Sacramento, California, United States|Syrentys Clinical Research, Santa Ana, California, United States|Mile High Research Center, Denver, Colorado, United States|TOPAZ Clinical Research, Apopka, Florida, United States|Parkinson's Disease & Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|Finlay Medical Research Group, Greenacres City, Florida, United States|Galiz Clinical Research, Hialeah, Florida, United States|Panax, Miami Lakes, Florida, United States|The Neurology Research Group, Miami, Florida, United States|Premier Clinical Research Institute, Miami, Florida, United States|Finlay Medical Research Group, Miami, Florida, United States|Next Phase Research Alliance - Cano Health, Miami, Florida, United States|IMIC, Inc., Miami, Florida, United States|Next Phase Research Alliance - MetroMed, Miami, Florida, United States|Next Phase Research Alliance, Miami, Florida, United States|CNS Healthcare, Orlando, Florida, United States|Pines Care Research Center, Pembroke Pines, Florida, United States|Neurostudies, Inc., Port Charlotte, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Axiom Clinical Research, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Columbus Research & Wellness Institute, Columbus, Georgia, United States|Behavioral Health Care Associates, Schaumburg, Illinois, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Coastal Health Care, Freeport, Maine, United States|Samuel and Alexia Bratton Memory Clinic, Easton, Maryland, United States|ActivMed Practices & Research, Inc., Methuen, Massachusetts, United States|The Alzheimer's Disease Center, Quincy, Massachusetts, United States|Bronson Neurobehavioral Health, Paw Paw, Michigan, United States|Cognitive Clinical Trials, Bellevue, Nebraska, United States|Cognitive Clinical Trials, Omaha, Nebraska, United States|ActivMed Practices & Research Inc., Portsmouth, New Hampshire, United States|Memory Enhancement Center of America, Eatontown, New Jersey, United States|AdvancedMed Research, Lawrenceville, New Jersey, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Albuquerque Neuroscience, Albuquerque, New Mexico, United States|Adirondack Medical Research Center, Glens Falls, New York, United States|Manhattan Behavioral Medicine, New York, New York, United States|Medical Research Network, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, New York, New York, United States|Winifred Masterson Burke Medical Research Institute, White Plains, New York, United States|ANI Neurology, PLLC Alzheimer's Memory Center, Charlotte, North Carolina, United States|Raleigh Neurological Associates, Raleigh, North Carolina, United States|PMG Winston-Salem, Winston-Salem, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Insight Clincial Trials, Shaker Heights, Ohio, United States|Cutting Edge Research Group, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research, Inc., Tulsa, Oklahoma, United States|Pearl Clinical Research, Norristown, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Palmetto Health, Columbia, South Carolina, United States|Metrolina Neurological Associates, PA, Rock Hill, South Carolina, United States|CNS Healthcare, Memphis, Tennessee, United States|Neurology Associates of Arlington, P.A., Mansfield, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Wasatch Clinical Research, LLC, Salt Lake City, Utah, United States|Kingfisher Cooperative, Spokane, Washington, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|KaRa Institute of Neurological Diseases, Macquarie Park, New South Wales, Australia|Pacific Private Clinic, Southport, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Geelong Private Medical Centre, Geelong, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|UMBAL ""Dr. Georgi Stranski"" EAD, Pleven, Bulgaria|MHAT ""Central Onco Hospital"" Ltd., Plovdiv, Bulgaria|MBAL Ruse AD, Ruse, Bulgaria|""First MHAT - Sofia"" EAD, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment ""Aleksandrovska"" EAD, Sofia, Bulgaria|Medical Arts Health Research, Penticton, British Columbia, Canada|Medical Arts Health Research, West Vancouver, British Columbia, Canada|Okanagan Clinical Trials, Kelowna, Britsh Columbia, Canada|Montreal Neurological Research Institute, Québec, Montreal, Canada|True North Clinical Research, Halifax, Nova Scotia, Canada|True North Clinical Research, Kentville, Nova Scotia, Canada|JBN Medical, Burlington, Ontario, Canada|Chatham-Kent Clinical Trials, Chatham, Ontario, Canada|The Centre for Memory and Aging, East York, Ontario, Canada|Cliniuqe de la Memoire de l'Outouais, Gatineau, Quebec, Canada|Neurosanatio, s.r.o., Litomyšl, Czech Republic, Czechia|Neurologie MU - Ondrej Koci, s.r.o., Novy Bor, Czech Republic, Czechia|CT Center MaVfe, s.r.o, Olomouc, Czech Republic, Czechia|Vestra Clinics, s.r.o., Rychnov Nad Kněžnou, Czech Republic, Czechia|NEUROHK, s.r.o., Chocen, Czechia|Clinline Services s.r.o., Hostivice, Czechia|Psychiatricka ambulance, Hradec Kralove, Czechia|Psychiatricka ambulance Supervize s.r.o., Kutná Hora, Czechia|Krajska nemocnice Liberec a.s., Liberec, Czechia|A-shine, s.r.o., Plzen, Czechia|Clintrial.s.r.o., Praha, Czechia|Fakultni nemocnice v Motole Neurologicka klinika 2.LF UK a FN Motol, Praha, Czechia|INEP medical s.r.o., Praha, Czechia|Neurologia Klinika Semmelweis Egyetem, Budapest, Hungary|Orszagos Klinikai Idegtudomanyi Intezat, Budapest, Hungary|Vaszary Kolos Korhaz, Esztergom, Hungary|Bekes Megyei Pandy Kalman Korhaz, Gyula, Hungary|Petz Aladar Megyei Oktato Korhaz, Győr, Hungary|Cermed Pawel Hernik, Bialystok, Poland|Podlaskie Centrum Psychogeriatrii, Bialystok, Poland|Przychondnia Srodmiescie, Bydgoszcz, Poland|Centrum Medyczne KERMED, Bydgoszcz, Poland|Szpital Powiatowy w Czeladzi, Czeladz, Poland|Centrum Zdrowia Psychicznego Biomed - Jan Latala, Kielce, Poland|Centrum Medyczne Plejady, Kraków, Poland|Centrum Opieki Zdrowotnej Orkan-Med, Ksawerow, Poland|Centrum Medyczne im. Dr Karola Jonschera w Lodzi, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie, Lublin, Poland|CRC Sp. Zo.o., Poznan, Poland|Euromedis Sp. Zo.o, Szczecin, Poland",NA,https://ClinicalTrials.gov/show/NCT02547818
55,NCT02496767,Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year,VITALITY-ALS,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Tirasemtiv|Drug: Placebo tablets,"Change From Baseline to Week 24 of the Double-blind, Placebo-controlled Phase in Percent Predicted Slow Vital Capacity (SVC)|Change From Baseline in the ALSFRS-R Respiratory Domain Score at the End of 48 Weeks of Double-blind, Placebo-controlled Treatment|Slope of Mega-score of Muscle Strength During the 48 Weeks of Double-blind, Placebo-controlled Treatment|Time to the First Occurrence of a Decline From Baseline in Percent Predicted SVC ≥ 20 Percentage Points or the Onset of Respiratory Insufficiency or Death All 48 Weeks of Double-blind, Placebo-controlled Treatment|Time to the First Occurrence of a Decline in SVC to ≤ 50% Predicted, or the Onset of Respiratory Insufficiency, or Death During the 48 Weeks of Double-blind, Placebo-controlled Treatment|Change From Baseline in the ALSFRS-R Total Score to the End of 48 Weeks of the Double-blind, Placebo-controlled Treatment|Time to the First Use of Mechanical Ventilatory Assistance or Death During All 48 Weeks of Double-blind, Placebo-controlled Treatment",Cytokinetics,All,"18 Years and older   (Adult, Older Adult)",Phase 3,744,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CY 4031|2014-005413-23,"September 3, 2015","March 9, 2017","September 27, 2017","July 14, 2015","June 19, 2020","September 9, 2020","St. Joseph's Hospital & Medical Center - Barrow Neurology Clinics, Phoenix, Arizona, United States|University of California San Diego, La Jolla, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California, Irvine, Orange, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Forbes Norris MDA/ALS Research Center, San Francisco, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|University of Colorado Hospital Anschutz Outpatient Pavilion, Aurora, Colorado, United States|Hospital for Special Care, New Britain, Connecticut, United States|George Washington University Medical Center, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Carol and Frank Morsini Center for Advanced Health Care - University of South Florida, Tampa, Florida, United States|The Emory Clinic, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan Hospital and Health System, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Saint Louis University, Saint Louis, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Neurology Associates, Lincoln, Nebraska, United States|Dartmouth Hitchcock Medical Center Dept of Neurology, Lebanon, New Hampshire, United States|Hospital for Special Surgery, New York, New York, United States|Neurological Institute Columbia University Medical Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Neurosciences Institute: Neurology - Charlotte, Charlotte, North Carolina, United States|Duke Neurological Disorders Clinic, Durham, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Providence Brain and Spine Institute ALS Center, Portland, Oregon, United States|Oregon Health and Science Center, Portland, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|The Penn Comprehensive Neuroscience Center, Philadelphia, Pennsylvania, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Neurology, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas Health Science Center, San Antonio, Texas, United States|University of Virgina Health System, Charlottesville, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|West Virginia University Department of Neurology, Morgantown, West Virginia, United States|Froedtert Memorial Lutheran Hospital, Department of Neurology, Milwaukee, Wisconsin, United States|UZ Leuven - Campus Gasthuisberg, Leuven, Vlaams Brabant, Belgium|University of Calgary, Calgary, Alberta, Canada|Edmonton Kaye Clinic, Edmonton, Alberta, Canada|Stan Cassidy Centre for Rehabilitation, Fredericton, New Brunswick, Canada|QE II Health Sciences Centre, NHI Site, Halifax, Nova Scotia, Canada|McMaster University Medical Centre, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Notre-Dame Hospital/CHUM, Montreal, Quebec, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|CHU de Quebec - Universite Laval Hopital de l'Enfant-Jesus, Quebec, Canada|Hopital R. Salengro, CHRU Lille, Lille Cedex, France|CHU Dupuytren, Limoges cedex, France|Hopital de la Timone, Marseille, France|Hopital Gui de Chauliac, Montpellier, France|CHU de Nice - Hopital Pasteur 2, Nice Cedex 1, France|Hopital de la Salpetriere, Paris, France|Bretonneau University Hospital, Tours Cedex 9, France|University of Ulm, Department of Neurology, Ulm, Baden-Wuerttemberg, Germany|Hannover Medical School, Department of Neurology, Hannover, Lower Saxony, Germany|Charite Campus Virchow-Klinikum, Neurology Department, Berlin, Germany|Clinical Research Centre, Beaumont Hospital, Dublin, Ireland|IRCCS Istituto Auxologico Italiano - U.O. Neurologia, Milan, Italy|Centro Clinico NEMO - Fondazione Serena Onlus, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy|Dipartimento di Neuroscienze ""Rita Levi Moltalcini"" A.O.U. Citta della Salute e della Scienza di Torino P.O. ""Molinette"", Torino, Italy|University Medical Center Utrecht, Utrecht, Netherlands|Hospital Santa Maria-Centro Hospitalar Lisboa Norte, Lisboa, Portugal|Hospital San Rafael, Madrid, Spain|Derriford Hospital, Plymouth, Devon, United Kingdom|Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom|Clinical Research Centre, Royal London Hospital, London, United Kingdom|Kings College Hospital, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02496767/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02496767/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02496767
56,NCT02484547,221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,EMERGE,Terminated,Has Results,Alzheimer's Disease,Drug: Aducanumab (BIIB037)|Drug: Placebo,Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score at Week 78|Change From Baseline in Mini Mental State Examination (MMSE) Score at Week 78|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (13 Items) (ADAS-Cog 13) at Week 78|Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment Version) (ADCS-ADL-MCI) Score at Week 78,Biogen,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,1643,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",221AD302|2015-000967-15,"September 15, 2015","August 5, 2019","August 5, 2019","June 29, 2015","September 2, 2021","September 2, 2021","University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Xenoscience Inc., Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Institute for Memory Impairments, Irvine, California, United States|Renewal Behavioral Health, Long Beach, California, United States|USC Keck School of Medicine, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Excell Research, Inc., Oceanside, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|Anderson Clinical Research, Redlands, California, United States|Pacific Research Network, San Diego, California, United States|University of California San Diego Medical Center, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|St Joseph Heritage Healthcare, Santa Rosa, California, United States|Stanford University Medical Center, Stanford, California, United States|University Of Colorado Denver, Aurora, Colorado, United States|IMMUNOe International Research Centers, Thornton, Colorado, United States|Associated Neurologists of Southern Connecticut, PC, Fairfield, Connecticut, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Bradenton Research Center, Inc., Bradenton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Quantum Laboratories Inc., Deerfield Beach, Florida, United States|Infinity Clinical Research, LLC, Hollywood, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Emory University Cognitive Neurology Clinic & ADRC, Atlanta, Georgia, United States|Medical Research Health and Education Foundation, Inc, Columbus, Georgia, United States|NeuroStudies.net, LLC, Decatur, Georgia, United States|Josephson, Wallack, Munshower Neurology, PC, Indianapolis, Indiana, United States|McLean Hospital, Belmont, Massachusetts, United States|Boston Center for Memory, Newton, Massachusetts, United States|Hattiesburg Clinic, PA, Hattiesburg, Mississippi, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|ActivMed Practices & Research, Portsmouth, New Hampshire, United States|AdvanceMed Research, Lawrenceville, New Jersey, United States|Empire Neurology, PC, Latham, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Ohio State University Medical Center, Dublin, Ohio, United States|Lehigh Center for Clinical Research, LLC, Allentown, Pennsylvania, United States|Penn Memory Center, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Roper St. Francis Healthcare, North Charleston, South Carolina, United States|Senior Adult Specialty Research, Austin, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|Clinical Trial Network, Houston, Texas, United States|University of Utah Health Sciences Center, Salt Lake City, Utah, United States|Clinical Neuroscience Research Association, Inc, Bennington, Vermont, United States|University of Washington Medical Center, Seattle, Washington, United States|Northwest Neurological, PLLC, Spokane, Washington, United States|A.Z. Klina, Brasschaat, Belgium|AZ Sint-Jan Brugge, Brugge, Belgium|Universitair Ziekenhuis Brussel, Bruxelles, Belgium|Centre Neurologique & de Réadaptation Fonctionnelle, Fraiture, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|AZ Groeninge - Campus Kennedylaan, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|AZ Delta, Roeselare, Belgium|Health Research., Kamloops, British Columbia, Canada|Health Research, West Vancouver, British Columbia, Canada|True North Clinical Research - Halifax Inc., Halifax, Nova Scotia, Canada|True North Clinical Research Kentville, Inc, Kentville, Nova Scotia, Canada|JBN Medical Diagnostic Services Inc., Burlington, Ontario, Canada|St. Joseph's HC- Parkwood Institute, London, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Recherches Neuro-Hippocampe Inc., Gatineau, Quebec, Canada|Recherche Sepmus, Inc., Greenfield Park, Quebec, Canada|DIEX Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada|Douglas Hospital Research Centre, Verdun, Quebec, Canada|Terveystalo Kamppi, Helsinki, Finland|Itä-Suomen yliopisto, Aivotutkimusyksikkö, Kuopio, Finland|CRST, Clinical Research Services Turku, Turku, Finland|Hôpital de la Timone, Marseille, Bouches-du-Rhône, France|CHU de Toulouse - Hôpital Purpan, Toulouse cedex 9, Haute Garonne, France|Centre de Recherche Clinique du Gérontopôle - Cité de la Santé, Toulouse, Haute Garonne, France|Hôpital Gui de Chauliac, Montpellier, Herault, France|CHU Rennes - Hopital Pontchaillou, Rennes cedex 09, Ille Et Vilaine, France|CHU Nantes - Hopital Nord Laënnec, Nantes cedex 1, Loire Atlantique, France|Hopital Roger Salengro - CHU Lille, Lille Cedex, Nord, France|Hôpital des Charpennes, Villeurbanne, Rhone, France|Hôpital Fernand Widal, Paris, France|Bezirkskrankenhaus Guenzburg, Gunzburg, Baden Wuerttemberg, Germany|ISPG - Institut fuer Studien zur Psychischen Gesundheit, Mannheim, Baden Wuerttemberg, Germany|Nervenfachaerztlichen Gemeinschaftspraxis Ulm, Ulm, Baden Wuerttemberg, Germany|Universitaetsklinikum Ulm, Ulm, Baden Wuerttemberg, Germany|Klinik Hohe Warte Bayreuth, Bayreuth, Bayern, Germany|Institut fuer Schlaganfall- und Demenzforschung (ISD), Muenchen, Bayern, Germany|Klinikum rechts der Isar der TU Muenchen, Muenchen, Bayern, Germany|Neuropraxis Muenchen Sued, Unterhaching, Bayern, Germany|Neuro Centrum Odenwald, Erbach, Hessen, Germany|Universitaetsklinikum Duesseldorf AoeR, Duesseldorf, Nordrhein Westfalen, Germany|Universitaetsklinikum Muenster, Muenster, Nordrhein Westfalen, Germany|Zentrum f. Neurologisch- Psychiatrische Studien und Begutachtung, Siegen, Nordrhein Westfalen, Germany|Schwerpunktpraxis fuer Neurologie, Psychiatrie und Klinische Studien, Bielefeld, North Rhine-Westphalia, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, Rheinland Pfalz, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Sachsen, Germany|Kopfzentrum Leipzig, Leipzig, Sachsen, Germany|Klinikum Altenburger Land GmbH, Altenburg, Thueringen, Germany|emovis GmbH, Berlin, Germany|Neurologie im Tempelhofer Hafen, Berlin, Germany|Ospedale degli Infermi, Ponderano, Biella, Italy|Azienda Ospedaliera Card. G. Panico, Tricase, Lecce, Italy|ASST di Monza, Monza, Milano, Italy|Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy|Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone, Palermo, Italy|Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia, Perugia, Italy|Fondazione Santa Lucia IRCCS, Roma, Italy|Umberto I Pol. di Roma-Università di Roma La Sapienza, Roma, Italy|Research Site, Obu-shi, Aichi-Ken, Japan|Research Site, Toon-shi, Ehime-Ken, Japan|Research Site, Fukuoka-shi, Fukuoka-Ken, Japan|Research Site, Kurume-shi, Fukuoka-Ken, Japan|Research Site, Otake-shi, Hiroshima-Ken, Japan|Research Site, Amagasaki-shi, Hyogo-Ken, Japan|Research site, Himeji-shi, Hyogo-Ken, Japan|Research Site, Himeji-shi, Hyogo-Ken, Japan|Research Site, Kobe-shi, Hyogo-Ken, Japan|Research Site, Kita-gun, Kagawa-Ken, Japan|Research Site, Kyoto-shi, Kyoto-Fu, Japan|Research Site, Kyoto-shi, Kyoto-Fu, Japan|Research Site, Tsu-shi, Mie-Ken, Japan|Research Site, Nishisonogi, Nagasaki-Ken, Japan|Research Site, Yufu-shi, Oita-Ken, Japan|Research Site, Kurashiki-shi, Okayama-Ken, Japan|Research Site, Okayama-shi, Okayama-Ken, Japan|Research Site, Tsukuba-gun, Okayama-Ken, Japan|Research Site, Kishiwada-shi, Osaka-Fu, Japan|Research Site, Osaka-shi, Osaka-Fu, Japan|Research Site, Osaka-shi, Osaka-Fu, Japan|Research Site, Osaka-shi, Osaka-Fu, Japan|Research Site, Sennan-shi, Osaka-Fu, Japan|Research Site, Suita-shi, Osaka-Fu, Japan|Research Site, Iwata-shi, Shizuoka-Ken, Japan|Research Site, Shizuoka-shi, Shizuoka-Ken, Japan|Research Site, Shizuoka-shi, Shizuoka-Ken, Japan|Alzheimer Research Center, Amsterdam, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|Podlaskie Centrum Psychogeriatrii, Bialystok, Poland|PALLMED Sp. z o.o., Bydgoszcz, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Novo-Med Zielinski i wspolnicy Sp. j., Katowice, Poland|SPZOZ Centralny Szpital Kliniczny UM w Lodzi, Lodz, Poland|Centrum Diagnostyczno - Terapeutyczne ""MEDICUS"" Sp.z o.o., Lubin, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland|Neurologiczny NZOZ Centrum Leczenia SM, Plewiska, Poland|NZOZ ""NEURO-KARD"", ""Ilkowski i Partnerzy"" Sp. Partn. Lek., Poznan, Poland|Centrum Medyczne Medyk, Rzeszow, Poland|Neuro-Care Gabriela Klodowska, Slaskie, Poland|NZOZ ""SENIOR"" Poradnia Psychogeriatryczna, Sopot, Poland|Osrodek Badan Klinicznych EUROMEDIS, Szczecin, Poland|mMED Maciej Czarnecki, Warszawa, Poland|Hospital General Universitario de Elche, Elche, Alicante, Spain|ALTHAIA Hospital Sant Joan de Deu, Manresa, Barcelona, Spain|Hospital Universitario Reina Sofía, Cordoba, Córdoba, Spain|Clinica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Quiron Dexeus, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Skånes Universitetssjukhus, Malmö, Malmö, Sweden|Sahlgrenska Universitetssjukhuset, Mölndal Sjukhus, Mölndal, Sweden|Karolinska Universitetssjukhuset, Huddinge, Stockholm, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Universitären Psychiatrischen Kliniken Basel (UPK), Basel, Switzerland|Medizinisches Zentrum MZB Biel, Biel/Bienne, Switzerland|Hôpitaux Universitaires de Genève - HUG, Geneve 14, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Ospedale Civico, Lugano, Switzerland|Institut fuer Regenerative Medizin (IREM) der Universitaet Zuerich, Zentrum fuer Praevention und Demenztherapie, Schlieren, Switzerland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02484547/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02484547/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02484547
57,NCT02483585,Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention,ARISE,Completed,Has Results,Migraine,Drug: Erenumab|Drug: Placebo,Change From Baseline in Monthly Migraine Days at Week 12|Percentage of Participants With at Least a 50% Reduction From Baseline in Monthly Migraine Days at Week 12|Change From Baseline in Monthly Acute Migraine-specific Medication Treatment Days at Week 12|Percentage of Participants With at Least a 5-point Reduction From Baseline in Average Impact on Everyday Activities Domain Score Measured by MPFID at Week 12|Percentage of Participants With at Least a 5-Point Reduction From Baseline in Average Impact on Physical Impairment Domain Score Measured by MPFID at Week 12|Number of Participants With Adverse Events|Number of Participants Who Developed Antibodies to Erenumab,Amgen,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,577,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20120297|2014-004463-20,"July 20, 2015","July 11, 2016","March 20, 2017","June 29, 2015","June 25, 2018","October 12, 2022","Research Site, Birmingham, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Culver City, California, United States|Research Site, Long Beach, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Monica, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Fairfield, Connecticut, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Oviedo, Florida, United States|Research Site, Palm Beach Gardens, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Gurnee, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Lenexa, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Princeton, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Williamsville, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Warwick, Rhode Island, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Virginia Beach, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Glostrup, Denmark|Research Site, Vejle, Denmark|Research Site, Bordeaux Cedex, France|Research Site, Nice cedex 1, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Pringy Cedex, France|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Amadora, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Torres Vedras, Portugal|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Zaragoza, Aragón, Spain|Research Site, Santander, Cantabria, Spain|Research Site, Valladolid, Castilla León, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Madrid, Spain|Research Site, Bad Zurzach, Switzerland|Research Site, Biel, Switzerland|Research Site, Geneve, Switzerland|Research Site, Lugano, Switzerland|Research Site, St Gallen, Switzerland|Research Site, Zollikon, Switzerland",NA,https://ClinicalTrials.gov/show/NCT02483585
58,NCT02477800,221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,ENGAGE,Terminated,Has Results,Alzheimer's Disease,Drug: Aducanumab (BIIB037)|Drug: Placebo,Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 78|Change From Baseline in Mini-Mental State Examination (MMSE) Score at Week 78|Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (13 Items) (ADAS-Cog 13) Score at Week 78|Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment Version) (ADCS-ADL-MCI) Score at Week 78,Biogen,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,1653,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",221AD301|2015-000966-72,"August 13, 2015","August 8, 2019","August 8, 2019","June 23, 2015","September 2, 2021","September 2, 2021","St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Center for Neurosciences, Tucson, Arizona, United States|Neurology Center of North Orange County, Fullerton, California, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Torrance Clinical Research Institute, Inc., Lomita, California, United States|University of California - Los Angeles, Los Angeles, California, United States|UCSF - Memory and Aging Center, San Francisco, California, United States|California Neuroscience Research Medical Group Inc., Sherman Oaks, California, United States|Southern California Research LLC, Simi Valley, California, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Compass Research Main, Orlando, Florida, United States|Palm Beach Neurological Center, Palm Beach Gardens, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|USF Health Byrd Institute, Tampa, Florida, United States|Meridien Research, Tampa, Florida, United States|Compass Research Main, The Villages, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Cleveland Clinic Florida - Weston, Weston, Florida, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas, United States|Via Christi Research, a division of Via Christi Hospitals Wichita, Inc., Wichita, Kansas, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Brigham & Women's Hosp End/Dbt, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|ActivMed Practices & Research, Methuen, Massachusetts, United States|Donald S. Marks, M.D., P.C., Plymouth, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Las Vegas Medical research, Las Vegas, Nevada, United States|Advanced Memory Research Institute of NJ, PC, Toms River, New Jersey, United States|Albany Medical College, Albany, New York, United States|New York University Medical Center PRIME, New York, New York, United States|University of Rochester, Rochester, New York, United States|ANI Neurology, PLLC d/b/a Alzheimer's Memory Center, Charlotte, North Carolina, United States|Raleigh Neurology Associates, P.A., Raleigh, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Northeastern Pennsylvania Memory and Alzheimer's Center, Plains, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina (MUSC), Charleston, South Carolina, United States|Neurology Clinic, PC, Cordova, Tennessee, United States|University of Tennessee Medical Center. Knoxville, Knoxville, Tennessee, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|National Clinical Research Inc.-Richmond, Richmond, Virginia, United States|Medical College of Wisconsin, Inc., Milwaukee, Wisconsin, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Central Coast Neurosciences Research, Gosford, East Gosford, New South Wales, Australia|Central Coast Neurosciences Research, Erina, New South Wales, Australia|KARA Institute for Neurological Diseases, North Ryde, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Toowoomba Base Hospital, Toowoomba, Queensland, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Neurodegenerative Disorders Research, West Perth, Western Australia, Australia|LKH - Universitaetsklinikum Graz, Graz, Austria|Christian-Doppler-Klinik - Universitätsklinikum Salzburg, Salzburg, Austria|Heritage Medical Research Clinic, Calgary, Alberta, Canada|The Medical Arts Health Research Group, Penticton, British Columbia, Canada|UBC Hospital, Vancouver, British Columbia, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|Toronto Sunnybrook Hospital, Toronto, Ontario, Canada|The Montreal Neurological Institute, Montreal, Quebec, Canada|McGill Centre for Studies in Aging, Verdun, Quebec, Canada|CHU de Quebec - Hôpital de l' Enfant Jésus, Quebec, Canada|CCBR - Ballerup - DK, Ballerup, Denmark|Rigshospitalet, København Ø, Denmark|CCBR - Vejle - DK, Vejle, Denmark|CCBR - Ålborg - DK, Ålborg, Denmark|CHU Strasbourg - Hôpital Hautepierre, Strasbourg Cedex, Bas Rhin, France|Hopital Louis Pasteur Colmar, Strasbourg, Bas Rhin, France|Groupe Hospitalier Pellegrin - Hôpital Pellegrin, Bordeaux, Gironde, France|CHU Reims - Hôpital Maison Blanche, Reims, Marne, France|Hopital Neurologique Pierre Wertheimer, Bron Cedex, Rhone, France|Groupe hospitalier Broca - La Rochefoucauld - La Collégiale, Paris, France|Groupe Hospitalier Pitie-Salpetriere, Paris, France|Praxis Dr. Scholz, Boeblingen, Baden Wuerttemberg, Germany|Aerztliche Gemeinschaftspraxis, Ostfildern, Baden Wuerttemberg, Germany|Neuro MVZ Stuttgart, Stuttgart, Baden Wuerttemberg, Germany|Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt, Bayern, Germany|Praxis Dr. med. Bergmann, Neuburg, Bayern, Germany|Neurologische Gemeinschaftspraxis Kassel, Kassel, Hessen, Germany|Klinische Forschung Hannover-Mitte GmbH, Hannover, Niedersachsen, Germany|Universitaetsklinikum Aachen AOeR, Aachen, Nordrhein Westfalen, Germany|Universitaetsklinikum Bonn AoeR, Bonn, Nordrhein Westfalen, Germany|Universitaetsklinikum Koeln, Cologne, Nordrhein Westfalen, Germany|Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany|Azienda Ospedaliero Universitaria Ospedali Riuniti, Torrette Di Ancona, Ancona, Italy|Fondazione Istituto G.Giglio di Cefalù, Cefalù, Palermo, Italy|Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Azienda Ospedaliero Universitaria San Martino, Genova, Italy|Ospedale San Raffaele, Milano, Italy|Casa di Cura del Policlinico, Milano, Italy|Azienda Ospedaliera Universitaria ""Federico II"", Napoli, Italy|Seconda Università degli Studi di Napoli, Napoli, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Azienda Ospedaliera Universitaria OO. RR. S. Giovanni di Dio e Ruggi D'Aragona, Salerno, Italy|A.O.U. Senese Policlinico Santa Maria alle Scotte, Siena, Italy|Research Site, Chiba-Shi, Chiba-Ken, Japan|Research Site, Inzai-shi, Chiba-Ken, Japan|Research Site, Kurume-shi, Fukuoka-ken, Japan|Research Site, Aizuwakamatsu-shi, Fukushima-Ken, Japan|Research Site, Asahikawa-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Atsugi-shi, Kanagawa-Ken, Japan|Research Site, Kamakura-shi, Kanagawa-Ken, Japan|Research Site, Kawasaki-Shi, Kanagawa-Ken, Japan|Yokohama-shi, Kanagawa-ken, Japan|Research Site, Yokohama-shi, Kanagawa-Ken, Japan|Research Site, Yokohama-shi, Kanagawa-Ken, Japan|Research Site, Kyoto-shi, Kyoto-Fu, Japan|Research Site, Nagaoka-shi, Niigata-Ken, Japan|Research Site, Iruma-gun, Saitama-Ken, Japan|Research Site, Kasukabe-shi, Saitama-Ken, Japan|Research Site, Bunkyo-ku, Tokyo-To, Japan|Research Site, Shinjuku-ku (I), Tokyo-To, Japan|Research Site, Shinjuku-ku, Tokyo-To, Japan|Research Site, Ota-ku, Tokyo, Japan|Research Site, Yamagata-shi, Yamagata-Ken, Japan|Research Site, Itabashi-ku, Japan|Research Site, Itabashi-ku, Japan|Research Site, Kiyose-shi, Japan|Research Site, Kodaira-shi, Japan|Inha University Hospital, Incheon, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Hospital Professor Doutor Fernando Fonseca, E.P.E., Amadora, Portugal|Hospital de Braga, Braga, Portugal|Centro Hospitalar e Universitário de Coimbra E.P.E, Coimbra, Portugal|CUF Alvalade, Lisboa, Portugal|Hospital Beatriz Ângelo, Loures, Portugal|Campus Neurologico Senior, Torres Vedras, Portugal|Policlinica Guipuzcoa, San Sebastian, Guipuzcoa, Spain|Hospital de Cruces, Barakaldo, Vizcaya, Spain|Fundacio ACE, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Clinica Ruber, Madrid, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan County, Taiwan|Southmead Hospital, Bristol, Avon, United Kingdom|Re:Cognition Health Ltd, London, Greater London, United Kingdom|Charing Cross Hospital, London, Greater London, United Kingdom|The National Hospital for Neurology and Neurosurgery Centre, London, Greater London, United Kingdom|Salford Royal, Salford, Greater Manchester, United Kingdom|The University of Edinburgh, Edinburgh, Lothian Region, United Kingdom|Manchester Royal Infirmary, Blackburn, Merseyside, United Kingdom|The RICE Centre, Bath, Somerset, United Kingdom|Glasgow Memory Clinic Ltd, Glasgow, Strathclyde, United Kingdom|Stobhill ACH Hospital, Glasgow, Strathclyde, United Kingdom|Ninewells Hospital, Dundee, Tayside Region, United Kingdom|Newcastle University, Newcastle upon Tyne, Tyne & Wear, United Kingdom|Kingshill Research Centre, Chippenham, Wiltshire, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02477800/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02477800/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02477800
59,NCT02456740,Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention,STRIVE,Completed,Has Results,Migraine,Drug: Erenumab|Drug: Placebo,Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment Period|Percentage of Participants With at Least a 50% Reduction From Baseline in Monthly Migraine Days in the Last 3 Months of the Double-blind Treatment Phase|Change From Baseline in Monthly Acute Migraine-specific Medication Treatment Days to the Last 3 Months of the Double-blind Treatment Period|Change From Baseline in Mean Monthly Average Physical Impairment Domain Score Measured by MPFID in the Last 3 Months of the Double-blind Treatment Phase|Change From Baseline in Mean Monthly Average Impact on Everyday Activities Score Measured by MPFID in the Last 3 Months of the Double-blind Treatment Phase,Amgen,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,955,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20120296|2014-004464-38,"July 17, 2015","September 5, 2016","June 19, 2017","May 28, 2015","July 10, 2018","October 12, 2022","Research Site, Phoenix, Arizona, United States|Research Site, Anaheim, California, United States|Research Site, Encino, California, United States|Research Site, Irvine, California, United States|Research Site, Los Alamitos, California, United States|Research Site, Newport Beach, California, United States|Research Site, Rancho Mirage, California, United States|Research Site, Redlands, California, United States|Research Site, Sherman Oaks, California, United States|Research Site, Simi Valley, California, United States|Research Site, Spring Valley, California, United States|Research Site, Boulder, Colorado, United States|Research Site, East Hartford, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Bradenton, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Leesburg, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Sunrise, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, Evansville, Indiana, United States|Research Site, Des Moines, Iowa, United States|Research Site, Newton, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Edgewood, Kentucky, United States|Research Site, Metairie, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, New Bedford, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Plymouth, Minnesota, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Springfield, Missouri, United States|Research Site, Amherst, New York, United States|Research Site, Plainview, New York, United States|Research Site, Rochester, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Willoughby Hills, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Cumberland, Rhode Island, United States|Research Site, Port Royal, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Bedford, Texas, United States|Research Site, Irving, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, West Jordan, Utah, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Brussel, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Liege, Belgium|Research Site, Lodelinsart, Belgium|Research Site, Surrey, British Columbia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Markham, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Levis, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Olomouc, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Helsinki, Finland|Research Site, Kuopio, Finland|Research Site, Oulu, Finland|Research Site, Turku, Finland|Research Site, Berlin (Hellersdorf), Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hüttenberg, Germany|Research Site, Kiel, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Leipzig, Germany|Research Site, München, Germany|Research Site, Wiesbaden, Germany|Research Site, Würzburg, Germany|Research Site, Leiden, Netherlands|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Swidnik, Poland|Research Site, Warszawa, Poland|Research Site, Bratislava, Slovakia|Research Site, Komarno, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Falköping, Sweden|Research Site, Helsingborg, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Uddevalla, Sweden|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Antalya, Turkey|Research Site, Bursa, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Izmir, Turkey|Research Site, Glasgow, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Sidcup, United Kingdom|Research Site, Stoke on Trent, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT02456740
60,NCT02442778,"Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type",NA,Completed,Has Results,Agitation in Participants With Dementia of the Alzheimer's Type,Drug: AVP-786-18|Drug: Placebo|Drug: AVP-786-28|Drug: AVP-786-42.63,"Change From Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score|Relative Change From Baseline to Week 12 in the Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC)-Agitation Score|Change From Baseline to Week 12 in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score|Change From Baseline to Week 12 in the NPI Agitation/Aggression Caregiver Distress Score|Change From Baseline to Week 12 in the NPI Aberrant Motor Behavior Domain Score|Change From Baseline to Week 12 in the Zarit Burden Interview (ZBI) Score|Change From Baseline to Week 12 in the NPI Irritability/Lability Domain Score|Change From Baseline to Week 12 in the NPI Total Score|Change From Baseline to Week 12 in the Clinical Global Impression of Severity of Illness (CGIS)-Agitation Domain Score|Change From Baseline to Week 12 in the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Overall Rating|Change From Baseline to Week 12 in the Patient Global Impression of Change (PGIC) Score|Change From Baseline to Week 12 in the Dementia Quality of Life (DEMQOL) Score|Change From Baseline in the Cornell Scale for Depression in Dementia (CSDD) Score|Number of Participants With the Change From Baseline in the General Medical Health Rating (GMHR) Score at Week 12|Change From Baseline to Week 12 in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score|Resource Utilization in Dementia (RUD) Score: Number of Hours Per Day the Caregiver Spent Assisting the Participant|Resource Utilization in Dementia (RUD) Score: Number of Days the Caregiver Spent Assisting the Participant|Resource Utilization in Dementia (RUD) Score: Number of Visits to Hospital, Emergency, and Healthcare Professional","Otsuka Pharmaceutical Development & Commercialization, Inc.",All,"50 Years to 90 Years   (Adult, Older Adult)",Phase 3,522,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",15-AVP-786-302,"November 11, 2015","August 14, 2019","September 9, 2019","May 13, 2015","September 9, 2022","September 9, 2022","Brain and Spine Center, Chandler, Arizona, United States|Territory Neurology & Research Institute, Tucson, Arizona, United States|Health Initiatives Research, Fayetteville, Arkansas, United States|Behavioral Research Specialists, LLC, Glendale, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|California Neurological Services, Panorama City, California, United States|Havana Research Institute, Pasadena, California, United States|Pacific Research Network, Inc, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Viking Clinical Research, Temecula, California, United States|Denver Neurological Research, LLC, Denver, Colorado, United States|JEM Research Institute, Atlantis, Florida, United States|Clinical Research Of Brandon, LLC, Brandon, Florida, United States|Meridien Research, Brooksville, Florida, United States|Moonshine Research Center, Inc, Doral, Florida, United States|Science Connections, LLC, Doral, Florida, United States|Finlay Medical Research Corp, Greenacres City, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|New Life Medical Research Center, Inc., Hialeah, Florida, United States|Reliable Clinical Research,LLC, Hialeah, Florida, United States|Research in Miami, Inc, Hialeah, Florida, United States|The Research Center, Inc, Hialeah, Florida, United States|Maxblue Institute, Hialeah, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Premier Clinical Research Institute, Inc., Miami, Florida, United States|Project 4 Research, Miami, Florida, United States|BioMed Research Institute, Miami, Florida, United States|CCM Clinical Research Group, Miami, Florida, United States|DADE Research Center, LLC, Miami, Florida, United States|AMB Research Center, Inc., Miami, Florida, United States|United Health Research Corp, Miami, Florida, United States|Advance Medical Research Center, Miami, Florida, United States|Coral Research Clinic Corp, Miami, Florida, United States|P&S Reasearch, Miami, Florida, United States|The Neurology Research Group, LLC, Miami, Florida, United States|Kendall Research Institute, Miami, Florida, United States|Nuovida Research Center Corp., Miami, Florida, United States|Collier Neurologic Specialists, LLC, Naples, Florida, United States|Lazlo J. Mate, MD, PA, North Palm Beach, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|IMIC Inc., Palmetto Bay, Florida, United States|University of West Florida, Pensacola, Florida, United States|Neurology Research Institute Palm Beach, LLC, West Palm Beach, Florida, United States|Emory Brain Health Center, Atlanta, Georgia, United States|Columbus Research & Wellness Institute, INC, Columbus, Georgia, United States|Josephson Wallack Munshower Neurology, PC, Indianapolis, Indiana, United States|Baptist Health Medical Group, Richmond, Kentucky, United States|The Samuel & Alexia Bratton Memory Clinic, Easton, Maryland, United States|Mir Neurology, Hagerstown, Maryland, United States|Boston Center for Memory, Newton, Massachusetts, United States|AMAC Research Institute, North Dartmouth, Massachusetts, United States|Michigan State University, East Lansing, Michigan, United States|Center for Emotional Fitness, Cherry Hill, New Jersey, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Brooklyn Medical Institute, Brooklyn, New York, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|Burke Rehabilitation Hospital, White Plains, New York, United States|Herbert Harris, MD, PhD, PA, Chapel Hill, North Carolina, United States|ANI Neurology PLLC dba Alzheimer's Memory Center, Charlotte, North Carolina, United States|Daystar Clinical Research Inc, Akron, Ohio, United States|Valley Medical Research, Centerville, Ohio, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|Cleveland Clinic Lou Ruvo Center for Brain Health at Lakewood Hospital, Lakewood, Ohio, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|The Birches at Newton / Family Medical Associates, Levittown, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|RH Johnson VA Medical Center, Charleston, South Carolina, United States|BG Neurology, Spartanburg, South Carolina, United States|Texas Neurology, P.A., Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Houston Methodist Neurological Institute, Houston, Texas, United States|Clinical Trial Network, Houston, Texas, United States|Texas Medical Research Associates, L.L.C., San Antonio, Texas, United States|Pharmaceuticals Research Associates, Inc., Salt Lake City, Utah, United States|Clinical Neuroscience Research Associates, Inc. dba The Memory Clinic, Bennington, Vermont, United States|Veteran Affairs Medical Center, Salem Virginia, Salem, Virginia, United States|IPC Research, Waukesha, Wisconsin, United States|Dr. Alexander McIntyre Inc., Calgary, Alberta, Canada|The Medical Art Health Research Group, Kelowna, Bristish Columbia, Canada|The Medical Art Health Research Group, Penticton, Bristish Columbia, Canada|The Medical Art Health Research Group, West Vancouver, Bristish Columbia, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02442778/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02442778/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02442778
61,NCT02439320,Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:,SAMURAI,Completed,Has Results,Acute Migraine,Drug: Lasmiditan 100 mg|Drug: Lasmiditan 200 mg|Drug: Placebo (matches lasmiditan doses),Percentage of Participants Who Are Headache Pain Free|Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free|Percentage of Participants Who Have Headache Relief After First Dose|Percentage of Participants With Headache Recurrence|Percentage of Participants Who Used Rescue Medication|Percentage of Participants Nausea Free|Percentage of Participants Phonophobia Free|Percentage of Participants Photophobia Free|Participants With Serious Adverse Events (SAE),Eli Lilly and Company|CoLucid Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2231,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",16888|H8H-CD-LAHJ|COL MIG-301,April 2015,July 2016,August 2016,"May 8, 2015","November 27, 2019","December 16, 2019","Southview Medical Group, P.C., Birmingham, Alabama, United States|Simon-Williamson Clinic, Birmingham, Alabama, United States|Achieve Clinical Research, LLC, Birmingham, Alabama, United States|East Valley Family Physicians, PC, Chandler, Arizona, United States|Radiant Research,Inc, Chandler, Arizona, United States|Warner Family Practice, Chandler, Arizona, United States|Clinical Research Advantage/Fountain Hills Family Practice, Fountain Hills, Arizona, United States|Neurological Physicians of Arizona, Inc, Gilbert, Arizona, United States|Thunderbird Internal Medicine, Glendale, Arizona, United States|Lenzmeier Family Practice, Glendale, Arizona, United States|Central Arizona Medical Associates, PC, Mesa, Arizona, United States|Desert Clinical Research, Mesa, Arizona, United States|Family Practice Specialists, Ltd, Phoenix, Arizona, United States|Clinical Research Advantage Inc./Central Phoenix Medical Center LLC, Phoenix, Arizona, United States|Thunderbird Internal Medicine, Phoenix, Arizona, United States|Tatum Highlands Medical Associates, PLLC, Phoenix, Arizona, United States|Radiant Research, Inc., Scottsdale, Arizona, United States|Fiel Family and Sports Medicine, Tempe, Arizona, United States|Arizona Community Physicians, Tucson, Arizona, United States|Orange Grove Family Practice, Tucson, Arizona, United States|Cassidy Medical Group, Carlsbad, California, United States|Allied Clinical Research, Gold River, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Radiant Research, Inc., Santa Rosa, California, United States|Cassidy Medical Group, Vista, California, United States|Mile High Primary Care, Aurora, Colorado, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|Clinical Research Advantage Inc/Colorado Springs Family Practice, Colorado Springs, Colorado, United States|Comprehensive Clinical Development- Washington DC, Washington, District of Columbia, United States|Meridien Research, Brooksville, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Suncoast Research Group, Miami, Florida, United States|CNS Healthcare, Orlando, Florida, United States|Radiant Research, Inc., Pinellas Park, Florida, United States|Infinity Clinical Research, LLC, Sunrise, Florida, United States|Meridien Research, Tampa, Florida, United States|Radiant Research Inc, Atlanta, Georgia, United States|Urban Family Practice, Marietta, Georgia, United States|Georgia Neurology and Sleep Medicine Associates, Suwanee, Georgia, United States|Northwest Clinical Trials, Boise, Idaho, United States|Advanced Clinical Research, Meridian, Idaho, United States|Michigan Avenue Internists, Chicago, Illinois, United States|Medical and Procedural Specialists of Illinois, Chicago, Illinois, United States|Radiant Research, Inc, Chicago, Illinois, United States|Evanston Premier Research LLC, Evanston, Illinois, United States|Clinical Research Advantage, Evansville, Indiana, United States|Family Medical Associates, Evansville, Indiana, United States|Ridge Family Practice, Council Bluffs, Iowa, United States|Radiant Research Inc./Continuum Health Care, Overland Park, Kansas, United States|Heartland Research, Wichita, Kansas, United States|Heartland Research, Wichita, Kansas, United States|Boston Clinical Trials, Boston, Massachusetts, United States|Radiant Research, Inc, Edina, Minnesota, United States|West Florissant Internists, Bridgeton, Missouri, United States|The Center for Pharmaceutical Research, Kansas City, Missouri, United States|Radiant Research, Inc, Saint Louis, Missouri, United States|Skyline Medical Center, Elkhorn, Nebraska, United States|Prairie Fields Family Medicine PC, Fremont, Nebraska, United States|Southwest Family Physicians, PC, Omaha, Nebraska, United States|James Mell, DO, Henderson, Nevada, United States|Clinical Research Advantage, Henderson, Nevada, United States|Nevada Family Care, Henderson, Nevada, United States|Diagnostic Center of Medicine, Las Vegas, Nevada, United States|Diagnostic Center of Medicine, Las Vegas, Nevada, United States|Clifford Molin/Clinical Research Advantage,Inc, Las Vegas, Nevada, United States|Comprehensive Clinical Development - Queens NY, Jamaica, New York, United States|Radiant Research,Inc, Akron, Ohio, United States|Radiant Research, Inc., Cincinnati, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|Radiant Research, Inc, Columbus, Ohio, United States|Oklahoma City Clinic - Edmund, Edmond, Oklahoma, United States|Oklahoma City Clinic - Midwest CIty, Midwest City, Oklahoma, United States|LION Research, Norman, Oklahoma, United States|Oklahoma City Clinic- Central/Clinical Research Advantage INC, Oklahoma City, Oklahoma, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Sunstone Medical Research,LLC, Medford, Oregon, United States|Oregon Center for Clinical Investigations, Inc., Portland, Oregon, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|West Bay Clinical Research, Warwick, Rhode Island, United States|Primary Care Associates, PA, Anderson, South Carolina, United States|Radiant Research, Inc, Anderson, South Carolina, United States|Medical Research South, Charleston, South Carolina, United States|Radiant Research, Inc, Greer, South Carolina, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Family Medical Associates of Texas, Allen, Texas, United States|Premier Family Physicians, Austin, Texas, United States|Radiant Research, Inc, Dallas, Texas, United States|Village Health Center, Plano, Texas, United States|Doctors of Internal Medicine, Plano, Texas, United States|Plano Internal Medicine, Plano, Texas, United States|Radiant Research, San Antonio, Texas, United States|Radiant Research, Murray, Utah, United States",NA,https://ClinicalTrials.gov/show/NCT02439320
62,NCT02438826,A Study of Galcanezumab in Participants With Chronic Cluster Headache,NA,Completed,Has Results,Chronic Cluster Headache,Drug: Galcanezumab 300 mg|Drug: Placebo,Overall Mean Change From Baseline in Weekly Cluster Headache Attack Frequency|Percentage of Participants With a 50% or Greater Reduction From Baseline in the Weekly Number of Cluster Headache Attacks|Percentage of Participants With a Sustained Response of 50% or Greater Reduction From Baseline in the Weekly Number of Cluster Headache Attacks|Percentage of Participants With a 30% Reduction in the Weekly Number of Cluster Headache Attacks|Percentage of Participants Reporting a Score of 1 or 2 on the Patient Global Impression of Improvement (PGI-I)|Percentage of Participants With Suicidal Ideation Assessed by Columbia - Suicide Severity Rating Scale (C-SSRS)|Percentage of Participants With Suicidal Behaviors Assessed by Columbia - Suicide Severity Rating Scale (C-SSRS)|Percentage of Participants Developing Anti-Drug Antibodies (ADA) to Galcanezumab (LY2951742)|Pharmacokinetics (PK): Serum Concentration of Galcanezumab,Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,240,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",15781|I5Q-MC-CGAM|2014-005429-11,"June 18, 2015","March 27, 2018","August 14, 2019","May 8, 2015","June 11, 2019","August 25, 2020","Mayo Clinic Hospital, Phoenix, Arizona, United States|California Medical Clinic for Headache, Santa Monica, California, United States|Stanford University Hospital, Stanford, California, United States|Colorado Neurological Institute, Englewood, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|New England Institute for Clinical Research, Stamford, Connecticut, United States|Mayo Clinic-Jacksonville, Jacksonville, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Michigan Head, Pain and Neurological Institute, Ann Arbor, Michigan, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Southwestern Medical Center - Dallas, Dallas, Texas, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Gent, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Liege, Belgium|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Montreal, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montréal, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glostrup, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Glostrup, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Helsinki, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Turku, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Nice, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Etienne Cedex 2, France|Praxis Dr. Stude, Bochum, Germany|Universtitätsklinikum Essen AöR, Essen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Jena, Germany|Migräne- und Kopfschmerzklinik GmbH & Co. KG, Königstein, Germany|Klinikum der Universität München Campus Großhadern, München, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Firenze, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Pavia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Nijmegen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Hull, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Liverpool, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Stoke-on-Trent, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02438826/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02438826/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02438826
63,NCT02425644,Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis,OPTIMUM,Completed,Has Results,Multiple Sclerosis,Drug: ponesimod|Drug: teriflunomide,Annualized Confirmed Relapse Rate|Change From Baseline in Fatigue-related Symptoms as Measured by the Symptoms Domain of the Fatigue Symptom and Impact Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS) Score to Week 108|Cumulative Number of Combined Unique Active Lesions (CUAL) Per Year From Baseline to Week 108|12-Week Confirmed Disability Accumulation (CDA) Assessed From Baseline to EOS|24-Week Confirmed Disability Accumulation (CDA) Assessed From Baseline to EOS,Actelion,All,18 Years to 55 Years   (Adult),Phase 3,1133,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AC-058B301|2012-000540-10,"June 4, 2015","May 16, 2019","May 16, 2019","April 24, 2015","June 11, 2021","January 4, 2023","Investigator Site 8045, Carlsbad, California, United States|Investigator Site 8311, Pomona, California, United States|Investigator Site 8036, Denver, Colorado, United States|Investigator Site 8065, Ormond Beach, Florida, United States|Investigator Site 8018, Tampa, Florida, United States|Investigator Site 8013, Indianapolis, Indiana, United States|Investigator Site 8040, Raleigh, North Carolina, United States|Investigator Site 8006, Columbus, Ohio, United States|Investigator Site 8015, Franklin, Tennessee, United States|Investigator Site 8042, Orem, Utah, United States|Investigator Site 3605, Grodno, Belarus|Investigator Site 3603, Minsk, Belarus|Investigator Site 3602, Minsk, Belarus|Investigator Site 3606, Vitebsk, Belarus|Investigator Site 3604, Vitebsk, Belarus|Investigator Site 9104, Sarajevo, Bosnia and Herzegovina|Investigator Site 2709, Plovdiv, Bulgaria|Investigator Site 2711, Sofia, Bulgaria|Investigator Site 2702, Sofia, Bulgaria|Investigator Site 2707, Sofia, Bulgaria|Investigator Site 2701, Sofia, Bulgaria|Investigator Site 2708, Sofia, Bulgaria|Investigator Site 2703, Sofia, Bulgaria|Investigator Site 8102, Edmonton, Alberta, Canada|Investigator Site 8120, Victoria, British Columbia, Canada|Investigator Site 8101, Ottawa, Ontario, Canada|Investigator Site 8113, Greenfield Park, Quebec, Canada|Investigator Site 2506, Osijek, Croatia|Investigator Site 2502, Zagreb, Croatia|Investigator Site 2508, Zagreb, Croatia|Investigator Site 2509, Zagreb, Croatia|Investigator Site 3009, Brno, Czechia|Investigator Site 3003, Brno, Czechia|Investigator Site 3010, Hradec Králové, Czechia|Investigator Site 3006, Jihlava, Czechia|Investigator Site 3002, Ostrava-Poruba, Czechia|Investigator Site 3007, Pardubice, Czechia|Investigator Site 3001, Praha 2, Czechia|Investigator Site 3008, Praha 5, Czechia|Investigator Site 3004, Teplice, Czechia|Investigator Site 2212, Tampere, Finland|Investigator Site 2202, Turku, Finland|Investigator Site 1713, Bordeaux Cedex, France|Investigator Site 1703, Clermont Ferrand Cedex 1, France|Investigator Site 1715, Nantes Cedex 1, France|Investigator Site 1706, Nice Cedex 1, France|Investigator Site 1705, Strasbourg Cedex, France|Investigator Site 3905, Tbilisi, Georgia|Investigator Site 3904, Tbilisi, Georgia|Investigator Site 3903, Tbilisi, Georgia|Investigator Site 3906, Tbilisi, Georgia|Investigator Site 3902, Tbilisi, Georgia|Investigator Site 1113, Dresden, Germany|Investigator Site 1107, Erfurt, Germany|Investigator Site 1109, Leipzig, Germany|Investigator Site 1104, Mainz, Germany|Investigator Site 1102, Ulm, Germany|Investigator Site 1303, Athens, Greece|Investigator Site 1301, Athens, Greece|Investigator Site 1307, Athens, Greece|Investigator Site 2903, Budapest, Hungary|Investigator Site 2905, Budapest, Hungary|Investigator Site 2910, Esztergom, Hungary|Investigator Site 2902, Gyor, Hungary|Investigator Site 2909, Kistarcsa, Hungary|Investigator Site 4005, Ashkelon, Israel|Investigator Site 4004, Haifa, Israel|Investigator Site 4006, Jerusalem, Israel|Investigator Site 4010, Zfat, Israel|Investigator Site 1403, Cefalu, Italy|Investigator Site 1409, Genova, Italy|Investigator Site 1413, L'Aquila, Italy|Investigator Site 1405, Roma, Italy|Investigator Site 3401, Riga, Latvia|Investigator Site 3402, Riga, Latvia|Investigator Site 3403, Riga, Latvia|Investigator Site 3502, Kaunas, Lithuania|Investigator Site 3503, Klaipeda, Lithuania|Investigator Site 3504, Siauliai, Lithuania|Investigator Site 7410, Chihuahua, Mexico|Investigator Site 7409, Monterrey, Mexico|Investigator Site 3219, Bialystok, Poland|Investigator Site 3215, Bydgoszcz, Poland|Investigator Site 3208, Gdansk, Poland|Investigator Site 3217, Katowice, Poland|Investigator Site 3203, Katowice, Poland|Investigator Site 3205, Konstancin-Jeziorna, Poland|Investigator Site 3216, Ksawerow, Poland|Investigator Site 3220, Lublin, Poland|Investigator Site 3202, Poznan, Poland|Investigator Site 3214, Poznan, Poland|Investigator Site 3207, Poznan, Poland|Investigator Site 3213, Wroclaw, Poland|Investigator Site 1602, Amadora, Portugal|Investigator Site 1605, Braga, Portugal|Investigator Site 1603, Coimbra, Portugal|Investigator Site 1604, Porto, Portugal|Investigator Site 2807, Bucuresti, Romania|Investigator Site 2811, Bucuresti, Romania|Investigator Site 2804, Bucuresti, Romania|Investigator Site 2802, Timisoara, Romania|Investigator Site 3821, Barnaul, Altai Krai, Russian Federation|Investigator Site 3818, Belgorod, Russian Federation|Investigator Site 3837, Bryansk, Russian Federation|Investigator Site 3836, Ekaterinburg, Russian Federation|Investigator Site 3811, Kazan, Russian Federation|Investigator Site 3822, Kemerovo, Russian Federation|Investigator Site 3814, Krasnoyarsk, Russian Federation|Investigator Site 3823, Kursk, Russian Federation|Investigator Site 3831, Moscow, Russian Federation|Investigator Site 3803, Moscow, Russian Federation|Investigator Site 3840, Moscow, Russian Federation|Investigator Site 3810, Moscow, Russian Federation|Investigator Site 3802, Nizhniy Novgorod, Russian Federation|Investigator Site 3834, Nizhny Novgorod, Russian Federation|Investigator Site 3835, Novgorod, Russian Federation|Investigator Site 3829, Novosibirsk, Russian Federation|Investigator Site 3839, Perm, Russian Federation|Investigator Site 3812, Pyatigorsk, Russian Federation|Investigator Site 3813, Saint Petersburg, Russian Federation|Investigator Site 3805, Samara, Russian Federation|Investigator Site 3825, Smolensk, Russian Federation|Investigator Site 3808, St. Petersburg, Russian Federation|Investigator Site 3833, St. Petersburg, Russian Federation|Investigator Site 3807, St. Petersburg, Russian Federation|Investigator Site 3815, St. Petersburg, Russian Federation|Investigator Site 3801, Tomsk, Russian Federation|Investigator Site 3819, Tver, Russian Federation|Investigator Site 3842, Yaroslavl, Russian Federation|Investigator Site 2601, Belgrade, Serbia|Investigator Site 2606, Belgrade, Serbia|Investigator Site 2607, Belgrade, Serbia|Investigator Site 2603, Kragujevac, Serbia|Investigator Site 2602, Nis, Serbia|Investigator Site 1509, Barcelona, Spain|Investigator Site 1505, Barcelona, Spain|Investigator Site 1504, Barcelona, Spain|Investigator Site 1502, Madrid, Spain|Investigator Site 1501, Malaga, Spain|Investigator Site 1506, Sevilla, Spain|Investigator Site 2103, Goteborg, Sweden|Investigator Site 2110, Stockholm, Sweden|Investigator Site 2101, Stockholm, Sweden|Investigator Site 9004, Trabzon, Turkey|Investigator Site 3714, Chernihiv, Ukraine|Investigator Site 3701, Chernihiv, Ukraine|Investigator Site 3713, Ivano-Frankivsk, Ukraine|Investigator Site 3711, Ivano-Frankivsk, Ukraine|Investigator Site 3723, Kharkiv, Ukraine|Investigator Site 3724, Kharkiv, Ukraine|Investigator Site 3716, Kyiv, Ukraine|Investigator Site 3715, Lviv, Ukraine|Investigator Site 3721, Lviv, Ukraine|Investigator Site 3703, Odessa, Ukraine|Investigator Site 3717, Poltava, Ukraine|Investigator Site 3730, Ternopil, Ukraine|Investigator Site 3718, Vinnytsia, Ukraine|Investigator Site 3722, Zaporizhia, Ukraine|Investigator Site 3725, Zhytomyr, Ukraine|Investigator Site 2015, Glasgow, United Kingdom|Investigator Site 2021, Lancashire, United Kingdom|Investigator Site 2003, Salford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02425644/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02425644/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02425644
64,NCT02397473,A Study Of Galcanezumab In Participants With Episodic Cluster Headache,NA,Completed,Has Results,Episodic Cluster Headache,Drug: Galcanezumab|Drug: Placebo,Overall Mean Change From Baseline in Number of Weekly Cluster Headache Attacks|Percentage of Participants With 50% or Greater Reduction From Baseline in the Weekly Number of Cluster Headache Attacks|Percentage of Participants Reporting a Score of 1 or 2 on the Patient Global Impression of Improvement (PGI-I)|Percentage of Participants With 50% or Greater Reduction From Baseline in Number of Weekly Cluster Headache Attacks|Percentage of Participants With 30% or Greater Reduction From Baseline in Number of Weekly Cluster Headache Attacks|Pharmacokinetics (PK): Serum Concentration of Galcanezumab|Percentage of Participants Developing Anti-Drug Antibodies (ADA) to Galcanezumab|Percentage of Participants With Suicidal Ideation Assessed by Columbia - Suicide Severity Rating Scale (C-SSRS)|Percentage of Participants With Suicidal Behaviors Assessed by Columbia - Suicide Severity Rating Scale (C-SSRS),Eli Lilly and Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,109,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",15780|I5Q-MC-CGAL|2015-000149-22,"May 22, 2015","February 12, 2018","June 4, 2018","March 25, 2015","March 13, 2019","September 9, 2019","Cedars Sinai Medical Center, Los Angeles, California, United States|Stanford University Hospital, Palo Alto, California, United States|California Medical Clinic for Headache, Santa Monica, California, United States|Colorado Neurological Institute, Englewood, Colorado, United States|New England Institute for Clinical Research, Stamford, Connecticut, United States|Mayo Clinic-Jacksonville, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|St. Anthony's Hospital, Saint Petersburg, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Atlanta Center of Medical Research, Atlanta, Georgia, United States|Michigan Head, Pain, and Neurological Institute, Ann Arbor, Michigan, United States|ClinVest, Springfield, Missouri, United States|Dent Neurological Institute, Amherst, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Gent, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Liege, Belgium|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Montreal, Canada|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Glostrup, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Helsinki, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jyväskylä, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Turku, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Nice, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Paris, France|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Etienne Cedex 2, France|Uniklinikum Essen AöR, Essen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Hamburg, Germany|Migräne- und Kopfschmerzklinik GmbH & Co. KG, Konigstein, Germany|Klinikum der Universität München Campus Großhadern, Munchen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Firenze, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pavia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nijmegen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., La Coruna, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Hull, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Liverpool, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., London, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT02397473/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT02397473/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02397473
65,NCT02352363,Randomized Safety Study of CVT-301 Compared to an Observational Control Group,NA,Completed,Has Results,Idiopathic Parkinson's Disease,Drug: CVT-301|Other: Observational cohort,Pulmonary Safety Assessed by Forced Expiratory Volume in 1 Second [FEV1]|Pulmonary Safety Assessed by Forced Vital Capacity [FVC].|Pulmonary Safety Assessed by Forced Expiratory Volume in 1 Second / Forced Vital Capacity Ratio.|Diffusion Capacity of the Lungs for Carbon Monoxide (DLco).,Acorda Therapeutics,All,"30 Years to 85 Years   (Adult, Older Adult)",Phase 3,408,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CVT-301-005,March 2015,May 2017,May 2017,"February 2, 2015","July 10, 2018","May 28, 2019","Acorda Site #7145, Scottsdale, Arizona, United States|Acorda Site # 7142, Fountain Valley, California, United States|Acorda Site #7139, Panorama City, California, United States|Acorda Site #7141, Sunnyvale, California, United States|Acorda Site #7137, Ormond Beach, Florida, United States|Acorda Site #7135, Saint Petersburg, Florida, United States|Acorda Site #7130, Sunrise, Florida, United States|Acorda Site #7133, Atlanta, Georgia, United States|Acorda Site #7134, Atlanta, Georgia, United States|Acorda Site #7131, Decatur, Georgia, United States|Acorda Site #7138, Honolulu, Hawaii, United States|Acorda Site #7140, Des Moines, Iowa, United States|Acorda Site #7150, Baton Rouge, Louisiana, United States|Acorda Site #7148, Toledo, Ohio, United States|Acorda Site #7004, Innsbruck, Austria|Acorda Site #7002, Linz, Austria|Acorda Site #7003, Vienna, Austria|Acorda Site #7011, Brussels, Belgium|Acorda Site #7012, Edegem, Belgium|Acorda Site #7013, Ghent, Belgium|Acorda Site #7024, Chocen, Czechia|Acorda Site #7025, Ostrava, Czechia|Acorda Site #7021, Pardubice, Czechia|Acorda Site #7022, Prague 10, Czechia|Acorda Site #7023, Rychnov nad Kneznou, Czechia|Acorda Site #7036, Amiens, France|Acorda Site #7037, Bordeaux, France|Acorda Site #7034, Marseille Cedex 05, France|Acorda Site #7031, MONTPELLIER Cedex 5, France|Acorda Site #7033, Nimes Cedex, France|Acorda Site #7032, Strasbourg, France|Acorda Site #7035, Toulouse Cedex 9, France|Acorda Site #7041, Achim, Germany|Acorda Site #7043, Beelitz-Heilstätten, Germany|Acorda Site #7049, Berlin, Germany|Acorda Site #7050, Bochum, Germany|Acorda Site #7048, Bremerhaven, Germany|Acorda Site #7047, Cologne, Germany|Acorda Site #7046, Marburg, Germany|Acorda Site #7042, Munich, Germany|Acorda Site #7044, Ulm, Germany|Acorda Site #7053, Budapest, Hungary|Acorda Site #7051, Budapest, Hungary|Acorda Site #7062, Jerusalem, Israel|Acorda Site #7064, Petah Tikva, Israel|Acorda Site #7061, Ramat Gan, Israel|Acorda Site #7063, Tel-Aviv, Israel|Acorda Site #7045, Den Haag, Netherlands|Acorda Site #7085, Gdansk, Poland|Acorda Site #7084, Katowice, Poland|Acorda Site #7083, Kracow, Poland|Acorda Site #7086, Kraków, Poland|Acorda Site #7087, Kraków, Poland|Acorda Site #7082, Lodz, Poland|Acorda Site #7081, Warsaw, Poland|Acorda Site #7088, Warsaw, Poland|Acorda Site #7094, Brasov, Romania|Acorda Site #7092, Brasov, Romania|Acorda Site #7093, Bucharest, Romania|Acorda Site #7091, Constanta, Romania|Acorda Site #7095, Targu Mures, Romania|Acorda Site #7101, Belgrade, Serbia|Acorda Site #7102, Belgrade, Serbia|Acorda Site #7103, Kragujevac, Serbia|Acorda Site #7112, Sant Cugat, Barcelona, Spain|Acorda Site #7116, Barcelona, Spain|Acorda Site #7111, Barcelona, Spain|Acorda Site #7120, Barcelona, Spain|Acorda Site #7119, Barcelona, Spain|Acorda Site #7113, Burgos, Spain|Acorda Site #7118, Madrid, Spain|Acorda Site #7114, Madrid, Spain|Acorda Site #7115, San Sebastian, Spain|Acorda Site #7123, Cambridge, United Kingdom|Acorda Site #7121, Glasgow, United Kingdom|Acorda Site #7122, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02352363/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02352363/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02352363
66,NCT02351882,Safety and Efficacy of Nabilone in Alzheimer's Disease,NA,Completed,No Results Available,Alzheimer Disease|Agitation|Weight Loss|Pain|Oxidative Stress,Drug: Nabilone|Drug: Placebo,Change in agitation; Cohen-Mansfield Agitation Inventory (CMAI)|Change in neuropsychiatric symptoms; Neuropsychiatric Inventory (NPI)|Change in cognition; Standardized Mini-mental State Examination (sMMSE)|Change in cognition; Severe Impairment Battery (SIB)|Change in cognition; Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)|Change in clinical representation; Alzheimer's Disease Cooperative Study - The Clinician Global Impression (ADCS - CGIC),Sunnybrook Health Sciences Centre,All,"55 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,38,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",318-2013,January 2015,January 2018,March 2019,"January 30, 2015",NA,"June 25, 2020","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",NA,https://ClinicalTrials.gov/show/NCT02351882
67,NCT02332447,Efficacy of Naloxone in Reducing Postictal Central Respiratory Dysfunction in Patients With Epilepsy,ENALEPSY,Completed,No Results Available,Epilepsy,Drug: naloxone|Drug: Placebo,Delay between the end of the seizure and recovery of oxygen saturation (SpO2) ≥ 90%|Delay between the end of the GTCS and recovery of oxygen saturation (SpO2) ≥ 90%,Hospices Civils de Lyon,All,"18 Years and older   (Adult, Older Adult)",Phase 3,485,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2014-853|2014-003003-30,January 2015,March 2015,July 2020,"January 6, 2015",NA,"March 2, 2021","Service de Neurologie Fonctionnelle et d'Epileptologie et Institut des Epilepsies Hôpital Neurologique, Lyon, France",NA,https://ClinicalTrials.gov/show/NCT02332447
68,NCT02322333,MLD10 in the Prevention of Migraine in Adults,NA,Completed,Has Results,Migraine,Drug: MLD10|Drug: Placebo,Migraine Headache Days|Headache Days|Headache Duration|Pain Severity|Acute Medication Usage|Migraine Disability Assessment Scale (MIDAS)|Subject Global Impression of Change (SGIC)|Physician Global Impression of Change (PGIC),Pharmalyte Solutions LLC|Clinvest,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,157,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",MLD10-002,March 2015,June 2017,June 2017,"December 23, 2014","October 9, 2020","October 9, 2020","The Research Center of Southern California, Carlsbad, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Physician Associates of Florida Research Department, Oviedo, Florida, United States|Dr. B. Abraham, P.C., Snellville, Georgia, United States|Westside Family Medical Center, P.C., Kalamazoo, Michigan, United States|StudyMetrix Research, Saint Peters, Missouri, United States|Clinvest Research, LLC, Springfield, Missouri, United States|Baptist Memorial Hospital, Memphis, Tennessee, United States|Nashville Neuroscience Group, Nashville, Tennessee, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02322333/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02322333/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02322333
69,NCT02313909,Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS),"NAVIGATE ESUS",Terminated,Has Results,Stroke,"Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Acetylsalicylic acid (Aspirin, BAY1019036)|Other: Rivaroxaban-Placebo|Other: Aspirin-Placebo","Incidence Rate of the Composite Efficacy Outcome (Adjudicated)|Incidence Rate of a Major Bleeding Event According to the International Society on Thrombosis and Haemostasis (ISTH) Criteria (Adjudicated)|Incidence Rate of Any of the Following: Cardiovascular Death, Recurrent Stroke, Systemic Embolism and Myocardial Infarction|Incidence Rate of All-Cause Mortality|Incidence Rate of the Following: Stroke, Ischemic Stroke, Disabling Stroke, Cardiovascular (CV) Death, Myocardial Infarction|Incidence Rate of Life-Threatening Bleeding Events|Incidence Rate of Clinically Relevant Non-Major Bleeding Events|Incidence Rate of Intracranial Hemorrhage","Bayer|Janssen Research & Development, LLC|Population Health Research Institute",All,"50 Years and older   (Adult, Older Adult)",Phase 3,7213,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",16573|2013-000768-27,"December 23, 2014","February 15, 2018","February 15, 2018","December 10, 2014","January 9, 2019","January 9, 2019","Tucson, Arizona, United States|Long Beach, California, United States|Stanford, California, United States|Torrance, California, United States|New Haven, Connecticut, United States|Gainesville, Florida, United States|Joliet, Illinois, United States|Iowa City, Iowa, United States|Lexington, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Worcester, Massachusetts, United States|Ann Arbor, Michigan, United States|Mount Clemens, Michigan, United States|New Brunswick, New Jersey, United States|Buffalo, New York, United States|New York, New York, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Cleveland, Ohio, United States|Portland, Oregon, United States|Portland, Oregon, United States|Erie, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|El Paso, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Temple, Texas, United States|Salt Lake City, Utah, United States|Seattle, Washington, United States|Banfield, Buenos Aires, Argentina|Ciudad Auton. de Buenos Aires, Buenos Aires, Argentina|Mar del Plata, Buenos Aires, Argentina|San Martín, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Rosario, Santa Fe, Argentina|Ciudad Auton. de Buenos Aires, Argentina|Córdoba, Argentina|Santa Fe, Argentina|Camperdown, New South Wales, Australia|Waratah, New South Wales, Australia|Brisbane, Queensland, Australia|Southport, Queensland, Australia|Launceston, Tasmania, Australia|Clayton, Victoria, Australia|Footscray, Victoria, Australia|Murdoch, Western Australia, Australia|Elizabeth Vale, Australia|Nedlands, Australia|Klagenfurt, Kärnten, Austria|Villach, Kärnten, Austria|Bad Pirawarth, Niederösterreich, Austria|St. Pölten, Niederösterreich, Austria|Vöcklabruck, Oberösterreich, Austria|Feldbach, Steiermark, Austria|Feldkirch, Vorarlberg, Austria|Salzburg, Austria|Wien, Austria|Wien, Austria|Brugge, West-Vlaanderen, Belgium|Antwerpen, Belgium|Brussel, Belgium|Bruxelles - Brussel, Belgium|Dendermonde, Belgium|Edegem, Belgium|Hasselt, Belgium|Salvador, Bahia, Brazil|Belo Horizonte, Minas Gerais, Brazil|Belo Horizonte, Minas Gerais, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Joinville, Santa Catarina, Brazil|Botucatu, Sao Paulo, Brazil|Campinas, Sao Paulo, Brazil|Matão, Sao Paulo, Brazil|Ribeirão Preto, Sao Paulo, Brazil|Ribeirão Preto, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Edmonton, Alberta, Canada|Lethbridge, Alberta, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Brandon, Manitoba, Canada|Saint John, New Brunswick, Canada|Halifax, Nova Scotia, Canada|Burlington, Ontario, Canada|Hamilton, Ontario, Canada|Kingston, Ontario, Canada|London, Ontario, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Ottawa, Ontario, Canada|Thunder Bay, Ontario, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|St. Jerome, Quebec, Canada|Quebec, Canada|Los Angeles, Bío-Bío, Chile|Osorno, Los Lagos, Chile|Puerto Montt, Los Lagos, Chile|Valdivia, Los Lagos, Chile|Viña del Mar, Valparaíso, Chile|Santiago, Chile|Santiago, Chile|Viña del Mar, Chile|Fuzhou, Fujian, China|Fuzhou, Fujian, China|Lanzhou, Gansu, China|Foshan, Guangdong, China|Guangzhou, Guangdong, China|Haikou, Hainan, China|Shijiazhuang, Hebei, China|Harbin, Heilongjiang, China|Zhengzhou, Henan, China|Wuhan, Hubei, China|Wuhan, Hubei, China|Wuhan, Hubei, China|Changsha, Hunan, China|Baotou, Inner Mongolia, China|Nantong, Jiangsu, China|Nanchang, Jiangxi, China|Changchun, Jilin, China|Shenyang, Liaoning, China|Qingdao, Shandong, China|Yantai, Shandong, China|Baoji, Shanxi, China|Xi'an, Shanxi, China|Kunming, Yunnan, China|Hangzhou, Zhejiang, China|Taizhou, Zhejiang, China|Wenzhou, Zhejiang, China|Beijing, China|Beijing, China|Chongqing, China|Guangzhou, China|Shanghai, China|Tianjin, China|Tianjin, China|Blansko, Czechia|Brno, Czechia|Brno, Czechia|Hradec Kralove, Czechia|Jihlava, Czechia|Olomouc, Czechia|Ostrava Vitkovice, Czechia|Ostrava-Poruba, Czechia|Praha 2, Czechia|Praha 3, Czechia|Vyskov, Czechia|Aalborg, Denmark|Aarhus C, Denmark|Copenhagen, Denmark|Glostrup, Denmark|Herlev, Denmark|Hillerød, Denmark|Helsinki, Finland|Lappeenranta, Finland|OYS, Finland|Sairaalamäki, Finland|Tampere, Finland|Turku, Finland|Vaasa, Finland|Antony Cedex, France|Bordeaux, France|Brest Cedex, France|Caen Cedex, France|Dijon, France|Le Chesnay, France|Limoges, France|Nantes, France|NIMES cedex 9, France|PARIS cedex 14, France|Paris, France|Paris, France|Paris, France|Paris, France|Saint Priest En Jarez, France|Strasbourg, France|Freiburg, Baden-Württemberg, Germany|Mannheim, Baden-Württemberg, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Würzburg, Bayern, Germany|Hannover, Niedersachsen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Meerbusch, Nordrhein-Westfalen, Germany|Wuppertal, Nordrhein-Westfalen, Germany|Halle, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Markkleeberg, Sachsen, Germany|Wermsdorf, Sachsen, Germany|Altenburg, Thüringen, Germany|Berlin, Germany|Hamburg, Germany|Athens, Greece|Athens, Greece|Ioannina, Greece|Larissa, Greece|Thessaloniki, Greece|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Eger, Hungary|Gyor, Hungary|Kistarcsa, Hungary|Miskolc, Hungary|Nagykanizsa, Hungary|Nyiregyhaza, Hungary|Sopron, Hungary|Szeged, Hungary|Zalaegerszeg, Hungary|Dublin, Ireland|Galway, Ireland|Ashkelon, Israel|Beer Sheva, Israel|Haifa, Israel|Haifa, Israel|Jerusalem, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Tel Aviv, Israel|L'Aquila, Abruzzo, Italy|Vibo Valentia, Calabria, Italy|Parma, Emilia-Romagna, Italy|Trieste, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Pavia, Lombardia, Italy|Ancona, Marche, Italy|Isernia, Molise, Italy|Cagliari, Sardegna, Italy|Perugia, Umbria, Italy|Perugia, Umbria, Italy|Perugia, Umbria, Italy|Verona, Veneto, Italy|Verona, Veneto, Italy|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Okazaki, Aichi, Japan|Seto, Aichi, Japan|Toyota, Aichi, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Koriyama, Fukushima, Japan|Fukuyama, Hiroshima, Japan|Asahikawa, Hokkaido, Japan|Hakodate, Hokkaido, Japan|Kushiro, Hokkaido, Japan|Kobe, Hyogo, Japan|Kobe, Hyogo, Japan|Kobe, Hyogo, Japan|Nishinomiya, Hyogo, Japan|Isehara, Kanagawa, Japan|Kawasaki, Kanagawa, Japan|Sendai, Miyagi, Japan|Sasebo, Nagasaki, Japan|Tenri, Nara, Japan|Kurashiki, Okayama, Japan|Matsubara, Osaka, Japan|Sakai, Osaka, Japan|Suita, Osaka, Japan|Hidaka, Saitama, Japan|Bunkyo-ku, Tokyo, Japan|Hachioji, Tokyo, Japan|Kodaira, Tokyo, Japan|Musashino, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Sumida-ku, Tokyo, Japan|Fukuoka, Japan|Fukuoka, Japan|Fukuoka, Japan|Hiroshima, Japan|Kakogawa, Japan|Kochi, Japan|Kyoto, Japan|Kyoto, Japan|Kyoto, Japan|Niigata, Japan|Okayama, Japan|Donggu,, Gwangju Gwang''yeogsi, Korea, Republic of|Anyang-si, Gyeonggido, Korea, Republic of|Goyang, Gyeonggido, Korea, Republic of|Seongnam-si, Gyeonggido, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Busan, Korea, Republic of|Daegu, Korea, Republic of|Daegu, Korea, Republic of|Incheon, Korea, Republic of|Seoul,, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Delegación Gustavo A. Madero, Distrito Federal, Mexico|México, D.F., Distrito Federal, Mexico|Morelia, Michoacán, Mexico|México D.F., México, Mexico|Monterrey, Nuevo Leon, Mexico|Merida, Yucatán, Mexico|Aguascalientes, Mexico|México D.F., Mexico|Bialystok, Poland|Chelm, Poland|Gdansk, Poland|Gdansk, Poland|Katowice, Poland|Konskie, Poland|Lodz, Poland|Lodz, Poland|Olsztyn, Poland|Sandomierz, Poland|Siedlce, Poland|Skarzysko-Kamienna, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Vilanova De Gaia, Porto, Portugal|Almada, Portugal|Amadora, Portugal|Coimbra, Portugal|Lisboa, Portugal|Porto, Portugal|Porto, Portugal|Vila Franca de Xira, Portugal|Chelyabinsk, Russian Federation|Ekaterinburg, Russian Federation|Kaluga, Russian Federation|Kazan, Russian Federation|Krasnoyarsk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tomsk, Russian Federation|Ulyanovsk, Russian Federation|Volgograd, Russian Federation|Yaroslavl, Russian Federation|Yekaterinburg, Russian Federation|Cape Town, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Durban, South Africa|Santiago de Compostela, A Coruña, Spain|Badalona, Barcelona, Spain|L'Hospitalet de Llobregat, Barcelona, Spain|Sant Joan Despi, Barcelona, Spain|Castellón de la Plana, Castellón, Spain|El Palmar (Murcia), Murcia, Spain|A Coruña, Spain|Badajoz, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Bilbao, Spain|Cáceres, Spain|Girona, Spain|Granada, Spain|León, Spain|Lleida, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Sevilla, Spain|Sevilla, Spain|Valencia, Spain|Valladolid, Spain|Zaragoza, Spain|Goteborg, Sweden|Hässleholm, Sweden|Lund, Sweden|Malmö, Sweden|Umeå, Sweden|Aarau, Aargau, Switzerland|Basel, Basel-Stadt, Switzerland|Lugano, Ticino, Switzerland|Baden, Switzerland|Bern, Switzerland|Fribourg, Switzerland|Genève, Switzerland|Zürich, Switzerland|Ankara, Turkey|Ankara, Turkey|Antakya, Turkey|Istanbul, Turkey|Istanbul, Turkey|Kahramanmaras, Turkey|Konya, Turkey|Konya, Turkey|High Wycombe, Buckinghamshire, United Kingdom|Milton Keynes, Buckinghamshire, United Kingdom|Cambridge, Cambridgeshire, United Kingdom|Exeter, Devon, United Kingdom|Colchester, Essex, United Kingdom|Westcliff-on-Sea, Essex, United Kingdom|Gloucester, Gloucestershire, United Kingdom|Watford, Hertfordshire, United Kingdom|Ashford, Kent, United Kingdom|Margate, Kent, United Kingdom|Leicester, Leicestershire, United Kingdom|Boston, Lincolnshire, United Kingdom|Harrow, London, United Kingdom|Great Yarmouth, Norfolk, United Kingdom|Taunton, Somerset, United Kingdom|Yeovil, Somerset, United Kingdom|Sheffield, South Yorkshire, United Kingdom|Stoke-On-Trent, Staffordshire, United Kingdom|Glasgow, Stratchclyde, United Kingdom|Gateshead, Tyne And Wear, United Kingdom|Sunderland, Tyne And Wear, United Kingdom|Wolverhampton, West Midlands, United Kingdom|Leeds, West Yorkshire, United Kingdom|Salisbury, Wiltshire, United Kingdom|Aberdeen, United Kingdom|Durham, United Kingdom|Edinburgh, United Kingdom|London, United Kingdom|London, United Kingdom|London, United Kingdom|London, United Kingdom|Luton, United Kingdom|Norwich, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02313909/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02313909/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02313909
70,NCT02271217,A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.,MILESTONE℠,Completed,Has Results,Post-Ischemic Stroke,Drug: Placebo|Drug: dalfampridine-ER 7.5mg|Drug: dalfampridine-ER 10mg,Proportion of Subjects Who Show at Least a 20% Improvement on the Two Minute Walk Test (2MinWT) at Week 12|Change From Baseline on the Walking Impact Scale (Walk-12) at Week 12 (Key Secondary),Acorda Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 3,377,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DALF-PS-1016,December 2014,September 2016,October 2016,"October 22, 2014","December 4, 2017","June 7, 2018","Acorda Site #117, Gilbert, Arizona, United States|Acorda Site #109, Berkeley, California, United States|Acorda Site #138, Long Beach, California, United States|Acorda Site #105, Newport Beach, California, United States|Acorda Site #170, Oceanside, California, United States|Acorda Site #142, Pasadena, California, United States|Acorda Site #153, Sacramento, California, United States|Acorda Site #151, San Diego, California, United States|Acorda Site #163, San Diego, California, United States|Acorda Site #124, Colorado Springs, Colorado, United States|Acorda Site #110, Danbury, Connecticut, United States|Acorda Site #149, Fairfield, Connecticut, United States|Acorda Site #130, Stamford, Connecticut, United States|Acorda Site #115, Atlantis, Florida, United States|Acorda Site #119, Deerfield Beach, Florida, United States|Acorda Site #147, Gainesville, Florida, United States|Acorda Site #128, Hialeah, Florida, United States|Acorda Site #143, Jacksonville, Florida, United States|Acorda Site #103, Miami, Florida, United States|Acorda Site #133, Miami, Florida, United States|Acorda Site #161, Naples, Florida, United States|Acorda Site #145, Sunrise, Florida, United States|Acorda Site #106, Tampa, Florida, United States|Acorda Site #186, Atlanta, Georgia, United States|Acorda Site #181, Kailua, Hawaii, United States|Acorda Site #171, Chicago, Illinois, United States|Acorda Site #148, Avon, Indiana, United States|Acorda Site #188, Fort Wayne, Indiana, United States|Acorda Site #156, Franklin, Indiana, United States|Acorda Site #146, Lexington, Kentucky, United States|Acorda Site #150, New Orleans, Louisiana, United States|Acorda Site #175, Fulton, Maryland, United States|Acorda Site #136, Boston, Massachusetts, United States|Acorda Site #121, Boston, Massachusetts, United States|Acorda Site #120, Worcester, Massachusetts, United States|Acorda Site #164, Bingham Farms, Michigan, United States|Acorda Site #127, Detroit, Michigan, United States|Acorda Site #123, East Lansing, Michigan, United States|Acorda Site #159, Grand Rapids, Michigan, United States|Acorda Site #101, Kansas City, Missouri, United States|Acorda Site #111, Great Falls, Montana, United States|Acorda Site #140, Reno, Nevada, United States|Acorda Site #131, New Brunswick, New Jersey, United States|Acorda Site #177, Stratford, New Jersey, United States|Acorda Site #172, New York, New York, United States|Acorda Site #102, New York, New York, United States|Acorda Site #179, Patchogue, New York, United States|Acorda Site #114, White Plains, New York, United States|Acorda Site #166, Chapel Hill, North Carolina, United States|Acorda Site #167, Durham, North Carolina, United States|Acorda Site #162, Mooresville, North Carolina, United States|Acorda Site #154, Raleigh, North Carolina, United States|Acorda Site #132, Winston-Salem, North Carolina, United States|Acorda Site #187, Bellevue, Ohio, United States|Acorda Site #160, Cleveland, Ohio, United States|Acorda Site #137, Columbus, Ohio, United States|Acorda Site #116, Dayton, Ohio, United States|Acorda Site #152, Corvallis, Oregon, United States|Acorda Site #168, Portland, Oregon, United States|Acorda Site #126, Portland, Oregon, United States|Acorda Site #158, Abington, Pennsylvania, United States|Acorda Site #122, Philadelphia, Pennsylvania, United States|Acorda Site #144, Providence, Rhode Island, United States|Acorda Site #157, Memphis, Tennessee, United States|Acorda Site #113, Dallas, Texas, United States|Acorda Site #165, Dallas, Texas, United States|Acorda Site #108, Houston, Texas, United States|Acorda Site #182, Alexandria, Virginia, United States|Acorda Site #176, Richmond, Virginia, United States|Acorda Site #107, Spokane, Washington, United States|Acorda Site #203, Fredericton, New Brunswick, Canada|Acorda Site #202, Halifax, Nova Scotia, Canada|Acorda Site #201, Greenfield Park, Quebec, Canada|Acorda Site #204, Montréal, Quebec, Canada",NA,https://ClinicalTrials.gov/show/NCT02271217
71,NCT02245737,An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease,AMARANTH,Terminated,Has Results,Alzheimer´s Disease,Drug: Lanabecestat|Drug: Placebo,Change From Baseline on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13)|Change From Baseline on the Alzheimer´s Disease Cooperative Study Activities of Daily Living Inventory Instrumental Items (ADCS-iADL)|Change From Baseline on the Functional Activities Questionnaire (FAQ) Score|Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) Score|Change From Baseline on the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score|Time to Progression as Measured by Loss of Clinical Dementia Rating (CDR) Global Score Stage|Change From Baseline in Neuropsychiatric Inventory (NPI) Score|Change From Baseline on the Mini-Mental State Examination (MMSE)|Pharmacodynamics (PD): Percent Change From Baseline in Concentration of Cerebrospinal Fluid (CSF) Biomarker Amyloid Beta (Aβ)1-42|PD: Percent Change From Baseline in Concentration of CSF Biomarker Aβ1-40|Change From Baseline in CSF Total Tau|Change From Baseline in CSF Phosphorylated Tau|Change From Baseline in Brain Amyloid Burden Using Florbetapir Amyloid Positron Emission Tomography (PET) Scan|Change From Baseline in Tau PET ((Flortaucipir F18)|Change From Baseline in Brain Metabolism Using Fluorodeoxyglucose (FDG)|Change From Baseline in Whole Brain Volume|Pharmacokinetics (PK): Plasma Concentration of Lanabecestat,AstraZeneca|Eli Lilly and Company,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,2218,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",16023|I8D-MC-AZES|2014-002601-38|D5010C00009,"September 30, 2014","October 4, 2018","October 4, 2018","September 22, 2014","August 6, 2019","December 3, 2019","Banner Alzheimer's Institute, Phoenix, Arizona, United States|St Josephs Hospital and Medical Center, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Territory Neurology & Research Institute, Tucson, Arizona, United States|Positron Research International, Fremont, California, United States|Alliance Research Centers, Laguna Hills, California, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Collaborative Neuroscience Network - CNS, Long Beach, California, United States|Pacific Research Network Inc, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Mile High Research Center, Denver, Colorado, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Brain Matters Research, Delray Beach, Florida, United States|Direct Helpers Medical Center, Hialeah, Florida, United States|Berma Research, Hialeah, Florida, United States|Galiz Research, Hialeah, Florida, United States|MaxBlue Institute, Hialeah, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Medical Research Center, Miami, Florida, United States|Allied Biomedical Research Institute, Inc., Miami, Florida, United States|Advance Medical Research Institute, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|JDH Medical Group, LLC, Miami, Florida, United States|Compass Research, Orlando, Florida, United States|IMIC, Inc., Palmetto Bay, Florida, United States|Suncoast Neuroscience Associates, Saint Petersburg, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Infinity Clinical Research, LLC, Sunrise, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Olympian Clinical Research, Tampa, Florida, United States|Compass Research, The Villages, Florida, United States|Premiere Research Institute at Palm Beach Neurology, West Palm Beach, Florida, United States|The Multiple Sclerosis Center of Atlanta, Atlanta, Georgia, United States|Atlanta Center of Medical Research, Atlanta, Georgia, United States|Carman Research, Smyrna, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Community Clinical Research Center, Anderson, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|ActivMed Practices & Research, Inc, Methuen, Massachusetts, United States|Boston Center for Memory, Newton, Massachusetts, United States|Springfield Neurology Associates, Springfield, Massachusetts, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Millennium Psychiatric Associates, LLV, Saint Louis, Missouri, United States|St. Louis Clinical Trials, LC, Saint Louis, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|AdvanceMed Research, Lawrenceville, New Jersey, United States|Alzheimer's Research Company, Manchester, New Jersey, United States|The Cognitive and Research Center of NJ, Springfield, New Jersey, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Neurology Specialists of Monmouth County, West Long Branch, New Jersey, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|SPRI Clinical Trials, LLC., Brooklyn, New York, United States|Alzheimer's Disease and Memory Disorders Center, Buffalo, New York, United States|Empire Neurology, PC, Latham, New York, United States|Clinilabs, Inc (New York), New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Valley Medical Primary Care, Centerville, Ohio, United States|Christ Hospital, Cincinnati, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|The Corvallis Clinic P.C., Corvallis, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Radiant Research, Greer, South Carolina, United States|Quillen College of Medicine, East TN State University, Johnson City, Tennessee, United States|Senior Adults Specialty Research Inc, Austin, Texas, United States|Texas Health Physicians Group, Dallas, Texas, United States|Medical Group of Texas, Fort Worth, Texas, United States|University of Texas Health Services Center - Houston, Houston, Texas, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|The Memory Clinic, Bennington, Vermont, United States|Southern Neurology, Kogarah, New South Wales, Australia|Griffith University, Gold Coast, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Delmont Private Hospital, Glen Iris, Victoria, Australia|Heidelberg Repatriation Hospital, Heidelberg, Victoria, Australia|The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia|Australian Alzheimer's Research Foundation, Nedlands, Western Australia, Australia|Neuro Trials Victoria Pty Ltd, Noble Park, Australia|Jessa Ziekenhuis, Hasselt, Limburg, Belgium|Hopital Universitaire Brugmann Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Hospital Universitaire Erasme Brussel, Brussel, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium|Heilig Hartziekenhuis, Roeselare, Belgium|The Medical Arts Health Research Group, Kamloops, British Columbia, Canada|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|University of British Columbia, Vancouver, British Columbia, Canada|Royal Jubilee Hospital, Victoria, British Columbia, Canada|True North Clinical Research Halifax, LLC, Halifax, Nova Scotia, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|CSSS-Institut Universitaire Gériatric de Sherbrooke, Sherbrooke, Qubec, Canada|Clinique de la Memoire de l'Outaouais, Gatineau, Quebec, Canada|NeuroSearch Developements, Greenfield Park, Quebec, Canada|Hopital Maisonneure-Rosemount, Montreal, Quebec, Canada|Hopital de L'Enfant Jesus, Quebec City, Quebec, Canada|Q&T Research Sherbrooke Inc, Sherbrooke, Quebec, Canada|CHU de Toulouse Hopital Purpan, Toulouse, Cedex 9, France|Hopital Neuro Pierre Wertheimer, Bron Cedex, France|CHU Dijonon, Dijon Cedex, France|CHRU Lille - Hopital Roger Salengro, Lille Cedex, France|CHU Hopital de la Timone, Marseille Cedex 05, France|Chu de Nantes Hopital Laennec, Nantes, France|Hopital Broca, Paris, France|Hopital de la Pitie Salpetriere, Paris, France|Hopital Lariboisière, Paris, France|CHU de Toulouse, Toulouse, France|Hopital des Charpennes, Villeurbanne, France|Universitätsklinikum Tübingen, Tübingen, Baden-Württemberg, Germany|Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany|Studien und Gedächtniszentrum München, München, Bayern, Germany|Klinikum Rechts der Isar der TU München, München, Bayern, Germany|Institut fur Psychogerontologie, Nürnberg, Bayern, Germany|Neurozentrum Prien, Prien am Chiemsee, Bayern, Germany|Institut für Neuropsychiatrie INP3, Wenzenbach, Bayern, Germany|Studienzentrum Nord-West, Westerstede, Niedersachsen, Germany|Praxis Dr. Lauter, Bochum, Nordrhein-Westfalen, Germany|St Josef-Hospital Bochum, Bochum, Nordrhein-Westfalen, Germany|Universitätsklinikum Bonn, Bonn, Nordrhein-Westfalen, Germany|Gemeinschaftspraxis für Neurologie Prof. Gereon Nelles, Köln, Nordrhein-Westfalen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Neurologische Praxis Siegen, Siegen, Nordrhein-Westfalen, Germany|Universitätsklinikum des Saarlandes, Homburg, Saarland, Germany|Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Sachsen-Anhalt, Germany|Universitätsklinikum Otto-von-Guericke-Universität, Magdeburg, Sachsen-Anhalt, Germany|Pharmakologisches Studienzentrum Chemnitz, Mittweida, Sachsen, Germany|Arztpraxis Dr. Christian Oehlwein, Gera, Thüringen, Germany|Gemeinschaftspraxis Dr. R. Ehret & Dr. W. von Pannwitz, Berlin, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|PTE KK Pszichiatriai es Pszichoterapias Klinika, Pecs, Baranya, Hungary|Semmelweis Medical University, Budapest, Hungary|Del-pesti Centrumkorház - Orszagos Hematologiai és Infektologiai Intezet, Budapest, Hungary|Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz, Debrecen, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Univerisity of Szeged, Szeged, Hungary|Ospedale Degli Infermi ASR USSL 12, Ponderano, Biella, Italy|Azienda Ospedaliera San Gerardo, Monza, Milano, Italy|Fondazione San Raffaele Giglio di Cefalu, Cefalu, Palermo, Italy|Universita Di Pisa, Pisa, PI, Italy|Università Politecnica delle Marche Torrette, Ancona, Italy|IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy|Fondazione Universitaria degli Studi G D'Annunzio, Chieti, Italy|Ente Ospedaliero Ospedali Galliera, Genova, Italy|Fondazione IRCCS Ca'Granda Ospedale Maggiore Policinico, Milano, Italy|Nuovo Ospedale Civile Sant'Agostino Estense, Modena, Italy|Policlinico Univ. Agostino Gemelli, Roma, Italy|Dip.to Med. Sperimentale -Polic.Umberto I -Univ. La Sapienza, Roma, Italy|Ospedale San Giovanni Calibita Fatebenefratelli, Roma, Italy|Policlinico Ospedale S. Andrea, Roma, Italy|Azienda Ospedaliera Citta della Salute della Scienza Torino, Torino, Italy|National Institute for Longevity Sciences NCGG, Obu, Aichi, Japan|National Chiba-East-Hospital, Chuo-ku, Chiba, Japan|National Hospital Organization Asahikawa Medical Center, Asahikawa, Hokkaido, Japan|Tsukuba University Hospital, Tsukuba, Ibaraki, Japan|Iwate Medical University Hospital, Morioka, Iwate, Japan|Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan|Nihon Kokan Hospital, Kawasaki, Kanagawa, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, Japan|Kyoto Prefectural University of Medicine, Kyoto-shi, Kyoto, Japan|Rakuwakai Otowarehabilitation Hospital, Kyoto-shi, Kyoto, Japan|Ina Central Hospital, Ina, Nagano, Japan|Matsumoto Medical Center, Matsumoto, Nagano, Japan|Katayama Medical Clinic, Kurashiki, Okayama, Japan|Shiroma Clinic, Urasoe, Okinawa, Japan|Koshokai aino hospital, Ibaraki, Osaka, Japan|Sakaguchi Clinic, Sakai, Osaka, Japan|National Sanatorium Toneyama Hospital, Toyonaka, Osaka, Japan|Saitama Medical University Hospital, Iruma-Gun, Saitama, Japan|Nippon Medical School Hospital, Bunkyo-Ku, Tokyo, Japan|The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan|Nozomi Memory Clinic, Mitaka-shi, Tokyo, Japan|Sangenjaya Nakamura Mental Clinic, Setagaya, Tokyo, Japan|Kanauchi Medical Clinic, Shinjuku-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|Memory Clinic Ochanomizu, Tsukuba, Tokyo, Japan|National Sanatorium Hokuriku Hospital, Nanto, Toyama, Japan|Fukuoka University Hospital, Fukuoka, Japan|Kyoto University Hospital, Kyoto, Japan|Kyoto Minami Hospital, Kyoto, Japan|Utano Hospital, Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|Dong-A University Medical Center, Seogu, Busan, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Geonggi-do, Korea, Republic of|The Catholic University of Korea-Bucheon St. Mary's Hospital, Bucheon-si, Gyeonggi-do, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Gyeonggido, Korea, Republic of|Gachon University Gil Medical Center, Namdong, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of|NZOZ Wroclawskie Centrum Alzheimerowskie, Wroclaw, Dolnoslaskie, Poland|Medycyna Milorzab, Lodz, Lódzkie, Poland|Podlaskie Centrum Psychogeriatrii, Białystok, Podlaskie, Poland|NZOZ Dom Sue Ryder - Pallmed Sp. z o.o., Bydgoszcz, Poland|NZOZ Wielospecjalistyczna Poradnia Lekarska, Katowice, Poland|Specjalistyczna Praktyka Lekarska prof. Grzegorz Opala, Katowice, Poland|Centrum Zdrowia Psychicznego, Kielce, Poland|Centrum Neurologii Klinicznej, Krakow, Poland|NZOZ Neuromed M. I M. Nastaj sp. P., Lublin, Poland|Instytut Medycyny Wsi, Lublin, Poland|NEURO-CARE Sp. z o.o. Sp. Komandytowa, Siemianowice Śląskie, Poland|Centrum Medyczne, Warszawa, Poland|Centralny Szpital Kliniczny MSW, Warszawa, Poland|Santa Cruz Behavioral PSC, Bayamon, Puerto Rico|Ivonne Z. Jimenez-Velazquez, MD, Carolina, Puerto Rico|Instituto de Neurologia Dra. Ivonne Fraga, San Juan, Puerto Rico|Michel A. Woodbury-Farina, MD., San Juan, Puerto Rico|SC Med Life SA, Bucuresti, Romania|SC Centrul Medical Sana SRL, Bucuresti, Romania|Policlinica CCBR S.R.L., Bucuresti, Romania|SC Med Life SA, Timisoara, Romania|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital General de Catalunya, Sant Cugat del Valles, Barcelona, Spain|Hospital Virgen Del Puerto, Plasencia, Caceres, Spain|Hospital Universitario De Getafe, Madrid, Getafe, Spain|Hospital Puerta De Hierro, Majadahonda, Madrid, Spain|Centro de Atencion Especializada (CAE) OROITU, Getxo, Vizcaya, Spain|Hospital del Mar, Barcelona, Spain|Hospital Santa Creu I Sant Pau, Barcelona, Spain|Fundacion ACE-Institut Catala de Neurociences Aplicades, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Reina Sofia, Cordoba, Spain|Hospital De La Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Son Espases, Palma de Mallorca, Spain|Hospital Univ Sant Joan de Reus, S.A., Reus, Spain|Fundacion CITA Alzheimer, San Sebastian, Spain|Hospital Doctor Peset, Valencia, Spain|Hospital Universitario La Fe de Valencia, Valencia, Spain|Plymouth Hospitals NHS Trust, Plymouth, Devon, United Kingdom|Cognitive Treatment & Research Unit, Crowborough, East Sussex, United Kingdom|Southern Health NHS, Southampton, Hampshire, United Kingdom|MAC UK Neuroscience Ltd, Blackpool, Lancs, United Kingdom|MAC Clinical Research, Stourton, Leeds, United Kingdom|MAC Clinical Research, Cannock, Staffordshire, United Kingdom|West London Mental Health NHS Trust, Brentford, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|Hammersmith Hospital, London, United Kingdom|Guildford Nuffield Hospital, London, United Kingdom|Re-Cognition Health Ltd, London, United Kingdom|MAC Clinical Research, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02245737/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02245737/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02245737
72,NCT02240030,Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes,SPAN-PD™,Completed,Has Results,Idiopathic Parkinson's Disease,Drug: CVT-301 Low Dose|Drug: CVT-301 High Dose|Other: Placebo,Unified Parkinson's Disease Rating Scale (UPDRS) Part III|Proportion of Patients Achieving Resolution of an OFF to an ON State Within 60 Minutes.|UPDRS Part III Motor Score at 20 Minutes|Proportion of Subjects Who Improved PGIC With CVT-301 vs. Placebo at Week 12|UPDRS Part III at 10 Min.|PD Patient Diary,Acorda Therapeutics,All,"30 Years to 85 Years   (Adult, Older Adult)",Phase 3,351,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CVT-301-004,November 2014,December 2016,December 2016,"September 15, 2014","April 17, 2018","May 28, 2019","Acorda Site #5020, Scottsdale, Arizona, United States|Acorda Site #5042, Fresno, California, United States|Acorda Site #5064, Fullerton, California, United States|Acorda Site #5035, Loma Linda, California, United States|Acorda Site #5027, Long Beach, California, United States|Acorda Site #5037, Los Angeles, California, United States|Acorda Site #5070, Pasadena, California, United States|Acorda Site #5047, Reseda, California, United States|Acorda Site #5068, Santa Ana, California, United States|Acorda Site #5069, Torrance, California, United States|Acorda Site #5052, Washington, District of Columbia, United States|Acorda Site #5046, Atlantis, Florida, United States|Acorda Site #5053, Aventura, Florida, United States|Acorda Site #5013, Boca Raton, Florida, United States|Acorda Site #5016, Jacksonville, Florida, United States|Acorda Site #5071, Maitland, Florida, United States|Acorda Site #5044, Orlando, Florida, United States|Acorda Site #5060, Palm Beach Gardens, Florida, United States|Acorda Site #5001, Port Charlotte, Florida, United States|Acorda Site #5065, Saint Petersburg, Florida, United States|Acorda Site #5012, Tampa, Florida, United States|Acorda Site #5040, Atlanta, Georgia, United States|Acorda Site #5025, Chicago, Illinois, United States|Acorda Site #5030, Chicago, Illinois, United States|Acorda Site #5011, Elk Grove Village, Illinois, United States|Acorda Site #5003, Kansas City, Kansas, United States|Acorda Site #5067, Baton Rouge, Louisiana, United States|Acorda Site #5057, Baltimore, Maryland, United States|Acorda Site #5056, Boston, Massachusetts, United States|Acorda Site #5018, Boston, Massachusetts, United States|Acorda Site #5002, Bingham Farms, Michigan, United States|Acorda Site #5014, West Bloomfield, Michigan, United States|Acorda Site #5041, Golden Valley, Minnesota, United States|Acorda Site #5006, Saint Louis, Missouri, United States|Acorda Site #5023, Las Vegas, Nevada, United States|Acorda Site #5028, Albany, New York, United States|Acorda Site #5039, Brooklyn, New York, United States|Acorda Site #5031, New York, New York, United States|Acorda Site #5032, New York, New York, United States|Acorda Site #5004, New York, New York, United States|Acorda Site #5038, Syracuse, New York, United States|Acorda Site #5048, Charlotte, North Carolina, United States|Acorda Site #5005, Cleveland, Ohio, United States|Acorda Site #5050, Norwood, Ohio, United States|Acorda Site #5062, Portland, Oregon, United States|Acorda Site #5036, Allentown, Pennsylvania, United States|Acorda Site #5010, Philadelphia, Pennsylvania, United States|Acorda Site #5058, Willow Grove, Pennsylvania, United States|Acorda Site #5022, Charleston, South Carolina, United States|Acorda Site #5029, Nashville, Tennessee, United States|Acorda Site #5019, Houston, Texas, United States|Acorda Site #5045, Houston, Texas, United States|Acorda Site #5049, Henrico, Virginia, United States|Acorda Site #5059, Virginia Beach, Virginia, United States|Acorda Site #5051, Kirkland, Washington, United States|Acorda Site #5103, London, Ontario, Canada|Acorda Site #5104, Ottawa, Ontario, Canada|Acorda Site #5105, Toronto, Ontario, Canada|Acorda Site #5201, Prague, Czechia|Acorda Site #5203, Prague, Czechia|Acorda Site #5304, Katowice, Poland|Acorda Site #5303, Krakow, Poland|Acorda Site #5306, Kraków, Poland|Acorda Site #5307, Kraków, Poland|Acorda Site #5302, Lodz, Poland|Acorda Site #5308, Warsaw, Poland|Acorda Site #5301, Warsaw, Poland|Acorda Site #5305, Zaspa, Poland|Acorda Site #5407, Pamplona, Navarre, Spain|Acorda Site #5404, Barcelona, Spain|Acorda Site #5406, Barcelona, Spain|Acorda Site #5405, Madrid, Spain|Acorda Site #5403, San Sebastián, Spain|Acorda Site #5401, Sant Cugat Del Vallès, Spain",NA,https://ClinicalTrials.gov/show/NCT02240030
73,NCT02224703,GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome,NA,Completed,Has Results,Epilepsy|Dravet Syndrome,Drug: GWP42003-P|Drug: Placebo Control,Change In Convulsive Seizures During The Treatment Period Compared To Baseline|Change In Total Seizures During The Treatment Period Compared To Baseline|Participants With A ≥50% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period|Caregiver Global Impression Of Change (CGIC) At The Last Visit,Jazz Pharmaceuticals,All,"2 Years to 18 Years   (Child, Adult)",Phase 3,199,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GWEP1424|2014-002939-34,"April 13, 2015","April 9, 2018","April 9, 2018","August 25, 2014","August 1, 2019","September 28, 2022","Birmingham, Alabama, United States|Little Rock, Arkansas, United States|Los Angeles, California, United States|Sacramento, California, United States|Hartford, Connecticut, United States|Miami, Florida, United States|Savannah, Georgia, United States|Chicago, Illinois, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Saint Paul, Minnesota, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Lebanon, New Hampshire, United States|Buffalo, New York, United States|Chapel Hill, North Carolina, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Austin, Texas, United States|Fort Worth, Texas, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Heidelberg, Australia|Randwick, Australia|Ramat Gan, Israel|Heeze, Netherlands|Zwolle, Netherlands|Kraków, Poland|Warszawa, Poland|Łódź, Poland|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Pamplona, Spain|Sevilla, Spain|Valencia, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02224703/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02224703/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02224703
74,NCT02224690,A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults,GWPCARE4,Completed,Has Results,Epilepsy|Lennox-Gastaut Syndrome,Drug: GWP42003-P 20 mg/kg/day Dose|Drug: Placebo,Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period|Number Of Participants With a ≥50% Reduction From Baseline in Drop Seizure Frequency During The Treatment Period|Percentage Change From Baseline In Total Seizure Frequency During The Treatment Period|Subject/Caregiver Global Impression Of Change Assessment (S/CGIC),Jazz Pharmaceuticals,All,"2 Years to 55 Years   (Child, Adult)",Phase 3,171,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GWEP1423|2014-002941-23,"April 28, 2015","March 18, 2016","March 18, 2016","August 25, 2014","July 27, 2018","September 28, 2022","Tampa, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Ames, Iowa, United States|Iowa City, Iowa, United States|Lexington, Kentucky, United States|Boston, Massachusetts, United States|Saint Paul, Minnesota, United States|Saint Louis, Missouri, United States|Lebanon, New Hampshire, United States|Bronx, New York, United States|Rochester, New York, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Winchester, Virginia, United States|Denekamp, BV Zwolle, Netherlands|Bydgoszcz, Poland|Gdańsk, Poland|Kraków, Poland|Lublin, Poland|Lublin, Poland|Poznań, Poland",NA,https://ClinicalTrials.gov/show/NCT02224690
75,NCT02224560,Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults,GWPCARE3,Completed,Has Results,Epilepsy|Lennox Gastaut Syndrome,Drug: GWP42003-P|Drug: Placebo control,Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period|Number Of Participants With A ≥50% Reduction From Baseline In Drop Seizure Frequency During The Treatment Period|Percentage Change From Baseline In Total Seizure Frequency During The Treatment Period|Subject/Caregiver Global Impression Of Change (S/CGIC) Assessment,Jazz Pharmaceuticals,All,"2 Years to 55 Years   (Child, Adult)",Phase 3,225,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GWEP1414|2014-002940-42,"June 8, 2015","May 19, 2016","May 19, 2016","August 25, 2014","July 27, 2018","September 28, 2022","Birmingham, Alabama, United States|Phoenix, Arizona, United States|Los Angeles, California, United States|Hartford, Connecticut, United States|Orlando, Florida, United States|Augusta, Georgia, United States|Boise, Idaho, United States|Rochester, Minnesota, United States|Buffalo, New York, United States|New York, New York, United States|New York, New York, United States|Clemmons, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|York, Pennsylvania, United States|Charleston, South Carolina, United States|Austin, Texas, United States|Fort Worth, Texas, United States|Charlottesville, Virginia, United States|Paris, France|Barcelona, Spain|Madrid, Spain|Pamplona, Spain|Sevilla, Spain|Valencia, Spain|Edinburgh, United Kingdom|Glasgow, United Kingdom|London, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT02224560
76,NCT02220933,Effect of MD1003 in Spinal Progressive Multiple Sclerosis,MS-SPI,Unknown status,No Results Available,Multiple Sclerosis,Drug: MD1003 100mg capsule|Drug: Placebo,Proportion of patients improved on either Expanded Disability Status Scale (EDSS) or time to walk 25 feet (TW25)|Multiple Sclerosis Walking Scale (MSWS)|Clinical Global Impression / Subject Global Impression (CGI / SGI)|Unidimensional Fatigue Impact Scale (U-FIS)|Multiple Sclerosis Quality of Life Scale (SEP-59)|Hole Peg Test (9-HPT),MedDay Pharmaceuticals SA,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,144,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MD1003CT2013-02MS-SPI|2013-002113-35,October 2013,January 2016,January 2018,"August 20, 2014",NA,"March 27, 2017","Hopital Pellegrin, Bordeaux, France|Hopital de la cote de Nacre, Caen, France|Hopital Gabriel Montpied, Clermont Ferrand, France|Hopital general du Bocage, Dijon, France|Hopital Pierre Wertheimer, Lyon, France|Hopital de la Timone, Marseille, France|Hopital Gui de Chauliac, Montpellier, France|Hopital Central, Nancy, France|Hopital Nord Laennec, Nantes, France|Hopital Pasteur, Nice, France|Groupe hospitalier la Pitié-Salpêtrière, Paris, France|Fondation Rothschild, Paris, France|Centre hospitalier Intercommunal Poissy/Saint-Germain-en-Laye, Poissy, France|Hopital Maison Blanche, Reims, France|Hopital Pontchaillou, Rennes, France|Hopital Hautepierre, Strasbourg, France|Hopital Purpan, Toulouse, France",NA,https://ClinicalTrials.gov/show/NCT02220933
77,NCT02220244,Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis,MS-ON,Unknown status,No Results Available,Multiple Sclerosis,Drug: MD1003 100mg capsule,Change from baseline of the best corrected visual acuity at 100% contrast|Visual field mean deviation change from baseline|Reappearance or improvement of the P00 wave on Visual Evoked Potential|Optical Coherence Tomography,MedDay Pharmaceuticals SA,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,105,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MD1003CT2013-01MS-ON|2013-002112-27,October 2013,December 2015,January 2018,"August 19, 2014",NA,"March 27, 2017","Hopital Pellegrin, Bordeaux, France|Hopital de la cote de Nacre, Caen, France|Hopital Gabriel Montpied, Clermont Ferrand, France|Hopital general du Bocage, Dijon, France|CHRU de Lille, Lille, France|Hopital Pierre Wertheimer, Lyon, France|Hopital de la Timone, Marseille, France|Hopital Gui de Chauliac, Montpellier, France|Hopital Central, Nancy, France|Hopital Nord Laennec, Nantes, France|Hopital Pasteur, Nice, France|Centre hospitalier national d'ophtalmologie des Quinze Vingts, Paris, France|Groupe hospitalier la Pitie-Salpetriere, Paris, France|Fondation Rothschild, Paris, France|Centre hospitalier Intercommunal Poissy/Saint-Germain-en-Laye, Poissy, France|Hopital Maison Blanche, Reims, France|Hopital Pontchaillou, Rennes, France|Hopital de Hautepierre, Strasbourg, France|Hopital Purpan, Toulouse, France|UCL Institute of Neurology, London, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT02220244
78,NCT02168842,Efficacy of Isradipine in Early Parkinson Disease,NA,Completed,Has Results,Parkinson Disease,Drug: Isradipine|Drug: Placebo (for Isradipine),Adjusted Mean Change in Total Unified Parkinson Disease Rating Scale (UPDRS) Score|Adjusted Mean Change in Adjusted UPDRS Score|Adjusted Mean Change in LED|Adjusted Mean Change in LED Cumulative|Adjusted Mean Change in UPDRS Part IV|Adjusted Mean Change in MDS-UPDRS nmEDL|Adjusted Mean Change in MDS-UPDRS mEDL|Adjusted Mean Change in UPDRS Score to 1 Year|Adjusted Mean Change in UPDRS Part II|Adjusted Mean Change in UPDRS Part III OFF|Adjusted Mean Change in SE/ADL|Adjusted Mean Change in Modified Rankin Score|Adjusted Mean Change in MoCA Score|Adjusted Mean Change in PDQ39 Total Score|Adjusted Mean Change in Ambulatory Capacity|Adjusted Mean Change in BDI Total Score|Risk of Need for Antiparkinsonian Therapy|Risk of Need for Dyskinesia|Risk of Need for Fluctuations,University of Rochester|National Institute of Neurological Disorders and Stroke (NINDS)|Michael J. Fox Foundation for Parkinson's Research|The Parkinson Study Group,All,"30 Years and older   (Adult, Older Adult)",Phase 3,336,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",STEADY-PD III|U01NS080818-01A1|U01NS080840-01A1,November 2014,November 2018,November 2018,"June 20, 2014","January 14, 2020","January 14, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|The Parkinsons & Movement Disorder Institute, Fountain Valley, California, United States|University of California, Irvine, California, United States|University of California San Diego, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Rocky Mountain Movement Disorders Center, Englewood, Colorado, United States|Institute of Neurodegenerative Disorders, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Pacific Health Research & Education Institute, Honolulu, Hawaii, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|LSU Health Science Center, Shreveport, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Struthers Parkinson's Center, Golden Valley, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Nebraska Medical Center, Omaha, Nebraska, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Atlantic Neuroscience Institute, Summit, New Jersey, United States|Albany Medical College, Albany, New York, United States|Health Quest Kingston, Kingston, New York, United States|Columbia University Medical Center, New York, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|University of Rochester, Rochester, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas Health Science Center, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Sentara Neurology Specialists, Virginia Beach, Virginia, United States|Booth Gardner Parkinson's Care Center, Kirkland, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|University of Calgary, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Ottawa Hospital Civic Site, Ottawa, Ontario, Canada|The Centre for Addiction and Mental Health, Toronto, Ontario, Canada|Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada|CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada|Centre Hospitalier Affilie, Quebec City, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02168842/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02168842/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02168842
79,NCT02153645,Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.,ALLAY-LID-I,Terminated,Has Results,Parkinson's Disease|Levodopa Induced Dyskinesias (LID),Drug: 240mg Amantadine HCl ER tablets|Drug: Placebo tablets|Drug: 320mg Amantadine HCl ER tablets,Unified Dyskinesia Rating Scale|Mobility State Self-Assessment - Subject Diary Cards,"Adamas Pharmaceuticals, Inc.",All,"30 Years to 85 Years   (Adult, Older Adult)",Phase 3,87,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",OS320-3005,"August 18, 2014","May 20, 2016","May 20, 2016","June 3, 2014","April 2, 2019","February 16, 2022","Tucson, Arizona, United States|Fountain Valley, California, United States|Irvine, California, United States|Pasadena, California, United States|Reseda, California, United States|Ventura, California, United States|Ventura, California, United States|Boulder, Colorado, United States|Hollywood, Florida, United States|Miami, Florida, United States|North Palm Beach, Florida, United States|Tampa, Florida, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Baton Rouge, Louisiana, United States|Ann Arbor, Michigan, United States|Ann Arbor, Michigan, United States|Summit, New Jersey, United States|Brooklyn, New York, United States|Manhasset, New York, United States|Patchogue, New York, United States|Raleigh, North Carolina, United States|Columbus, Ohio, United States|Round Rock, Texas, United States|Orem, Utah, United States|Kirkland, Washington, United States|London, Ontario, Canada|Ottawa, Ontario, Canada|Rennes, Ille-et-Vilaine, France|Amiens, France|Bron, France|Clermont-Ferrand, France|Creteil, France|Lille, France|Marseille, France|Montauban, France|Nimes, France|Paris, France|Poitiers, France|Toulouse, France|Haag, Bayern, Germany|Weissensee, Berlin, Germany|Erbach, Hessen, Germany|Achim, Niedersachsen, Germany|Bochum, Nordrhein-Westfalen, Germany|Berlin, Germany|Berlin, Germany|Wurzburg, Germany|Manresa, Barcelona, Spain|Sevilla, Barcelona, Spain|Alcorcón, Madrid, Spain|Castellana, Madrid, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Pamplona, Spain",NA,https://ClinicalTrials.gov/show/NCT02153645
80,NCT02099383,BUN/Cr-based Hydration Therapy to Improve Outcomes for Dehydrated Patients With Acute Ischemic Stroke.,HYDO,Completed,No Results Available,Stroke|Dehydration,Other: normal saline,rate of stroke-in-evolution|rate of favorable outcome,Chang Gung Memorial Hospital,All,"Child, Adult, Older Adult",Phase 3,244,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CPRPG6D0011,April 2014,July 2020,July 2020,"March 28, 2014",NA,"September 8, 2021","Chang Gung Memorial Hospital, Chiayi, Taiwan",NA,https://ClinicalTrials.gov/show/NCT02099383
81,NCT02091375,Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1),NA,Completed,Has Results,Epilepsy|Dravet Syndrome,Drug: GWP42003-P 20 mg/kg/day Dose|Drug: Placebo control,"Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period|Number Of Participants With A ≥50% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period|Number of Participants With A ≥25%, ≥75% Or 100% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period|Percentage Change From Baseline In Non-Convulsive Seizure Frequency During The Treatment Period|Caregiver Global Impression Of Change In Seizure Duration (CGICSD)|Number Of Participants Using Rescue Medication|Number Of Participants With Inpatient Hospitalizations Due To Epilepsy|Change From Baseline In Sleep Disruption 0 To 10 Numerical Rating Scale (0 to 10 NRS) Score|Change From Baseline In Epworth Sleepiness Scale (ESS) Score|Change From Baseline In Quality Of Life In Childhood Epilepsy (QOLCE) Score|Change From Baseline In Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) Score|Caregiver Global Impression Of Change (CGIC)",Jazz Pharmaceuticals,All,"2 Years to 18 Years   (Child, Adult)",Phase 3,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GWEP1332 Part B|2014-002941-23,"March 30, 2015","November 26, 2015","November 26, 2015","March 19, 2014","July 20, 2018","September 28, 2022","Miami, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Iowa City, Iowa, United States|Boston, Massachusetts, United States|Rochester, Minnesota, United States|New York, New York, United States|Winston-Salem, North Carolina, United States|Columbus, Ohio, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Marseille, France|Paris, France|Strasbourg, France|Toulouse, France|Gdańsk, Poland|Kraków, Poland|Glasgow, United Kingdom|Liverpool, United Kingdom|London, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT02091375
82,NCT02080364,Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease,STEADFAST,Terminated,Has Results,Alzheimer's Disease,Drug: Azeliragon|Drug: Placebo,Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) Total Score|Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-sb)|Change From Baseline in Magnetic Resonance Imaging (MRI) Brain Volumetric Measures|Change From Baseline in the Normalized Mean Composite SUVR of the 5 Regions|Change From Baseline in Alzheimer's Disease Cooperative Study- Activities of Daily Living Inventory (ADCS-ADL)|Change From Baseline in Mini-Mental State Examination (MMSE)|Change From Baseline in Neuropsychiatric Inventory (NPI)|Change From Baseline in Dementia Quality of Life (DEMQOL)|Change From Baseline in Continuous Oral Word Association Task (COWAT)|Change From Baseline in Category Fluency Test (CFT),vTv Therapeutics,All,"50 Years and older   (Adult, Older Adult)",Phase 3,880,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TTP488-301,April 2015,"June 1, 2018","June 1, 2018","March 6, 2014","May 7, 2021","May 7, 2021","Phoenix, Arizona, United States|Phoenix, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Bellflower, California, United States|Costa Mesa, California, United States|Fullerton, California, United States|Glendale, California, United States|Imperial, California, United States|Irvine, California, United States|Laguna Hills, California, United States|Long Beach, California, United States|Long Beach, California, United States|Orange, California, United States|Riverside, California, United States|San Bernardino, California, United States|San Francisco, California, United States|Santa Ana, California, United States|Atlantis, Florida, United States|Brooksville, Florida, United States|Delray Beach, Florida, United States|Hallandale Beach, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Lake Worth, Florida, United States|Leesburg, Florida, United States|Miami Beach, Florida, United States|Miami Lakes, Florida, United States|Miami Lakes, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Pensacola, Florida, United States|Sarasota, Florida, United States|Sunrise, Florida, United States|Atlanta, Georgia, United States|Columbus, Georgia, United States|Chicago, Illinois, United States|Fairway, Kansas, United States|Prairie Village, Kansas, United States|Lexington, Kentucky, United States|Baltimore, Maryland, United States|Newton, Massachusetts, United States|Plymouth, Massachusetts, United States|Quincy, Massachusetts, United States|Hattiesburg, Mississippi, United States|Creve Coeur, Missouri, United States|Princeton, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Lake Success, New York, United States|New York, New York, United States|Staten Island, New York, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Wilmington, North Carolina, United States|Winston-Salem, North Carolina, United States|Canton, Ohio, United States|Shaker Heights, Ohio, United States|Oklahoma City, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Portland, Oregon, United States|Media, Pennsylvania, United States|Norristown, Pennsylvania, United States|Plains, Pennsylvania, United States|East Providence, Rhode Island, United States|East Providence, Rhode Island, United States|Charleston, South Carolina, United States|Mount Pleasant, South Carolina, United States|Cordova, Tennessee, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Wichita Falls, Texas, United States|Murray, Utah, United States|Kirkland, Washington, United States|Richland, Washington, United States|Southport, Queensland, Australia|Caulfield, Victoria, Australia|Geelong, Victoria, Australia|Heidelberg West, Victoria, Australia|Nedlands, Western Australia, Australia|West Perth, Western Australia, Australia|Calgary, Alberta, Canada|Medicine Hat, Alberta, Canada|Kentville, Nova Scotia, Canada|Chatham, Ontario, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Gatineau, Quebec, Canada|Greenfield Park, Quebec, Canada|Cork, Ireland|Dublin 8, Ireland|Galway, Ireland|Christchurch, Canterbury, New Zealand|Christchurch, Canterbury, New Zealand|Cape Town, South Africa|Cape Town, South Africa|Johannesburg, South Africa|St. George, South Africa|Glasgow, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Northampton, United Kingdom|Oxford, United Kingdom|Penarth, United Kingdom|Preston, United Kingdom|Sheffield, United Kingdom|Southhampton, United Kingdom|Swindon, United Kingdom|Warrington, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02080364/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02080364/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02080364
83,NCT02017340,A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease,NILVAD,Completed,No Results Available,Alzheimer's Disease,Drug: Nilvadipine|Drug: Placebo,Alzheimer's Disease Assessment Scale (ADAS) Cog|Clinical Dementia Rating Scale Sum of Boxes (CDR-sb)|Disability Assessment for Dementia (DAD),"Prof Brian Lawlor|University of Dublin, Trinity College|Molecular Medicine Ireland LBG|Alzheimer Europe|Archer Pharmaceuticals, Inc.|E-Search Limited|University College Dublin|King's College London|Istituto Di Ricerche Farmacologiche Mario Negri|University Hospital, Lille|University of Ulm|Szeged University|Göteborg University|University College Cork|Aristotle University Of Thessaloniki|Stichting Katholieke Universiteit|St. James's Hospital, Ireland",All,"50 Years and older   (Adult, Older Adult)",Phase 3,511,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NILVAD2012|2012-002764-27|279093,"April 24, 2013","December 16, 2016","December 16, 2016","December 20, 2013",NA,"March 6, 2017","Centre Hospitalier Universitaire d'Amiens (CHU Amiens), Amiens, France|Centre Hospitalier Universitaire de Bethune (CH Bethune), Bethune, France|Centre Hospitalier Universitaire de Caen (CHU Caen), Caen, France|Centre Hospitalier Universitaire de Calais (CHU Calais), Calais, France|Centre Hospitalier Universitaire de Lens (CHU Lens), Lens, France|Centre Hospitalier Regional et Universitaire de Lille (CHRU Lille), Lille, France|Centre Hospitalier Universitaire de Saint Philibert (GHICL), Lille, France|University of Ulm, Ulm, Germany|""G. Papanicolaou"" Hospital, Athens, Greece|""G.Papageorgiou"" Hospital, Athens, Greece|AXEPA Hospital, Athens, Greece|Szeged University, Szeged, Hungary|University College Cork, Cork, Ireland|St James Hospital, Dublin, Ireland|Hospital of Brescia, Brescia, Italy|Hospital Castellanza, Castellanza, Italy|Hospital of Genoa, Genoa, Italy|Hospital of Milan, Milan, Italy|Hospital of Arnhem, Arnhem, Netherlands|Hospital of Maastricht, Maastricht, Netherlands|Hospital of Nijmegen, Nijmegen, Netherlands|Gothenburg Univeristy, Gothenburg, Sweden|Kings College London, London, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT02017340
84,NCT02006654,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor,STARBRIGHT,Completed,Has Results,Alzheimer's Disease,Drug: Placebo|Drug: Idalopirdine,Change in Cognition|Change in Global Impression|Change in Daily Functioning|Change in Behavioural Disturbance|Change in Individual Behavioural Disturbance Items|Change in NPI Anxiety Item Score in Patients With an NPI Anxiety Item Score of at Least 2 at Baseline|Clinical Improvement|Clinical Worsening|Change in Cognitive Aspects of Mental Function|Change in Health-related Quality of Life (EQ-5D) Utility Score|Change in Health-related Quality of Life (EQ-5D VAS),"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",All,"50 Years and older   (Adult, Older Adult)",Phase 3,734,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",14863A|2012-004765-40,March 2014,January 2017,January 2017,"December 10, 2013","February 7, 2018","February 7, 2018","US612, Mesa, Arizona, United States|US625, Bellflower, California, United States|US626, Costa Mesa, California, United States|US604, Oxnard, California, United States|US627, Santa Ana, California, United States|US609, Danbury, Connecticut, United States|US614, Norwalk, Connecticut, United States|US608, Deerfield Beach, Florida, United States|US616, Hialeah, Florida, United States|US620, Miami, Florida, United States|US603, North Palm Beach, Florida, United States|US631, Port Charlotte, Florida, United States|US622, Elk Grove Village, Illinois, United States|US611, Elkhart, Indiana, United States|US606, Prairie Village, Kansas, United States|US601, Farmington Hills, Michigan, United States|US607, Saint Louis, Missouri, United States|US613, Lawrenceville, New Jersey, United States|US635, Manchester, New Jersey, United States|US630, Toms River, New Jersey, United States|US621, Albany, New York, United States|US632, Staten Island, New York, United States|US633, Charlotte, North Carolina, United States|US623, Oklahoma City, Oklahoma, United States|US618, Norristown, Pennsylvania, United States|US619, Houston, Texas, United States|AU603, Caulfield, Australia|AU609, Glen Iris, Australia|AU602, Heidelberg West, Australia|AU604, Kanwal, Australia|AU606, Newcastle, Australia|AU601, West Perth, Australia|AU610, Woodville south, Australia|BR608, Belo Horizonte, Brazil|BR609, Itapira, Brazil|BR607, Rio de Janeiro, Brazil|CZ602, Chocen, Czechia|CZ608, Chocen, Czechia|CZ605, Havlickuv Brod, Czechia|CZ606, Kladno, Czechia|CZ603, Plzen, Czechia|CZ601, Prague, Czechia|CZ607, Praha 10 - Strasnice, Czechia|CZ604, Praha 6, Czechia|DE612, Bad Homburg, Germany|DE610, Bad Honnef, Germany|DE609, Berlin, Germany|DE617, Berlin, Germany|DE604, Erbach, Germany|DE611, Freiburg, Germany|DE607, Gelsenkirchen, Germany|DE605, Homburg, Germany|DE608, Karlstadt, Germany|DE602, Mittweida, Germany|DE601, Munich, Germany|DE606, Rostock, Germany|DE603, Ulm, Germany|DE616, Unterhaching, Germany|IL605, Bat Yam, Israel|IL601, Haifa, Israel|IL604, Holon, Israel|IL602, Ramat Gan, Israel|IL603, Tel Aviv, Israel|KR601, Seongnam-si, Korea, Republic of|KR602, Seoul, Korea, Republic of|KR603, Seoul, Korea, Republic of|KR604, Seoul, Korea, Republic of|MX602, Mexico, Mexico|MX601, Monterrey, Mexico|MX603, Monterrey, Mexico|MX604, Monterrey, Mexico|MX605, Monterrey, Mexico|MX606, Saltillo, Mexico|RS602, Belgrade, Serbia|RS603, Kragujevac, Serbia|RS601, Novi Sad, Serbia|SG601, Singapore, Singapore|SG602, Singapore, Singapore|SK601, Banska Bystrica, Slovakia|SK603, Bratislava, Slovakia|SK605, Bratislava, Slovakia|SK604, Rimavska Sobota, Slovakia|SK602, Svidnik, Slovakia|ES601, Barcelona, Spain|ES603, Barcelona, Spain|ES604, Barcelona, Spain|ES608, Barcelona, Spain|ES611, Bilbao, Spain|ES612, Burgos, Spain|ES602, Lleida, Spain|ES613, Madrid, Spain|ES610, Sant Cugat del Vallès, Spain|ES606, Sevilla, Spain|ES605, Terrassa, Spain|ES607, Valencia, Spain|CH603, Biel, Switzerland|CH605, Lausanne, Switzerland|CH602, Les Acacias, Switzerland|CH601, Schlieren, Switzerland|TR602, Balova, Turkey|TR601, Istanbul, Turkey|TR603, İstanbul, Turkey|TR605, Istanbul, Turkey|TR606, Izmir, Turkey|TR607, Samsun, Turkey|GB601, Brentford, United Kingdom|GB603, Northampton, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT02006654
85,NCT02006641,Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil,STARBEAM,Completed,Has Results,Alzheimer's Disease,Drug: Placebo|Drug: Idalopirdine,Change in Cognition|Change in Daily Functioning|Change in Global Impression|Change in Behavioural Disturbance|Change in Individual Behavioural Disturbance Items|Change in NPI Anxiety Item Score in Patients With an NPI Anxiety Item Score of at Least 2 at Baseline|Number of Participants With Clinical Improvement|Number of Participants With Clinical Worsening|Change in Cognitive Aspects of Mental Function|Change in Health-related Quality of Life (EQ-5D) Utility Score|Change in Health-related Quality of Life (EQ-5D VAS),"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",All,"50 Years and older   (Adult, Older Adult)",Phase 3,858,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",14862A|2012-004764-22,February 2014,December 2016,December 2016,"December 10, 2013","February 20, 2018","February 20, 2018","US338, Phoenix, Arizona, United States|US342, Fayetteville, Arkansas, United States|US322, Anaheim, California, United States|US305, Carson, California, United States|US346, Costa Mesa, California, United States|US327, Fullerton, California, United States|US315, Lomita, California, United States|US351, Oceanside, California, United States|US307, Redlands, California, United States|US301, Santa Rosa, California, United States|US337, New London, Connecticut, United States|US332, Stamford, Connecticut, United States|US308, Delray Beach, Florida, United States|US320, Hallandale Beach, Florida, United States|US347, Hialeah, Florida, United States|US340, Lake Worth, Florida, United States|US303, Miami, Florida, United States|US313, Miami, Florida, United States|US335, Naples, Florida, United States|US345, Orange City, Florida, United States|US309, Palm Beach Gardens, Florida, United States|US302, Sunrise, Florida, United States|US304, Atlanta, Georgia, United States|US360, Augusta, Georgia, United States|US318, Decatur, Georgia, United States|US334, Lake Charles, Louisiana, United States|US350, Belmont, Massachusetts, United States|US344, Boston, Massachusetts, United States|US310, Saint Paul, Minnesota, United States|US321, Hattiesburg, Mississippi, United States|US330, Creve Coeur, Missouri, United States|US339, Manchester, New Jersey, United States|US312, Staten Island, New York, United States|US316, Charlotte, North Carolina, United States|US336, Winston-Salem, North Carolina, United States|US323, Cincinnati, Ohio, United States|US349, Cleveland, Ohio, United States|US306, Columbus, Ohio, United States|US352, Lakewood, Ohio, United States|US333, Oklahoma City, Oklahoma, United States|US314, Allentown, Pennsylvania, United States|US324, Pittsburgh, Pennsylvania, United States|US341, Pittsburgh, Pennsylvania, United States|US325, Reading, Pennsylvania, United States|US319, Port Royal, South Carolina, United States|US356, Cordova, Tennessee, United States|US343, Fort Worth, Texas, United States|US354, Houston, Texas, United States|AR303, Banfield, Argentina|AR301, Ciudad Autonoma Buenos Aires, Argentina|AR304, Ciudad Autonoma Buenos Aires, Argentina|AR308, Ciudad Autonoma Buenos Aires, Argentina|AR311, Ciudad Autonoma Buenos Aires, Argentina|AR313, Ciudad Autonoma Buenos Aires, Argentina|AR314, Ciudad Autonoma Buenos Aires, Argentina|AR315, Ciudad Autonoma Buenos Aires, Argentina|AR312, Ciudad Autonoma de Buenos Aires, Argentina|AR309, Cordoba, Argentina|AR307, Córdoba, Argentina|AR305, Godoy Cruz, Argentina|AR310, Mendoza, Argentina|AR302, Santa Fe, Argentina|AR306, Santiago del Estero, Argentina|BR307, Curitiba, Brazil|BR309, Curitiba, Brazil|BR301, Rio de Janeiro, Brazil|BR306, Rio de Janeiro, Brazil|BR308, San Paolo, Brazil|CA301, Halifax, Canada|CA302, Kelowna, Canada|CA306, Montreal, Canada|CA304, Qubec, Canada|CA303, Sherbrooke, Canada|CA305, Toronto, Canada|HR304, Zabok, Croatia|HR301, Zagreb, Croatia|HR302, Zagreb, Croatia|HR303, Zagreb, Croatia|CZ305, Brno, Czechia|CZ306, Chocen, Czechia|CZ309, Chocen, Czechia|CZ308, Pardubice, Czechia|CZ310, Praha 10 - Strasnice, Czechia|CZ304, Praha 10, Czechia|CZ307, Praha 2, Czechia|CZ301, Praha 6, Czechia|CZ303, Praha 6, Czechia|CZ302, Rychnov nad Kneznou, Czechia|EE301, Tallinn, Estonia|EE303, Tallin, Estonia|EE302, Tartu, Estonia|FI302, Kuopio, Finland|FI303, Oulu, Finland|FI301, Turku, Finland|FR301, Bordeaux, France|FR308, Bron, France|FR307, Colmar cedex, France|FR304, Dijon, France|FR309, Elancourt, France|FR302, Marseille cedex 5, France|FR303, Nice Cedex 1, France|FR306, Reims, France|FR305, Rouen, France|HU304, Budapest, Hungary|HU305, Budapest, Hungary|HU301, Esztergom, Hungary|HU303, Gyor, Hungary|HU302, Szeged, Hungary|IE301, Cork, Ireland|IL302, Haifa, Israel|IL303, Holon, Israel|IL304, Ramat Gan, Israel|IT306, Brescia, Italy|IT309, Brescia, Italy|IT311, Genova, Italy|IT312, Monza, Italy|IT302, Naples, Italy|IT313, Palermo, Italy|IT307, Perugia, Italy|IT301, Pisa, Italy|IT305, Roma, Italy|IT308, Roma, Italy|IT304, Torino, Italy|IT310, Torrette, Italy|KR303, Busan, Korea, Republic of|KR301, Incheon, Korea, Republic of|KR308, Seongnam-si, Korea, Republic of|KR302, Seoul, Korea, Republic of|KR304, Seoul, Korea, Republic of|KR305, Seoul, Korea, Republic of|KR306, Seoul, Korea, Republic of|KR307, Seoul, Korea, Republic of|KR309, Seoul, Korea, Republic of|LT302, Kaunas, Lithuania|LT303, Kaunas, Lithuania|LT301, Vilnius, Lithuania|LT304, Vilnius, Lithuania|PL301, Bialystok, Poland|PL304, Bydgoszcz, Poland|PL308, Gdynia, Poland|PL309, Krakow, Poland|PL302, Lodz, Poland|PL310, Lubin, Poland|PL306, Lublin, Poland|PL307, Oswiecim, Poland|PL303, Poznan, Poland|PT301, Amadora, Portugal|PT302, Coimbra, Portugal|TW301, Kaohsiung, Taiwan|TW302, Kaohsiung, Taiwan|TW303, Taichung, Taiwan|TW304, Taipei, Taiwan|TW305, Taipei, Taiwan|GB307, Amersham, United Kingdom|GB301, Glasgow, United Kingdom|GB303, London, United Kingdom|GB308, London, United Kingdom|GB306, Plymouth, United Kingdom|GB305, Preston, United Kingdom|GB304, Southampton, United Kingdom|GB302, Swindon, United Kingdom|GB309, Warrington, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT02006641
86,NCT01994720,[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES],SOCRATES,Completed,Has Results,Acute Ischaemic Stroke|Transient Ischaemic Attack,Drug: ticagrelor|Drug: Acetylsalicylic acid (ASA),"Number of Participants With Composite of Stroke/MI/Death|Number of Participants With Ischaemic Stroke|Net Clinical Outcome|Number of Participants With Composite of Ischaemic Stroke, MI and CV Death|Number of Participants With All-Cause Death|Number of Participants With CV Death|Number of Participants With MI|Number of Participants by Severity of Stroke and Overall Disability|Number of Participants With Stroke|Number of Participants With Fatal Stroke|Number of Participants With Disabling Stroke|Change in NIHSS|EQ-5D at Visit 1 (Enrolment)|EQ-5D at Visit 2 (Day 7+-2d)|EQ-5D (EuroQol Five Dimensions Questionnaire) at End of Treatment Visit|EQ-5D (EuroQol Five Dimensions Questionnaire) at Premature Treatment Discontinuation Visit|Number of Participants With PLATO Major Bleeding Event|Number of Participants With Premature Discontinuation of Study Drug Due to Any Bleeding Adverse Event",AstraZeneca,All,"40 Years to 130 Years   (Adult, Older Adult)",Phase 3,13307,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",D5134C00001|2012-003895-38,"January 7, 2014","March 2, 2016","March 2, 2016","November 26, 2013","June 12, 2017","June 12, 2017","Research Site, Montgomery, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Fayetteville, Arkansas, United States|Research Site, Fort Smith, Arkansas, United States|Research Site, Fullerton, California, United States|Research Site, Glendale, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport, California, United States|Research Site, Oakland, California, United States|Research Site, San Diego, California, United States|Research Site, Stanford, California, United States|Research Site, Torrance, California, United States|Research Site, Englewood, Colorado, United States|Research Site, Altamonte Springs, Florida, United States|Research Site, Aventura, Florida, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Bradenton, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lakeland, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Pompano Beach, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Weston, Florida, United States|Research Site, Columbus, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Glenview, Illinois, United States|Research Site, Harvey, Illinois, United States|Research Site, Joliet, Illinois, United States|Research Site, Park Ridge, Illinois, United States|Research Site, Springfield, Illinois, United States|Research Site, Urbana, Illinois, United States|Research Site, Anderson, Indiana, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Des Moines, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, Alexandria, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Annapolis, Maryland, United States|Research Site, Frederick, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Royal Oak, Michigan, United States|Research Site, Southfield, Michigan, United States|Research Site, West Bloomfield Township, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Robbinsdale, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Bridgeton, Missouri, United States|Research Site, Columbia, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Great Falls, Montana, United States|Research Site, Helena, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Bayonne, New Jersey, United States|Research Site, Edison, New Jersey, United States|Research Site, Englewood, New Jersey, United States|Research Site, Flemington, New Jersey, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Ridgewood, New Jersey, United States|Research Site, West Orange, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, New York, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Syracuse, New York, United States|Research Site, The Bronx, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Maumee, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Clackamas, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Abington, Pennsylvania, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Baytown, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Harlingen, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, Southlake, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Roanoke, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Huntington, West Virginia, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Buenos Aires, Argentina|Research Site, Capital Federal, Argentina|Research Site, Ciudad Autónoma de Bs. As., Argentina|Research Site, Mar del Plata, Argentina|Research Site, Rosario, Argentina|Research Site, San Martin, Argentina|Research Site, Adelaide, Australia|Research Site, Bedford Park, Australia|Research Site, Camperdown, Australia|Research Site, Clayton, Australia|Research Site, Darlinghurst, Australia|Research Site, Footscray, Australia|Research Site, Herston, Australia|Research Site, New Lambton Heights, Australia|Research Site, Parkville, Australia|Research Site, Southport, Australia|Research Site, Sydney, Australia|Research Site, Woodville, Australia|Research Site, Aalst, Belgium|Research Site, Assebroek, Belgium|Research Site, Brugge, Belgium|Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Gent, Belgium|Research Site, Godinne, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Tielt, Belgium|Research Site, Wilrijk, Belgium|Research Site, Botucatu, Brazil|Research Site, Curitiba, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirao Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Salvador, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Botevgrad, Bulgaria|Research Site, Dupnitsa, Bulgaria|Research Site, Gotse Delchev, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Lukovit, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Pernik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Teteven, Bulgaria|Research Site, Yambol, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, London, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Thunder Bay, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Concepcion, Chile|Research Site, Los Angeles, Chile|Research Site, Santiago, Chile|Research Site, Talcahuano, Chile|Research Site, Temuco, Chile|Research Site, Valdivia, Chile|Research Site, Viña del Mar, Chile|Research Site, Baotou, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chongqin, China|Research Site, Guang Zhou, China|Research Site, Guangzhou, China|Research Site, Guilin, China|Research Site, Haikou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Huai'an, China|Research Site, Jinan, China|Research Site, Lanzhou, China|Research Site, Linhai, China|Research Site, Nanjing, China|Research Site, Ningbo, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Taiyuan, China|Research Site, Tianjin, China|Research Site, Wenzhou, China|Research Site, Wu Han, China|Research Site, Xi'an, China|Research Site, Xiamen, China|Research Site, Yangzhou, China|Research Site, Zhanjiang, China|Research Site, Brno, Czechia|Research Site, Chomutov, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jihlava, Czechia|Research Site, Liberec, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 2, Czechia|Research Site, Trutnov, Czechia|Research Site, Antony, France|Research Site, Bayonne, France|Research Site, Bordeaux Cedex, France|Research Site, Bourg en Bresse, France|Research Site, Brest Cedex 2, France|Research Site, Bron, France|Research Site, Caen, France|Research Site, Corbeil Essonnes Cedex, France|Research Site, Creteil, France|Research Site, Dijon, France|Research Site, La Roche sur Yon, France|Research Site, Le Chesnay Cedex, France|Research Site, Le Coudray Cedex, France|Research Site, Lille, France|Research Site, NICE Cedex 01, France|Research Site, PARIS Cedex 12, France|Research Site, Paris Cedex 13, France|Research Site, Paris Cedex 18, France|Research Site, Paris, France|Research Site, Pringy Cedex, France|Research Site, Rennes, France|Research Site, Rouen Cedex, France|Research Site, Saint Herblain, France|Research Site, Saint-priest En Jarez, France|Research Site, Strasbourg Cedex, France|Research Site, Toulouse, France|Research Site, Tours, France|Research Site, Altenburg, Germany|Research Site, Bad Neustadt, Germany|Research Site, Berlin, Germany|Research Site, Erlangen, Germany|Research Site, Essen, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Karlsruhe, Germany|Research Site, Kassel, Germany|Research Site, Minden, Germany|Research Site, Münster, Germany|Research Site, Osnabrück, Germany|Research Site, Wiesbaden, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Hongkong, Hong Kong|Research Site, Kowloon, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Balassagyarmat, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Győr, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Miskolc, Hungary|Research Site, Nagykanizsa, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pécs, Hungary|Research Site, Sopron-Balf, Hungary|Research Site, Szekszárd, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Petach Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Tel Aviv, Israel|Research Site, Carrara, Italy|Research Site, Citta' di Castello, Italy|Research Site, Foligno, Italy|Research Site, Genova, Italy|Research Site, Gubbio, Italy|Research Site, Lecco, Italy|Research Site, Milano, Italy|Research Site, Modena, Italy|Research Site, Pavia, Italy|Research Site, Perugia, Italy|Research Site, Piacenza, Italy|Research Site, Pisa, Italy|Research Site, Reggio Emilia, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Siena, Italy|Research Site, Varese, Italy|Research Site, Verona, Italy|Research Site, Vibo Valentia, Italy|Research Site, Aki-gun, Japan|Research Site, Asahikawa-shi, Japan|Research Site, Chiba-shi, Japan|Research Site, Chikushi-gun, Japan|Research Site, Chikushino-shi, Japan|Research Site, Chitose-shi, Japan|Research Site, Daito-shi, Japan|Research Site, Date-gun, Japan|Research Site, Eniwa-shi, Japan|Research Site, Fujinomiya-shi, Japan|Research Site, Fukui-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukushima-shi, Japan|Research Site, Fukuyama-shi, Japan|Research Site, Gifu-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Hakodate-shi, Japan|Research Site, Hamada-shi, Japan|Research Site, Hanamaki-shi, Japan|Research Site, Hatsukaichi-shi, Japan|Research Site, Hidaka-shi, Japan|Research Site, Higashiibaraki-gun, Japan|Research Site, Higashiosaka-shi, Japan|Research Site, Hitachi-shi, Japan|Research Site, Ina-shi, Japan|Research Site, Itami-shi, Japan|Research Site, Izumisano-shi, Japan|Research Site, Izumo-shi, Japan|Research Site, Kaga-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kakegawa-shi, Japan|Research Site, Kamakura-shi, Japan|Research Site, Kashiwazaki-shi, Japan|Research Site, Kasuga-shi, Japan|Research Site, Kawasaki-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Kochi-shi, Japan|Research Site, Koga-shi, Japan|Research Site, Komatsu-shi, Japan|Research Site, Komoro-shi, Japan|Research Site, Koshigaya-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kure-shi, Japan|Research Site, Kurume-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Maizuru-shi, Japan|Research Site, Marugame-shi, Japan|Research Site, Matsudo-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagano-shi, Japan|Research Site, Nagasaki-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nakano-ku, Japan|Research Site, Nakano-shi, Japan|Research Site, Narita-shi, Japan|Research Site, Nihonmatsu-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Okinawa-shi, Japan|Research Site, Onga-gun, Japan|Research Site, Ookawa-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Saga-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Saijo-shi, Japan|Research Site, Sakai-shi, Japan|Research Site, Sanuki-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sayama-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shiroishi-shi, Japan|Research Site, Shizuoka-shi, Japan|Research Site, Suita-shi, Japan|Research Site, Suwa-shi, Japan|Research Site, Tachikawa-shi, Japan|Research Site, Takasaki-shi, Japan|Research Site, Takayama-shi, Japan|Research Site, Tokushima-shi, Japan|Research Site, Toyama-shi, Japan|Research Site, Toyohashi-shi, Japan|Research Site, Toyota-shi, Japan|Research Site, Tsu-shi, Japan|Research Site, Ube-shi, Japan|Research Site, Ueda-shi, Japan|Research Site, Uji-shi, Japan|Research Site, Ureshino-shi, Japan|Research Site, Utsunomiya-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Zentsuji-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of|Research Site, Aguascalientes, Mexico|Research Site, Culiacan, Mexico|Research Site, D.F, Mexico|Research Site, Del. Cuauhtemoc, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Monterrey, Mexico|Research Site, Bellavista, Peru|Research Site, Callao, Peru|Research Site, Cusco, Peru|Research Site, Lima, Peru|Research Site, Baguio City, Philippines|Research Site, Cagayan de Oro City, Philippines|Research Site, Cebu, Philippines|Research Site, Iloilo City, Philippines|Research Site, Manila, Philippines|Research Site, Pasay City, Philippines|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Białystok, Poland|Research Site, Chełm, Poland|Research Site, Działdowo, Poland|Research Site, Gdańsk, Poland|Research Site, Gryfice, Poland|Research Site, Katowice, Poland|Research Site, Kielce, Poland|Research Site, Końskie, Poland|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, Olsztyn, Poland|Research Site, Ostrołęka, Poland|Research Site, Sandomierz, Poland|Research Site, Warszawa, Poland|Research Site, Włocławek, Poland|Research Site, Łódź, Poland|Research Site, Bucharest, Romania|Research Site, Iasi, Romania|Research Site, Oradea, Romania|Research Site, Sibiu, Romania|Research Site, Timisoara, Romania|Research Site, Tirgu-Mures, Romania|Research Site, Belgorod, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Irkutsk, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Levoca, Slovakia|Research Site, Martin, Slovakia|Research Site, Nitra, Slovakia|Research Site, Spisska Nova Ves, Slovakia|Research Site, Trnava, Slovakia|Research Site, Zilina, Slovakia|Research Site, Albacete, Spain|Research Site, Badalona(Barcelona), Spain|Research Site, Barcelona, Spain|Research Site, Gerona, Spain|Research Site, Lleida, Spain|Research Site, Madrid, Spain|Research Site, Pamplona, Spain|Research Site, Santiago(A Coruña), Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valladolid, Spain|Research Site, Falun, Sweden|Research Site, Göteborg, Sweden|Research Site, Halmstad, Sweden|Research Site, Karlstad, Sweden|Research Site, Lidköping, Sweden|Research Site, Linköping, Sweden|Research Site, Malmö, Sweden|Research Site, Mora, Sweden|Research Site, Norrköping, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Västerås, Sweden|Research Site, Östersund, Sweden|Research Site, Aarau, Switzerland|Research Site, Basel, Switzerland|Research Site, Bern, Switzerland|Research Site, Chur, Switzerland|Research Site, Genève 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Lugano, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Villars-sur-Glâne, Switzerland|Research Site, Zürich, Switzerland|Research Site, Changhua City, Taiwan|Research Site, Chiayi, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan Hsien, Taiwan|Research Site, Bangkok, Thailand|Research Site, Chonburi, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Muang, Thailand|Research Site, Patumthani, Thailand|Research Site, Rajthevi, Thailand|Research Site, Ratchathewi, Thailand|Research Site, Ankara, Turkey|Research Site, Antalya, Turkey|Research Site, Eskisehir, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Konya, Turkey|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh City, Vietnam|Research Site, Hochiminh, Vietnam",NA,https://ClinicalTrials.gov/show/NCT01994720
87,NCT01973205,Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine,NA,Completed,Has Results,Acute Migraine,Drug: Acetaminophen 250 mg and Aspirin 250 mg|Drug: Placebo,Number of Subjects Who Are Pain Free at the 2-hour Assessment|Number of Subjects Who Are Nausea Free at the 2-hour Assessment|Number of Subjects Who Are Free of Photophobia at the 2-hour Assessment.|Number of Subjects Who Are Free of Phonophobia at the 2-hour Assessment.,Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 3,900,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",863-P-303,October 2013,July 2014,July 2014,"October 31, 2013","June 11, 2015","June 11, 2015","Birmingham, Alabama, United States|Anaheim, California, United States|San Francisco, California, United States|Ft Lauderdale, Florida, United States|Jupiter, Florida, United States|Oviedo, Florida, United States|West Palm Beach, Florida, United States|Evansville, Indiana, United States|Ann Arbor, Michigan, United States|Berlin, New Jersey, United States|Bronx, New York, United States|Rochester, New York, United States|Williamsville, New York, United States|Raleigh, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Mount Pleasant, South Carolina, United States|Salt Lake City, Utah, United States|Kenosha, Wisconsin, United States",NA,https://ClinicalTrials.gov/show/NCT01973205
88,NCT01968460,"Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease",NA,Completed,Has Results,Parkinson's Disease,"Drug: P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),|Drug: Placebo|Drug: P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),","Total UPDRS I, II, III Scores|UPDRS ADL (Part II)|CGI-S|UPDRS Motor (Part III)|PDQ39",Pharma Two B Ltd.,All,"35 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,149,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",P2B001/001,December 2013,May 2015,June 2015,"October 24, 2013","April 7, 2023","April 7, 2023","P2B001 Site Birmingham, Birmingham, Alabama, United States|P2B001 Site Los Angeles, Los Angeles, California, United States|P2B001 Site Aurora, Aurora, Colorado, United States|P2B001 Manchester, Manchester, Connecticut, United States|P2B001 Site New Haven, New Haven, Connecticut, United States|P2B001 Site Boca Raton, Boca Raton, Florida, United States|P2B001 Site Port Charlotte, Port Charlotte, Florida, United States|P2B001 Site Tampa, Tampa, Florida, United States|P2B001 Site Augusta, Augusta, Georgia, United States|P2B001 site Chicago, Chicago, Illinois, United States|P2B001 Site Kansas City, Kansas City, Kansas, United States|P2B001 Site Boston, Boston, Massachusetts, United States|P2B001 Site west Bloomfield, West Bloomfield, Michigan, United States|P2B001 Site Golden Valley, Golden Valley, Minnesota, United States|P2B001 Site Camden, Camden, New Jersey, United States|P2B001 Site New Brunswick, New Brunswick, New Jersey, United States|P2B001 site Commack, Commack, New York, United States|P2B001 Site New York, New York, New York, United States|P2B001 Site Durham, Durham, North Carolina, United States|P2B001 Site Cincinnati, Cincinnati, Ohio, United States|P2B001 Site Toledo, Toledo, Ohio, United States|P2B001 Site Tulsa, Tulsa, Oklahoma, United States|P2B001 Site Houston, Houston, Texas, United States|P2B001 Site Roanoke, Roanoke, Virginia, United States|P2B001 Site Rambam Israel, Haifa, Israel|P2B001 Site Belinson, Pethch Tikva, Israel|P2B001 Site Sheba Medical Center, Ramat Gan, Israel|P2B001 Site Asaf Harofe, Rishon LeZion, Israel|P2B001 Site Sourasky Medical Center, Tel Aviv, Israel",NA,https://ClinicalTrials.gov/show/NCT01968460
89,NCT01963208,Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension,NA,Completed,Has Results,Drug Resistant Partial Onset Seizure,Drug: ganaxolone|Drug: Placebo,"Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period|Double Blind: Cohort 2: Number of Participants With ≥50% Responder Rate During Titration + Maintenance Period|Double Blind: Cohort 2: Change From Baseline in the Number of Seizure Free Days Per 28-day Period During Titration + Maintenance Period|Double Blind: Cohort 2: Number of Participants With Clinical Global Impression of Change - Improvement (CGI-I) at Week 14|Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Maintenance Period|Double Blind: Cohort 2: Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period|Double Blind: Cohort 2: Change From Baseline in 28-day Seizure Frequency During Maintenance Period|Double Blind: Cohort 2: Change From Baseline in the Number of Seizure Free Days Per 28-day Period During Maintenance Period|Double Blind: Cohort 2: Percentage of Responders Experiencing a ≥R% (80%, 60%, 40%, and 20%) Reduction From Baseline to the End of Treatment Period in 28-day Seizure Frequency During Titration + Maintenance Period|Double Blind: Cohort 2: Percentage of Responders Experiencing a ≥R% (80%, 60%, 40%, and 20%) Reduction From Baseline to the End of Treatment Period in 28-day Seizure Frequency During Maintenance Period|Double Blind: Cohort 2: Percentage of Seizure Free Participants During the Maintenance Period|Double Blind: Cohort 2: Percentage of Participants Who Experienced at Least One 28-day Seizure Free Period During Titration + Maintenance Phase|Double Blind: Cohort 2: Longest Percent of Time Spent Seizure-free During Titration + Maintenance Period|Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency for Different Subtypes of Seizures During Titration + Maintenance Period|Double Blind: Cohort 2: Number of Participants With Patient Global Impression of Change - Improvement (PGI-I) at Week 8 and Week 14|Double Blind: Cohort 2: Number of Participants With Clinical Global Impression of Change - Improvement (CGI-I) at Week 8",Marinus Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,405,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1042-0603,October 2013,May 2016,October 2016,"October 16, 2013","February 14, 2023","February 14, 2023","University of Alabama Epilepsy Center, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Xenoscience Inc., Phoenix, Arizona, United States|The MORE Foundation, Sun City, Arizona, United States|Clinical Trials Inc., Little Rock, Arkansas, United States|Neuro-Pain Medical Center, Inc, Fresno, California, United States|Neurological Research Institute, Santa Monica, California, United States|University of Colorado- Anschutz Outpatient Pavilion, Aurora, Colorado, United States|Neuroscience Consulants, Miami, Florida, United States|Medsol Clinical Research Center, Port Charlotte, Florida, United States|Consultants in Epilepsy & Neurology, Boise, Idaho, United States|Bluegrass Epilepsy Research, LLC, Lexington, Kentucky, United States|Mid-Atlantic Epilepsy Center, Bethesda, Maryland, United States|Bringham and Women's Hospital, Boston, Massachusetts, United States|Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States|The Comprehensive Epilepsy Care Center for Children and Adults, Chesterfield, Missouri, United States|Cooper Medical Center of Rowan University, Camden, New Jersey, United States|Northeast Regional Epilepsy Group, Hackensack, New Jersey, United States|Five Towns Neuroscience Research, Cedarhurst, New York, United States|Northeast Regional Epilepsy Group, Middletown, New York, United States|Winthrop University Hospital, Mineola, New York, United States|New York University Comprehensive Epilepsy Center, New York, New York, United States|Northeast Regional Epilepsy Group, New York, New York, United States|Wake Forest Health Sciences, Winston-Salem, North Carolina, United States|Ohio Clinical Research Partners, LLC, Canton, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Lynn Health Institute, Oklahoma City, Oklahoma, United States|Sooner Clinical Research, Oklahoma City, Oklahoma, United States|Jefferson Comprehensive Epilepsy Center, Philadelphia, Pennsylvania, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|Neurology Consultants of Dallas, Dallas, Texas, United States|Texas Epilepsy Group, Dallas, Texas, United States|Rainier Clinical Research Center, Inc., Renton, Washington, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|The Prince of Wales Hospital, Randwick, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Flinders Medical Center, Bedford Park, South Australia, Australia|St. Vincent's Hospital, Fitzroy, Victoria, Australia|The Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, Australia|The Royal Melbourne Hospital, Parkville, Victoria, Australia|MHAT, Blagoevgrad, Bulgaria|UMHAT Dr. Georgi Stranski Clinic of Neurology, Pleven, Bulgaria|Medical Centre-Teodora, Ruse, Bulgaria|Medical Center Excelsior 4, Sofia, Bulgaria|SHATNP, Sofia, Bulgaria|MHAT Lyulin Department of Neurology, Sofia, Bulgaria|UMHAT Alexandrovska Clinic of Nerve Diseases, Sofia, Bulgaria|Medical Center Ekvita Ltd, Varna, Bulgaria|Epilepsieklinik, Bernau, Germany|Krankenhaus Mara Epilepsie-Zentrum, Bielefeld, Germany|Klinik fur Epileptologie, Bonn, Germany|Neuro-Consil, Dussseldorf, Germany|Universitatsklinikum GieBen und Marburg, Marburg, Germany|Universitatsklin Kum Ulm, Ulm, Germany|Novo-Med, Jaworowa, Poland|Centrum Medycne Dendryt, Katowice, Poland|Indywidualna Praktyka ul Narutowicza, Lublin, Poland|Wojewodzki Szpital Specjalistyczny Oddzial, Lublin, Poland|Fundacja Epileptologii Wiertnicza, Warszawa, Poland|Instytut Psychiatrii i Neurologii, Warszawa, Poland|Kazan State Medical University, Kazan, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhniy Novgorod, Russian Federation|Novosibirsk, Russian Federation|City Neurological Center, Novosibirsk, Russian Federation|Saint Petersburg, Russian Federation|Saint Petersburg, Russian Federation|Saint Petersburg, Russian Federation|Samara, Russian Federation|Yaroslavl, Russian Federation","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT01963208/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT01963208/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01963208
90,NCT01955161,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil,STARSHINE,Completed,Has Results,Alzheimer's Disease,Drug: Placebo|Drug: Idalopirdine,Change in Cognition|Change in Daily Functioning|Change in Global Impression|Change in Behavioural Disturbance|Change in Individual Behavioural Disturbance Items|Change in NPI Anxiety Item Score in Patients With an NPI Anxiety Item Score of at Least 2 at Baseline|Clinical Improvement|Clinical Worsening|Change in Cognitive Aspects of Mental Function|Change in Health-related Quality of Life (EQ-5D) Utility Score|Change in Health-related Quality of Life (EQ-5D VAS),"H. Lundbeck A/S|Otsuka Pharmaceutical Co., Ltd.",All,"50 Years and older   (Adult, Older Adult)",Phase 3,933,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",14861A|2012-004763-45,October 2013,July 2016,July 2016,"October 7, 2013","September 19, 2017","September 19, 2017","US027, Birmingham, Alabama, United States|US012, Phoenix, Arizona, United States|US024, Little Rock, Arkansas, United States|US053, Glendale, California, United States|US023, Imperial, California, United States|US015, La Jolla, California, United States|US045, Long Beach, California, United States|US002, Los Angeles, California, United States|US058, San Francisco, California, United States|US018, Santa Ana, California, United States|US060, Denver, Colorado, United States|US042, Boca Raton, Florida, United States|US021, Bradenton, Florida, United States|US050, Brooksville, Florida, United States|US019, Orlando, Florida, United States|US038, Port Charlotte, Florida, United States|US001, West Palm Beach, Florida, United States|US020, Atlanta, Georgia, United States|US048, Kailua, Hawaii, United States|US030, Chicago, Illinois, United States|US051, Joliet, Illinois, United States|US040, Indianapolis, Indiana, United States|US036, Freeport, Maine, United States|US032, Newton, Massachusetts, United States|US035, Kalamazoo, Michigan, United States|US041, Flowood, Mississippi, United States|US054, Saint Louis, Missouri, United States|US046, Princeton, New Jersey, United States|US028, Toms River, New Jersey, United States|US044, Toms River, New Jersey, United States|US049, Albany, New York, United States|US010, Amherst, New York, United States|US014, Manhasset, New York, United States|US008, New York, New York, United States|US029, New York, New York, United States|US056, New York, New York, United States|US037, Orangeburg, New York, United States|US043, Staten Island, New York, United States|US007, Centerville, Ohio, United States|US006, Columbus, Ohio, United States|US052, Edmond, Oklahoma, United States|US026, Portland, Oregon, United States|US057, Jenkintown, Pennsylvania, United States|US047, Arlington, Virginia, United States|US025, Madison, Wisconsin, United States|US004, Milwaukee, Wisconsin, United States|AR002, Buenos Aires, Argentina|AR003, Buenos Aires, Argentina|AR006, Buenos Aires, Argentina|AR007, Buenos Aires, Argentina|AR009, Cordoba, Argentina|AR004, Mar del Plata, Argentina|AR005, Mendoza, Argentina|AR008, Mendoza, Argentina|AR010, Rosario, Argentina|BE003, Brugge, Belgium|BE002, Brussels, Belgium|BE004, Bruxelles, Belgium|BE005, Leuven, Belgium|BE001, Roeselare, Belgium|BE006, Thuin, Belgium|BG005, Plovdiv, Bulgaria|BG001, Sofia, Bulgaria|BG002, Sofia, Bulgaria|BG003, Sofia, Bulgaria|BG004, Sofia, Bulgaria|BG006, Sofia, Bulgaria|BG007, Varna, Bulgaria|CA002, Gatineau, Canada|CA006, London, Canada|CA008, Newmarket, Canada|CA001, Toronto, Canada|CA004, Toronto, Canada|CL004, Antofagasta, Chile|CL002, Santiago, Chile|CL003, Santiago, Chile|CL005, Santiago, Chile|CL001, Valdivia, Chile|CZ006, Brno, Czechia|CZ007, Kutna Hora, Czechia|CZ004, Pardubice, Czechia|CZ003, Praha 10, Czechia|CZ001, Praha 2, Czechia|CZ002, Praha 6, Czechia|CZ005, Rychnov nad Kneznou, Czechia|DK003, Aarhus N, Denmark|DK001, Copenhagen, Denmark|DK002, Odense C, Denmark|FR006, Besancon Cedex, France|FR008, Limoges Cedex1, France|FR003, Nantes Cedex, France|FR005, Paris cedex 10, France|FR001, Paris, France|FR004, Saint Etienne Cedex 2, France|FR002, Toulouse, France|DE002, Berlin, Germany|DE006, Ellwangen, Germany|DE010, Günzburg, Germany|DE005, Hannover, Germany|DE007, Heidelberg, Germany|DE009, Munchen, Germany|DE008, Ulm, Germany|DE004, Unterhaching, Germany|IT004, Ancona, Italy|IT006, Brescia, Italy|IT002, Firenze, Italy|IT005, Genoa, Italy|IT003, Lamezia Terme, Italy|IT001, Milano, Italy|IT007, Palermo, Italy|PL004, Gliwice, Poland|PL007, Katowice, Poland|PL005, Poznan, Poland|PL006, Sopot, Poland|PL002, Szczecin, Poland|PL003, Warszawa, Poland|PL008, Wroclaw, Poland|RO002, Bucharest, Romania|RO001, Tirgu Mures, Romania|ZA003, Bloemfontein, South Africa|ZA006, Cape Town, South Africa|ZA007, Cape Town, South Africa|ZA004, George, South Africa|ZA005, Port Elizabeth, South Africa|ZA001, Pretoria, South Africa|ZA002, Rosebank, South Africa|ES002, Alicante, Spain|ES006, Barcelona, Spain|ES005, Manresa, Spain|ES004, Salamanca, Spain|ES001, San Sebastian, Spain|ES003, Santiago de Compostela, Spain|UA008, Dnipropetrovsk, Ukraine|UA006, Kherson,Vil. Stepanivka, Ukraine|UA005, Kyiv, Ukraine|UA007, Kyiv, Ukraine|UA001, Lviv, Ukraine",NA,https://ClinicalTrials.gov/show/NCT01955161
91,NCT01953601,Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019),APECS,Terminated,Has Results,Amnestic Mild Cognitive Impairment|Alzheimer's Disease|Prodromal Alzheimer's Disease,Drug: Verubecestat 12 mg (Parts 1 and 2)|Drug: Verubecestat 40 mg (Parts 1 and 2)|Other: Placebo (Part 1),Part 1 (Base Study). Least Squares Mean (LSM) Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 104|Part 2 (Extension Study). Mean Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 130|Part 1 (Base Study). Percentage of Participants Who Experienced ≥1 Adverse Event (AE)|Part 1 (Base Study). Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event (AE)|Part 2 (Extension Study). Percentage of Participants Who Experienced ≥1 Adverse Event (AE)|Part 2 (Extension Study). Percentage of Participants Who Discontinued From Study Drug Due to an Adverse Event (AE)|Part 1 (Base Study). Event-Rate Per 100 Participant Years for Progression to a Clinical Diagnosis of Probable AD Dementia|Part 1 (Base Study). Estimated Least Squares Mean Difference Between the Last (Week 104) and First (Week 13) Post-dose CDR-SB Assessment|Part 1 (Base Study). Least Squares Mean Change From Baseline in the 3-Domain Composite Cognition Score (CCS-3D) at Week 104|Part 1 (Base Study). Least Squares Mean Percent Change From Baseline in Total Hippocampal Volume (THV) at Week 104|Part 1 (Base Study). Least Squares Mean Change From Baseline in Composite Cortical Amyloid Standard Uptake Value Ratio (SUVR) Assessed With Amyloid Tracer [18F]Flutemetamol Using Positron Emission Tomography (PET) Imaging at Week 104|Part 1 (Base Study). Least Squares Mean Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment Version) (ADCS-ADL MCI) Score at Week 104|Part 1 (Base Study). Mean Percent Change From Baseline in Cerebrospinal Fluid (CSF) Total Tau Concentration at Week 104,Merck Sharp & Dohme LLC,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,1454,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",8931-019|2012-005542-38|142502|MK-8931-019,"November 5, 2013","April 17, 2018","April 17, 2018","October 1, 2013","May 17, 2019","May 17, 2019",NA,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT01953601/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01953601
92,NCT01939314,Sphenopalatine Nerve Block for Headache Tx360,NA,Completed,Has Results,Headache|Migraine,Drug: Bupivacaine|Drug: Placebo,Number of Participants Who Reported a 50% or Greater Reduction in Pain at 15 Minutes as Measured on the 100mm Visual Analog Scale|Categorical Pain Relief|Headache Free at 24 Hours,Indiana University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,93,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",TX 360 HA -Schaffer|Tian Medical Inc.,October 2012,December 2013,December 2013,"September 11, 2013","July 27, 2015","July 27, 2015","Indiana University, Indianapolis, Indiana, United States",NA,https://ClinicalTrials.gov/show/NCT01939314
93,NCT01922258,Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type,NA,Completed,Has Results,Agitation Associated With|Alzheimer's Disease|Alzheimer's Type|Mental Disorder|Nervous System Diseases,"Drug: Brexpiprazole, OPC-34712","Change From Baseline to Week 12/Early Termination in the Cohen-Mansfield Agitation Inventory (CMAI) Total Score|Change in the Clinical Global Impression Severity of Illness (CGI-S) Score, as Related to Symptoms of Agitation","Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S",All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 3,270,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",331-12-284,September 2013,March 2017,March 2017,"August 14, 2013","July 7, 2020","November 20, 2020","Imperial, California, United States|Lakewood, California, United States|Long Beach, California, United States|Long Beach, California, United States|Panorama City, California, United States|Universal City, California, United States|Denver, Colorado, United States|Bradenton, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Orange City, Florida, United States|Atlanta, Georgia, United States|Smyrna, Georgia, United States|Honolulu, Hawaii, United States|Indianapolis, Indiana, United States|Quincy, Massachusetts, United States|South Dartmouth, Massachusetts, United States|Ann Arbor, Michigan, United States|Brooklyn, New York, United States|Buffalo, New York, United States|New Hyde Park, New York, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Austin, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Woodstock, Vermont, United States|Burgas, Bulgaria|Kardzhali, Bulgaria|Pazardzhik, Bulgaria|Ruse, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Veliko Tarnovo, Bulgaria|Penticton, British Columbia, Canada|Kentville, Canada|Kuopio, Finland|Turku, Finland|Bourg en Bresse, France|Douai, France|Elancourt, France|Limoges, France|Nice, France|Toulouse, France|Tonnel'nyy, Stavropol Region, Russian Federation|Ekaterinburg, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Ljubljana, Slovenia|Maribor, Slovenia|Sempeter pri Gorici, Slovenia|Donetsk, Ukraine|Kharkiv, Ukraine|Kharkov, Ukraine|Kherson, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Poltava, Ukraine|Simferopol, Ukraine|Vinnytsia, Ukraine|Crewe, United Kingdom|Manchester, United Kingdom|Margate, United Kingdom|Torpoint, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT01922258/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT01922258/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01922258
94,NCT01872598,Masitinib in Patients With Mild to Moderate Alzheimer's Disease,NA,Completed,No Results Available,Alzheimer Disease,Drug: Masitinib|Drug: Placebo|Drug: Standard of care,ADCS-ADL|ADAS-Cog|MMSE|CIBIC-plus,AB Science,All,"50 Years and older   (Adult, Older Adult)",Phase 3,721,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AB09004,January 2012,December 2020,December 2020,"June 7, 2013",NA,"February 13, 2023","MHAT Sveta Marina, Varna, Bulgaria|General Hospital of Thessaloniki, Thessaloniki, Greece|Centrum Zdrowia Stołeczna 7, Białystok, Poland|Spitalul Universitar de Urgenta Elias, Bucuresti, Romania|Hospital Universitario Ramón y Cajal, Madrid, Spain|Municipal Institution Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnikov, Dnipropetrovsk, Ukraine",NA,https://ClinicalTrials.gov/show/NCT01872598
95,NCT01862640,"A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation",NA,Completed,Has Results,Agitation Associated With|Alzheimer's Disease|Alzheimer's Type|Mental Disorder|Nervous System Diseases,"Drug: Brexpiprazole, OPC-34712|Drug: Placebo Oral Tablet","Change From Baseline In The Cohen-Mansfield Agitation Inventory (CMAI) Total Score After 12 Weeks Of Brexpiprazole Treatment|Change From Baseline In The Clinical Global Impression-Severity Of Illness (CGI-S) Score, As Related To Symptoms Of Agitation After 12 Weeks Of Brexpiprazole Treatment","Otsuka Pharmaceutical Development & Commercialization, Inc.|H. Lundbeck A/S",All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 3,433,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",331-12-283,"July 11, 2013","March 15, 2017","March 15, 2017","May 24, 2013","June 16, 2020","December 31, 2020","Tuscaloosa, Alabama, United States|Phoenix, Arizona, United States|Bellflower, California, United States|Costa Mesa, California, United States|Downey, California, United States|Orange, California, United States|Redlands, California, United States|Yorba Linda, California, United States|Norwalk, Connecticut, United States|Coconut Creek, Florida, United States|Hialeah, Florida, United States|Hialeah, Florida, United States|Hialeah, Florida, United States|Lauderhill, Florida, United States|Miami Springs, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Sarasota, Florida, United States|Decatur, Georgia, United States|Suwanee, Georgia, United States|Weymouth, Massachusetts, United States|Saint Louis, Missouri, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Manchester, New Jersey, United States|Mount Arlington, New Jersey, United States|Toms River, New Jersey, United States|Hickory, North Carolina, United States|Oklahoma City, Oklahoma, United States|Franklin, Tennessee, United States|Bedford, Texas, United States|Waukesha, Wisconsin, United States|Rijeka, Croatia|Zadar, Croatia|Zagreb, Croatia|Zagreb, Croatia|Mittweida, Saxony, Germany|Achim, Germany|Berlin, Germany|Bielefeld, Germany|Bochum, Germany|Hamburg, Germany|Koln, Germany|Ostfildern, Germany|Westerstede, Germany|Ekaterinburg, Russian Federation|Samara, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tonnel'nyy, Russian Federation|Belgrade, Serbia|Kovin, Serbia|Kragujevac, Serbia|Nis, Serbia|Novi Knezevac, Serbia|Novi Sad, Serbia|Vrsac, Serbia|Barcelona, Spain|Getafe, Spain|Girona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Pamplona, Spain|Salamanca, Spain|Valencia, Spain|Valencia, Spain|Zamora, Spain|Kharkiv, Ukraine|Kherson, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Odessa, Ukraine|Odessa, Ukraine|Poltava, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT01862640/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT01862640/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01862640
96,NCT01828437,Addition of Pyridoxine to Prednisolone in Infantile Spasms,NA,Completed,No Results Available,Infantile Spasms,Drug: Pyridoxine plus prednisolone|Drug: Prednisolone,Proportion of children who achieved complete cessation spasm for at least 48 hours as per parental reports at the end of 2 weeks in both the groups.|• Proportion of children who achieved more than 50 % reduction of clinical spasms as per parental reports at the end of 2 weeks,Lady Hardinge Medical College,All,3 Months to 36 Months   (Child),Phase 3,62,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PYRIPREDIS,November 2012,March 2014,March 2014,"April 10, 2013",NA,"January 15, 2019","Lady Hardinge Medical College, New Delhi, India",NA,https://ClinicalTrials.gov/show/NCT01828437
97,NCT01800097,Treatment of Post Stroke Fatigue With a Wakefulness Promoting Agent,NA,Terminated,No Results Available,Stroke|Post Stroke Fatigue,Drug: modafinil|Drug: placebo,Multidimensional Fatigue Inventory (MFI- 20)|MFI-20|Fatigue severity scale (FSS)|FSS,Herlev Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 3,41,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ModaA001,October 2012,March 2015,March 2015,"February 27, 2013",NA,"June 24, 2015","Department of Neurology, Herlev Hospital,, Herlev, Denmark",NA,https://ClinicalTrials.gov/show/NCT01800097
98,NCT01795859,First Time Use of SD-809 in Huntington Disease,First-HD,Completed,Has Results,Chorea,Drug: SD-809|Drug: Placebo,Change From Baseline (Average of Screening and Day 0) in the Average TMC Scores From Weeks 9 & 12|Number of Participants With Treatment Success at the End of Therapy as Measured by the Patient Global Impression of Change (PGIC)|Number of Participants With Treatment Success at the End of Therapy Based on Clinical Global Impression of Change (CGIC)|Change in the Short Form 36 Health Survey (SF-36) Physical Functioning Score (Based on Items 3a to 3j) From Baseline to Week 12|Change in Berg Balance Test (BBT),"Teva Branded Pharmaceutical Products R&D, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,90,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SD-809-C-15,"August 5, 2013","December 5, 2014","December 5, 2014","February 21, 2013","August 11, 2017","September 20, 2017","Teva Investigational Site 057, Birmingham, Alabama, United States|Teva Investigational Site 038, Phoenix, Arizona, United States|Teva Investigational Site 298, Fayetteville, Arkansas, United States|Teva Investigational Site 050, Los Angeles, California, United States|Teva Investigational Site 052, Englewood, Colorado, United States|Teva Investigational Site 333, Washington, D.C., District of Columbia, United States|Teva Investigational Site 196, Boca Raton, Florida, United States|Teva Investigational Site 160, Gainesville, Florida, United States|Teva Investigational Site 014, Miami, Florida, United States|Teva Investigational Site 032, Atlanta, Georgia, United States|Teva Investigational Site 045, Indianapolis, Indiana, United States|Teva Investigational Site 024, Iowa City, Iowa, United States|Teva Investigational Site 029, Kansas City, Kansas, United States|Teva Investigational Site 083, Wichita, Kansas, United States|Teva Investigational Site 087, Louisville, Kentucky, United States|Teva Investigational Site 028, Baltimore, Maryland, United States|Teva Investigational Site 040, Boston, Massachusetts, United States|Teva Investigational Site 027, Saint Louis, Missouri, United States|Teva Investigational Site 194, Las Vegas, Nevada, United States|Teva Investigational Site 328, Camden, New Jersey, United States|Teva Investigational Site 026, New Brunswick, New Jersey, United States|Teva Investigational Site 037, Albany, New York, United States|Teva Investigational Site 002, New York, New York, United States|Teva Investigational Site 342, Patchogue, New York, United States|Teva Investigational Site 119, Durham, North Carolina, United States|Teva Investigational Site 089, Cincinnati, Ohio, United States|Teva Investigational Site 020, Columbus, Ohio, United States|Teva Investigational Site 093, Toledo, Ohio, United States|Teva Investigational Site 341, Tulsa, Oklahoma, United States|Teva Investigational Site 031, Nashville, Tennessee, United States|Teva Investigational Site 007, Houston, Texas, United States|Teva Investigational Site 199, Houston, Texas, United States|Teva Investigational Site 100, Salt Lake City, Utah, United States|Teva Investigational Site 137, Burlington, Vermont, United States|Teva Investigational Site 220, Kirkland, Washington, United States|Teva Investigational Site 096, Seattle, Washington, United States|Teva Investigational Site 104, Milwaukee, Wisconsin, United States|Teva Investigational Site 144, Kew Vic, Australia|Teva Investigational Site 054, Sydney, Australia|Teva Investigational Site 098, Montreal, Canada|Teva Investigational Site 300, North York, Canada|Teva Investigational Site 231, Ottawa, Canada|Teva Investigational Site 300, Ottawa, Canada",NA,https://ClinicalTrials.gov/show/NCT01795859
99,NCT01767909,The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF),NA,Completed,Has Results,Amnestic Mild Cognitive Impairment|Alzheimer's Disease,Drug: Insulin (Humulin® R U-100)|Drug: Placebo,Change in Global Measure of Cognition as Measured by the Alzheimer's Disease Assessment Scale-Cognitive 12 (ADAS-Cog12)|Change in Memory Composite as Measured by Story Recall (Immediate Paragraph Recall and Delayed Paragraph Recall) and Free and Cued Selective Reminding Test (FCSRT)|Change in Daily Functioning as Measured by the ADCS-MCI Activities of Daily Living (ADCS-ADL-MCI)|Change in Cognitive Deficit as Measured by Clinical Dementia Rating - Sum of Boxes (CDR-SB)|Change in Hippocampal and Entorhinal Atrophy as Measured by Magnetic Resonance Imaging (MRI)|Change in CSF Biomarkers of AD,University of Southern California|National Institute on Aging (NIA)|Alzheimer's Therapeutic Research Institute|Wake Forest University Health Sciences,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,240,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ADC-046-INI|RF1AG041845,"January 8, 2014","December 11, 2018","December 11, 2018","January 15, 2013","May 18, 2020","May 18, 2020","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Barrow Neurology Clinics, Phoenix, Arizona, United States|University of California, Irvine, Irvine, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Mount Sinai School of Medicine, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Case Western Reserve University, Beachwood, Ohio, United States|Tulsa Clinical Research, Tulsa, Oklahoma, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Roper St. Francis Hospital, Charleston, South Carolina, United States|Baylor College of Medicine, Houston, Texas, United States|U of WA / VA Puget Sound Alzheimer's Disease Research Center, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT01767909/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT01767909/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01767909
100,NCT01741701,A Pilot Study of Oxaloacetate in Subjects With Treated PD,NA,Completed,Has Results,Parkinson's Disease,Drug: Oxaloacetate (OAA)|Drug: Placebo,Unified Parkinson's Disease Rating Scale (UPDRS) Total Score|Unified Parkinson's Disease Rating Scale (UPDRS) ADL + Motor Score|Parkinson's Disease Questionnaire - 39 (PDQ-39)|Montreal Cognitive Assessment (MoCA)|Geriatric Depression Scale (GDS)|NonMotor Symptom Questionnaire (NMSQuest),University of Kansas Medical Center|Terra Biological LLC,All,"30 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,33,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",13397,December 2012,October 2014,October 2014,"December 5, 2012","March 17, 2016","March 17, 2016","University of Kansas Medical Center, Kansas City, Kansas, United States",NA,https://ClinicalTrials.gov/show/NCT01741701
101,NCT01741194,AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext,NOURISH-AD,Completed,No Results Available,Alzheimer's Disease,Drug: AC-1204|Drug: Placebo,Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)|Clock Draw Interpretation Scale (CDIS)|Alzheimer's Disease Co-operative Study - Clinical Global Impression of Change (ADCS-CGIC)|Alzheimer's Disease Co-operative Study - Activities of Daily Living (ADCS-ADL)|Quality of Life - Alzheimer's Disease (QoL-AD)|Resource Utilization in Dementia (RUD-Lite)|Incidence of treatment-emergent adverse events,Cerecin,All,66 Years to 90 Years   (Older Adult),Phase 2|Phase 3,418,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",AC-12-010,March 2013,"October 24, 2016","April 14, 2017","December 4, 2012",NA,"August 2, 2021","University of Alabama at Birmingham, Department of Neurology, Memory Disorders Division, Birmingham, Alabama, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|HOPE Research Institute, Phoenix, Arizona, United States|Principals Research Group, Hot Springs, Arkansas, United States|Clinical Trials, Inc., Little Rock, Arkansas, United States|CITrials, Inc., Bellflower, California, United States|Southern Research LLC, Beverly Hills, California, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Diligent Clinical Trials, Downey, California, United States|UCSD Comprehensive Alzheimer's Program, La Jolla, California, United States|Alliance Research Centers, Laguna Hills, California, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Collaborative Neuroscience Network, Long Beach, California, United States|Alliance for Research, Long Beach, California, United States|Renew Behavioral Health, Long Beach, California, United States|Pacific Research Network, San Diego, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Research Across America, Santa Ana, California, United States|Neurological Research Institute, Santa Monica, California, United States|Redwood Research Medical Group, Santa Rosa, California, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|IMMUNOe Research Centers, Centennial, Colorado, United States|The Mile High Research Center, Denver, Colorado, United States|Chase Medical Research of Greater New Haven, Hamden, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|Meridian Research, Brooksville, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Suncoast Neuroscience Associates, Saint Petersburg, Florida, United States|The Roskamp Institute, Sarasota, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|NeuroTrials Research, Inc, Atlanta, Georgia, United States|IU Health Partners Adult Neurology Clinic, Indianapolis, Indiana, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Pharmasite Research, Inc., Baltimore, Maryland, United States|Alzheimers Disease Center, Quincy Medical Center, Somerville, Massachusetts, United States|Springfield Neurology Associates, Springfield, Massachusetts, United States|Borgess Research Institute, Kalamazoo, Michigan, United States|Saint Louis University Medical School /Department of Neurology & Psychiatry, Saint Louis, Missouri, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|NeuroCognitive Institute, Mount Arlington, New Jersey, United States|The Cognitive Research Center of New Jersey, Springfield, New Jersey, United States|Memory Enhancement Center of NJ, Toms River, New Jersey, United States|Neurology Specialists of Monmouth County, West Long Branch, New Jersey, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Integrative Clinical Trials, LLC, Brooklyn, New York, United States|SPRI Clinical Trials, LLC, Brooklyn, New York, United States|The Litwin-Zucker Research Center, Manhasset, New York, United States|Parker Jewish Institute For Health Care & Rehabilitation, New Hyde Park, New York, United States|NYU Langone Medical Center Comprehensive Center on Brain Aging, New York, New York, United States|Eastside Comprehensive Medical Center, LLC, New York, New York, United States|Nathan S. Kline Institute Geriatric Psychiatry Program, Orangeburg, New York, United States|New Hope Clinical Research, Charlotte, North Carolina, United States|Ani Neurology, PLLC dba Alzheimer's Memory Ctr, Charlotte, North Carolina, United States|Neuro-Behavioral Clinical Research, Inc., Canton, Ohio, United States|Valley Medical Research, Centerville, Ohio, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|Insight Clinical Trials LLC, Shaker Heights, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Summit Research Network (Oregon) Inc., Portland, Oregon, United States|Drexel Neurological Associates, Philadelphia, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Clinical Research Solutions, Franklin, Tennessee, United States|Clinical Neuroscience Solutions, Inc, Memphis, Tennessee, United States|Senior Adults Specialty Research, Inc, Austin, Texas, United States|Texas Neurology, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|National Clinical Research - Richmond, Inc., Richmond, Virginia, United States|VA Puget Sound-Alzhemier's Disease Research Center, Seattle, Washington, United States",NA,https://ClinicalTrials.gov/show/NCT01741194
102,NCT01739348,An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738),EPOCH,Terminated,Has Results,Alzheimer's Disease,Drug: Verubecestat (Part I and Part II)|Drug: Placebo (Part I)|Drug: Verubecestat (Part II),[Part I (Base Study)] Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score|[Part I (Base Study)] Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score|[Part II (Extension Study)] Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score|[Part II (Extension Study)] Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score|[Part I (Base Study)] Number of Participants Who Experienced an Adverse Event|[Part II (Extension Study)] Number of Participants Who Experienced an Adverse Event|[Part I (Base Study)] Number of Participants Who Discontinued From Study Drug Due to an Adverse Event|[Part II (Extension Study)] Number of Participants Who Discontinued From Study Drug Due to an Adverse Event|[Part I (Base Study)] Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score|[Part I (Base Study)] Percent Change From Baseline in Total Hippocampal Volume (THV)|[Part I (Base Study)] Fold Change From Baseline in Cerebrospinal Fluid (CSF) Total Tau|[Part I (Base Study)] Change From Baseline in Cortical Amyloid Load Assessed by [18F]Flutemetamol PET Standard Uptake Value Ratio (SUVR)|[Part I (Base Study)] Percentage of Participants Achieving Responder Status|[Part I (Base Study)] Change From Baseline in Neuropsychiatric Inventory (NPI) Score|[Part I (Base Study)] Change From Baseline in Mini-Mental State Examination (MMSE) Score,Merck Sharp & Dohme LLC,All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,2211,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",P07738|MK-8931-017|2011-003151-20|132229,"November 30, 2012","April 14, 2017","April 14, 2017","December 3, 2012","May 16, 2018","October 24, 2018",NA,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT01739348/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01739348
103,NCT01738178,Caffeine as a Therapy for Parkinson's Disease,NA,Completed,No Results Available,Parkinson's Disease,Drug: Caffeine|Drug: Placebo,"Motor manifestations associated with Parkinson's disease|MDS-UPDRS components and subscales - each individual component will be assessed, including:|Cognition|Sleep|Quality of life|Medication utilization|Tolerability and side effects of caffeine","McGill University Health Centre/Research Institute of the McGill University Health Centre|Pontifícia Universidade Católica do Paraná|University of Calgary|University of Newfoundland and Eastern Health|University Health Network, Toronto|UBC Hospital|Movement Disorder Clinic - Deer Lodge Centre|The Ottawa Hospital",All,"45 Years to 75 Years   (Adult, Older Adult)",Phase 3,119,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2778,April 2014,"May 1, 2016","December 1, 2016","November 30, 2012",NA,"March 22, 2017","Parana Parkinson Association - Pontifical Catholic University of Parana, Curitiba, PR, Brazil|Heritage Medical Research Clinic - University of Calgary, Calgary, Alberta, Canada|UBC Hospital - Pacific Parkinson's Research Centre, Vancouver, British Columbia, Canada|Movement Disorder Clinic - Deer Lodge Centre, Winnipeg, Manitoba, Canada|Memorial University of Newfoundland, St-John's, Newfoundland and Labrador, Canada|The Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|Toronto western Hospital - Movement Disorders Research Centre, Toronto, Ontario, Canada|McGill University Health Center, Montreal, Quebec, Canada",NA,https://ClinicalTrials.gov/show/NCT01738178
104,NCT01713946,A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures,EXIST-3,Completed,Has Results,Tuberous Sclerosis Complex-associated Refractory Seizures,Drug: RAD001|Drug: Placebo|Drug: Antiepileptic drug (1 to 3 only)|Drug: open label RAD001 (only used for post-extension phase),"Core Phase: European Medicine Agency (EMA): Seizure Frequency Response Rate|Core Phase: Food & Drug Administration (FDA): Percentage Change From Baseline in Partial Onset-seizure Frequency|Percentage of Seizure-free Patients During the Maintenance Period of the Core Phase|Core Phase: Percentage of Patients With at Least a 25% Reduction in Seizure Frequency|Core Phase: Distribution of Reduction From Baseline in Seizure Frequency|Core Phase: Changes From Baseline in Number of Seizure-free Days|Core Phase: Probability That a Patient Remains On-treatment up to a Specified Time Point|Core Phase: Change From Baseline in the QOLCE Overall Quality-of-life Score for Patients <11 Years|Core Phase: Change From Baseline in the QOLIE-AD-48 Overall Quality-of-life Score for Patients >=11 to 18 Years|Core Phase: Change From Baseline in the QOLIE-31-P Overall Quality-of-life Score for Patients Aged >=18 Years|Core Phase: Change From Baseline in the Overall Vineland-II Adaptive Behavior Composite (ABC) Score|Long Term Evaluation: Effect of Everolimus Over Time in the Overall Vineland-II Adaptive Behavior Composite (ABC) Score|Core Phase: Change From Baseline in Wechsler Nonverbal Composite Score|Long Term Evaluation: Effect of Everolimus Over Time in the Overall Wechsler Nonverbal Composite Score|Core Phase: Response Rate in Seizure Frequency by Time Normalized Minimum Concentration|Core Phase: Median Percentage Change From Baseline in Seizure Frequency by Time Normalized Minimum Concentration|Long Term Evaluation: Relationship Between Seizure Frequency and Time-normalized Everolimus Concentration at Trough (Cmin,TN) - Repeated Measures Analysis|Core Phase: Impact of Everolimus on Anti-epileptic Drugs (AEDs) Concentrations|Long Term Evaluation: Percentage Change From Start of Everolimus in Seizure Frequency by Time Window|Seizure Free Rates by Time Window|Core Phase: Incidence of Suicide Attempt, Suicidal Ideation or Behavior During Core Phase Per Columbia Suicide Severity Rating Scale (C-SSRS) Outcomes|Long Term Evaluation: Incidence of Suicide Attempt, Suicidal Ideation or Behavior During Core Phase Per Columbia Suicide Severity Rating Scale (C-SSRS) Outcomes",Novartis Pharmaceuticals|Novartis,All,"2 Years to 65 Years   (Child, Adult, Older Adult)",Phase 3,366,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CRAD001M2304|2011-000860-90,"April 29, 2013","October 25, 2017","October 25, 2017","October 25, 2012","November 7, 2018","November 7, 2018","University of Alabama at Birmingham SC, Birmingham, Alabama, United States|TGen/APNNA, Phoenix, Arizona, United States|University of California at Los Angeles SC, Los Angeles, California, United States|Children's Hospital Oakland SC, Oakland, California, United States|Children's Hospital of Orange County SC, Orange, California, United States|Rady Children's Hospital SC, San Diego, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Connecticut Childrens Medical Center SC, Hartford, Connecticut, United States|University of Chicago SC - 2, Chicago, Illinois, United States|Kennedy Krieger Institute SC, Baltimore, Maryland, United States|Children's Hospital Boston SC, Boston, Massachusetts, United States|Minnesota Epilepsy Group - PA SC, Saint Paul, Minnesota, United States|Washington University School of Medicine SC-2, Saint Louis, Missouri, United States|Morristown Memorial Hospital SC-2, Morristown, New Jersey, United States|New York University Medical Center SC-3, New York, New York, United States|Cincinnati Children's Hospital Medical Center SC, Cincinnati, Ohio, United States|Oregon Health and Science University SC - 3, Portland, Oregon, United States|Children's Hospital of Philadelphia SC, Philadelphia, Pennsylvania, United States|LeBonheur Childrens Medical Group SC, Memphis, Tennessee, United States|Texas Scottish Rite Hospital for Children Texas Scottish, Dallas, Texas, United States|Texas Children s Hospital SC, Houston, Texas, United States|The University of Texas Medical School-Houston SC, Houston, Texas, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Randwick, New South Wales, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Perth, Western Australia, Australia|Novartis Investigative Site, Jette, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Cali, Valle Del Cauca, Colombia|Novartis Investigative Site, Bogotá, Colombia|Novartis Investigative Site, Medellín, Colombia|Novartis Investigative Site, Aarhus, Denmark|Novartis Investigative Site, Amiens Cedex 1, France|Novartis Investigative Site, Angers cedex 09, France|Novartis Investigative Site, Bron Cedex, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Kehl-Kork, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Ioannina, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Nyiregyhaza, Hungary|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Bari, BA, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Siena, SI, Italy|Novartis Investigative Site, Okayama-city, Okayama, Japan|Novartis Investigative Site, Izumi-city, Osaka, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Shizuoka-city, Shizuoka, Japan|Novartis Investigative Site, Setagaya-ku, Tokyo, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Heeze, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Utrecht, Netherlands|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Samara, Samara Region, Russian Federation|Novartis Investigative Site, Voronezh, Voronezh Region, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Sevilla, Andalucía, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Tainan, Taiwan ROC, Taiwan|Novartis Investigative Site, Kaohsiung City, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Buckinghamshire, United Kingdom|Novartis Investigative Site, Cambridge, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Sheffield, United Kingdom|Novartis Investigative Site, York, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT01713946/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT01713946/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01713946
105,NCT01695460,"A Randomized, Parallel, Double-blind, Placebo-controlled Study of Vitamin D as Prophylactic Treatment for Migraine",NA,Completed,No Results Available,Migraine According to International Headache Society (IHS) Criteria (ICHD-II),Drug: D3 Vitamin ®|Drug: Placebo,The number of migraine attacks|Evaluation of pain during migraine attacks|Hypersensitivity|Migraine Symptoms|Quantitative Sensory Testing|Measuring levels of a biomarker. Changes in the levels of these biomarkers.,"Aalborg University|CCBR Aalborg A/S, Aalborg, Denmark|Aalborg University Hospital",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",N-20120052|Projekt #831302,September 2012,December 2015,December 2015,"September 28, 2012",NA,"December 29, 2015","CCBR Aalborg A/S, Aalborg, Denmark|Aalborg University, Aalborg, Denmark",NA,https://ClinicalTrials.gov/show/NCT01695460
106,NCT01689246,Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease,NA,Completed,No Results Available,Alzheimer's Disease,Drug: TRx0237 150 mg/day|Drug: TRx0237 250 mg/day|Drug: Placebo,Change from Baseline on Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)|Change from Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11)|Number of study participants who tolerate oral doses of TRx0237 as determined by safety parameter changes|Change from Baseline on Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)|Change from Baseline on Mini-Mental Status Examination (MMSE)|Change in expected decline of whole brain volume as measured by brain MRI,TauRx Therapeutics Ltd,All,"up to 89 Years   (Child, Adult, Older Adult)",Phase 3,891,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TRx-237-015,January 2013,November 2015,November 2015,"September 21, 2012",NA,"March 14, 2018","Xenoscience, Inc/ 21st Century Neurology, Phoenix, Arizona, United States|Feldman, Robert MD, Laguna Hills, California, United States|University of Southern California, Los Angeles, California, United States|Shankle Clinic and Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Pacific Research Network, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|JEM Research, Atlantis, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|CNS Healthcare, Inc, Jacksonville, Florida, United States|Compass Research, LLC-North Clinic, Leesburg, Florida, United States|Miami Research Associates, Miami, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|iResearch Atlanta, Decatur, Georgia, United States|Alexian Brothers Neurosciences Institute, Elk Grove, Illinois, United States|ActivMed Practices & Research, Methuen, Massachusetts, United States|Olive Branch Family Medical, Olive Branch, Mississippi, United States|Memory Enhancement Centers of America, Inc, Eatontown, New Jersey, United States|CRI Worldwide, Marlton, New Jersey, United States|The Cognitive Research Center of New Jersey, Springfield, New Jersey, United States|Advanced Memory Research Institute of NJ PC, Toms River, New Jersey, United States|Neurological Associates of Albany, P. C., Albany, New York, United States|SPRI, Brooklyn, New York, United States|Neurobehavioral Clinical Research, Canton, Ohio, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|FutureSearch Trials of Neurology, Austin, Texas, United States|Division of Rehabilitation and Aged Care, Hornsby, New South Wales, Australia|Southern Neurology Pty Limited, Kogarah, New South Wales, Australia|Academic Department for Old Age Psychiatry, Prince of Wales Hospital, Randwick, New South Wales, Australia|Discipline of Psychiatry, University of Qld, Herston, Queensland, Australia|Royal Adelaide Hospital Memory Trials Centre, Adelaide, South Australia, Australia|Memory Unit, Neurology, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Medical and Cognitive Research Unit, Austin Health Heidelberg Repatriation Hospital, Heidelberg West, Victoria, Australia|McCusker Alzheimer's Research Foundation Inc, Nedlands, Western Australia, Australia|Neurodegenerative Disorders Research Pty Ltd, Perth, Western Australia, Australia|UMHAT ""Alexandrovska"" Clinic of Neurology Diseases Department of Neurodegenerative and Immune and Infectious Diseases of Central Nervous System with Sector for Treatment of Neuroinfections, Sofia, Bulgaria|UMHAT ""Alexandrovska"" Clinic of Psychiatry First Department of Psychiatry, Sofia, Bulgaria|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|True North Clinical Research Kentville Inc, Kentville, Nova Scotia, Canada|Toronto Memory Program, North York, Ontario, Canada|University Hospital Centre Zagreb, Zagreb, Croatia|University Psychiatric Hospital Vrapce, Zagreb, Croatia|Neurozentrum Achim Dr. med. Andreas Mahler, Achim, Germany|Charité, University Medicine Berlin, CBF, Neurology, Berlin, Germany|Memory Clinic, ECRC, Berlin, Germany|Neurologia Ospedale Maggiore Policlinico, Milano, Italy|Istituto Neurologico Carlo Besta, Milano, Italy|IRCCS Istituto neurologico Casimiro Mondino, Pavia, Italy|Clinica Neurologica, Università di Perugia-Ospedale S. Maria della Misericordia, Perugia, Italy|Universita' Cattolica del Sacro Cuore, Roma, Italy|Azienda Ospedaliera Universitaria Sant'Andrea di Roma- Unita' di Neurologia, Roma, Italy|Dipartimento di Neuroscienze Universita' di Torino, Torino, Italy|Azienda Ospedaliera S.maria Della Misericordia, Udine, Italy|U.O. Di Neurologia Ospedale di Circolo e Fondazione Macchi, Varese, Italy|Dong-A Medical Center, Busan, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Seoul National University Boramae Medical Center, Seoul, Korea, Republic of|University Kuala Lumpur Royal College of Medicine, Ipoh, Malaysia|Hospital Sultan Ismail, Johor Bahru, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Taiping Hospital, Taiping, Malaysia|Podlaskie Centrum Psychogeriatrii, Białystok, Poland|Pallmed sp zoo prowadząca NZOZ Dom Sue Ryder; Centrum Psychoneurologii Wieku Podeszłego, Bydgoszcz, Poland|NZOZ Wielospecjalistyczna Poradnia Lekarska SYNAPSIS, Katowice, Poland|Gabinet Neurologiczny, Indywidualna Specjalistyczna Praktyka Lekarska, Mosina, Poland|NZOZ Neuro-Kard Ilkowski i Partnerzy Spółka Partnerska Lekarzy, Poznań, Poland|Euromedis Sp. z o.o., Szczecin, Poland|Usługi Lekarskie Sp.c Palasik, Żabierek, Warszawa, Poland|mMED, Warszawa, Poland|MTZ Clinical Research Sp. z o.o., Warszawa, Poland|County Emergency Clinical Hospital Arad, Psychiatry Department, Arad, Romania|CMDTA ""Neomed"", Brasov, Romania|University Emergency Central Military Hospital ""Dr.Carol Davila"", Psychiatry Department, Bucharest, Romania|Psychomedical Consult, Bucharest, Romania|Clinical Municipal Hospital ""Dr. Gavril Curteanu"", Psychiatry Department, Oradea, Romania|Psychiatry Hospital ""Dr. Gheorghe Preda"", Center of Mental Health, Sibiu, Romania|Psychiatry Hospital ""Dr. Gheorghe Preda"", Department of Psychiatry III, Sibiu, Romania|Emergency Clinical County Hospital Sibiu, Neurology Department, Sibiu, Romania|State Budgetary Healthcare Institution of Sverdlovsk region ""Sverdlovsk Regional Clinical Psychiatric Hospital"", Ekaterinburg, Russian Federation|Non-governmental Healthcare Institution ""Central Clinical Hospital #6 of the JSC ""Russian Railways"", Moscow, Russian Federation|Mental Health Research Center of the Russian Academy of Medical Sciences, Gerontopsychiatry department, Moscow, Russian Federation|Mental Health Research Center of the Russian Academy of Medical Sciences, Moscow, Russian Federation|CityClinical Hospital #34, City Scientific Practical Neurological Center, Novosibirsk, Russian Federation|City Geriatric Medical and Social Center, Saint Petersburg, Russian Federation|Saint Nicholas Psychiatric Hospital, Saint Petersburg, Russian Federation|Saint Petersburg Psychoneurological Research Institute n. a. V.M. Bekhterev, Saint Petersburg, Russian Federation|National University Hospital (NUH), Singapore, Singapore|National Neuroscience Institute (NNI), Singapore, Singapore|Tan Tock Seng Hospital (TTSH), Singapore, Singapore|Changi General Hospital, Singapore, Singapore|Hospital Universitario de Ceuta, Ceuta, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Viamed Montecanal, Zaragoza, Spain|Changhua Christian Hospital, Changhua, Taiwan|Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|En Chu Kong Hospital, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|National Yang-Ming University School of Medicine, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan|NHS Grampian, Department of Old Age Psychiatry Royal Cornhill Hospital, Aberdeen, United Kingdom|RICE - The Research Institute for the Care of Older People, Bath, United Kingdom|Belfast Health and Social Care Trust (BHSCT), Belfast, United Kingdom|The Barberry Centre, Birmingham, United Kingdom|MAC Clinical Research Ltd, Blackpool, United Kingdom|MAC Clinical Research Ltd, Bradford, United Kingdom|MAC Clinical Research Ltd, Cannock, United Kingdom|MAC Clinical Research Ltd, Leeds, United Kingdom|Re: Cognition Health Ltd., London, United Kingdom|Charing Cross Hospital, London, United Kingdom|Dementia Research Centre, London, United Kingdom|MAC Clinical Research Ltd, Manchester, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT01689246
107,NCT01689233,Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease,NA,Completed,No Results Available,Alzheimer's Disease,Drug: TRx0237 200 mg/day|Drug: Placebo,Change from Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11)|Change from Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)|Number of study participants who tolerate oral doses of TRx0237 as determined by safety parameter changes|Change from Baseline in Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)|Change from Baseline in Mini-Mental Status Examination (MMSE)|Change from Baseline in Neuropsychiatric Inventory (NPI)|Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)|Change in expected decline of whole brain volume as measured by brain MRI,TauRx Therapeutics Ltd,All,"up to 89 Years   (Child, Adult, Older Adult)",Phase 3,800,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TRx-237-005,October 2012,May 2016,May 2016,"September 21, 2012",NA,"March 14, 2018","Xenoscience, Inc / 21st Century Neurology, Phoenix, Arizona, United States|NoesisPharma Clinical Trials, Phoenix, Arizona, United States|CITrials, Bellflower, California, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Southern California Research, LLC, Fountain Valley, California, United States|Feldman, Robert MD, Laguna Hills, California, United States|Synergy East, Lemon Grove, California, United States|Collaborative Neuroscience Network, Long Beach, California, United States|Neuro-Therapeutics, Inc., Pasadena, California, United States|Anderson Clinical Research, Redlands, California, United States|Pacific Research Network, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Neurological Research Institute, Santa Monica, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Mile High Research Center, Denver, Colorado, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Coastal Connecticut Research, LLC, New London, Connecticut, United States|Research Center for Clinical Studies, Inc, Norwalk, Connecticut, United States|JEM Research, Atlantis, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|The Roskamp Institute, Inc., Sarasota, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|USF Health Byrd Alzheimer's Institute, Tampa, Florida, United States|Compass Research, LLC - North Clinic, The Villages, Florida, United States|Premiere Research Institute (Palm Beach Neurology), West Palm Beach, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|Neurostudies.net, Decatur, Georgia, United States|Alexian Brothers Neurosciences Institute, Elk Grove, Illinois, United States|Ruan Neurology Clinic and Research Center, Des Moines, Iowa, United States|CBH Health, LLC, Rockville, Maryland, United States|Quest Research Institute, Farmington Hills, Michigan, United States|Neurological Research Center - Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Olive Branch Family Medical, Olive Branch, Mississippi, United States|Millennium Psychiatric Associates, Creve Coeur, Missouri, United States|Memory Enhancement Centers of America, Inc, Eatontown, New Jersey, United States|Advanced Memory Research Institute of NJ PC, Toms River, New Jersey, United States|Albuquerque Neuroscience, Albuquerque, New Mexico, United States|Neurological Associates of Albany, P. C., Albany, New York, United States|MedicalPsych Care, PLLC, Elmsford, New York, United States|Columbia University Taub Institute, New York, New York, United States|Research Foundation for Mental Hygiene, Inc., Orangeburg, New York, United States|Wake Research Associates, Raleigh, North Carolina, United States|Clinical Trials of America, Inc, Winston-Salem, North Carolina, United States|Neurobehavorial Clinical Research, Canton, Ohio, United States|Oklahoma Clinical Research Center, Oklahoma City, Oklahoma, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|RI Hospital, Providence, Rhode Island, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Clinical Neuroscience Solutions CNS Healthcare, Memphis, Tennessee, United States|Senior Adults Specialty Research, Inc., Austin, Texas, United States|FutureSearch Trials of Dallas, LP, Dallas, Texas, United States|PRA Health Sciences, Salt Lake City, Utah, United States|Independent Psychiatric Consultants, Waukesha, Wisconsin, United States|Discipline of Psychiatry, University of Queensland, Herston, Queensland, Australia|University Hospital Brussels Department of Neurology, Bruxelles, Belgium|University Hospital Gent Department of Neurology, Gent, Belgium|Jessa Hospital, Hasselt, Belgium|Regional Hospital Sint-Trudo, Sint-Truiden, Belgium|GasthuisZusters Antwerpen Sint-Augustinus, Wilrijk, Belgium|University of British Columbia Hospital, Clinic for Alzheimer Disease and Related Disorders, Vancouver, British Columbia, Canada|Parkwood Institute, London, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|University Hospital Centre Zagreb, Department of Neurology, Zagreb, Croatia|University Psychiatric Hospital Vrapče, Zagreb, Croatia|University of Eastern Finland, Brain Research Unit Mediteknia, Kuopio, Finland|Clinical Research Services Turku (CRST), Turku, Finland|Hôpitaux Civils de Colmar, Colmar Cedex, France|Hôpital La Grave, Toulouse, France|Hôpital de Charpennes, Villeurbanne, France|Neurozentrum Achim Dr. med. Andreas Mahler, Achim, Germany|University Medicine Berlin - Charité, CBF, Neurology, Berlin, Germany|Memory Clinic, ECRC, Berlin, Germany|Arzeneimittelforschung Leipzig GmbH, Leipzig, Germany|Klinik und Poliklinik für Psychiatrie und Psychotherapie Zentrum für Nervenheilkunde - Universitätsklinikum Rostock, Rostock, Germany|A.O.U. Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi, Ancona, Italy|IRCCS San Giovanni di Dio - Fatebenefratelli, Brescia, Italy|Fondazione Universita 'G. D'Annunzio di Chieti, Chieti Scalo, Italy|Clinical Neurology Department of Neuroscience (DINOGMI) - University of Genoa, Genova, Italy|Azienda Ospedaliera Universitaria Sant'Andrea di Roma - Unita' di Neurologia, Roma, Italy|Alzheimer Center Southwest Netherlands, Erasmus MC, Rotterdam, Netherlands|Fundacio ACE, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitari Mútua de Terrassa, Terrassa, Spain|Grampian NHS, Royal Cornhill Hospital, Aberdeen, United Kingdom|Sussex Partnership NHS Foundation Trust, Cognitive Treatment and Research Unit, Crowborough, United Kingdom|Re:Cogniton Health, London, United Kingdom|Memory Assessment and Research Centre (MARC), Southampton, United Kingdom|Kingshill Research Centre, Victoria Hospital, Swindon, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT01689233
108,NCT01667484,Adderall XR and Processing Speed in Multiple Sclerosis (MS),NA,Completed,No Results Available,Impaired Processing Speed|Cognitive Impairment|Multiple Sclerosis,Drug: Adderall XR 5mg|Drug: Adderall XR 10 mg|Drug: Placebo,Change in score of Paced Auditory Serial Addition Test (PASAT)|Change in Score of Symbol Digit Modalities Test (SDMT),London Health Sciences Centre,All,18 Years to 59 Years   (Adult),Phase 2|Phase 3,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",102774,September 2012,February 2013,February 2015,"August 17, 2012",NA,"May 12, 2015","London Health Sciences Center and St. Joseph's Heathcare Center (Parkwood), London, Ontario, Canada",NA,https://ClinicalTrials.gov/show/NCT01667484
109,NCT01665144,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),NA,"Active, not recruiting",Has Results,Secondary Progressive Multiple Sclerosis,Drug: BAF312|Drug: Placebo,Percentage of Participants With 3-month Confirmed Disibility Progression (CDP) Events as Measured by the Expanded Disability Status Scale (EDSS)|Efficacy of BAF312 Relative to Placebo in Confirmed Worsening of 25 Foot Walk Test|Efficacy of BAF312 Relative to Placebo in Reducing the Increase in T2 Lesion Volume|The Delay in Time to Confirmed Disability Progression as Measured by EDSS.|Efficacy of BAF Relative to Placebo in Annualized Relapses Rate and Time to the First Relapse|Overall Response Rate on the MSWS-12.|Effect on Inflammatory Disease Activity and Burden of Disease as Measured by MRI|Effect on 3-month Confirmed Disability Progression as Defined by EDSS in Predefined Sub-groups,Novartis Pharmaceuticals|Novartis,All,18 Years to 60 Years   (Adult),Phase 3,1652,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CBAF312A2304,"December 20, 2012","April 29, 2016","March 1, 2024","August 15, 2012","October 31, 2018","January 13, 2023","Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Berkeley, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Oceanside, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Basalt, Colorado, United States|Novartis Investigative Site, Boulder, Colorado, United States|Novartis Investigative Site, Colorado Springs, Colorado, United States|Novartis Investigative Site, Englewood, Colorado, United States|Novartis Investigative Site, Fairfield, Connecticut, United States|Novartis Investigative Site, Delray Beach, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Maitland, Florida, United States|Novartis Investigative Site, Ormond Beach, Florida, United States|Novartis Investigative Site, Port Charlotte, Florida, United States|Novartis Investigative Site, Sunrise, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Vero Beach, Florida, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Evanston, Illinois, United States|Novartis Investigative Site, Flossmoor, Illinois, United States|Novartis Investigative Site, Lenexa, Kansas, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Golden Valley, Minnesota, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Lebanon, New Hampshire, United States|Novartis Investigative Site, Freehold, New Jersey, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Patchogue, New York, United States|Novartis Investigative Site, Stony Brook, New York, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Akron, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Springfield, Oregon, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Providence, Rhode Island, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Lubbock, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Burlington, Vermont, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Capital Federal, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Camperdown, New South Wales, Australia|Novartis Investigative Site, Kogarah, New South Wales, Australia|Novartis Investigative Site, Liverpool, New South Wales, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Klagenfurt, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Fraiture En Condroz, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Pelt, Belgium|Novartis Investigative Site, Sijsele, Belgium|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Burnaby, British Columbia, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Kingston, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Changchun, Jilin, China|Novartis Investigative Site, Taiyuan, Shanxi, China|Novartis Investigative Site, Xi'an, Shanxi, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Brno, Czech Rep., Czechia|Novartis Investigative Site, Teplice, Czech Republic, Czechia|Novartis Investigative Site, JIhlava, Czechia|Novartis Investigative Site, Prague 5, Czechia|Novartis Investigative Site, Praha, Czechia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Nancy, Cedex, France|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, CAEN Cedex, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Marseille Cedex 05, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Nimes, France|Novartis Investigative Site, Paris Cedex 13, France|Novartis Investigative Site, Rennes, France|Novartis Investigative Site, St Herblain, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Regensburg, Bavaria, Germany|Novartis Investigative Site, Aschaffenburg, Germany|Novartis Investigative Site, Bad Mergentheim, Germany|Novartis Investigative Site, Bayreuth, Germany|Novartis Investigative Site, Berg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Boblingen, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Erbach, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Homburg, Germany|Novartis Investigative Site, Itzehoe, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Kassel, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Neuburg an der Donau, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Prien, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Schwendi, Germany|Novartis Investigative Site, Siegen, Germany|Novartis Investigative Site, Stade, Germany|Novartis Investigative Site, Stadtroda, Germany|Novartis Investigative Site, Teupitz, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Unterhaching, Germany|Novartis Investigative Site, Wiesbaden, Germany|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Heraklion Crete, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Budapest, HUN, Hungary|Novartis Investigative Site, Budapest, HUN, Hungary|Novartis Investigative Site, Budapest, HUN, Hungary|Novartis Investigative Site, Esztergom, HUN, Hungary|Novartis Investigative Site, Balassagyarmat, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Eger, Hungary|Novartis Investigative Site, Miskolc, Hungary|Novartis Investigative Site, Nyiregyhaza, Hungary|Novartis Investigative Site, Veszprem, Hungary|Novartis Investigative Site, Dublin 9, D9, Ireland|Novartis Investigative Site, Dublin 4, Ireland|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Cefalu, PA, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Toon-city, Ehime, Japan|Novartis Investigative Site, Asahikawa-city, Hokkaido, Japan|Novartis Investigative Site, Morioka, Iwate, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Suita, Osaka, Japan|Novartis Investigative Site, Kawagoe, Saitama, Japan|Novartis Investigative Site, Tokorozawa city, Saitama, Japan|Novartis Investigative Site, Kodaira, Tokyo, Japan|Novartis Investigative Site, Ota-ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Aomori, Japan|Novartis Investigative Site, Chiba, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Riga, LV, Latvia|Novartis Investigative Site, Riga, Latvia|Novartis Investigative Site, Riga, Latvia|Novartis Investigative Site, Kaunas, LTU, Lithuania|Novartis Investigative Site, Klaipeda, Lithuania|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Breda, CK, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Eindhoven, Netherlands|Novartis Investigative Site, Hoorn, Netherlands|Novartis Investigative Site, Sittard-Geleen, Netherlands|Novartis Investigative Site, Tilburg, Netherlands|Novartis Investigative Site, Grudziadz, Poland|Novartis Investigative Site, Katowice, Poland|Novartis Investigative Site, Kielce, Poland|Novartis Investigative Site, Konskie, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Amadora, Portugal|Novartis Investigative Site, Braga, Portugal|Novartis Investigative Site, Coimbra, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Constanta, Jud. Constanta, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Suceava, Romania|Novartis Investigative Site, Targu Mures, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Ufa, Russian Federation|Novartis Investigative Site, Banska Bystrica, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Martin, Slovakia|Novartis Investigative Site, Nitra, Slovakia|Novartis Investigative Site, Presov, Slovakia|Novartis Investigative Site, Trencin, Slovakia|Novartis Investigative Site, Trnava, Slovakia|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, L Hospitalet De Llobregat, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, El Palmar, Murcia, Spain|Novartis Investigative Site, Bilbao, Pais Vasco, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Goeteborg, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Aarau, CH, Switzerland|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Lugano, Switzerland|Novartis Investigative Site, Luzern, Switzerland|Novartis Investigative Site, St Gallen, Switzerland|Novartis Investigative Site, Zuerich, Switzerland|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Altunizade, Turkey|Novartis Investigative Site, Haseki / Istanbul, Turkey|Novartis Investigative Site, Kocaeli, Turkey|Novartis Investigative Site, Mecidiyekoy/Istanbul, Turkey|Novartis Investigative Site, Samsun, Turkey|Novartis Investigative Site, Trabzon, Turkey|Novartis Investigative Site, Salford, Manchester, United Kingdom|Novartis Investigative Site, Headington, Oxfordshire, United Kingdom|Novartis Investigative Site, Sheffield, South Yorkshire, United Kingdom|Novartis Investigative Site, Bristol, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT01665144
110,NCT01661322,Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke,TARDIS,Terminated,No Results Available,Stroke,"Drug: Aspirin, Dipyradimole, Clopidogrel",The primary outcome is ordinal stroke severity at 90 days|Safety|Serious adverse events|Death|Platelet function.,University of Nottingham,All,"50 Years and older   (Adult, Older Adult)",Phase 3,3096,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,08093|2007-006749-42,April 2009,September 2017,September 2017,"August 9, 2012",NA,"June 11, 2018","Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT01661322
111,NCT01639014,Effect of F2695 on Functional Recovery After Ischemic Stroke,LIFE,Completed,No Results Available,Ischemic Stroke,Drug: F2695|Drug: placebo,"Percentage of patients with a Modified Rankin Scale (mRS) less than or equal to 1 at Week 12|Percentage of patients with NIHSS score less than or equal to 5 at Week 12|Percentage of patients with at least one moderate to severe depressive|Change from baseline to Week 12 of the mean NIHSS total and motor scores|Safety and tolerability assessed by the investigator including SAEs, AEs, vital signs, ECG,physical examination and laboratory tests|Percentage of patients with a mRS score less than or equal to 2 at Week 12",Pierre Fabre Medicament,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,532,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",F02695 LP 2 05|2012-001592-37,July 2012,February 2015,February 2015,"July 12, 2012",NA,"April 1, 2015","Cliniques Universitaires Saint Luc, Brussels, Belgium|Universitair Ziekenhuis Gent, Ghent, Belgium|Universitaire Ziekenhuis Gasthuisberg, Leuven, Belgium|Clinique Saint-Joseph, Liege, Belgium|Regional Ziekenhuis Sint-Trudo, Sint-Truiden, Belgium|Sint-Andriesziekenhuis, Tielt, Belgium|Academisch Ziekenhuis Sint Augustinus, Wilrijk, Belgium|Fakultní nemocnice u sv. Anny v Brne, Brno, Czech Republic|Fakultní nemocnice Hradec Králové, Hradec Kralové, Czech Republic|Litomyšlská Nemocnice, a.s., Litomyšl, Czech Republic|Fakultní nemocnice Olomouc, Olomouc, Czech Republic|Vítkovická nemocnice a.s., Ostrava - Vítkovice, Czech Republic|Fakultní Nemocnice Ostrava, Ostrava, Czech Republic|Hopital Jean Minjoz Centre Hospitalier Universitaire Besancon, Besançon, France|Clinique des Cèdres, Cornebarrieu, France|Centre Hospitalier de Lens, Lens, France|Hôpital Roger Salengro, Lille, France|Groupe Hospitalier Paris Saint Joseph, Paris, France|Hopital Lariboisière, Paris, France|Centre Hospitalier Universitaire de Poitiers Hôpital de la Milétrie, Poitiers, France|Centre Hospitalier Universitaire de Saint Etienne, Hôpital Nord, Saint Priest en Jarez, France|Hôpital Purpan, Toulouse, France|Neurologische Klinik GmbH, Bad Neustadt/Saale, Germany|Universitätsklinik Charité, Campus Mitte, Berlin, Germany|Universitätsklinikum Bonn, Bonn, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Universitätsklinikum Essen, Essen, Germany|Freiburger Universitätsklinik, Freiburg, Germany|Asklepios Klinik Altona, Hamburg, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitätsklinikum Münster, Münster, Germany|Asklepios Fachklinikum Teupitz, Teupitz, Germany|Jahn Ferenc Dél-pesti Kórház, Budapest, Hungary|Magyar Honvédség Honvédkórház, Budapest, Hungary|Semmelweis Egyetem Neurológiai Klinika, Budapest, Hungary|Debreceni Egyetem Orvos- és Egészségtudományi Centrum, Debrecen, Hungary|Petz Aladár Megyei Oktató Kórház, Gyor, Hungary|Kaposi Mór Megyei Oktató Kórhaz, Kaposvár, Hungary|BAZ Megyei és Egyetemi Oktató Kórház, Miskolc, Hungary|Kanizsai Dorottya Kórház, Nagykanizsa, Hungary|Jósa András Oktató Kórház, Nyíregyháza, Hungary|Soproni Erzsébet Oktató Kórház, Sopron, Hungary|Fejér Megyei Szent György Kórház, Székesfehérvár, Hungary|Azienda Sanitaria Ospedaliera ""San Giovanni Battista"", Foligno, Italy|Azienda Ospedaliera San Gerardo, Monza, Italy|IRCCS ""Istituto Neurologico C. Mondino"", Pavia, Italy|Ospedale Santa Maria della Misericordia, Perugia, Italy|IRCCS Fondazione Santa Lucia, Roma, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Hospital Garcia de Orta, Almada, Portugal|Hospitais da Universidade de Coimbra, Coimbra, Portugal|Hospital de Santa Maria, Lisboa, Portugal|Centro Hospitalar do Porto / Hospital Geral de Santo António, Porto, Portugal|Hospital de São João, Porto, Portugal|Municipal Healthcare Institution ""Municipal Clinical Hospital # 3"", Chelyabinsk, Russian Federation|Regional Hospital #1, Ekaterinburg, Ekaterinburg, Russian Federation|Professor S.V. Ochapovsky Territorial Clinical Hospital #1, Krasnodar, Russian Federation|Clinical Hospital Number 31, Moscow, Russian Federation|Non-state Healthcare Institution ""N.A. Semashko Central Clinical Hospital #2 of JSC ""Russian Railway, Moscow, Russian Federation|Scientific Research Neurology Institute of Russian Academy of Medical Services, Moscow, Russian Federation|State Budget Healthcare Institution ""City clinical hospital #20"", Moscow, Russian Federation|State Institution of Healthcare of Moscow City ""City Clinical Hospital #61"", Moscow, Russian Federation|State Institution ""Saint Petersburg I.I. Dzhanelidze Research Institute of Emergency"", Petersburg Saint, Russian Federation|Municipal Medical Institute ""N.I.Pirogov City Clinical hospital #1"", Samara, Russian Federation|State Healthcare Institution ""Samara M.I.Kalinin Regional Clinical Hospital"", Samara, Russian Federation|Smolensk State Medical Academy of RosZdrav, Smolensk, Russian Federation|Bashkirian State Medical University, Ufa, Russian Federation|Hospital General de Albacete, Albacete, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario de Girona Doctor Josep Trueta, Gerona, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain|Hospital de Tortosa Verge de la Cinta, Tortosa, Spain|Hospital Clinico Universitario de Valladolid, Valladolid, Spain|Danderyds Sjukhus AB, Danderyd, Sweden|Sahlgrenska Universitetsjukhuset, Göteborg, Sweden|Universitetssjukhuset Linköping, Linköping, Sweden|Skånes Universitetssjukhus i Lund, Lund, Sweden|Mora lasarett, Mora, Sweden|Kärnsjukhuset i Skövde-KSS, Skövde, Sweden|Universitätsspital Basel, Basel, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Klinik Hirslanden, Zürich, Switzerland",NA,https://ClinicalTrials.gov/show/NCT01639014
112,NCT01604785,Low-dose Propofol for Pediatric Migraine,NA,Completed,Has Results,Migraine Headache,Drug: Propofol|Drug: Standard Treatment,Change in Self-Assessed Pain|Rebound Headache at 24 Hour Follow-up Phone Call|Emergency Department Length of Stay,Oregon Health and Science University,All,"7 Years to 18 Years   (Child, Adult)",Phase 2|Phase 3,74,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,Meckler01,November 2012,August 2016,August 2016,"May 24, 2012","December 31, 2018","December 31, 2018","Oregon Health & Science University, Portland, Oregon, United States",NA,https://ClinicalTrials.gov/show/NCT01604785
113,NCT01568073,"Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With ""Wearing-off"" Phenomenon",NA,Completed,Has Results,Parkinson's Disease,Drug: BIA 9-1067|Drug: Entacapone|Drug: Placebo|Drug: Levodopa|Drug: Carbidopa|Drug: Benserazide,"Efficacy of 3 BIA 9-1067 (5 mg, 25 mg, and 50 mg) Compared With 200 mg of Entacapone or Placebo,|Total UPDRS SCORE (I, II (ON), and III)|Parkinson's Disease Sleep Scale (PDSS)|Non-motor Symptoms Scale (NMSS)",Bial - Portela C S.A.,All,"30 Years to 83 Years   (Adult, Older Adult)",Phase 3,600,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BIA-91067-301|2010-021860-13,March 2011,November 2013,November 2013,"April 2, 2012","January 8, 2015","September 18, 2015","Bial - Portela & Cª, S.A., S. Mamede do Coronado, Portugal",NA,https://ClinicalTrials.gov/show/NCT01568073
114,NCT01561053,A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease,AMBAR,Completed,Has Results,Alzheimer's Disease,Biological: Albumin 5%|Biological: Albumin 20%|Biological: Immunoglobulin,Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score (Changes From Baseline to 14 Months)|Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Total Score (Changes From Baseline to 14 Months),"Instituto Grifols, S.A.|Grifols Biologicals, LLC",All,"55 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,347,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",IG1002,"April 19, 2012","March 6, 2018","March 6, 2018","March 22, 2012","July 31, 2019","July 31, 2019","Northern California Research, Sacramento, California, United States|Mountain View Clinical Research, Inc, Denver, Colorado, United States|Howard University, Washington, District of Columbia, United States|Bradenton Research Center, Inc., Bradenton, Florida, United States|Quantum Laboratories, Deerfield Beach, Florida, United States|Galiz Research, LLC, Hialeah, Florida, United States|Largo Medical Center, Largo, Florida, United States|L&L Research Choices, Inc, Miami, Florida, United States|Allied Biomedical Research Institute, Miami, Florida, United States|Miami Dade Medical Research Institute, LLC, Miami, Florida, United States|Neurology Associates of Osmond Beach, Ormond Beach, Florida, United States|PharmaSeek LLC (DMI Research), Pinellas Park, Florida, United States|iResearch Atlanta, LLC, Decatur, Georgia, United States|RTR Medical Group, Savannah, Georgia, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Mid-Atlantic Geriatric/ARC, Manchester, New Jersey, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Neurology Specialists Inc, Dayton, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Wesley Neurology Clinic, Cordova, Tennessee, United States|Hospital General de Elche, Elche, Alicante, Spain|Hospital Universitario del Vinalopó, Elche, Alicante, Spain|Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital General de Catalunya, Sant Cugat Del Vallès, Barcelona, Spain|Hospital Universitari Mútua de Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Canary Islands, Spain|Hospital Universitario de Getafe, Getafe, Madrid, Spain|Fundació ACE, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Parc Hospitalari Martí i Julià, Girona, Spain|Hospital Universitari de Santa Maria, Lleida, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario Doctor Peset, Valencia, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Spain|Hospital Viamed Montecanal, Zaragoza, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT01561053/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT01561053/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01561053
115,NCT01462812,Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine,NA,Completed,Has Results,Migraine Headache,Drug: Sumatriptan|Drug: Placebo,Headache Relief,Optinose US Inc.,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,223,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",OPN-SUM-MIG-3301,January 2011,June 2012,June 2012,"October 31, 2011","May 6, 2015","May 6, 2015","San Francisco Clinical Research Center, San Francisco, California, United States|California Medical Clinic for Headache, Santa Monica, California, United States|Associated Neurologists of Southern CT, P.C., Fairfied, Connecticut, United States|Premiere Research Institute, West Palm Beach, Florida, United States|MedVadis, Watertown, Massachusetts, United States|Michigan Head and Pain Institute, Ann Arbor, Michigan, United States|ClinVest, Springfield, Missouri, United States|Mercy Health Research, St. Louis, Missouri, United States|DENT Neurologic Institute, Amherst, New York, United States|Headache Wellnes Center, Greensboro, North Carolina, United States|PMG Research of Raleigh North carolina, LLC, Raleigh, North Carolina, United States|PMG Research of Winston Salem, LLC, Winston Salem, North Carolina, United States|Neurology Center of Ohio, Toledo, Ohio, United States|Jefferson Headache Center, Philadelphia, Pennsylvania, United States|Coastal Carolina Research Center, Mt. Pleasant, South Carolina, United States",NA,https://ClinicalTrials.gov/show/NCT01462812
116,NCT01433497,Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis,NA,Completed,No Results Available,"Multiple Sclerosis, Secondary Progressive|Multiple Sclerosis, Primary Progressive|Multiple Sclerosis, Relapse Free",Drug: Masitinib|Drug: Placebo,EDSS|MSQOL-54|MSFC,AB Science,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,656,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AB07002,August 2011,September 2019,February 2020,"September 14, 2011",NA,"April 8, 2020","""St. Ivan Rilski"" University Multiprofile Hospital for Active Treatment, Sofia, Bulgaria|GHICL hopital ST vincent de Paul, Lille, France|Hôpital de Gui de Chauliac, Montpellier, France|Universitätsklinikum Gießen und Marburg, Marburg, Germany|Rehibilitation Center ""KENTAVROS"", Volos, Greece|KO-MED Centra Kliniczne Lublin II, Lublin, Poland|Centrul Medical Clubul Sănătăţii, Campulung, Romania|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",NA,https://ClinicalTrials.gov/show/NCT01433497
117,NCT01432704,Colecalciferol as an Add-on Treatment to Subcutaneously-Administered Interferon-beta-1b for Treatment of Multiple Sclerosis (MS),100207MS-H,Completed,No Results Available,Multiple Sclerosis,Drug: colecalciferol,To evaluate the safety and tolerability of add-on -treatment with colecalciferol of MS patients treated with interferon beta-1b and|To estimate the effect of interferon-beta-1b with an add-on of colecalciferol versus interferon-beta-1b with an add-on of placebo on MRI T2 BOD at 12 months in comparison with MRI T2 BOD at baseline|Number of Gadolinium-enhancing lesions on T1 and /or new enlarging lesions on T2/PD based on MRI done 12 months following randomisation compared with the MRI done at the time of randomisation,University of Turku|Bayer,All,18 Years to 50 Years   (Adult),Phase 2|Phase 3,70,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EudraCT 2007-001958-99,March 2008,May 2011,August 2011,"September 13, 2011",NA,"September 13, 2011",NA,NA,https://ClinicalTrials.gov/show/NCT01432704
118,NCT01416181,A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis,ASCEND in SPMS,Terminated,Has Results,Secondary Progressive Multiple Sclerosis,Drug: natalizumab|Drug: Placebo,"Part 1: Percentage of Participants With Confirmed Progression of Disability in One or More of the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), or 9-Hole Peg Test (9HPT)|Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Part 1: Percentage of Participants With a T25FW Response|Part 1: Change From Baseline in the 12-Item MS Walking Scale (MSWS-12)|Part 1: Change From Baseline in Manual Ability Score Based on the ABILHAND Questionnaire|Part 1: Change From Baseline in the Multiple Sclerosis Impact Scale-29 Physical (MSIS-29 Physical) Score|Part 1: Percentage Change From Week 24 in Whole Brain Volume at Week 96|Part 1: Percentage of Participants Defined as Confirmed Progressors on EDSS Functional System Scores|Part 2: Percentage of Participants With Disability Worsening at 156 Weeks|Part 2: Absolute Change From Baseline (Part 1) in T25FW|Part 2: Percentage Change From Baseline (Part 1) in T25FW|Part 2: Absolute Change From Baseline (Part 1) in 9HPT (Dominant Hand)|Part 2: Percentage Change From Baseline (Part 1) in 9HPT (Dominant Hand)|Part 2: Absolute Change From Baseline (Part 1) in 9HPT (Non-Dominant Hand)|Part 2: Percentage Change From Baseline (Part 1) in 9HPT (Non-Dominant Hand)|Part 2: Absolute Change From Baseline (Part 1) in EDSS|Part 2: Percentage Change From Baseline (Part 1) in EDSS|Part 2: Absolute Change From Baseline (Part 1) in the 6-Minute Walk Test (6MWT)|Part 2: Percentage Change From Baseline (Part 1) in the 6MWT|Part 2: Absolute Change From Baseline (Part 1) in the MSIS-29 Physical Score|Part 2: Percentage Change From Baseline (Part 1) in the MSIS-29 Physical Score|Part 2: Absolute Change From Baseline (Part 1) in the Symbol Digit Modalities Test (SDMT)|Part 2: Percentage Change From Baseline (Part 1) in the SDMT|Part 2: Absolute Change From Baseline (Part 2) in the Work Productivity and Activity Impairment - Multiple Sclerosis (WPAI-MS) Questionnaire|Part 2: Percentage Change From Baseline (Part 2) in the WPAI-MS Questionnaire|Part 2: Percentage Change From Week 24 (Part 1) in Whole Brain Volume|Part 2: Percentage Change From Baseline (Part 1) in Whole Gray Matter Brain Volume|Part 2: Summary of New/Enlarging T2 Lesion Counts|Part 2: Percentage Change From Baseline (Part 1) in Number of New/Enlarging T2 Lesions",Biogen,All,18 Years to 58 Years   (Adult),Phase 3,889,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",101MS326|2010-021978-11,"September 13, 2011","July 28, 2015","April 13, 2016","August 12, 2011","June 27, 2017","September 11, 2017","Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Fullerton, California, United States|Research Site, Los Angeles, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Tampa, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Lake Barrington, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Kansas City, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Burlington, Massachusetts, United States|Research Site, Omaha, Nebraska, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Teaneck, New Jersey, United States|Research Site, Latham, New York, United States|Research Site, New York, New York, United States|Research Site, Advance, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Uniontown, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Clackamas, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Nashville, Tennessee, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, La Louviere, Belgium|Research Site, Melsbroek, Belgium|Research Site, Overpelt, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Kingston, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Hradec Kralove, Bohemia, Czechia|Research Site, Brno, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha, Czechia|Research Site, Arthus C, Denmark|Research Site, Esbjerg, Denmark|Research Site, Glostrup, Denmark|Research Site, København Ø, Denmark|Research Site, Odense, Denmark|Research Site, Jyväskylä, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Nice, Alpes Maritimes, France|Research Site, Marseille cedex 5, Bouches-du-Rhône, France|Research Site, Nantes, Loire Atlantique, France|Research Site, Nancy, Meurthe et Moselle, France|Research Site, Lille Cedex, Nord, France|Research Site, Bron cedex, Rhone, France|Research Site, Salouel, Somme, France|Research Site, Bordeaux, France|Research Site, Bad Wilbad, Baden Wuerttemberg, Germany|Research Site, Tuebingen, Baden Wuerttemberg, Germany|Research Site, Bad Mergentheim, Baden-Wuerttemberg, Germany|Research Site, Muenchen, Bayern, Germany|Research Site, Muenchen, Bayern, Germany|Research Site, Hennigsdorf, Brandenburg, Germany|Research Site, Teupitz, Brandenburg, Germany|Research Site, Kassel, Hessen, Germany|Research Site, Duesseldorf, Nordrhein Westfalen, Germany|Research Site, Muenster, Nordrhein Westfalen, Germany|Research Site, Dresden, Sachsen, Germany|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Jerusalem, Israel|Research Site, Ramat Gan, Israel|Research Site, Baggiovara, Modena, Italy|Research Site, Cefalu, Palermo, Italy|Research Site, Gallarate, Varese, Italy|Research Site, Bari, Italy|Research Site, Florence, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Naples, Italy|Research Site, Napoli, Italy|Research Site, Palermo, Italy|Research Site, Pavia, Italy|Research Site, Rome, Italy|Research Site, Rome, Italy|Research Site, Amsterdam, Netherlands|Research Site, Breda, Netherlands|Research Site, Hertogenbosch, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Sittard-Geleen, Netherlands|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Olsztyn, Poland|Research Site, Plewiska, Poland|Research Site, Poznan, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa-Miedzylesie, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Belgorod, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tyumen, Russian Federation|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, El Palmar, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Málaga, Spain|Research Site, Santa Cruz de Tenerife, Spain|Research Site, Sevilla, Spain|Research Site, Göteborg, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Umeå, Sweden|Research Site, Örebro, Sweden|Research Site, Irvine, Ayrshire, United Kingdom|Research Site, Edgbaston, Birmingham, United Kingdom|Research Site, Exeter, Devon, United Kingdom|Research Site, Plymouth, Devon, United Kingdom|Research Site, London, Greater London, United Kingdom|Research Site, London, Greater London, United Kingdom|Research Site, Hammersmith, London, United Kingdom|Research Site, Edinburgh, Lothian Region, United Kingdom|Research Site, Salford, Manchester, United Kingdom|Research Site, Liverpool, Merseyside, United Kingdom|Research Site, Norwich, Norfolk, United Kingdom|Research Site, Nottingham, Nottinghamshire, United Kingdom|Research Site, Morriston, Swansea, United Kingdom|Research Site, Newcastle, Tyne, United Kingdom|Research Site, Brighton, United Kingdom|Research Site, London, United Kingdom|Research Site, Sheffield, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT01416181
119,NCT01412333,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,NA,Completed,Has Results,Relapsing Multiple Sclerosis,Drug: Interferon beta-1a|Drug: Ocrelizumab-matching placebo|Drug: Ocrelizumab|Drug: Interferon beta-1a-matching placebo,"Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks|Time to Onset of Confirmed Disability Progression (CDP) for at Least 12 Weeks During the Double-Blind Treatment Period|Number of T1 Gadolinium (Gd)-Enhancing Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double-Blind Treatment|Number of New, and/or Enlarging T2 Hyperintense Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double Blind Treatment|Percentage of Participants With Confirmed Disability Improvement (CDI) for at Least 12 Weeks|Time to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks During the Double-Blind Treatment Period|Number of T1 Hypointense Lesions During the Double-Blind Treatment|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score to Week 96|Percent Change in Brain Volume as Detected by Brain Magnetic Resonance Imaging (MRI) From Week 24 to Week 96|Change From Baseline in Short Form Health Survey-36 (SF-36) Physical Component Summary (PCS) Score at Week 96|Percentage of Participants Who Have No Evidence of Disease Activity (NEDA) up to Week 96|Number of Participants With Adverse Events (AEs)|Exposure to Ocrelizumab (Area Under the Concentration - Time Curve, AUC)|Number of Participants With Anti-Drug Antibodies (ADAs) to Ocrelizumab",Hoffmann-La Roche,All,18 Years to 55 Years   (Adult),Phase 3,835,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WA21093|2010-020315-36,"September 20, 2011","May 12, 2015","December 30, 2022","August 9, 2011","July 18, 2017","March 3, 2023","Hope Research Institute, Phoenix, Arizona, United States|HonorHealth Neurology, Scottsdale, Arizona, United States|Territory Neurology and Research Institute, Tucson, Arizona, United States|Collaborative Neuroscience Research, LLC, Long Beach, California, United States|Stanford University Medical Center, Palo Alto, California, United States|University of Colorado, Denver, Colorado, United States|Advanced Neurosciences Research LLC, Fort Collins, Colorado, United States|Associated Neurologists of Southern CT PC, Fairfield, Connecticut, United States|Infinity Clinical Research, Hollywood, Florida, United States|University of Miami; Dept. of Neurology MS Center, Miami, Florida, United States|Neurological Services of Orlando, Orlando, Florida, United States|Lovelace Scientific Resources, Sarasota, Florida, United States|University of South Florida, Tampa, Florida, United States|Atlanta Neuroscience Institute, Atlanta, Georgia, United States|Josephson Wallack Munshower Neurology PC, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|MidAmerica Neuroscience Institute, Prairie Village, Kansas, United States|Associates in Neurology PSC, Lexington, Kentucky, United States|Dragonfly Research, LLC, Wellesley, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Wayne State University; Department of Neurology, Detroit, Michigan, United States|The Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States|Rutgers New Jersey Medical School, Newark, New Jersey, United States|Holy Name Hospital, Teaneck, New Jersey, United States|MS Comprehensive Care Center, Teaneck, New Jersey, United States|Shore Neurology, Toms River, New Jersey, United States|Empire Neurology, PC, Latham, New York, United States|Weill Cornell MC-NY Presbyter; Dept. of Neurology/Neuroscience, Judith Jaffe Multiple Sclerosis Ctr, New York, New York, United States|South Shore Neurologic Associates P.C., Patchogue, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|SUNY at Stony Brook, Stony Brook, New York, United States|The Neurological Institute PA, Charlotte, North Carolina, United States|Neurology Associates PA, Hickory, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Columbus Neuroscience, Columbus, Ohio, United States|Abington Neurological Associates, Abington, Pennsylvania, United States|Absher Neurology PA, Greenville, South Carolina, United States|Neurology Clinic PC, Cordova, Tennessee, United States|Sibyl Wray MD Neurology PC, Knoxville, Tennessee, United States|Advanced Neurosciences Institute, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Bhupesh Dihenia M.D. P.A., Lubbock, Texas, United States|Central Texas Neurology Consultants, Round Rock, Texas, United States|Integra Clinical Research, Llc, San Antonio, Texas, United States|Neurology Center of San Antonio, San Antonio, Texas, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|ALPI-Inst. de Rehabilitacion Marcelo Fitte, Buenos Aires, Argentina|STAT Research S.A., Ciudad de Buenos Airesa, Argentina|Grodno State Medical University, Grodno, Belarus|City Clinical Hospital #9, Minsk, Belarus|Vitebsk; Regional Diagnostic Center, Vitebsk, Belarus|Vitebsk Regional Clinical Hospital, Vitebsk, Belarus|UZ Antwerpen, Edegem, Belgium|University Clinic Ctr Sarajevo, Sarajevo, Bosnia and Herzegovina|Uni Hospital Center Tuzla, Tuzla, Bosnia and Herzegovina|Santa Casa de Misericordia; de Belo Horizonte, Belo Horizonte, MG, Brazil|Hospital Universitario Gaffree e Guinle, Rio de Janeiro, RJ, Brazil|Hospital das Clinicas - UNICAMP, Campinas, SP, Brazil|MHATNP Sv.Naum EAD; Clinic for intensive treatment of neurology diseases, Sofia, Bulgaria|Fifth MHAT-Sofia AD; Neuro Dept with Vascular Unit, Sofia, Bulgaria|MHAT National Cardiology Hospital, EAD; Neurology, Sofia, Bulgaria|UMHAT Alexandrovska, EAD; Neurology, Sofia, Bulgaria|Multiple Sclerosis Clinic, Calgary, Alberta, Canada|University of Alberta; Northern Alberta Trials & Research Centre, Edmonton, Alberta, Canada|Vancouver Hospital - UBC Hospital Site, Vancouver, British Columbia, Canada|The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|Clinique NeuroOutaouais, Gatineau, Quebec, Canada|Recherche Sepmus Inc., Greenfield Park, Quebec, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|Hôpital Maisonneuve - Rosemont; Recherche Clinique de Neurologie, Montréal, Quebec, Canada|General Hospital Pula, Pula, Croatia|General Hospital Varazdin, Varazdin, Croatia|Clinical Hospital Centre Zagreb;Clinic for Neurology, Zagreb, Croatia|Uni Hospital Centre Dubrava, Zagreb, Croatia|Fakultni nemocnice Brno, Brno, Czechia|Neurospol s.r.o., Havirov, Czechia|Pardubicka Krajska Nemocnice; Department of Neurology, Pardubice, Czechia|Krajska zdravotni, a. s. ? Nemocnice Teplice, o. z.; Neurologicke oddeleni, Teplice, Czechia|Hopital Neurologique Pierre Wertheimer, Bron, France|Hôpital General - Service de neurologie; Service de neurologie, Dijon Cedex, France|Hôpital Saint Philibert, Lommé, France|Groupe Hospitalier Pitie-Salpetriere, Paris, France|Hôpital Maison Blanche; Service de Neurologie, Reims, France|CHU toulouse - Hôpital Purpan; Departement de Neurologie, Toulouse, France|Sankt Gertrauden Krankenhaus; Neurologisches Facharztzentrum, Berlin, Germany|Neurologische Praxis Bonn, Bonn, Germany|Universitätsklinikum Düsseldorf; Klinik für Neurologie, Düsseldorf, Germany|Zentrum fuer ambulante Neurologie, Essen, Germany|Universitaetsklinikum Frankfurt; Klinik für Neurologie, Frankfurt, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Ratsapotheke Mittweida, Mittweida, Germany|Klinikum Grosshadern der LMU, Muenchen, Germany|Klinikum rechts der Isar der TU Muenchen; Neurologische Klinik und Poliklinik im Neuro-Kopf-Zentrum, München, Germany|Neurologische Gemeinschaftspraxis Dr. Lang, Prof. Schreiber, Dr. Krauß, Dr. Kornhuber, Ulm, Germany|St Vincents University Hospital, Dublin 4, Ireland|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, Lazio, Italy|Policlinico Universitario Agostino Gemelli, Roma, Lazio, Italy|A.O. Universitaria S. Martino Di Genova, Genova, Liguria, Italy|Fondazione IRCCS Istituto Neurologico Carlo Besta; Farmacia Interna, Milano, Lombardia, Italy|Ospedale Civile di Montichiari; Centro Sclerosi Multipla, Montichiari, Lombardia, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi Di Ancona, Torrette - Ancona, Marche, Italy|Ospedale degli Infermi, Ponderano, Piemonte, Italy|Ospedale Generale Regionale F. Miulli, Acquaviva delle Fonti, Puglia, Italy|Ospedale Casa Sollievo Della Sofferenza IRCCS, San Giovanni Rotondo, Puglia, Italy|Fond. Ist. S. Raffaele - giglio, Cefalu, Sicilia, Italy|Mexico Centre for Clinical Research, Ciudad de México, Mexico CITY (federal District), Mexico|Clinical Research Institute, Tlalnepantla de Baz, Mexico CITY (federal District), Mexico|Instituto Biomedico De Investigacion A.C., Aguascalientes, Mexico|Hospital CIMA Chihuahua; Centro de Investigación Clínicatorre de Consultoriospiso 4, Chihuahua, Mexico|Hospital Angeles Culiacan; Neurociencias, Culiacan, Mexico|Hospital Mexico Americano SC; Departamento de Electroencefalografía, Guadalajara, Mexico|Haukeland Universitetssykehus, Bergen, Norway|Vitamed, Bydgoszcz, Poland|MA-LEK Clinical Sp. Z o.o., Katowice, Poland|Krakowska Akademia Neurologii Sp z o.o. Centrum Neurologii K, Krakow, Poland|SPZOZ Uniwersytecki Szp. Klin. nr1 im.N.Barlickiego UM;Oddzial Kliniczny Neurologii, Lodz, Poland|Centrum Neurologii Krzysztof Selmaj, Lodz, Poland|Samodz.Publi.Szpital Kliniczny; nr 4 w Lublinie, Lublin, Poland|Wojewodzki Specjalistyczny Szpital w Olsztynie; Oddzial Neurologiczny z Pododdzialem Udarowym, Olsztyn, Poland|Neuro-Care Gabriela Klodowska, Siemianowice ?l?skie, Poland|mMED Maciej Czarnecki, Warszawa, Poland|State institution of health care - Territorial Clinical Hospital, Barnaul, Russian Federation|State autonomous institution of healthcare Inter-regional clinical and diagnostic center, Kazan, Russian Federation|Kirov City Clinical Hospital #1; Neurology Department, Kirov, Russian Federation|SBHI of Nizhny Novgorod region City Clinical Hospital #3; neurology department, Nizniy Novgorod, Russian Federation|Perm SMA n.a. academ. E.A. Vagner, Perm, Russian Federation|City Clinical Hospital#2, Pyatigorsk, Russian Federation|St. Petersburg State Medical University n.a. I.P. Pavlov; Hematology, transfusiology and transplanta, Saint-Petersburg, Russian Federation|Saratov State Medical University of RosZdrav; Neurology, Saratov, Russian Federation|MUDr. Beata Dupejova Neurologicka ambulancia s.r.o, Banska Bystrica, Slovakia|Fakultna Nemocnica Roosevelta, Banska Bystrica, Slovakia|Vseobecna nemocnica s poliklinikou Levoca a.s., Levoca, Slovakia|Institut Catala d?Oncologia Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge; Servicio de Neurologia, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital General Univ. de Alicante, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Girona Dr Josep Trueta, Girona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Neurologia, Madrid, Spain|Hospital Universitario Clinico San Carlos, Madrid, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain|Hospital Clinico Universitario de Valencia; Servicio de Neurologia, Valencia, Spain|Sahlgrenska Sjukhuset; Neurology, Göteborg, Sweden|Karolinska Universitetssjukhuset Solna Neurology, Stockholm, Sweden|Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden|Norrlands Universitetssjukhus, Umeå, Sweden|Hacettepe University Medical Faculty; Neurology, Ankara, Turkey|Haseki Training and Research Hospital, Istanbul, Turkey|Istanbul Universitesi - Cerrahpasa Cerrahpasa Tip Fakultesi; Noroloji Anabilim Dali, Istanbul, Turkey|Istanbul Bilim Universty Medical Fac., Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Kocaeli University Medical Faculty, Kocaeli, Turkey|Ondokuz Mayis Univ. Med. Fac.; Neurology, Samsun, Turkey|Karadeniz Tecnical Uni. Med. Fac.; Neurology, Trabzon, Turkey|Mun.Med.Proph.Inst.?Chernihiv Reg.Hosp.?; Neurology Department, Chernihiv, Ukraine|City Clinical Hospital #4, Dnipropetrovsk, Ukraine|State Institution V.K. Gusak Institute of Urgent and Recover; Dep of Reconstructive Angioneurology a, Donetsk, Ukraine|Road Clinical Hospital of Donetsk Station; Neurology Department, Donetsk, Ukraine|Regional Clinical Hospital; Neurology Department, Ivano-Frankivsk, Ukraine|Royal Devon and Exeter Hospital (Wonford), Exeter, United Kingdom|Kings College Hospital; Neurosciences Clinical Trials Office, London, United Kingdom|City General Hospital; Department of Neurology, Stoke on Trent, United Kingdom|Morriston Hospital, Swansea, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT01412333
120,NCT01409694,Alzheimer's Disease - Input of Vitamin D With mEmantine Assay,AD-IDEA,Completed,No Results Available,Alzheimer Disease,Drug: Memantine|Drug: Vitamin D|Drug: Vitamin D placebo,Change in cognitive performance|Change in other cognitive scores|Change in functional performance|Change in posture and gait|Between-group comparison of compliance to treatment and tolerance,"University Hospital, Angers",All,"60 Years and older   (Adult, Older Adult)",Phase 3,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2010-024506-35,September 2011,January 2016,January 2016,"August 4, 2011",NA,"September 22, 2016","University Hospital, Angers, France",NA,https://ClinicalTrials.gov/show/NCT01409694
121,NCT01405508,Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy,NA,Completed,Has Results,Epilepsy,Drug: Brivaracetam tablets|Drug: Brivaracetam bolus|Drug: Brivaracetam infusion|Other: Placebo,Number of Subjects With at Least One Treatment-emergent Adverse Event During the Study (Maximum 40 Days)|Number of Subjects Who Withdrew Due to a Treatment-emergent Adverse Event During the Study (Maximum 40 Days)|Number of Subjects With at Least One Injection-related Treatment-emergent Adverse Event (TEAE) During the Evaluation Period.,UCB Pharma,All,"16 Years to 70 Years   (Child, Adult, Older Adult)",Phase 3,105,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,N01258|2008-004714-27,August 2011,July 2012,July 2012,"July 29, 2011","April 13, 2016","July 11, 2018","001, Phoenix, Arizona, United States|775, Little Rock, Arkansas, United States|780, Lexington, Kentucky, United States|008, Bethesda, Maryland, United States|778, Columbus, Ohio, United States|776, Nashville, Tennessee, United States|777, Dallas, Texas, United States|036, Charlottesville, Virginia, United States|917, Brno, Czechia|915, Hradec Kralove, Czechia|916, Kromeriz, Czechia|913, Ostrava Poruba, Czechia|332, Bielefeld, Germany|903, Bonn, Germany|795, Katowice, Poland|479, Poznan, Poland|794, Warszawa, Poland",NA,https://ClinicalTrials.gov/show/NCT01405508
122,NCT01397422,Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study),EASED,Completed,Has Results,Dyskinesia|Levodopa Induced Dyskinesia|Parkinson's Disease,Drug: ADS-5102 (extended release amantadine HCl),"Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score From Baseline to Week 8|Change in the Fatigue Severity Score (FSS) From Baseline to Week 8|Change in Total Objective Score (III, IV) of the UDysRS From Baseline to Week 8|Change in ON Time Without Troublesome Dyskinesia (ON Without Dyskinesia Plus ON With Non-troublesome Dyskinesia) From Baseline to Week 8; Based on a Standardized PD Home Diary|Change in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Combined Scores (Parts I, II, III) From Baseline to Week 8|Clinician's Global Impression of Change (CGI-C) in Overall PD Symptoms From Baseline to Week 8","Adamas Pharmaceuticals, Inc.",All,"30 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,83,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ADS-PAR-AM201,July 2011,May 2013,October 2013,"July 19, 2011","November 6, 2017","December 13, 2017","Sun City, Arizona, United States|Fountain Valley, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Oxnard, California, United States|Pasadena, California, United States|Reseda, California, United States|Sunnyvale, California, United States|Ventura, California, United States|Fairfield, Connecticut, United States|Boca Raton, Florida, United States|Bradenton, Florida, United States|Port Charlotte, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|Winfield, Illinois, United States|Des Moines, Iowa, United States|Kansas City, Kansas, United States|Boston, Massachusetts, United States|West Bloomfield, Michigan, United States|Toms River, New Jersey, United States|New York, New York, United States|Durham, North Carolina, United States|Raleigh, North Carolina, United States|Toledo, Ohio, United States|Tulsa, Oklahoma, United States|Houston, Texas, United States|San Antonio, Texas, United States|Richmond, Virginia, United States|Kirkland, Washington, United States|Milwaukee, Wisconsin, United States",NA,https://ClinicalTrials.gov/show/NCT01397422
123,NCT01390220,Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters,ARTEMIS1,Terminated,Has Results,Epilepsy,Drug: USL261|Drug: Placebo,Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP)|Participants With Seizure(s) >10 Minutes to 4 Hours After Administration of the Double-blind Dose|Occurrence of Seizure With a Start Time >10 Minutes After Administration of the Double-blind Dose|Time to Next Seizure With a Start Time >10 Minutes After Administration of the Double-blind Dose,UCB Biopharma S.P.R.L.|UCB Pharma,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,292,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P261-401|2011-001318-32,June 2011,March 2017,March 2017,"July 8, 2011","May 31, 2019","October 10, 2019","United States, Arizona, Phoenix, Arizona, United States|United States, Arizona, Tucson, Arizona, United States|United States, Arkansas, Little Rock, Arkansas, United States|United States, California, Fresno, California, United States|United States, California, Irvine, California, United States|United States, California, Loma Linda, California, United States|United States, California, Sacramento, California, United States|United States, California, Ventura, California, United States|United States, Colorado, Aurora, Colorado, United States|United States, Connecticut, New Haven, Connecticut, United States|United States, Florida, Gainesville, Florida, United States|United States, Florida, Gulf Breeze, Florida, United States|United States, Florida, Port Charlotte, Florida, United States|United States, Florida, Tampa, Florida, United States|United States, Florida, Wellington, Florida, United States|United States, Idaho, Boise, Idaho, United States|United States, Illinois, Chicago, Illinois, United States|United States, Kansas, Manhattan, Kansas, United States|United States, Kentucky, Lexington, Kentucky, United States|United States, Maryland, Baltimore, Maryland, United States|United States, Michigan, Detroit, Michigan, United States|United States, Minnesota, Saint Paul, Minnesota, United States|United States, Missouri, Chesterfield, Missouri, United States|United States, Missouri, Saint Louis, Missouri, United States|United States, Nevada, Reno, Nevada, United States|United States, New Hampshire, Lebanon, New Hampshire, United States|United States, New Jersey, Flemington, New Jersey, United States|United States, New Jersey, Hackensack, New Jersey, United States|United States, New York, Bronx, New York, United States|United States, New York, New York, New York, United States|United States, New York, Stony Brook, New York, United States|United States, North Carolina, Durham, North Carolina, United States|United States, North Carolina, Winston-Salem, North Carolina, United States|United States, Ohio, Columbus, Ohio, United States|United States, Oklahoma, Oklahoma City, Oklahoma, United States|United States, Oregon, Portland, Oregon, United States|United States, Pennsylvania, Philadelphia, Pennsylvania, United States|United States, Tennessee, Memphis, Tennessee, United States|United States, Tennessee, Nashville, Tennessee, United States|United States, Texas, Dallas, Texas, United States|United States, Texas, Fort Worth, Texas, United States|United States, Texas, Greenville, Texas, United States|United States, Texas, San Antonio, Texas, United States|United States, Texas, Temple, Texas, United States|United States, Virginia, Norfolk, Virginia, United States|United States, Wisconsin, Madison, Wisconsin, United States|Australia, New South Wales, Chatswood, New South Wales, Australia|Australia, New South Wales, Randwick, New South Wales, Australia|Australia, Queensland, Herston, Queensland, Australia|Australia, Vctoria, Heidelberg West, Victoria, Australia|Australia, Victoria, Parkville, Victoria, Australia|Canada, Ontario, Toronto, Ontario, Canada|Canada, Quebec, Montreal, Quebec, Canada|Germany, Baden-Wurttemberg, Freiburg, Baden-Wurttemberg, Germany|Germany, Bayern, Munich, Bayern, Germany|Germany, Hessen, Marburg, Hessen, Germany|Germany, Nordrhein-Westfalen, Bonn, Nordrhein-Westfalen, Germany|Germany, Westfalen-Lippe, Bielefeld, Wetsfalen-Lippe, Germany|Hungary, Budapest, Hungary|Hungary, Kazincbarcika, Hungary|Israel, Haifa, Israel|Israel, Holon, Israel|Israel, Jerusalem, Israel|Israel, Petach Tikva, Israel|Israel, Ramat Gan, Israel|Israel, Tel Aviv, Israel|Italy, Firenze, Italy|Italy, Genova, Italy|Italy, Milano, Italy|Italy, Napoli, Italy|Italy, Pavia, Italy|Italy, San Fermo della Battaglia, Italy|New Zealand, Auklund, Grafton, Auklund, New Zealand|New Zealand, Canterbury, Christchurch, Canterbury, New Zealand|Poland, Gdansk, Poland|Poland, Katowice, Poland|Poland, Krakow, Poland|Poland, Olsztyn, Poland|Spain, Andalucia, Sevilla, Andalucia, Spain|Spain, Catalonia, Barcelona, Catalonia, Spain|Spain, Catalonia, Girona, Catalonia, Spain|Spain, Madrid, Fuencarral-El Pardo, Madrid, Spain|Spain, Madrid, Moncloa-Aravaca, Madrid, Spain|Spain, Madrid, Pozuelo De Alarcón, Madrid, Spain|Ukraine, Ivano-Frankivsk, Ivano-Frankivsk, Ukraine|Ukraine, Kharkiv, Ukraine|Ukraine, Odessa, Ukraine|Ukraine, Poltava, Ukraine|Ukraine, Ternopil, Ukraine|Ukraine, Vinnytsya, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT01390220/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT01390220/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01390220
124,NCT01283594,Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off,NA,Completed,No Results Available,Parkinson's Disease,Drug: Tozadenant (SYN115) 60 mg BID|Drug: Placebo|Drug: Levodopa (L-dopa)|Drug: Tozadenant (SYN115) 120 mg BID|Drug: Tozadenant (SYN115) 180 mg BID|Drug: Tozadenant (SYN115) 240 mg BID,"Assess efficacy of different doses of SYN115 for reducing the mean total hours of awake time per day spent in the off state|To assess the effect of SYN115 on dyskinesia|To assess the effect of SYN115 on UPDRS scores|To assess investigator and patient impressions of PD severity and change|To assess the effect of SYN115 on non motor symptoms of PD|To assess the safety and tolerability of SYN115|To assess the effects of SYN115 on daytime drowsiness, impulsive behavior, development of melanoma and suicidal ideation",Biotie Therapies Inc.,All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,420,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SYN115-CL02,March 2011,October 2012,October 2012,"January 26, 2011",NA,"January 17, 2019","Birmingham, Alabama, United States|La Jolla, California, United States|Loma Linda, California, United States|Los Angeles, California, United States|Oxnard, California, United States|San Francisco, California, United States|Denver, Colorado, United States|Manchester, Connecticut, United States|New Haven, Connecticut, United States|Boca Raton, Florida, United States|Gainesville, Florida, United States|Miami, Florida, United States|Tampa, Florida, United States|Weston, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Boise, Idaho, United States|Springfield, Illinois, United States|Indianapolis, Indiana, United States|Des Moines, Iowa, United States|Kansas City, Kansas, United States|Lexington, Kentucky, United States|Baltimore, Maryland, United States|West Bloomfield, Michigan, United States|Minneapolis, Minnesota, United States|Commack, New York, United States|New York, New York, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Toledo, Ohio, United States|Tulsa, Oklahoma, United States|Allentown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Dallas, Texas, United States|Houston, Texas, United States|Roanoke, Virginia, United States|Milwaukee, Wisconsin, United States|Buenos Aires, Argentina|Santa Fe, Argentina|Edmonton, Alberta, Canada|Halifax, Nova Scotia, Canada|Ottawa, Ontario, Canada|Montreal, Quebec, Canada|Quebec City, Quebec, Canada|Santiago, Chile|Valdivia, Chile|Brasov, Romania|Bucharest, Romania|Constanta, Romania|Timisoara, Romania|Târgu-Mureş, Romania|Dnipropetrovsk, Ukraine|Donetsk, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Poltava, Ukraine|Vinnytsia, Ukraine|Zaporizhzhya, Ukraine",NA,https://ClinicalTrials.gov/show/NCT01283594
125,NCT01281189,Phase 3 Study of Dexpramipexole in ALS,EMPOWER,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Dexpramipexole|Drug: Placebo,Composite Assessment of Function and Survival (CAFS) at 12 Months|Death up to 12 Months (CAFs Individual Component)|Change From Baseline in ALSFRS-R at 12 Months (CAFs Individual Component)|Death or Respiratory Insufficiency (DRI) up to Month 18|Death up to 18 Months|≤50% Predicted Upright Slow Vital Capacity (SVC) or Died up to 18 Months,Knopp Biosciences,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,942,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",223AS302|EUDRA CT NO: 2010-022818-19,March 2011,November 2012,November 2012,"January 21, 2011","June 7, 2021","June 7, 2021","Barrow Neurological Institute - St. Joseph's Hospital, Phoenix, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|University of California at San Francisco - Fresno, Fresno, California, United States|University of California, Irvine, Orange, California, United States|University of California, Davis, Sacramento, California, United States|California Pacific Medical Center, San Francisco, California, United States|Hospital for Special Care, New Britain, Connecticut, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|University of South Florida Medical Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Massachusetts General Hospital, Charlestown, Massachusetts, United States|St. Mary's Health Care, Grand Rapids, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Neurology Associates, P.C., Lincoln, Nebraska, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Columbia University, New York, New York, United States|Research Foundation of the State University of New York, Syracuse, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Providence ALS Center, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|ALS Center at Penn, Philadelphia, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Neurology, Dallas, Texas, United States|Methodist Neurological Institute, Houston, Texas, United States|University of Texas Health Sciences Center, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States|University of Washington, Seattle, Washington, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Calvary Health Care Bethlehem, Melbourne, Victoria, Australia|AZ St-Lucas, Gent, Belgium|UZ Leuven, Leuven, Belgium|Univ of Calgary / Foothills MC, Calgary, Alberta, Canada|CHUM - Hopital Notre Dame, Montreal, Quebec, Canada|Mcgill University, Montreal, Quebec, Canada|London Health Sciences Centre, London, Canada|Sunnybrook and Women's College and Health Sciences Centre, Toronto, Canada|University of British Columbia, Vancouver, Canada|CHRU de Lille - Hôpital Roger Salengro, Lille, France|CHU de Limoges - Hôpital Dupuytren, Limoges, France|Centre Hospitalier La Timone, Marseille, France|CHU Gui de Chauliac, Montpellier, France|CHU de Nice - Hôpital de l'Archet 1, Nice, France|Hôpital La Pitié Salpétrière, Paris, France|Charité - Universitätsmedizin Berlin, Berlin, Germany|Bergmannsheil Gmbh, Bochum, Germany|Medizinische Hochschule Hannover (MHH), Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|University of Ulm, RKU, Ulm, Germany|Beaumont Hospital, Dublin, Ireland|Academisch Medisch Centrum, Amsterdam, Netherlands|UMC St. Radboud, Nijmegen, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Hospital Universitario de Bellvitge, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital La Paz, Madrid, Spain|Hospital Carlos III, Madrid, Spain|Sahlgrenska Universitetssjukhuset, Göteborg, Sweden|Karolinska Universitetssjukhuset, Solna, Stockholm, Sweden|Queen Elizabeth Hospital, Birmingham, United Kingdom|Walton Centre for Neurology & Neurosurgery, Liverpool, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Newcastle University Hospital - Clinical Ageing Research Unit, Newcastle, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Sheffield Institute for Transnational Neuroscience, Sheffield, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT01281189
126,NCT01252355,Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta,TERACLES,Terminated,Has Results,Multiple Sclerosis Relapse,Drug: Teriflunomide|Drug: Placebo (for teriflunomide)|Drug: Interferon-beta (IFN-beta),"Annualized Relapse Rate (ARR) (Poisson Regression Estimates)|Brain Magnetic Resonance Imaging (MRI) Assessment: Number of Gadolinium Enhancing (Gd-enhancing) T1-lesions Per Scan (Poisson Regression Estimates)|Time to 12-Week Sustained Disability Progression|Brain MRI Assessment: Volume of Gd-enhancing T1-lesions Per MRI Scan|Brain MRI Assessment: Change From Baseline in Total Lesion Volume (Burden of Disease) at Week 24|Time to Relapse: Kaplan-Meier Estimates of the Probability of no Relapse at Week 24, 48, and 72|Change From Baseline in Fatigue Impact Scale (FIS) Total Score at Week 24|Change From Baseline in Short Form Generic Health Survey - 36 Items, Version 2 (SF-36v2) Summary Scores at Week 24|Resource Utilization When Relapse|Overview of Adverse Events (AEs)",Sanofi,All,18 Years to 55 Years   (Adult),Phase 3,534,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC6058|2010-023172-12|U1111-1115-2414,January 2011,April 2013,April 2013,"December 3, 2010","May 22, 2014","June 9, 2014","Investigational Site Number 840049, Cullman, Alabama, United States|Investigational Site Number 840005, Cordova, Alaska, United States|Investigational Site Number 840003, Phoenix, Arizona, United States|Investigational Site Number 840011, Oceanside, California, United States|Investigational Site Number 840036, Fort Collins, Colorado, United States|Investigational Site Number 840012, Maitland, Florida, United States|Investigational Site Number 840013, Ormond Beach, Florida, United States|Investigational Site Number 840055, Pompano Beach, Florida, United States|Investigational Site Number 840021, St. Petersburg, Florida, United States|Investigational Site Number 840004, Tampa, Florida, United States|Investigational Site Number 840047, Tampa, Florida, United States|Investigational Site Number 840034, Chicago, Illinois, United States|Investigational Site Number 840037, Elk Grove Village, Illinois, United States|Investigational Site Number 840033, Louisville, Kentucky, United States|Investigational Site Number 840041, Baltimore, Maryland, United States|Investigational Site Number 840028, Baltimore, Maryland, United States|Investigational Site Number 840016, Clinton Township, Michigan, United States|Investigational Site Number 840031, St Louis, Missouri, United States|Investigational Site Number 840030, St Louis, Missouri, United States|Investigational Site Number 840009, Missoula, Montana, United States|Investigational Site Number 840023, Albuquerque, New Mexico, United States|Investigational Site Number 840015, New York, New York, United States|Investigational Site Number 840027, Charlotte, North Carolina, United States|Investigational Site Number 840006, Bismark, North Dakota, United States|Investigational Site Number 840007, Fargo, North Dakota, United States|Investigational Site Number 840046, Dayton, Ohio, United States|Investigational Site Number 840017, Toledo, Ohio, United States|Investigational Site Number 840043, Tulsa, Oklahoma, United States|Investigational Site Number 840002, Nashville, Tennessee, United States|Investigational Site Number 840040, Round Rock, Texas, United States|Investigational Site Number 840020, San Antonio, Texas, United States|Investigational Site Number 840032, Vienna, Virginia, United States|Investigational Site Number 032002, Argentina, Argentina|Investigational Site Number 032003, Buenos Aires, Argentina|Investigational Site Number 032004, Caba, Argentina|Investigational Site Number 036008, Bedford Park, Australia|Investigational Site Number 036005, Chatswood, Australia|Investigational Site Number 036001, Heidelberg West, Australia|Investigational Site Number 036004, Kogarah, Australia|Investigational Site Number 036010, New Lambton, Australia|Investigational Site Number 040001, Graz, Austria|Investigational Site Number 040004, Linz, Austria|Investigational Site Number 056005, Charleroi, Belgium|Investigational Site Number 056004, Gent, Belgium|Investigational Site Number 056003, Hasselt, Belgium|Investigational Site Number 056006, La Louvière, Belgium|Investigational Site Number 056002, Leuven, Belgium|Investigational Site Number 056001, Sijsele-Damme, Belgium|Investigational Site Number 056007, Wilrijk, Belgium|Investigational Site Number 076009, Joinville, Brazil|Investigational Site Number 076012, Passo Fundo, Brazil|Investigational Site Number 076003, Porto Alegre, Brazil|Investigational Site Number 076007, Sao Paulo, Brazil|Investigational Site Number 076013, Sao Paulo, Brazil|Investigational Site Number 124005, Calgary, Canada|Investigational Site Number 124004, Edmonton, Canada|Investigational Site Number 124003, Gatineau, Canada|Investigational Site Number 124006, Kingston, Canada|Investigational Site Number 124007, Montreal, Canada|Investigational Site Number 124008, Ottawa, Canada|Investigational Site Number 124002, Regina, Canada|Investigational Site Number 124001, Sherbrooke, Canada|Investigational Site Number 124009, Winnipeg, Canada|Investigational Site Number 152003, Santiago, Chile|Investigational Site Number 152004, Santiago, Chile|Investigational Site Number 152005, Viña Del Mar, Chile|Investigational Site Number 170001, Barranquilla, Colombia|Investigational Site Number 170005, Bogota, Colombia|Investigational Site Number 170007, Bogota, Colombia|Investigational Site Number 170009, Medellin, Colombia|Investigational Site Number 208002, Aarhus C, Denmark|Investigational Site Number 233002, Tallinn, Estonia|Investigational Site Number 233001, Tartu, Estonia|Investigational Site Number 246003, Helsinki, Finland|Investigational Site Number 246006, Hyvinkää, Finland|Investigational Site Number 246004, Oulu, Finland|Investigational Site Number 246002, Pori, Finland|Investigational Site Number 246001, Turku, Finland|Investigational Site Number 250003, Besancon, France|Investigational Site Number 250010, Clermont Ferrand Cedex 1, France|Investigational Site Number 250002, Lyon Cedex 03, France|Investigational Site Number 250004, Montpellier Cedex 5, France|Investigational Site Number 250001, Nancy Cedex, France|Investigational Site Number 250006, Nantes Cedex 01, France|Investigational Site Number 276009, Bad Mergentheim, Germany|Investigational Site Number 276020, Bamberg, Germany|Investigational Site Number 276003, Bayreuth, Germany|Investigational Site Number 276015, Berlin, Germany|Investigational Site Number 276016, Berlin, Germany|Investigational Site Number 276021, Berlin, Germany|Investigational Site Number 276012, Bonn, Germany|Investigational Site Number 276005, Dresden, Germany|Investigational Site Number 276032, Düsseldorf, Germany|Investigational Site Number 276018, Erbach, Germany|Investigational Site Number 276004, Erlangen, Germany|Investigational Site Number 276028, Freiburg, Germany|Investigational Site Number 276006, Gießen, Germany|Investigational Site Number 276010, Hamburg, Germany|Investigational Site Number 276022, Hennigsdorf, Germany|Investigational Site Number 276024, Kassel, Germany|Investigational Site Number 276001, Leipzig, Germany|Investigational Site Number 276013, Mainz, Germany|Investigational Site Number 276023, Minden, Germany|Investigational Site Number 276002, Münster, Germany|Investigational Site Number 276031, Rostock, Germany|Investigational Site Number 276008, Wiesbaden, Germany|Investigational Site Number 276026, Wuppertal, Germany|Investigational Site Number 300002, Athens, Greece|Investigational Site Number 300001, Athens, Greece|Investigational Site Number 300003, Heraklion, Greece|Investigational Site Number 300006, Thessaloniki, Greece|Investigational Site Number 348002, Budapest, Hungary|Investigational Site Number 348006, Budapest, Hungary|Investigational Site Number 348010, Budapest, Hungary|Investigational Site Number 348009, Eger, Hungary|Investigational Site Number 348003, Esztergom, Hungary|Investigational Site Number 348001, Szeged, Hungary|Investigational Site Number 348005, Szekesfehervar, Hungary|Investigational Site Number 348007, Zalaegerszeg, Hungary|Investigational Site Number 380009, Catania, Italy|Investigational Site Number 380002, Cefalù, Italy|Investigational Site Number 380003, Fidenza, Italy|Investigational Site Number 380004, Gallarate, Italy|Investigational Site Number 380012, Montichiari, Italy|Investigational Site Number 380010, Napoli, Italy|Investigational Site Number 380011, Napoli, Italy|Investigational Site Number 380006, Padova, Italy|Investigational Site Number 380005, Roma, Italy|Investigational Site Number 380008, Roma, Italy|Investigational Site Number 380014, Verona, Italy|Investigational Site Number 410002, Goyang-Si, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410001, Seoul, Korea, Republic of|Investigational Site Number 440002, Kaunas, Lithuania|Investigational Site Number 440004, Klaipeda, Lithuania|Investigational Site Number 440003, Siauliai, Lithuania|Investigational Site Number 528001, Breda, Netherlands|Investigational Site Number 528005, Nieuwegein, Netherlands|Investigational Site Number 528002, Sittard-Geleen, Netherlands|Investigational Site Number 528006, Venray, Netherlands|Investigational Site Number 578002, Tønsberg, Norway|Investigational Site Number 620001, Amadora, Portugal|Investigational Site Number 620002, Coimbra, Portugal|Investigational Site Number 620004, Coimbra, Portugal|Investigational Site Number 620003, Setubal, Portugal|Investigational Site Number 643012, Kaluga, Russian Federation|Investigational Site Number 643007, Kazan, Russian Federation|Investigational Site Number 643001, Kemerovo, Russian Federation|Investigational Site Number 643013, Moscow, Russian Federation|Investigational Site Number 643006, Nizhny Novgorod, Russian Federation|Investigational Site Number 643004, Nizhny Novgorod, Russian Federation|Investigational Site Number 643015, Novosibirsk, Russian Federation|Investigational Site Number 643010, Rostov-On-Don, Russian Federation|Investigational Site Number 643009, Rostov-On-Don, Russian Federation|Investigational Site Number 643016, Samara, Russian Federation|Investigational Site Number 643005, Smolensk, Russian Federation|Investigational Site Number 643011, St-Petersburg, Russian Federation|Investigational Site Number 643018, St-Petersburg, Russian Federation|Investigational Site Number 643003, St-Petersburg, Russian Federation|Investigational Site Number 643017, St-Petersburg, Russian Federation|Investigational Site Number 643002, St-Petersburg, Russian Federation|Investigational Site Number 643014, Yaroslavl, Russian Federation|Investigational Site Number 703002, Martin, Slovakia|Investigational Site Number 703001, Trnava, Slovakia|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724002, Barcelona, Spain|Investigational Site Number 724009, Córdoba, Spain|Investigational Site Number 724003, Girona, Spain|Investigational Site Number 724004, Madrid, Spain|Investigational Site Number 724005, Madrid, Spain|Investigational Site Number 724007, Murcia, Spain|Investigational Site Number 724008, Sevilla, Spain|Investigational Site Number 752004, Göteborg, Sweden|Investigational Site Number 752003, Stockholm, Sweden|Investigational Site Number 752001, Stockholm, Sweden|Investigational Site Number 788002, Manouba, Tunisia|Investigational Site Number 788005, Monastir, Tunisia|Investigational Site Number 788004, Sfax, Tunisia|Investigational Site Number 788006, Tunis, Tunisia|Investigational Site Number 826008, Birmingham, United Kingdom|Investigational Site Number 826005, Leeds, United Kingdom|Investigational Site Number 826006, Liverpool, United Kingdom|Investigational Site Number 826003, London, United Kingdom|Investigational Site Number 826004, Plymouth, United Kingdom|Investigational Site Number 826001, Salford, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT01252355
127,NCT01247324,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,NA,Completed,Has Results,Relapsing Multiple Sclerosis,Drug: Interferon beta-1a|Drug: Ocrelizumab-matching placebo|Drug: Ocrelizumab|Drug: Interferon beta-1a-matching placebo,"Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks|Time to Onset of Confirmed Disability Progression (CDP) for at Least 12 Weeks During the Double-Blind Treatment Period|Number of T1 Gadolinium (Gd)-Enhancing Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double-Blind Treatment|Number of New, and/or Enlarging T2 Hyperintense Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) During the Double Blind Treatment|Percentage of Participants With Confirmed Disability Improvement (CDI) for at Least 12 Weeks|Time to Onset of Confirmed Disability Progression (CDP) for at Least 24 Weeks During the Double-Blind Treatment Period|Number of T1 Hypointense Lesions During the Double-Blind Treatment|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score to Week 96|Percent Change in Brain Volume as Detected by Brain Magnetic Resonance Imaging (MRI) From Week 24 to Week 96|Change From Baseline in Short Form Health Survey-36 (SF-36) Physical Component Summary (PCS) Score at Week 96|Percentage of Participants Who Have No Evidence of Disease Activity (NEDA) up to Week 96|Number of Participants With Adverse Events (AEs)|Exposure to Ocrelizumab (Area Under the Concentration - Time Curve, AUC)|Number of Participants With Anti-Drug Antibodies (ADAs) to Ocrelizumab",Hoffmann-La Roche,All,18 Years to 55 Years   (Adult),Phase 3,821,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",WA21092|2010-020337-99,"August 31, 2011","April 2, 2015","December 31, 2022","November 24, 2010","July 18, 2017","March 3, 2023","21st Century Neurology, Phoenix, Arizona, United States|Mercy Medical Group, Carmichael, California, United States|Scripps Clinic, La Jolla, California, United States|MS Center of California, Laguna Hills, California, United States|Southern California Permanente Medical Group, Los Angeles, California, United States|Neuro-Therapeutics Inc., Pasadena, California, United States|University of California at San Francisco, San Francisco, California, United States|Health First Physicians Inc., Melbourne, Florida, United States|Mercy Research Institute, Miami, Florida, United States|Miami Research Associates, South Miami, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|Shepherd Center Inc., Atlanta, Georgia, United States|Emory University; Department of Neurology, Atlanta, Georgia, United States|NeuroTrials Research, Inc., Atlanta, Georgia, United States|Northwestern University; Dept. of Neurology, Chicago, Illinois, United States|Consultants in Neurology Ltd, Northbrook, Illinois, United States|American Health Network Institute, LLC, Avon, Indiana, United States|Massachusetts General Hospital., Boston, Massachusetts, United States|Michigan Neurology Associates P.C., Clinton Township, Michigan, United States|Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, United States|The Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States|Washington University; Wash Uni. Sch. Of Med, Saint Louis, Missouri, United States|The MS Center for Innovations In Care, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University of New Mexico, Albuquerque, New Mexico, United States|The MS Center; Advance Neurology and Pain, Advance, North Carolina, United States|Atrium Health Neurosciences Institute ? Charlotte, Charlotte, North Carolina, United States|OnSite Clinical Solutions LLC, Charlotte, North Carolina, United States|Neurology Associates PA, Hickory, North Carolina, United States|University Neurology Inc., Cincinnati, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States|Providence Neurological Specialties, Portland, Oregon, United States|Albert Einstein Medical Center; Depatment of Neurosensory sciences, Philadelphia, Pennsylvania, United States|Magee-Woman's Hospital, Pittsburgh, Pennsylvania, United States|Uni of Texas Health Science Center At Houston, Houston, Texas, United States|Bhupesh Dihenia M.D. P.A., Lubbock, Texas, United States|Uni of Vermont Medical Center;, Burlington, Vermont, United States|Multicare Research Institute; Multicare Neuroscience Center of Washington, Tacoma, Washington, United States|Instituto centenario, Buenos Aires, Argentina|Hospital Español, Ciudad Autonoma Bs As, Argentina|Fundacion Rosarina de Neurorehabilitacion, Rosario, Argentina|Royal North Shore Hospital; Department of Neurology, St Leonards, New South Wales, Australia|Barmherzige Brueder Konventspital, Linz, Austria|AZ Sint Jan, Brugge, Belgium|Cliniques Universitaires Saint-Luc; Neurology, Bruxelles, Belgium|AZ Delta (Campus Rumbeke), Roeselare, Belgium|Hospital das Clinicas - UFG;Reumatologia, Goiania, GO, Brazil|IMV Pesquisa Neurológica, Porto Alegre, RS, Brazil|Clinica Neurologica; Neurocirurgica de Joinville, Joinville, SC, Brazil|MHAT Avis Medica; Neurology Department, Pleven, Bulgaria|First MHAT; Clinic of Neurology, Sofia, Bulgaria|MHATNP Sv.Naum EAD; Clinic in neurology diseases for movement disorders, Sofia, Bulgaria|ACIBADEM CITY CLINIC TOKUDA HOSPITAL EAD; Clinic of Neurology and Sleep Medicine, Sofia, Bulgaria|Military Medical Academy; Neurology, Sofia, Bulgaria|Hospital Carlos Van Buren, Valparaiso, Chile|Fakultni nemocnice u sv. Anny; Neurologicka klinika, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Nemocnice Jihlava; NEU-Neurologicke oddeleni, Jihlava, Czechia|Krajska Nemocnice Pardubice Neurologicka Klinika, Pardubice, Czechia|VFN Praha Poliklinika Rs Centrum - Budova A, Prague, Czechia|Krajska zdravotni, a. s. ? Nemocnice Teplice, o. z.; Neurologicke oddeleni, Teplice, Czechia|West Tallinn Central Hospital, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|FinnMedi Oy, Tampere, Finland|Groupe Hospitalier Pellegrin, Bordeaux, France|CHU Hopital Gabriel Montpied; Service de Neurologie, Clermont Ferrand, France|Hopital Central; Neurologie, Nancy, France|CHU de Nîmes Hopital Caremeau; Service de Neurologie, Nimes, France|Hopital Hautepierre - CHU Strasbourg; Service de Neurologie, Strasbourg, France|Charité Universitaetsmedizin Berlin, Campus Charité Mitte, Berlin, Germany|Universitätsklinikum ""Carl Gustav Carus""; MS Center Dresden, Dresden, Germany|Asklepiosklinik Barmbek; Abteilung Neurologie, Hamburg, Germany|Diakoniekrankenhaus Henriettenstiftung gGMBH; Klinik für Neurologie und klinische Neurophysiologie, Hannover, Germany|Universitaetsklinikum Mainz - PS; Klinik und Poliklinik fuer Neurologie, Mainz, Germany|Praxis Dr. med. Mathias Niedhammer, Facharzt für Neurologie, Oldenburg, Germany|Neurozentrum Prien Elisabeth Hans-Thümmler Stefan Braune, Prien, Germany|Universitätsklinikum Rostock, Zentrum für Nervenheilkunde; Klinik und Poliklinik für Neurologie, Rostock, Germany|Universitätsklinikum Tübingen, Zentrum für Neurologie, Tübingen, Germany|Studienzentrum Nordwest, Dr. med. Joachim Springub / Herr Wolfgang Schwarz, Westerstede, Germany|Semmelweis Egyetem AOK; Neurologiai Klinika, Budapest, Hungary|Fovarosi Onkormanyzat Jahn Ferenc Del-Pesti, Budapest, Hungary|Szent Borbala Korhaz; Neurology, Tatabánya, Hungary|Chaim Sheba Medical Center; Neurology Department, Ramat-Gan, Israel|Azienda Ospedaliera Sant'Andrea, Roma, Lazio, Italy|Irccs Ospedale San Raffaele, Milano, Lombardia, Italy|Azienda Socio Sanitaria Territoriale della Valle Olona (pres, Gallarate, Valle D?Aosta, Italy|Azienda Ospedaliera di Padova; Clinica Neurologica, Padova, Veneto, Italy|Maritime Medicine Centre of Latvia Hospital of Vecmilgravis Department of Neurology, Riga, Latvia|P. Stradins Clinical University Hospital; Neurology, Riga, Latvia|Kaunas Medical University Hospital, Kaunas, Lithuania|Klaipeda University Hospital Public Institution, Klaipeda, Lithuania|Vilnius University Hospital Santariskiu Clinic, Vilnius, Lithuania|Grupo Médico Camino S.C., Ciudad de México, Mexico CITY (federal District), Mexico|Hospital Universitario Dr Jose Eleuterio Gonzalez; Universidad Autónoma de Nuevo León, Monterrey, Mexico|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Policlinico Especializado en Neurologia, Callao, Peru|Clinica Anglo Americana, Lima, Peru|Hospital Nacional Dos de Mayo, Lima, Peru|Clinica Centenario Peruano Japonesa; Neurology, Pueblo Libre, Peru|COPERNICUS Podmiot Leczniczy Sp. z o. o. Szpital im. M. Kopernika; Oddzia? Neurologiczny, Gdansk, Poland|Specjal. Praktyka Lekarska; Prof. Grzegorz Opala, Katowice, Poland|MA-LEK Clinical Sp. Z o.o., Katowice, Poland|Neurologiczny NZOZ Centrum Leczenia SM; Osrodek Badan Klinicznych, Plewiska, Poland|Hospital de Braga; Servico de Neurologia, Braga, Portugal|Sverdlovsk Regional Clinical Hospital 1, Ekaterinburg, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Central Clinical Hospital #2 N.A. Semashko OAO RJHD, Moscow, Russian Federation|FGBU FNKC FMBA of Russia, Moscow, Russian Federation|FSBIH Siberian Regional Medical Centre of FMBA of Russia, Novosibirsk, Russian Federation|MRC for Oncology and Neurology Biotherapy, Novosibirsk, Russian Federation|Samara State Medical University, Samara, Russian Federation|Reg. SI of Health Care Smolensk Regional Clinical Hospital, Smolensk, Russian Federation|MMA of Ministry of Defense of Russia named after S.M. Kirov, St. Petersburg, Russian Federation|St.-Peterburg State institution of health care City multifield hospital #2, St. Petersburg, Russian Federation|Regional Multiple Sclerosis Centre b/o CC ECM ""Neftyanik"", Tyumen, Russian Federation|Military Medical Academy, Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Clinical Center Nis, NIS, Serbia|FNsP Bratislava - Nemocnica Stare mesto, Bratislava, Slovakia|FNsP Bratislava, Nemocnica Ruzinov, Bratislava, Slovakia|Univerzitna nemocnica Bratislava Nemocnica sv. Cyrila a Metoda; Nemocnicna lekaren, Bratislava, Slovakia|Fakultna nemocnica s poliklinikou Zilina, Zilina, Slovakia|Dr CC Coetzee Inc, Durban, South Africa|Complejo Hospitalario Nuestra Señora de la Candelaria; Servicio de Neurologia, Santa Cruz De Tenerife, Tenerife, Spain|Hospital de Basurto, Bilbao, Vizcaya, Spain|Hospital Universitario Puerta De Hierro Majadahonda; Servicio de Neurología, Madrid, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Universitätsspital Basel Medizin Neurologie; Neurologische Poliklinik, Basel, Switzerland|Ospedale Regionale Lugano Civico Medizin Neurologie; Neurologia, Lugano, Switzerland|Hopital Razi, Mannouba, Tunisia|Hopital Universitaire Fattouma Bourguiba, Monastir, Tunisia|Hopital Charles Nicolle, Tunis, Tunisia|MMPIDon.Reg.Cl.&Ter.Med.Com.Neur.Dept.DNMU n.a.M.Gorkiy; Ch. of Nervous Diseases and Med. Genetics, Donetsk, Ukraine|St.In.Inst. of Neurol.Psych.and Narcol.of the AMSU; Dept. of Neuroinfection and Multiply Sclerosis, Kharkov, Ukraine|Kyiv City Cl.Hosp.#4 Depart.of Neurology #2NMU; Department of Neurology, Kyiv, Ukraine|Lviv Regional Clinical Hospital; Department of Neurology, Lviv, Ukraine|Vin.Reg.Psych.Hosp.N.A Yuschenko O.I., Vnmu N.A. Pyrogov; Department of Nervous Diseases, Vinnytsya, Ukraine|Walton Centre NHS Foundation Trust, Neuroscience Research Centre; CLINICAL TRIALS UNIT, Liverpool, United Kingdom|Royal London Hospital; Neurology, London, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT01247324
128,NCT01227655,Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.,BIPARKII,Completed,Has Results,Parkinson's Disease,Drug: BIA 9-1067|Drug: Placebo|Drug: Levodopa|Drug: Carbidopa|Drug: Benserazide,"Efficacy of 2 BIA 9-1067 (25 mg, and 50 mg) Compared With Placebo, When Administered With the Existing Treatment of L-DOPA Plus a DDCI (DOPA Decarboxylase Inhibitor)|UPDRS (Unified Parkinson's Disease Rating Scale) Sections I (ON), II (ON and OFF), and III (ON)|Parkinson's Disease Sleep Scale (PDSS)|Non-motor Symptoms Scale (NMSS)",Bial - Portela C S.A.,All,"30 Years to 83 Years   (Adult, Older Adult)",Phase 3,427,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BIA-91067-302|2010-022366-27,March 2011,July 2012,July 2012,"October 25, 2010","January 13, 2015","October 19, 2015","Bial - Portela & Cª, S.A., S. Mamede do Coronado, Portugal",NA,https://ClinicalTrials.gov/show/NCT01227655
129,NCT01227265,Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037),NA,Completed,Has Results,Parkinson Disease|Idiopathic Parkinson Disease|Idiopathic Parkinson's Disease,Drug: Preladenant|Drug: Placebo,"Change From Baseline in Average ""Off"" Time (Hours Per Day) at Week 12|Number of Participants With Systolic Blood Pressure (SBP) ≥180 mmHg and 20 mmHg Increase|Number of Participants With Diastolic Blood Pressure (DBP) ≥105 mmHg and 15 mmHg Increase|Percentage of Participants With Suicidality|Change From Baseline in Total Epworth Sleepiness Scale (ESS) at Week 12|Percentage of Participants With >30% Change (Reduction) From Baseline at Week 12 in Mean ""Off"" Time|Change From Baseline in Average ""On"" Time (Hours Per Day) Without Troublesome Dyskinesia at Week 12",Merck Sharp & Dohme LLC,All,"30 Years to 85 Years   (Adult, Older Adult)",Phase 3,476,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",P07037|2010-020112-11|MK-3814-028,"November 19, 2010","April 4, 2013","April 16, 2013","October 25, 2010","April 12, 2016","September 24, 2018",NA,NA,https://ClinicalTrials.gov/show/NCT01227265
130,NCT01224106,A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease,Scarlet Road,Completed,Has Results,Alzheimer's Disease,Drug: Gantenerumab|Drug: Placebo,"Mean Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Total Score at Week 104 (Double-Blind Treatment Phase)|Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) (OLE Phase)|Mean Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog-11) Scores at Week 104 (Double-Blind Treatment Phase)|Time to Onset of Dementia at Week 104 (Double-Blind Treatment Phase)|Mean Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Composite Score at Week 104 (Double-Blind Treatment Phase)|Mean Change From Baseline in Free and Cued Selective Reminding Test (FCSRT) Score at Week 104 (Double-Blind Treatment Phase)|Mean Change From Baseline in Functional Activities Questionnaire (FAQ) Score at Week 104 (Double-Blind Treatment Phase)|Mean Change From Baseline in CDR-Global Score at Week 104 (Double-Blind Treatment Phase)|Mean Change From Baseline in Neuropsychiatric Inventory (NPI) Questionnaire Score at Week 104 (Double-Blind Treatment Phase)|Percentage Change From Baseline in Cerebrospinal Fluid Biomarkers (Phosphorylated-tau [P-tau], Amyloid Beta 1-42 [Abeta 1-42], Total Tau [T-tau]) at Week 104 (Double-Blind Treatment Phase)|Percentage Change From Baseline in Hippocampal Volume at Week 104 (Double-Blind Treatment Phase)|Percentage Change From Baseline in Cortical Composite Sustained Uptake Volume Ratio (SUVr) in Different Brain Regions at Week 156 (Double-Blind Treatment Phase)|Gantenerumab Plasma Concentrations at Different Time Points (Double-Blind Treatment Phase)|Mean Change From Baseline in Mini Mental State Exam (MMSE) Score at Week 104 (Double-Blind Treatment Phase)|Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) (Double-Blind Treatment Phase)|Percentage of Participants With Anti-Drug Antibodies (ADAs) (Double-Blind Treatment Phase)|Mean Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog-11) Scores at Week 156 (OLE Phase)|Mean Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Total Score at Week 156 (OLE Phase)|Mean Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog-13) Scores at Week 156 (OLE Phase)|Time to Onset of Dementia at Week 156 (OLE Phase)|Mean Change From Baseline in Free and Cued Selective Reminding Test (FCSRT) Score at Week 156 (OLE Phase)|Mean Change From Baseline in Functional Activities Questionnaire (FAQ) Score at Week 156 (OLE Phase)|Mean Change From Baseline in CDR-Global Score at Week 156 (OLE Phase)|Percentage Change From Baseline in Hippocampal Volume at Week 152 (OLE Phase)|Percentage Change From Baseline in Cortical Composite Sustained Uptake Volume Ratio (SUVr) in Different Brain Regions at Week 156 (OLE Phase)|Gantenerumab Plasma Concentrations at Different Time Points (OLE Phase)|Mean Change From Baseline in Mini Mental State Exam (MMSE) Score at Week 156 (OLE Phase)|Percentage of Participants With Anti-Drug Antibodies (ADAs) (OLE Phase)",Hoffmann-La Roche,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 3,799,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WN25203|2010-019895-66,"November 30, 2010","September 10, 2020","September 10, 2020","October 19, 2010","December 13, 2021","December 13, 2021","Banner Alzheimer's Institute, Phoenix, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Yale University ADRU, New Haven, Connecticut, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Infinity Clinical Research, Hollywood, Florida, United States|Accelerated Enrollment Solutions, Orlando, Florida, United States|Roskamp Institute, Inc., Sarasota, Florida, United States|Compass Research, The Villages, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Indiana University, Indianapolis, Indiana, United States|Boston Center for Memory, Newton, Massachusetts, United States|Western Michigan University Homer Stryker M.D. School of Medicine Center for Clinical Research, Kalamazoo, Michigan, United States|Neurological Research Center, Hattiesburg, Mississippi, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Nathan Kline Institute, Orangeburg, New York, United States|University of Rochester Medical Center; Monroe Community Hospital, Rochester, New York, United States|Alzheimer's Memory Center, Matthews, North Carolina, United States|Oregon Health and Science University, Layton Aging and Alzheimer's Disease Center, Portland, Oregon, United States|Northeastern Pennsylvania Memory, Plains, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Senior Adults Specialty Research, Austin, Texas, United States|Texas Neurology PA, Dallas, Texas, United States|Clinical Neuroscience Research Associates, Inc., Bennington, Vermont, United States|Hospital Italiano, Buenos Aires, Argentina|IME - Instituto Médico Especializado; Ensayos Clínicos, Buenos Aires, Argentina|ALPI-Inst. de Rehabilitacion Marcelo Fitte, Buenos Aires, Argentina|CEMIC, Buenos Aires, Argentina|Mulieris, Caba, Argentina|Instituto De Neurología Cognitiva - INECO, Caba, Argentina|FLENI, Caba, Argentina|Instituto Kremer, Córdoba, Argentina|CENPIA; Neurología - Psicología, La Plata, Argentina|Hornsby Ku-ring-gai Hospital; Division of Rehabilitation & Aged Care, Hornsby, New South Wales, Australia|Prince of Wales Hospital, Academic Department for Old Age Psychiatry, Randwick, New South Wales, Australia|Royal Adelaide Hospital; Memory Trials Centre, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital; Neurology, Woodville, South Australia, Australia|Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre, Heidelberg West, Victoria, Australia|Australian Alzheimer's Research Foundation, Nedlands, Western Australia, Australia|UZ Leuven Gasthuisberg, Leuven, Belgium|Hospital das Clinicas - UFPR; Ciencias da Saude, Curitiba, PR, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Hospital Mae de Deus, Porto Alegre, RS, Brazil|Hospital das Clinicas - FMUSP; Psiquiatria, Sao Paulo, SP, Brazil|Universidade Federal de Sao Paulo - UNIFESPX; Neurologia, São Paulo, SP, Brazil|True North Clinical Research, New Minas, Nova Scotia, Canada|Kawartha Centre - Redefining Healthy Aging, Peterborough, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Centre for Memory and Aging, Toronto, Ontario, Canada|NeuroSearch Developpements inc, Greenfield Park, Quebec, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Neurological and Psychiatric, Montreal, Quebec, Canada|CHAUQ - Hôpital Enfant-Jésus, Quebec City, Quebec, Canada|Biomedica Research Group, Santiago, Chile|Especialidades Medicas LYS, Santiago, Chile|St. Anne´s University Hospital; Clinical Trials Department, Brno, Czechia|Vestra Clinics s.r.o., Rychnov nad Kneznou, Czechia|Aarhus Universitetshospital, Neurologisk Afdeling F, Demensklinikken, Aarhus N, Denmark|Rigshospitalet, Hukommelsesklinikken, Koebenhavn Oe, Denmark|CRST Oy, Turku, Finland|Hopital Avicenne; Neurologie, Bobigny, France|Hopital Pellegrin; Cmrr Aquitaine, Bordeaux, France|Hopital Pierre Wertheimer; Laboratoire De Neuro Psychologie, Bron, France|CHU De Caen; Service De Neurologie Dejerine, Caen, France|Hopital B Roger Salengro; Cmrr Lille, Lille, France|Ch Pitie Salpetriere; Cmrr Ile De France Salpetriere, Paris, France|CHU de Rouen Hopital; Service de Neurologie, Rouen, France|Hop Guillaume Et Rene Laennec; Cmrr St Herblain, St Herblain, France|Hopital Hautepierre; Centre dInvestigation Clinique, Strasbourg, France|Hopital de La Grave, Toulouse, France|Univ Berlin; Klin fur Psychi & Psycho Charite, Berlin, Germany|Universitätsklinikum Bonn; Medizinische Klinik und Poliklinik I; Allgemeine Innere Medizin, Bonn, Germany|Klinikum Joh.Wolfg.Goethe-UNI Zentrum d. Psychiatrie Klinik f. Psychiatrie Psychosomatik, Frankfurt, Germany|PANAKEIA - Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Zentralinstitut für Seelische Gesundheit Abt.Gerontopsychiatrie, Mannheim, Germany|Pharmakologisches Studienzentrum, Mittweida, Germany|Neurologische Praxis Dr. Andrej Pauls, München, Germany|Klinikum rechts der Isar der TU München; Klinik für Psychiatrie und Psychotherapie, München, Germany|Office of Dr Klaus Steinwachs Neurology & Psychiatry, Nürnberg, Germany|Universitätsklinikum Rostock Zentrum für Nervenheilkunde, Rostock, Germany|Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, Germany|Nuovo Ospedale Civile S. Agostino-Estense; Clinica Neurologica - Dipartimento di Neuroscienze, Modena, Emilia-Romagna, Italy|Universita' Di Parma Istituto Neurologia, Parma, Emilia-Romagna, Italy|Azienda Ospedaliera Spedali Civili; Scienze Neurologiche, Brescia, Lombardia, Italy|IRCCS ""Centro S. Giovanni di Dio"" Fatebenefratelli -UO Alzheimer, Brescia, Lombardia, Italy|Irccs Multimedica Santa Maria; Unita' Di Neurologia, Castellanza, Lombardia, Italy|Fondazione San Raffaele Del Monte Tabor; Dipartimento Di Neurologia, Milano, Lombardia, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi Di Ancona, Torrette - Ancona, Marche, Italy|Uni Di Firenze Dip. Scienze Neurol Psic Sod Neurologia 1, Firenze, Toscana, Italy|Seoul National University Bundang Hospital; Neurology Department, Gyeonggi-do, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center., Seoul, Korea, Republic of|Hospital Mexico Americano, Guadalajara, Mexico CITY (federal District), Mexico|Hospital Universitario; Dr. Jose E. Gonzalez, Monterrey, Nuevo LEON, Mexico|Hospital Angeles de Culiacán, Neurociencias Estudios Clínicos SC, Culiacan, Mexico|Unidad de Investigacion en Enfermedades Cronico-Degenerativa; Reumatologia, Guadalajara, Mexico|Estimulacion Magnetica Trnscraneal de Mexico SC., Mexico City, Mexico|Centro Medico San Francisco; Geriatrics, Monterrey, Mexico|Hospital Universitario de Saltillo, Saltillo, Mexico|Jeroen Bosch Ziekenhuis; Polikliniek Geriatrie, 'S Hertogenbosch, Netherlands|Brain Research Center B.V, Amsterdam, Netherlands|Podlaskie Centrum Psychogeriatrii, Białystok, Poland|PALLMED Sp. z o.o. prowadząca NZOZ DOM SUE RYDER, Bydgoszcz, Poland|NEURO - KARD Ośrodek Badań Klinicznych, Poznań, Poland|Przychodnia Specjalistyczna PROSEN, Warszawa, Poland|mMED Maciej Czarnecki, Warszawa, Poland|Hospital Prof. Dr. Fernando Fonseca; Servico de Neurologia, Amadora, Portugal|Hospital de Santa Maria; Servico de Neurologia, Lisboa, Portugal|Sverdlovsk Regional Clinical Psychoneurological War Veteran Hospital, Ekaterinburg, Russian Federation|State autonomous institution of healthcare Inter-regional clinical and diagnostic center, Kazan, Russian Federation|Saint Petersburg State Institution of Healthcare City Geriatric Medico-Social Center, Saint Petersburg, Russian Federation|City Clinical Hospital # 2 n.a. V.I. Razumovsky, Saratov, Russian Federation|Russian Medical Military Academy n.a. S.M.Kirov; Neurology Department, St. Petersburg, Russian Federation|Fundació ACE, BArcelon, Barcelona, Spain|Hospital Mutua De Terrasa; Servicio de Neurologia, Terrassa, Barcelona, Spain|Hospital de Cruces; Servicio de Neurologia, Barakaldo, Vizcaya, Spain|Hospital del Mar; Servicio de Neurologia, Barcelona, Spain|Hospital Clinic i Provincial; Servicio de Neurologia, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia, Barcelona, Spain|Hospital Ramon y Cajal; Servicio de Neurologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Neurologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Neurologia, Madrid, Spain|Hospital Universitario Dr. Peset; Servicio de Neurologia, Valencia, Spain|Skånes Universitetssjukhus Malmö, Minneskliniken, Malmö, Sweden|Felix Platter-Spital Medizin Geriatrie, Basel, Switzerland|HUG; Département de santé mentale et de psychiatrie Unité de psychiatrie gériatrique, Chêne-Bourg, Switzerland|Akdeniz University School of Medicine, Neurology Department, Antalya, Turkey|Istanbul University Istanbul School of Medicine; Neurology, Istanbul, Turkey|Ondokuz Mayis University School of Medicine; Neurology, Samsun, Turkey|Addenbrooke's Hospital, Cambridge, United Kingdom|Llandough Hospital; Llandough Hospital Memory Team 3rd Floor Academic Building, Cardiff, United Kingdom|St Margaret's Hospital, Epping, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|Charing Cross Hospital; Dept of Neurosciences, London, United Kingdom|Campus for Ageing & Vitality; Clincal Ageing Research Unit, Newcastle, United Kingdom|Moorgreen Hospital; Memory Assessment & Rsch Ctr, Southampton, United Kingdom|Victoria Centre; Kingshill Research Centre, Swindon, United Kingdom|Hollins Park Hospital, Warrington, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT01224106/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT01224106/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01224106
131,NCT01194570,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,NA,Completed,Has Results,"Multiple Sclerosis, Primary Progressive",Drug: Ocrelizumab|Other: Placebo,Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 12 Weeks During the Double-Blind Treatment Period|Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 24 Weeks During the Double-Blind Treatment Period|Percent Change From Baseline in Timed 25-Foot Walk (T25-FW) at Week 120|Percent Change From Baseline in Total Volume of T2 Lesions at Week 120|Percent Change in Total Brain Volume From Week 24 to Week 120|Change in From Baseline Physical Component Summary Score (PCS) SF- 36 Health Survey (SF-36) at Week 120|Percentage of Participants With at Least One Adverse Event (AE),Hoffmann-La Roche,All,18 Years to 55 Years   (Adult),Phase 3,735,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WA25046|2010-020338-25,"March 2, 2011","July 23, 2015","December 31, 2022","September 3, 2010","December 26, 2017","March 16, 2023","Phoenix Neurological Associates Ltd, Phoenix, Arizona, United States|Barrow Neurology Clinic, Phoenix, Arizona, United States|Mayo Clinic- Scottsdale, Scottsdale, Arizona, United States|Arizona Neuroscience Research, LLC, Phoenix, Arkansas, United States|Sutter East Bay Medical Foundation, Berkeley, California, United States|MS Center of Southern California, Newport Beach, California, United States|Univ of CA Davis Med Ctr; Neurology, Sacramento, California, United States|Univ of CA San Francisco; Department of Neurology, San Francisco, California, United States|University of Colorado; Anschutz Medical Campus Department of Neurology, Aurora, Colorado, United States|University of Miami School of Medicine; Dept. of Neurology Movement Disorder Center, Miami, Florida, United States|Vero Beach Neurology and Research Institute, Vero Beach, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|MidAmerica Neuroscience Institute, Prairie Village, Kansas, United States|Wayne State University; Department of Neurology, Detroit, Michigan, United States|Henry Ford Health System; Neurology & Neurosurgery, Detroit, Michigan, United States|Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, United States|University of Minnesota; Clin. Neuro Research Unit, Minneapolis, Minnesota, United States|Washington University School of Medicine; Department of Neurology, Saint Louis, Missouri, United States|Holy Name Hospital, Teaneck, New Jersey, United States|University of New Mexico; MS Specialty Clinic, Albuquerque, New Mexico, United States|Winthrop University Hospital, Mineola, New York, United States|Weill Medical College of Cornell University; Judith Jaffe MS Ctr, New York, New York, United States|Mount Sinai School of Medicine; Neurology, New York, New York, United States|Comprehensive MS Care Center at South Shore Neurologic Assoc., Patchogue, New York, United States|Neurology Assoc of Stony Brook, Stony Brook, New York, United States|Carolinas Medical Center; Ms Center, Charlotte, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|The Ohio State University Wexner Medical Center; Department of Neurology, Columbus, Ohio, United States|Oklahoma Medical Research Foundation; MS Center of Excellence, Oklahoma City, Oklahoma, United States|Trustees of the University of Pennsylvania; Neurology, Philadelphia, Pennsylvania, United States|The Neurology Foundation, Inc., Providence, Rhode Island, United States|Neurology Clinic PC, Cordova, Tennessee, United States|University of Texas Southwestern, Dallas, Texas, United States|Maxine Mesinger MS Clinic/Baylor College of Medicine; Neurology, Houston, Texas, United States|Neurological Associates, Inc., Richmond, Virginia, United States|Swedish Neuroscience Institute; Multiple Sclerosis Center, Seattle, Washington, United States|Royal Hobart Hospital, Hobart, Tasmania, Australia|St Vincent's Hospital Melbourne; Clinical Neuroscience and Neurological Research, Fitzroy, Victoria, Australia|Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie, Innsbruck, Austria|Kepler Universitätsklinikum GmbH - Neuromed Campus; Neurologie, Linz, Austria|Kepler Universitätskliniken GmbH - Med Campus III; Neurologie & Psychiatrie, Linz, Austria|Christian-Doppler-Klinik - Universitätsklinikum; Universitätskliniik für Neurologie, Salzburg, Austria|Medizinische Universitat Wien Medical University of Vienna, Wien, Austria|CHU Tivoli, La Louvière, Belgium|AZ Alma vzw (Sijsele), Sijsele, Belgium|Hospital das Clinicas - UFG;Reumatologia, Goiania, GO, Brazil|Santa Casa de Misericordia; de Belo Horizonte, Belo Horizonte, MG, Brazil|Hospital Universitario Clementino Fraga Filho - UFRJ, Rio de Janeiro, RJ, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Shat Np Sveti Naum; 3Rd Clinic of Neurology, Sofia, Bulgaria|Multiprofile Hosp. for Active Treatment;National Cardiology Hosp., Sofia, Bulgaria|Foothills Medical Centre, Calgary, Alberta, Canada|University of British Columbia UBC Hospital; Multiple Sclerosis (MS) Clinic - Vancouver, Vancouver, British Columbia, Canada|Health Sciences Centre, Winnipeg, Manitoba, Canada|The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|St. Michael'S Hospital, Toronto, Ontario, Canada|Recherche Sepmus Inc., Greenfield Park, Quebec, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|Fakultni nemocnice Brno; Interni kardiologicka klinika, Brno, Czechia|Vseobecna fakultni nemocnice v Praze; MS Centrum, Neurologicka klinika, Praha 2, Czechia|Krajska zdravotni, a. s. ? Nemocnice Teplice, o. z.; Neurologicke oddeleni, Teplice, Czechia|Helsingin yliopistollinen keskussairaala, Helsinki, Finland|Tampereen yliopisto; Kliinisen lääketieteen laitos, Neurologian yksikkö, Tampere, Finland|Turku University Central Hospital; Pharmacy, Turku, Finland|Groupe Hospitalier Pellegrin; Service de neurochirurgie B, Bordeaux, France|Hopital Neurologique et Neurochirurgical Pierre Wertheimer; Service de Neurologie A, Bron, France|Hopital Cote De Nacre; Unite Neurologie Generale, Caen, France|Hopital Gabriel Montpied CHU de Clermont-Ferrand; Service de Neurologie B, Clermont-Ferrand, France|Hopital Roger Salengro Service de Neurologie, Lille, France|CHU de la Timone - Hopital d Adultes; Service de Neurologie, Marseille, France|Hopital Gui de Chauliac; Neurologie, Montpellier, France|CHRU Nancy; Service de neurologie, Nancy, France|Hôpital Guillaume et René Laënnec; Service Neurologie, Nantes, France|Hôpital Pasteur; Service de Neurologie, Nice, France|Groupe Hospitalo-Universitaire Caremeau; Service Neurologie, Nimes, France|Fondation Rothschild; Service de Neurologie, Paris, France|Groupe Hospitalier Pitié- Salpétrière; Service Neurologie, Paris, France|Hôpital de Poissy; Service neurologie, Poissy, France|Hôpital Maison Blanche; Service de Neurologie, Reims, France|Chu De Strasbourg; Hopital Civil, Strasbourg, France|Hopital Purpan; Fédération de neurologie, Toulouse, France|Klinikum Bayreuth GmbH; Neurologische Klinik, Bayreuth, Germany|Marianne-Strauß-Klinik; Behandlung Kempfen für Multip Sklero Kranke gemeinnütz GmbH, Berg, Germany|Charite - Universitatsmedizin Berlin; Klinik fur Neurologie, Berlin, Germany|Jüdisches Krankenhaus Berlin; Abteilung fur Neurologie, Berlin, Germany|Berufsgenossenschaftliches Uni-Klinikum Bergmannsheil GmbH, Bochum, Germany|Universitätsklinikum ""Carl Gustav Carus""; Klinik und Poliklinik für Neurologie, Dresden, Germany|Heinrich Heine Universität Düsseldorf; Neurologische Klinik, Düsseldorf, Germany|Klinikum Joh.Wolfg.Goethe-UNI Senckenbergisches Institut für Neuroonkologie, Frankfurt am Main, Germany|Universitätsklinikum Gießen und Marburg GmbH; Neurologie, Gießen, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Kliniken der Stadt Koln gGmbH, Koln, Germany|Universität Leipzig; Innere Medizin, Neurologie, Dermatologie, Leipzig, Germany|Klinikum rechts der Isar der Technischen Universität München, Munchen, Germany|Universitatsklinikum Munster, Münster, Germany|Medizinische Einrichtungen des Bezirks Oberpfalz GmbH; Neurologie, Regensburg, Germany|Universitätsklinikum Tübingen, Zentrum für Neurologie, Tübingen, Germany|Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, Germany|DKD Helios Klinik (Deutsche Klinik für Diagnostik GmbH), Wiesbaden, Germany|401 Military Hospital of Athens; Neurology Department, Athens, Greece|AHEPA Univ. General Hospital of Thessaloniki; B' Neurology Dept., Thessaloniki, Greece|Georgios Papanikolaou General Hosp. of Thessaloniki, Thessaloniki, Greece|Fövárosi Önkormányzat uzsoki utcai Kórház, Budapest, Hungary|Jahn Ferenc Del-Pesti Korhaz es Rendelointezet, Budapest, Hungary|Vaszary Kolos Korhaz; Neurology, Esztergom, Hungary|Pécsi Tudományegyetem, Pécs, Hungary|Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ; Neurológiai Klinika, Szeged, Hungary|Veszprém Megyei Csolnoky Ferenc Kórház; Reumatológia, Veszprem, Hungary|Barzilai Medical Center; Neurology Department, Ashkelon, Israel|Hadassah University Hospital Ein Kerem; Neurology Department, Jerusalem, Israel|Rabin Medical Center; Multiple Sclerosis Clinic, Petach Tikva, Israel|The Chaim Sheba Medical Center; Multiple Sclerosis Center, Ramat-Gan, Israel|Medical Center Ziv Safed; Neurology Department, Safed, Israel|Tel Aviv Sourasky Medical Center; Department of Neurology, Tel Aviv, Israel|A.O. Universitaria S. Martino Di Genova, Genova, Liguria, Italy|Hospital San Raffaele, Milano, Lombardia, Italy|Azienda Sanitaria Ospedaliera S. Luigi Gonzaga; Centro Regionale Sclerosi Multipla - Neurologia II, Orbassano, Piemonte, Italy|Ospedale Binaghi; Centro Sclerosi Multipla, Cagliari, Sardegna, Italy|Hospital of Lithuanian University of Health. Sciences Kaunas Clinics, Kaunas, Lithuania|Klaipeda University Hospital Public Institution, Klaipeda, Lithuania|Siauliai Hospital, Siauliai, Lithuania|Instituto Biomedico De Investigacion A.C., Aguascalientes, Mexico|Instituto Nacional de Neurologia y Neurocirugia, Mexico City, Mexico|Eleccion Salud SC, Mexico, Mexico|Centro de Estudios Clinicos y Espec. Med. SC, Monterrey, Mexico|Erasmus MC; Afdeling Neurologie, Rotterdam, Netherlands|Zuyderland Medisch Centrum - Sittard Geleen, Sittard-Geleen, Netherlands|Waikato Hospital; Neurology, Hamilton, New Zealand|Wellington Hospital; Department of Neurology, Wellington, New Zealand|Oslo universitetssykehus HF, Ullevål; Nevrologisk avdeling, Oslo, Norway|Hospital IV Alberto Sabogal Sologuren; Unidad de Investigacion, Bellavista, Peru|Clinica Anglo Americana, Lima, Peru|Hospital Nacional Dos de Mayo - Centro de Investigacion en Oncología, Lima, Peru|Niepubliczny Zaklad Opieki Zdrowotnej KENDRON ; Poradnia Neurologiczna, Bialystok, Poland|Akson - Clinical Research Maciejowski - Bielecki Sp. Jawna, Jaroslaw, Poland|Diagnomed Clinical Research Sp. z o.o., Katowice, Poland|Niepubliczny Zaklad Opieki Zdrowotnej; Neuro-Medic, Katowice, Poland|Zespol Opieki Zdrowotnej w Konskich; Oddzial Neurologiczny, Konskie, Poland|SPZOZ Uni. Szpital Kliniczny nr 1 im. Norberta Barlickiego Uni. Medycznego w Lodzi ; Neurologii, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie; Klinika Neurochirurgii i Neurochirurgii Dzi, Lublin, Poland|Hospital Garcia de Orta; Servico de Neurologia, Almada, Portugal|Hospital Prof. Dr. Fernando Fonseca; Servico de Neurologia, Amadora, Portugal|HUC; Servico de Neurologia, Coimbra, Portugal|Hospital Geral; Servico de Neurologia, Coimbra, Portugal|Hospital de Santa Maria; Servico de Neurologia, Lisboa, Portugal|Hospital Geral de Santo Antonio; Servico de Neurologia, Porto, Portugal|Elias Emergency University Hospital Neurology Dept; Neurology Department, Bucharest, Romania|SC Clubul Sanatatii SRL, Campulung, Romania|Spitalul Clinic Judetean de Urgenta Targu Mures; Clinica Neurologie, Targu Mures, Romania|Timisoara Emergency County Clinical Hospital, Timi?oara, Romania|Research Medical Complex ""Vashe Zdorovie""; Neurology Department, Kazan, Russian Federation|Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Neurologia, Salt, Girona, Spain|Hospital Donostia, San Sebastian, Guipuzcoa, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Intermedios y Urgencias Pediatricas, Santiago de Compostela, LA Coruña, Spain|Hospital de Basurto Servicio de Neurologia, Bilbao, Vizcaya, Spain|Hospital General Univ. de Alicante, Alicante, Spain|Hospital del Mar; Servicio de Neurologia, Barcelona, Spain|Hospital Universitari Vall d'Hebron; Servicio de Neumo-Inmunologia, Barcelona, Spain|Hospital Clinic i Provincial; Servicio de Neurologia, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia, Barcelona, Spain|Universitario de La Princesa; Servicio de Neurología, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Neurologia, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Neurología, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Neurologia, Malaga, Spain|Hospital Universitario Virgen Macarena; Servicio de Neurologia, Sevilla, Spain|Universitätsspital Basel; Neurologie, Basel, Switzerland|Ospedale Regionale di Lugano - Civico; Neurologia, Lugano, Switzerland|CNPE City Clinical Hospital #3 of Chernivtsi City Council, Chernivtsi, Chernihiv Governorate, Ukraine|Municipal Non-profit Enterprise Odessa Regional Clinical Hospital of Odessa Regional Council, Odesa, Kherson Governorate, Ukraine|Municipal Non-profit Enterprise of Kyiv Regional Council Kyiv Regional Clinical Hospital, Kyiv, KIEV Governorate, Ukraine|Ukrainian State Inst. of Med. and Social Problems of Disability; Neuro, Dnipropetrovsk, Ukraine|Dnipropetrovsk State Medical Academy; Dept of Neurology, Dnipropetrovsk, Ukraine|Kh. Med. Ac. of P.-Gr. Ed.; Cl. Cen. Hosp. of UkrZal.; 3rd Dept. Neurology, Kharkiv, Ukraine|Ams of Ukraine; Inst. of Neurology, Psychiatry & Narcology, Kharkov, Ukraine|Kyiv City Clinical Hospital #4 MAHC of Kyiv; Chair of Neurology, Kyiv, Ukraine|Volyn Regional Clinical Hospital, Lutsk, Ukraine|Lviv Regional Clinical Hospital; Department of Neurology, Lviv, Ukraine|Vinnytsya National Med. Uni. n.a. M.I. Pyrohov; Dept. of Neurology #3, Vinnytsya, Ukraine|Walton Centre NHS Foundation Trust, Neuroscience Research Centre; CLINICAL TRIALS UNIT, Liverpool, United Kingdom|Barts and the London NHS Trust, London, United Kingdom|Kings College Hospital; Neurology, London, United Kingdom|Royal Victoria Infirmary; Neurology Dept., Newcastle Upon Tyne, United Kingdom|Uni Hospital Queens Medical Centre; Neurology, Nottingham, United Kingdom|Indiana University Medical Center; Department of Neurology, Indianapolis, Uruguay",NA,https://ClinicalTrials.gov/show/NCT01194570
132,NCT01188811,Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS),NA,Completed,Has Results,"Multiple Sclerosis, Chronic Progressive",Drug: lipoic acid|Drug: Placebo,Brain Atrophy by MRI|Disability Measures: Mobility|Safety Measure: Adverse Events,VA Office of Research and Development|Oregon Health and Science University,All,"40 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,54,U.S. Fed|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B7493-W,October 2010,August 2015,August 2015,"August 26, 2010","February 2, 2017","February 2, 2017","VA Portland Health Care System, Portland, OR, Portland, Oregon, United States",NA,https://ClinicalTrials.gov/show/NCT01188811
133,NCT01155479,A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664),PARADYSE,Terminated,Has Results,Parkinson Disease,Drug: Preladenant 2 mg tablet|Drug: Preladenant 5 mg tablet|Drug: Preladenant 10 mg tablet|Drug: Rasagiline 1 mg capsule|Drug: Placebo for Rasagiline 1 mg capsule|Drug: Placebo for Preladenant,Change From Baseline in the Sum of Unified Parkinson's Disease Rating Scale Parts 2 and 3 Scores (UPDRS2+3)|Number of Participants With Adverse Events (AEs) in Part 1|Number of Participants Who Discontinued Study Due to an AE in Part 1|Number of Participants With Adverse Events (AEs) in Part 2|Number of Participants Who Discontinued Study Due to an AE in Part 2|Percentage of Responders (Participants With a ≥20% Improvement in UPDRS2+3)|Change From Baseline in the UPDRS Part 2 Score (Activities of Daily Living [ADL]),Merck Sharp & Dohme LLC,All,"30 Years to 85 Years   (Adult, Older Adult)",Phase 3,1022,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P05664|2009-013552-72|MK-3814-024,"July 6, 2010","July 16, 2013","July 16, 2013","July 1, 2010","July 28, 2016","November 7, 2018",NA,NA,https://ClinicalTrials.gov/show/NCT01155479
134,NCT01155466,A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938),NA,Completed,Has Results,Parkinson Disease,Drug: Preladenant 2 mg tablet|Drug: Preladenant 5 mg tablet|Drug: Preladenant 10 mg tablet|Drug: Placebo to Preladenant Tablet|Drug: Rasagiline 1 mg capsule|Drug: Placebo to Rasagiline capsule,"Change From Baseline in Mean ""Off"" Time|Numberof Participants With Systolic Blood Pressure >=180 mm Hg|Number of Participants With Diastolic Blood Pressure >=105 mm Hg|Number of Participants With Alanine Aminotransferase >=3 Times the Upper Limit of Normal|Number of Participants With Aspartate Aminotransferase >=3 Times the Upper Limit of Normal|Percentage of Participants With Suicidality|Change From Baseline at Week 12 in Epworth Sleepiness Scale (ESS)|Percentage of Participants With >30% Change (Reduction) From Baseline at Week 12 in Mean ""Off"" Time|Change From Baseline at Week 12 in Mean ""On"" Time Without Troublesome Dyskinesia",Merck Sharp & Dohme LLC,All,"30 Years to 85 Years   (Adult, Older Adult)",Phase 3,778,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P04938|2009-015161-31|CTRI/2011/07/001896|MK-3814-015,"July 14, 2010","December 20, 2012","December 20, 2012","July 1, 2010","February 11, 2016","November 6, 2018",NA,NA,https://ClinicalTrials.gov/show/NCT01155466
135,NCT01143064,Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury,SyNAPSe,Completed,No Results Available,Brain Injuries,Drug: Progesterone|Drug: Lipid emulsion without progesterone,"Glasgow Outcome Scale (GOS)|Mortality|Glasgow Outcome Scale|Glasgow Outcome Scale - Extended (GOS-E)|Short Form (36) Health Survey (SF-36)|Effect of progesterone on Intracranial Pressure (ICP), Cerebral Perfusion Pressure (CPP), and Therapeutic Intensity Level (TIL)|Effect of progesterone on the progression of intracranial pathology","BHR Pharma, LLC|PRA Health Sciences|Syneos Health",All,"16 Years to 70 Years   (Child, Adult, Older Adult)",Phase 3,1195,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BHR-100-301|2010-018283-16,June 2010,March 2014,March 2014,"June 14, 2010",NA,"June 19, 2014","University of South Alabama Medical Center, Mobile, Alabama, United States|LAC+USC Medical Center, Los Angeles, California, United States|University of California San Diego Medical Center, San Diego, California, United States|Denver Health Medical Center, Denver, Colorado, United States|Christiana Care Health System Hospital, Newark, Delaware, United States|Delray Medical Center, Delray Beach, Florida, United States|Tallahassee Memorial Healthcare, Tallahassee, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Saint John's Hospital, Springfield, Illinois, United States|Wishard Health Services, Indianapolis, Indiana, United States|Methodist Hospital, Indianapolis, Indiana, United States|Mercy Medical Center, Des Moines, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Louisville Hospital, Louisville, Kentucky, United States|LSU Health - Shreveport, Shreveport, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Maine Medical Center, Portland, Maine, United States|Baystate Medical Center, Springfield, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|St. Mary's of Michigan, Saginaw, Michigan, United States|University of Missouri Health Care, Columbia, Missouri, United States|Truman Medical Center Hospital Hill, Kansas City, Missouri, United States|Lester E. Cox Memorial Hospital, Springfield, Missouri, United States|The Nebraska Medical Center, Omaha, Nebraska, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Albany Medical Center Hospital, Albany, New York, United States|Westchester Medical Center, Valhalla, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University-Baptist Medical Center, Winston-Salem, North Carolina, United States|Summa Health System, Akron, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|St. Elizabeth Health Center, Youngstown, Ohio, United States|OU Medical Center, Oklahoma City, Oklahoma, United States|Legacy Emanuel Hospital & Health Center, Portland, Oregon, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of South Carolina School of Medicine, Columbia, South Carolina, United States|Johnson City Medical Center, Johnson City, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Tech University Health Sciences Center, El Paso, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Marshall University Joan C. Edwards School of Medicine, Huntington, West Virginia, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Hospital Francisco Lopez Lima, General Roca, Rio Negro, Argentina|Hospital de Emergencias Clemente Alvarez (HECA), Rosario, Santa Fe, Argentina|Hospital Central de Mendoza, Mendoza, Argentina|Hospital San Martin, Paraná, Argentina|Hospital Nacional ""Profesor Alejandro Posadas"", Provincia de Buenos Aires, Argentina|Hospital Regional De Comodoro Rivadavia (HRCR), Provincia de Chubut, Argentina|Hospital Dr. José Maria Cullen, Santa Fé, Argentina|Medizinische Universität Graz, Graz, Austria|Medizinische Universität Innsbruck, Innsbruck, Austria|Unfallkrankenhaus Salzburg, Salzburg, Austria|Landesklinikum Wiener Neustadt, Vienna, Austria|ULB Erasme, Brussels, Belgium|Ziekenhuis Oost-Limburg, Location Sint Jan, Genk, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|University Hospital of the Free University Brussels (UZ Brussel), Jette, Belgium|University Hospital Gasthuisberg, Leuven, Belgium|Chengdu Military General Hospital, Chengdu, China|The First Affiliated Hospital of Fujian Medical University, Fuzhou, China|The 2nd Affiliated Hospital of Zhejiang University, Hangzhou, China|The Second Hospital of Shandong University, Jinan, China|Huashan Hospital of Fudan University, Shanghai, China|Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China|General Hospital of Tianjin Medical University, Tianjin, China|The Affiliated Hospital of Xuzhou Medical College, Xuzhou, China|Fakultní nemocnice Brno Neurochirurgická klinika, Brno, Czech Republic|Fakultní nemocnice u sv. Anny v Brnĕ, Neurochirurgická klinika, Brno, Czech Republic|Fakultní Nemocnice Plzeň, Neurochirurgicé Oddĕlení, Plzeň, Czech Republic|Fakultní nemocnice Kralovske Vinohrady, Praha, Czech Republic|Tampere University Hospital, Tampere, Finland|Groupe Hospitalier Pellegrin, Bordeaux, France|Hôpital Pierre Wertheimer, Bron, France|Centre Hospitalier Universitaire de Grenoble- Hópital Michallon, La Tronche, France|CHRU de Lille- Hópital Roger Salengro, Lille, France|Centre Hospitalier Universitaire de Limoges, Limoges, France|Centre Hospitalier Universitaire Hôpital Nord, Marseille, France|Hópital Central - CHU de Nancy, Nancy, France|Groupe Hospitalier La Salpêtrière, Paris, France|Charité - Universitätsmedizin Berlin, Berlin, Germany|Klinikum der J.W. Goethe-Universität, Frankfurt, Germany|Universitätsmedizin Göttingen, Göttingen, Germany|Berufsgenossenschaftliche Kliniken, Halle, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Krankenhaus Merheim, Köln, Germany|Universitätsklinikum Gießen und Marburg gGmbH, Marburg, Germany|Klinikum Nürnberg, Nürnberg, Germany|Niels-Stensen-Kliniken, Osnabrück, Germany|Universitätsklinikum Ulm, Ulm, Germany|Honvédelmi Minisztérium Állami Egészségügyi Központ, Budapest, Hungary|Pécsi Tudományegyetem Általános Orvostudományi Kar, Pécs, Hungary|Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ, Szeged, Hungary|Rambam Medical Center, Haifa, Israel|Hadassah Medical Organization, Jerusalem, Israel|Rabin Medical Center, Petach-Tikva, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Chaim Sheba Medical Center, Tel-Hashomer, Israel|Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano, Italy|Fondazione San Raffaele del Monte Tabor, Milano, Italy|Azienda Ospedaliera San Gerardo, Monza, Italy|Azienda Ospedaliero Universitaria Maggiore della Caritá, Novara, Italy|Azienda Ospedaliera San Camillo Forlanini, Rome, Italy|Azienda Ospedaliero Universitaria Integrata di Verona, Verona, Italy|Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia|Sarawak General Hospital, Kuching, Sarawak, Malaysia|VU Medisch Centrum, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Spitalul Clinic Judetean de Urgenta Timisoara, Timisoara, Romania|State Budget Educational Institution of Higher Professional Education ""Kemerovskaya State Medical Academy of Federal Agency of Healthcare and Social Development"", Kemerovo, Russian Federation|State Professional Institution of High Professional Education ""Krasnoyarsk State Medical University named after Prof. V.F. Voyno-Yasenetsky of Ministry of Health and Social Development"", Krasnoyarsk, Russian Federation|State Institution ""Burdenko Neurosurgical Institute of RAMS"", Moscow, Russian Federation|State Healthcare Facility ""Murmansk Regional Clinical Hospital n.a. Bayandin"", Murmansk, Russian Federation|Saint Petersburg Healthcare Institution ""City Mariinsky Hospital"", St. Petersburg, Russian Federation|State Institution of Health Care ""Sverdlovsk Regional Clinical Hospital #1"", Yekaterinburg, Russian Federation|National Neuroscience Institute, Singapore, Singapore|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Parc Taulí, Sabadell, Barcelona, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitario de Bellvitge, Barcelona, Spain|Hospital Universitario Vall Hebrón, Barcelona, Spain|Hospital Universitario de Girona Dr. Josep Trueta, Girona, Spain|Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitari Son Espases, Palma de Mallorca, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Clínico Universitario De Valencia, Valencia, Spain|Hospital Universitari i Politecnic La Fé de Valencia, Valencia, Spain|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chiang Mai University, Chiang Mai, Thailand|Faculty of Medicine, Prince of Songkla University, Hat yai, Thailand|Khon Kaen Hospital, Khon Kaen, Thailand|Royal Preston Hospital, Fulwood, Preston, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Leeds Teaching Hospitals NHS, Leeds General Infirmary, Leeds, United Kingdom|The Royal London Hospital, London, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Southampton University Hospital, Southampton, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT01143064
136,NCT01093261,Corticosteroid Therapy for Glucocorticoid Insufficiency Related to Traumatic Brain Injury,Corti-TC,Completed,No Results Available,Traumatic Brain Injury|Trauma|Adrenal Insufficiency|Pneumonia,Drug: Placebo|Drug: Hydrocortisone Fludrocortisone,rate of hospital acquired pneumonia|Neurological recovery|other infections|Organ failures|Length of ICU stay|Duration of mechanical ventilation support|Mortality from all causes|Time to amines withdrawal|Post traumatic stress disorder|Glucocorticoid function,Nantes University Hospital|Société Française d'Anesthésie et de Réanimation,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Phase 3,336,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BRD/10/01-L|SFAR,August 2010,November 2012,December 2012,"March 25, 2010",NA,"September 14, 2017","University hospital, Amiens, France|University Hospital, Angers, France|University Hospital, Beaujon, France|University hospital, Bordeaux, France|University Hospital, Brest, France|Universtiy Hospital, Caen, France|University Hospital, Clermont Ferrand, France|University hospital, Creteil, France|University Hospital, Creteil, France|University Hospital, Grenoble, France|University Hospital, Montpellier, France|University Hospital, Nantes, France|University Hospital, Nimes, France|European Hospital Georges Pompidou, Paris, France|Saint Louis Hospital, Paris, France|University hospital, Poitiers, France|University Hospital, Strasbourg, France|University Hospital, Toulouse, France",NA,https://ClinicalTrials.gov/show/NCT01093261
137,NCT01064401,Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis,(DECIDE),Completed,Has Results,Relapsing-Remitting Multiple Sclerosis,Biological: BIIB019 (Daclizumab High Yield Process)|Drug: Interferon beta-1a Placebo|Biological: Interferon beta-1a|Drug: Daclizumab High Yield Process Placebo,Adjusted Annualized Relapse Rate (ARR)|Adjusted Mean Number of New or Newly Enlarging T2 Hyperintense Lesions up to Week 96|Proportion of Participants With Sustained Disability Progression at 144 Weeks|Proportion of Participants Relapse-free at Week 144|Percentage of Participants With a ≥ 7.5 Point Worsening From Baseline in the Multiple Sclerosis Impact Scale (MSIS-29) Physical Impact Score at 96 Weeks,Biogen|AbbVie,All,18 Years to 55 Years   (Adult),Phase 3,1841,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",205MS301|2009-012500-11,May 2010,March 2014,July 2014,"February 8, 2010","July 11, 2016","July 11, 2016","Research Site, Gilbert, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, La Jolla, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Naples, Florida, United States|Research Site, Pompano Beach, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, Sunrise, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Evanston, Illinois, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Des Moines, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Worchester, Massachusetts, United States|Research Site, Clinton Township, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Buffalo, New York, United States|Research Site, Latham, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Winston Salem, North Carolina, United States|Research Site, Medford, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburg, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Franklin, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, Kirkland, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Godoy Cruz, Mendoza, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Camperdown, New South Wales, Australia|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Auchenflower, Queensland, Australia|Research Site, Woodville, South Australia, Australia|Research Site, Fitzroy, Victoria, Australia|Research Site, Heidelberg West, Victoria, Australia|Research Site, Belo Horizonte, Bahia, Brazil|Research Site, Brasilia, Distrito Federal, Brazil|Research Site, Recife, Pernambuco, Brazil|Research Site, Porto Alegre, Rio Grande, Brazil|Research Site, Sao Paulo, Rio Grande, Brazil|Research Site, Campinas, Sao Paulo, Brazil|Research Site, Ribeirão Preto, Sao Paulo, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Saint John, Newfoundland and Labrador, Canada|Research Site, London, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montréal, Quebec, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Brno, Jihocesky Kraj, Czech Republic|Research Site, Jihlava, Kraj Vysocina, Czech Republic|Research Site, Olomouc, Olomoucký kraj, Czech Republic|Research Site, Praha 10, Praha, Czech Republic|Research Site, Praha 2, Praha, Czech Republic|Research Site, Havirov, Severomoravksy Krav, Czech Republic|Research Site, Brno, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Jihlava, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Pardubice, Czech Republic|Research Site, Copenhagen, Denmark|Research Site, Glostrup, Denmark|Research Site, Odense C, Denmark|Research Site, Århus, Denmark|Research Site, Tampere, Western Finalnd, Finland|Research Site, Helsinki, Finland|Research Site, Oulu, Finland|Research Site, Seinäjoki, Finland|Research Site, Turku, Finland|Research Site, Strasbourg, Alsace, France|Research Site, Caen Cedex 5, Basse-normandie, France|Research Site, Bobigny, Ile-de-france, France|Research Site, Paris Cedex 5, Ile-de-france, France|Research Site, Paris, Ile-de-france, France|Research Site, Amiens, Picardie, France|Research Site, Nice, Provence Alpes Cote D'azur, France|Research Site, Lyon, Rhone-alpes, France|Research Site, Bourdeaux, France|Research Site, Dijon, France|Research Site, Lille, France|Research Site, Lomme, France|Research Site, Marseille Cedex 9, France|Research Site, Nancy, France|Research Site, Toulouse Cedex 3, France|Research Site, Tbilisi, Georgia|Research Site, Freiburg, Baden-wuerttemberg, Germany|Research Site, Bad Mergentheim, Baden-Wurttemberg, Germany|Research Site, Bamberg, Bayern, Germany|Research Site, Bayreuth, Bayern, Germany|Research Site, München, Bayern, Germany|Research Site, Neuburg an der Donau, Bayern, Germany|Research Site, Marburg, Hessen, Germany|Research Site, Essen, Nordrhein Westfalen, Germany|Research Site, Koln, Nordrhein Westfalen, Germany|Research Site, Munster, Nordrhein-Westfalen, Germany|Research Site, Trier, Rheinland-Pfalz, Germany|Research Site, Dresden, Sachsen, Germany|Research Site, Berlin, Germany|Research Site, Hamburg, Germany|Research Site, Tübingen, Germany|Research Site, Athens, Attica, Greece|Research Site, Heraklion, Crete, Greece|Research Site, Thessaloniki, Macedoni, Greece|Research Site, Székesfehérvár, Fejer, Hungary|Research Site, Gyor, Gyor-moson-sopron, Hungary|Research Site, Budapest, Hungary|Research Site, Esztergom, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Veszprém, Hungary|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Delhi, Dwivdee, India|Research Site, Bangalore, Karnataka, India|Research Site, Trivandrum, Kerala, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nagpur, Maharashtra, India|Research Site, New Delhi, India|Research Site, Dublin, Ireland|Research Site, Ashkelon, Ashqelon, Israel|Research Site, Tzrifin, Beer Yaakov, Israel|Research Site, Petach Tikva, Petah Tiqwa, Israel|Research Site, Beer-Sheva, Israel|Research Site, Haifa, Israel|Research Site, Kfar Saba, Israel|Research Site, Tzfat, Israel|Research Site, Cefalù, PA, Italy|Research Site, Orbassano, Torino, Italy|Research Site, Bari, Italy|Research Site, Cagliari, Italy|Research Site, Catania, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Padova, Italy|Research Site, Roma, Italy|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Chisinau, Moldova, Republic of|Research Site, Lublin, Dolnoslaskie, Poland|Research Site, Bydgoszcz, Kujawsko-pomorskie, Poland|Research Site, Grudziadz, Kujawsko-pomorskie, Poland|Research Site, Lódz, Lodzkie, Poland|Research Site, Kraków, Malopolskie, Poland|Research Site, Warszawa, Mazowieckie, Poland|Research Site, Bialystok, Podlaskie, Poland|Research Site, Gdansk, Pomorskie, Poland|Research Site, Katowice, Slaskie, Poland|Research Site, Kielce, Swietokrzycie, Poland|Research Site, Olsztyn, Warminsko-mazurskie, Poland|Research Site, Poznan, Wielkopolskie, Poland|Research Site, Szczecin, Zachodniopomorskie, Poland|Research Site, Bydgoszczas, Poland|Research Site, Plewiska, Poland|Research Site, Bucurest, Bucuresti, Romania|Research Site, Cluj-Napoca, Cluj, Romania|Research Site, Timisoara, Timis, Romania|Research Site, Iasi, Romania|Research Site, Târgu Mures, Romania|Research Site, Kazan, Povolje-Tatarstan, Russian Federation|Research Site, Ekaterinburg, Ural, Russian Federation|Research Site, Yaroslavl, Yaroslavlr, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Kaluga, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tumen, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Kragujevac, Serbia|Research Site, Nis, Serbia|Research Site, Novi Sad, Serbia|Research Site, L´Hospitalet de Llobregat, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Cordoba, Spain|Research Site, Girona, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Göteborg, Sweden|Research Site, Linköping, Sweden|Research Site, Malmö, Sweden|Research Site, Stockholm, Sweden|Research Site, Basel, Switzerland|Research Site, Lugano, Switzerland|Research Site, Dnepropetrovsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyviv, Ukraine|Research Site, Odessa, Ukraine|Research Site, Poltava, Ukraine|Research Site, Vinnitsa, Ukraine|Research Site, Zaporozhye, Ukraine|Research Site, Brighton, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, London, United Kingdom|Research Site, New Castle Upon Tyne, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Romford, United Kingdom|Research Site, Salford, United Kingdom|Research Site, Sheffield, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT01064401
138,NCT01047254,Bupropion for the Treatment of Apathy in Alzheimer's Dementia,APA-AD,Completed,No Results Available,Apathy in Dementia,Drug: Elontril|Drug: placebo,Change in Apathy Evaluation Scale (AES) score|NPI total score;NPI caregivers' distress total score;ADCS-ADL; QoL-AD; RUD;ADAScog;MMSE,"University Hospital, Bonn|University of Cologne|Physician of neurology, psychiatry and psychotherapy Horn, MD; Bad Honnef|Charite University, Berlin, Germany|Universität Duisburg-Essen|University of Erlangen-Nürnberg|University of Freiburg|University Medical Center Goettingen|Universität des Saarlandes|Johannes Gutenberg University Mainz|Heidelberg University|Philipps University Marburg Medical Center|Ludwig-Maximilians - University of Munich|University of Rostock|University Hospital Tuebingen|University of Ulm",All,"55 Years to 90 Years   (Adult, Older Adult)",Phase 3,110,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2007-005352-17,January 2010,July 2014,July 2014,"January 12, 2010",NA,"May 9, 2017","Department of Psychiatry, University Bonn, Bonn, Germany",NA,https://ClinicalTrials.gov/show/NCT01047254
139,NCT01007864,Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists,PIVICOG-PD,Completed,No Results Available,Idiopathic Parkinson's Disease,Drug: piribedil|Drug: pramipexole or ropinirole,"The primary efficacy variable will be the 'median reaction time during the second 15 minutes (minutes 16-30)' of the subtest 'vigilance', visual test condition 'moving bar', of the Test battery for Attention Performances (TAP) at end of treatment.|Other vigilance parameters of the TAP test|Other neuropsychological tests: Test of verbal fluency (RWT), Verbal learning memory test (VLMT), Stroop test (FWIT)|Epworth Sleepiness Scale (ESS)|Parkinson's Disease Sleeping Scale (PDSS)|Unified Parkinson's Disease Rating Scale (UPDRS) subscores I to IV and total score|Parkinson's disease quality of life questionnaire (PDQ-39)|Clinical Global Impressions (CGI) (except item 3.2)|Patient Global Impression (PGI)",Desitin Arzneimittel GmbH|FGK Clinical Research GmbH,All,"35 Years to 80 Years   (Adult, Older Adult)",Phase 3,80,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,PIR-007/K,January 2010,December 2011,December 2011,"November 4, 2009",NA,"May 24, 2012","Ulm, Baden-Württemberg, Germany|Wolfach, Baden-Württemberg, Germany|München, Bayern, Germany|Berlin-Steglitz, Berlin, Germany|Marburg, Hessen, Germany|Göttingen, Niedersachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Gera, Thüringen, Germany|Stadtroda, Thüringen, Germany|Berlin, Germany|Berlin, Germany",NA,https://ClinicalTrials.gov/show/NCT01007864
140,NCT00974974,A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).,NA,Completed,Has Results,Parkinson's Disease,Drug: IPX066|Drug: IR CD-LD,"Percentage of ""Off"" Time During Waking Hours at End of Study|""Off"" Time|""On"" Time Without Troublesome Dyskinesia","Impax Laboratories, LLC",All,"30 Years and older   (Adult, Older Adult)",Phase 3,471,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IPX066-B09-02,September 2009,January 2011,March 2011,"September 11, 2009","January 14, 2016","August 11, 2020","Investigator 17, Birmingham, Alabama, United States|Investigator 49, Phoenix, Arizona, United States|Investigator 7, Little Rock, Arkansas, United States|Investigator 3, La Jolla, California, United States|Investigator 31, Sunnyvale, California, United States|Investigator 6, Torrance, California, United States|Investigator 51, Aurora, Colorado, United States|Investigator 10, New Haven, Connecticut, United States|Investigator 64, Bradenton, Florida, United States|Investigator 61, Hollywood, Florida, United States|Investigator 5, Ocala, Florida, United States|Investigator 15, Port Charlotte, Florida, United States|Investigator 8, Port Charlotte, Florida, United States|Investigator 4, Saint Petersburg, Florida, United States|Investigator 46, Augusta, Georgia, United States|Investigator 38, Boise, Idaho, United States|Investigator 19, Chicago, Illinois, United States|Investigator 40, Chicago, Illinois, United States|Investigator 39, Des Moines, Iowa, United States|Investigator 29, Kansas City, Kansas, United States|Investigator 1, Bingham Farms, Michigan, United States|Investigator 21, New Brunswick, New Jersey, United States|Investigator 25, Albany, New York, United States|Investigator 8, Commack, New York, United States|Investigator 12, New York, New York, United States|Investigator 11, Durham, North Carolina, United States|Investigator 9, Raleigh, North Carolina, United States|Investigator 20, Cincinnati, Ohio, United States|Investigator 42, Toledo, Ohio, United States|Investigator 60, Tulsa, Oklahoma, United States|Investigator 14, Charleston, South Carolina, United States|Investigator 16, Dallas, Texas, United States|Investigator 13, Houston, Texas, United States|Investigator 65, Tacoma, Washington, United States|Investigator 2, Milwaukee, Wisconsin, United States|Investigator 24, London, Ontario, Canada|Investigator 18, Ottawa, Ontario, Canada|Investigator 26, Quebec, Canada|Investigator 32, Strasbourg Cedex, Alsace, France|Investigator 22, Dijon, Bourgogne, France|Investigator 58, Paris, Ile-de-france, France|Investigator 33, Toulouse, Midi-pyrenees, France|Investigator 52, Lille, NORD Pas-de-calais, France|Investigator 30, Sachsen, Dresden, Germany|Investigator 27, Westerstede, Niedersachsen, Germany|Investigator 23, Berlin, Germany|Investigator 72, Berlin, Germany|Investigator 28, Berlin, Germany|Investigator 67, Berlin, Germany|Investigator 48, Bydgoszcz, Kujawsko-pomorskie, Poland|Investigator 59, Lublin, Lubelskie, Poland|Investigator 37, Kraków, Malopolskie, Poland|Investigator 36, Warszawa, Mazowieckie, Poland|Investigator 35, Mosina, Wielkopoloskie, Poland|Investigator 54, Szczecin, Zachodniopomorskie, Poland|Investigator 34, Katowice, Poland|Investigator 69, Târgu-Mureş, Mures, Romania|Investigator 68, Brasov, Romania|Investigator 62, Bucuresti, Romania|Investigator 63, Târgu Mureş, Romania|Investigator 43, Terrassa, Barcelona, Spain|Investigator 70, Barcelona, Spain|Investigator 57, Barcelona, Spain|Investigator 45, Barcelona, Spain|Investigator 50, Madrid, Spain|Investigator 53, Madrid, Spain|Investigator 55, Dnepropetrovsk, Dnipropetrovsk, Ukraine|Investigator 56, Vinnitsa, Vinnytsya, Ukraine|Investigator 47, Zaporozhye, Zaporizhzhya, Ukraine|Investigator 71, Donetsk, Ukraine|Investigator 44, Kharkiv, Ukraine|Investigator 66, Odessa, Ukraine|Investigator 41, Zaporozhye, Ukraine",NA,https://ClinicalTrials.gov/show/NCT00974974
141,NCT00947895,Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone,RECLAIM,Terminated,No Results Available,Multiple Sclerosis,Drug: Methylprednisolone|Drug: ACTH|Other: IV placebo|Other: IM placebo,Improvement in EDSS (Expanded Disability Status Scale) and Kurtzke Functional Scale (to assess individual disabilities).|Improvement in MSFC (Multiple Sclerosis Functional Composite)18 and its three individual components.|Safety and tolerability of ACTH and MP in patients with an acute relapse of multiple sclerosis after sub-response to an initial course of intravenous methylprednisolone.,"Neurologique Foundation, Inc.|Mallinckrodt",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,30,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Q1001,October 2009,January 2011,January 2011,"July 28, 2009",NA,"March 22, 2016","Neurologique Foundation, Inc., Ponte Vedra, Florida, United States",NA,https://ClinicalTrials.gov/show/NCT00947895
142,NCT00943748,Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease,FAIR-PARK-I,Completed,No Results Available,Parkinson's Disease,Drug: deferiprone|Drug: placebo,"Decrease the iron overload (as measured by the T2* MRI sequence) in the substantia nigra in patients with Parkinson's disease (PD) after 6 months of deferiprone treatment, relative to the placebo group.|Other radiological criteria: Modification of T2* in MRI of the caudal nucleus head, putamen and pallidum|Parkinsonian syndrome: UPDRS III|Cognitive and behavioral functions: function, attention (simple and choice reaction times), drowsiness and sleep (Epworth scale, Parkinson Disease Sleep Scale), depression (MADRS).|The Clinical Global Impression scored by the examiner and the patient|Specific biochemistry screen: heavy metal profile, oxidative stress and dopamine metabolism|Complete blood count (CBC) with weekly leukocyte counts, standard blood biochemistry profile, blood iron profile, ECG, blood pressure, bodyweight, adverse event reporting.|Ancillary study involving analysis of the cerebrospinal fluid (CSF).","University Hospital, Lille",All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2008-006842-25|2008_19/0838|A90113-62,October 2009,August 2011,October 2011,"July 22, 2009",NA,"September 3, 2012","Service de Neurologie, Clinique Neurologique, EA 2683, IFR 114, Lille, France",NA,https://ClinicalTrials.gov/show/NCT00943748
143,NCT00920946,A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease,HORIZON,Completed,No Results Available,Huntington Disease,Drug: Dimebon|Other: Placebo,A comparison between the mean changes from baseline in the Dimebon 20 mg TID treatment group and the placebo group on the MMSE|A comparison of the distributions of the CIBIC-plus (ADCS CGIC)in the Dimebon 20 mg TID treatment group and the placebo group|A comparison between the mean changes from baseline of the Dimebon 20 mg TID treatment group and the placebo group on the NPI|A comparison between the mean changes from baseline of the Dimebon 20 mg TID treatment group and the placebo group on the ADCS-ADL|A comparison between the mean changes from baseline of the Dimebon 20 mg TID treatment group and the placebo group on the UHDRS'99 Total Motor Score,"Medivation, Inc.|Pfizer",All,"30 Years and older   (Adult, Older Adult)",Phase 3,403,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",DIM20,July 2009,July 2011,NA,"June 15, 2009",NA,"October 12, 2016","Scottsdale, Arizona, United States|Davis, California, United States|Irvine, California, United States|La Jolla, California, United States|San Francisco, California, United States|Gainsville, Florida, United States|Miami, Florida, United States|Boise, Idaho, United States|Indianapolis, Indiana, United States|Kansas City, Kansas, United States|Wichita, Kansas, United States|Charlestown, Massachusetts, United States|Golden Valley, Minnesota, United States|St. Louis, Missouri, United States|New York, New York, United States|Rochester, New York, United States|Durham, North Carolina, United States|Winstom-Salem, North Carolina, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Milwaukee, Wisconsin, United States|Wentworthville, New South Wales, Australia|Melbourne, Victoria, Australia|Perth, Australia|Vancouver, British Columbia, Canada|London, Ontario, Canada|Montreal, Quebec, Canada|Copenhagen, Denmark|Oberer Eslebberg, Ulm, Germany|Aachen, Germany|Bochum, Germany|Hamburg, Germany|Stockholm, Sweden|Birmingham, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT00920946
144,NCT00906399,Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis,ADVANCE,Completed,Has Results,Relapsing Multiple Sclerosis,Drug: BIIB017 (peginterferon beta-1a)|Drug: Placebo,Annualized Relapse Rate (ARR) at 1 Year|Number of New Or Newly Enlarging T2 Hyperintense Lesions at 1 Year|Proportion of Participants Relapsed at 1 Year|Estimated Proportion of Participants With Sustained Disability Progression at 1 Year,Biogen,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,1516,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",105MS301|2008-006333-27,June 2009,October 2012,October 2013,"May 21, 2009","September 19, 2014","September 19, 2014","Research Site, Phoenix, Arizona, United States|Research Site, Ponte Vedra Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Des Moines, Iowa, United States|Research Site, Lexington, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Teaneck, New Jersey, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Franklin, Tennessee, United States|Research Site, Round Rock, Texas, United States|Research Site, 'Sint-Truiden, Belgium|Research Site, Bruxelles, Belgium|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, London, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Santiago, Chile|Research Site, Barranquilla, Atlantico, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Bogota, Colombia|Research Site, Osijek, Croatia|Research Site, Zagreb, Croatia|Research Site, Brno, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Ostrava - Vitkovice, Czech Republic|Research Site, Ostrava-Poruba, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Teplice, Czech Republic|Research Site, Parnu, Estonia|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Amiens, France|Research Site, Clermont-Ferrand, France|Research Site, Lyon, France|Research Site, Marseille, France|Research Site, Nice, France|Research Site, Tbilisi, Georgia|Research Site, Tbilisi, Georgia|Research Site, Tbilisi, Georgia|Research Site, Tbilisi, Georgia|Research Site, Bayreuth, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Erbach, Germany|Research Site, Erlangen, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Koln, Germany|Research Site, Leipzig, Germany|Research Site, Marburg, Germany|Research Site, Munchen, Germany|Research Site, Munster, Germany|Research Site, Prien, Germany|Research Site, Ulm, Germany|Research Site, Westerstede, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, Saket, Delhi, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Rajkot, Gujarat, India|Research Site, Bangalore, Karnataka, India|Research Site, Indore, Madhyr Pradesh, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nagpur, Maharashtra, India|Research Site, Nasik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Amritsar, Punjab, India|Research Site, Jaipur, Rajasthan, India|Research Site, Chennai, Tamil Nadu, India|Research Site, Coimbatore, Tamil Nadu, India|Research Site, Kolkata, West Bengal, India|Research Site, Bangalore, India|Research Site, Mangalore, India|Research Site, Navi Mumbai, India|Research Site, Nehru Nagar, India|Research Site, Riga, Latvia|Research Site, Aquas Calientes, Mexico|Research Site, Chihuahua, Mexico|Research Site, Mexico City, Mexico|Research Site, Mexico DF, Mexico|Research Site, Monterrey, Nuevo Leon, Mexico|Research Site, Tijuana, Baja California, Mexico|Research Site, Breda, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Auckland, New Zealand|Research Site, Christchurch, New Zealand|Research Site, Dunedin, New Zealand|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, San Isidro, Peru|Research Site, Bialystok, Poland|Research Site, Bialystok, Poland|Research Site, Bydgoszcz, Poland|Research Site, Gdansk, Poland|Research Site, Gdansk, Poland|Research Site, Gdansk, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Konskie, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Olsztyn, Poland|Research Site, Plewiska, Poland|Research Site, Poznan, Poland|Research Site, Poznan, Poland|Research Site, Szczecin, Poland|Research Site, Szczecin, Poland|Research Site, Warsawa, Poland|Research Site, Warsawa, Poland|Research Site, Warsawa, Poland|Research Site, Warsawa, Poland|Research Site, Wroclaw, Poland|Research Site, Zabrze, Poland|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Campulung, Romania|Research Site, Iasi, Romania|Research Site, Sibiu, Romania|Research Site, Targu Mures, Romania|Research Site, Chelyabinsk, Russian Federation|Research Site, Kaluga, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Kursk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Kragujevac, Serbia|Research Site, Nis, Serbia|Research Site, Cordoba, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Sevilla, Spain|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Poltava, Ukraine|Research Site, Simferopol, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Vinnytsya, Ukraine|Research Site, London, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Salford, United Kingdom|Research Site, Sheffield, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT00906399
145,NCT00905372,Effect of LY2062430 on the Progression of Alzheimer's Disease,EXPEDITION,Completed,No Results Available,Alzheimer's Disease,Drug: LY2062430|Drug: Placebo,Change from baseline to endpoint in Alzheimer's Disease Assessment Scale-Cognitive subscore (ADAS-Cog11)|Change from baseline to endpoint in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL)|Change from baseline to endpoint in Clinical Dementia Rating-Sum of Boxes (CDR-SB)|Change from baseline to endpoint in Neuropsychiatric Inventory (NPI)|Change from baseline to endpoint in volumetric magnetic resonance imaging (vMRI)|Change from baseline to endpoint in Mini-Mental State Examination (MMSE)|Change from baseline to endpoint in Resource Utilization in Dementia-Lite (RUD-Lite)|Change from baseline to endpoint in EuroQol 5-Dimensional Health-related Quality of Life Scale Proxy version (EQ-5D Proxy)|Change from baseline to endpoint in Quality of Life in Alzheimer's Disease (QoL-AD)|Change from baseline to endpoint in plasma LY2062430 to investigate a relationship between plasma LY2062430 and plasma A Beta levels.|Change from baseline to endpoint in plasma A Beta,Eli Lilly and Company,All,"55 Years and older   (Adult, Older Adult)",Phase 3,1000,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",6747|H8A-MC-LZAM,May 2009,April 2012,April 2012,"May 20, 2009",NA,"September 25, 2012","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sun City, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tuscon, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Little Rock, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Carson, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Irvine, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Laguna Hills, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lomita, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orange, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oxnard, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Ana, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fairfield, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamden, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Norwalk, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newark, Delaware, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Washington, District of Columbia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boca Raton, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami Springs, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., North Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orange City, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sunrise, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Canton, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Decatur, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rockville, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belmont, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Grand Rapids, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Traverse City, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albany, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bronx, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Latham, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orangeburg, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winston-Salem, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beachwood, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toledo, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eugene, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., East Providence, Rhode Island, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greer, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sioux Falls, South Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bennington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Burlington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Norfolk, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roanoke, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cordoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mendoza, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pueyrredon Cordoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosario, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Fe, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Curitiba, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Itapira, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio De Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Medicine Hat, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kelowna, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Penticton, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ottawa, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenfield Park, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherbrooke, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aichi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hiroshima, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan",NA,https://ClinicalTrials.gov/show/NCT00905372
146,NCT00904683,Effect of LY2062430 on the Progression of Alzheimer's Disease,EXPEDITION2,Completed,No Results Available,Alzheimer's Disease,Drug: LY2062430|Drug: Placebo,Change from Baseline to Week 80 in Alzheimer's Disease Assessment Scale - Cognitive Subscore 14-Item Scale (ADAS-Cog14)|Change from Baseline to Week 80 in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score|Change from Baseline to Week 80 in Neuropsychiatric Inventory (NPI) Score|Change from Baseline to Week 80 in volumetric Magnetic Resonance Imaging (vMRI)|Change from Baseline to Week 80 in Mini-Mental State Examination (MMSE) Score|Change from Baseline to Week 80 in Resource Utilization in Dementia - Lite (RUD-Lite) Score|Change from Baseline to Week 80 in EuroQol 5-Dimensional Health-related Quality of Life Scale Proxy version (EQ-5D Proxy) Score|Change from Baseline to Week 80 in Quality of Life in Alzheimer's Disease (QoL-AD) Score|Change from Baseline to Week 80 in Plasma Amyloid Beta Levels|Change from Baseline to Week 80 in Alzheimer's Disease Assessment Scale - Cognitive Subscore 11-Item and 12-Item Scale (ADAS-Cog11 and ADAS-Cog12)|Change from Baseline to Week 80 in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) Score,Eli Lilly and Company,All,"55 Years and older   (Adult, Older Adult)",Phase 3,1040,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",11934|H8A-MC-LZAN,May 2009,June 2012,June 2012,"May 20, 2009",NA,"December 13, 2012","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Francisco, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Monica, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa Bay, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hattiesburg, Mississippi, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Creve Coeur, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kansas City, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amherst, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Staten Island, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bankstown, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Darlinghurst, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gosford, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kogarah, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chermside, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toowoomba, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Box Hill, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glen Iris, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg Heights, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Melbourne, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Subiaco, Western Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aix En Provence, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munchen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., München, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Regensburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Biella, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boggiovara, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cassino, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chieti, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lido Di Camaiore, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ehime, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Incheon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seongnam-Si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suwon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bialystok, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bydgoszcz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gliwice, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Katowice, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krakow, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chelyabinsk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ekaterinburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rostov-On-Don, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Getafe, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plasencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Terrassa, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Joenkoeping, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kalmar, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lund, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmo, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Molndal, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockholm, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Umea, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Niao Sung Hsiang, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yung-Kang, Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uckfield, E Susx, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scotland, Glasgow, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Greater London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Camberwell, London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sheffield, Syorks, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Swindon, Wiltshire, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT00904683
147,NCT00893867,Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke,MACSI,Terminated,No Results Available,Acute Ischemic Stroke,Drug: DP-b99|Drug: Placebo,"Modified Rankin Scale (mRS) categorical analysis (""shift"")|Recovery, defined as a score of ≤ 1 on modified Rankin Score|Safety and tolerability|recovery as assessed by an NIHSS of not more than 1|'home time'",D-Pharm Ltd.,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,446,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Ptcl-01373,December 2009,April 2012,April 2012,"May 6, 2009",NA,"October 24, 2012","Research Center of Southern California, Oceanside, California, United States|Associated Neurologists, P.C., Danbury, Connecticut, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|The University of Kentucky The Methodist Hospital, Lexington, Kentucky, United States|University of Louisville, Kentucky Neuroscience Research, Louisville, Kentucky, United States|Tufts Medical Center, Boston, Massachusetts, United States|Capital Health Regional Medical Center Neuroscience Institute, Trenton, New Jersey, United States|Presbitarian Hospital, Charlotte, North Carolina, United States|St. Elizabeth's Medical Center, Youngstown, Ohio, United States|Legacy Meridian Park Medical Center, Tualatin, Oregon, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|The Methodist Hospital, Houston, Texas, United States|Carilion Clinic, Roanoke, Virginia, United States|Medizinische Universität Innsbruck, Innsbruck, Austria|Landeskrankenhaus Klagenfurt, Klagenfurt, Austria|Abt. Neurologie und Psychiatrie, Linz, Austria|LKH St. Pölten Department of Neurology, St. Pölten, Austria|Santa Casa de Misericordia de Belo Horizonte Departamento de Neurologia, Belo Horizonte, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil|Hospital Moinhos de Vento, Porto Alegre, Brazil|Hospital Mãe de Deus, Porto Alegre, Brazil|Santa Casa de Misericórdia de Porto Alegre Policlinica Santa Clara Sala de Neurologia, Porto Alegre, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto Unidade de Emergência Centro de Estudos, Ribeirão Preto, Brazil|UNIFESP, San Paulo, Brazil|Hospital São José de Joinville, Santa Catarina, Brazil|Hospital Santa Marcelina, Sao Paulo, Brazil|Hamilton Health Sciences Centre, Hamilton, Ontario, Canada|Grey Nun's Community Hospital, Edmonton, Canada|University of Alberta Hospital, Edmonton, Canada|Hamilton Health Sciences Centre, Hamilton, Canada|Kingston General Hospital, Kingston, Canada|Chinook Regional Hospital, Lethbridge, Canada|CHA- Hôpital de l'Enfant-Jésus, Quebec, Canada|University Hospital Brno, Brno, Czech Republic|University Hospital Hradec Kralove, Clinic of Neurology, Hradec Kralove, Czech Republic|Hospital Jihlava Clinic of Neurology, Jihlava, Czech Republic|Hospital Vítkovice Clinic of Neurology, Ostrava, Czech Republic|County Hospital Pardubice Clinic of Neurology, Pardubice, Czech Republic|Clinic of Neurology, Stroke Center, Charles University, Prague, Czech Republic|University Hospital Kralovske Vinohrady, Prague, Czech Republic|University Hospital Motol Clinic of Neurology, Prague, Czech Republic|CHU Jean Minjoz Besançon, Besancon, France|Hopital Pellegrin-Tripode, Bordeaux, France|CHU Henri Mondor, Créteil, France|Hopital Gui de Chauliac, Montpellier, France|Hôpital Bichat, Paris, France|Hôpital Lariboisière - Service Neurologie, Paris, France|Hôpital Saint Jean, Perpignan, France|Ärztlicher Direktor Neurologische Klinik, Neurologische Klink GmbH der Rhoen-Klinikum AG, Bad Neustadt / Saale, Germany|Marien-Krankenhaus gGmbH, Abteilung für Neurologie, Bergisch Gladbach, Germany|DRK Kliniken Berlin, Klinik fuer Neurologie, Berlin, Germany|Vivantes Klinikum Neukölln, Klinik für Neurologie, Stroke Unit, Berlin, Germany|Klinikum Bremen-Mitte, Bremen, Germany|Klinikum Bremerhaven-Reinkenheide gGmbH, Neurologische Klinik, Bremerhaven, Germany|Klinikum Chemnitz GmbH Chefarzt Klinik für Neurologie, Chemnitz, Germany|Helios Klinikum Erfurt GmbH, Erfurt, Germany|Universitätsklinikum Erlangen, Neurologische klinik, Erlangen, Germany|Universitätsklinikum Essen, Klinik und Poliklinik für Neurologie, Essen, Germany|Neurologische Universitätsklinik Freiburg, Neurozentrum, Freiburg, Germany|Klinikum Fulda, Neurologische Klinik, Fulda, Germany|Evangelische Kliniken Gelsenkirchen GmbH Klinik für Neurologie und Klinische Neurophysiologie, Gelsenkirchen, Germany|Georg-August-Universitat Gottingen Neurologische Klinik, Gottingen, Germany|Ernst Moritz Arndt University, Grifswald, Germany|Askepios Klinik Altona, Hamburg, Germany|Askepios Klinik Heidberg, Hamburg, Germany|Klinikum Köln Merheim, Department of Neurology, Koln, Germany|Universitätsklinikum Leipzig AöR, Klinik und Poliklinik für Neurologie, Leipzig, Germany|Klinikum der Otto-von-Guericke-Universität Magdeburg, Neurologische Universitätsklinik, Magdeburg, Germany|Johannes Gutenberg Universitat, Klinik und Poliklinik fur Neurologie, Mainz, Germany|Klinikum 1 Minden, Neurologische Klinik, Minden, Germany|Universität Rostock Chefarzt Abteilung Neurologie, Rostock, Germany|ASKLEPIOS Fachklinikum Teupitz, Teupitz, Germany|Krankenhaus der Bramherzigen Brüder, Trier, Germany|Universitätsklinikum Ulm, Abteilung für Neurologie im RKU, Ulm, Germany|Heinrich Braun Klinikum Zwickau, Zwickau, Germany|Fővárosi Önkormányzat Péterfy Sándor utcai Kórház- Rendelőintézet és Baleseti Központ, Budapest, Hungary|Állami Egészségügyi Központ, Budapest, Hungary|Kenezy Korhaz Rendelointezet Egezsegugyi Szolgaltato Nonprofit Kft., Debrecen, Hungary|University of Debrecen, Medical and Health Science Center, Debrecen, Hungary|Aladár Petz County Teaching Hospital, Gyor, Hungary|PM Flór Ferenc County Hospital, Kistarcsa, Hungary|Borsod-Abaúj-Zemplén County Hospital Miskolc, Miskolc, Hungary|Pécsi Tudományegyetem Klinikai Központ, Pecs, Hungary|Zala Megyei Kórház, Zalaegerszeg, Hungary|Bnai Zion Medical Center, Haifa, Israel|Neurological Dept. Edith Wolfson Medical Center, Holon, Israel|Meir Medical Center, Kfar Saba, Israel|Sourasky Medical Center, Tel Aviv, Israel|Chaim Sheba Medical Center, Tel Hashomer, Israel|Ospedale Regionale Valle d'Aosta, Aosta, Italy|Dipartimento di Neuroscienze, Ospedale di Brotzu, Cagliari, Italy|Ospedale di Circolo di Varese, Lombardia, Italy|Istituto Scientifico San Raffaele - Stroke Unit, Milano, Italy|Istituto Neurologico C. Mondino, Pavia, Italy|Università di Perugia, Division of Internal and Cardiovascular Medicine - Stroke Unit, Perugia, Italy|Presidio Ospedaliero di Piacenza, Piacenza, Italy|Azienda Ospedaliera Sant'Andrea, Stroke Unit, Rome, Italy|Istituto Patologia Generale U.C.S.C, Rome, Italy|U.O.C. Stroke Unit, Rome, Italy|Università di Roma ""La Sapienza"" - Stroke Unit, Rome, Italy|Azienda Ospedaliera Universitaria ""Santa Maria della Misericordia"" Stroke Unit, Udine, Italy|Dong-A Medical Center, Busan, Korea, Republic of|Inje University BUSAN Paik Hospital, Busan, Korea, Republic of|Inje University ILSAN Paik Hospital, Goyang, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|ASAN Medical Center, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's hospital, Seoul, Korea, Republic of|Catharina Ziekenhuis Neurologie, Eindhoven, Netherlands|Medisch Spectrum Twente Hoofd Afdeling Vasculaire Neurologie, Enschede, Netherlands|Atrium MC Parkstad, Heerlen, Netherlands|Isala Klinieken Ploikliniek Neurologie, Zwolle, Netherlands|Pomerania Traumatology Center, Regional Specialist Hospital im. Nicolaus Copernicus, Gdansk, Poland|Medical University of Lublin, Department of Neurology, Stroke Unit, Lublin, Poland|Samodzielny Publiczny Zespol Zakladow Opieki Zdrowotnej w Sandomierzu, Sandomierz, Poland|Szpital Powiatowy im. Marii Curie - Skłodowskiej w Skarżysku-Kamiennej, Skarżysko-Kamienna, Poland|Wojewodzki Szpital Specjalistyczny Nr 1 im. Prof. Jozefa Gasinskiego, Tychy, Poland|Instytut Psychiatrii i Neurologii Oddział Neurologiczny z Pododdziałem Udarowym, Warsaw, Poland|Medical University of Warsaw, Department of Neurology, Warsaw, Poland|Szpital Wolski im. dr Anny Gostyńskiej Samodzielny Publiczny Zakład Opieki Zdrowotnej, Oddział Neurologii, Warsaw, Poland|Wojskowy Instytut Medyczny, Oddział Neurologii, Warsaw, Poland|Hospital Professor Doutor Fernando Fonseca, EPE, Amadora, Portugal|Centro Hospitalar de Coimbra EPE, Coimbra, Portugal|Hospitais da Universidadde de Coimbra, EPE, Coimbra, Portugal|Centro de Estudos Egas Moniz - Hospital de Santa Maria, Lisboa, Portugal|Hospital de São Sebastião, EPE, Santa Maria da Feira, Portugal|Neurology Clinic, Faculty Hospital in Martin, Martin, Slovakia|University Hospital Nitra, Nitra, Slovakia|Hospital un Poliklinic, Spisska Nova Ves, Slovakia|Faculty Hospital Trnava, Trnava, Slovakia|Neurology dept.,Hospital Zilina, Zilina, Slovakia|Fichmed, Bloemfontein, South Africa|Constantiaberg Medi-clinic, Cape Town, South Africa|Union Hospital, Gauteng, South Africa|Helderberg Research Institute, Western Cape, South Africa|Triervlei Trial Centre, Western Cape, South Africa|Clinical Projects Research, Worcester, South Africa|Hospital Universitario de Albacete, Albacete, Spain|Hospital De La Santa Ta Creu i Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Germans Triasy Pujol, Barcelona, Spain|Hospital Vall D'hebron, Barcelona, Spain|Hospital Gregorio Maranon, Madrid, Spain|Hospital La Princesa, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Universitario Clinico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain|Consorcio Hospital General Universitario Valencia, Valencia, Spain|Hospital Clinico Universitario De Valladolid, Valladolid, Spain|Universitätsspital Basel, Neurologie, Basel, Switzerland|Universitätsspital Zürich, Klinik für Neurologie, Zurich, Switzerland",NA,https://ClinicalTrials.gov/show/NCT00893867
148,NCT00868166,Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS,MITOTARGET,Completed,Has Results,Amyotrophic Lateral Sclerosis,Drug: Olesoxime|Drug: Placebo Comparator|Drug: Riluzole,Overall Survival Rate at 18 Months|Percentage of Participants With Failure Over 18 Months|Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R)|Percentage of Participants With a Global ALS FRS-R Score of <30 or Death|Slow Vital Capacity (SVC) Percent Predicted|Percentage of Participants With SVC Percent Predicted <70% or Had Died Over 18 Months|Global Score of Manual Muscle Testing (MMT) of 34 Muscle Groups|The Single-Item Mc Gill Quality of Life Scale,Hoffmann-La Roche|European Commission,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,512,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",WN29853|EudraCT Number:2008-007320-25|TRO19622 CL E Q 1015-1,"April 30, 2009","September 30, 2011","September 30, 2011","March 24, 2009","February 15, 2019","February 25, 2020","University Hospital Gasthuisberg - Dept Neurology - Herestraat 49, Leuven, Belgium|HCL Hôpital Neurologique et Neurochirurgical Pierre Wertheimer - Neurologie C et Laboratoire d'électromyographie - 59, boulevard Pinel, Bron Cedex, France|CHRU de LILLE - Hôpital Roger Salengro - Centre SLA-MMN - Sce de Neurologie et Pathologie du Mouvement, Lille, France|Centre SLA Limoges - Service de Neurologie, Limoges, France|Hôpital La Timone - Service Neurologie et Maladies Neuromusculaires, Marseille, France|Clinique du Motoneurone - Sce d'Explorations Neurologiques - Hôpital Gui de Chauliac, Montpellier, France|CHU de Nice - Hôpital de l'Archet 1 - Centre de Référence pour les Maladies Neuromusculaires et la SLA, Nice, France|Groupe Hospitalier PITIE-SALPETRIERE - Fédération des Maladies du Système Nerveux, Paris, France|Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Neurologische Poliklinik Ambulanz für ALS und andere Motoeneuronenerkrankungen, Berlin, Germany|Universitätsklinik und Poliklinik für Neurologie - Martin-Luther-Universität Halle-Wittenberg, Halle, Germany|Neurologische Klinik Medizinische Hochschule, Hannover, Germany|Universitäts- und Rehabilitationskliniken Ulm (RKU) - Neurologische Universitätsklinik, Ulm, Germany|Hospital Carlos III - Unidad de ELA - Sinesio Delgado, 10, Madrid, Spain|King's MND Care and Research Center - Academic Neurosciences Building PO Box 41 Institute of Psychiatry, London, United Kingdom|Academic Neurology Unit - University of Sheffield - Section of Neuroscience - Division of Genomic Medicine - School of Medicine and Biomedical Sciences, Sheffield, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT00868166
149,NCT00860366,Efficacy Study of Combined Treatment With Uric Acid and rtPA in Acute Ischemic Stroke,Urico-Ictus,Completed,No Results Available,Acute Ischemic Stroke,Drug: Uric Acid|Other: Vehicle,"Proportion of patients achieving a mRS of 0 to 1 at 3 months after treatment, or 2 in those patients with a mRS 2 prior to the inclusion in the study|Proportion of patients with NIHSS <2 at 2 hours after completing the experimental treatment.|Proportion of patients with NIHSS <1 at day 90.|Proportion of patients achieving a Barthel scale of 95 to 100 at day 90|All-cause mortality within the first 90 days.|Final Infarction Volume measured by means of MRI or multimodal CT at 72 hours of onset (in specific centers)|Proportion of patients with an intracranial hemorrhage associated to a worsening of 4 points in the NIHSS within the first 36 hours of treatment.","Angel Chamorro, MD|Carlos III Health Institute|Fundacion Clinic per a la Recerca Biomédica",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,421,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",URICOICTUS-1-2007|EudraCT 2007-002687-95|FIS EC07-90276,June 2011,August 2013,October 2013,"March 12, 2009",NA,"March 10, 2015","Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, Bellvitge, Barcelona, Spain|Corporació Sanitària del Parc Taulí, Sabadell, Barcelona, Spain|Hospital Universitari Mútua de Terrassa, Terrassa, Barcelona, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|Hospital General Universitario de Albacete, Albacete, Spain|Hospital de la Santa Creu y Sant Pau, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Dr Josep Trueta, Girona, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain",NA,https://ClinicalTrials.gov/show/NCT00860366
150,NCT00829374,Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil,CONCERT,Completed,No Results Available,Alzheimer's Disease,Drug: Dimebon|Drug: Placebo comparator,"Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Alzheimer's Disease Assessment Scale - Cognitive Subscale|Clinician's Interview Based Impression of Change, plus caregiver input (CIBIC-plus)|Neuropsychiatric Inventory (NPI)|Resource Utilization in Dementia Lite (RUD lite)|Euro Quality of Life 5 (EQ-5D)","Medivation, Inc.|Pfizer",All,"50 Years and older   (Adult, Older Adult)",Phase 3,1003,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",DIM18,March 2009,December 2011,December 2011,"January 27, 2009",NA,"September 27, 2016","Phoenix, Arizona, United States|Sun City, Arizona, United States|Tucson, Arizona, United States|Costa Mesa, California, United States|Encino, California, United States|Escondido, California, United States|Fresno, California, United States|Garden Grove, California, United States|La Jolla, California, United States|Los Alamitos, California, United States|Los Angeles, California, United States|Martinez, California, United States|Newport, California, United States|Paramount, California, United States|Pasadena, California, United States|San Diego, California, United States|San Francisco, California, United States|Boulder, Colorado, United States|Denver, Colorado, United States|New Haven, Connecticut, United States|Washington, District of Columbia, United States|Deerfield Beach, Florida, United States|Delray Beach, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Honolulu, Hawaii, United States|Indianapolis, Indiana, United States|Lexington, Kentucky, United States|Eaton, Maryland, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Las Vegas, Nevada, United States|Mt Arlington, New Jersey, United States|Princeton, New Jersey, United States|Albany, New York, United States|Cedarhurst, New York, United States|New York, New York, United States|Rochester, New York, United States|Durham, North Carolina, United States|Beachwood, Ohio, United States|Toledo, Ohio, United States|Jenkintown, Pennsylvania, United States|Norristown, Pennsylvania, United States|Providence, Rhode Island, United States|Austin, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Charlottesville, Virginia, United States|Seattle, Washington, United States|Middleton, Wisconsin, United States|Newcastle, New South Wales, Australia|Sydney, New South Wales, Australia|Brisbane, Queensland, Australia|Adelaide, South Australia, Australia|Geelong, Victoria, Australia|Melbourne, Victoria, Australia|Perth, Western Australia, Australia|Antwerp, Belgium|Leuven, Belgium|Sint-Truiden, Belgium|Kuppio, Finland|Oulu, Finland|Turku, Finland|Bordeaux, France|Concert, France|Lille, France|Montpellier, France|Nice, France|Toulouse, France|Berlin, Germany|Bochum, Germany|Freiburg, Germany|Hattingen, Germany|Mannheim, Germany|Munich, Germany|Brescia, Italy|Florence, Italy|Genoa, Italy|Perugia, Italy|Rome, Italy|Christchurch, Canterbury, New Zealand|Auckland, New Zealand|Malmo, Sweden|Norrkoping, Sweden|Stockholm, Sweden|Brentford, Middlesex, United Kingdom|Rushden, Northhamptonshire, United Kingdom|Glasgow, Scotland, United Kingdom|Worthington, West Sussex, United Kingdom|Bath, United Kingdom|Blackpool, United Kingdom|Bradford, United Kingdom|Greater Manchester, United Kingdom|London, United Kingdom|Newcastle upon Tyne, United Kingdom|Norfolk, United Kingdom|Oxford, United Kingdom|Southampton, United Kingdom|Swindon, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT00829374
151,NCT00822900,Progesterone for the Treatment of Traumatic Brain Injury III,ProTECT,Terminated,Has Results,Traumatic Brain Injury,Drug: Progesterone|Drug: Placebo,Favorable Outcome as Determined by the Glasgow Outcome Scale-Extended (GOSE)|Mortality|Disability Rating Scale|Potentially Associated Adverse Events: Phlebitis/Thrombophlebitis|Potentially Associated Adverse Events: Pulmonary Embolism|Potentially Associated Adverse Events: Acute Ischemic Stroke|Potentially Associated Adverse Events: Deep Venous Thrombosis (DVT)|Potentially Associated Adverse Events: Unexplained Increased Liver-enzyme Level|Potentially Associated Adverse Events: Sepsis|Potentially Associated Adverse Events: Pneumonia|Potentially Associated Adverse Events: Central Nervous System (CNS) Infection|Potentially Associated Adverse Events: Myocardial Infarction (MI),David Wright|Medical University of South Carolina|Neurological Emergencies Treatment Trials Network (NETT)|Emory University,All,"18 Years and older   (Adult, Older Adult)",Phase 3,882,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB00014409|1RO1 NS062778-01,March 2010,May 2014,July 2014,"January 15, 2009","July 3, 2015","January 20, 2016","Maricopa Integrated Health System, Phoenix, Arizona, United States|Banner Good Samaritan, Phoenix, Arizona, United States|Scottsdale Healthcare, Scottsdale, Arizona, United States|University of Arizona Medical Center, Tuscon, Arizona, United States|Santa Clara Valley Hospital, Palo Alto, California, United States|Stanford Medical Center, Palo Alto, California, United States|San Francisco General Hospital, San Francisco, California, United States|Regional Medical Center-San Jose, San Jose, California, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|University of Maryland Shock Trauma, Baltimore, Maryland, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Sinai Grace Hospital, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Beaumont Royal Oak Hospital, Royal Oak, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|North Memorial Hospital, Robbinsdale, Minnesota, United States|Regions Hospital, St. Paul, Minnesota, United States|St. Johns Mercy Medical Center, St. Louis, Missouri, United States|Columbia New York Presbyterian Hospital, New York, New York, United States|University Hospital, Cincinnatti, Ohio, United States|Oregon Health Sciences University, Portland, Oregon, United States|St. Luke's Hospital, Bethlehem, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Hahnemann University Hospital, Philadelphia, Pennsylvania, United States|University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Thomas Jefferson UniversityHospital, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Regional Medical Center/Elvis Presley Memorial Trauma Center (The MED), Memphis, Tennessee, United States|Austin/Brackenridge, Austin, Texas, United States|Memorial Hermann, Houston, Texas, United States|Brooke Army Medical Center, San Antonio, Texas, United States|Virginia Commonwealth, Richmond, Virginia, United States|Froedtert East Hospital, Milwaukee, Wisconsin, United States",NA,https://ClinicalTrials.gov/show/NCT00822900
152,NCT00818662,A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease,NA,Completed,Has Results,Alzheimer´s Disease,"Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg|Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg|Biological: Placebo solution: Human Albumin 0.25% - 4 mL/kg|Biological: Placebo solution: Human Albumin 0.25% - 2 mL/kg","Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)|Change From Baseline at 18 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)|Change From Baseline at 9 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)|Change From Baseline at 9 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)|Change From Baseline at 9 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment|Change From Baseline at 18 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment|Change From Baseline at 18 Months in the Modified Mini-Mental State Examination (3MS) Examination|Change From Baseline at 18 Months in the Neuropsychiatric Inventory (NPI) Assessment|Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Participant Response|Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Caregiver Response|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Forward|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Backward|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: FAS Verbal Fluency|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Symbol Substitution|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Animals Category Fluency|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part A|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part B|Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Clock Drawing Test|Number of Participants Experiencing Study Product-related Non-serious Adverse Events (Non-SAEs), by System Organ Class|Number of Participants Experiencing Study Product-related Serious Adverse Events (SAEs), by System Organ Class|Number of Participants Experiencing Any Non-serious Adverse Events (Non-SAEs), by System Organ Class|Number of Participants Experiencing Any Serious Adverse Events (SAEs), by System Organ Class|Number of Infusions Temporally Associated With Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)|Number of Infusions With Causally Associated Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)|Number of Infusions Discontinued, Slowed, or Interrupted Due to an Adverse Event (AE)|Number of Participants Experiencing a Clinically Significant Decrease in Hemoglobin (>1.5 g/dL) Between Consecutive Visits|Number of Participants Experiencing a Clinically Significant Rash",Baxalta now part of Shire|Alzheimer's Disease Cooperative Study (ADCS)|Takeda,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 3,390,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",160701,"December 19, 2008","December 10, 2012","December 10, 2012","January 8, 2009","October 28, 2014","May 19, 2021","Birmingham, Alabama, United States|Phoenix, Arizona, United States|Sun City, Arizona, United States|Tucson, Arizona, United States|Irvine, California, United States|La Jolla, California, United States|Los Angeles, California, United States|National City, California, United States|Orange, California, United States|New Haven, Connecticut, United States|Washington, District of Columbia, United States|Miami Beach, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|Chicago, Illinois, United States|Iowa City, Iowa, United States|Kansas City, Kansas, United States|Lexington, Kentucky, United States|Burlington, Massachusetts, United States|Paw Paw, Michigan, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Liverpool, New York, United States|New York, New York, United States|Rochester, New York, United States|Cleveland, Ohio, United States|Tulsa, Oklahoma, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Providence, Rhode Island, United States|North Charleston, South Carolina, United States|Franklin, Tennessee, United States|Dallas, Texas, United States|Salt Lake City, Utah, United States|Madison, Wisconsin, United States|Vancouver, British Columbia, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada",NA,https://ClinicalTrials.gov/show/NCT00818662
153,NCT00724048,A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease,HART,Completed,No Results Available,Huntington Disease,Drug: ACR16 10 mg|Drug: ACR16 22.5 mg|Drug: ACR16 45 mg|Other: Placebo,Sum score of items 4-10 and 13-15 of the UHDRS motor assessment|Clinical Global Impressions (CGI)|Adverse event profile,"Teva Branded Pharmaceutical Products R&D, Inc.",All,"30 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,227,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ACR16 C009,October 2008,June 2011,June 2011,"July 29, 2008",NA,"July 22, 2016","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California, San Diego, California, United States|Colorado Neurological Institute, Littleton, Colorado, United States|University of South Florida, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Charlestown, Massachusetts, United States|Struthers Parkinson's Center, St. Louis Park, Minnesota, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Albany Medical College, Albany, New York, United States|North Shore-LIJ Health System, Manhasset, New York, United States|University of Rochester, Rochester, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States|Ohio State University Parkinson's Center, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Tennessee Health Science Center, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Booth Gardner Parkinson's Care Center, Kirkland, Washington, United States|University of Alberta Glenrose Rehab Hospital, Edmonton, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|London Health Sciences Centre, London, Ontario, Canada|The Centre for Addiction and Mental Health, Markham, Ontario, Canada|Parkinsons and Neurodegenerative Disordes Clinic, Ottawa, Ontario, Canada|Hotel-Dieu Hospital-CHUM, Montreal, Quebec, Canada",NA,https://ClinicalTrials.gov/show/NCT00724048
154,NCT00712426,"Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)",CREST-E,Terminated,No Results Available,Huntington's Disease,Drug: Creatine Monohydrate|Drug: Placebo,"Change in Total Functional Capacity|Clinical symptoms (changes in other UHDRS scores); safety (frequency of adverse events); tolerability (proportion of subjects completing study at assigned dosage level), quality of life, other biological markers.",Massachusetts General Hospital|University of Rochester|National Center for Complementary and Integrative Health (NCCIH),All,"18 Years and older   (Adult, Older Adult)",Phase 3,553,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2007P000827|U01AT000613,September 2009,December 2014,January 2015,"July 10, 2008",NA,"March 11, 2016","University of Alabama, Birmingham, Alabama, United States|University of California, Irvine, Irvine, California, United States|University of California Davis, Sacramento, California, United States|University of Connecticut, Farmington, Connecticut, United States|University of Florida (McKnight Brain Institute), Gainesville, Florida, United States|University of South Florida, Tampa, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Hereditary Neurological Disease Center (HNDC), Wichita, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Struthers Parkinson's Center, Golden Valley, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Nebraska Medical Center, Omaha, Nebraska, United States|Cooper University Hospital, Camden, New Jersey, United States|Albany Medical College, Albany, New York, United States|North Shore-LIJ Health System, Manhasset, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Duke University, Durham, North Carolina, United States|Wake Forest University School of Medicine, Winston Salem, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Tennessee Health Science Center, Memphis, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Booth Gardner Parkinson's Care Center (Evergreen Healthcare), Kirkland, Washington, United States|Westmead Hospital, Wentworthville, New South Wales, Australia|Neurodegenerative Disorders Research, Subiaco, Western Australia, Australia|University of Alberta Hospital, Edmonton, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Movement Disorder Clinic Deer Lodge Center, Winnipeg, Manitoba, Canada|CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada|University of Quebec Infant-Jesus Hospital (Centre Hospitalier Affilie), Quebec City, Quebec, Canada|Auckland City Hospital, Auckland, New Zealand|New Zealand Brain Research Institute, Christchurch, New Zealand",NA,https://ClinicalTrials.gov/show/NCT00712426
155,NCT00706147,"Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis",NA,Completed,No Results Available,Amyotrophic Lateral Sclerosis,Drug: Arimoclomol|Drug: Placebo,"Time to death, tracheostomy or permanent assisted ventilation will be the primary outcome measure.|Rate of decline of ALSFRS-R (ALS functional rating scale-revised) over a period of up to 12 months.|Disease progression as measured by the rate of decline of FEV6.|Safety and tolerability of arimoclomol will be evaluated by using vital signs and weight, clinical laboratory measures, physical examination, report of adverse events, and the proportion of subjects completing the study on assigned treatment.",University of Miami|Massachusetts General Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,38,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20100758|3517,January 2009,December 2014,November 2016,"June 27, 2008",NA,"January 11, 2019","University of Miami Miller School of Medicine, Miami, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",NA,https://ClinicalTrials.gov/show/NCT00706147
156,NCT00704379,Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury,NA,Completed,Has Results,Traumatic Brain Injury,Drug: Placebo|Drug: Sertraline,"Time to Onset of Diagnostic and Statistical Manual (DSM) IV Defined Mood and Anxiety Disorders Associated With Traumatic Brain Injury (TBI)|Total Community Integration Questionnaire Scores|Iowa Gambling Task Score|Memory Function Composite|Social Functioning Examination Total Score|Neuroimaging Variables (i.e., Fractional Anisotropy [FA] of Frontal White Matter Such as the Cingulate Gyrus)",Baylor College of Medicine|National Institute of Neurological Disorders and Stroke (NINDS),All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,94,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention",R01NS055827|1R01NS055827-01A2,June 2008,April 2014,April 2014,"June 24, 2008","May 12, 2015","August 25, 2015","Baylor College of Medicine, Houston, Texas, United States",NA,https://ClinicalTrials.gov/show/NCT00704379
157,NCT00676143,Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients,NA,Terminated,Has Results,Alzheimer Disease,Drug: bapineuzumab|Drug: placebo,"Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)/11 Subscale Total Score at Week 78|Change From Baseline in Disability Assessment for Dementia (DAD) Total Score at Week 78|Change From Baseline in Brain Amyloid Burden at Week 71|Change From Baseline in Cerebrospinal Fluid (CSF) Phospho-tau Levels at Week 71|Change From Baseline in Brain Volume, as Assessed by Magnetic Resonance Imaging Brain Boundary Shift Integral (MRI BBSI), at Week 71|Divergence of Effect on the ADAS-Cog/11 Total Scores From Week 39 to Week 78|Divergence of Effect on the DAD Total Scores From Week 39 to Week 78|Time to First Median Placebo Deterioration on ADAS-Cog/11 Total Score (European Union [EU] Analysis Plan)|Time to First Clinically Meaningful Deterioration on ADAS-Cog/11 Total Score (United States [US] Analysis Plan)|Time to First Median Placebo Deterioration on DAD Total Score (EU Analysis Plan)|Time to First Clinically Meaningful Deterioration on DAD Total Score (US Analysis)|Change From Baseline in Dependence Scale Total Score at Week 78|Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (EU Analysis Plan)|Percentage of Responders for ADAS-Cog/11 Total Score at Week 78 (US Analysis Plan)|Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (EU Analysis Plan)|Percentage of Responders for DAD Total Score at Week 78 (US Analysis Plan)|Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SOB) Total Score at Week 78",Pfizer,All,"50 Years to 88 Years   (Adult, Older Adult)",Phase 3,1100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3133K1-3001|B2521002|2007-005995-14,January 2008,October 2012,November 2012,"May 12, 2008","June 10, 2016","June 10, 2016","Center for Psychiatric Medicine, Birmingham, Alabama, United States|Participant and Clinical Interactions Resources, Birmingham, Alabama, United States|UAB Clinical Research Pharmacy-Russell Clinic, Birmingham, Alabama, United States|University of Alabama-Birmingham, Birmingham, Alabama, United States|Dedicated Clinical Research, Goodyear, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Jeffrey S. Gitt, DO, PC, Phoenix, Arizona, United States|The Compounding Center, Phoenix, Arizona, United States|HOPE Research Institute, Phoenix, Arizona, United States|Clinical Trials, Inc., Little Rock, Arkansas, United States|AC Institute, Incorporated, Carson, California, United States|Collaborative Neuroscience Network, Inc, Long Beach, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Alpine Clinical Research Center, Inc., Boulder, Colorado, United States|Associated Neurologists, PC, Boulder, Colorado, United States|Mile HIgh Research Center, Denver, Colorado, United States|Associated Neurologists of Southern Connecticut, P.C., Fairfield, Connecticut, United States|Bendheim Cancer Center, Greenwich, Connecticut, United States|Center for Healthy Aging, Greenwich, Connecticut, United States|Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Hospital Research Unit, New Haven, Connecticut, United States|Investigational Drug Service, New Haven, Connecticut, United States|Moshe Hasbani, MD, New Haven, Connecticut, United States|Norman S. Werdiger, MD, New Haven, Connecticut, United States|MR Research Center, New Haven, Connecticut, United States|Yale PET Center, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|JEM Research Institute, LLC, Atlantis, Florida, United States|JEM Research Institute, Atlantis, Florida, United States|Medical Specialist of the Palm Beaches, Atlantis, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Palm Beach Neurological Center, Palm Beach Gardens, Florida, United States|Neurostudies Inc, Port Charlotte, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|University of South Florida, Tampa, Florida, United States|Dekalb Neurology Associates, LLC/NeuroStudies.net, LLC, Decatur, Georgia, United States|Neurostudies.net, Decatur, Georgia, United States|NeuroStudies.net, Lawrenceville, Georgia, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Southern Illinois University School of Medicine Department, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Massachusetts General Hosptial, Boston, Massachusetts, United States|Brigham & Womens Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston Univeristy ADCRP, Boston, Massachusetts, United States|General Clincial Research Center (Infusion Location), Boston, Massachusetts, United States|IDS Pharmacy (Drug Receipt). Attn:Hyesson Hong, Boston, Massachusetts, United States|Shields MRI, Dartmouth, Massachusetts, United States|Neuroscience Research of the Berkshires, Pittsfield, Massachusetts, United States|Springfield Neurology Associates, LLC, Springfield, Massachusetts, United States|University of Michigan Health System, Ann Arbor,, Michigan, United States|University of Michigan Hospital and Health System, Ann Arbor, Michigan, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|The Center for Pharmaceutical Research P.C., Kansas City, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Pharmcare USA, Edison, New Jersey, United States|Alzheimer's Research Corp./Merician Institute for Aging, Manchester, New Jersey, United States|Neurological Care of Central New York, Liverpool, New York, United States|Carolina Neuropsychological Services, Inc, Raleigh, North Carolina, United States|Healthsouth Blue Ridge Surgery Center, Raleigh, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Wake Radiology Associates, Raleigh, North Carolina, United States|Ohio State University Imaging@Martha Moorehouse, Columbs, Ohio, United States|The Ohio State University, Columbs, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Summit Research Network(Oregon) Inc., Portland, Oregon, United States|Providence Brain Institute, Portland, Oregon, United States|Providence Cognitive Assessment Clinic, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Dr. Michael Gabe (Clinic), Silverton, Oregon, United States|Abington Memorial Hosptial, Abington, Pennsylvania, United States|Abington Neurological Associates, Abington, Pennsylvania, United States|Abington Neurological Assoc, Abington, Pennsylvania, United States|Andorra MRI of Flourtown, Flourtown, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Investigational New Drug Services, Philadelphia, Pennsylvania, United States|University of Pennsylvania-Penn Memory Center, Philadelphia, Pennsylvania, United States|UPENN Clinical and Transitional Research Center, Philadelphia, Pennsylvania, United States|Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Simpson's Pharmacy, Pawtucket, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Hospitals and Clinics, Charleston, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|MUSC, Charleston, South Carolina, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|Texas Neurology, P.A., Dallas, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Integra Clinical Research, San Antonio, Texas, United States|Integra Clinical Research, LLC, San Antonio, Texas, United States|Integra Clinical Research, San Antonio, Texas, United States|Vista Infusions, San Antonio, Texas, United States|Inventive Infusion Solutions, San Antonio, Texas, United States|Inventive Infusions Solutions, San Antonio, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|The Pharmacy, Bennington, Vermont, United States|Waisman Center (PET only), Madison, Wisconsin, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|Wm S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, United States|University of Wisconsin Hospitals and Clinics, Madison, Wisconsin, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|Instituto Medico Congreso, Buenos Aires, Argentina|Cemic University Hospital, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Instituto Kremer, Cordoba, Argentina|Gosford Hospital; Pharmacy Dept, Gosford, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|Hornsby Kuringai Hospital, Hornsby, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|CDAMS Ballarat Base Hospital, Ballarat, Victoria, Australia|Heidelberg Repatriation Hospital, West Heidelberg, Victoria, Australia|Hollywood Hospital; Pharmacy Dept, Nedlands, Western Australia, Australia|McCusker Alzheimer's Research Foundation, Inc., Nedlands, Western Australia, Australia|Medizinische Universitaet Graz, Graz, Austria|Landeskrankenhaus Klagenfurt, Klagenfurt, Austria|Allg. Krankenhaus der Stadt Wien, Wien, Austria|SZ Sued - Kaiser-Franz-Josef-Spital, Wien, Austria|Donauspital, Wien, Austria|ZNA Middelheim, Antwerpen, Belgium|Az. St. Jan Ruddershove 35, Brugge, Belgium|Cliniques Universitaires St Luc, Brussels, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium|H.-Hartziekenhuis Roeselare-Menen, Roeselare, Belgium|Psicomedica Research Group, Santiago, Chile|Especialidades Medicas LyS, Santiago, Chile|University Hospital Center Zagreb, Zagreb, Croatia|Ita-Suomen Yliopisto, Kuopio, Finland|University of Turku / CRST, Turku, Finland|CHU Pellegrin, Bordeaux Cedex, France|Hopital neurologique du Pr A. Vighetto, Bron, France|Centre d'Imagerie medicale de Basse Normandie, Caen, France|CHU de Caen, Caen, France|Hôpitaux Civils de Colmar, Colmar, France|CHU de Dijon, Dijon, France|CHRU de Lille, Lille, France|Hôpital la Timone, Marseille, France|CHU Hôpital Gui de Chaulliac, Montpellier, France|CHU Nord - Hôpital Guillaume et René Laënnec, Nantes - Saint Herblain, France|Hôpital Cimiez C.M.R.R., Nice, France|Service d'Imagerie Medicale, Nice, France|Groupe Hospitalier Broca-La Rochefoucauld, Paris, France|Hôpital Pitié-Salpétrière, Paris, France|Hospital Jean Bernard CIC, Poitiers, France|C.H.U de Reims, Reims, France|CHU de Rennes, Rennes Cedex, France|CHU - Hopital Charles Nicolle, Rouen, France|Hôpital Purpan, Toulouse, France|CHU Toulouse - Site Casselardit, Toulouse, France|Charite-Universitätsmedizin Berlin, Berlin, Germany|St. Josef-Klinikum, Bochum, Germany|Universitaetsklinikum Dresden, Dresden, Germany|Klinikum der Albert-Ludwigs-Universitaet Freiburg, Freiburg, Germany|Ortenau Klinikum Offenburg, Offenburg, Germany|Universitaetsklinikum Ulm, Ulm, Germany|A.O. Umberto I, Ancona, Italy|Sezione di Neurologia - Dipartimento di Neuroscienze, Ancona, Italy|Clinica Neurologica - II Neurologia, Brescia, Italy|Dipartimento di Neuroscienze,, Catania, Italy|Unita' Operativa Complessa di Neurologia, Catania, Italy|CeSI (Centro di Scienze dell'invecchiamento) -, Chieti, Italy|Fondazione IRCCS- Istituto Neurologico Carlo Besta, Milano, Italy|Ospedale S. Gerardo, Monza, Italy|Clinica Neurologica, Roma, Italy|Unita' Operativa C - Riabilitazione Neurologica, Roma, Italy|Universita degli Studi di Siena, Siena, Italy|Nagoya City University Hospital, Nagoya, Aichi,, Japan|National Hospital Organization Tokyo National Hospital, Kiyose, Tokyo, Japan|Yachiyo Hospital, Aichi, Japan|Kashiwado Hospital, Chiba, Japan|National Hospital Organization Chiba-East Hospital, Chiba, Japan|Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan|National Hospital Organization Kokura Medical Center, Fukuoka, Japan|Maebashi Red Cross Hospital, Gunma, Japan|Gunma University Hospital, Gunma, Japan|Shinozuka Hospital, Gunma, Japan|National Hospital Organization Hiroshima-nishi Medical Ctr., Hiroshima, Japan|Kobe University Hospital, Hyogo, Japan|Nishi-Kobe Medical Center, Hyogo, Japan|Kobe City Hospital Org Kobe City Medical Cente West Hp, Hyogo, Japan|Iwate Medical University Hospital, Iwate, Japan|Kagawa University Hospital, Kagawa, Japan|Nippon Medical School Musashi Kosugi Hospital, Kanagawa, Japan|Yokohama City University Medical Center, Kanagawa, Japan|Shonan Atsugi Hospital, Kanagawa, Japan|Rakuwakai Otowa Hospital, Kyoto, Japan|National Hospital Organization Minami-Kyoto Hospital, Kyoto, Japan|National Hospital Organization Maizuru Medical Center, Kyoto, Japan|National Hospital Organization Matsumoto Medical Center, Nagano, Japan|National Hospital Organization Niigata National Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|National Hospital Organization Minami-Okayama Medical Center, Okayama, Japan|Osaka City University Hospital, Osaka, Japan|Osaka University Hospital, Osaka, Japan|Kansai Medical University Takii Hospital, Osaka, Japan|National HP.Org.Shizuoka Inst.Epilepsy,Neurological Disorder, Shizuoka, Japan|Juntendo University Hospital, Tokyo, Japan|Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan|Tokyo Metropolitan Health and Med. Treatment Co. Ebara Hosp, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Tokyo Medical University Hachioji Medical Center, Tokyo, Japan|OCA Hospital, Monterrey, Nuevo León, Mexico|Instituto Biomedico de Investigacion A.C, Aguascalientes, Mexico|Amphia Ziekenhuis, Breda, Noord Brabant, Netherlands|Tergooi Ziekenhuizen, Hilversum, Noord Holland, Netherlands|Kennemer Gasthuis, Haarlem, The Netherlands, Netherlands|Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Medisch Centrum Alkmaar, Alkmaar, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Erasmus MC, Rotterdam, Netherlands|The Memory Clinic, Auckland, NZ, New Zealand|Signet Research, Christchurch, New Zealand|NZOZ Dom Suer Ryder, Pallmed Sp. z o.o., Bydgoszcz, Poland|Szpital Uniwersytecki, Oddzial Kliniczny Klinik Chorob Wewnetrznych i, Krakow, Poland|NZOZ ""NEURO-KARD"" ""ILKOWSKI I PARTNERZY"" Spolka Partnerska Lekarzy, Poznan, Poland|Oddzial Neurologiczny i Udarowy Szpital Wolski im. dr Anny Gostynskiej,, Warszawa, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny, Katedra i Klinika, Warszawa, Poland|Hospital Fernando da Fonseca, Amadora, Portugal|Hospitais Da Universidade De Coimbra, Coimbra, Portugal|Hospital Santa Maria, Lisboa, Portugal|Klinicki centar Srbije, Belgrade, Serbia|Clinical Centre Kragujevac, Clinic of Psichiatry, Kragujevac, Serbia|Klinicki Centar Vojvodina, Novi Sad, Serbia|Diagnostic Imaging Center, Sremska Kamenica, Serbia|Institute for Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia|Psychiatricka ambulancia, Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Bratislava, Slovakia|Psychiatricka nemocnica Michalovce, n.o., Michalovce, Slovakia|Vseobecna nemocnica Rimavska Sobota, Rimavska Sobota, Slovakia|Boithuso Caregivers, Johannesburg, Gauteng, South Africa|The Osteoporosis and Memory Centre, Johannesburg, Gauteng, South Africa|Denmar Clinic, Pretoria, Gauteng, South Africa|St Augustine's Medical Centre 2, Durban, Kwa Zulu Natal, South Africa|Flexivest Fourteen Research Center, Bellville, Western Cape, South Africa|Panorama Psychiatry and Memory Clinic, Panorama, Western Cape, South Africa|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain|Hospital Virgen del Puerto, Plasencia, Caceres, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain|CLONUS, Palma de Mallorca, Islas Baleares, Spain|Hospital de Donostia, San Sebastian, Pais Vasco, Spain|Hospital de Cruces, Baracaldo, Vizcalla, Spain|Hospital del Mar, Barcelona, Spain|Fundacio ACE Institut Catala de Neurociences Aplicades, Barcelona, Spain|Centro Internacional de Medicina Avanzda (CIMA), Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Divino Valles, Burgos, Spain|Hospital de la Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Malmo University Hospital, Malmo, Sweden|Uppsala Imanet AB, Uppsala, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|ORKI, enheten for radiologi, Uppsala, Sweden|Memory Clinic Neuro-Psychologie Zentrum, Basel, BS, Switzerland|Hopitaux Universitaires de Geneve, Les Acacias, GE, Switzerland|CHUV Lausanne, Lausanne, VD, Switzerland|Hopitaux Universitaires de Geneve, Thonex-Geneva, Switzerland|MAC UK Neuroscience Ltd, Blackpool, Lancashire, United Kingdom|MAC UK Neuroscience, Research Assessment Centre, Trafford Park, Manchester, United Kingdom|Pollard Park Health Centre, Bradford, United Kingdom|Clinical Investigation and Research Unit (CIRU), Brighton, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|Kings College Hospital, London, United Kingdom|Dept. of Neurosciences Charing Cross Hospital, London, United Kingdom|Newcastle General Hospital, Newcastle upon Tyne, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Llandough Hospital, Penarth, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom|Grenoside Grange Hospital, Sheffield, United Kingdom|Victoria Hospital, Swindon, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT00676143
158,NCT00667810,Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients,NA,Terminated,Has Results,Alzheimer Disease,Drug: bapineuzumab|Drug: placebo,The Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)/11 Total Score at Week 78|The Change From Baseline in the Disability Assessment for Demential (DAD) Total Score at Week 78|The Change From Baseline in Brain Amyloid Burden at Week 71.|The Change From Baseline in Phospho-tau Levels in the Cerebrospinal Fluid (CSF) at Week 71.|The Change From Baseline in Brain Volume at Week 71|Divergence of Effect on the ADAS-Cog/11 Total Scores From Week 39 to Week 78|Divergence of Effect on the DAD Total Scores From Week 39 to Week 78|Time to Median Placebo Deterioration on ADAS-Cog/11 Total Score (European Union [EU] Analysis Plan)|Time to First Clinically Meaningful Deterioration on ADAS-Cog/11 Total Score (United States [US] Analysis Plan)|Time to Median Placebo Deterioration on DAD Total Score|Time to First Clinically Meaningful Deterioration on DAD Total Score (US Analysis Plan)|Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (European Union Analysis Plan)|Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (US Analysis Plan)|Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (European Union Analysis Plan)|Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (US Analysis Plan)|Change From Baseline in Dependence Scale Total Score at Week 78|Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SOB) Total Score at Week 78,Pfizer,All,"50 Years to 89 Years   (Adult, Older Adult)",Phase 3,901,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3133K1-3000|B2521001|2007-005994-79,June 2008,October 2012,August 2013,"April 28, 2008","January 8, 2016","January 8, 2016","University of Alabama-Birmingham, Birmingham, Alabama, United States|Dedicated Clinical Research, Goodyear, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Jeffrey S. Gitt, DO, PC, Phoenix, Arizona, United States|The Compounding Center (IP Mixing Only), Phoenix, Arizona, United States|Hope Research Institute, Phoenix, Arizona, United States|Clinical Trials, Inc., Little Rock, Arkansas, United States|ATP Clinical Research, Incorporated, Costa Mesa, California, United States|Pharmacology Research Institute, Encino, California, United States|Margolin Brain Institute, Fresno, California, United States|Infusion Care Pharmacey, Laguna Hills, California, United States|Senior Clinical Trials, Incorporated, Laguna Hills, California, United States|Faculty Physicians and Surgeons of Loma Linda University School of Medicine, Loma Linda, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Collaborative Neuroscience Network, Inc., Long Beach, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Coordinated Clinical Research, San Diego, California, United States|LabCorp, San Diego, California, United States|Sharp and Children's MRI Center, LLC, San Diego, California, United States|Sharp Infusion Therapy Center, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Alpine Clinical Research Center, Inc., Boulder, Colorado, United States|Associated Neurologists, PC, Boulder, Colorado, United States|The Mile High Research Center, Denver, Colorado, United States|Associated Neurologists, PC, Danbury, Connecticut, United States|Associated Neurologists of Southern Connecticut, P.C., Fairfield, Connecticut, United States|Bendheim Cancer Center, Greenwich, Connecticut, United States|Center for Healthy Aging, Greenwich, Connecticut, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Norman S. Werdiger, MD, New Haven, Connecticut, United States|Institutional Review Board / Ethics Committee, New Haven, Connecticut, United States|Yale PET Center, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|JEM Research Institute LLC, Atlantis, Florida, United States|Medical Specialists of the Palm Beaches, Atlantis, Florida, United States|Bradenton Research Center, Incorporated, Bradenton, Florida, United States|North Broward Medical Center, Deerfield Beach, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neurologic Consultants, P.A., Fort Lauderdale, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Advanced Imaging, Ocala, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Palm Beach Neurological Center, Palm Beach Gardens, Florida, United States|Neurostudies Inc, Port Charlotte, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|South Bay Internal Medicine, Sun City, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|NeuroTrials Research, Incorporated, Atlanta, Georgia, United States|Columbus Diagnostic Center (MRI), Columbus, Georgia, United States|Medical Research and Health Education Foundation, Incorporated, Columbus, Georgia, United States|Dekalb Neurology Associates, LLC/NeuroStudies.net, LLC, Decatur, Georgia, United States|NeuroStudies.net, Decatur, Georgia, United States|Neurostudies.net, Lawerenceville, Georgia, United States|Neurostudies.net, Lawrenceville, Georgia, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Methodist Center for Senior Health, Peoria, Illinois, United States|Methodist Medical Center Research Department, Peoria, Illinois, United States|Methodist Diagnostic Center, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Psychology Associates, Mishawaka, Indiana, United States|KU - Wichita, Wichita, Kansas, United States|Drug Shipment/ Storage, Wichitia, Kansas, United States|Four Rivers Clinical Research, Incorporated, Paducah, Kentucky, United States|Radio Pharmacy, Paducah, Kentucky, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Louisiana Research Associates Inc, New Orleans, Louisiana, United States|James Gary Booker, MD, APMC, Shreveport, Louisiana, United States|Foers Medical Arts Pharmacy, Bethesda, Maryland, United States|CBH Health, LLC, Rockville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Bringham and Women's Hospital, Boston, Massachusetts, United States|Boston University, Boston, Massachusetts, United States|General Clinical Research Center, Boston, Massachusetts, United States|IDS Pharmacy, Boston, Massachusetts, United States|ActivMed Practices and Research, Inc., Haverhill, Massachusetts, United States|Neurocare, Incorporated, Newton, Massachusetts, United States|Springfield Neurology Associates, LLC, Springfield, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|University of Michigan Hospital, Ann Arbor, Michigan, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Michigan State University, Lansing, Michigan, United States|Marty's Pharmacy, Flowood, Mississippi, United States|Precise Research Centers, Flowood, Mississippi, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|The Center for Pharmaceutical Research, Kansas City, Missouri, United States|Advanced Neurology Specialists, Great Falls, Montana, United States|Spectrum Home Solutions, Great Falls, Montana, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|Memory Enhancement Center of New Jersey, Inc., Toms River, New Jersey, United States|Northeast Radiology, Brewster, New York, United States|Neurological Care of Central New York, Liverpool, New York, United States|AD-CARE, University of Rochester Medical Center, Rochester, New York, United States|University of Rochester/Strong Memorial Hospital, Rochester, New York, United States|Clinical Study Center of Asheville, LLC, Asheville, North Carolina, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Clinical Trials of America, Incorporated, Hickory, North Carolina, United States|The Compounding Pharmacy, Hickory, North Carolina, United States|Carolina Neuropsychological Services, Inc., Raleigh, North Carolina, United States|Healthsouth Blue Ridge Surgery Center, Raleigh, North Carolina, United States|Raleigh Neurology Associates, PA, Raleigh, North Carolina, United States|Wake Radiology Associates, Raleigh, North Carolina, United States|Ohio State University Imaging at Martha Morehouse, Columbus, Ohio, United States|The Ohio State University Hospitals Clinic, Columbus, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Neurology & Neuroscience Center of Ohio, Toledo, Ohio, United States|Professional Corporation of Psychiatry, Oklahoma City, Oklahoma, United States|Red River Medical Recearch Center, LLC, Oklahoma City, Oklahoma, United States|Flourish Integrative Pharmacy, Oklahoma City, Oklahoma, United States|Providence Brain Institute, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Abington Neurological Associates, Abington, Pennsylvania, United States|Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Hospital of the University of Pennslyvania, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania (PET), Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Investigational New Drug Services, IDS Pharmacy, Philadelphia, Pennsylvania, United States|Penn Memory Center, Philadelphia, Pennsylvania, United States|UPENN Clinical and Translational Research Center (CTRC), Philadelphia, Pennsylvania, United States|Clinical Trials Research Services, LLC, Pittsburgh, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Simpson's Pharmacy, Pawtucket, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Hospitals and Clinics, Charleston, South Carolina, United States|Medical University of South Carolina Investigational Drug Service, Charleston, South Carolina, United States|Radiant Research, Incorporated, Greer, South Carolina, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|Neurology Clinic, PC, Cordova, Tennessee, United States|Austin Infusion Centers, Austin, Texas, United States|Senior Adults Specialty Research, Austin, Texas, United States|Texas Neurology, P.A., Dallas, Texas, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Integra Clinical Research, LLC, San Antonio, Texas, United States|Vista Infusions, San Antonio, Texas, United States|Inventive Infusion Solutions, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Wichita Falls, Texas, United States|Southwestern Vermont Healthcare, Bennington, Vermont, United States|The Memory Clinic, Bennington, Vermont, United States|University of Virginia Neurology, Charlottesville, Virginia, United States|University of Virginia General Clinical Research Center, Charlottesville, Virginia, United States|University of Viriginia Investigational Pharmacy, Charlottesville, Virginia, United States|Pacific Medical Centers, Bothell, Washington, United States|Pacific Medical Centers, Seattle, Washington, United States|Cemic University Hospital, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Gosford Hospital, Gosford, New South Wales, Australia|Hornsby Kuringai Hospital, Hornsby, New South Wales, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|CDAMS Ballarat Base Hospital, Ballarat, Victoria, Australia|Heidelberg Repatriation Hospital/ Medical and Cognitive Research Unit, West Heidelberg, Victoria, Australia|Hollywood Private Hospital, Nedlands, Western Australia, Australia|McCusker Alzheimer's Research Foundation Inc., Nedlands, Western Australia, Australia|Royal Adelaide Hospital, Adelaide SA, Australia|ZNA Middelheim / Neurologie, Antwerpen, Belgium|Az. St. Jan Ruddershove 35, Brugge, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|University Hospital Gathuisberg, Leuven, Belgium|H.-Hartziekenhuis Roeselare-Menen, Roeselare, Belgium|Centre for Memory and Aging, North York, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Centre de Recherche ADAPRA Inc., L'Ancienne-Lorette, Quebec, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Recherche Clinique de Neurologie, Montreal, Quebec, Canada|Diex Research Sherbrooke Inc., Sherbrooke, Quebec, Canada|ALPHA Recherche Clinique, Quebec, Canada|Psicomedica Research Group, Santiago, Chile|Especialidades Medicas L&S, Santiago, Chile|Sestre milosrdnice Zagreb, Zagreb, Croatia|University Hospital Center Zagreb, Zagreb, Croatia|Ita-Suomen Yliopisto, Kuopio, Finland|Turku University Hospital, Turku, Finland|CHRU Hôtel Dieu, Rennes, Cedex, France|CHU Hopital Nord, Amiens, France|Hôpital Neurologique, Bron, France|CHU de Caen, Caen, France|Hôpitaux Civils de Colmar, Colmar, France|CHU de Dijon, Dijon, France|Hôpital Roger Salengro, Lille, France|Hopital Sainte Marguerite, Marseille, France|Hôpital la Timone, Marseille, France|CHU Hôpital Gui de Chaulliac, Montpellier, France|CHU Nord - Hôpital Guillaume et René Laënnec, Nantes - Saint Herblain, France|Hôpital Cimiez, Nice, France|Groupe Hospitalier Pitie-Salpetriere, Paris Cedex 13, France|Groupe Hospitalier Broca-La Rochefoucauld, Paris, France|CHU La Milétrie, Poitiers, France|C.H.U de Reims, Reims, France|CHU - Hopital Charles Nicolle, Rouen, France|Hôpital Purpan, Toulouse, France|CHU Purpan - Hôpital Casselardit, Toulouse, France|Klinik fur Psychiatrie und Psychotherapie, Berlin, Germany|St. Josef-Klinikum, Bochum, Germany|Ortenau Klinikum, Offenburg, Germany|Universitaet Regensburg, Regensburg, Germany|Universita Politecnica delle Marche, Ancona, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Unita' Operativa Complessa di Neurologia, Catania, Italy|CeSI (Centro di Scienze dell'invecchiamento) -, Chieti, Italy|Universita degli Studi di Firenze, Firenze, Italy|Ospedale S. Raffaele, Milano, Italy|Ospedale S. Raffaele, Milano, Italy|Fondazione IRCCS- Istituto Neurologico Carlo Besta, Milano, Italy|Azienda Ospedaliera S. Gerardo di Monza Università di Milano Bicocca, Monza, Italy|Ospedale S. Gerardo, Monza, Italy|Clinica Neurologica, Roma, Italy|Unita' Operativa C - Riabilitazione Neurologica, Roma, Italy|Universita degli Studi di Siena, Siena, Italy|Nagoya City University Hospital, Nagoya, Aichi,, Japan|Tokyo Metoropolitan Health and Med. Treatment Co. Ebara Hosp, Ota-ku, Tokyo, Japan|Yachiyo Hospital, Aichi, Japan|Kashiwado Hospital, Chiba, Japan|National Hospital Organization Chiba-East Hospital, Chiba, Japan|Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan|National Hospital Organization Kokura Medical Center, Fukuoka, Japan|Maebashi Red Cross Hospital, Gunma, Japan|Gunma University Hospital, Gunma, Japan|Shinozuka Hospital, Gunma, Japan|National Hospital Organization Hiroshima-nishi Medical Ctr., Hiroshima, Japan|Kobe University Hospital, Hyogo, Japan|Nishi-Kobe Medical Center, Hyogo, Japan|Kobe City Hospital Org Kobe City Medical Cente West Hp, Hyogo, Japan|Iwate Medical University Hospital, Iwate, Japan|Kagawa University Hospital, Kagawa, Japan|Nippon Medical School Musashikosugi Hospital, Kanagawa, Japan|Yokohama City University Medical Center, Kanagawa, Japan|Shonan Atsugi Hospital, Kanagawa, Japan|Rakuwakai Otowa Hospital, Kyoto, Japan|National Hospital Organization Minami-Kyoto Hospital, Kyoto, Japan|National Hospital Organization Maizuru Medical Center, Kyoto, Japan|National Hospital Organization Matsumoto Medical Center, Nagano, Japan|National Hospital Organization Niigata National Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|National Hospital Organization Minami-Okayama Medical Center, Okayama, Japan|Osaka City University Hospital, Osaka, Japan|Osaka University Hospital, Osaka, Japan|Kansai Medical University Takii Hospital, Osaka, Japan|National HP.Org.Shizuoka Inst.Epilepsy,Neurological Disorder, Shizuoka, Japan|Juntendo University Hospital, Tokyo, Japan|Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Tokyo Medical University Hachioji Medical Center, Tokyo, Japan|National Hospital Organization Tokyo National Hospital, Tokyo, Japan|Seoul National University Bundang Hospital, Department of Psychiatry, Seongnam-si, Gyeonggi-do, Korea, Republic of|KonKuk University Hospital, Department of NeuroPsychiatry, Seoul, Korea, Republic of|OCA Hospital, Monterrey, Nuevo León, Mexico|Instituto Biomedico de Investigacion A.C, Aguascalientes, Mexico|Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Kennemer Gasthuis, Haarlem, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Jeroen Bosch Ziekenhuis, s. Hertogenbosch, Netherlands|The Memory Clinic, Auckland, NZ, New Zealand|Signet Research, Christchurch, New Zealand|NZOZ Dom Suer Ryder, Pallmed Sp. z o.o., Bydgoszcz, Poland|NZOZ ""SYNAPSA"", ul. Niska 5/1, Kielce, Poland|Szpital Uniwersytecki w Krakowie,Oddzial Kliniczny Klinik Chorób Wewnetrznych, Krakow, Poland|NZOZ ""NEURO-KARD"" ""ILKOWSKI I PARTNERZY"" Spolka Partnerska Lekarzy, Poznan, Poland|Oddzial Neurologiczny i Udarowy Szpital Wolski im. dr Anny Gostynskiej,, Warszawa, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny, Katedra i Klinika, Warszawa, Poland|Hospital Fernando da Fonseca, Amadora, Portugal|Hospitais Da Universidade De Coimbra, Coimbra, Portugal|Hospital Santa Maria, Lisboa, Portugal|Interregional clinicodiagnostic center, Kazan, Russian Federation|Nizhny Novgorod regional clinical hospital n.a. N.A.Semashko, Nizhny Novgorod, Russian Federation|Saint-Petersburg State institution of healthcare, City geriatric medico-social center, Saint-Petersburg, Russian Federation|Saint Petersburg Psychoneurological Research Institute n.a. V.M.Bekhterev, Saint-Petersburg, Russian Federation|Saint-Petersburg Psychoneurological Research Institute n.a. V.M.Bekhterev, Saint-Petersburg, Russian Federation|Chair of nervous system diseases, Saint-Petersburg, Russian Federation|Klinicki centar Vojvodine, Novi Sad, Vojvodina, Serbia|Klinicki centar Srbije, Belgrade, Serbia|Klinicki centar Srbije, Beograd, Serbia|Clinical Centre Kragujevac, Kragujevac, Serbia|1. Neurologicka klinika, Bratislava, Slovakia|Psychiatricka ambulancia, Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Bratislava, Slovakia|Neurologicka klinika, Martin, Slovakia|Psychiatricka nemocnica Michalovce, n.o., Michalovce, Slovakia|Vseobecna nemocnica Rimavska Sobota, Rimavska Sobota, Slovakia|Neurologicke oddelenie FNsP Zilina, Zilina, Slovakia|Boithuso Caregivers, Johannesburg, Gauteng, South Africa|The Osteoporosis and Memory Centre, Johannesburg, Gauteng, South Africa|Denmar Clinic, Pretoria, Gauteng, South Africa|St Augustine's Medical Centre 2, Durban, Kwa Zulu Natal, South Africa|Panorama Psychiatry and Memory Clinic, Panorama, Western Cape, South Africa|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital Mutua de Terrasa, Terrassa, Barcelona, Spain|Hospital Virgen del Puerto, Plasencia, Caceres, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain|CLONUS, Palma de Mallorca, Islas Baleares, Spain|Hospital de Cruces, Baracaldo, Spain|Hospital del Mar, Barcelona, Spain|Fundació ACE Institut Catala de Neurociences Aplicades, Barcelona, Spain|Clínica CIMA, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Divino Valles, Burgos, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Skanes Universitetssjukhus, Neuropsykiatriska, Malmo, Sweden|PET center, Uppsala, Sweden|The clinic: Minnes- och geriatrikmottagningen, Uppsala, Sweden|MRI Dept: ORKI, Uppsala, Sweden|Memory Clinic Neuro-Psychologie Zentrum, Basel, BS, Switzerland|Hopitaux Universitaires de Geneve, Les Acacias, GE, Switzerland|CHUV Lausanne, Lausanne, VD, Switzerland|Hopitaux Universitaires de Geneve, Thonex-Geneva, Switzerland|MAC UK Neuroscience Ltd, Blackpool, Lancashire, United Kingdom|MAC UK Neuroscience, Ltd., Bradford, West Yorkshire, United Kingdom|Clinical Investigation and Research Unit (CIRU), Brighton, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|Kings College Hospital, London, United Kingdom|Dept. of Neurosciences Charing Cross Hospital, London, United Kingdom|Newcastle General Hospital, Newcastle upon Tyne, United Kingdom|Northampton General Hospital NHS Trust, Northampton, United Kingdom|Llandough Hospital, Penarth, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom|Grenoside Grange Hospital, Sheffield, United Kingdom|Kingshill Research Centre, Swindon, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT00667810
159,NCT00666887,Minocycline in Clinically Isolated Syndromes (CIS),MinoCIS,Completed,No Results Available,Clinically Isolated Syndromes|Early Single Relapse of Multiple Sclerosis,Drug: Minocycline|Drug: Placebo,"To demonstrate that 100 mg of oral minocycline twice daily reduces the conversion of CIS to McDonald Criteria MS (McDMS) by an absolute 25% as compared to placebo, over a 6 month follow-up period.|To confirm that this early treatment benefit is maintained at two years.|Change in T2 lesion volume|Cumulative number of enhancing T1 lesions|cumulative combined unique lesions (new enhancing T1-weighted lesions plus new and enlarging T2 lesions, without lesion double counting)",Dr. Luanne Metz|Multiple Sclerosis Society of Canada|University of Calgary,All,18 Years to 60 Years   (Adult),Phase 3,142,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",Grant ID # 21569|Health Canada Control #120007,January 2009,December 2014,July 2015,"April 25, 2008",NA,"February 27, 2017","University of Calgary, Calgary Health Region, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Fraser Health Multiple Sclerosis Clinic, Burnaby, British Columbia, Canada|UBC Hospital, Vancouver, British Columbia, Canada|MS Research Unit, Health Sciences Centre, Winnipeg, Manitoba, Canada|Dalhousie MS Research Unit, Halifax, Nova Scotia, Canada|MS Clinic, London Health Sciences Centre, London, Ontario, Canada|The Ottawa Hospital, Multiple Sclerosis Research Clinic, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Clinique Neuro Rive-Sud, Greenfield Park, Quebec, Canada|CHUM Notre-Dame, Montreal, Quebec, Canada|CHAUQ Enfant-Jesus, Quebec City, Quebec, Canada",NA,https://ClinicalTrials.gov/show/NCT00666887
160,NCT00665223,A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease,MermaiHD,Completed,No Results Available,Huntington's Disease,Drug: ACR16|Drug: Placebo,"The primary objective is to assess the effects of ACR16 on voluntary motor function in HD patients, as defined as the sum score of items 4-10 and 13-15 of the UHDRS motor assessment (a modified motor score mMS) at 26 weeks of treatment.|Safety and tolerability assessed from adverse event profile.|The effects of ACR16 on CGI, cognitive function, behaviour and symptoms of depression and anxiety.","Teva Branded Pharmaceutical Products R&D, Inc.",All,"30 Years and older   (Adult, Older Adult)",Phase 3,437,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ACR16 C008,April 2008,June 2011,June 2011,"April 23, 2008",NA,"July 21, 2016","LKH -Univ. Klinikum Graz, Universitaetsklinik fur Psychiatrie Graz, Graz, Styria, Austria|Innsbruck Medical University, Anichstraße 35, Innsbruck, Tyrol, Austria|University Hospital Gasthuisberg, Leuven, Flemish Brabant, Belgium|Hôpital Purpan, Place Docteur-Baylac, Bâtiment F, Toulouse Cedex 9, Midi-Pyrénées region, France|CHU Roger Salengro, Lille Cedex, Nord-Pas de Calais, France|Hôpital Nord, CHU d'Amiens, Service de Neurologie, Amiens Cedex 1, Picardie, France|CHU La Timone, 264 Rue Saint Pierre, Marseille Cedex 05, Provence-Alpes-Cote d'Azur, France|Universitätsklinik Ulm, Neurologie/ Oberer Eselberg 45/1, Ulm, Baden-Württemberg, Germany|Klinikum rechts der Isar der Technischen Universität München, Neurologische Klinik und Poliklinik, Ismaninger Str. 22, München, Bavaria, Germany|Isar Amper Klinikum gemeinnützige GmbH, Klinik Taufkirchen (Vils), Bräuhausstr.5, Taufkirchen (Vils), Bavaria, Germany|St. Josef Hospital, Ruhr University Bochum, Gudrunstraße 56, Bochum, North Rhine-Westphalia, Germany|Westfaelische Wilhelms-Universitaet Muenster, Klinik fur Neurologie, Muenster, North Rhine-Westphalia, Germany|Universitat Dresden, Klinikum Carl Gustav Carus, Fetscherstr. 74, Dresden, Saxony, Germany|Klinik für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Schumannstrasse 20/21, Berlin, Germany|Fondazione IRCCS Istituto Nazionale Neurologico ""Carlos Besta"", Department of Movement Disorders, 11 via Celoria, Milano, Lombardy, Italy|IRCCS Neuromed, Localita Camarelle, Pozzilli, Molise, Italy|University Hospital of Coimbra, Av. Rissaya Barreto, Coimbra, Baixo Mondego, Portugal|Centro de Estudos Egas Moniz, Faculdade de Medicina de Lisboa, Av. Prof. Egas Moniz, Lisboa, Portugal|Hospital Mútua de Terrassa, C/ Castell, Terrassa, Catalonia, Spain|Hospital Clinic of Barcelona, Calle Villarroel, 170, Barcelona, Spain|Hospital Ramon y Cajal, Carretera Colemenar km 9.100, Madrid, Spain|Hospital Universitario La Fe, Avda. Campanar 21,, Valencia, Spain|R&D Headquarters, Barberry Centre, 25 Vincent Drive, Birmingham, England/West Midlands, United Kingdom|Department of Clinical Genetics, St Mary's Hospital, Hathersage Road, Manchester, North West England, United Kingdom|First Floor Argyll House, Fosterhill, Cornhill Road, Aberdeen, Scotland, United Kingdom|SE Scotland Genetic Service, Western General Hospital, Crewe Road, Edinburgh, Scotland, United Kingdom|Churchill Hospital, Old Road, Headington, Oxford, South East England, United Kingdom|Academic Neurology Unit, E Floor Medical School Beech Hill Road, Sheffield, South Yorkshire, United Kingdom|Institute of Human Genetics, Centre for Life, Central Parkway, Newcastle on Tyne, Tyne and Wear, United Kingdom|Cardiff University School of Medicine, Department of Neurology & Medical Genetics, Heath Park, Cardiff, Wales, United Kingdom|Cambridge Centre for Brain repair, Cambridge University, Cambridge, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT00665223
161,NCT00664209,Treating H. Pylori in Parkinson's Patients With Motor Fluctuations,NA,Terminated,Has Results,Parkinson's Disease|Helicobacter Infections|Motor Fluctuations,"Drug: clartihromycin, amoxicillin, and omeprazole|Drug: placebo","""Off"" Time|Improvement in UPDRS Total Scores|Improvement in UDPRS Part III|Improvement in Quality of Life as Assessed by PDQ-39|Participants With Side Effects From Study Treatment","University of California, Los Angeles|Michael J. Fox Foundation for Parkinson's Research",Male,"Child, Adult, Older Adult",Phase 3,64,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MJJF Clinical Discovery 2007|441437-JB-58330,January 2008,June 2011,June 2012,"April 22, 2008","December 2, 2017","December 2, 2017","UCLA Neurology, Los Angeles, California, United States",NA,https://ClinicalTrials.gov/show/NCT00664209
162,NCT00608881,Coenzyme Q10 in Huntington's Disease (HD),2CARE,Terminated,Has Results,Huntington's Disease,Drug: coenzyme Q10|Other: placebo,Joint Rank (Combination of Time to Death (for Subjects Who Died) and Change in Total Functional Capacity Score (TFC) From Baseline to Month 60 (for Subjects Who Survived))|Change in Total Functional Capacity (TFC) Score From Baseline to Month 60|Change in Functional Checklist Score From Baseline to Month 60|Change in Independence Scale Score From Baseline to Month 60|Change in Total Motor Score From Baseline to Month 60|Change in Behavioral Frequency Score From Baseline to Month 60|Change in Behavioral Frequency x Severity Score From Baseline to Month 60|Change in Symbol Digit Modalities Test (SDMT) From Baseline to Month 60|Change in Verbal Fluency Test From Baseline to Month 60|Change in Stroop Interference Test - Color Naming From Baseline to Month 60|Change in Stroop Interference Test - Word Reading From Baseline to Month 60|Change in Stroop Interference Test - Interference From Baseline to Month 60|Time to a Two-Point Decline in TFC Score or Death|Time to a Three-Point Decline in TFC Score or Death|Number Completing Study at Assigned Dosage Level,Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS)|University of Rochester,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 3,609,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2CARE 01.00|5U01NS052592|5R01NS052619,March 2008,November 2014,May 2015,"February 6, 2008","March 30, 2016","March 30, 2016","University of Alabama At Birmingham, Pediatric Neurology Childrens, Harbor Bldg Suite 314, 1600 7Th Avenue South, Birmingham, Alabama, United States|Mayo Clinic Arizona, 13400 East Shea Boulevard, Csu-Cp21B, Scottsdale, Arizona, United States|WASHINGTON REGIONAL MEDICAL CENTER, 3215 N. North Hills Blvd, Fayetteville, Arkansas, United States|University of California Irvine, Department of Neurology, 100 Irvine Hall, Irvine, California, United States|University of California Davis, Medical Center Dept of Neurology, Acc Building Suite 3700, 4860 Y Street, Sacramento, California, United States|Colorado Neurological Institute, Movement Disorders Center, 701 East Hampden Avenue Suite 510, Littleton, Colorado, United States|University of Florida Center for Movement Disorders and Neurorestoration, 3450 Hull Road, 4th Floor, Gainesville, Florida, United States|UNIVERSITY OF MIAMI, 1150 NW 14th STREET, #401, Miami, Florida, United States|University of South Florida, College of Medicine Dept of Neurology, 12901 Bruce B Downs Blvd Mdc-55, Tampa, Florida, United States|Emory University, Wesley Woods Center, 1841 Clifton Road NE Room 314, Atlanta, Georgia, United States|Idaho Elks Rehabilitation Hospital, 600 North Robbins Road, Boise, Idaho, United States|Rush University Medical Center, Department of Neurological Sciences, 1725 West Harrison Suite 755, Chicago, Illinois, United States|Indiana University School of Medicine, Outpatient Clinical Research Facility, 535 Barnhill Drive Room #150, Indianapolis, Indiana, United States|University of Iowa Hospital and Clinics, 200 Hawkins Road, Room W263 General Hospital, Iowa City, Iowa, United States|University of Kansas Medical Center, Department of Neurology, 3599 Rainbow Blvd Mail Stop 2012, Kansas City, Kansas, United States|Hereditary Neurological Disease Centre (Hndc),3223 N. Webb, Suite 4, Wichita, Kansas, United States|University of Maryland School of Medicine, 22 South Greene Street, N4 W49-B, Baltimore, Maryland, United States|Johns Hopkins University, 600 North Wolfe Street, Meyer 2-181, Baltimore, Maryland, United States|Boston University School of Medicine, Department of Neurology, 715 Albany Street C329, Boston, Massachusetts, United States|Massachusetts General Hospital, 149 13Th Street Suite 2241, Charlestown, Massachusetts, United States|University of Michigan, 1500 E Medical Center Drive, B1 H202 Nuclear Medicine, Ann Arbor, Michigan, United States|Struthers Parkinson'S Center, 6701 Country Club Drive, Golden Valley, Minnesota, United States|Washington University School of Medicine, Box 8111, 660 South Euclid, St Louis, Missouri, United States|University of Las Vegas School of Medicine, 1707 W. Charleston Blvd, Suite 220, Las Vegas, Nevada, United States|Cooper University Hospital, Camden, New Jersey, United States|Nj Neuroscience Institute, Jfk Medical Center, 65 James Street, Edison, New Jersey, United States|Albany Medical College, Parkinson'S Disease & Movement Disorders Ctr, Albany, New York, United States|North Shore-Lij Health System, 350 Community Drive Room 110, Research Institute, Manhasset, New York, United States|Columbia University, Sergievsky Center P&S Box 16, 630 West 168Th Street, New York, New York, United States|University of Rochester, Department of Neurology, 919 Westfall Road Building C Suite 220, Rochester, New York, United States|Duke University, 932 Morreene Road #213, Durham, North Carolina, United States|Wake Forest University, Baptist Med Center, Department of Neurology, Medical Center Boulevard, Winston Salem, North Carolina, United States|University of Cincinnati/Cincinnati Children'S Hospital, 222 Piedmont Avenue, Suite 3200, Cincinnati, Ohio, United States|OHIO STATE UNIVERSITY , 2006 Kenny Road, Columbus, Ohio, United States|ST. LUKE'S HOSPITAL, 240 Centronia Road, Allentown, Pennsylvania, United States|University of Pennsylvania, Pennsylvania Hospital Department of Neurology , 330 South 9Th Street, Philadelphia, Pennsylvania, United States|University of Pittsburgh Kaufmann Medical Building, 3471 Fifth Avunue, Suite 811, Pittsburgh, Pennsylvania, United States|BUTLER HOSPTIAL MOVEMENT DISORDER PROGRAM, 345 Blackstone Boulevard, Providence, Rhode Island, United States|The University of Tennesee Health Science Cen, 855 Monroe Avenue, Department of Neurology, Room 415 Link Bldg, Memphis, Tennessee, United States|UN oF TEXAS SOUTHWESTERN MED CENTER DALLAS, 5323 HARRY HINES BOULEVARD H1.108, Dallas, Texas, United States|Baylor College of Medicine, 6550 Fannin Suite 1801, Houston, Texas, United States|Westmead Hospital, Department of Neurology Level 1, Po Box 533, Wentworthville, New South Wales, Australia|University of Calgary, Heritage Medical Research Clinic, Trw Bldg 5 Floor, 3280 Hospital Dri. NW, Calgary, Alberta, Canada|University of Alberta, Glenrose Rehab Hosp, Movement Disorder Clinic , Rm 0601 Gleneast 10230 - 111 Avenue, Edmonton, Alberta, Canada|Department of Medical Genetics, Ubc Hospital, Room S179-2211 Westbrook Mall, Vancouver, British Columbia, Canada|London Health Sciences Centre, University Hospital, 339 Windermere Road, London, Ontario, Canada|Centre For Movement Disorders, 2780 Bur Oak Avenue, Markham, Ontario, Canada|NORTH YORK GENERAL HOSPITAL (2), 4001 Leslie Street, Toronto, Ontario, Canada|North York General Hospital, 4001 Leslie Street, Toronto, Ontario, Canada",NA,https://ClinicalTrials.gov/show/NCT00608881
163,NCT00605215,BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®),BRAVO,Completed,Has Results,Multiple Sclerosis,Drug: Laquinimod|Drug: Placebo|Drug: Avonex®,Annualized Rate of Confirmed Relapses|Change From Baseline in Disability as Assessed by the Multiple Sclerosis Functional Composite (MSFC) Score|Percent Change From Baseline in Brain Volume|Accumulation of Physical Disability Measured by the Number of Participants With Confirmed Progression of EDSS,"Teva Branded Pharmaceutical Products R&D, Inc.",All,18 Years to 55 Years   (Adult),Phase 3,1331,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MS-LAQ-302|2007-005450-23,"April 24, 2008","June 10, 2011","June 10, 2011","January 30, 2008","April 21, 2022","April 21, 2022","Teva Investigational Site 1267, Birmingham, Alabama, United States|Teva Investigational Site 1237, Phoenix, Arizona, United States|Teva Investigational Site 1252, Phoenix, Arizona, United States|Teva Investigational Site 1279, Phoenix, Arizona, United States|Teva Investigational Site 1276, Tucson, Arizona, United States|Teva Investigational Site 1272, Pasadena, California, United States|Teva Investigational Site 1238, Sacramento, California, United States|Teva Investigational Site 1280, Aurora, Colorado, United States|Teva Investigational Site 1255, Orlando, Florida, United States|Teva Investigational Site 1282, Sarasota, Florida, United States|Teva Investigational Site 1275, Atlanta, Georgia, United States|Teva Investigational Site 1250, Peoria, Illinois, United States|Teva Investigational Site 1260, Indianapolis, Indiana, United States|Teva Investigational Site 1268, Lenexa, Kansas, United States|Teva Investigational Site 1277, New Orleans, Louisiana, United States|Teva Investigational Site 1263, Shreveport, Louisiana, United States|Teva Investigational Site 1269, Baltimore, Maryland, United States|Teva Investigational Site 1274, Grand Rapids, Michigan, United States|Teva Investigational Site 1239, Lebanon, New Hampshire, United States|Teva Investigational Site 1265, Teaneck, New Jersey, United States|Teva Investigational Site 1273, Albany, New York, United States|Teva Investigational Site 1264, Amherst, New York, United States|Teva Investigational Site 1283, Cedarhurst, New York, United States|Teva Investigational Site 1249, Raleigh, North Carolina, United States|Teva Investigational Site 1262, Winston-Salem, North Carolina, United States|Teva Investigational Site 1261, Akron, Ohio, United States|Teva Investigational Site 1241, Canton, Ohio, United States|Teva Investigational Site 1245, Cleveland, Ohio, United States|Teva Investigational Site 1247, Columbus, Ohio, United States|Teva Investigational Site 1244, Portland, Oregon, United States|Teva Investigational Site 1258, Philadelphia, Pennsylvania, United States|Teva Investigational Site 1281, Nashville, Tennessee, United States|Teva Investigational Site 1284, San Antonio, Texas, United States|Teva Investigational Site 1248, Richmond, Virginia, United States|Teva Investigational Site 1270, Roanoke, Virginia, United States|Teva Investigational Site 1253, Tacoma, Washington, United States|Teva Investigational Site 5914, Pleven, Bulgaria|Teva Investigational Site 5915, Pleven, Bulgaria|Teva Investigational Site 5917, Plovdiv, Bulgaria|Teva Investigational Site 4212, Ruse, Bulgaria|Teva Investigational Site 5916, Shumen, Bulgaria|Teva Investigational Site 5920, Sofia, Bulgaria|Teva Investigational Site 5907, Sofia, Bulgaria|Teva Investigational Site 5910, Sofia, Bulgaria|Teva Investigational Site 5909, Sofia, Bulgaria|Teva Investigational Site 5919, Sofia, Bulgaria|Teva Investigational Site 5906, Sofia, Bulgaria|Teva Investigational Site 5908, Sofia, Bulgaria|Teva Investigational Site 5911, Sofia, Bulgaria|Teva Investigational Site 5912, Sofia, Bulgaria|Teva Investigational Site 5918, Stara Zagora, Bulgaria|Teva Investigational Site 5913, Varna, Bulgaria|Teva Investigational Site 4211, Veliko Tarnovo, Bulgaria|Teva Investigational Site 6003, Osijek, Croatia|Teva Investigational Site 6004, Split, Croatia|Teva Investigational Site 6005, Varazdin, Croatia|Teva Investigational Site 6001, Zagreb, Croatia|Teva Investigational Site 6002, Zagreb, Croatia|Teva Investigational Site 6006, Zagreb, Croatia|Teva Investigational Site 5422, Brno, Czechia|Teva Investigational Site 5419, Olomouc, Czechia|Teva Investigational Site 5418, Praha 2, Czechia|Teva Investigational Site 5420, Praha 5- Motol, Czechia|Teva Investigational Site 5421, Teplice, Czechia|Teva Investigational Site 5508, Kohtla-Jarve, Estonia|Teva Investigational Site 5507, Tallinn, Estonia|Teva Investigational Site 5509, Tartu, Estonia|Teva Investigational Site 8102, Tbilisi, Georgia|Teva Investigational Site 8104, Tbilisi, Georgia|Teva Investigational Site 8103, Tbilisi, Georgia|Teva Investigational Site 6701, Bayreuth, Germany|Teva Investigational Site 6703, Berlin, Germany|Teva Investigational Site 6402, Berlin, Germany|Teva Investigational Site 6700, Berlin, Germany|Teva Investigational Site 6702, Dresden, Germany|Teva Investigational Site 6401, Hannover, Germany|Teva Investigational Site 6403, Munster, Germany|Teva Investigational Site 6400, Ulm, Germany|Teva Investigational Site 8043, Haifa, Israel|Teva Investigational Site 8041, Jerusalem, Israel|Teva Investigational Site 8040, Ramat Gan, Israel|Teva Investigational Site 8042, Ramat Gan, Israel|Teva Investigational Site 3056, Bologna, Italy|Teva Investigational Site 3062, Catania, Italy|Teva Investigational Site 3053, Cefalu, Italy|Teva Investigational Site 3054, Chieti, Italy|Teva Investigational Site 3061, Empoli, Italy|Teva Investigational Site 3049, Firenze, Italy|Teva Investigational Site 3055, Napoli, Italy|Teva Investigational Site 3048, Rome, Italy|Teva Investigational Site 3052, Rome, Italy|Teva Investigational Site 3050, Rome, Italy|Teva Investigational Site 3060, Rome, Italy|Teva Investigational Site 3051, Torino, Italy|Teva Investigational Site 5708, Kaunas, Lithuania|Teva Investigational Site 5707, Siauliai, Lithuania|Teva Investigational Site 6502, Bitola, North Macedonia|Teva Investigational Site 6500, Skopje, North Macedonia|Teva Investigational Site 6501, Skopje, North Macedonia|Teva Investigational Site 5337, Bialystok, Poland|Teva Investigational Site 5329, Gdansk, Poland|Teva Investigational Site 5338, Gdansk, Poland|Teva Investigational Site 6602, Gorzow Wielkopolski, Poland|Teva Investigational Site 5333, Grodzisk Mazowiecki, Poland|Teva Investigational Site 5339, Katowice, Poland|Teva Investigational Site 5334, Katowice, Poland|Teva Investigational Site 6603, Kielce, Poland|Teva Investigational Site 4213, Konskie, Poland|Teva Investigational Site 5332, Koscierzyna, Poland|Teva Investigational Site 5345, Krakow, Poland|Teva Investigational Site 5328, Lodz, Poland|Teva Investigational Site 5330, Olsztyn, Poland|Teva Investigational Site 5331, Szczecin, Poland|Teva Investigational Site 5336, Warsaw, Poland|Teva Investigational Site 5340, Warszawa, Poland|Teva Investigational Site 5341, Warszawa, Poland|Teva Investigational Site 5335, Wroclaw, Poland|Teva Investigational Site 1243, Guaynabo, Puerto Rico|Teva Investigational Site 5218, Bucharest, Romania|Teva Investigational Site 5214, Bucuresti, Romania|Teva Investigational Site 5213, Bucuresti, Romania|Teva Investigational Site 5215, Cluj-Napoca, Romania|Teva Investigational Site 5217, Constanta, Romania|Teva Investigational Site 8209, Craiova, Romania|Teva Investigational Site 5216, Iasi, Romania|Teva Investigational Site 5219, Sibiu, Romania|Teva Investigational Site 5043, Barnaul, Russian Federation|Teva Investigational Site 5033, Moscow, Russian Federation|Teva Investigational Site 5032, Moscow, Russian Federation|Teva Investigational Site 5041, Moscow, Russian Federation|Teva Investigational Site 5038, Novosibirsk, Russian Federation|Teva Investigational Site 5042, Novosibirsk, Russian Federation|Teva Investigational Site 5035, Saint Petersburg, Russian Federation|Teva Investigational Site 5037, Samara, Russian Federation|Teva Investigational Site 5036, St. Petersburg, Russian Federation|Teva Investigational Site 5034, St. Petersburg, Russian Federation|Teva Investigational Site 5044, Ufa, Russian Federation|Teva Investigational Site 6200, Bratislava, Slovakia|Teva Investigational Site 6201, Bratislava, Slovakia|Teva Investigational Site 6202, Nitra, Slovakia|Teva Investigational Site 6203, Zilina, Slovakia|Teva Investigational Site 9007, Bloemfontein, South Africa|Teva Investigational Site 9001, Cape Town, South Africa|Teva Investigational Site 9004, Johannesburg, South Africa|Teva Investigational Site 9003, Johannesburg, South Africa|Teva Investigational Site 9008, Pietermaritzburg, South Africa|Teva Investigational Site 9005, Pretoria, South Africa|Teva Investigational Site 9006, Rosebank, South Africa|Teva Investigational Site 3147, Barcelona, Spain|Teva Investigational Site 3154, Figueres-Girona, Spain|Teva Investigational Site 3149, L'Hospitalet de Llobregat, Spain|Teva Investigational Site 3152, Madrid, Spain|Teva Investigational Site 3151, Malaga, Spain|Teva Investigational Site 3148, Sevilla, Spain|Teva Investigational Site 3153, Tortosa-Tarragona, Spain|Teva Investigational Site 6503, Chernihiv, Ukraine|Teva Investigational Site 5823, Chernivtsi, Ukraine|Teva Investigational Site 5811, Dnipropetrovsk, Ukraine|Teva Investigational Site 5812, Donetsk, Ukraine|Teva Investigational Site 5814, Ivano-Frankivsk, Ukraine|Teva Investigational Site 5817, Kharkiv, Ukraine|Teva Investigational Site 5818, Kharkiv, Ukraine|Teva Investigational Site 5815, Kharkiv, Ukraine|Teva Investigational Site 5822, Kyiv, Ukraine|Teva Investigational Site 5809, Lviv, Ukraine|Teva Investigational Site 5820, Odessa, Ukraine|Teva Investigational Site 5821, Poltava, Ukraine|Teva Investigational Site 5810, Vinnytsya, Ukraine|Teva Investigational Site 5819, Zaporizhzhya, Ukraine|Teva Investigational Site 5816, Zaporizhzhya, Ukraine",NA,https://ClinicalTrials.gov/show/NCT00605215
164,NCT00575055,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier),NA,Completed,No Results Available,Alzheimer's Disease,Drug: Bapineuzumab 0.5 mg/kg|Drug: Placebo Control|Drug: Bapineuzumab 1.0 m/kg,Cognitive and Functional|Cognitive and Global|Imaging and biochemical biomarkers of disease status,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Pfizer",All,"50 Years to 88 Years   (Adult, Older Adult)",Phase 3,1121,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ELN115727-302,December 2007,April 2012,April 2012,"December 17, 2007",NA,"November 25, 2013","University of Alabama Hospital (UAB), Birmingham, Alabama, United States|Dedicated Clinical Research, Inc., Goodyear, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|HOPE Research Institute, LLC, Phoenix, Arizona, United States|Banner Research Institute, Sun City, Arizona, United States|University of Arizona College of Medicine, Health Sciences Center, Tucson, Arizona, United States|Northwest NeuroSpecialists, PLLC, Tucson, Arizona, United States|Clinical Trials Inc., Little Rock, Arkansas, United States|East Bay Physicians Medical Group, Berkeley, California, United States|AVI Clinical Research, Carson, California, United States|ATP Clinical Research, Inc, Costa Mesa, California, United States|Pharmacology Research Institute, Encino, California, United States|Margolin Brain Institute, Fresno, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Coordinated Clinical Research, La Jolla, California, United States|University of California San Diego, La Jolla, California, United States|Senior Clinical Trials, Inc, Laguna Hills, California, United States|Collaborative NeuroScience Network, Inc., Long Beach, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Vintage Institute for Clinical Research, Inc, Los Angeles, California, United States|UCLA Department of Neurology, Los Angeles, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|Neurology Center, Oceanside, California, United States|University of California Irvine Medical Center, Orange, California, United States|Neuro-Therapeutics Inc., Pasadena, California, United States|Sutter Neuroscience Medical Group, Sacramento, California, United States|University of California Davis Alzheimer's Disease Research Center, Sacramento, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|University of California at San Francisco Medical Center at Parnassus, San Francisco, California, United States|Neurological Research Institute, Santa Monica, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|Mile High Research Center, Denver, Colorado, United States|Advanced Neurosciences Research, LLC, Fort Collins, Colorado, United States|Associated Neurologists, PC, Danbury, Connecticut, United States|Associated Neurologists of Southern CT, P.C., Fairfield, Connecticut, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc, Norwalk, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Christiana Care Health Services, Newark, Delaware, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|JEM Research, LLC, Atlantis, Florida, United States|Bradenton Research Center, Inc, Bradenton, Florida, United States|Quantum Laboratories, Inc., Deerfield Beach, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Neurologic Consultants, P.A., Fort Lauderdale, Florida, United States|Clinical Physiology Associates, Inc., Fort Myers, Florida, United States|Emerald Coast Mood & Memory, PA., Fort Walton Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Ft. Myers, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Mayo Clinic College of Medicine, Jacksonville, Florida, United States|Neurology Associates, Maitland, Florida, United States|Melbourne Internal Medicine Associates, MIMA, Melbourne, Florida, United States|Pharmax Research Clinic, LLC, Miami, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Allied Clinical Trials, Inc., Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Palm Beach Neurological Center/Advanced Research Consultants, Palm Beach Gardens, Florida, United States|Neurostudies, Inc, Port Charlotte, Florida, United States|The Roskamp Institute, Inc, Sarasota, Florida, United States|Miami Research Associates, South Miami, Florida, United States|Suncoast Neuroscience Associates, Inc., St Petersburg, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Johnnie B. Byrd Sr. Alzheimer's Center and Research Institute, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|University of South Florida Suncoast Alzheimer's and Gerontology Center, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University, School of Medicine, Atlanta, Georgia, United States|Multiple Sclerosis Center of Atlanta, Atlanta, Georgia, United States|NeuroTrials Research, Inc., Atlanta, Georgia, United States|Medical Research and Health Educational Foundation, Inc, Columbus, Georgia, United States|DeKalb Neurology Associates, LLC, Decatur, Georgia, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Southern Illinois University, School of Medicine, Springfield, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Mid America Neuroscience Institute, Lenexa, Kansas, United States|Associates in Neurology, PSC, Lexington, Kentucky, United States|University of Kentucky, Lexington, Kentucky, United States|Four Rivers Clinical Research, Inc, Paducah, Kentucky, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States|J. Gary Booker, MD, APMC, Shreveport, Louisiana, United States|Maine Medical Partners Neurology, Scarborough, Maine, United States|University of Maryland, Baltimore, Maryland, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|McLean Hospital, Belmont, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|ActivMed Practices and Research, Inc, Haverhill, Massachusetts, United States|Neurocare, Inc, Newton, Massachusetts, United States|Neuroscience Research of the Berkshires, Pittsfield, Massachusetts, United States|Donald S. Marks, MD, P.C., Plymouth, Massachusetts, United States|Springfield Neurology Associates, Springfield, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Borgess Medical Center/Borgess Research Institute, Kalamazoo, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Saint Luke's Hospital, Mid America Brain and Stroke Institute, Kansas City, Missouri, United States|The Center for Pharmaceutical Research, Kansas City, Missouri, United States|St. Louis University School of Medicine, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Deaconess Billings Clinical Research Center, Billings, Montana, United States|Advanced Neurology Specialists, Great Falls, Montana, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Alzheimer's Research Corporation (ARC), Manchester, New Jersey, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Princeton Medical Institute, Princeton, New Jersey, United States|University of Medicine and Dentistry of New Jersey, Stratford, New Jersey, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|Upstate Clinical Research, LLC, Albany, New York, United States|Neurological Associates Albany PC, Albany, New York, United States|Neuroscience Research Center at Albany Medical Center, Albany, New York, United States|Five Towns Neuroscience Research, Cedarhurst, New York, United States|Advanced BioBehavioral Sciences, Elmsford, New York, United States|Empire Neurology, PC, Latham, New York, United States|Neurological Care of CNY, Liverpool, New York, United States|Parker Jewish Institute for Health Care & Rehabilitation, New Hyde Park, New York, United States|NYU School of Medicine/Psychiatry, New York, New York, United States|Mt. Sinai School of Medicine, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester Medical Center @ Monroe Community Hospital, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Clinical Trials of America, Inc, Hickory, North Carolina, United States|New Hope Clinical Research, Hickory, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University Hospitals of Cleveland, Case Medical Center, Memory and Cognition Center, Beachwood, Ohio, United States|Neuro-Behavioral Clinical Research, Inc, Canton, Ohio, United States|NeuroCare Center, Inc, Canton, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Neurology Specialists, Inc., Dayton, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Red River Medical Research Center, LLC, Oklahoma City, Oklahoma, United States|Providence Medical Group-Medford Neurology, Medford, Oregon, United States|Summit Research Group, LLC, Portland, Oregon, United States|Providence Health Service System, AD Center, Brain Institute, Portland, Oregon, United States|Oregon Health & Sciences University, Portland, Oregon, United States|Abington Neurological Assoc, Abington, Pennsylvania, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Penn Memory Center, Philadelphia, Pennsylvania, United States|Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, United States|Clinical Trials Research Services, LLC, Pittsburgh, Pennsylvania, United States|University of Virginia, Pittsburgh, Pennsylvania, United States|Universtiy of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, N. Charleston, South Carolina, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|Neurology Clinic, PC, Cordova, Tennessee, United States|Psychiatric Consultants, PC, Franklin, Tennessee, United States|East Tennessee State University, Johnson City, Tennessee, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Texas Neurology, PA, Dallas, Texas, United States|University of North Texas/Health Sciences Center-Fort Worth, Fort Worth, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Integra Clinical Research, LLC, San Antonio, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|University of Utah, Dept. of Neurology, Salt Lake City, Utah, United States|The Memory Clinic, Bennington, Vermont, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Innovative Clinical Research Center, Alexandria, Virginia, United States|Alliance Research Group, LLC, Richmond, Virginia, United States|University of Washington Veterans Affairs, Seattle, Washington, United States|Pacific Medical Centers, Seattle, Washington, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",NA,https://ClinicalTrials.gov/show/NCT00575055
165,NCT00574132,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier),NA,Completed,No Results Available,Alzheimer's Disease,Drug: Bapineuzumab 0.5 mg/kg|Drug: Placebo Control|Drug: Bapineuzumab 1.0 m/kg,Cognitive and Functional|Cognitive and Global|Imaging and biochemical biomarkers of disease status,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Pfizer",All,"50 Years to 88 Years   (Adult, Older Adult)",Phase 3,1331,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ELN115727-301,December 2007,June 2012,June 2012,"December 17, 2007",NA,"November 25, 2013","University of Alabama Hospital (UAB), Birmingham, Alabama, United States|Dedicated Clinical Research, Inc., Goodyear, Arizona, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|HOPE Research Institute, LLC, Phoenix, Arizona, United States|Banner Research Institute, Sun City, Arizona, United States|University of Arizona College of Medicine, Health Science Center, Tucson, Arizona, United States|Northwest Neurospecialists, PLLC, Tucson, Arizona, United States|Clinical Trials Inc., Little Rock, Arkansas, United States|East Bay Physicians Medical Group, Berkeley, California, United States|AVI Clinical Research, Carson, California, United States|ATP Clinical Research, Inc, Costa Mesa, California, United States|Pharmacology Research Institute, Encino, California, United States|Margolin Brain Institute, Fresno, California, United States|Neurology Center of North Orange County, Fullerton, California, United States|Integrated Medical and Behavioral Associates, Glendale, California, United States|Sun Valley Behavioral Medical Center, Imperial, California, United States|Coordinated Clinical Research, La Jolla, California, United States|University of California San Diego/Shela Marcos Alzheimer's Disease Research Center, La Jolla, California, United States|Senior Clinical Trials, Laguna Hills, California, United States|Collaborative Neuroscience Network, Long Beach, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Vintage Institute for Clinical Research, Inc, Los Angeles, California, United States|UCLA Department of Neurology, Los Angeles, California, United States|Synergy Research, National City, California, United States|Pharmacology Research Institute, Newport Beach, California, United States|The Neurology Center, Oceanside, California, United States|University of California, Irvine Medical Center, Orange, California, United States|Neuro-Therapeutics Inc., Pasadena, California, United States|The Southwest Institute for Clinical Research, Inc., Rancho Mirage, California, United States|Sutter Neuroscience Medical Group, Sacramento, California, United States|University of California, Davis, Alzheimer's Disease Center, Sacramento, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States|Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States|Neurological Research Institute, Santa Monica, California, United States|Schuster Medical Research Institute, Sherman Oaks, California, United States|Diablo Clinical Research, Inc, Walnut Creek, California, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|Mile High Research Center, Denver, Colorado, United States|Advanced Neurosciences Research, LLC, Fort Collins, Colorado, United States|Associated Neurologists, PC, Danbury, Connecticut, United States|Associated Neurologists of Southern CT, P.C., Fairfield, Connecticut, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States|Yale University School of Medicine, Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Research Center for Clinical Studies, Inc, Norwalk, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Christiana Care Health Services, Newark, Delaware, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|JEM Research, LLC, Atlantis, Florida, United States|Bradenton Research Center, Inc, Bradenton, Florida, United States|Quantum Laboratories, Inc., Deerfield Beach, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Neurologic Consultants, P.A., Fort Lauderdale, Florida, United States|Clinical Physiology Associates, Inc., Fort Myers, Florida, United States|Emerald Coast Mood & Memory, PA., Fort Walton Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Ft. Myers, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Sunrise Clinical Research, Inc., Hollywood, Florida, United States|Mayo Clinic College of Medicine, Jacksonville, Florida, United States|Neurology Associates, Maitland, Florida, United States|Melbourne International Medicine Associates, MIMA, Melbourne, Florida, United States|Pharmax Research Clinic, LLC, Miami, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Allied Clinical Trials, Inc., Miami, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Medical Research Group of Central Florida, Orange City, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Palm Beach Neurological Center/Advanced Research Consultants, Palm Beach Gardens, Florida, United States|Broward Research Group, Inc., Pembroke Pines, Florida, United States|Neurostudies, Inc, Port Charlotte, Florida, United States|Roskamp Institute, Sarasota, Florida, United States|Miami Research Associates, South Miami, Florida, United States|Suncoast Neuroscience Associates, Inc., St Petersburg, Florida, United States|Meridien Research, St. Petersburg, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Johnnie B. Byrd Sr. Alzheimer's Center and Research Institute, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|University of South Florida Suncoast Alzheimer's and Gerontology Center, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University/School of Medicine, Atlanta, Georgia, United States|MS Center of Atlanta, Atlanta, Georgia, United States|NeuroTrials Research, Inc., Atlanta, Georgia, United States|Medical Research and Health Education Foundation, Inc., Columbus, Georgia, United States|Dekalb Neurology Associates, Decatur, Georgia, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Southern Illinois University, School of Medicine, Springfield, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Kansas Multi-Specialist Group, Kansas City, Kansas, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Mid America Neuroscience Institute, Lenexa, Kansas, United States|Associates in Neurology, PSC, Lexington, Kentucky, United States|University of Kentucky, Lexington, Kentucky, United States|Four Rivers Clinical Research, Paducah, Kentucky, United States|Lake Charles Clinical Trials, Lake Charles, Louisiana, United States|Louisiana Research Associates, Inc., New Orleans, Louisiana, United States|Louisana State University Health Sciences Center, Shreveport, Louisiana, United States|J. Gary Booker, MD, APMC, Shreveport, Louisiana, United States|Maine Medical Partners Neurology, Scarborough, Maine, United States|University of Maryland, Baltimore, Maryland, United States|Johns Hopkins School of Medicine, Baltimore, Maryland, United States|CBH Health, LLC, Rockville, Maryland, United States|McLean Hospital, Belmont, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|ActivMed Practices and Research, Inc, Haverhill, Massachusetts, United States|Neurocare, Inc., Newton, Massachusetts, United States|Neuroscience Research of the Berkshires, Pittsfield, Massachusetts, United States|Donald S. Marks, MD, P.C., Plymouth, Massachusetts, United States|Memory Wellness Clinic, Springfield, Massachusetts, United States|Springfield Neurology Associates, Springfield, Massachusetts, United States|Coastal Research Associates, Inc., Weymouth, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Borgess Medical Center/Borgess Research Institute, Kalamazoo, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Precise Research Centers, Flowood, Mississippi, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Saint Luke's Hospital, Mid America Brain and Stroke Institute, Kansas City, Missouri, United States|The Center for Pharmaceutical Research, Kansas City, Missouri, United States|St. Louis University School of Medicine, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Deaconess Billings Clinical Research Center, Billings, Montana, United States|Advanced Neurology Specialists, Great Falls, Montana, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Coastal Neurology, PA, Dover, New Hampshire, United States|Dartmouth Hitchcock Medical Center, Dept of Neurology, Lebanon, New Hampshire, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|The Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Alzheimer's Research Corporation (ARC), Manchester, New Jersey, United States|The NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Princeton Medical Institute, Princeton, New Jersey, United States|University of Medicine and Dentistry of New Jersey, Stratford, New Jersey, United States|Shore Neurology, P.A., Toms River, New Jersey, United States|Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States|University of New Mexico, Health Sciences Center, Albuquerque, New Mexico, United States|Upstate Clinical Research, LLC, Albany, New York, United States|Neurological Associates of Albany, P.C., Albany, New York, United States|Neuroscience Research Center at Albany Medical Center, Albany, New York, United States|Social Psychiatry Research Institute, Brooklyn, New York, United States|Five Towns Neuroscience Research, Cedarhurst, New York, United States|Advanced Bio-Behavioral Sciences, Elmsford, New York, United States|Empire Neurology, PC, Latham, New York, United States|Neurological Care of CNY, Liverpool, New York, United States|Parker Jewish Institute for Health Care & Rehabilitation, New Hyde Park, New York, United States|NYU School of Medicine/Psychiatry, New York, New York, United States|Mt. Sinai School of Medicine, New York, New York, United States|Columbia University/Medical Center, New York, New York, United States|Dent Neurologic Institute, New York, New York, United States|Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States|University of Rochester Medical Center @ Monroe Community Hospital, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Clinical Trials of America, Inc, Hickory, North Carolina, United States|New Hope Clinical Research, Hickory, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Rakesh Ranjan, M.D. & Associates, Inc., Beachwood, Ohio, United States|Neuro-Behavioral Clinical Research, Inc, Canton, Ohio, United States|NeuroCare Center, Inc, Canton, Ohio, United States|University Memory and Aging Center University Hospitals of Cleveland/Case Medical Center, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Neurology Specialists, Inc., Dayton, Ohio, United States|Neurology and Neuroscience Center of Ohio, Toledo, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Red River Medical Research Center, LLC, Oklahoma City, Oklahoma, United States|Providence Medical Group-Medford Neurology, Medford, Oregon, United States|Summit Research Group, Inc., Portland, Oregon, United States|Providence Health Service System, AD Center, Brain Institute, Portland, Oregon, United States|Oregon Health & Sciences University, Portland, Oregon, United States|Abington Neurological Associates, Ltd, Abington, Pennsylvania, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Penn Memory Center, Philadelphia, Pennsylvania, United States|Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Clinical Trials Research Services, LLC, Pittsburg, Pennsylvania, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, N. Charleston, South Carolina, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|Neurology Clinic, PC, Cordova, Tennessee, United States|Psychiatric Consultants, PC, Franklin, Tennessee, United States|East Tennessee State University, Johnson City, Tennessee, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Senior Adults Specialty Research (SASR), Austin, Texas, United States|Texas Neurology, PA, Dallas, Texas, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States|University of North Texas/Health Sciences Center-Fort Worth, Fort Worth, Texas, United States|Claghorn-Lesem Research Clinic, Ltd., Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Integra Clinical Research, LLC, San Antonio, Texas, United States|Grayline Clinical Drug Trials, Inc, Wichita Falls, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|University of Utah, Dept of Neurology, Salt Lake City, Utah, United States|The Memory Clinic, Bennington, Vermont, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Innovative Clinical Research Center, Alexandria, Virginia, United States|University of Virginia, Charlottesville, Virginia, United States|Alliance Research Group, LLC, Richmond, Virginia, United States|University of Washington Veterans Affairs, Seattle, Washington, United States|Pacific Medical Centers, Seattle, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|University of Wisconson Medical School of Medicine and Public Health, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Independent Pyschiatric Consultants, Waukesha, Wisconsin, United States|Medizinische Universität Graz, Graz, Styria, Austria|Medizinische Universität Wien, Wien, Vienna, Austria|University of Calgary, Foothills Medical Centre, Calgary, Alberta, Canada|Medical Arts Health Research Group, Kamloops, British Columbia, Canada|Medical Arts Health Research Group, Kelowna, British Columbia, Canada|Medical Arts Health Research Group, Penticton, British Columbia, Canada|University of British Columbia (UBC) Hospital, Vancouver, British Columbia, Canada|Hotel Dieu Hospital/Queens University Memorial Clinics, Kingston, Ontario, Canada|Saint Joseph's Health Care London, Saint Joseph's Hospital, London, Ontario, Canada|Parkwood Hospital, London, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Kawartha Regional Memory Clinic, Peterborough, Ontario, Canada|Neurology Research Inch./Toronto Memory Program, Toronto, Ontario, Canada|Toronto Centre for Memory and Aging, Toronto, Ontario, Canada|Ontario Shores Centre for Mental Health Scienes, Whitby, Ontario, Canada|Neuro Rive-Sud Memory Clinic, Greenfield Park, Quebec, Canada|Hopital Maisonneuve-Rosemont, Comite d' ethique de la recherche, Montreal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|Diex Research Sherbrooke Inc., Sherbrooke, Quebec, Canada|Douglas Mental Health University Institute, Verdun, Quebec, Canada|Universitätsklinik Tübingen, Tübingen, Baden-wuerttemberg, Germany|Universitätsklinik Ulm, Ulm, Baden-wuerttemberg, Germany|Universitätsklinik Freiburg, Freiburg, Baden-Württemberg, Germany|Universitätsklinikum Ulm, Günzburg, Bayern, Germany|Ludwig-Maximilians-Universität München, München, Bayern, Germany|Klinikum Rechts der Isar der Technischen Universität München, München, Bayern, Germany|Universitätsklinikum Regensburg, Regensburg, Byern, Germany|Saint Josefs Hospital, Bochum, Nordrhein-westfalen, Germany|Universitätsklinikum des Saarlandes, Homburg/Saar, Saarland, Germany|AFL Arzneimittelforschung Leipzig GmbH, Leipzig, Sachen, Germany|ABX-CRO advanced pharmaceutical services Forschungsgesellschaft GmbH, Dresden, Saschen, Germany|UKE Hamburg, Hamburg, Germany",NA,https://ClinicalTrials.gov/show/NCT00574132
166,NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two",CARE-MS II,Completed,Has Results,"Multiple Sclerosis, Relapsing-Remitting",Biological: Alemtuzumab 12 mg|Biological: Alemtuzumab 24 mg|Biological: Interferon beta-1a,Percentage of Participants With Sustained Accumulation of Disability (SAD)|Annualized Relapse Rate|Percentage of Participants Who Were Relapse Free at Year 2|Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Year 2|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score at Year 2|Percent Change From Baseline in Magnetic Resonance Imaging Time Constant 2 (MRI-T2) Hyperintense Lesion Volume at Year 2,"Genzyme, a Sanofi Company|Bayer|Sanofi",All,18 Years to 55 Years   (Adult),Phase 3,840,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"CAMMS32400507|2007-001162-32|CAMMS324,|ISRCTN70702834|ACTRN12608000426381|NTR1469|CARE-MS II",October 2007,September 2011,September 2011,"October 24, 2007","January 8, 2015","April 17, 2017","North Central Neurology Associates, P.C., Cullman, Alabama, United States|Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Hope Research Institute, Phoenix, Arizona, United States|Mayo Clinic Arizona, Department of Neurology, Scottsdale, Arizona, United States|Northwest NeuroSpecialists, PLLC, Tucson, Arizona, United States|East Bay Physicians Medical Group/Sutter East Bay Medical Foundation, Berkeley, California, United States|Neurology Center of North Orange County, La Habra, California, United States|Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, United States|Neuro-Therapeutics Inc., Pasadena, California, United States|Neuro-Therapeutics, Inc, Pasadena, California, United States|University of California, Davis Medical Center, Sacramento, California, United States|Stanford University School of Medicine, Stanford, California, United States|University of Colorado Hospital, Anschutz Outpatient Pavilioin, Aurora, Colorado, United States|Neurological Consultants, Denver, Colorado, United States|Advanced Neurosciences Research, Fort Collins, Colorado, United States|Yale University, New Haven, Connecticut, United States|George Washington University Medical Faculty Associates, Washington, District of Columbia, United States|University of Florida Neuroscience Institute, Jacksonville, Florida, United States|Neurology Associates, P.A., Maitland, Florida, United States|Neurological Associates, Pompano Beach, Florida, United States|Negroski, Stein, Sutherland and Hanes Neurology, Sarasota, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|University of South Florida, Department of Neurology, Tampa, Florida, United States|Emory University, Department of Neurology, Atlanta, Georgia, United States|Shepherd Center, Inc., Atlanta, Georgia, United States|Idaho Falls Multiple Sclerosis Center, PLLC, Idaho Falls, Idaho, United States|University of Chicago Medical Center, Department of Neurology, Chicago, Illinois, United States|Consultants in Neurology, Ltd, Northbrook, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Indiana University School of Medicine, Department of Neurology, Indianapolis, Indiana, United States|Josephson Wallack Munshower Neurology P.C., Indianapolis, Indiana, United States|Iowa Health Physicians, Des Moines, Iowa, United States|Ruan Neurology Clinic and Research Center, Des Moines, Iowa, United States|University of Kansas Medical Center, Department of Neurology, Kansas City, Kansas, United States|MidAmerica Neuroscience Institute, Lenexa, Kansas, United States|Associates in Neurology, PSC, Lexington, Kentucky, United States|University of Louisville Research Foundation, Louisville, Kentucky, United States|Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States|Caritas St. Elizabeth's Medical Center, Boston, Massachusetts, United States|Partners Multiple Sclerosis Center/Brigham and Women's Hospital, Boston, Massachusetts, United States|Springfield Neurology Associates, LLC, Springfield, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan Department of Neurology, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Wayne State University, School of Medicine, Department of Neurology, Detroit, Michigan, United States|Spectrum Health Medical Group, Neurology (Previously known as Michigan Medical P.C., Neurology), Grand Rapids, Michigan, United States|Michigan Neurology Associates, P.C., St. Clair Shores, Michigan, United States|Northern Michigan Neurology, Traverse City, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Neurology Consultants of Kansas City, Inc., Kansas City, Missouri, United States|Montana Neurobehavioral Specialists, Missoula, Montana, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|Renown Institute for Neurosciences / Renown regional Medical Center, Reno, Nevada, United States|Dartmouth-Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|MS Center at Holy Name Hospital, Teaneck, New Jersey, United States|University of New Mexico, Health Sciences Center, MS Specialty Clinic, Alburquerque, New Mexico, United States|Empire Neurology, PC, Latham, New York, United States|Winthrop University Hospital, Clinical Trials Center, Mineola, New York, United States|Mount Sinai School of Medicine, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, New York, New York, United States|Comprehensive Multiple Sclerosis Care Center at South Shore Neurologic Associates, P.C., Patchogue, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|SUNY Upstate Medical University, Department of Neurology, Syracuse, New York, United States|University of North Carolina-Chapel Hill, Department of Neurology, Chapel Hill, North Carolina, United States|Wake Forest University Health Science, Department of Neurology, Winston-Salem, North Carolina, United States|Cleveland Clinic Foundation, Mellen Center, Cleveland, Ohio, United States|Neurology Specialists, Inc., Dayton, Ohio, United States|Oak Clinic for Multiple Sclerosis, Uniontown, Ohio, United States|MS Center of Oklahoma, Oklahoma City, Oklahoma, United States|Lehigh Valley Hospital, Neuroscience and Pain Research, Allentown, Pennsylvania, United States|Northshore Clinical Associates, Erie, Pennsylvania, United States|University of Pittsburgh, Kaufmann Medical Building, Pittsburgh, Pennsylvania, United States|The Neurology Foundation, Inc., Providence, Rhode Island, United States|Neurology Clinic, P.C., Cordova, Tennessee, United States|Advanced Neurosciences Institute, Franklin, Tennessee, United States|Biomedical Research Alliance of NY, LLC, Franklin, Tennessee, United States|Hope Neurology PC, Knoxville, Tennessee, United States|Vanderbilt Multiple Sclerosis Center, Nashville, Tennessee, United States|Clinical Center for Multiple Sclerosis, Dallas, Texas, United States|Central Texas Neurology, Round Rock, Texas, United States|Integra Clinical Research, San Antonio, Texas, United States|Neurology Center of San Antonio, San Antonio, Texas, United States|MS Center of Greater Washington, P.C., Vienna, Virginia, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Rockwood Clinical Research Center, Spokane, Washington, United States|DIABAID, Buenos Aires, Argentina|Westmead Hospital, Westmead, New South Wales, Australia|The Wesley Research Institute, Auchenflower, Queensland, Australia|Griffith School of Medicine, Gold Coast Campus, Griffith University, Southport, Queensland, Australia|Clinical Cognitive Research Unit/Clinical Trials, The Queen Elizabeth Hospital, Neurology Department, Woodville South, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|St. Vincent's Hospital, MS Education & Research, Department of Clinical Neurosciences, Fitzroy, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Royal Melbourne Hospital, Department of Neurology, Parkville, Victoria, Australia|Concord Repatriation General Hospital, Neurosciences Department, Concord, Australia|Southern Neurology, Kogarah, Australia|Liverpool Hospital, Neurology Department, Liverpool, Australia|AKH Wien, Universitätsklinikum für Neurologie, Wien, Austria|Cliniques Universitaires Saint-Luc, Neurology, Brussel, Belgium|CHU Ourthe Amblève, Neurology, Esneux, Belgium|University Hospital Leuven, Campus Gasthuisberg, Neurology, Leuven, Belgium|Hospital da Restauracao, Recife, PE, Brazil|Hospital Sao Lucas PUC-RS, Porto Alegre, RS, Brazil|Hospital de Clínicas USP, Sao Paulo, Brazil|Irmandade da Santa Casa de Misericordia de Sao Paulo, Sao Paulo, Brazil|UBC Hospital, Vancouver, British Columbia, Canada|Multiple Sclerosis Clinic, Connell 7, Kingston General Hospital, Kingston, Ontario, Canada|London Health Sciences Centre- University Hospital, London, Ontario, Canada|The Ottawa Hospital, General Campus, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Centre de Sante et de Services Sociaux de Gatineau-Hull Hospital, Gatineau, Quebec, Canada|Clinique Neuro rive-sud, Recherche sepmus inc, Greenfield park, Quebec, Canada|Hospital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|Clinical Hospital Centre Rijeka, Clinic for Neurology, Rijeka, Croatia|General Hospital Varazdin, Department of neurology, Varazdin, Croatia|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Clinical Hospital Sestre Milosrdnice, Zagreb, Croatia|General Hospital "" Sveti Duh"", Department of neurology, Zagreb, Croatia|MS Center, Department of Neurology, Hradec Kralove, Czech Republic|St. Anne's University Hospital Brno, Pekarska, Czech Republic|Department of Neurology 1st Faculty of Medicine and General Teaching Hospital, MS Center, Praha 2, Czech Republic|Krajska zdravotni a.s. - Hospital Teplice, Teplice, Czech Republic|Århus Universitetshospital, Scleroseklinikken, Århus Sygehus, Aarhus, Denmark|Scleroseklinikken, Rigshospitalet, København, Denmark|Odense University Hospital, Odense, Denmark|CHU Clermont-Ferrand, Hôpital Gabriel Montpied, Clermont-Ferrand, France|Hôpital General, Service de Neurologie, Dijon Cedex, France|Hospital Roger Salengro, Lille Cedex, France|Hôpital Pitié Salpétrière, Service de Neurologie, Paris, France|Sevice de Neurologie, Rennes Cedex, France|Hôpital Civil, Departement de Neurologie, Strasbourg Cedex, France|Krankenhaus Hohe Warte, Betriebsstätte der Bayreuth, Bayreuth, Germany|Judisches Krankenhaus Berlin, Berlin, Germany|Neurologisches Fachzentrum Berlin, Berlin, Germany|Neurologische Universitätsklinik Bonn, Bonn, Germany|Multiple Sklerose Zentrum am, Zentrum für klinische Neurowissenschaften, Neurologische Uniklinik Dresden, Dresden, Germany|Asklepios Klinic Barmbek, Hamburg, Germany|Medizinische Hochshule Hannover, Hannover, Germany|Oberhavelkliniken Hennigsdorf, Hennigsdorf, Germany|Klinikum Ingolstadt, Neurologische Klinik, Ingolstadt, Germany|Klinikum Rechts der Isar, Klinik für Neurologie, Muenchen, Germany|Klinik und Poliklinik fur Neurologie der Universitat Rockstock, Rostock, Germany|Universitatsklinik Ulm, Ulm, Germany|Fachkrankenhaus Hubertusburg, Wermsdorf, Germany|Hadassah Medical Center Ein Karem, Jerusalem, Israel|Tel Aviv Sourasky Medical Center, Department of Neurology, Tel Aviv, Israel|Sheba Medical Centre, Tel Hashomer, Israel|Ospedale Binaghi - Centro Sclerosi Multipla, Cagliari, Italy|Ospedale S. Antonio Abate di Gallarate, Gallarate, Italy|Università di Genova Dipartimento di Neuroscienze Oftalmologia e Genetica, Genova, Italy|Ospedale Civile di Brescia c/o Ospedale Richiedei, Centro di riferimento per la Sclerosi Multiple, Montichiari, Italy|Ospedale San Luigi di Orbassano, Orbassano, Italy|Azienda Ospedaliera Sant'Andrea Neurologia, Roma, Italy|Hospital Medica Sur CIF-BIOTEC, Delegacion, Tlalpan, Mexico|Unidad de Investigación en Salud de Chihuahua, S.C., Chihuahua, Mexico|Hospital Angeles del Pedregal; Camino a Santa Teresa, Mexico City, Mexico|Jeroen Bosch Ziekenhuis, Hertogenbosch, Netherlands|Orbis Medisch Centrum, Department of Neurology, Sittard, Netherlands|Independent Public Healthcare Facility, Norbert Barlicki University Hospital No. 1 of the Medical University of Lodz, Lodz, Poland|Independent Public Teaching Hospital No. 4 in Lublin, Lublin, Poland|Heliodor Swiecicki Teaching Hospital of the Poznan, University of Medical Sciences, Poznan, Poland|Research Medical Complex ""Your Health"" Ltd, Kazan, Russian Federation|Institution of the Russian Academy of Medical Sciences, ""Neurology Scientific Center under RAMS"", Moscow, Russian Federation|Moscow State Medical Institution City Clinical Hospital #11, Moscow City Center for Multiple Sclerosis, Moscow, Russian Federation|Moscow State Public Medical Institution, City Clinical Hospital #11, Moscow, Russian Federation|Municipal Treatment and Prevention Institution, ""City Hospital #33"", Nizhniy Novgorod, Russian Federation|Federal State Institution: Siberian District Medical Center, Novosibirsk, Russian Federation|State Medical Institution, ""Samara Regional Clinical Hospital n.a. M.I. Kalinin"", Samara, Russian Federation|Institution of the Russian Academy of Sciences, ""Institute of the Human Brain n.a. N.P. Bekhtereva within the Russian Academy of Sciences"", St. Petersburg, Russian Federation|St. Petersburg Pavlov State Medical University, Department of Neurology and Neurosurgery with a Clinic, St. Petersburg, Russian Federation|St.Petersburg State Medical Institution, ""City Multispecialty Hospital #2"", St. Petersburg, Russian Federation|St.Petersburg State Medical Institution, ""Nikolayevskaya Hospital"", St. Petersburg, Russian Federation|Clinic of Neurology, Clinical Centre of Serbia, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Clinical Centre of Kragujevac, Kragujevac, Serbia|Clinical Centre Vojvodina Institute of Neurology, Novi Sad, Serbia|Servicio de Neurología Hospital Vall d'Hebron Paseo de Vall d'Hebron, Barcelona, Spain|Servicio de Neurología Hospital Clínico San Carlos, Madrid, Spain|Servicio de Neurología Hospital Carlos Haya, Malaga, Spain|Servicio de Neurología Hospital Virgen de la Macarena, Sevilla, Spain|Sahlgrenska University Hospital, Neurologkliniken, Gothenburg, Sweden|Norrlands Universitets sjukhus, Umea, Sweden|Institute of Neurology, Psychiatry and Narcology under the Academy of Medical Sciences of Ukraine, Kharkov, Ukraine|Kyiv Municipal Clinical Hospital #4, Department of Demyelinating Diseases of the Nervous System, Kyiv, Ukraine|Danylo Halytsky Lviv National Medical University, Department of Neurology, Lviv, Ukraine|Department Of Neurosciences, Addenbrookes Hospital, Cambridge, England, United Kingdom|Centre for Neuroscience & Trauma, Blizard Institute of Cell and Molecular Science Barts and The London School of Medicine and Dentistry, London, England, United Kingdom|Frenchay Hospital, Bristol, United Kingdom|Salford Royal NHS Foundation Trust, Clinical Trials Unit, Salford, United Kingdom|Department of Neurology Glossop Road, Royal Hallamshire Hospital, Sheffield, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT00548405
167,NCT00545662,Study of Citicoline for the Treatment of Traumatic Brain Injury (COBRIT),COBRIT,Terminated,Has Results,Traumatic Brain Injury,Drug: Placebo|Drug: citicoline,Functional and Cognitive Outcome,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,1213,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BA-HD042|HD042687-04|HD042738-05|HD042678-03|HD042653-05|HD042689-05|HD042736-04|HD 042686-01A1|HD042652-04|HD042823-05,July 2007,May 2011,May 2011,"October 17, 2007","December 19, 2012","December 19, 2012","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|Temple University, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Tennessee Health Sciences Center, Memphis, Tennessee, United States|University of Texas, Southwestern Medical Center, Dallas, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States",NA,https://ClinicalTrials.gov/show/NCT00545662
168,NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One",CARE-MS I,Completed,Has Results,"Multiple Sclerosis, Relapsing-Remitting",Biological: Alemtuzumab|Biological: Interferon beta-1a,Percentage of Participants With Sustained Accumulation of Disability (SAD)|Annualized Relapse Rate|Percentage of Participants Who Were Relapse Free at Year 2|Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Year 2|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score at Year 2|Percent Change From Baseline in Magnetic Resonance Imaging Time Constant 2 (MRI-T2) Hyperintense Lesion Volume at Year 2,"Genzyme, a Sanofi Company|Bayer|Sanofi",All,18 Years to 50 Years   (Adult),Phase 3,581,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,CAMMS323|ISRCTN21534255|ACTRN12608000435381|CARE-MS I|2007-001161-14,August 2007,April 2011,April 2011,"September 17, 2007","November 24, 2014","November 24, 2014","North Central Neurology Associates, P.C., Cullman, Alabama, United States|Barrow Neurological Institute, St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|Northwest NeuroSpecialists, PLLC, Tucson, Arizona, United States|Advanced Neurosciences Research, Fort Collins, Colorado, United States|Neurological Associates, Pompano Beach, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Idaho Falls Multiple Sclerosis Center, PLLC, Idaho Falls, Idaho, United States|Consultants in Neurology, Ltd., Northbrook, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|MidAmerican Neuroscience Institute, Lenexa, Kansas, United States|Associates in Neurology, PSC, Lexington, Kentucky, United States|University of Louisville Research Foundation, Louisville, Kentucky, United States|Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Wayne State University, Detroit, Michigan, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of New Mexico, Health Sciences Center, MS Specialty Clinic, Albuquerque, New Mexico, United States|Empire Neurology, Latham, New York, United States|Comprehensive Multiple Sclerosis Care Center at South Shore Neurologic Associates, P.C., Patchogue, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Carolinas Medical Center (CMC), Neurosciences & Spine Institute (NSSI), Charlotte, North Carolina, United States|The Ohio State University Medical Center, Multiple Sclerosis Center, Columbus, Ohio, United States|Oak Clinic for Multiple Sclerosis, Uniontown, Ohio, United States|MS Center of Oklahoma, Oklahoma City, Oklahoma, United States|Lehigh Valley Hospital Neurosciences and Pain Research, Allentown, Pennsylvania, United States|Advanced Neurosciences Institute, Franklin, Tennessee, United States|Biomedical Research Alliance of NY, LLC, Franklin, Tennessee, United States|Hope Neurology PC, Knoxville, Tennessee, United States|Baylor College of Medicine, Maxine Mesinger MS Clinic, Houston, Texas, United States|Central Texas Neurology, Round Rock, Texas, United States|Integra Clinical Research, San Antonio, Texas, United States|Neurology Center of San Antonio, San Antonio, Texas, United States|DIABAID, Buenos Aires, Argentina|The Wesley Research Institute, Auchenflower, Queensland, Australia|Griffith University School of Medicine, Southport, Queensland, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|St Vincent's Hospital, Fitzroy, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Royal Melbourne Hospital, Department of Neurology, Ward 4 East, Parkville, Victoria, Australia|Concord Repatriation General Hospital, Concord, Australia|Westmead Hospital, Westmead, Australia|Hospital da Restauracao, Av Governador Agamenon Magalhaes, Recife, Pernambuco, Brazil|Hospital Sao Lucas PUC-RS, Porto Alegre, RS, Brazil|Hospital de Clínicas USP, Sao Paulo, SP, Brazil|University of Calgary and Foothills Medical Cenre, Calgary, Alberta, Canada|UBC Hospital, Vancouver, British Columbia, Canada|The Ottawa Hospital, General Campus, Ottawa, Ontario, Canada|Clinique Nuero-outaouais, Gatineau, Quebec, Canada|Clinique Neuro rive-sud, Recherche Sepmus, Inc., Greenfield park, Quebec, Canada|Clinical Hospital Centre Rijeka, Rijeka, Croatia|General Hospital Varazdin, Varazdin, Croatia|Clinical Hospital Centre ""Sestre Milosrdnice"", Zagreb, Croatia|Clinical Hospital Centre Zagreb, Zagreb, Croatia|General Hospital ""Sveti Duh"", Zagreb, Croatia|Department of Neurology, 1st Faculty of Medicine and General Teaching Hospital, Praha 2, Czech Republic|Krajska zdravotni a.s., Hospital Teplice, Teplice, Czech Republic|Hopital Purpan, Toulouse, France|Judisches Krankenhaus Berlin, Berlin, Germany|Universitätsklinik Carl Gustav Carus Dresden, Dresden, Germany|Klinikum der Goethe Universität Frankfurt, Frankfurt, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Oberhavelkliniken Hennigsdorf, Hennigsdorf, Germany|Asklepios Klinikum Brandenburg, Teupitz, Germany|Hospital Angeles del Pedregal, Camino de Santa Teresa, Mexico City, Mexico|Hospital Medica Sur CIF-BIOTEC, Mexico City, Mexico|Clinical Neurology Centre Sp. z o.o. (Ltd), Cracow, Poland|Independent Public Healthcare Facility, Norbert Barlicki University Hospital No. 1 of the Medical University of Lodz, Lodz, Poland|Independent Public Teaching Hospital No. 4 in Lublin, Lublin, Poland|Heliodor Swiecicki Teaching Hospital of the Poznan University of Medical Sciences, Poznan, Poland|Research Medical Complex ""Your Health"" Ltd, Kazan, Russian Federation|Moscow City Hospital #11, Moscow, Russian Federation|Moscow State Medical Institution City Clinical Hospital #11, Moscow, Russian Federation|Scientific Neurology Center RAMS, Moscow, Russian Federation|Municipal City Hospital #33, Nizhniy Novgorod, Russian Federation|Federal State Institution Siberian Rettitorial Medical Center under Federal Medical-Biological Agency of Russia, Novosibirsk, Russian Federation|City Clinical Hospital #2, Pyatigorsk, Russian Federation|Samara Regional Clinical Hospital n.a. Kalinin, Samara, Russian Federation|Institute of Human Brain RAS, St. Petersburg, Russian Federation|Nikolaevskaya Hospital, St. Petersburg, Russian Federation|St. Petersburg Pavlov State Medical University, St. Petersburg, Russian Federation|State Medical Institution: Republican Clinical Hospital n.a. G.G. Kuvatov, Ufa, Russian Federation|Clinical Centre Serbia, Institute for Neurology, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Clinical centre Kragujevac, Kragujevac, Serbia|Clinical Center Nis, Clinic for neurology, Nis, Serbia|Clinical Centre of Vojvodina, Clinic for neurology, Novi Sad, Serbia|Sahlgrenska University Hospital, Goteborg, Sweden|Chernihiv Regional Hospital, Chernihiv, Ukraine|Institute of Neurology, Psychiatry and Narcology under the Academy of Medical Sciences of Ukraine, Department of Neuroinfection and Multiple Sclerosis, Kharkiv, Ukraine|Hospoital of the Directorate of the Medical Corps within the Ukrainian Security Service, Neurology Department, Kyiv, Ukraine|Kyiv Municipal Clinical Hospital #4, Kyiv, Ukraine|Danylo Halytsky Lviv National Medical University, Lviv, Ukraine|Department Of Neurosciences, Addenbrookes Hospital, Cambridge, England, United Kingdom|Centre for Neuroscience & Trauma, Blizard Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, London, England, United Kingdom|University Hospital of Wales, Cardiff, Wales, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT00530348
169,NCT00459420,Caffeine for Excessive Daytime Somnolence in Parkinson's Disease,NA,Completed,No Results Available,Parkinson's Disease|Excessive Daytime Somnolence,Drug: Caffeine 100-200 mg BID|Drug: placebo,Change in Epworth Sleepiness Scale|Unified Parkinson Disease Rating Scale|Clinical Global Impression of Change|Pittsburgh Sleep Quality Index|Fatigue Severity Scale|Stanford Sleep Scale|PDQ-39|SF-36|Tolerability of Caffeine|Beck Depression Inventory,Ron Postuma|Canadian Institutes of Health Research (CIHR)|University of Toronto|McGill University Health Centre/Research Institute of the McGill University Health Centre,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,58,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GEN-06-68,April 2007,July 2011,July 2011,"April 12, 2007",NA,"April 16, 2015","Toronto Western Hospital, Toronto, Ontario, Canada|Montreal General Hospital, Montreal, Quebec, Canada",NA,https://ClinicalTrials.gov/show/NCT00459420
170,NCT00457730,A Study to Test the Use of Duloxetine for Pain in MS,NA,Completed,Has Results,Multiple Sclerosis,Drug: Duloxetine|Drug: Placebo,Percent Change in Worst Pain Score|Percent Change in Average Pain Score.|Global Impression of Change,"Brown, Theodore R., M.D., MPH|Eli Lilly and Company",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,38,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment",1083575|WIRB Protocol Number: 20061712,January 2007,August 2012,August 2012,"April 6, 2007","April 6, 2015","April 27, 2015","Evergreen Healthcare, Kirkland, Washington, United States",NA,https://ClinicalTrials.gov/show/NCT00457730
171,NCT00451451,Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis,CONFIRM,Completed,Has Results,Relapsing-Remitting Multiple Sclerosis,Drug: BG00012|Drug: Placebo|Drug: Glatiramer Acetate,Annualized Relapse Rate|Number of New or Newly Enlarging T2 Hyperintense Lesions|Number of New T1 Hypointense Lesions|Proportion of Subjects Relapsed|Proportion of Subjects Experiencing Progression of Disability Assessed Using the Expanded Disability Status Scale (EDSS),Biogen,All,18 Years to 55 Years   (Adult),Phase 3,1417,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",109MS302,June 2007,August 2011,August 2011,"March 23, 2007","June 2, 2014","January 26, 2015","Research Site, Birmingham, Alabama, United States|Research Site, Cullman, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, La Jolla, California, United States|Research Site, Loma Linda, California, United States|Research Site, Pasadena, California, United States|Research Site, Sacramento, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Boulder, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Fort Collins, Colorado, United States|Research Site, Maitland, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, Pompano Beach, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, Tallahassee, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Meridan, Idaho, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Kansas City, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Clinton Township, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Dover, New Hampshire, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Freehold, New Jersey, United States|Research Site, Teaneck, New Jersey, United States|Research Site, Amherst, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Cedarhurst, New York, United States|Research Site, Mineola, New York, United States|Research Site, Patchogue, New York, United States|Research Site, Plainview, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Bellevue, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Edmond, Oklahoma, United States|Research Site, Eugene, Oregon, United States|Research Site, Medford, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Souderton, Pennsylvania, United States|Research Site, Cordova, Tennessee, United States|Research Site, Franklin, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Galveston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Round Rock, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, Richmond, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Gomel, Belarus|Research Site, Minsk, Belarus|Research Site, Vitebsk, Belarus|Research Site, Lommel, Belgium|Research Site, Sijsele-Damme, Belgium|Research Site, Woluwe, Belgium|Research Site, Tuzla, B&H Federation, Bosnia and Herzegovina|Research Site, Banja Luka, Republic Srpska, Bosnia and Herzegovina|Research Site, Sarajevo B&H Federation, Bosnia and Herzegovina|Research Site, Plovdiv, Bulgaria|Research Site, Rousse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Edmonton, Canada|Research Site, London, Canada|Research Site, Montreal, Canada|Research Site, Osijek, Canada|Research Site, San Jose, Costa Rica|Research Site, Rijeka, Croatia|Research Site, Zagreb, Croatia|Research Site, Ostrava-Moravska, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Kuressaare, Estonia|Research Site, Parnu, Estonia|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Caen, France|Research Site, Dijon, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Nancy, France|Research Site, Nimes, France|Research Site, Strasbourg, France|Research Site, Bamberg, Germany|Research Site, Bayreuth, Germany|Research Site, Berg Starnberger, Germany|Research Site, Berlin, Germany|Research Site, Dusseldorf, Germany|Research Site, Erbach, Germany|Research Site, Erlangen, Germany|Research Site, Giessen, Germany|Research Site, Halle (Saale), Germany|Research Site, Hanburg, Germany|Research Site, Heidelberg, Germany|Research Site, Koln, Germany|Research Site, Magdeburg, Germany|Research Site, Marburg, Germany|Research Site, Munchen, Germany|Research Site, Regensburg, Germany|Research Site, Schwerin, Germany|Research Site, Athens, Greece|Research Site, Larisa, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Calicut, India|Research Site, Chandigarh, India|Research Site, Chennai, India|Research Site, Cochin, India|Research Site, Coimbatore, India|Research Site, Kochi, India|Research Site, Kolkata, India|Research Site, Lucknow, India|Research Site, Ludhiana, India|Research Site, Mangalore, India|Research Site, Mumbai, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Cork, Ireland|Research Site, Dublin, Ireland|Research Site, Galway, Ireland|Research Site, Holon, Israel|Research Site, Safed, Israel|Research Site, Riga, Latvia|Research Site, Skopje, Macedonia, The Former Yugoslav Republic of|Research Site, Guadalajara, Jal, Mexico|Research Site, Morelia, Michoacan, Mexico|Research Site, Monterrey, Nuevo Leon, Mexico|Research Site, Aguascalientes, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico DF, Mexico|Research Site, Mexico DF, Mexico|Research Site, Mexico, Mexico|Research Site, Monterray, Mexico|Research Site, Chisinau, Moldova, Republic of|Research Site, Kishinev, Moldova, Republic of|Research Site, Hamilton, New Zealand|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Katowice, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Szczecin, Poland|Research Site, Warsaw, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Guaynabo, Puerto Rico|Research Site, Bucuresti, Romania|Research Site, Iasi, Romania|Research Site, Oradea, Romania|Research Site, Tirgu Mures, Romania|Research Site, Tirgu-Mures, Romania|Research Site, Belgrade, Serbia|Research Site, Kragujevac, Serbia|Research Site, Nis, Serbia|Research Site, Novi Sad, Serbia|Research Site, Kosice, Slovakia|Research Site, Martin, Slovakia|Research Site, Barcelona, Spain|Research Site, Bilbao, Spain|Research Site, Cordoba, Spain|Research Site, Gandia, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Sevilla, Spain|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Odessa, Ukraine|Research Site, Poltava, Ukraine|Research Site, Simferopol, Ukraine|Research Site, Zaporozhye, Ukraine",NA,https://ClinicalTrials.gov/show/NCT00451451
172,NCT00449865,NET-PD LS-1 Creatine in Parkinson's Disease,NA,Terminated,Has Results,Parkinson's Disease,Drug: creatine|Other: placebo,"The Global Outcome Combined Information on Change From Baseline in Schwab England Activities of Daily Living, 39-Item Parkinson's Disease Questionnaire, Ambulatory Capacity, Symbol Digit Modalities, and Modified Rankin at 5 Years.",University of Rochester|National Institute of Neurological Disorders and Stroke (NINDS),All,"Child, Adult, Older Adult",Phase 3,1741,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS43128 NET-PD|CRC,March 2007,September 2013,May 2014,"March 21, 2007","April 2, 2015","April 2, 2015","University Of Alabama, Birmingham, 350 Sparks Center, 1720 7th Avenue South, Birmingham, Alabama, United States|Barrow Neurological Clinics At, St Joseph's Hospital & Medical Center, 500 West Thomas Road Suite 720,, Phoenix, Arizona, United States|Parkinson's & Movement Disorder Institute, 9940 Talbert Avenue, Suite 204,, Fountain Valley, California, United States|University Of Southern California, Healthcare Consultation Building II, 1520 San Pablo Street Suite 3000, Los Angeles, California, United States|University Of California San Francisco, Parkinson's Disease Clinic And Research Cen, 505 Parnassus Avenue M-798, San Francisco, California, United States|The Parkinson's Institute, 675 Almanor Avenue, Sunnyvale, California, United States|University Of Colorado Health Sciences Ctr, 4200 East 9th Avenue Campus Box C238, Department Of Clinical Pharmacy, Denver, Colorado, United States|Neurodegenerative Disorders, 60 Temple Street Suite 8b, New Haven, Connecticut, United States|VA Medical Center, 1601 Southwest Archer Road, Neurology Service (151), Gainesville, Florida, United States|University Of Florida, Mcknight Brain Institute, 100 South Newell Drive Room L3-100, Gainesville, Florida, United States|University Of Florida Jacksonville, 580 West 8th Street, Tower 1 8th Floor,, Jacksonville, Florida, United States|University Of Miami, 1501 North West 9th Avenue Second Floor, Department Of Neurology D4-5, Miami, Florida, United States|University Of South Florida, Movement Disorders Center, 5 Tampa General Circle Suite 410, Tampa, Florida, United States|Emory University, Wesley Woods Health Center, 1841 Clifton Road NE Room 328, Atlanta, Georgia, United States|Medical College Of Georgia, Movement Disorders Clinic, 1429 Harper Street HF 1121, Augusta, Georgia, United States|Pacific Health Research Institute, 405 North Kuakini Street, Suite 1011,, Honolulu, Hawaii, United States|Northwestern University, 710 North Lake Shore Drive, Chicago, Illinois, United States|Rush University Medical Center, Department Of Neurological Sciences, 1725 West Harrison Suite 755,, Chicago, Illinois, United States|Evanston Northwestern Healthcare, Department Of Neurology, 2100 Pfingsten Road Suite B110, Glenview, Illinois, United States|Southern Illinois University School Of Medicine, PO Box 19645, Springfield, Illinois, United States|Indiana University School Of Medicine, Outpatient Clinical Research Facility, 535 Barnhill Drive Room #150, Indianapolis, Indiana, United States|University Of Kansas Medical Center, 3599 Rainbow Blvd, Department Of Neurology Mail Stop # 2012, Kansas City, Kansas, United States|University Of Kentucky Clinical Research, C201 Kentucky Clinic, 740 South Limestone Street, Lexington, Kentucky, United States|Ochsner Clinic Foundation, 1514 Jefferson Highway, Dept. Of Neurology 7th Floor, New Orleans, Louisiana, United States|LSU Health Science Center Shreveport, 1501 Kings Highway, Room 3-436, Shreveport, Louisiana, United States|University Of Maryland School Of Medicine, Department Of Neurology, 22 South Greene Street N4W46, Baltimore, Maryland, United States|Johns Hopkins University, 601 North Caroline Street, Suite 5064, Baltimore, Maryland, United States|Brigham & Women's Hospital, Neurology Department ASB2, 75 Francis Street, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, 330 Brookline Avenue Shapiro 809D, Boston, Massachusetts, United States|University Of Michigan, 1500 E Medical Center Drive, B1 H202 Nuclear Medicine,, Ann Arbor, Michigan, United States|Michigan State University, Department Of Neurology A217 Clinical Center, 138 Service Road, East Lansing, Michigan, United States|Struthers Parkinson's Center, 6701 Country Club Drive,, Golden Valley, Minnesota, United States|Washington University School Of Medicine, 660 South Euclid Avenue, Campus 8111,, St Louis, Missouri, United States|Dartmouth Hitchcock Medical Center, One Medical Center Drive, 2 Buck Road, Lebanon, New Hampshire, United States|UMDNJ Robert Wood Johnson Medical School, Dept Of Neurology Suite 6100, 125 Paterson Street, New Brunswick, New Jersey, United States|SUNY Downstate Medical Center, 450 Clarkson Avenue, Department Of Neurology Box 1213, Brooklyn, New York, United States|Northshore-LIJ Health System, The Feinstein Institute FPR Medical Research, 350 Community Drive Room,, Manhasset, New York, United States|Duke University Medical Center, Duke Health Center At Morreene Road, 932 Morreene Road Room 213,, Durham, North Carolina, United States|OHSU Oregon Health &Science University, Department Of Neurology, 3181 South West Sam Jackson Park Road, Portland, Oregon, United States|Thomas Jefferson University, 1015 Chestnut Street Suite 520, Philadelphia, Pennsylvania, United States|University of Pennsylvania; Pennsylvania Hospital, Penn Neurological Institute, 330 South Ninth Street, Philadelphia, Pennsylvania, United States|Thomas Jefferson University/Lankenau Hospital, Lankenau Medical Building Suite 161 East, 100 Lancaster Avenue, Wynnewood, Pennsylvania, United States|Medical University Of South Carolina, Charleston Memorial Hospital, 326 Calhoun Street Suite 308, Charleston, South Carolina, United States|Vanderbilt University Medical Center, 2311 Pierce Avenue, Room 2217,, Nashville, Tennessee, United States|University Of Texas Southwestern Med Ctr. At Dallas, 5323 Harry Hines Boulevard H1-108, Dallas, Texas, United States|Baylor College Of Medicine, 6550 Fannin Suite 1801, Houston, Texas, United States|University Of Vermont, Department Of Neurology , Given Building C-219, 89 Beaumont Avenue, Burlington, Vermont, United States|University Of Virginia Neurology Fontaine, Department Of Neurology, 500 Ray C Hunt Drive, Charlottesville, Virginia, United States|University Of Calgary Movement Disorders Program, Dept Of Clin Neurosciences Area 3 Neurology, 3350 Hospital DR NW Health Sciences Centre, Calgary, Alberta, Canada|University Of Alberta, 10230-111 Avenue Room 0601, Movement Disorders Clinic Glenrose Rehab Hospital, Edmonton, Alberta, Canada",NA,https://ClinicalTrials.gov/show/NCT00449865
173,NCT00420212,Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis,DEFINE,Completed,Has Results,Relapsing-Remitting Multiple Sclerosis,Drug: BG00012|Drug: Placebo,Proportion of Subjects Relapsed|Number of New or Newly Enlarging T2 Hyperintense Lesions|Number of Gadolinium-enhancing T1-weighted Lesions|Number of Subjects With Gadolinium (Gd)-Enhancing Lesions|Annualized Relapse Rate|Proportion of Subjects Experiencing Progression of Disability Assessed Using the Expanded Disability Status Scale (EDSS),Biogen,All,18 Years to 55 Years   (Adult),Phase 3,1234,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",109MS301,January 2007,February 2011,February 2011,"January 11, 2007","June 2, 2014","January 26, 2015","Research Site, Gilbert, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, San Francisco, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Vero Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Evanston, Illinois, United States|Research Site, Palos Heights, Illinois, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Des Moines, Iowa, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Brighton, Massachusetts, United States|Research Site, Hopedale, Massachusetts, United States|Research Site, Lexington, Massachusetts, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Columbia, Missouri, United States|Research Site, St. Louis, Missouri, United States|Research Site, Henderson, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Albany, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Dayton, Ohio, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, East Providence, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Research Site, San Antonio, Texas, United States|Research Site, Newport News, Virginia, United States|Research Site, Wien, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Chatswood, New South Wales, Australia|Research Site, Fitzroy, Australia|Research Site, Geelong, Australia|Research Site, Heidelberg, Australia|Research Site, Kogarah, Australia|Research Site, Liverpool, Australia|Research Site, Melbourne, Australia|Research Site, Newcastle, Australia|Research Site, Wien, Vienna, Austria|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Antwerpen, Belgium|Research Site, Brugge, Belgium|Research Site, Charleroi, Belgium|Research Site, Diepenbeek, Belgium|Research Site, Leuven, Belgium|Research Site, Lommel, Belgium|Research Site, Sijsele-Damme, Belgium|Research Site, Woluwe, Belgium|Research Site, Banja Luka, Republic of Srpksa, Bosnia and Herzegovina|Research Site, Burnaby, British Columbia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Levis, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Montreal, Canada|Research Site, Zagreb, Croatia|Research Site, Brno, Czech Republic|Research Site, Jihlava, Czech Republic|Research Site, Opava, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Plzen, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Teplice, Czech Republic|Research Site, Clermont Ferrand, France|Research Site, Nice, France|Research Site, Paris, France|Research Site, Rennes, France|Research Site, Bad Neustadt-Saale, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Dusseldorf, Germany|Research Site, Essen, Germany|Research Site, Gieben, Germany|Research Site, Halle, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Leipzig, Germany|Research Site, Minden, Germany|Research Site, Munchen, Germany|Research Site, Munster, Germany|Research Site, Osnabruck, Germany|Research Site, Westerstede, Germany|Research Site, Athens, Greece|Research Site, Ioannina, Greece|Research Site, Thessaloniki, Greece|Research Site, Guatemala City, Guatemala|Research Site, Chenna, India|Research Site, Coimbatore, India|Research Site, Delhi, India|Research Site, Hyderabad, India|Research Site, Kolkata, India|Research Site, Lucknow, India|Research Site, Mangalore, India|Research Site, Mumbai, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Ashkelon, Israel|Research Site, Beer Yaakov, Israel|Research Site, Jerusalem, Israel|Research Site, Tel Hashomer, Israel|Research Site, Roma, Italy|Research Site, Skopje, Macedonia, The Former Yugoslav Republic of|Research Site, Guadalajara, Mexico|Research Site, Mexico City, Mexico|Research Site, San Luis Potosi, Mexico|Research Site, Chisinau, Moldova, Republic of|Research Site, Kishinev, Moldova, Republic of|Research Site, Breda, Netherlands|Research Site, Sittard, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Grafton, New Zealand|Research Site, Hamilton, New Zealand|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Poznan, Poland|Research Site, Szczecin, Poland|Research Site, Warsaw, Poland|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Timisoara, Romania|Research Site, Belgrade, Serbia|Research Site, Kragujevac, Serbia|Research Site, Nis, Serbia|Research Site, Novi Sad, Serbia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Martin, Slovakia|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Rosebank, South Africa|Research Site, Basel, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Zurich, Switzerland|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Odessa, Ukraine|Research Site, Poltava, Ukraine|Research Site, Zaporozhye, Ukraine|Research Site, London, United Kingdom|Research Site, Newcastle, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Staffordshire, United Kingdom|Research Site, Vienna, Virgin Islands (U.S.)",NA,https://ClinicalTrials.gov/show/NCT00420212
174,NCT00355134,Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis,FREEDOMS II,Completed,Has Results,Multiple Sclerosis,Drug: Fingolimod|Drug: Placebo,Aggregate Annualized Relapse Rate (ARR) Estimate up to Month 24|Aggregate Annualized Relapse Rate (ARR) Estimate up to End of Study|Percent Change From Baseline in Brain Volume|Number of New or Newly Enlarged T2 Lesions|Number of Gadolinium-enhanced T1 Lesions|Change From Baseline in Lesion Volume at Month 24 (Core Phase)|Percentage of Participants Free of 3-month Confirmed Disability Progression at Month 24 and End of Study|Percentage of Participants Free of 6-month Confirmed Disability Progression at Month 24 and End of Study|Percentage of Participants Relapse-free up to Month 24|Percentage of Participants Relapse-free up to End of Study|Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Z-score,Novartis,All,18 Years to 55 Years   (Adult),Phase 3,1083,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CFTY720D2309,June 2006,June 2011,August 2011,"July 21, 2006","June 26, 2012","August 7, 2012","University of Alabama Birmingham, Birmingham, Alabama, United States|North Central Neurology Associates, PC, Cullman, Alabama, United States|University of South Alabama - Dept of Neurology, Mobile, Alabama, United States|Barrow Neurology Clinic, Phoenix, Arizona, United States|Research and Education Institute of Alta Bates Summit Medical Center, Berkeley, California, United States|University of California - Irvine, Deptarment of Neurology, Irvine, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|The Neurology Center, Oceanside, California, United States|Neuro-Therapeutics, Inc., Pasadena, California, United States|UC Davis Medical Center, Sacramento, California, United States|Multiple Sclerosis Center at UCSF, San Francisco, California, United States|University of Colorado, Denver, Colorado, United States|Associated Neurologists, PC, Danbury, Connecticut, United States|Associated Neurologists of Southern CT, P.C., Fairfield, Connecticut, United States|Yale University - Yale Multiple Sclerosis Center, New Haven, Connecticut, United States|Georgetown University Hospital - Dept of Neurology, Washington, District of Columbia, United States|Sunrise Clinical Research, Inc., Hollywood, Florida, United States|University of Florida Health Sciences Center/Shands Jacksonville, Jacksonville, Florida, United States|Neurology Associates, PA, Maitland, Florida, United States|University of Miami, Department of Neurology, Miami, Florida, United States|Neurological Associates, Pompano Beach, Florida, United States|Roskamp Institute, Clinical Trials Division, Sarasota, Florida, United States|Neurology Clinical Research, Inc, Sunrise, Florida, United States|AMO Corporation, Tallahassee, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|The MS Center of Vero Beach, Vero Beach, Florida, United States|MS Center of Atlanta, Atlanta, Georgia, United States|Medical College of Georgia, Augusta, Georgia, United States|Northwestern University Medical School - Dept of Neurology, Chicago, Illinois, United States|Rush University Medical Center Department of Neurological Sciences, Chicago, Illinois, United States|University of Chicago - Dept of Neurology, Chicago, Illinois, United States|Alexian Brothers Neurosciences Research, Elk Grove Village, Illinois, United States|South Suburban Neurology, Flossmoor, Illinois, United States|Neurologic Associates, Ltd., Palos Heights, Illinois, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Ruan Neurology Clinical Research Center, Des Moines, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Mid America Neuroscience Institute, Lenexa, Kansas, United States|Kentucky Research Associates, Louisville, Kentucky, United States|University of Maryland, Baltimore, Maryland, United States|Johns Hopkins MS Center, Baltimore, Maryland, United States|Caritas St. Elizabeth's Medical Center, Brighton, Massachusetts, United States|Newton Wesley Hospital, Newton, Massachusetts, United States|Springfield Neurology, Springfield, Massachusetts, United States|UMass Memorial Medical Center, Worchester, Massachusetts, United States|University of Michigan Mulitiple Sclerosis Clinic, Ann Arbor, Michigan, United States|Wayne State University MS Clinic, Detroit, Michigan, United States|Henry Ford Hospital, Department of Neurology, Detroit, Michigan, United States|Michigan State University MS Clinic, East Lansing, Michigan, United States|Michigan Medical, P.C., Grand Rapids, Michigan, United States|Michigan Neurology Associates, PC, St. Clair Shores, Michigan, United States|St. Luke's Hospital - Mid-America Brain and Stroke Institute, Kansas City, Missouri, United States|The MS Center for Innovation in Care, St. Louis, Missouri, United States|Institute for Neurosciences, Reno, Nevada, United States|Multiple Sclerosis Center, Lebanon, New Hampshire, United States|Gimbel Multiple Sclerosis Center at Holy Name Hospital, Teaneck, New Jersey, United States|University of New Mexico Health Science Center, Albuquerque, New Mexico, United States|Empire Neurology, PC, Latham, New York, United States|NYU Hospital for Joint Diseases, New York, New York, United States|Cornell University - NY Presbyterian Hospital, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Island Neurological Associates, PC, Plainview, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Alpha Neurology, Staten Island, New York, United States|SUNY Stony Brook, Stony Brook, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|UNC - Chapel Hill Neuroscience Hospital, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Neurology & Neuroscience Associates, Inc., Akron, Ohio, United States|Northern Ohio Neuroscience, LLC., Bellevue, Ohio, United States|NeuroCare Center, Inc, Canton, Ohio, United States|River Hills Health Care, Cincinnati, Ohio, United States|Ohio State University, Columbus, Ohio, United States|University of Toledo Health Science Campus, Toledo, Ohio, United States|Oak Clinic, Uniontown, Ohio, United States|MS Center of Oklahoma, Mercy Neuroscience Institute, Oklahoma City, Oklahoma, United States|Neurologial Associates of Tulsa, Tulsa, Oklahoma, United States|Oregon Neurology, Tualatin, Oregon, United States|University of Pennsylvania, Department of Neurology, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Department of Neurology, Philadelphia, Pennsylvania, United States|Allegheny Neurological Associates, Pittsburgh, Pennsylvania, United States|University of Pittsburgh - Dept of Neurology, Pittsburgh, Pennsylvania, United States|Absher Neurology, Greenville, South Carolina, United States|Mountain Empire Neurological Associates, PC, Bristol, Tennessee, United States|Advanced Neurosciences Institute, Nashville, Tennessee, United States|Vanderbilt Stallworth Rehabilitation Hospital, Nashville, Tennessee, United States|University of Texas - Houston Medical School, Houston, Texas, United States|Investigational Site - Private Practice, Lubbock, Texas, United States|Integra Clinical Research, LLC, San Antonio, Texas, United States|Neurology Health Care Service - Fletcher Allen Hospital, Burlington, Vermont, United States|University of Virginia - Fontaine Adult Neurology, Charlottesville, Virginia, United States|Virginia Mason Multiple Sclerosis Center, Seattle, Washington, United States|Seattle Neuroscience Institute at Swedish Medical Center, Seattle, Washington, United States|University Health Associates - West Virgina University, Morgantown, West Virginia, United States|Dean Foundation, Madison, Wisconsin, United States|University of Wisconsin Medical School, Madison, Wisconsin, United States|St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Novartis Investigative Site, North Gosford, New South Wales, Australia|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Warsaw, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Targu Mures, Romania|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Yenisehir/Izmir, Turkey|Novartis Investigative Site, Bristol, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT00355134
175,NCT00349622,Clinical Trial Ceftriaxone in Subjects With ALS,NA,Completed,Has Results,Amyotrophic Lateral Sclerosis|ALS,Drug: ceftriaxone|Other: placebo,"Survival|Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year|Change in % Vital Capacity From Screening to One Year|Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year|Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year|Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year",Massachusetts General Hospital|National Institute of Neurological Disorders and Stroke (NINDS),All,"18 Years and older   (Adult, Older Adult)",Phase 3,513,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",U01NS049640-02|NINDS|NINDS CRC,July 2006,November 2012,November 2012,"July 7, 2006","April 1, 2014","April 21, 2014","Phoenix Neurological Associates, Phoenix, Arizona, United States|University of California, Davis, Davis, California, United States|University of California, San Francisco- Fresno, Fresno, California, United States|Loma Linda University School of Medicine (CA), Loma Linda, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Irvine - MDA ALS Neuromuscular Center, Orange, California, United States|California Pacific Medical Center, San Francisco, California, United States|University of California, San Francisco, San Francisco, California, United States|University of Colorado Health Sciences Center, Aurora, Colorado, United States|Hospital for Special Care, New Britain, Connecticut, United States|George Washington University, Washington, District of Columbia, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|ALS Center at Emory University, Atlanta, Georgia, United States|Medical College of Georgia, Augusta, Georgia, United States|Northwestern University Medical School, Chicago, Illinois, United States|Indiana University (Regenstrief Health Center), Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Saint Mary's Healthcare, Grand Rapids, Michigan, United States|Hennepin County Medical Center (Berman Center), Minneapolis, Minnesota, United States|St. Louis University, St. Louis, Missouri, United States|Washington University, St. Louis, Missouri, United States|Bryan LGH Medical Center (University of Nebraska), Lincoln, Nebraska, United States|UMDNJ- Robert Wood Johnson School of Medicine, New Brunswick, New Jersey, United States|Albany Medical Center, Albany, New York, United States|Beth Israel Medical Center (NY), New York, New York, United States|Cornell Medical Center, New York, New York, United States|Columbia University, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Clinic (Providence Clinic), Portland, Oregon, United States|Pennsylvania State University, Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University College of Medicine (Hahnemann Campus), Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|Texas Neurology, Dallas, Texas, United States|Methodist Neurological Institute, Houston, Texas, United States|University of Utah Health Sciences Center, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|University of Calgary, Calgary, Alberta, Canada|Univeristy of Alberta ALS Clinic, Edmonton, Alberta, Canada|Dalhousie University, Halifax, Nova Scotia, Canada|London Health Sciences Center, University Campus, London, Ontario, Canada|University of Toronto, Toronto, Ontario, Canada|CHUM (Centre Hospitalier de l'Université de Montréal), Notre-Dame Hospital, Montreal, Quebec, Canada|Montreal Neurological Institute (McGill University), Montreal, Quebec, Canada|Laval University, Quebec City, Quebec, Canada",NA,https://ClinicalTrials.gov/show/NCT00349622
176,NCT00340834,Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase,TRANSFORMS,Completed,Has Results,Multiple Sclerosis,Drug: Fingolimod 1.25 mg|Drug: Fingolimod 0.5 mg|Drug: Interferon β-1a 30 µg,Estimated Annualized Aggregate Relapse Rate (ARR) in the Core Phase of the Study|Number of New or Newly Enlarged T2 Lesions in Comparison With Baseline in the Core Phase of the Study|Percentage of Participants Free of 3-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Core Phase of the Study|Estimated Annualized Aggregate Relapse Rate (ARR) in the Core and Extension Phases of the Study|Number of New or Newly Enlarged T2 Lesions in the Extension Phase of the Study|Percentage of Participants Free of 3-month and 6-month Disability Progression Assessed With the Expanded Disability Status Scale (EDSS) at the End of the Extension Phase of the Study,Novartis,All,18 Years to 55 Years   (Adult),Phase 3,1292,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",CFTY720D2302|CFTY720D2302E1,May 2006,July 2011,July 2011,"June 21, 2006","May 16, 2011","September 21, 2017","North Central Neurology Associates, PC, 1809 Kress Street, Cullman, Alabama, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|The Neurology Center, 3907 Waring Road, Suite 3, Oceanside, California, United States|Associated Neurologists, PC, 69 Sand Pit Road, Suite 300, Danbury, Connecticut, United States|Associated Neurologists of Southern CT, PC, 75 Kings Highway Cutoff, Fairfield, Connecticut, United States|Yale University Multiple Sclerosis Center, New Haven, Connecticut, United States|University of Florida Health Science Center, Jacksonville, Florida, United States|Neurology Associates, PA, 301 N. Maitland Avenue, Suite A1, Maitland, Florida, United States|University of Miami, Department of Neurology, Miami, Florida, United States|Neurological Associates, Pompano Beach, Florida, United States|Roskamp Institute, 2040 Whitfield Ave., Sarasota, Florida, United States|AMO Corporation, Tallahassee, Florida, United States|Axiom Clinical Research of Florida, 2919 Swann Avenue, Suite 401, Tampa, Florida, United States|University of South Florida, Department of Neurology, Tampa, Florida, United States|The MS Center of Vero Beach, Vero Beach, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Mid America Neuroscience Institute, 8550 Marshall Drive, Suite 100, Lenexa, Kansas, United States|University Physician Group, #1 Barnes-Jewish Hospital Plaza, Suite 16304, Saint Louis, Missouri, United States|Neuroscience and Spine Center, Charlotte, North Carolina, United States|Raleigh Neurology Associates, 1540 Sunday Drive, Raleigh, North Carolina, United States|Neurology & Neuroscience Associates, Inc, Akron, Ohio, United States|Northern Ohio Neuroscience, LLC, Bellevue, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Oregon Neurology, Tualatin, Oregon, United States|University of Pittsburgh, Department of Neurology, Pittsburgh, Pennsylvania, United States|Absher Neurology, 274-A Commonwealth Drive, Greenville, South Carolina, United States|Mountain Empire Neurological Associates, PC, 3183 West State Street, Suite 1201, Bristol, Tennessee, United States|Advanced Neurosciences Institute, Franklin, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|Private Practice, 3815 23rd Street, Lubbock, Texas, United States|Integra Clinical Research, 4242 Medical Drive, Suite 6100, San Antonio, Texas, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Rockwood Clinic, P.S., Spokane, Washington, United States|West Virginia University Health Associates, Morgantown, West Virginia, United States|Center for Neurological Disorders - Aurora St. Luke's Med Center, Milwaukee, Wisconsin, United States|Ineba, Guarda Vieja 4435, Capital Federal, Buenos Aires, Argentina|Fundacion Rosarina de Neurorehabilitacion, Rosario, Santa Fe, Argentina|Instituto de Neurociencias de Rosario, Rosario, Santa Fe, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Fundacion Lenox Cordoba, Cordoba, Argentina|Hospital J. M. Ramos Mejia, General Urquiza 609, Buenos Aires, Argentina|FLENI, Montaneses 2325, Buenos Aires, Argentina|Strategic Health Evaluators, Chatswood, New South Wales, Australia|Royal Prince Alfred Hospital, Department of Medicine, Level, Missenden R, Camperdown, New South Wales, Australia|Liverpool Hospital, Neurology Department, Health Services Building, 4th Floor, Goulburn and Campbell Street, Liverpool, New South Wales, Australia|Gosford Private Hospital, North Gosford, New South Wales, Australia|St George Private Hospital, Suite 7E, Level 5, South Street, Kogarah, New South Wales, Australia|Box Hill Hopsital, Level 3, 16 Arnold Street, Box Hill, Victoria, Australia|Royal Melbourne Hospital, Suite 30, Grattan St., Parkbville, Victoria, Australia|Landesklinikum St. Poelten, Probst-Ruehrer-Str. 4, St. Poelten, Sankt Poelten, Austria|Landes-Narvenklinik Wagner-Jauregg, Abteilung fuer Neurologie, Linz, Austria|Universitätsklinik f. Neurologie Innsbruck, Anichstrasse 35, Innsbruck, Austria|Landes-Nervenklinik Christian Doppler Klinik, Ignaz Harrerstr. 79 , Salzburg, Austria|Evangel.Krankenh./Wien-Waehring Außenstelle, Vienna, Austria|Univ.-Klinik fuer Neurologie AKH, Vienna, Austria|Cliniques Universitaires Saint Luc, Avenue Hippocrate 10, Bruxelles, Belgium|UZ Brussel, Laarbeeklaan 101, Brussels, Belgium|Nationaal Multiple Sclerose Centrum v.z.w, Melsbroek, Belgium|Regionaal Ziekenhuis Sint-Trudo - Campus Sint-Jozef, Sint-Truiden, Belgium|Hospital Sao Rafael, Salvador, BA, Brazil|Hospital das Clincas - UNICAMP, Campinas, SP, Brazil|Hospital das Clinicas da FMRPUSP, Ribeirao Preto, SP, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Hospital dos Servidores do Estado, Rio de Janeiro, Brazil|Hospital Universitario Gaffree e Guinle, Rio de Janeiro, Brazil|Fraser Health MS Clinic, Burnaby Hospital, 3935 Kincaid Street, Vancouver, British Columbia, Canada|UBC MS Research, 2211 Westbrook Mall, Vancouver, British Columbia, Canada|Nepean Medical Centre, 1 Centrepointe Drive, Suite 407, Ottawa, Ontario, Canada|St. Michael's Hospital, Chief, Division of Neurology, 30 Bond Street,Suite 3007 - Shuter Wing, Toronto, Ontario, Canada|Centre Hospitalier Universitaire de Sherbrooke, 3001 12th Avenue North, Fleurimont, Quebec, Canada|Charles Lemoyne Hospital, Greenfield Park, Quebec, Canada|CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada|Montreal Neurological Institute, 3801 University Street, Montreal, Quebec, Canada|The Ottawa General Hospital, 501 Smyth Rd., Ottawa, Canada|Private Clinic, 48 Sidi Gaber St., Alexandria, Egypt|35, Dokki St., Apt. 4, Cairo, Egypt|Al Azhar University, 11 Talaat Harb St, Fourth Floor, Apt 18, Cairo, Egypt|Private Clinic, 35 Dokki St., Apt. 4, Cairo, Egypt|Private Clinic, 7 Batal Ahmed Abdelaziz St Abdeen, Cairo, Egypt|Hopital La Timone Cpcet, Rue Jean Moulin, Marseille, France|Hopital Central, 29 Avenue du Marechal de Lattre de Tassigny, Nancy, France|Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux Cedex, France|Hopital De Purpan, Place du Dr. Baylac, Toulouse Cedex, France|Centre Hospitalier de Poissy, 10 rue du Champ Gaillard, Poissy, France|Hoppital Pasteur, Archet II, 30 avenue de la Voie, Romaine, France|Investigational Site, Bamberg, Germany|Investigational Site, Berlin, Germany|Investigational Site, Berlin, Germany|Investigational Site, Bremen, Germany|Investigational Site, Buchholz, Germany|Investigational Site, Dresden, Germany|Investigational Site, Dusseldorf, Germany|Investigational Site, Erbach/Odenwald, Germany|Investigational Site, Essen, Germany|Investigational Site, Freiburg, Germany|Investigational Site, Greifswald, Germany|Investigational Site, Hamburg, Germany|Investigational Site, Hannover, Germany|Investigational Site, Heidelberg, Germany|Investigational Site, Hennigsdorf, Germany|Investigational Site, Koeln, Germany|Investigational Site, Lengerich, Germany|Investigational Site, Mainz, Germany|Investigational Site, Muenchen, Germany|Investigational Site, Munchen, Germany|Investigational Site, Potsdam, Germany|Investigational Site, Teupitz, Germany|Investigational Site, Trier, Germany|Investigational Site, Tubingen, Germany|Investigational Site, Ulm, Germany|Investigational Site, Ulm, Germany|Investigational Site, Wermsdorf, Germany|Investigational Site, Wurzburg, Germany|Univ. Hospital of Heraklion, Voutes, Heraklion, Crete, Greece|Errikos Dinan General Hospital, 107 Mesogion Ave., Athens, Greece|General Hospital of Athens G. Gennimatas, 154 Mesogeion Ave., Athens, Greece|Metropolitan Hospital, Ethnarchou Makariou 6 & Eleftheriou Venizelou 1, Athens, Greece|General University Hospital of Patra-RIO, Patra - RIO, Greece|Ahepa University General Hospital of Thessaloniki, 1 Stilp. Kyriakidi Str., Thessaloniki, Greece|Debreceni Egyetem Orvos es Egszstd. Centr., Debrecen, Hungary|Petz Aladár Megyei Oktató Kórház, Györ, Hungary|Veszprem Megyei Csolnoky Ferenc Korhaz, Korhaz u. 1, Veszprem, Hungary|Pecsi Tudomanyegyetem Neurologiai Klinika, Pecs, Hungary|Peterfy Sandor u. Hospital, Neurology, u. 8-20m, Budapest, Hungary|Uzsoki korhaz, Uzsoki u. 29., Budapest, Hungary|Azienda Sanitaria Osp. S. Luigi, Gonzaga, Orbassano, Italy|Ospedale S. Antonio Abate, via Pastori, 4, Gallarate, VA, Italy|Presidio Ospedaliero Roberto Binaghi, Cagliari, Italy|Azienda Ospedaliera Universitaria Arcispedale Sant'Anna, Ferrara, Italy|Presidio Ospedaliero di Vaio Fidenza, Fidenza, Italy|Osp. Magg. Pol. Mangiagalli e Regina Elena - Fond. IRCCS, Milano, Italy|Az. Osp. Niguarda Ca' Granda, Milano, Italy|Presidio Ospedaliero di Montichiari, Montichiari, Italy|IRCCS Neurologico C. Mondino, Pavia, Italy|Az. Osp. Ospedale Consorziale e Policlinico, piazza Giulio Cesare, 11 Bari, Italy|Az. Osp. Ospedale S. Martino - Università degli Studi, via Antonio De Toni, 5, Genova, Italy|Ist. Neurol. Mediterraneo Neuromed, Via Atinense, 18, Pozzilli, Italy|Ospedali Riuniti Umberto I - GM Lancisi - G.Salesi, via Conca, 71, Torrette di Ancona, Italy|Osp. Clinicizzato Colle dell'Ara - Università G. D'Annunzio, via dei Vestini, 5 Chieti, Italy|Azienda Ospedaliera Sant'Andrea - Università La Sapienza, Via di Grottarossa, 1035/1039, Roma, Italy|Azienda Ospedaliera di Padova - Università degli Studi, Via Giustiniani, 2, Padova, Italy|Az. Osp. Universitaria Policlinico Tor Vergata, via Montpellier, 1, Roma, Italy|Ospedale San Raffaele - IRCCS, via Olgettina, 48/60, Milano, Italy|Policlinico - Università degli Studi Federico II, via Pansini, 5, Napoli, Italy|Istituto di Scienze Neurologiche Università di Catania, via Santa Sofia, 78, Catania, Italy|Ospedale Bellaria Maggiore, via Toscana Nazionale, 17/19, Bologna, Italy|Azienda Ospedaliera Careggi - Università degli Studi, Viale Giovan Battista Morgagni, 85, Firenze, Italy|National Cancer Center, 809 Madu 1-dong, Ilsan-gu, Kyunggi, Goyang, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Korea, Republic of|Yonsei Univ. Med. Center,Severance Hospital, 134 Shinchon-dong, Suedaemoon-ku, Seoul, Korea, Republic of|Kyung Pook National University Hospital, Taegu, Korea, Republic of|Hospital Fernando Fonseca, Amadora, Portugal|Hospitais da Universidade de Coimbra, Av. Dr. Bissaya Barreto, Coimbra, Portugal|Hospital Sto. António dos, Capuchos, Portugal|Hospital de São João, Porto, Portugal|Hospital de S. Bernardo, Rua Camilo Castelo Branco, Setubal, Portugal|Complejo Hospitalario Carlos Haya, Avda. Carlos Haya, s/n, Málaga, Spain|Hospital Universitario Virgen Macarena, Avenida Dr. Fedriani, 3, Sevilla, Spain|Ciutat Sanitaria I, Universitaria De Bellvitge, c/o Feixa Llarga, Hospitalet de Llobregat, Barcelona, Spain|Hospital de Basurto, Bilbao, Spain|Hospital Clinico San Carlos, C/ Dr. Martin Lagos, s/n, Madrid, Spain|Unitat de Neuroimmunologia Clinica, Hospital Vall d'Hebron, EUI-planta 2, Pg. Vall d'Hebron 119-29, Barcelona, Spain|Puerta de Huerro Univeristy Hospital, San Martin de Porres, 4, Madrid, Spain|Hospital Universitario La Fe., Valencia, Spain|Universitätsspital Zuerich, Neurologische Klinik, Frauenklinikstrasse 26, Zuerich, Switzerland|Universitätsspital Basel, Neurochirugishen Poliklinik, Petersgraben 4, Basel, Switzerland|Novartis, Investigational Site, United Kingdom|Charing Cross Hospital, London, United Kingdom|The Walton Centre for Neurology and Neurosurgery, Lower Lane, Fazakerly, Liverpool, United Kingdom|Norfolk & Norwich University Hospital, Norwick, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT00340834
177,NCT00331890,ICTUS Study: International Citicoline Trial on Acute Stroke,ICTUS,Terminated,No Results Available,Acute Stroke|Cerebral Infarction,Drug: Citicoline|Drug: Placebo,"Total recovery at three months of onset, based on a global test analysis including NIHSS, mRS and Barthel Index|mRS at 3 months|Barthel Index at 3 months|Safety and tolerability",Ferrer Internacional S.A.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2298,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GF-ICTUS-04,October 2006,February 2012,March 2012,"May 31, 2006",NA,"June 20, 2012","Klinikum AltenburgerLand GmbH, Altenburg, Germany|Neurologie EVKB, Bielefeld, Germany|Neurologische Klinik Heinrich-Heine Universität, Dusseldorf, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Ernst-Moritz-Arndt-Universität Greifswald, Greifswald, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Neurologische Klinik Universitatsklinikum Heidelberg, Heidelberg, Germany|Klinikum Ingolstadt, Ingolstadt, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Johannes Wesling Klinikum Minden, Minden, Germany|Klinikum Großhadern der Universität München, München, Germany|Universitätsklinikum Münster, Münster, Germany|Hospital Garcia de Orta, EPE, Almada, Portugal|Hospital Garcia de Orta, Almada, Portugal|Hospital Fernando Fonseca, Amadora - Sintra, Portugal|Hospital Sao Marcos, Braga, Portugal|Hospitais da Universidade Coimbra, Coimbra, Portugal|Centro Hospitalar de Coimbra, Coimbra, Portugal|Hospital de Sao Jose, Lisbon, Portugal|Hospital de Santa Maria, Lisbon, Portugal|Hospital de Santo Antonio, Porto, Portugal|Hospital de Sao Joao, Porto, Portugal|Hospital Sao Sebastiao, Santa Maria da Feira, Portugal|Centro Hospitalar de Setúbal, Setubal, Portugal|Centro Hospitalar de Setúbal, EPE, Setúbal, Portugal|Hospital Sao Pedro, Vila Real, Portugal|Hospital Son Dureta, Palma de Mallorca, Baleares, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital de Mataro, Mataro, Barcelona, Spain|Consorci Hospitalari Parc Tauli, Sabadell, Barcelona, Spain|Hospital Moises Broggi, Sant Joan Despi, Barcelona, Spain|Hospital Clinico Universitario de Santiago, Santiago de Compostela, La Coruña, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|Hospital Meixoeiro, Vigo, Pontevedra, Spain|Hospital de Cruces, Barakaldo, Vizcaya, Spain|Hospital de Basurto, Bilbao, Vizcaya, Spain|Hospital General de Albacete, Albacete, Spain|Hospital del Mar, Barcelona, Spain|Hospital de la Santa Creu I Sant Pau, Barcelona, Spain|Hospital Sagrat Cor, Barcelona, Spain|Hospital Vall d´Hebron, Barcelona, Spain|Hospital General Yague, Burgos, Spain|Hospital San Pedro de Alcantara, Caceres, Spain|Hospital de Girona Dr. Josep Trueta, Girona, Spain|Hospital de Leon, Leon, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Complejo Hospitalario Xeral Calde, Lugo, Spain|Hospital de La Princesa, Madrid, Spain|Hospital Universitario Gregorio Marañon, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Central de Defensa (del Aire), Madrid, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitario Nuestra Señora De Valme, Sevilla, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Clinico Universitario, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Clínico de Valladolid, Valladolid, Spain|Hospital Universitario, Valladolid, Spain",NA,https://ClinicalTrials.gov/show/NCT00331890
178,NCT00235716,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease",TEAM-AD,Completed,Has Results,Alzheimer's Disease,Drug: dl-alpha-tocopherol|Drug: Memantine|Drug: Placebo,Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS/ADL) Inventory Change From Baseline|Mini-Mental State Examination Change From Baseline|Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) Change From Baseline|Neuropsychiatric Inventory Change From Baseline|Caregiver Activity Survey Change From Baseline|Dependence Scale: Time to Event Analysis (Increase of of One Dependence Level),"US Department of Veterans Affairs|Forest Laboratories|DSM Nutritional Products, Inc.|VA Office of Research and Development",All,"40 Years and older   (Adult, Older Adult)",Phase 3,613,U.S. Fed|Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",546,August 2007,September 2012,October 2012,"October 10, 2005","January 29, 2014","July 23, 2014","VA Medical Center, Bay Pines, Bay Pines, Florida, United States|VA Medical Center, Miami, Miami, Florida, United States|VA Medical Center, Iowa City, Iowa City, Iowa, United States|VA Maryland Health Care System, Baltimore, Baltimore, Maryland, United States|VA Medical Center, Jamaica Plain Campus, Boston, Massachusetts, United States|VA Ann Arbor Healthcare System, Ann Arbor, Michigan, United States|VA Medical Center, Minneapolis, Minneapolis, Minnesota, United States|Salisbury VAMC, Salisbury, North Carolina, United States|VA Medical Center, Cleveland, Cleveland, Ohio, United States|Ralph H Johnson VA Medical Center, Charleston, Charleston, South Carolina, United States|VA North Texas Health Care System, Dallas, Dallas, Texas, United States|VA Puget Sound Health Care System, Seattle, Seattle, Washington, United States|Wlliam S. Middleton Memorial Veterans Hospital, Madison, Madison, Wisconsin, United States|VA Medical Center, San Juan, San Juan, Puerto Rico",NA,https://ClinicalTrials.gov/show/NCT00235716
179,NCT00235495,Albumin in Acute Ischemic Stroke Trial,ALIAS,Terminated,Has Results,Ischemic Stroke,Biological: Albumin|Drug: Saline,The Number of Participants With Favorable Outcome Defined as National Institute of Health Stroke Scale (NIHSS) Score of 0-1 and/or Modified Rankin Scale (mRS) of 0-1.|Number of Participants With a Composite Outcome of mRS 0-1 and/or NIHSS 0-1 and/or Decrease in NIHSS From Baseline by 10 or More Points|Number of Participants With a NIHSS of 0-1 at 24 Hours|Number of Participants With a NIHSS 0-1 at 90 Days.|The Number of Participants With a Score on the mRS 0-1 at 90 Days.|The Number of Participants With a Score on the mRS of 0-2 at 90 Days.|Number of Participants With a Favorable Outcome Per Modified Rankin Scare (mRS)|Barthel Index (BI) 95-100|Number of Participants With an EuroQol (EQ-5D) Favorable Score < 0.78|Number of Participants With a Stroke Specific Quality of Life Scale (SSQOL) Score of >=3|Trailmaking A|Trailmaking B|Number of Participants With Neurological Deterioration Within 48 Hours|Neurological Death Within 7 Days|Recurrent Ischemic Stroke Within 30 Days|Atrial Fibrillation Within 48 Hours|Pulmonary Edema Within 48 Hours|Shortness of Breath Within 48 Hours|Symptomatic Intracerebral Hemorrhage (ICH) Within 24 Hours|Asymptomatic ICH Within 24 Hours|Death Within 30 Days|Death Within 90 Days,University of Miami|National Institute of Neurological Disorders and Stroke (NINDS)|University of Calgary|Medical University of South Carolina|Neurological Emergencies Treatment Trials Network (NETT),All,"18 Years to 83 Years   (Adult, Older Adult)",Phase 3,841,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20060083|U01NS054630|NIH NINDS 5U01 NS040406-08|20060233,June 2006,February 2013,February 2013,"October 10, 2005","September 11, 2019","December 17, 2019","Mayo Clinic Hospital, Phoenix, Arizona, United States|University of Arizona Medical Center-South Campus, Tucson, Arizona, United States|University of Arizona Medical Center, Tucson, Arizona, United States|John Muir Medical Ctr-Concord, Concord, California, United States|El Camino Hospital, Mountain View, California, United States|UCSF Medical Center, San Francisco, California, United States|UCSF-San Francisco General Hospital, San Francisco, California, United States|California Pacific Medical Center, Davies Campus, San Francisco, California, United States|California Pacific Medical Center, Pacific Campus, San Francisco, California, United States|O'Connor Hospital, San Jose, California, United States|UCLA Medical Center, Santa Monica, Santa Monica, California, United States|Stanford University Medical Center, Stanford, California, United States|John Muir Medical Ctr-Walnut Creek, Walnut Creek, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Christiana Hospital, Newark, Delaware, United States|University of Florida/Shands, Jacksonville, Florida, United States|Jackson Memorial Hospital, University of Miami, Miami, Florida, United States|The Villages Research Group, Ocala, Florida, United States|Neuroscience Research Institute at Florida Hospital Orlando, Orlando, Florida, United States|Intercoastal Neurology/Medical Research Center, Sarasota, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Loyola University Medical Center, Maywood, Illinois, United States|St. Elizabeth Medical Center South, Edgewood, Kentucky, United States|St. Elizabeth Hospital, Florence, Kentucky, United States|University of Kentucky Hospital, Lexington, Kentucky, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Upper Chesapeake Medical Center, Bel Air, Maryland, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Sinai-Grace Hospital, Detroit, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|University of Minnesota Medical Center Fairview, Minneapolis, Minnesota, United States|HealthEast Care System/St. Joseph's Hospital, Saint Paul, Minnesota, United States|Saint Louis University, Saint Louis, Missouri, United States|Atlantic Neuroscience Institute, Overlook Hospital, Summit, New Jersey, United States|New York Methodist Hospital, Brooklyn, New York, United States|Buffalo General Medical Center, Buffalo, New York, United States|Mercy Hospital of Buffalo, Buffalo, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Columbia University Medical Center, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Med Health and Hospitals, Raleigh, North Carolina, United States|Christ Hospital, Cincinnati, Ohio, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Good Samaritan Hospital, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Mercy Health Fairfield Hospital, Fairfield, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|OHSU Legacy Emmanuel Hospital, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Sacred Heart Medical Center, Springfield, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Hahnemann University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Seton Medical Center, Austin, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Memorial Hermann Texas Medical Center, Houston, Texas, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|Froedtert Memorial Hospital, Milwaukee, Wisconsin, United States|Foothills Hospital, University of Calgary, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Grey Nuns Community Hospital, Edmonton, Alberta, Canada|Royal Island Hospital, Kamloops, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Science Centre, Halifax, Nova Scotia, Canada|London Health Sciences Centre-University Hospital, London, Ontario, Canada|Trillium Health Centre, Mississauga, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, Canada|University of Toronto, St. Michael's Hospital, Toronto, Ontario, Canada|Hopital Charles LeMoyne, Centre de Recherche, Greenfield Park, Quebec, Canada|Centre de Sante et de Service Sociaux de Chicoutimi, Saguenay, Quebec, Canada|Helsinki University Central Hospital, Helsinki, Finland|Tampere University Hospital, Tampere, Finland|Hadassah Medical Organization, Hadassah University Hospital, Ein Kerem, Jerusalem, Israel|Chaim Sheba Medical Center at Tel-Hashomer, Tel Hashomer, Ramat Gan, Israel|Soroka Medical Center, Beer Sheva, Israel|Rambam Health Care Campus, Haifa, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel",NA,https://ClinicalTrials.gov/show/NCT00235495
180,NCT00211887,Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx,NA,Completed,Has Results,Relapsing Remitting Multiple Sclerosis,Drug: Interferon beta 1-a|Drug: glatiramer acetate|Other: placebo,ARR - PDEs|Confirmed Progression on the Expanded Disability Status Scale|Change in the Multiple Sclerosis Functional Composite|Change in MRI Composite Score,Fred Lublin|National Institute of Neurological Disorders and Stroke (NINDS)|Icahn School of Medicine at Mount Sinai,All,18 Years to 60 Years   (Adult),Phase 3,1008,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GCO 02-0526|02-0526|CRC|U01NS045719,January 2005,April 2012,March 2013,"September 21, 2005","April 3, 2014","April 3, 2014","University of Alabama - Birmingham, Birmingham, Alabama, United States|Barrow Neurology Clinic, Phoenix, Arizona, United States|Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States|Northwest Neurospecialists PLLC, Tucson, Arizona, United States|Sutter East Bay Medical Group, Berkeley, California, United States|Neurology Center North Orange County, La Habra, California, United States|VA West Los Angeles Healthcare Center, Los Angeles, California, United States|University of California - Davis Medical Center, Sacramento, California, United States|Alpine Clinical Research Center, Boulder, Colorado, United States|Patricia Fodor P.C., Colorado Springs, Colorado, United States|University of Colorado Health Sciences Center, Denver, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Neurology Associates, PA, Maitland, Florida, United States|University of Miami - Neurology, Miami, Florida, United States|MS Center of Atlanta, Atlanta, Georgia, United States|Shepherd Center, Atlanta, Georgia, United States|Northwest University, Chicago, Illinois, United States|Consultants in Neurology - Multiple Sclerosis Center, Northbrook, Illinois, United States|University of Illinois College of Medicine, Peoria, Illinois, United States|Ruan Neurology Clinic and Research Center, Des Moines, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Maryland Center for MS, Baltimore, Maryland, United States|Tufts-New England Medical Center, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Minneapolis Clinic - MS Center, Golden Valley, Minnesota, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|St. Louis University - St. Louis VA, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Northern Rockies MS Center, Billings, Montana, United States|Dartmouth Medical School, Lebanon, New Hampshire, United States|CentraState Medical Center, Freehold, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Neuro Associates of Albany, PC, Albany, New York, United States|Albany Medical College, Albany, New York, United States|The Jacobs Neurological Institute, Buffalo, New York, United States|Winthrop Neurology Faculty Practice, Mineola, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|NYU Hospital For Joint Diseases, New York, New York, United States|South Shore Neurologic Associates Inc., Patchogue, New York, United States|University of Rochester, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|CMC-Neuroscience & Spine Institute, Division of Neurology, MS Center, Charlotte, North Carolina, United States|Meritcare Neuroscience, Fargo, North Dakota, United States|NeuroCare Center, Inc., Canton, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Neurology Specialists, Dayton, Ohio, United States|Medical College Of Ohio, Toledo, Ohio, United States|Oak Clinic for Multiple Sclerosis, Uniontown, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny MS Treatment Center, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas - Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Neurological Research Center, Inc., Bennington, Vermont, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Neurological Associates, Inc., Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|MS Center at Evergreen, Seattle, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Regional MS Center at St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Foothills Medical Centre, Calgary, Alberta, Canada|Capital Health and the University of Alberta, Edmonton, Alberta, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|St. Michael's Hospital-Multiple Sclerosis Research Center, Toronto, Ontario, Canada",NA,https://ClinicalTrials.gov/show/NCT00211887
181,NCT00091949,Insulin Resistance Intervention After Stroke Trial,IRIS,Completed,Has Results,Stroke|Myocardial Infarction|Diabetes,Drug: pioglitazone|Drug: placebo,"Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction|Fatal or Non-fatal Stroke Alone|Acute Coronary Syndrome|Development of Overt Diabetes|All Cause Mortality|Decline in Cognitive Status|Composite Outcome of Fatal or Non-fatal Stroke, Fatal or Non-fatal MI or Episode of Serious Congestive Heart Failure","Yale University|National Institute of Neurological Disorders and Stroke (NINDS)|Takeda Pharmaceuticals North America, Inc.",All,"40 Years and older   (Adult, Older Adult)",Phase 3,3876,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",0201013034|5U01NS044876-10,February 2005,November 2015,November 2015,"September 22, 2004","October 28, 2016","April 27, 2020","University of Alabama, Birmingham, Alabama, United States|University of South Alabama, Mobile, Alabama, United States|University of Arizona, Tucson, Arizona, United States|Shanti Clinical Trials (NINDS-CRC site), Colton, California, United States|UCSF-Fresno, Fresno, California, United States|Scripps Clinic, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|University of California-Davis, Sacramento, California, United States|University of California, San Diego, California, United States|University of California, San Francisco, California, United States|Denver Health and Hospital Authority, Denver, Colorado, United States|Hartford, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|National Rehabilitation Hospital, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|University of Florida, Jacksonville, Florida, United States|MIMA Century Research Associates, Melbourne, Florida, United States|Pines Neurological Associates (NINDS-CRC site), Pembroke Pines, Florida, United States|Floria Neurovascular Institute, Tampa, Florida, United States|Cook County (Stroger) Hospital, Chicago, Illinois, United States|Rush University, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|Ingalls Memorial Hospital (NINDS-CRC site), Harvey, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|Tri-City Neruology (NINDS-CRC site), Saint Charles, Illinois, United States|Indiana Medical Research, Elkhart, Indiana, United States|Associates In Neurology (NINDS-CRC site), Valparaiso, Indiana, United States|Iowa Health Des Moines Clinical Trials Office, Des Moines, Iowa, United States|Ruan Neuroscience Center/Mercy Medical Center, Des Moines, Iowa, United States|University of Iowa, Iowa City, Iowa, United States|Northeast Iowa Medical Education Foundation (NINDS-CRC site), Waterloo, Iowa, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|University of Kentucky Research Foundation, Lexington, Kentucky, United States|Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States|Penobscot Bay Neurology, Rockport, Maine, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University, Boston, Massachusetts, United States|Caritas St. Elizabeth's Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Minneapolis Clinic of Neurology, Robbinsdale, Minnesota, United States|Hattiesburg Clinic (NINDS-CRC site), Hattiesburg, Mississippi, United States|St. Luke's Brain and Stroke Institute, Kansas City, Missouri, United States|Washington University, Saint Louis, Missouri, United States|St. John's Mercy Medical Center, Saint Louis, Missouri, United States|St. Louis University, Saint Louis, Missouri, United States|Billings Clinic, Billings, Montana, United States|Advanced Neurology Specialists, Great Falls, Montana, United States|University of Nebraska, Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cooper University Hospital, Camden, New Jersey, United States|Kessler Medical Rehab Research Corp, West Orange, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Albany Medical Center, Albany, New York, United States|SUNY Downstate, Brooklyn, New York, United States|New York Methodist Hospital, Brooklyn, New York, United States|SUNY Buffalo, Buffalo, New York, United States|St. Vincent's Hospital Manhattan, New York, New York, United States|Cornell University, New York, New York, United States|University of Rochester, Rochester, New York, United States|Southtowns Neurology of WNY (NINDS-CRC site), West Seneca, New York, United States|Burke Medical Research Institute, White Plains, New York, United States|Clinical Research of Winston-Salem, Winston-Salem, North Carolina, United States|Guilford Neurologic Associates, Winston-Salem, North Carolina, United States|Altru Health System, Grand Forks, North Dakota, United States|University of Cincinnati, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Metrohealth Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Lankenau Institute for Medical Research, Bryn Mawr, Pennsylvania, United States|Penn Stat-Hershey Medical Center (NINDS-CRC site), Hershey, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|Allegheny Singer Research Institute, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|University of Tennessee, Memphis, Tennessee, United States|Vanderbilt, Nashville, Tennessee, United States|Baylor Research Institute, Dallas, Texas, United States|University of Texas, Southwestern, Dallas, Texas, United States|Methodist Neurological Institute, Houston, Texas, United States|University of Texas, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Vermont, Burlington, Vermont, United States|University of Virginia, Charlottesville, Virginia, United States|Sentara Medical Group, Norfolk, Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Flinders Medical Centre, Bedford Park, New South Wales, Australia|Royal Prince Alfred, Camperstown, New South Wales, Australia|John Hunter Hospital (University of Newcastle), New Lambton Heights, New South Wales, Australia|Box Hill Hospital (Eastern Health), Box Hill, Victoria, Australia|Western Hospital (University of Melbourne), Footscray, Victoria, Australia|Austin Health (National Stroke Research Institute), Heidelberg Heights, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Royal Perth, Perth, Western Australia, Australia|University of Alberta, Edmonton, Alberta, Canada|Center for Neurologic Research, Lethbridge, Alberta, Canada|Vancouver Island Health Research Centre, Victoria, British Columbia, Canada|Robarts Research Institute, London, Ontario, Canada|Ottawa Hospital-General Campus, Ottawa, Ontario, Canada|Intermountain Research Consultants, Thunder Bay, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Hôpital Charles LeMoyne, Greenfield Park, Quebec, Canada|McGill-Montreal General, Montreal, Quebec, Canada|McGill-Jewish General, Montreal, Quebec, Canada|Centre Hospitalier Affilie Universitaire de Quebec, Quebec City, Quebec, Canada|CHUM-Centre de recherche, Hôpital Notre-Dame, Montreal, Canada|Klinikum Altenburger Land, Altenburg, Germany|Neurologische Klinik, Bad Neustadt, Germany|University Hospital-Dresden, Dresden, Germany|University Duesseldorf/Heinrich-Heine University, Duesseldorf, Germany|University of Erlangen, Erlangen, Germany|Alfried Krupp Hospital, Essen, Germany|University Hospital Frankfurt, Frankfurt, Germany|Freiburg University, Freiburg, Germany|Ernst-Moritz-Arndt-University Greifswald, Griefswald, Germany|Martin-Luther-Universitaet Halle-Wittenberg, Halle, Germany|University Medical Center Hamburg-Eppendorf, Hamburg, Germany|University Heidelberg, Heidelberg, Germany|Friedrich Schiller-University Jena, Jena, Germany|University Hospital Mainz, Mainz, Germany|University Hospital Muenster, Muenster, Germany|Klinikum der Universitat Muenchen, Munich, Germany|University of Ulm, Ulm, Germany|Soroka Medical Center, Beer Sheva, Israel|B'nai Zion Medical Center, Haifa, Israel|Bnai-Zion Medical Center, Haifa, Israel|Rambam Medical Center, Haifa, Israel|Wolfson Medical Center, Holon, Israel|Rabin Medical Center-Golda Campus, Petach Tikva, Israel|Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Medical Center, Tel Aviv, Israel|Genoa University Hospital, Genoa, Italy|University of Laquila, Laquila, Italy|University Vita Salute San Raffaele, Milan, Italy|IRCCS FONdazione Istituto Neurologico C. Mondino, Pavia, Italy|University of Perugia, Perugia, Italy|University of Rome (S. Andrea Hospital), Roma, Italy|University of Rome La Sapienza, Rome, Italy|Sacred Heart Catholic University, Rome, Italy|Jazzolino Hospital, Vibo Valentia, Italy|University of Puerto Rico, San Juan, Puerto Rico|Royal Bournemouth, Bournemouth, Dorset, United Kingdom|Queen Elizabeth The Queen Mother Hospital, Margate, Kent, United Kingdom|Blackpool Victoria Hospital, Blackpool, Lancashire, United Kingdom|Wansbeck General Hospital, Ashington, Northumberland, United Kingdom|Stobhill Hospital, Glasgow, Scotland, United Kingdom|Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom|Southern General Hospital, Glasgow, Scotland, United Kingdom|Queen Elizabeth Hospital Gateshead, Gateshead, Tyne And Wear, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Monklands Hospital, Airdrie, United Kingdom|William Harvey Hospital, Ashford, United Kingdom|Royal United Hospital, Bath, United Kingdom|Addenbrookes Foundation NHS Trust (Cambridge), Cambridge, United Kingdom|Countess of Chester Foundation Trust, Cheshire, United Kingdom|Dewsbury District Hospital, Dewsbury, United Kingdom|Southend University Hospital, Essex, United Kingdom|Devon PCT, Exeter, United Kingdom|Royal Devon and Exeter, Exeter, United Kingdom|Royal Surrey County Hospital, Guildford, United Kingdom|Calderdale Royal Hospital, Halifax, United Kingdom|The Royal Liverpool and Broadgreen University Hospitals, Liverpool, United Kingdom|University Hospital Aintree, Liverpool, United Kingdom|Kings College London, London, United Kingdom|Saint Georges University of London, London, United Kingdom|Luton and Dubstable Hospital, Luton, United Kingdom|James Cook University Hospital, Middlesbrough, United Kingdom|Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom|Torbay Hospital (South Devon Healthcare NHS Foundation Trust), Torquay, United Kingdom|North Tyneside General Hospital, Tyne And Wear, United Kingdom",NA,https://ClinicalTrials.gov/show/NCT00091949
182,NCT00059332,Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial,FAST-MAG,Completed,Has Results,Cerebrovascular Accident,Drug: Magnesium Sulfate|Drug: Normal Saline,Modified Rankin Scale|Modified Rankin Score of 0 or 1|Modified Rankin Score ≤2|NIH Stroke Scale|Barthel Index|Stroke Impact Scale|Serious Adverse Events|Symptomatic Intracranial Hemorrhage|Mortality,"Jeffrey L. Saver|National Institute of Neurological Disorders and Stroke (NINDS)|University of California, Los Angeles",All,"40 Years to 95 Years   (Adult, Older Adult)",Phase 3,1700,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",U01NS044364,January 2005,March 2013,March 2013,"April 24, 2003","August 21, 2015","August 21, 2015","The Clinical Coordinating Center is: UCLA School of Medicine, 710 Westwood Plaza, Los Angeles, California, United States",NA,https://ClinicalTrials.gov/show/NCT00059332
